0001144204-14-018633.txt : 20140328 0001144204-14-018633.hdr.sgml : 20140328 20140328142906 ACCESSION NUMBER: 0001144204-14-018633 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20131231 FILED AS OF DATE: 20140328 DATE AS OF CHANGE: 20140328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEPHROS INC CENTRAL INDEX KEY: 0001196298 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133971809 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32288 FILM NUMBER: 14725010 BUSINESS ADDRESS: STREET 1: 41 GRAND AVENUE CITY: RIVER EDGE, STATE: NJ ZIP: 07661 BUSINESS PHONE: 201.343.5202 MAIL ADDRESS: STREET 1: 41 GRAND AVENUE CITY: RIVER EDGE, STATE: NJ ZIP: 07661 10-K 1 v367659_10k.htm FORM 10-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 10-K
 
 
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2013
 
 
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the Transition Period from                                to
 
Commission File Number 001-32288
 
NEPHROS, INC.
(Exact name of registrant specified in its charter)
 
Delaware
 
13-3971809
(State or Other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification No.)
 
41 Grand Avenue
River Edge, NJ 07661
(Address of Principal Executive Offices)
 
(201) 343-5202
(Telephone Number, Including Area Code)
 
Securities Registered Pursuant to Section 12(b) of the Exchange Act: None
 
Securities registered under Section 12(g) of the Exchange Act:
 
(Title of Class)
Common Stock, $.001 par value per share
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes   ¨  No   x
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.    Yes     ¨        No     x
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      x        No   ¨
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes x   No ¨
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.   ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer  ¨
 
Accelerated filer  ¨
 
Non-accelerated filer  ¨
 
Smaller reporting company  x
 
 
 
 
(Do not check if a smaller reporting company)
 
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ¨ No    x
 
The aggregate market value of the voting stock held by non-affiliates of the registrant, as of June 28, 2013, was approximately $10,181,000. Such aggregate market value was computed by reference to the closing price of the common stock as reported on the OTCQB Marketplace operated by the OTC Markets Group, Inc., or OTCQB, on June 28, 2013.  For purposes of making this calculation only, the registrant has defined affiliates as including only directors and executive officers and shareholders holding greater than 10% of the voting stock of the registrant as of June 28, 2013.
 
As of March 25, 2014 there were 25,225,704 shares of the registrant’s common stock, $0.001 par value, outstanding.
 
DOCUMENTS INCORPORATED BY REFERENCE
 
Certain portions of the registrant’s Proxy Statement (the “2014 Proxy Statement”), which will be filed with the SEC in connection with the 2014 Annual Meeting of Stockholders, are incorporated by reference into Part III of this Form 10-K.  The 2014 Proxy Statement will be filed within 120 days of December 31, 2013.
 
 
 
NEPHROS, INC. AND SUBSIDIARY
 
TABLE OF CONTENTS
 
 
Page
PART I
 
Item 1. Business
4
Item 1A. Risk Factors
13
Item 2. Properties
22
Item 3. Legal Proceedings
22
Item 4. Mine Safety Disclosures
22
PART II
 
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and  Issuer Purchases of Equity Securities
23
Item 6. Selected Financial Data
23
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
23
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
30
Item 8. Financial Statements
31
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
52
Item 9A. Controls and Procedures
52
Item 9B. Other Information
52
PART III
 
Item 10. Directors, Executive Officers and Corporate Governance
53
Item 11. Executive Compensation
53
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
53
Item 13. Certain Relationships and Related Transactions, and Director Independence
53
Item 14. Principal Accounting Fees and Services
53
Item 15. Exhibits
54
Signatures
58
 
 
2

 
FORWARD LOOKING STATEMENTS
 
Certain statements in this Annual Report on Form 10-K constitute “forward-looking statements”. Such statements include statements regarding the efficacy and intended use of our technologies under development, the timelines for bringing such products to market and the availability of funding sources for continued development of such products and other statements that are not historical facts, including statements which may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include, but are not limited to, the risks that:
 
· we may not be able to continue as a going concern;
 
· the voluntary recalls of point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications announced on October 30, 2013 and the related circumstances could subject us to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact our sales and revenues;
 
· we face significant challenges in obtaining market acceptance of our products, which could adversely affect our potential sales and revenues;
 
· there are product-related deaths or serious injuries or product malfunctions, which could trigger recalls, class action lawsuits and other events that could cause us to incur expenses and may also limit our ability to generate revenues from such products;
 
· we face potential liability associated with the production, marketing and sale of our products, and/or the expense of defending against claims of product liability, could materially deplete our assets and generate negative publicity which could impair our reputation;
 
· to the extent our products or marketing materials are found to violate any provisions of the FDC Act or any other statutes or regulations then we could be subject to enforcement actions by the FDA or other governmental agencies;
 
· we may not be able to obtain funding if and when needed or on terms favorable to us in order to continue operations;
 
· we may not have sufficient capital to successfully implement our business plan;
 
· we may not be able to effectively market our products;
 
· we may not be able to sell our water filtration products or chronic renal failure therapy products at competitive prices or profitably;
 
· we may encounter problems with our suppliers, manufacturers and distributors;
 
· we may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures;
 
· we may not obtain appropriate or necessary regulatory approvals to achieve our business plan;
 
· products that appeared promising to us in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre-clinical or clinical trials;
 
· we may not be able to secure or enforce adequate legal protection, including patent protection, for our products; and
 
· we may not be able to achieve sales growth in key geographic markets.
 
More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Annual Report on Form 10-K, is set forth in our filings with the SEC, including our other periodic reports filed with the SEC. We urge investors and security holders to read those documents free of charge at the SEC’s web site at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.
 
 
3

 
PART I
 
Item 1. Business
 
Overview
 
Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. Our filters, which we call ultrafilters, are primarily used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and/or blood. Because our ultrafilters capture contaminants as small as 0.005 microns in size, they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites and endotoxins.
 
Our ultrafilters use proprietary hollow fiber technology. We believe the hollow fiber design allows our ultrafilters to optimize the three elements critical to filter performance:
 
· Filtration - as low as 0.005 microns
· Flow rate - minimal disruption
· Filter life - up to 12 months
 
We were founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize an alternative method to hemodialysis (HD). We have extended our filtration technologies to meet the demand for liquid purification in other areas, in particular water purification.
 
Our Products
 
Presently, we offer ultrafilters for sale to customers in four markets:
 
o Dialysis Centers - Water/Bicarbonate: Filtration of water or bicarbonate concentrate used in hemodialysis devices
 
o Dialysis Centers - Blood: Clearance of toxins from blood using an alternative method to HD in patients with chronic renal failure
 
o Military and Outdoor Recreation: Highly compact, individual water purification devices used by soldiers to produce drinking water in the field
 
o Hospitals and Other Commercial Facilities: Filtration of water for drinking and washing
  
Our Target Markets
 
Dialysis Centers - Water/Bicarbonate. To perform hemodialysis, all dialysis clinics have dedicated water purification systems to produce water and bicarbonate concentrate. Water and bicarbonate concentrate are essential ingredients for making dialysate, the liquid that removes waste material from the blood. Within the U.S., there are approximately 5,700 clinics with 100,000 dialysis machines providing over 50 million dialysis treatments to 370,000 patients annually.
 
Medicare is the main payer for dialysis treatment in the U.S. To be eligible for Medicare reimbursement, dialysis centers must meet the minimum standards for water and bicarbonate concentrate quality set by the Association for the Advancement of Medical Instrumentation (AAMI), the American National Standards Institute (ANSI) and the International Standards Organization (ISO). We anticipate that the stricter standards approved by these organizations in 2009 will be adopted by Medicare in the near future.
 
Published studies have shown that the use of ultrapure dialysate can make patients healthier and reduce their dependence on erythropoietin (EPO), an expensive drug used in conjunction with HD. By reducing the level of dialysate contaminants, specifically cytokine-inducing substances that can pass into a patient’s blood stream, cytokine levels within a patient stay low, thus reducing systemic inflammation. When inflammation is low, inflammatory morbidities are reduced and a patient’s responsiveness to EPO is enhanced, consequently the overall need for the drug is reduced.
 
We believe that our ultrafilters are attractive to dialysis centers because they exceed currently approved and newly proposed standards for water and bicarbonate concentrate purity, assist in achieving those standards and may help dialysis centers reduce costs associated with the amount of EPO required to treat a patient. Our in-line filters are easily installed into the fluid circuits supplying water and bicarbonate concentrate just prior to entering each dialysis machine.
 
 
4

 
Dialysis Centers - Blood. The current standard of care in the U.S. for patients with chronic renal failure is HD, a process in which toxins are cleared via diffusion. Patients typically receive HD treatment at least 3 times weekly for 3-4 hours per treatment. HD is most effective in removing smaller, easily diffusible toxins. For patients with acute renal failure, the current standard of care in the U.S. is hemofiltration (HF), a process where toxins are cleared via convection. HF offers a much better removal of larger sized toxins when compared to HD. However, HF treatment is performed on a daily basis, and typically takes 12-24 hours.
 
Hemodiafiltration (HDF) is an alternative dialysis modality that combines the benefits of HD and HF into a single therapy by clearing toxins using both diffusion and convection. Though not widely used in the U.S., HDF is much more prevalent in Europe and is performed in approximately 16% of patients. Clinical experience and literature show the following multiple clinical and patient benefits of HDF:
 
• Enhanced clearance of middle and large molecular weight toxins
• Improved survival - up to a 35% reduction in mortality risk
• Reduction in the occurrence of dialysis-related amyloidosis
• Reduction in inflammation
• Reduction in medication such as EPO and phosphate binders
• Improved patient quality of life
• Reduction in number of hospitalizations and overall length of stay
 
However, like HF, HDF can be resource intensive and can require a significant amount of time to deliver one course of treatment.
 
We have developed a modified approach to HDF which is more patient-friendly, less resource-intensive, and can be used in conjunction with current HD machines. We refer to our approach as an online mid-dilution hemodiafiltration (mid-HDF) system and it consists of our OLpūr H2H Module and OLpūr MD 220 Hemodiafilter. The OLpūr H2H HDF Module and OLpūr MD 220 Hemodiafilter is cleared by the U.S. Food and Drug Administration (FDA) to market for use with a UF controlled hemodialysis machine that provides ultrapure dialysate in accordance with current ANSI/AAMI/ISO standards, for the treatment of patients with chronic renal failure in the United States. Our on-line mid-dilution HDF system is the only on-line mid-dilution HDF system of its kind to be cleared by the FDA to date.
 
We have completed preparation of our OLpūr H2H HDF Modules and have manufactured initial lots of our OLpūr MD220 Hemodiafilters, H2H Substitution filters and H2H water filters. We have finalized our service contract and are in the process of finalizing site selection in anticipation of market release.  We have experienced delays with the approval process at our initial placement site in the U.S. but expect to place our on-line mid-dilution HDF system in a U.S. dialysis clinic in the second quarter of 2014. We have not begun to broadly market our on-line mid-dilution HDF system and are actively seeking a commercialization partner in the U.S.
 
Military and Outdoor Recreation. The military is heavily reliant on the use of bottled water to support its soldiers in the field. Bottled water is not always available, is very costly to move, resource intensive, and prone to constant supply disruptions. Soldiers conducting operations in isolated and rugged terrain must be able to use available local water sources when unable to resupply from bulk drinking water sources or bottled water. Therefore, the soldier needs the capability to purify water from indigenous water sources in the absence of available potable water. Soldiers must have the ability to remove microbiological contaminants in the water to Environmental Protection Agency specified levels.
 
We offer our individual water purification device (IWPD), which allows a soldier in the field to derive biologically safe water from any fresh water source. Our IWPD is available in both in-line and point-of-use configurations. Our IWPD is one of the few portable filters that has been validated by the military to meet the NSF Protocol P248 standard. It has also been approved by U.S. Army Public Health Command (USAPHC) and U.S. Army Test and Evaluation Command (ATEC) for deployment. To date, we have received purchase orders for approximately 2,000 IWPDs from individual units of the U.S. armed forces.
 
In response to a Special Notice Announcement from the U.S. Army, Nephros submitted its (IWPD) containing the Nephros proprietary ultrafilter technology for consideration as part of a standard issue personal hydration pack for soldiers in the field. Nephros has been informed by the Military Government Review Agency that its IWPD has been validated to meet the military’s NSF P248 standard as a microbiological water treatment device for military operations.  In February 2013, Nephros submitted its response to a U.S. Army request for proposal (RFP) relating to IWPDs. In March 2013, we received notification from the U.S. Army that the Government has completed the initial evaluation of our proposal and found Nephros to be within the competitive range to commence negotiations. We also received a request for 180 of our IWPDs to be used as test assets during the Limited User Evaluation (LUE) phase of the source selection.   As of March 2014, we have confirmed with the U.S. Army that the RFP LUE period was still ongoing.  The U.S. Army may award several, one or no contracts as a result of this solicitation. The maximum quantity of all contracts combined is not to exceed 450,000 units or $45,000,000 over a 3 year period.
 
 
5

 
In addition to the RFP, we continue to make our IWPD available to the U.S. military.  During 2013, we signed distributor agreements with W.S. Darley & Company, Source One Distribution Inc. and Atlantic Diving Supply, Inc.  The UF40L and 30L recently were listed on the Darley website.
 
In September 2013, we were awarded the contract for 30 UF-40L units in response to RFI Solicitation Number: M67854-13-I-7310 from the U.S. Marine Corp Warfighting Laboratory. We are currently waiting for final feedback from this testing.
 
Hospitals and Other Commercial Facilities.  In October 2013, We announced the voluntary recalls of our point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications. As a result, we recalled all production lots of our POU filters, and also requested that customers remove and discard certain labeling/promotional materials for the products. In addition, we also requested, for the DSU in-line ultrafilter, that customers remove and discard certain labeling/promotional materials for the product.  These voluntary recalls did not affect our dialysis products. We are working towards a resolution of the issues raised by the FDA and we are unable to predict at this time what additional effect this recall might have on our business, financial condition, future prospects or reputation or whether we may be subject to future actions from the FDA.
 
We have launched our new NanoGuard-D and NanoGuard-S in-line ultrafilters for the filtration of water which is to be used for drinking and washing.  The NanoGuard-D and NanoGuard-S trap particulates greater than 5nm in size and the water permeability (the ease at which water can pass through a membrane at a given pressure) of the membrane is higher than membranes with a similar pore size.  This provides improved flow performance relative to the physical size of the filter.  We anticipate that the filters will be used as a component of a facility water treatment system and also for filtering water to be used in ice machines.
 
We were incorporated under the laws of the State of Delaware in April 1997. Our principal executive offices are located at 41 Grand Avenue, River Edge, New Jersey, 07661, and our telephone number is (201) 343-5202. We also have an office in Dublin, Ireland. For more information about Nephros, please visit our website at www.nephros.com.

Going Concern
 
The accompanying financial statements have been prepared assuming that we will continue as a going concern. Our recurring losses and difficulty in generating sufficient cash flow to meet our obligations and sustain our operations raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
We have incurred significant losses in operations in each quarter since inception. For the years ended December 31, 2013 and 2012, we incurred net losses of $3,698,000 and $3,262,000, respectively. In addition, we have not generated positive cash flow from operations for the years ended December 31, 2013 and 2012. To become profitable, we must increase revenue substantially and achieve and maintain positive gross and operating margins. If we are not able to increase revenue and gross and operating margins sufficiently to achieve profitability, our results of operations and financial condition will be materially and adversely affected.
 
There can be no assurance that our future cash flow will be sufficient to meet our obligations and commitments. If we are unable to generate sufficient cash flow from operations in the future to service our commitments, we will be required to adopt alternatives, such as seeking to raise debt or equity capital, curtailing its planned activities or ceasing its operations. There can be no assurance that any such actions could be effected on a timely basis or on satisfactory terms or at all, or that these actions would enable us to continue to satisfy its capital requirements.
 
 
6

 
Recent Developments
 
On February 19, 2014, the Company entered into the First Amendment to License Agreement (the “First Amendment”), by and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011 by and between the Company and Bellco.  Pursuant to the First Amendment, the Company and Bellco agreed to extend the term of the License Agreement through December 31, 2021.  The First Amendment also expands the territory covered by the License Agreement to include Sweden, Denmark, Norway, Finland, Korea, Mexico, Brazil, China and the Netherlands.  The First Amendment further provides new minimum sales targets which, if not satisfied, will, at the discretion of the Company, result in conversion of the license to non-exclusive status. The Company has agreed to reduce the fixed royalty payment payable to the Company for the period beginning on January 1, 2015 through and including December 31, 2021. Beginning on January 1, 2015 through and including December 31, 2016, Bellco will pay us a royalty based on the number of units of our patented mid-dilution dialysis filters (MD190, MD220) sold per year in the Territory as follows: for the first 125,000 units sold,  €1.75 per unit; thereafter, €1.25 per unit.  In addition, the Company will receive a total of €450,000 in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. In addition, the First Amendment provides that, in the event that the Company pursues a transaction to sell, assign or transfer all right, title and interest to the licensed patents to a third party, the Company will provide Bellco with written notice thereof and a right of first offer with respect to the contemplated transaction for a period of thirty (30) days.
 
On October 30, 2013, we initiated a voluntary recall of our point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications. We initiated the voluntary recall of these POU filters because the FDA informed us that promotional materials for these non-medical water filtration products were determined to promote claims which constitute marketing the product as a medical device. In addition, we received reports from one customer of high bacterial counts that may be associated with the breakage of fiber in four filters. According to the reports received, one death and one infection may have occurred due to the failure mode associated with this voluntary recall. Investigation into these reports is ongoing. Prior to receiving the complaints mentioned previously, we received 29 additional complaints of high bacterial counts that may be associated with the breakage of filter fiber, since we began marketing the products. We have had no reports of adverse events associated with these 29 complaints. We are recalling all production lots of these POU filters, and are also requesting that customers remove and discard certain labeling/promotional materials for the products. We initiated the voluntary recall of the DSU in-line ultrafilter because the FDA informed us that promotional materials for these non-medical water filtration products were determined to promote claims which constitute marketing the product as a medical device. We are requesting that customers remove and discard certain labeling/promotional materials for the product.  In March 2014, the Company requested the closeout of its October 2013 voluntary product recall.  The Company has fully reserved the recalled product and will destroy the respective product by April 20, 2014. 
 
Manufacturing and Suppliers
 
We do not, and do not intend to in the near future, manufacture any of our products and components. With regard to the OLpūr MD190 and MD220, on June 27, 2011, we entered into a license agreement, effective July 1, 2011, as amended by the First Amendment, with Bellco S.r.l., an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of our patented mid-dilution dialysis filters (MD190, MD220), referred to herein as the Products. Under the agreement, as amended by the First Amendment, we granted Bellco a license to manufacture, market and sell the Products under its own name, label and CE mark in Italy, France, Belgium, Spain, Canada, Denmark, Finland, Norway and Sweden on an exclusive basis, and to do the same on a non-exclusive basis in the United Kingdom, Greece, Brazil, China, Korea, Mexico and the Netherlands and, upon our written approval, other European countries where we do not sell the Products as well as non-European countries, all such countries herein referred to as the Territory.  
 
Sales and Marketing
 
Under the Bellco license agreement, as discussed above, we granted Bellco a license to manufacture, market and sell the Products under its own name, label and CE mark in the Territory. In addition, if requested by us, Bellco will be required to sell the Products to our distributors in the Territory.
 
Our New Jersey office oversees global sales and marketing activity of our ultrafilter products. We are in discussions with several medical products and filtration products suppliers to act as non-exclusive distributors of our ultrafilter products to medical and non-medical institutions. In May 2012, we signed a non-exclusive U.S. distributor agreement with Vantage. In July 2012, we signed non-exclusive U.S. distributor agreements with TQM and Ameriwater. In February 2013 we signed a non-exclusive North American distributor agreement with Chem-aqua.   In February 2014 we signed a non-exclusive North American distributor agreement with Mar Cor Purification. For each prospective market for our ultrafilter products, we are pursuing alliance opportunities for joint product development and distribution. Our ultrafilter manufacturer in Europe shares certain intellectual property rights with us for one of our Dual Stage Ultrafilter (DSU) designs.
 
 
7

 
Research and Development
 
Our research and development efforts continue on several fronts directly related to our current product lines. We are also working on additional machine devices, next-generation user interface enhancements and other product enhancements.
 
We were awarded research contracts from the Office of Naval Research (ONR) for development of a potable dual-stage military water purifying filter. The initial research contract was awarded in 2006 for approximately $1 million and work was completed in August 2009. The second research contract was awarded in August 2009 and was an expansion of the 2006 ONR contract which is being performed as part of the Marine Corps Advanced Technology Demonstration (ATD) project. The primary objective of this expanded research program is to select concepts and functional prototype filter/pump units which were developed during the first phase of the project, and further develop them into smaller field-testable devices that can be used for military evaluation purposes. An advantage of our ultrafilter is the removal of viruses which are not removed with commercially available off-the-shelf microfilter devices. Such devices generally rely on a secondary chemical disinfection step to make the water safe to drink. The expanded contract also includes research geared toward improving membrane performance, improving device durability, developing larger squad-level water purifier devices, and investigating desalination filter/pump devices for emergency-use purposes.
 
Approximately $317,000 was been billed to the projects during the year ended December 31, 2012.  Approximately $2,700,000 of revenue has been recognized on both research contracts.  The second research contract project ended in March 2012.
 
In March 2010, we entered into a development agreement with STERIS Corporation to jointly develop filtration-based products for medical device applications. We received an initial payment upon entering into the agreement of $40,000 and were eligible to receive additional payments upon successful completion of product development milestones. During 2010, we completed the initial milestone under the joint collaboration agreement with STERIS Corporation and further milestones under the agreement during the first three quarters of 2011. Completion of these milestones resulted in aggregate payments to us of $100,000 during 2010, of which approximately $67,000 was recognized in 2010 and approximately $33,000 was recognized in 2011. In the fourth quarter of 2013, this development agreement was terminated and, in exchange, STERIS paid us $15,000. 
 
Major Customers
 
For the years ended December 31, 2013 and 2012, three customers accounted for 86% and 68%, respectively, of the Company’s sales.  In addition, as of December 31, 2013 and 2012, those three customers accounted for 97% and 88%, respectively, of the Company’s accounts receivable.
 
Competition
 
With respect to the water filtration market, we expect to compete with companies that are well entrenched in the water filtration domain. These companies include Pall Corporation, which manufactures end-point water filtration systems, as well as 3M and Siemens. Our methods of competition in the water filtration domain include:
 
 
·
developing and marketing products that are designed to meet critical and specific customer needs more effectively than competitive devices;
 
 
 
 
·
offering unique attributes that illustrate our product reliability, “user-friendliness,” and performance capabilities;
 
 
 
 
·
selling products to specific customer groups where our unique product attributes are mission-critical; and
 
 
 
 
·
pursuing alliance opportunities for joint product development and distribution.
 
The dialyzer and renal replacement therapy market is subject to intense competition. Accordingly, our future success will depend on our ability to meet the clinical needs of physicians and nephrologists, improve patient outcomes and remain cost-effective for payers.
 
We compete with other suppliers of ESRD therapies, supplies and services. These suppliers include Fresenius Medical Care AG, and Baxter, currently two of the primary machine manufacturers in hemodialysis. At present, Fresenius Medical Care AG and Baxter also manufacture HDF machines.
 
The markets in which we sell our dialysis products are highly competitive. Our competitors in the sale of hemodialysis products include Baxter International Inc., Fresenius Medical Care AG, Asahi Kasei Medical Co. Ltd., B. Braun Melsungen AG, Nipro Medical Corporation Ltd., Nikkiso Co., Ltd., Terumo Medical Corporation and Toray Medical Co., Ltd.
 
Other competitive considerations include pharmacological and technological advances in preventing the progression of ESRD in high-risk patients such as those with diabetes and hypertension, technological developments by others in the area of dialysis, the development of new medications designed to reduce the incidence of kidney transplant rejection and progress in using kidneys harvested from genetically-engineered animals as a source of transplants.
 
 
8

 
We are not aware of any other companies using technology similar to ours in the treatment of ESRD. Our competition would increase, however, if companies that currently sell ESRD products, or new companies that enter the market, develop technology that is more efficient than ours. We believe that in order to become competitive in this market, we will need to develop and maintain competitive products and take and hold sufficient market share from our competitors. Therefore, we expect our methods of competing in the ESRD marketplace to include:
 
 
•
continuing our efforts to develop, have manufactured and sell products which, when compared to existing products, perform more efficiently and are available at prices that are acceptable to the market;
 
 
 
 
•
displaying our products and providing associated literature at major industry trade shows in the United States;
 
 
 
 
•
initiating discussions with dialysis clinic medical directors, as well as representatives of dialysis clinical chains, to develop interest in our products; 
 
 
 
 
•
pursuing alliance opportunities in certain territories for distribution of our products and possible alternative manufacturing facilities; and
 
 
 
 
•
entering into license agreements similar to the Bellco S.r.l. agreement to expand market share.
 
Intellectual Property
 
Patents
 
We protect our technology and products through patents and patent applications. In addition to the United States, we also applied for patents in other jurisdictions, such as the European Patent Office, Canada and Japan, to the extent we deem appropriate. We have built a portfolio of patents and applications covering our products, including their hardware design and methods of hemodiafiltration.
 
We believe that our patent strategy will provide a competitive advantage in our target markets, but our patents may not be broad enough to cover our competitors’ products and may be subject to invalidation claims. Our U.S. patents for the “Method and Apparatus for Efficient Hemodiafiltration” and for the “Dual-Stage Filtration Cartridge,” have claims that cover the OLpur MDHDF filter series and the method of hemodiafiltration employed in the operation of the products. Technological developments in ESRD therapy could reduce the value of our intellectual property. Any such reduction could be rapid and unanticipated. We have issued patents on our water filtration products and applications in process to cover various applications in residential, commercial, and remote environments.
 
As of December 31, 2013, we have eighteen issued U.S. patents, one issued Eurasian patent, seven Mexican patents, four South Korean patents, three Russian patents, six Chinese patents, nine French patents, nine German patents, five Israeli patents, seven Italian patents, three Spanish patents, nine United Kingdom patents, fourteen Japanese patents, three Hong Kong patents, nine Canadian patents, one Australian patent, two patents in Brazil, one patent in Sweden and one patent in Netherlands. Our issued U.S. patents expire between 2018 and 2027. In addition, we have three pending U.S. patent applications, four pending patent applications in Canada, five pending patent applications in the European Patent Office, two pending patent applications in Brazil, one pending patent application in China, four pending patent applications in Israel, two pending patent applications in India and one pending patent application in South Korea. Our pending patent applications relate to a range of dialysis technologies, including cartridge configurations, cartridge assembly, substitution fluid systems, and methods to enhance toxin removal.
 
Trademarks
 
As of December 31, 2013, we secured registrations of the trademarks CENTRAPUR, H2H, OLpur and the Arrows Logo in the European Union. Applications for these trademarks are pending registration in the United States. We also have applications for registration of a number of other marks pending in the United States Patent and Trademark Office.
 
Governmental Regulation
 
The research and development, manufacturing, promotion, marketing and distribution of our ESRD therapy products in the United States, Europe and other regions of the world are subject to regulation by numerous governmental authorities, including the FDA, the European Union and analogous agencies.
 
 
9

 
United States
 
The FDA regulates the manufacture and distribution of medical devices in the United States pursuant to the FDC Act. All of our ESRD therapy products are regulated in the United States as medical devices by the FDA under the FDC Act. Under the FDC Act, medical devices are classified in one of three classes, namely Class I, II or III, on the basis of the controls deemed necessary by the FDA to reasonably ensure their safety and effectiveness.
 
•          Class I devices are medical devices for which general controls are deemed sufficient to ensure their safety and effectiveness. General controls include provisions related to (1) labeling, (2) producer registration, (3) defect notification, (4) records and reports and (5) quality service requirements, or QSR.
 
•          Class II devices are medical devices for which the general controls for the Class I devices are deemed not sufficient to ensure their safety and effectiveness and require special controls in addition to the general controls. Special controls include provisions related to (1) performance and design standards, (2) post-market surveillance, (3) patient registries and (4) the use of FDA guidelines.
 
•          Class III devices are the most regulated medical devices and are generally limited to devices that support or sustain human life or are of substantial importance in preventing impairment of human health or present a potential, unreasonable risk of illness or injury. Pre-market approval by the FDA is the required process of scientific review to ensure the safety and effectiveness of Class III devices.
 
Before a new medical device can be introduced to the market, FDA clearance of a pre-market notification under Section 510(k) of the FDC Act or FDA clearance of a pre-market approval, or PMA, application under Section 515 of the FDC Act must be obtained. A Section 510(k) clearance will be granted if the submitted information establishes that the proposed device is “substantially equivalent” to a legally marketed Class I or Class II medical device or to a Class III medical device for which the FDA has not called for pre-market approval under Section 515. The Section 510(k) pre-market clearance process is generally faster and simpler than the Section 515 pre-market approval process.
 
For any devices cleared through the Section 510(k) process, modifications or enhancements that could significantly affect the safety or effectiveness of the device or that constitute a major change to the intended use of the device will require a new Section 510(k) pre-market notification submission. Accordingly, if we do obtain Section 510(k) pre-market clearance for any of our ESRD therapy and DSU products, we will need to submit another Section 510(k) pre-market notification if we significantly affect that product’s safety or effectiveness through subsequent modifications or enhancements.
 
On July 1, 2009, we received FDA clearance of the DSU to be used to filter biological contaminants from water and bicarbonate concentrate used in hemodialysis procedures.
 
On June 30, 2010, we received a final decision letter from the FDA for our 510(k) submission which stated that the FDA could not reach a substantial equivalence determination for our hemodiafiltration (HDF) system. On August 11, 2011, Nephros filed a new 510(k) application with the FDA for clearance of the Company’s hemodiafiltration (HDF) system for end-stage renal disease. On April 30, 2012, the Company announced that it received 510(k) clearance from the FDA to market the OLpūr H2H Module and OLpūr MD 220 Hemodiafilter for use with a UF controlled hemodialysis machine that provides ultrapure dialysate in accordance with current ANSI/AAMI/ISO standards, for the treatment of patients with chronic renal failure in the United States.
 
The FDC Act requires that medical devices be manufactured in accordance with the FDA’s current QSR regulations which require, among other things, that:
 
• the design and manufacturing processes be regulated and controlled by the use of written procedures;
• the ability to produce medical devices which meet the manufacturer’s specifications be validated by extensive and detailed testing of every aspect of the process;
• any deficiencies in the manufacturing process or in the products produced be investigated;
• detailed records be kept and a corrective and preventative action plan be in place; and
• manufacturing facilities be subject to FDA inspection on a periodic basis to monitor compliance with QSR regulations.
 
If violations of the applicable QSR regulations are noted during FDA inspections of our manufacturing facilities or the manufacturing facilities of our contract manufacturers, there may be a material adverse effect on our ability to produce and sell our products.
 
In addition to the requirements described above, the FDC Act requires that:
 
• all medical device manufacturers and distributors register with the FDA annually and provide the FDA with a list of those medical devices which they distribute commercially;
 
 
10

 
• information be provided to the FDA on death or serious injuries alleged to have been associated with the use of the products, as well as product malfunctions that would likely cause or contribute to death or serious injury if the malfunction were to recur; and
• certain medical devices not cleared with the FDA for marketing in the United States meet specific requirements before they are exported.
 
European Union
 
The European Union began to harmonize national regulations comprehensively for the control of medical devices in member nations in 1993, when it adopted its Medical Devices Directive 93/42/EEC. The European Union directive applies to both the manufacturer’s quality assurance system and the product’s technical design and discusses the various ways to obtain approval of a device (dependent on device classification), how to properly CE Mark a device and how to place a device on the market.
 
The regulatory approach necessary to demonstrate to the European Union that the organization has the ability to provide medical devices and related services that consistently meet customer requirements and regulatory requirements applicable to medical devices requires the certification of a full quality management system by a notified body. Initially, we engaged TÜV Rheinland of North America, Inc. (“TÜV Rheinland”) as the notified body to assist us in obtaining certification to the International Organization for Standardization, or ISO, 13485/2003 standard, which demonstrates the presence of a quality management system that can be used by an organization for design and development, production, installation and servicing of medical devices and the design, development and provision of related services.
 
European Union requirements for products are set forth in harmonized European Union standards and include conformity to safety requirements, physical and biological properties, construction and environmental properties, and information supplied by the manufacturer. A company demonstrates conformity to these requirements, with respect to a product, by pre-clinical tests, biocompatibility tests, qualification of products and packaging, risk analysis and well-conducted clinical investigations approved by ethics committees.
 
Once a manufacturer’s full quality management system is determined to be in compliance with ISO 13485/2003 and other statutory requirements, and the manufacturer’s products conform to harmonized European standards, the notified body will recommend and document such conformity. The manufacturer will receive a CE marking and ISO certifications, and then may place a CE mark on the relevant products. The CE mark, which stands for Conformité Européenne, demonstrates compliance with the relevant European Union requirements. Products subject to these provisions that do not bear the CE mark cannot be imported to, or sold or distributed within, the European Union.
 
In July 2003, we received a certification from TÜV Rheinland that our quality management system conforms to the requirements of the European Community. At the same time, TÜV Rheinland approved our use of the CE marking with respect to the design and production of high permeability hemodialyzer products for ESRD therapy. In April 2010, we changed our notified body from TÜV Rheinland to BSI America, Inc. and expanded our scope to include design and development and production of water filters.
 
Under the Bellco license agreement, as discussed above, we granted Bellco a license to manufacture, market and sell the Products under its own name, label and CE mark in the Territory. In addition, if requested by us, Bellco will be required to sell the Products to our distributors in the Territory.
 
Regulatory Authorities in Regions Outside of the United States and the European Union
 
We also plan to sell our ESRD therapy products in foreign markets outside the United States which are not part of the European Union. Requirements pertaining to medical devices vary widely from country to country, ranging from no health regulations to detailed submissions such as those required by the FDA. We believe the extent and complexity of regulations for medical devices such as those produced by us are increasing worldwide. We anticipate that this trend will continue and that the cost and time required to obtain approval to market in any given country will increase, with no assurance that such approval will be obtained. Our ability to export into other countries may require compliance with ISO 13485, which is analogous to compliance with the FDA’s QSR requirements. In November 2007 and May 2011, the Therapeutic Products Directorate of Health Canada, the Canadian health regulatory agency, approved our OLpur MD220 Hemodiafilter and our DSU, respectively, for marketing in Canada. Other than the CE marking and Canadian approval of our OLpur MD220 Hemodiafilter and DSU products, we have not obtained any regulatory approvals to sell any of our products and there is no assurance that any such clearance or certification will be issued.
 
Reimbursement
 
In both domestic markets and markets outside of the United States, sales of our ESRD therapy products will depend in part, on the availability of reimbursement from third-party payers. In the United States, ESRD providers are reimbursed through Medicare, Medicaid and private insurers. In countries other than the United States, ESRD providers are also reimbursed through governmental and private insurers. In countries other than the United States, the pricing and profitability of our products generally will be subject to government controls. Despite the continually expanding influence of the European Union, national healthcare systems in its member nations, including reimbursement decision-making, are neither regulated nor integrated at the European Union level. Each country has its own system, often closely protected by its corresponding national government.
 
 
11

 
Product Liability and Insurance
 
The production, marketing and sale of our products have an inherent risk of liability in the event of product failure or claim of harm caused by product operation. We have acquired product liability insurance for our products in the amount of $2 million. A successful claim in excess of our insurance coverage could materially deplete our assets. Moreover, any claim against us could generate negative publicity, which could decrease the demand for our products, our ability to generate revenues and our profitability.
 
Some of our existing and potential agreements with manufacturers of our products and components of our products do or may require us (1) to obtain product liability insurance or (2) to indemnify manufacturers against liabilities resulting from the sale of our products. If we are not able to maintain adequate product liability insurance, we will be in breach of these agreements, which could materially adversely affect our ability to produce our products. Even if we are able to obtain and maintain product liability insurance, if a successful claim in excess of our insurance coverage is made, then we may have to indemnify some or all of our manufacturers for their losses, which could materially deplete our assets.
 
Employees
 
As of December 31, 2013, we employed a total of 8 employees, 7 of whom were full time and 1 who is employed on a part-time basis. We also have engaged 2 consultants on an ongoing basis. Of the 10 total employees and consultants, 3 are employed in a sales/marketing/customer support capacity, 3 in general and administrative and 4 in research and development.
 
Available Information
 
We make available free of charge on our website (http://www.nephros.com) our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports, as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. We provide electronic or paper copies of filings free of charge upon request. The public may read and copy any  materials filed with the SEC at the SEC’s Public Reference Room at 100 F Street N.E. Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding issuers that file with the SEC at http://www.sec.gov.
 
 
12

 
Item 1A. Risk Factors
 
Risks Related to Our Company
 
Our independent registered public accounting firm, in its audit report related to our financial statements for the fiscal year ended December 31, 2013, expressed substantial doubt about our ability to continue as a going concern.
 
Our independent registered public accounting firm has included an explanatory paragraph in its report on our financial statements included in this Annual Report on Form 10-K for the year ended December 31, 2013 expressing doubt as to our ability to continue as a going concern. The accompanying financial statements have been prepared assuming that we will continue as a going concern. However, there can be no assurance that we will be able to do so. Our recurring losses and difficulty in generating sufficient cash flow to meet our obligations and sustain our operations raise substantial doubt about our ability to continue as a going concern, and our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Based on our current cash flow projections, we will need to raise additional funds through either the licensing or sale of our technologies or the additional public or private offerings of our securities. However, there is no guarantee that we will be able to obtain further financing, or do so on reasonable terms. If we are unable to raise additional funds on a timely basis, or at all, we would be materially adversely affected.
 
We have a history of operating losses and a significant accumulated deficit, and we may not achieve or maintain profitability in the future.
 
We have not been profitable since our inception in 1997. As of December 31, 2013, we had an accumulated deficit of approximately $101,228,000, primarily as a result of historical operating losses. We expect to continue to incur additional losses for the foreseeable future as a result of a high level of operating expenses, significant up-front expenditures, including the cost of clinical trials, production and marketing activities and very limited revenue from the sale of our products. We began sales of our first product in March 2004, and we may never realize sufficient revenues from the sale of our products or be profitable. Each of the following factors, among others, may influence the timing and extent of our profitability, if any:
 
· the market acceptance of our technologies and products in each of our target markets;
 
· our ability to effectively and efficiently manufacture, market and distribute our products;
 
· our ability to sell our products at competitive prices which exceed our per unit costs; and
 
· our ability to continue to develop products and maintain a competitive advantage in our industry.
 
If we violate any provisions of the FDC Act or any other statutes or regulations, then we could be subject to enforcement actions by the FDA or other governmental agencies.
 
We face a significant compliance burden under the FDC Act and other applicable statutes and regulations which govern the testing, labeling, storage, record keeping, distribution, sale, marketing, advertising and promotion of our medically approved products.
 
On October 30, 2013, we initiated a voluntary recall of our point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications. We initiated the voluntary recall of these POU filters because the FDA informed us that promotional materials for these non-medical water filtration products were determined to promote claims which constitute marketing the product as a medical device. In addition, we received reports from one customer of high bacterial counts that may be associated with the breakage of fiber in four filters. According to the reports received, one death and one infection may have occurred due to the failure mode associated with this voluntary recall. Investigation into these reports is ongoing. Prior to receiving the complaints mentioned previously, we received 29 additional complaints of high bacterial counts that may be associated with the breakage of filter fiber, since we began marketing the products. We have had no reports of adverse events associated with these 29 complaints. We are recalling all production lots of these POU filters, and are also requesting that customers remove and discard certain labeling/promotional materials for the products. We initiated the voluntary recall of the DSU in-line ultrafilter because the FDA informed us that promotional materials for these non-medical water filtration products were determined to promote claims which constitute marketing the product as a medical device. We are requesting that customers remove and discard certain labeling/promotional materials for the product.
 
 
13

 
If we violate the FDC Act or other regulatory requirements (either with respect to our POU or DSU ultrafilters or otherwise) at any time during or after the product development and/or approval process, we could be subject to enforcement actions by the FDA or other agencies, including:
 
· fines;
· injunctions;
· civil penalties;
· recalls or seizures of products;
· total or partial suspension of the production of our products;
· withdrawal of any existing approvals or pre-market clearances of our products;
· refusal to approve or clear new applications or notices relating to our products;
· recommendations that we not be allowed to enter into government contracts; and
· criminal prosecution.
 
Any of the above could have a material adverse effect on our business, financial condition and results of operations.
 
We cannot assure you that our products will be safe or that there will not be product-related deaths, serious injuries or product malfunctions. Further, we are required under applicable law to report any circumstances relating to our medically approved products that could result in deaths or serious injuries. These circumstances could trigger recalls, class action lawsuits and other events that could cause us to incur expenses and may also limit our ability to generate revenues from such products.
 
We cannot assure you that our products will be safe or that there will not be product-related deaths or serious injuries or product malfunctions, which could trigger recalls, class action lawsuits and other events that could cause us to incur significant expenses, limit our ability to market our products and generate revenues from such products or cause us reputational harm.
 
In particular, the voluntary recalls of the POU and DSU in-line ultrafilters used in hospital water treatment applications announced on October 30, 2013 and the related circumstances could subject us to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact our sales and revenues.
 
Under the Food, Drug and Cosmetic Act (FDC Act), we are required to submit medical device reports, or MDRs, to the FDA to report device-related deaths, serious injuries and malfunctions of medically approved products that could result in death or serious injury if they were to recur. Depending on their significance, MDRs could trigger events that could cause us to incur expenses and may also limit our ability to generate revenues from such products, such as the following:
 
 · information contained in the MDRs could trigger FDA regulatory actions such as inspections, recalls and patient/physician notifications;
 · because the reports are publicly available, MDRs could become the basis for private lawsuits, including class actions; and
 · if we fail to submit a required MDR to the FDA, the FDA could take enforcement action against us.
 
If any of these events occur, then we could incur significant expenses and it could become more difficult for us to market and sell our products and to generate revenues from sales. Other countries may impose analogous reporting requirements that could cause us to incur expenses and may also limit our ability to generate revenues from sales of our products.
 
Product liability associated with the production, marketing and sale of our products, and/or the expense of defending against claims of product liability, could materially deplete our assets and generate negative publicity which could impair our reputation.
 
The production, marketing and sale of kidney dialysis and water-filtration products have inherent risks of liability in the event of product failure or claim of harm caused by product operation. In particular, the voluntary recalls of the POU and DSU in-line ultrafilters used in hospital water treatment applications announced on October 30, 2013 and the related circumstances could subject us to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact our sales and revenues. Furthermore, even meritless claims of product liability may be costly to defend against. Although we have acquired product liability insurance for our products, we may not be able to maintain or obtain this insurance on acceptable terms or at all. Because we may not be able to obtain insurance that provides us with adequate protection against all potential product liability claims, a successful claim in excess of our insurance coverage could materially deplete our assets. Moreover, even if we are able to obtain adequate insurance, any claim against us could generate negative publicity, which could impair our reputation and adversely affect the demand for our products, our ability to generate sales and our profitability.
 
Some of the agreements that we may enter into with manufacturers of our products and components of our products may require us:
 
•              to obtain product liability insurance; or
•              to indemnify manufacturers against liabilities resulting from the sale of our products.
 
 
14

 
For example, the agreement with our contract manufacturer, or CM, requires that we obtain and maintain certain minimum product liability insurance coverage and that we indemnify our CM against certain liabilities arising out of our products that they manufacture, provided they do not arise out of our CM’s breach of the agreement, negligence or willful misconduct. If we are not able to obtain and maintain adequate product liability insurance, then we could be in breach of these agreements, which could materially adversely affect our ability to produce our products and generate revenues. Even if we are able to obtain and maintain product liability insurance, if a successful claim in excess of our insurance coverage is made, then we may have to indemnify some or all of our manufacturers for their losses, which could materially deplete our assets.
 
We face significant challenges in obtaining market acceptance of our products, which could adversely affect our potential sales and revenues.
 
Our products are new to the market, and we do not yet have an established market or customer base for our products. Acceptance of our products in the marketplace by both potential users, including chronic renal failure patients, and potential purchasers, including nephrologists, dialysis clinics and other health care providers, is uncertain, and our failure to achieve sufficient market acceptance will significantly limit our ability to generate revenue and be profitable. Market acceptance will require substantial marketing efforts and the expenditure of significant funds by us to inform dialysis patients and nephrologists, dialysis clinics and other health care providers of the benefits of using our products. We may encounter significant clinical and market resistance to our products and our products may never achieve market acceptance. We may not be able to build key relationships with physicians, clinical groups and government agencies, pursue or increase sales opportunities in Europe or elsewhere, or be the first to introduce hemodiafiltration therapy in the United States. Product orders may be cancelled, patients or customers currently using our products may cease to do so and patients or customers expected to begin using our products may not. Factors that may affect our ability to achieve acceptance of our chronic renal failure therapy products in the marketplace include whether:
 
· such products will be safe for use;
 
· such products will be effective;
 
· such products will be cost-effective;
 
· we will be able to demonstrate product safety, efficacy and cost-effectiveness;
 
· there are unexpected side effects, complications or other safety issues associated with such products; and
 
· government or third party reimbursement for the cost of such products is available at reasonable rates, if at all.
 
Acceptance of our water filtration products in the marketplace is also uncertain, and our failure to achieve sufficient market acceptance and sell such products at competitive prices will limit our ability to generate revenue and be profitable. Our water filtration products and technologies may not achieve expected reliability, performance and endurance standards. Our water filtration products and technology may not achieve market acceptance, including among hospitals, or may not be deemed suitable for other commercial, military, industrial or retail applications.
 
Many of the same factors that may affect our ability to achieve acceptance of our chronic renal failure therapy products in the marketplace will also apply to our water filtration products, except for those related to side effects, clinical trials and third party reimbursement.
 
 
15

 
If we are not able to successfully scale-up production of our products, then our sales and revenues will suffer.
 
In order to commercialize our products, we need to be able to produce them in a cost-effective way on a large scale to meet commercial demand, while maintaining extremely high standards for quality and reliability. If we fail to successfully commercialize our products, then we will not be profitable.
 
We expect to rely on a limited number of independent manufacturers to produce our products. Our manufacturers’ systems and procedures may not be adequate to support our operations and may not be able to achieve the rapid execution necessary to exploit the market for our products. Our manufacturers could experience manufacturing and control problems as they begin to scale-up our future manufacturing operations, if any, and we may not be able to scale-up manufacturing in a timely manner or at a commercially reasonable cost to enable production in sufficient quantities. If we experience any of these problems with respect to our manufacturers’ initial or future scale-ups of manufacturing operations, then we may not be able to have our products manufactured and delivered in a timely manner. Our products are new and evolving, and our manufacturers may encounter unforeseen difficulties in manufacturing them in commercial quantities or at all.
 
If we cannot develop adequate distribution, customer service and technical support networks, then we may not be able to market and distribute our products effectively and/or customers may decide not to order our products and, in either case, our sales and revenues will suffer.
 
Our strategy requires us to distribute our products and provide a significant amount of customer service and maintenance and other technical service. To provide these services, we have begun, and will need to continue, to develop a network of distribution and a staff of employees and independent contractors in each of the areas in which we intend to operate. We cannot assure that we will be able to organize and manage this network on a cost-effective basis. If we cannot effectively organize and manage this network, then it may be difficult for us to distribute our products and to provide competitive service and support to our customers, in which case customers may be unable, or decide not, to order our products and our sales and revenues will suffer.
 
We have limited experience selling our products to healthcare facilities, and we might be unsuccessful in increasing our sales.
 
Our business strategy depends in part on our ability to sell our products to hospitals and other healthcare facilities that include dialysis clinics. We have limited experience with respect to sales and marketing. If we are unsuccessful at manufacturing, marketing and selling our products, our operations and potential revenues will be materially adversely affected.
 
We cannot sell our products, including certain modifications thereto, until we obtain the requisite regulatory approvals and clearances in the countries in which we intend to sell our products. If we fail to receive, or experience a significant delay in receiving, such approvals and clearances, then we may not be able to get our products to market and enhance our revenues.
 
Our business strategy depends in part on our ability to get our products into the market as quickly as possible. We have obtained a Conformité Européene, or CE, mark, which demonstrates compliance with the relevant European Union requirements and is a regulatory prerequisite for selling our products in the European Union and certain other countries that recognize CE marking (collectively, “European Community”), for our OLpur mid dilution hemodiafilter series product and our Dual Stage Ultrafilter (“DSU”). We have not yet obtained the CE mark for any of our other products. On April 30, 2012, we announced that we received clearance from the FDA to market our OLpūr MD220 Hemodiafilter and OLpūr H2H Module for use with a hemodialysis machine that provides ultrapure dialysate in accordance with current ANSI/AAMI/ISO standards, for the treatment of chronic renal failure patients. We have not begun to broadly market these products and are actively seeking a commercialization partner in the U.S.
 
There is no assurance that any existing products that have not yet been approved, or any new products developed by us in the future, will be approved for marketing. The clearance and/or approval processes can be lengthy and uncertain and each requires substantial commitments of our financial resources and our management’s time and effort. We may not be able to obtain further CE marking or regulatory approval for any of our existing or new products in a timely manner or at all. Even if we do obtain regulatory approval, approval may be only for limited uses with specific classes of patients, processes or other devices. Our failure to obtain, or delays in obtaining, the necessary regulatory clearance and/or approvals would prevent us from selling our affected products in the applicable regions. If we cannot sell some of our products in such regions, or if we are delayed in selling while waiting for the necessary clearance and/or approvals, our ability to generate revenues from these products will be limited.
 
We intend to market our products globally. Requirements pertaining to the sale of our products vary widely from country to country. It may be very expensive and difficult for us to meet the requirements for the sale of our products in many countries. As a result, we may not be able to obtain the required approvals in a timely manner, if at all. If we cannot sell our products in a particular region, then the size of our potential market could be reduced, which would limit our potential sales and revenues.
 
 
16

 
Clinical studies that may be required for our products are costly and time-consuming, and their outcome is uncertain.
 
Before obtaining regulatory approvals for the commercial sale of any of our products, other than those for which we have already received marketing approval in the United States and elsewhere, we must demonstrate through clinical studies that our products are safe and effective.
 
For products other than those for which we have already received marketing approval, if we do not prove in clinical trials that our products are safe and effective, we will not obtain marketing approvals from the applicable regulatory authorities. In particular, one or more of our products may not exhibit the expected medical benefits, may cause harmful side effects, may not be effective in treating dialysis patients or may have other unexpected characteristics that preclude regulatory approval for any or all indications of use or limit commercial use if approved. The length of time necessary to complete clinical trials varies significantly and is difficult to predict. Factors that can cause delay or termination of our clinical trials include:
 
· slower than expected patient enrollment due to the nature of the protocol, the proximity of subjects to clinical sites, the eligibility criteria for the study, competition with clinical trials for similar devices or other factors;
 
· lower than expected retention rates of subjects in a clinical trial;
 
· inadequately trained or insufficient personnel at the study site to assist in overseeing and monitoring clinical trials;
 
· delays in approvals from a study site’s review board, or other required approvals;
 
· longer treatment time required to demonstrate effectiveness;
 
· lack of sufficient supplies of the product;
 
· adverse medical events or side effects in treated subjects; and
 
· lack of effectiveness of the product being tested.
 
Even if we obtain positive results from clinical studies for our products, we may not achieve the same success in future studies of such products. Data obtained from clinical studies are susceptible to varying interpretations that could delay, limit or prevent regulatory approval. In addition, we may encounter delays or rejections based upon changes in regulatory policy for device approval during the period of product development and regulatory review of each submitted new device application. Moreover, regulatory approval may entail limitations on the indicated uses of the device. Failure to obtain requisite governmental approvals or failure to obtain approvals of the scope requested will delay or preclude our licensees or marketing partners from marketing our products or limit the commercial use of such products and will have a material adverse effect on our business, financial condition and results of operations.
 
In addition, some or all of the clinical trials we undertake may not demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals, which could prevent or delay the creation of marketable products. Our product development costs will increase if we have delays in testing or approvals, if we need to perform more, larger or different clinical trials than planned or if our trials are not successful. Delays in our clinical trials may harm our financial results and the commercial prospects for our products. Additionally, we may be unable to complete our clinical trials if we are unable to obtain additional capital.
 
We may be required to design and conduct additional clinical trials.
 
We may be required to design and conduct additional clinical trials to further demonstrate the safety and efficacy of our products, which may result in significant expense and delay. Regulatory agencies may require new or additional clinical trials because of inconclusive results from current or earlier clinical trials, a possible failure to conduct clinical trials in complete adherence to certain regulatory standards, the identification of new clinical trial endpoints, or the need for additional data regarding the safety or efficacy of our products. It is possible that regulatory authorities may not ultimately approve our products for commercial sale in any jurisdiction, even if we believe future clinical results are positive.
 
Significant additional governmental regulation could subject us to unanticipated delays which would adversely affect our sales and revenues.
 
Our business strategy depends in part on our ability to get our products into the market as quickly as possible. Additional laws and regulations, or changes to existing laws and regulations that are applicable to our business may be enacted or promulgated, and the interpretation, application or enforcement of the existing laws and regulations may change. We cannot predict the nature of any future laws, regulations, interpretations, applications or enforcements or the specific effects any of these might have on our business. Any future laws, regulations, interpretations, applications or enforcements could delay or prevent regulatory approval or clearance of our products and our ability to market our products. Moreover, changes that result in our failure to comply with the requirements of applicable laws and regulations could result in the types of enforcement actions by the FDA and/or other agencies as described above, all of which could impair our ability to have manufactured and to sell the affected products.
 
 
17

 
Protecting our intellectual property in our technology through patents may be costly and ineffective. If we are not able to adequately secure or enforce protection of our intellectual property, then we may not be able to compete effectively and we may not be profitable.
 
Our future success depends in part on our ability to protect the intellectual property for our technology through patents. We will only be able to protect our products and methods from unauthorized use by third parties to the extent that our products and methods are covered by valid and enforceable patents or are effectively maintained as trade secrets. Our 18 granted U.S. patents will expire at various times from 2018 to 2027, assuming they are properly maintained.
 
The protection provided by our patents, and patent applications if issued, may not be broad enough to prevent competitors from introducing similar products into the market. Our patents, if challenged or if we attempt to enforce them, may not necessarily be upheld by the courts of any jurisdiction. Numerous publications may have been disclosed by, and numerous patents may have been issued to, our competitors and others relating to methods and devices for dialysis of which we are not aware and additional patents relating to methods and devices for dialysis may be issued to our competitors and others in the future. If any of those publications or patents conflict with our patent rights, or cover our products, then any or all of our patent applications could be rejected and any or all of our granted patents could be invalidated, either of which could materially adversely affect our competitive position.
 
Litigation and other proceedings relating to patent matters, whether initiated by us or a third party, can be expensive and time-consuming, regardless of whether the outcome is favorable to us, and may require the diversion of substantial financial, managerial and other resources. An adverse outcome could subject us to significant liabilities to third parties or require us to cease any related development, product sales or commercialization activities. In addition, if patents that contain dominating or conflicting claims have been or are subsequently issued to others and the claims of these patents are ultimately determined to be valid, then we may be required to obtain licenses under patents of others in order to develop, manufacture, use, import and/or sell our products. We may not be able to obtain licenses under any of these patents on terms acceptable to us, if at all. If we do not obtain these licenses, we could encounter delays in, or be prevented entirely from using, importing, developing, manufacturing, offering or selling any products or practicing any methods, or delivering any services requiring such licenses.
 
If we file patent applications or obtain patents in foreign countries, we will be subject to laws and procedures that differ from those in the United States. Such differences could create additional uncertainty about the level and extent of our patent protection. Moreover, patent protection in foreign countries may be different from patent protection under U.S. laws and may not be as favorable to us. Many non-U.S. jurisdictions, for example, prohibit patent claims covering methods of medical treatment of humans, although this prohibition may not include devices used for such treatment.
 
If we are not able to secure and enforce protection of our trade secrets through enforcement of our confidentiality and non-competition agreements, then our competitors may gain access to our trade secrets, we may not be able to compete effectively and we may not be profitable. Such protection may be costly and ineffective.
 
We attempt to protect our trade secrets, including the processes, concepts, ideas and documentation associated with our technologies, through the use of confidentiality agreements and non-competition agreements with our current employees and with other parties to whom we have divulged such trade secrets. If these employees or other parties breach our confidentiality agreements and non-competition agreements, or if these agreements are not sufficient to protect our technology or are found to be unenforceable, then our competitors could acquire and use information that we consider to be our trade secrets and we may not be able to compete effectively. Policing unauthorized use of our trade secrets is difficult and expensive, particularly because of the global nature of our operations. The laws of other countries may not adequately protect our trade secrets.
 
If we are not able to maintain sufficient quality controls, then the approval or clearance of our products by the European Union, the FDA or other relevant authorities could be withdrawn, delayed or denied and our sales and revenues will suffer.
 
Approval or clearance of our products could be withdrawn, delayed or denied by the European Union, the FDA and the relevant authorities of other countries if our manufacturing facilities do not comply with their respective manufacturing requirements. The European Union imposes requirements on quality control systems of manufacturers, which are inspected and certified on a periodic basis and may be subject to additional unannounced inspections. Failure by our manufacturers to comply with these requirements could prevent us from marketing our products in the European Community. The FDA also imposes requirements through quality system requirements, or QSR, regulations, which include requirements for good manufacturing practices, or GMP. Failure by our manufacturers to comply with these requirements could prevent us from obtaining FDA approval of our products and from marketing such products in the United States. Although the manufacturing facilities and processes that we use to manufacture our OLpur MDHDF filter series have been inspected and certified by a worldwide testing and certification agency (also referred to as a notified body) that performs conformity assessments to European Union requirements for medical devices, they have not been inspected by the FDA. A “notified body” is a group accredited and monitored by governmental agencies that inspects manufacturing facilities and quality control systems at regular intervals and is authorized to carry out unannounced inspections. We cannot be sure that any of the facilities or processes we use will comply or continue to comply with their respective requirements on a timely basis or at all, which could delay or prevent our obtaining the approvals we need to market our products in the European Community and the United States.
 
 
18

 
To market our products in the European Community, the United States and other countries, where approved, manufacturers of such products must continue to comply or ensure compliance with the relevant manufacturing requirements. Although we cannot control the manufacturers of our products, we may need to expend time, resources and effort in product manufacturing and quality control to assist with their continued compliance with these requirements. If violations of applicable requirements are noted during periodic inspections of the manufacturing facilities of our manufacturers, then we may not be able to continue to market the products manufactured in such facilities and our revenues may be materially adversely affected.
 
We may face significant risks associated with international operations, which could have a material adverse effect on our business, financial condition and results of operations.
 
We expect to manufacture and to market our products globally. Our international operations are subject to a number of risks, including the following:
 
· fluctuations in exchange rates of the United States dollar could adversely affect our results of operations;
   
· we may face difficulties in enforcing and collecting accounts receivable under some countries’ legal systems;
   
· local regulations may restrict our ability to sell our products, have our products manufactured or conduct other operations;
   
· political instability could disrupt our operations;
   
· some governments and customers may have longer payment cycles, with resulting adverse effects on our cash flow; and
   
· some countries could impose additional taxes or restrict the import of our products.
 
Any one or more of these factors could increase our costs, reduce our revenues, or disrupt our operations, which could have a material adverse effect on our business, financial condition and results of operations.
 
Risks Related to Owning Our Common Stock
 
There currently is a limited trading market for our Common Stock.
 
Our Common Stock currently does not meet all of the requirements for initial listing on a registered stock exchange. Our Common Stock is quoted on the OTCQB. Trading in our Common Stock on the OTCQB has been very limited. As a result, an investor may find it difficult to dispose of or to obtain accurate quotations as to the market value of our Common Stock, and our Common Stock may be less attractive for margin loans, for investment by financial institutions, as consideration in future capital raising transactions or other purposes. There is no guarantee that we will ever become listed on the Nasdaq Capital Market, or any other exchange, or that a liquid trading market for our Common Stock will develop.
 
Our Common Stock could be further diluted as a result of the issuance of additional shares of Common Stock, warrants or options.
 
In the past we have issued Common Stock and warrants in order to raise money. We have also issued stock options and restricted stock as compensation for services and incentive compensation for our employees, directors and consultants. We have shares of Common Stock reserved for issuance upon the exercise of certain of these securities and may increase the shares reserved for these purposes in the future. Our issuance of additional Common Stock, convertible securities, options and warrants could affect the rights of our stockholders, could reduce the market price of our Common Stock or could result in adjustments to exercise prices of outstanding warrants (resulting in these securities becoming exercisable for, as the case may be, a greater number of shares of our Common Stock), or could obligate us to issue additional shares of Common Stock.
 
Market sales of large amounts of our Common Stock, or the potential for those sales even if they do not actually occur, may have the effect of depressing the market price of our Common Stock, the supply of Common Stock available for resale could be increased which could stimulate trading activity and cause the market price of our Common Stock to drop, even if our business is doing well. Furthermore, the issuance of any additional shares of our Common Stock or securities convertible into our Common Stock could be substantially dilutive to holders of our Common Stock if they do not invest in future offerings.
 
 
19

 
The prices at which shares of the Common Stock trade have been and will likely continue to be volatile.
 
In the two years ended December 31, 2013, our Common Stock has traded at prices ranging from a high of $3.19 to a low of $0.31 per share. Due to the lack of an active trading market for our Common Stock, you should expect the prices at which our Common Stock might trade to continue to be highly volatile. The expected volatile price of our stock will make it difficult to predict the value of your investment, to sell your shares at a profit at any given time, or to plan purchases and sales in advance. A variety of other factors might also affect the market price of our Common Stock. These include, but are not limited to:
 
· achievement or rejection of regulatory approvals by our competitors or us;
· publicity regarding actual or potential clinical or regulatory results relating to products under development by our competitors or us;
· delays or failures in initiating, completing or analyzing clinical trials or the unsatisfactory design or results of these trials;
· announcements of technological innovations or new commercial products by our competitors or us;
· developments concerning proprietary rights, including patents;
· regulatory developments in the United States and foreign countries;
· economic or other crises and other external factors;
· period-to-period fluctuations in our results of operations;
· threatened or actual litigation;
· changes in financial estimates by securities analysts; and
· sales of our Common Stock.
 
We are not able to control many of these factors, and we believe that period-to-period comparisons of our financial results will not necessarily be indicative of our future performance.
 
In addition, the stock market in general, and the market for biotechnology companies in particular, has experienced extreme price and volume fluctuations in recent years that might have been unrelated or disproportionate to the operating performance of individual companies. These broad market and industry factors might seriously harm the market price of our Common Stock, regardless of our operating performance. Securities class action litigation has often been instituted against companies following periods of volatility in the overall market and in the market price of a company’s securities. This litigation, if instituted against us, could result in very substantial costs, divert our management’s attention and resources and harm our business, operating results and financial condition.
 
We have never paid dividends and do not intend to pay cash dividends.
 
We have never paid dividends on our Common Stock and currently do not anticipate paying cash dividends on our Common Stock for the foreseeable future. Consequently, any returns on an investment in our Common Stock in the foreseeable future will have to come from an increase in the value of the stock itself. As noted above, the lack of an active trading market for our Common Stock will make it difficult to value and sell our Common Stock. While our dividend policy will be based on the operating results and capital needs of our business, it is anticipated that all earnings, if any, will be retained to finance our future operations.
 
Because we are subject to the “penny stock” rules, you may have difficulty in selling our Common Stock.
 
Our Common Stock is subject to regulations of the SEC relating to the market for penny stocks. Penny stock, as defined by the Penny Stock Reform Act, is any equity security not traded on a national securities exchange that has a market price of less than $5.00 per share. The penny stock regulations generally require that a disclosure schedule explaining the penny stock market and the risks associated therewith be delivered to purchasers of penny stocks and impose various sales practice requirements on broker-dealers who sell penny stocks to persons other than established customers and accredited investors. The broker-dealer must make a suitability determination for each purchaser and receive the purchaser’s written agreement prior to the sale. In addition, the broker-dealer must make certain mandated disclosures, including the actual sale or purchase price and actual bid offer quotations, as well as the compensation to be received by the broker-dealer and certain associated persons. The regulations applicable to penny stocks may severely affect the market liquidity for your Common Stock and could limit your ability to sell your securities in the secondary market.
 
Several provisions of the Delaware General Corporation Law, our fourth amended and restated certificate of incorporation, as amended, and our second amended and restated bylaws could discourage, delay or prevent a merger or acquisition, which could adversely affect the market price of our Common Stock.
 
Several provisions of the Delaware General Corporation Law, our fourth amended and restated certificate of incorporation, as amended, and our second amended and restated bylaws could discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, and the market price of our Common Stock could be reduced as a result. These provisions include:
 
· authorizing our board of directors to issue “blank check” preferred stock without stockholder approval;
   
· providing for a classified board of directors with staggered, three-year terms;
   
· prohibiting us from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder unless certain provisions are met;
 
 
20

 
· prohibiting cumulative voting in the election of directors;
   
· limiting the persons who may call special meetings of stockholders; and
   
· establishing advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings.
 
As a smaller reporting company with little or no name recognition and with several risks and uncertainties that could impair our business operations, we are not likely to generate widespread interest in our Common Stock. Without widespread interest in our Common Stock, our Common Stock price may be highly volatile and an investment in our Common Stock could decline in value.
 
Unlike many companies with publicly traded securities, we have little or no name recognition in the investment community. We are a relatively new company and very few investors are familiar with either our company or our products. We do not have an active trading market in our Common Stock, and one might never develop, or if it does develop, might not continue.
 
Additionally, the market price of our Common Stock may fluctuate significantly in response to many factors, many of which are beyond our control. Risks and uncertainties, including those described elsewhere in this “Risk Factors” section could impair our business operations or otherwise cause our operating results or prospects to be below expectations of investors and market analysts, which could adversely affect the market price of our Common Stock. As a result, investors in our Common Stock may not be able to resell their shares at or above their purchase price and could lose all of their investment.
 
Securities class action litigation is often brought against public companies following periods of volatility in the market price of such company’s securities. We may become subject to this type of litigation in the future. Litigation of this type could be extremely expensive and divert management’s attention and resources from running our company.
 
If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results, which could have a material adverse effect on our business, financial condition and the market value of our securities.
 
Effective internal controls over financial reporting are necessary for us to provide reliable financial reports. If we cannot provide reliable financial reports, our reputation and operating results may be harmed.
If management is unable to express a favorable opinion on the effectiveness of our internal controls, we could lose investor confidence in the accuracy and completeness of our financial reports. Any failure to achieve and maintain effective internal controls could have an adverse effect on our business, financial position and results of operations.
 
Our directors, executive officers and Lambda Investors LLC control a significant portion of our stock and, if they choose to vote together, could have sufficient voting power to control the vote on substantially all corporate matters.
 
As of March 21, 2014, our directors, executive officers and Lambda Investors LLC, our largest stockholder, beneficially owned approximately 48% of our outstanding Common Stock, representing approximately 60% on a fully-diluted basis. As a result of this ownership, Lambda Investors has the ability to exert significant influence over our policies and affairs, including the election of directors. Lambda Investors, whether acting alone or acting with other stockholders, could have the power to elect all of our directors and to control the vote on substantially all other corporate matters without the approval of other stockholders. Furthermore, such concentration of voting power could enable Lambda Investors, whether acting alone or acting with other stockholders, to delay or prevent another party from taking control of our company even where such change of control transaction might be desirable to other stockholders. The interests of Lambda Investors in any matter put before the stockholders may differ from those of any other stockholder.
 
Future sales of our Common Stock could cause the market price of our Common Stock to decline.
 
The market price of our Common Stock could decline due to sales of a large number of shares in the market, including sales of shares by Lambda Investors or any other large stockholder, or the perception that such sales could occur. These sales could also make it more difficult or impossible for us to sell equity securities in the future at a time and price that we deem appropriate to raise funds through future offerings of Common Stock. Future sales of our Common Stock by stockholders could depress the market price of our Common Stock.
 
Shares eligible for future sale may adversely affect the market.
 
From time to time, certain of our stockholders may be eligible to sell all or some of their shares of Common Stock by means of ordinary brokerage transactions in the open market pursuant to Rule 144 promulgated under the Securities Act, subject to certain limitations. In general, pursuant to Rule 144, non-affiliate stockholders may sell freely after holding their shares for six months and affiliates may sell freely after holding their shares for one year, in each case, subject to current public information, notice and other requirements. Any substantial sales of our Common Stock pursuant to Rule 144 may have a material adverse effect on the market price of our Common Stock.
 
 
21

 
Item 2. Properties
 
Our U.S. facilities are located at 41 Grand Avenue, River Edge, New Jersey, 07661 and consist of approximately 4,688 square feet of space.  The term of the rental agreement is for one year commencing December 1, 2013 with a monthly cost of approximately $8,400. We use our facilities to house our corporate headquarters and research facilities.
 
Our facilities in Europe are currently located at A5 Clonlara Avenue, Baldonnell Business Park, Dublin, Ireland, and consist of approximately 500 square feet of space.  The lease agreement was entered into on July 1, 2010. The lease term is renewable for 6 month terms with a 2 month notice to discontinue, on a rolling basis.  Our monthly cost is 500 Euro (approximately $700).
 
We use our facilities to house our accounting, operations and customer service departments. We believe this space will be adequate to meet our needs. We do not own any real property for use in our operations or otherwise.
 
Item 3. Legal Proceedings
 
There are no currently pending legal proceedings and, as far as we are aware, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject.
 
Item 4. Mine Safety Disclosures
 
Not applicable.
 
 
22

 
PART II
 
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
 
Our common stock is quoted on the OTCQB Marketplace operated by the OTC Markets Group, Inc., or OTCQB, under the symbol “NEPH.” The following table sets forth the high and low bid and ask prices for our common stock as reported on the OTCQB for each quarter listed. All prices have been adjusted to reflect the effect of the reverse split effective March 11, 2011. Such over the counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
 
Quarter Ended
 
High
 
Low
 
March 31, 2012
 
$
1.09
 
$
0.44
 
June 30, 2012
 
$
3.19
 
$
0.80
 
September 30, 2012
 
$
1.98
 
$
1.15
 
December 31, 2012
 
$
1.40
 
$
1.02
 
March 31, 2013
 
$
1.49
 
$
0.73
 
June 30, 2013
 
$
1.25
 
$
0.63
 
September 30, 2013
 
$
1.71
 
$
0.85
 
December 31, 2013
 
$
1.25
 
$
0.31
 
 
As of March 20, 2014, there were approximately 20 holders of record and approximately 1,000 beneficial holders of our common stock.
 
We have neither paid nor declared dividends on our common stock since our inception. We do not anticipate paying any dividends on our common stock in the foreseeable future. We expect to retain future earnings, if any, for use in our development activities and the operation of our business. The payment of any future dividends will be subject to the discretion of our board of directors and will depend, among other things, upon our results of operations, financial condition, cash requirements, prospects and other factors that our board of directors may deem relevant. Additionally, our ability to pay future dividends may be restricted by the terms of any debt financing, tax considerations and applicable law.
 
Recent Sales of Unregistered Securities
 
Except as previously reported in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K, we have not sold any equity security during the three years ended December 31, 2013 which was not registered under the Securities Act of 1933, as amended.
 
 Issuer Repurchases of Equity Securities
 
There were no repurchases of our common stock during the fourth quarter of 2013.
 
Item 6. Selected Financial Data
 
Not required.
 
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
The following discussion includes forward-looking statements about our business, financial condition and results of operations, including discussions about management’s expectations for our business. These statements represent projections, beliefs and expectations based on current circumstances and conditions and in light of recent events and trends, and you should not construe these statements either as assurances of performances or as promises of a given course of action. Instead, various known and unknown factors are likely to cause our actual performance and management’s actions to vary, and the results of these variances may be both material and adverse. A list of the known material factors that may cause our results to vary, or may cause management to deviate from its current plans and expectations, is included in Item 1A “Risk Factors.” The following discussion should also be read in conjunction with the consolidated financial statements and notes included herein.
 
 
23

 
Going Concern
 
Our independent registered public accounting firm has included an explanatory paragraph in their report on our financial statements included in this Form 10-K which expressed doubt as to our ability to continue as a going concern. The accompanying financial statements have been prepared assuming that we will continue as a going concern. However, there can be no assurance that we will be able to do so. Our recurring losses and difficulty in generating sufficient cash flow to meet our obligations and sustain our operations raise substantial doubt about our ability to continue as a going concern, and our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
Business Overview
 
Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. Our filters, which we call ultrafilters, are primarily used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and/or blood. Because our ultrafilters capture contaminants as small as 0.005 microns in size, they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins.
 
Our ultrafilters use proprietary hollow fiber technology. We believe the hollow fiber design allows our ultrafilters to optimize the three elements critical to filter performance:
 
• Filtration - as low as 0.005 microns
• Flow rate - minimal disruption
• Filter life - up to 12 months
 
We were founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize an alternative method to hemodialysis (HD). We have extended our filtration technologies to meet the demand for liquid purification in other areas, in particular water purification.
 
The following trends, events and uncertainties may have a material impact on our potential sales, revenue and income from operations:
 
· the market acceptance of our products in the United States and of our technologies and products in each of our target markets;
· our ability to effectively and efficiently manufacture, market and distribute our products;
· our ability to sell our products at competitive prices which exceed our per unit costs;
· the consolidation of dialysis clinics into larger clinical groups; and
· the current U.S. healthcare plan is to bundle reimbursement for dialysis treatment which may force dialysis clinics to change therapies due to financial reasons.
 
To the extent we are unable to succeed in accomplishing the foregoing, our sales could be lower than expected and dramatically impair our ability to generate income from operations.
 
Recently Adopted Accounting Pronouncements
 
There are no recent accounting pronouncements that are expected to have an effect on our consolidated financial statements set forth in Item 8 of this Annual Report on Form 10-K.
 
 
24

 
Critical Accounting Policies and Estimates
 
Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires application of management’s subjective judgments, often requiring the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Our actual results may differ substantially from these estimates under different assumptions or conditions. While our significant accounting policies are described in more detail in the notes to consolidated financial statements included in this Annual Report on Form 10-K for the year ended December 31, 2013, we believe that the following accounting policies require the application of significant judgments and estimates.
 
Revenue Recognition
 
Revenue is recognized in accordance with Accounting Standards Codification ("ASC") Topic 605. Four basic criteria must be met before revenue can be recognized: (i) persuasive evidence that an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.
 
We recognize revenue related to product sales when delivery is confirmed by our external logistics provider and the other criteria of ASC Topic 605 are met. Product revenue is recorded net of returns and allowances. All costs and duties relating to delivery are absorbed by us. Shipments for all products are currently received directly by our customers.
 
We recognize the fixed license revenue under the Bellco license agreement on a straight line basis over the forty-two month expected obligation period which ends on December 31, 2014. Any difference between payments received and recognized revenue is reported as deferred revenue.
 
Deferred revenue on the accompanying December 31, 2013 consolidated balance sheet is approximately $703,000 and is related to the Bellco license agreement. We have recognized approximately $1,756,000 of revenue related to this license agreement to date and approximately $711,000 for the twelve months ended December 31, 2013, resulting in $703,000 being deferred over the remainder of the expected obligation period. We amortize the deferred revenue monthly over the expected obligation period which ends on December 31, 2014. This will result in expected recognized revenue of approximately $703,000 in the year ended December 31, 2014.
 
 Stock-Based Compensation
 
We account for stock-based compensation in accordance with ASC 718 by recognizing the fair value of stock-based compensation in net income. The fair value of our stock option awards are estimated using a Black-Scholes option valuation model. This model requires the input of highly subjective assumptions and elections including expected stock price volatility and the estimated life of each award. In addition, the calculation of compensation costs requires that we estimate the number of awards that will be forfeited during the vesting period. The fair value of stock-based awards is amortized over the vesting period of the award. For stock awards that vest based on performance conditions (e.g. achievement of certain milestones), expense is recognized when it is probable that the condition will be met.
 
Accounts Receivable
 
We provide credit terms to our customers in connection with purchases of our products. We periodically review customer account activity in order to assess the adequacy of the allowances provided for potential collection issues and returns. Factors considered include economic conditions, each customer’s payment and return history and credit worthiness. Adjustments, if any, are made to reserve balances following the completion of these reviews to reflect our best estimate of potential losses.
 
Inventory Reserves
 
Our inventory reserve requirements are based on factors including the products’ expiration date and estimates for the future sales of the product. If estimated sales levels do not materialize, we will make adjustments to our assumptions for inventory reserve requirements.
 
 
25

 
Accrued Expenses
 
We are required to estimate accrued expenses as part of our process of preparing financial statements. This process involves identifying services which have been performed on our behalf, and the level of service performed and the associated cost incurred for such service as of each balance sheet date in our consolidated financial statements. Examples of areas in which subjective judgments may be required include costs associated with services provided by contract organizations for the preclinical development of our products, the manufacturing of clinical materials, and clinical trials, as well as legal and accounting services provided by professional organizations. In connection with such service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual levels of services incurred by such service providers. The majority of our service providers invoice us monthly in arrears for services performed. In the event that we do not identify certain costs, which have begun to be incurred, or we under- or over-estimate the level of services performed or the costs of such services, our reported expenses for such period would be too low or too high. The date on which certain services commence, the level of services performed on or before a given date and the cost of such services are often determined based on subjective judgments. We make these judgments based upon the facts and circumstances known to us in accordance with generally accepted accounting principles.
 
Results of Operations
 
Fluctuations in Operating Results
 
Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our annual results of operations will be impacted for the foreseeable future by several factors including the progress and timing of expenditures related to our research and development efforts, marketing expenses related to product launches, timing of regulatory approval of our various products and market acceptance of our products. Due to these fluctuations, we believe that the period to period comparisons of our operating results are not a good indication of our future performance.
 
The Fiscal Year Ended December 31, 2013 Compared to the Fiscal Year Ended December 31, 2012
 
Revenues
 
Total revenues for the year ended December 31, 2013 were approximately $1,740,000 compared to approximately $1,807,000 for the year ended December 31, 2012.  Total revenues decreased approximately $67,000, or 4%, as a result of decreases of approximately $117,000 related to the Office of Naval Research, whose contract ended as of March 2012, and approximately $216,000 related to the sales credits recorded to reflect the impact of a voluntary product recall of point of use filters (POU) announced on October 30, 2013. These decreases were partially offset by an increase of approximately $31,000 related to the Bellco license agreement as well as underlying increases in total water filter sales.  Total water filter sales increased by 23% from $1,005,000 in 2012 to $1,240,000 in 2013 reflecting growth in key business segments of dialysis water and hospital water.  Dialysis water and hospital water sales increased by approximately 66% and 25%, respectively.  These increases were partially offset by decreases in military water sales of approximately 83%.
 
Revenues were not significantly impacted by inflation or changing prices for the years ended December 31, 2013 or 2012.
 
Cost of Goods Sold
 
Cost of goods sold was approximately $898,000 for the year ended December 31, 2013 compared to approximately $737,000 for the year ended December 31, 2012. The increase of approximately $161,000, or 22%, in cost of goods sold was related to the increase in inventory reserves of approximately $210,000, $203,000 of which is a result of the October 2013 voluntary product recall and an increase in cost of goods sold of approximately $119,000 related to increased sales of water filters in key business segments during the year ended December 31, 2013. The increases were partially offset by a decrease in sales related to the Office of Naval Research combined with the impact of a voluntary product recall of point of use filters (POU) of approximately $168,000. 
 
Research and Development
 
Research and development expenses were approximately $826,000 and $632,000, respectively, for the years ended December 31, 2013 and December 31, 2012. This increase of approximately $194,000, or 31%, is primarily due to an increase in research and development material and other project costs primarily related to our OLpūr H2H Module of approximately $104,000 and an increase in personnel related costs of approximately $88,000 during the year ended December 31, 2013 compared to the year ended December 31, 2012.
 
Depreciation and Amortization Expense
 
Depreciation and amortization expense was approximately $223,000 for the year ended December 31, 2013 compared to approximately $151,000 for the year ended December 31, 2012, representing an increase of 48%. The increase of approximately $72,000 is due to amortization related to the asset recognized in conjunction with the License and Supply Agreement that began in the second quarter of the year ended December 31, 2012.
 
 
26

 
Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were approximately $3,110,000 for the year ended December 31, 2013 compared to approximately $3,620,000 for the year ended December 31, 2012, representing a decrease of $510,000 or 14%. The decrease is primarily due to a decrease in legal and professional services expenses.  In the twelve months ended December 31, 2013, approximately $229,000 of legal and professional services expenses were recorded in equity as a result of the May 2013 rights offering and approximately $204,000 were recorded as amortization of debt discount as they were fees paid in relation to the February 2013 Senior Secured Note.  In addition, travel and other expenses decreased approximately $130,000 during the year ended December 31, 2013 compared to the year ended December 30, 2012.  These decreases were partially offset by an increase in personnel related expenses of approximately $53,000, primarily a result of increased expenses related to bonus and stock-based compensation expense. 
 
Interest Income
 
There was no interest income recognized for the year ended December 31, 2013 compared to approximately $2,000 for the year ended December 31, 2012. The decrease reflects the impact of having less cash on hand during the year ended December 31, 2013 compared to the year ended December 31, 2012.
 
Interest Expense
 
Interest expense for the year ended December 31, 2013 was $94,000.  There was no interest expense recognized for the year ended December 31, 2012. Interest expense for the year ended December 31, 2013 primarily relates to interest on the February 2013 Senior Secured Note and November 2013 Senior Secured Note each issued to Lambda Investors LLC of approximately $71,000 and interest of approximately $21,000 related to outstanding payables due to a vendor.
 
Amortization of Debt Discount
 
The Company accounts for debt issuance costs in accordance with ASC 835, which requires that costs paid directly to the issuer of the notes be reported in the balance sheet as a debt discount and amortized over the term of the associated debt. Amortization of debt discounts of approximately $257,000 for the year ended December 31, 2013, was due to fees paid to Lambda Investors LLC of approximately $204,000 and approximately $53,000 as a result of the issuance of the February 2013 Senior Secured Note and the November 2013 Senior Secured Note, respectively.
 
Other Income/Expense
 
Other income (expense), net, of approximately $33,000 includes approximately $50,000 of other expense for the year ended December 31, 2013, primarily due to approximately $36,000 related to foreign currency losses and approximately $14,000 related to the May 2013 rights offering warrant modification.  Other expense was partially offset by other income of approximately $17,000, which consisted primarily of a refund of approximately $15,000 received as a result of the Steris agreement termination. 
 
Other expense in the amount of approximately $14,000 for the year ended December 31, 2012 was primarily the result of approximately $18,000 related to the write-offs of vendor invoices which are no longer due. Other expense was partially offset by $4,000 related to foreign currency losses on invoices paid to an international supplier.
 
Off-Balance Sheet Arrangements
 
We did not engage in any off-balance sheet arrangements during the years ended December 31, 2013 and 2012.
 
Liquidity and Capital Resources
 
Our future liquidity sources and requirements will depend on many factors, including:
 
· the availability of additional financing, through the sale of equity securities or otherwise, on commercially reasonable terms or at all;
 
· the costs involved in connection with the voluntary recalls of our point of use and DSU in-line ultrafilters used in hospital water treatment applications announced on October 30, 2013 and the related circumstances;
 
· the market acceptance of our products, and our ability to effectively and efficiently produce and market our products;
 
 
27

 
· the continued progress in, and the costs of, clinical studies and other research and development programs;
 
· the costs involved in filing and enforcing patent claims and the status of competitive products; and
 
· the cost of litigation, including potential patent litigation and any other actual or threatened litigation.
 
 We expect to put our current capital resources to the following uses:
 
·      for the marketing and sales of our water-filtration products;
 
·      to pursue business development opportunities with respect to our chronic renal treatment system; and
 
·      for working capital purposes.
 
In response to liquidity issues experienced with our auction rate securities, and in order to facilitate greater liquidity in our short-term investments, on March 27, 2008, our board of directors adopted an Investment, Risk Management and Accounting Policy. Such policy limits the types of instruments or securities in which we may invest our excess funds in the future to: U.S. Treasury Securities; Certificates of Deposit issued by money center banks; Money Funds by money center banks; Repurchase Agreements; and Eurodollar Certificates of Deposit issued by money center banks. This policy provides that our primary objectives for investments shall be the preservation of principal and achieving sufficient liquidity to meet our forecasted cash requirements. In addition, provided that such primary objectives are met, we may seek to achieve the maximum yield available under such constraints.
 
At December 31, 2013, we had an accumulated deficit of approximately $101,228,000, and we expect to incur additional losses in the foreseeable future at least until such time, if ever, that we are able to increase product sales or licensing revenue.
 
On February 19, 2014, the Company entered into the First Amendment to License Agreement (the “First Amendment”), by and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011 by and between the Company and Bellco.  Pursuant to the First Amendment, the Company and Bellco agreed to extend the term of the License Agreement through December 31, 2021. The First Amendment also expands the Territory covered by the License Agreement to include Sweden, Denmark, Norway, Finland, Korea, Mexico, Brazil, China and the Netherlands. The First Amendment further provides new minimum sales targets which, if not satisfied, will, at the discretion of the Company, result in conversion of the license to non-exclusive status. The Company has agreed to reduce the fixed royalty payment payable to the Company for the period beginning on January 1, 2015 through and including December 31, 2021. Beginning on January 1, 2015 through and including December 31, 2016, Bellco will pay us a royalty based on the number of units of Products sold per year in the Territory as follows: for the first 125,000 units sold,  €1.75 per unit; thereafter, €1.25 per unit.  In addition, the Company will receive a total of €450,000 in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. In addition, the First Amendment provides that, in the event that the Company pursues a transaction to sell, assign or transfer all right, title and interest to the licensed patents to a third party, the Company will provide Bellco with written notice thereof and a right of first offer with respect to the contemplated transaction for a period of thirty (30) days.  Anticipated payments from this License Agreement will be a positive source of cash flow to us.
 
On April 23, 2012, we entered into a License and Supply Agreement (the “License and Supply Agreement”) with Medica, an Italy-based medical product manufacturing company, for the marketing and sale of certain filtration products based upon Medica’s proprietary Medisulfone ultrafiltration technology in conjunction with our filtration products (collectively, the “Filtration Products”), and to engage in an exclusive supply arrangement for the Filtration Products. Under the License and Supply Agreement, Medica granted to us an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale and sell the Filtration Products worldwide, excluding Italy for the first three years, during the term of the License and Supply Agreement. In addition, we granted to Medica an exclusive license under our intellectual property to make the Filtration Products during the term of the License and Supply Agreement. In exchange for the rights granted, we have agreed to make minimum annual aggregate purchases from Medica of €300,000, €500,000 and €750,000 for the years 2012, 2013 and 2014, respectively. In the year ended December 31, 2013, our aggregate purchase commitments totaled approximately €532,000. For calendar years thereafter, annual minimum amounts will be mutually agreed upon between Medica and us. In exchange for the license, we paid Medica €1,500,000 in three installments: €500,000 on April 23, 2012, €600,000 on February 4, 2013, and €400,000 on May 23, 2013. As part of the agreement, we have granted to Medica 300,000 options to purchase our common stock which will vest over the first three years of the agreement.  As of September 2013, we have an understanding with Medica whereby we have agreed to pay interest to Medica at a 12% annual rate calculated on the principal amount of any outstanding invoices that are not paid pursuant to the original payment terms.
 
As of the date of this Annual Report, we expect that the proceeds from the March 2014 rights offering and the First Amendment with Bellco will allow us to fund our operations into the third quarter of fiscal year 2014.  This assumption excludes the impact of future cash receipts from operations.  Our cash flow currently is not, and historically has not been, sufficient to meet our obligations and commitments. We must seek and obtain additional financing to fund our operations. If we cannot raise sufficient capital, in connection with offerings of our common stock or through other means, we will be forced to curtail our planned activities and operations or cease operations entirely and you will lose all of your investment in our Company. There can be no assurance that we could raise sufficient capital on a timely basis or on satisfactory terms or at all.
 
 
28

 
Net cash used in operating activities was approximately $3,583,000 for the year ended December 31, 2013 compared to approximately $1,547,000 for the year ended December 31, 2012. The most significant items contributing to this net increase of approximately $2,036,000 in cash used in operating activities during the year ended December 31, 2013 compared to the year ended December 31, 2012 are highlighted below:
 
· during 2013, our net loss increased by approximately $436,000 compared to 2012;
 
· during 2013, our accounts receivable decreased by approximately $820,000 compared to a decrease of approximately $1,006,000 during 2012;
 
· during 2013, our deferred revenue decreased by approximately $711,000 compared to an increase of approximately $680,000 during 2012; and
 
· during 2013, our accounts payable and accrued expenses increased by approximately $59,000 in the aggregate compared to an increase of approximately $904,000 during 2012;
 
· during 2013, license and supply fee payable decreased by $1,318,000;
 
Offsetting the above changes are the following items:
 
· during 2013, depreciation and amortization expense increased by approximately $72,000 compared to 2012;
 
· during 2013, we recorded amortization of debt issuance costs of $257,000, whereas amortization of debt issuance costs in 2012 were $0;
 
· during 2013, we recorded noncash interest expense of approximately $39,000, whereas noncash interest expense in 2012 was $0;
 
· during 2013, our stock-based compensation expense, a non-cash expense, increased by approximately $132,000 compared to 2012;
 
· during 2013, we recorded an inventory reserve of  approximately $210,000 compared to $82,000 in 2012;
 
· during 2013, we recognized a gain on the sale of property and equipment of approximately $3,000 compared to a gain of approximately $55,000 in 2012 ;
 
· during 2013, our inventory increased by approximately $60,000 compared to an increase of approximately $147,000 during 2012;
 
Net cash provided by investing activities for the year ended December 31, 2013 was approximately $3,000 related to the sale of fully depreciated manufacturing equipment.  Net cash used in investing activities for the year ended December 31, 2012 was $612,000 related to approximately $659,000 for the purchase of intangible assets associated with the Medica License and Supply Agreement and approximately $8,000 used for the purchase of equipment.  Cash used in investing activities for the year ended December 31, 2012 was partially offset by proceeds received of approximately $55,000 related to the sale of property and equipment.
 
Net cash provided by financing activities for the year ended December 31, 2013 of $4,120,000, net of equity issuance costs of approximately $229,000, resulted primarily from gross proceeds of $3.0 million related to the issuance of common stock related to the May 2013 rights offering, proceeds from the issuance of the February 2013 Senior Secured Note and the November 2013 Senior Secured Note of $2.8 million and approximately $248,000 of proceeds resulting from the exercise of warrants. Net cash provided by financing activities was partially offset by the repayment of the $1.3 million February 2013 Senior Secured Note and payment of financing costs of $399,000.  Net cash provided by financing activities was approximately $503,000 for the year ended December 31, 2012 as a result of the exercise of warrants.
 
 
29

 
Contractual Obligations and Commercial Commitments
 
The following tables summarize our approximate minimum contractual obligations and commercial commitments as of December 31, 2013:
 
 
 
 
 
Payments Due in Period
 
 
 
Total
 
 
Within
1 Year
 
 
Years
1 - 3
 
 
Years
4 - 5
 
 
More than
5 Years
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Leases
 
$
108,000
 
 
$
100,000
 
 
$
8,000
 
 
$
-
 
 
$
-
 
Employment Contracts
 
 
788,000
 
 
 
350,000
 
 
 
438,000
 
 
 
-
 
 
 
-
 
Total
 
$
896,000
 
 
$
450,000
 
 
$
446,000
 
 
$
-
 
 
$
-
 
 
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
 
Not required.
 
 
30

 
Item 8. Financial Statements
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
To the Board of Directors and Stockholders of
Nephros, Inc.
 
We have audited the accompanying consolidated balance sheets of Nephros, Inc. and Subsidiary (collectively, “the Company”) as of December 31, 2013 and 2012, and the related consolidated statements of operations, changes in stockholders’ equity (deficit) and cash flows in the two year period ended December 31, 2013. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
 
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
 
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Nephros, Inc. and Subsidiary as of December 31, 2013 and 2012, and the results of their operations and their cash flows in the two year period ended December 31, 2013, in conformity with accounting principles generally accepted in the United States of America.
 
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred negative cash flow from operations and net losses since inception. These conditions, among others, raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
/s/ Rothstein Kass
 
Roseland, New Jersey
March 27, 2014
 
 
31

 
     
NEPHROS, INC. AND SUBSIDIARY
 
CONSOLIDATED BALANCE SHEETS
 
(In Thousands, Except Share Amounts)
 
 
 
December 31, 2013
 
 
December 31, 2012
 
ASSETS
 
 
 
 
 
 
 
 
Current assets:
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
579
 
 
$
47
 
Accounts receivable
 
 
122
 
 
 
935
 
Inventory, less allowances of $365 at December 31, 2013 and $269 at December 31, 2012
 
 
162
 
 
 
312
 
Prepaid expenses and other current assets
 
 
125
 
 
 
109
 
Total current assets
 
 
988
 
 
 
1,403
 
Property and equipment, net
 
 
7
 
 
 
16
 
Other assets, net of accumulated amortization
 
 
1,894
 
 
 
2,109
 
Total assets
 
$
2,889
 
 
$
3,528
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
 
 
Senior secured note payable, net of debt discount of $142
 
$
1,358
 
 
$
-
 
Accounts payable
 
 
1,073
 
 
 
1,070
 
License and supply agreement fee payable
 
 
-
 
 
 
1,318
 
Accrued expenses
 
 
365
 
 
 
321
 
Deferred revenue, current portion
 
 
703
 
 
 
707
 
Total current liabilities
 
 
3,499
 
 
 
3,416
 
Long-term portion of deferred revenue
 
 
-
 
 
 
707
 
Total liabilities
 
 
3,499
 
 
 
4,123
 
 
 
 
 
 
 
 
 
 
Commitments and Contingencies (Note 12)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stockholders’ deficit:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preferred stock, $.001 par value; 5,000,000 shares authorized at December 31, 2013 and 2012; no shares issued and outstanding at December 31, 2013 and 2012.
 
 
-
 
 
 
-
 
Common stock, $.001 par value; 90,000,000 shares authorized at December 31, 2013 and 2012; 18,082,043 and 11,949,824 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively.
 
 
18
 
 
 
12
 
Additional paid-in capital
 
 
100,526
 
 
 
96,847
 
Accumulated other comprehensive income
 
 
74
 
 
 
76
 
Accumulated deficit
 
 
(101,228)
 
 
 
(97,530)
 
Total stockholders’ deficit
 
 
(610)
 
 
 
(595)
 
Total liabilities and stockholders’ deficit
 
$
2,889
 
 
$
3,528
 
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
32

 
NEPHROS, INC. AND SUBSIDIARY
 
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
 
(In Thousands, Except Share and Per Share Amounts)
 
 
 
Years Ended December 31,
 
 
 
2013
 
 
2012
 
Net revenue:
 
 
 
 
 
 
 
 
Product revenues
 
$
1,029
 
 
$
1,127
 
Licensing revenues
 
 
711
 
 
 
680
 
Total net revenues
 
 
1,740
 
 
 
1,807
 
 
 
 
 
 
 
 
 
 
Cost of goods sold
 
 
898
 
 
 
737
 
Gross margin
 
 
842
 
 
 
1,070
 
Operating expenses:
 
 
 
 
 
 
 
 
Research and development
 
 
826
 
 
 
632
 
Depreciation and amortization
 
 
223
 
 
 
151
 
Selling, general and administrative
 
 
3,110
 
 
 
3,620
 
Total operating expenses
 
 
4,159
 
 
 
4,403
 
Loss from operations
 
 
(3,317)
 
 
 
(3,333)
 
Interest income
 
 
-
 
 
 
2
 
Interest expense
 
 
(94)
 
 
 
-
 
Gain on sale of equipment
 
 
3
 
 
 
55
 
Amortization of debt discount
 
 
(257)
 
 
 
-
 
Other income (expense)
 
 
(33)
 
 
 
14
 
Net loss
 
 
(3,698)
 
 
 
(3,262)
 
Other comprehensive income, foreign currency translation adjustments
 
 
(2)
 
 
 
27
 
Total comprehensive loss
 
 
(3,700)
 
 
 
(3,235)
 
Net loss per common share, basic and diluted
 
$
(0.24)
 
 
$
(0.29)
 
Weighted average common shares outstanding, basic and diluted
 
 
15,624,999
 
 
 
11,223,878
 
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
33

 
   
NEPHROS, INC. AND SUBSIDIARY
 
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
 
(In Thousands, Except Share Amounts)
 
 
 
Common Stock
 
 
Additional
Paid-in
 
 
Accumulated
Other
Comprehensive
 
 
Accumulated
 
 
 
 
 
 
 
Shares
 
 
Amount
 
 
Capital
 
 
Income
 
 
Deficit
 
 
Total
 
Balance, December 31, 2011
 
 
10,501,477
 
 
$
10
 
 
$
95,630
 
 
$
49
 
 
$
(94,268)
 
 
$
1,421
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comprehensive income:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(3,262)
 
 
 
(3,262)
 
Net unrealized gains on foreign currency translation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27
 
 
 
 
 
 
 
27
 
Comprehensive loss
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(3,235)
 
Exercise of warrants
 
 
1,448,347
 
 
 
2
 
 
 
501
 
 
 
 
 
 
 
 
 
 
 
503
 
Noncash stock-based compensation
 
 
 
 
 
 
 
 
 
 
443
 
 
 
 
 
 
 
 
 
 
 
443
 
Issuance of stock options related to licensing agreement
 
 
 
 
 
 
 
 
 
 
273
 
 
 
 
 
 
 
 
 
 
 
273
 
Balance, December 31, 2012
 
 
11,949,824
 
 
$
12
 
 
$
96,847
 
 
$
76
 
 
$
(97,530)
 
 
$
(595)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comprehensive income:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(3,698)
 
 
 
(3,698)
 
Net unrealized losses on foreign currency translation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(2)
 
 
 
 
 
 
 
(2)
 
Comprehensive loss
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(3,700)
 
Shareholder rights offering, net
 
 
5,000,000
 
 
 
5
 
 
 
2,766
 
 
 
 
 
 
 
 
 
 
 
2,771
 
Issuance of restricted stock
 
 
340,220
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-
 
Exercise of warrants
 
 
791,999
 
 
 
1
 
 
 
247
 
 
 
 
 
 
 
 
 
 
 
248
 
Noncash stock-based compensation
 
 
 
 
 
 
 
 
 
 
652
 
 
 
 
 
 
 
 
 
 
 
652
 
Warrant modification
 
 
 
 
 
 
 
 
 
 
14
 
 
 
 
 
 
 
 
 
 
 
14
 
Balance, December 31, 2013
 
 
18,082,043
 
 
$
18
 
 
$
100,526
 
 
$
74
 
 
$
(101,228)
 
 
$
(610)
 
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
34

 
   
NEPHROS, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
 
 
 
Years Ended December 31,
 
 
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Operating activities
 
 
 
 
 
 
 
Net loss
 
$
(3,698)
 
$
(3,262)
 
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
 
 
 
 
Depreciation of property and equipment
 
 
9
 
 
9
 
Amortization of other assets
 
 
214
 
 
142
 
Non-cash stock-based compensation, including stock options and restricted stock
 
 
575
 
 
443
 
Warrant inducement
 
 
14
 
 
-
 
Inventory reserve
 
 
210
 
 
82
 
Amortization of debt discount
 
 
257
 
 
-
 
Noncash interest
 
 
39
 
 
-
 
Gain on disposal of property and equipment
 
 
(3)
 
 
(55)
 
Loss on foreign currency transactions
 
 
26
 
 
7
 
(Increase) decrease in operating assets:
 
 
 
 
 
 
 
Accounts receivable
 
 
820
 
 
1,006
 
Inventory
 
 
(60)
 
 
(147)
 
Prepaid expenses and other current assets
 
 
(16)
 
 
4
 
Long-term receivable
 
 
 
 
 
-
 
Increase (decrease) in operating liabilities:
 
 
 
 
 
 
 
Accounts payable and accrued expenses
 
 
59
 
 
904
 
License and supply agreement fee payable
 
 
(1,318)
 
 
-
 
Deferred revenue
 
 
(711)
 
 
(680)
 
Net cash used in operating activities
 
 
(3,583)
 
 
(1,547)
 
 
 
 
 
 
 
 
 
Investing activities
 
 
 
 
 
 
 
Purchase of property and equipment
 
 
-
 
 
(8)
 
Purchase of intangible assets
 
 
-
 
 
(659)
 
Proceeds from sales of property and equipment
 
 
3
 
 
55
 
Net cash provided by (used in) investing activities
 
 
3
 
 
(612)
 
 
 
 
 
 
 
 
 
Financing activities
 
 
 
 
 
 
 
Proceeds from issuance of common stock, net of equity issuance costs of $229
 
 
2,771
 
 
-
 
Proceeds from issuance of Senior Secured Notes
 
 
2,800
 
 
 
 
Payment of financing costs
 
 
(399)
 
 
-
 
Proceeds from exercise of warrants
 
 
248
 
 
503
 
Payment of Senior Secured Note
 
 
(1,300)
 
 
-
 
Net cash provided by financing activities
 
 
4,120
 
 
503
 
Effect of exchange rates on cash and cash equivalents
 
 
(8)
 
 
34
 
Net increase (decrease) in cash and cash equivalents
 
 
532
 
 
(1,622)
 
Cash and cash equivalents, beginning of year
 
 
47
 
 
1,669
 
Cash and cash equivalents, end of year
 
$
579
 
$
47
 
 
 
 
 
 
 
 
 
Supplemental disclosure of cash flow information
 
 
 
 
 
 
 
Cash paid for taxes
 
$
2
 
$
18
 
Restricted stock issued to settle liability
 
$
77
 
$
-
 
Payable related to license and supply agreement
 
$
-
 
$
1,318
 
Receivable related to license agreement
 
$
-
 
$
791
 
Fair value of stock options granted to Medica
 
$
-
 
$
273
 
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
35

 
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 1 - Organization and Nature of Operations
 
Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. Nephros was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced End Stage Renal Disease (“ESRD”) therapy technology and products. The Company has two products in various stages of development in the hemodiafiltration, or HDF, modality to deliver improved therapy for ESRD patients. These are the OLpur MDHDF filter series or “dialyzers,” designed expressly for HDF therapy, the OLpur H2H, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy. In 2009, the Company introduced its Dual Stage Ultrafilter (“DSU”) water filter system, which represents a new and complementary product line to the Company’s existing ESRD therapy business. The DSU incorporates the Company’s unique and proprietary dual stage filter architecture.

On June 4, 2003, Nephros International Limited was incorporated under the laws of Ireland as a wholly-owned subsidiary of the Company.  In August 2003, the Company established a European Customer Service and financial operations center in Dublin, Ireland.

Note 2 - Summary of Significant Accounting Policies
  
Principles of Consolidation and Basis of Presentation
 
The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nephros International Limited.  All intercompany accounts and transactions have been eliminated in consolidation.
 
These consolidated financial statements were approved by management and the Board of Directors and are available for issuance as of the date of the audit opinion.  Subsequent events have been evaluated through this date.
 
Use of Estimates in the Preparation of Financial Statements
 
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates.  Certain prior year amounts have been reclassified to conform to the current year presentation.
 
Going Concern and Management’s Response
 
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s recurring losses and difficulty in generating sufficient cash flow to meet its obligations and sustain its operations raise substantial doubt about its ability to continue as a going concern. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
The Company has incurred significant losses in operations in each quarter since inception. For the years ended December 31, 2013 and 2012, the Company has incurred net losses of $3,698,000 and $3,262,000, respectively. In addition, the Company has not generated positive cash flow from operations for the years ended December 31, 2013 and 2012. To become profitable, the Company must increase revenue substantially and achieve and maintain positive gross and operating margins. If the Company is not able to increase revenue and gross and operating margins sufficiently to achieve profitability, its results of operations and financial condition will be materially and adversely affected.
 
The voluntary recalls of point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications announced on October 30, 2013 and the related circumstances could subject the Company to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact the Company’s sales and revenues.
 
 
36

   
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 2 - Summary of Significant Accounting Policies (continued)
 
On June 27, 2011, the Company entered into a License Agreement,  effective July 1, 2011, with Bellco S.r.l., as licensee (“Bellco”), an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of Nephros’ patented mid-dilution dialysis filters.  This Agreement provided the Company with payments of €500,000, €750,000, and €600,000 on July 1, 2011, January 15, 2012 and January 15, 2013, respectively. On February 19, 2014, the Company entered into the First Amendment to License Agreement (the “First Amendment”), by and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011. As a result of the amendment, the Company will receive a total of €450,000 in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. See Note 12, Commitments and Contingencies for further discussion.  
 
On February 4, 2013 and November 12, 2013, the Company issued senior secured notes to Lambda Investors LLC in the principal amount of $1.3 million and $1.5 million, respectively. As of December 31, 2013, the $1.5 million note is outstanding. The $1.3 million note was repaid on May 22, 2013.  For a more detailed discussion of the terms of the senior secured notes, see Note 6, Senior Secured Notes.
 
On March 21, 2014 the Company completed a rights offering which resulted in gross proceeds of $2.1 million. See Note 14, Subsequent Events, for further discussion.
 
There can be no assurance that the Company’s future cash flow will be sufficient to meet its obligations and commitments. If the Company is unable to generate sufficient cash flow from operations in the future to service its commitments the Company will be required to adopt alternatives, such as seeking to raise debt or equity capital, curtailing its planned activities or ceasing its operations. There can be no assurance that any such actions could be effected on a timely basis or on satisfactory terms or at all, or that these actions would enable the Company to continue to satisfy its capital requirements.
 
Cash and Cash Equivalents
 
The Company invests its excess cash in bank deposits and money market accounts.  The Company considers all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash equivalents.  Cash equivalents are carried at fair value, which approximate cost, and primarily consist of money market funds maintained at major U.S. financial institutions.
 
Accounts Receivable
 
The Company provides credit terms to customers in connection with purchases of the Company’s products. Management periodically reviews customer account activity in order to assess the adequacy of the allowances provided for potential collection issues and returns. Factors considered include economic conditions, each customer’s payment and return history and credit worthiness. Adjustments, if any, are made to reserve balances following the completion of these reviews to reflect management’s best estimate of potential losses.  There were no allowances for doubtful accounts at December 31, 2013 or 2012.  There was no allowance for sales returns at December 31, 2013 or 2012.  There were no write offs of accounts receivable to bad debt expense during 2013 or 2012.
 
Inventory
 
The Company engages third parties to manufacture and package inventory held for sale, takes title to certain inventory once manufactured, and warehouses such goods until packaged for final distribution and sale. Inventory consists of finished goods and raw materials (fiber) held at the manufacturers’ facilities, and are valued at the lower of cost or market using the first-in, first-out method. The Company’s inventory reserve requirements are based on factors including the products’ expiration date and estimates for the future sales of the product. If estimated sales levels do not materialize, the Company will make adjustments to its assumptions for inventory reserve requirements.
 
  
37

 
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 2 - Summary of Significant Accounting Policies (continued)
 
In March 2014, the Company requested the closeout of its October 2013 voluntary product recall.  The Company has fully reserved the recalled product and will destroy the respective product by April 20, 2014.
 
Patents
 
The Company has filed numerous patent applications with the United States Patent and Trademark Office and in foreign countries. All costs and direct expenses incurred in connection with patent applications have been expensed as incurred.
 
Property and Equipment, net
 
Property and equipment, net is stated at cost less accumulated depreciation.  These assets are depreciated over their estimated useful lives of three to seven years using the straight line method.
 
Impairment for Long-Lived Assets
 
The Company adheres to Accounting Standards Codification (“ASC”) Topic 360 and periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. An estimate of the asset’s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its carrying value or its estimated net realizable market value. There were no impairment losses for long-lived assets recorded for the years ended December 31, 2013 and December 31, 2012.
 
Fair Value of Financial Instruments
 
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturity of these instruments.
 
Revenue Recognition
 
Revenue is recognized in accordance with ASC Topic 605.  Four basic criteria must be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.
 
The Company recognizes revenue related to product sales when delivery is confirmed by its external logistics provider and the other criteria of ASC Topic 605 are met. Product revenue is recorded net of returns and allowances.  All costs and duties relating to delivery are absorbed by Nephros. All shipments are currently received directly by the Company’s customers.
 
Deferred revenue was approximately $703,000 and $1,414,000 on the accompanying consolidated balance sheets as of December 31, 2013 and 2012, respectively, and is related to the License Agreement with Bellco. The Company has recognized approximately $1,756,000 of revenue related to this license agreement to date, including approximately $711,000 for the year ended December 31, 2013, resulting in $703,000 being deferred over the remainder of the expected obligation period. The Company amortizes the deferred revenue monthly over the expected obligation period which ends on December 31, 2014. This will result in expected recognized revenue of approximately $703,000 for each of the year ending December 31, 2014. Total payments of approximately  $2,459,000, including the  final payment of approximately $791,000  received in January 2013, were related to the License Agreement with Bellco.  
 
Shipping and Handling Costs
 
Shipping and handling costs are recorded as cost of goods sold and are approximately $30,000 and $33,000 for the years ended December 31, 2013 and 2012, respectively.
 
 
38

 
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 2 - Summary of Significant Accounting Policies (continued)
 
Research and Development Costs
 
Research and development costs are expensed as incurred.
 
Stock-Based Compensation
 
The Company accounts for stock-based compensation in accordance with ASC Topic 718 by recognizing the fair value of stock-based compensation in the consolidated statement of operations and comprehensive loss.  The fair value of the Company’s stock option awards are estimated using a Black-Scholes option valuation model. This model requires the input of highly subjective assumptions and elections including expected stock price volatility and the estimated life of each award. In addition, the calculation of compensation costs requires that the Company estimate the number of awards that will be forfeited during the vesting period. The fair value of stock-based awards is amortized over the vesting period of the award.  For stock-based awards that vest based on performance conditions (e.g. achievement of certain milestones), expense is recognized when it is probable that the condition will be met.
 
Amortization of Debt Issuance Costs
 
The Company accounts for debt issuance costs in accordance with ASC 835, which requires that costs paid directly to the issuer of  the notes be reported in the balance sheet as a debt discount and amortized over the term of the associated debt. Debt issuance costs of $399,000 for the year ended December 31, 2013 are associated with the senior secured notes issued to Lambda Investors LLC on February 4, 2013 and November 12, 2013. Approximately $257,000 of these costs were amortized as of December 31, 2013 and are included in amortization of debt discount on the consolidated statements of operations and comprehensive loss. There were no debt issuance costs for the year ended December 31, 2012.
 
Other Income (Expense), net
 
Other income (expense), net, of approximately $33,000 includes approximately $50,000 of other expense for the year ended December 31, 2013, primarily due to approximately $36,000 related to foreign currency losses and approximately $14,000 related to the May 2013 rights offering warrant modification. Other expense was partially offset by other income of approximately $17,000, which consisted primarily of a refund of approximately $15,000 received as a result of the Steris agreement termination. Other income (expense), net, in the amount of approximately $14,000 for the year ended December 31, 2012 is due primarily to approximately $18,000 in write-offs of old vendor invoices which are no longer due, offset partially by approximately $4,000 of net foreign currency losses on invoices paid to and due to an international supplier.
 
Income Taxes
 
The Company accounts for income taxes in accordance with ASC Topic 740, which requires accounting for deferred income taxes under the asset and liability method. Deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable in future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities.
 
For financial reporting purposes, the Company has incurred a loss in each period since its inception. Based on available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2013 and 2012.
 
ASC Topic 740 prescribes, among other things, a recognition threshold and measurement attributes for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company’s income tax return.  ASC 740 utilizes a two-step approach for evaluating uncertain tax positions.  Step one, or recognition, requires a company to determine if the weight of available evidence indicates a tax position is more likely than not to be sustained upon audit, including resolution of related appeals or litigation processes, if any.  Step two, or measurement, is based on the largest amount of benefit, which is more likely than not to be realized on settlement with the taxing authority.  The Company is subject to income tax examinations by major taxing authorities for all tax years subsequent to 2010.  The adoption of the provisions of ASC 740 did not have a material impact on the Company’s consolidated financial statements.  During the years ended December 31, 2013 and 2012, the Company recognized no adjustments for uncertain tax positions.  However, management’s conclusions regarding this policy may be subject to review and adjustment at a later date based on factors including, but not limited to, on-going analyses of and changes to tax laws, regulation and interpretations, thereof.
 
 
39

 
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 2 - Summary of Significant Accounting Policies (continued)
 
Loss per Common Share
 
In accordance with ASC 260-10, net loss per common share amounts (“basic EPS”) are computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding and excluding any potential dilution. Net loss per common share amounts assuming dilution (“diluted EPS”) is generally computed by reflecting potential dilution from conversion of convertible securities and the exercise of stock options and warrants. The following securities have been excluded from the dilutive per share computation as they are antidilutive:
 
 
 
2013
 
 
2012
 
Stock options
 
 
2,410,134
 
 
 
2,294,714
 
Warrants
 
 
13,887,598
 
 
 
14,679,971
 
Unvested restricted stock
 
 
75,450
 
 
 
-
 
 
Foreign Currency Translation
 
Foreign currency translation is recognized in accordance with ASC Topic 830.  The functional currency of Nephros International Limited is the Euro and its translation gains and losses are included in accumulated other comprehensive income. The balance sheet is translated at the year-end rate. The statement of operations is translated at the weighted average rate for the year.
 
Comprehensive Income (Loss)
 
Comprehensive income (loss), as defined in ASC 220,  is the total of net income (loss) and all other non-owner changes in equity (or other comprehensive income (loss)) such as foreign currency translation adjustments. For the years ended December 31, 2013 and 2012, the comprehensive loss was approximately $3,700,000 and $3,235,000, respectively.
 
Recently Adopted Accounting Pronouncements
 
There were no recent accounting pronouncements that are expected to have an effect on the Company’s consolidated financial statements.
 
 
40

 
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 3 - Inventory
 
The Company’s inventory components as of December 31, 2013 and 2012 were as follows:
 
 
 
December 31,
 
 
 
2013
 
 
2012
 
Total Gross Inventory, Finished Goods
 
$
527,000
 
 
$
581,000
 
Less: Inventory reserve
 
 
(365,000)
 
 
 
(269,000)
 
Total Inventory
 
$
162,000
 
 
$
312,000
 

Note 4 - Prepaid Expenses and Other Current Assets
 
Prepaid expenses and other current assets as of December 31, 2013 and 2012 were as follows:
 
 
 
December 31,
 
 
 
2013
 
2012
 
Prepaid insurance premiums
 
$
70,000
 
$
78,000
 
Security deposit
 
 
21,000
 
 
21,000
 
Other
 
 
34,000
 
 
10,000
 
Prepaid expenses and other current assets
 
$
125,000
 
$
109,000
 

Note 5 - Property and Equipment, Net
 
Property and equipment as of December 31, 2013 and 2012 was as follows:
 
 
 
 
 
December 31,
 
 
 
Life
 
2013
 
 
2012
 
Manufacturing equipment
 
 
3-5 years
 
$
599,000
 
 
$
602,000
 
Research equipment
 
 
5 years
 
 
37,000
 
 
 
37,000
 
Computer equipment
 
 
3-4 years
 
 
59,000
 
 
 
59,000
 
Furniture and fixtures
 
 
7 years
 
 
39,000
 
 
 
39,000
 
Property and equipment, gross
 
 
 
 
 
734,000
 
 
 
737,000
 
Less: accumulated depreciation
 
 
 
 
 
727,000
 
 
 
721,000
 
Property and equipment, net
 
 
 
 
$
7,000
 
 
$
16,000
 
 
Depreciation expense for each of the years ended December 31, 2013 and 2012 was $9,000,  including amortization expense relating to research and development assets.
 
During 2013, the Company sold fully depreciated equipment totaling approximately $3,000 which is reflected as gain on sale of equipment on the consolidated statements of operations and comprehensive loss. During 2012, the Company agreed to sell its manufacturing equipment to Medica for approximately €42,500, or $55,000. All assets at the manufacturing plant were fully depreciated as of the date of the sale. Approximately €42,500, or $55,000, is recognized as gain on sale of equipment on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2012.
 
 
41

 
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 6 – Senior Secured Notes
 
On February 4, 2013, the Company issued a senior secured note to Lambda Investors LLC in the principal amount of $1.3 million. The note bore interest at the rate of 12% per annum and was scheduled to mature on August 4, 2013, at which time all principal and accrued interest was due. However, the Company paid amounts due under the note on May 22, 2013 with the cash proceeds from the rights offering that closed in May 2013.  In connection with the note, the Company paid Lambda Investors an 8%, or $104,000, sourcing/transaction fee. In addition, the Company paid Lambda Investors’ legal fees and other expenses incurred in connection with the note in the amount of $50,000 as well as Lambda Investors’ legal fees and other expenses incurred in connection with the May 2013 rights offering in the amount of $50,000.  Those payments totaling $204,000 are reflected as amortization of debt discount. 
 
On November 12, 2013, the Company issued a senior secured note to Lambda Investors LLC in the principal amount of $1.5 million. The note bore interest at the rate of 12% per annum and was scheduled to mature on May 12, 2014, at which time all principal and accrued interest was due. However, the Company paid amounts due under the note on March 18, 2014 with the cash proceeds from the rights offering that closed in March 2014. In connection with the note, the Company paid Lambda Investors an 8%, or $120,000, sourcing/transaction fee. In addition, the Company paid Lambda Investors’ legal fees and other expenses incurred in connection with the note in the amount of $75,000. Those payments totaling $195,000 were made on November 12, 2013 and are reflected as a debt discount which is being amortized over the term of the senior secured note. Approximately $53,000 is reflected as amortization of debt discount on the consolidated statements of operations and comprehensive loss for the year the ended December 31, 2013.
 
On March 21, 2014 the Company completed a rights offering which resulted in gross proceeds of $2.1 million.  A portion of the proceeds was used for the repayment of a $1.5 million note, plus all accrued interest thereon of $61,000.  See Note 13, Subsequent Events, for further discussion.

Note 7 - Accrued Expenses
 
Accrued expenses as of December 31, 2013 and 2012 were as follows:
 
 
 
December 31,
 
 
 
2013
 
 
2012
 
Accrued Legal
 
$
149,000
 
 
$
90,000
 
Accrued Product Recall
 
 
60,000
 
 
 
 
 
Accrued Directors’ Compensation
 
 
-
 
 
 
77,000
 
Accrued Management Bonus
 
 
81,000
 
 
 
-
 
Accrued Interest
 
 
39,000
 
 
 
-
 
Accrued Travel
 
 
-
 
 
 
84,000
 
Accrued Other
 
 
36,000
 
 
 
70,000
 
Accrued Expenses
 
$
365,000
 
 
$
321,000
 
 
 
42

 
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 8 - Income Taxes
 
A reconciliation of the income tax provision computed at the statutory tax rate to the Company’s effective tax rate is as follows:
 
 
2013
 
 
2012
 
U.S. federal statutory rate
 
 
35.00
%
 
35.00
%
State & local taxes
 
 
5.22
%
 
5.36
%
Tax on foreign operations
 
 
0.40
%
 
(0.78)
%
State research and development credits
 
 
1.09
%
 
1.06
%
Other
 
 
(3.00)
%
 
(2.29)
%
Valuation allowance
 
 
(38.71)
%
 
(38.35)
%
Effective tax rate
 
 
-
 
 
-
 
 
Significant components of the Company’s deferred tax assets as of December 31, 2013 and 2012 are as follows:
 
 
 
2013
 
 
2012
 
Deferred tax assets:
 
 
 
 
 
 
 
 
Net operating loss carry forwards
 
$
27,029,000
 
 
$
25,721,000
 
Research and development credits
 
 
1,096,000
 
 
 
1,054,000
 
Nonqualified stock option compensation expense
 
 
1,801,000
 
 
 
1,701,000
 
Other temporary book - tax differences
 
 
408,000
 
 
 
441,000
 
Total deferred tax assets
 
 
30,334,000
 
 
 
28,917,000
 
Valuation allowance for deferred tax assets
 
 
(30,334,000)
 
 
 
(28,917,000)
 
Net deferred tax assets
 
$
-
 
 
$
-
 
 
A valuation allowance has been recognized to offset the Company’s net deferred tax asset as it is more likely than not that such net asset will not be realized. The Company primarily considered its historical loss and potential Internal Revenue Code Section 382 limitations to arrive at its conclusion that a valuation allowance was required.
 
At December 31, 2013, the Company had Federal and New Jersey income tax net operating loss carryforwards of $87,292,000 and foreign income tax net operating loss carryforwards of $8,305,000. The Company also had Federal research tax credit carryforwards of $1,096,000 at December 31, 2013 and $1,054,000 at December 31, 2012. The Federal net operating loss and tax credit carryforwards will expire at various times between 2014 and 2026 unless utilized.
 
It is the Company’s policy to report interest and penalties, if any, related to unrecognized tax benefits in income tax expense.
 
 
43

 
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 9 - Stock Plans, Share-Based Payments and Warrants
 
Stock Plans
 
In 2000, the Company adopted the Nephros 2000 Equity Incentive Plan. In January 2003, the Board of Directors adopted an amendment and restatement of the plan and renamed it the Amended and Restated Nephros 2000 Equity Incentive Plan (the “2000 Plan”), under which 106,538 shares of common stock had been authorized for issuance upon exercise of options granted.
 
As of December 31, 2013 and 2012, 831 and 2,053 options, respectively, had been issued to non-employees under the 2000 Plan and were outstanding. During the twelve months ended December 31, 2013, 1,222 non-employee options expired.  The remaining outstanding options, all of which are fully vested, will expire on March 15, 2014. As of December 31, 2013 and 2012, 2,003 and 7,230 options, respectively, had been issued to employees under the 2000 Plan and were outstanding. During the twelve months ended December 31, 2013, 5,227 employee options expired.  The remaining employee options, all of which are fully vested, will expire on March 15, 2014.
 
The Board retired the 2000 Plan in June 2004, and thereafter no additional awards may be granted under the 2000 Plan.
 
In 2004, the Board of Directors adopted and the Company’s stockholders approved the Nephros, Inc. 2004 Stock Incentive Plan. During the year ended December 31, 2013, the Company’s stockholders approved an amendment to such plan (as amended, the “2004 Plan”), that increased the number of shares of the Company’s common stock that are authorized for issuance by the Company pursuant to grants of awards under the 2004 Plan to 4,500,000.
 
As of December 31, 2013, 1,360,059 options had been issued to employees under the 2004 Plan and were outstanding. The options expire on various dates between April 27, 2015 and March 24, 2021, and vest upon a combination of the following: immediate vesting or straight line vesting of two or four years. At December 31, 2013, there were 2,407,318 shares available for future grants under the 2004 Plan. As of December 31, 2013, 715,692 options had been issued to non-employees under the 2004 Plan and were outstanding. Such options expire at various dates between November 11, 2014 and November 18, 2021, and vest upon a combination of the following: immediate vesting or straight line vesting of two or four years. In addition, 331,550 options were issued in 2012 to the Company’s CEO per terms of his employment agreement and are outstanding as of December 31, 2013.
 
As of December 31, 2012, 1,316,628 options had been issued to employees under the 2004 Plan and were outstanding. The options expire on various dates between April 27, 2015 and May 23, 2023, and vest upon a combination of the following: immediate vesting or straight line vesting of two to four years. At December 31, 2012, there were 19,904 shares available for future grants under the 2004 Plan. As of December 31, 2012, 637,253 options had been issued to non-employees under the 2004 Plan and were outstanding. Such options expire at various dates between November 11, 2014 and December 31, 2023, and vest upon a combination of the following: immediate vesting or straight line vesting of two to four years.
  
Share-Based Payment
 
Prior to the Company’s initial public offering, options were granted to employees, non-employees and non-employee directors at exercise prices which were lower than the fair market value of the Company’s stock on the date of grant. After the date of the Company’s initial public offering, stock options are granted to employees, non-employees and non-employee directors at exercise prices equal to the fair market value of the Company’s stock on the date of grant. Stock options granted have a life of 10 years. 
 
Expense is recognized, net of expected forfeitures, over the vesting period of the options. For options that vest upon the achievement of certain milestones, expense is recognized when it is probable that the condition will be met. Stock based compensation expense recognized for the years ended December 31, 2013 and 2012 was approximately $418,000 or less than $0.03 per share and approximately $443,000 or less than $0.04 per share, respectively.
 
 
44

 
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 9 - Stock Plans, Share-Based Payments and Warrants (continued) 
 
Gerald J. Kochanski, Chief Financial Officer, Treasurer and Corporate Secretary of Nephros, Inc., resigned effective June 15, 2013. The Company agreed, in consideration of Mr. Kochanski providing certain consulting services to the Company, to extend the exercise period of his outstanding vested stock options from September 15, 2013 to March 14, 2014. This modification did not result in any additional compensation expense. In addition, as a result of Mr. Kochanski’s resignation, 90,945 stock options that were granted to him were forfeited on June 15, 2013. Of these 90,945 stock options, 25,000 were granted during the twelve month period ended December 31, 2013.
 
The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the below assumptions related to risk-free interest rates, expected dividend yield, expected lives and expected stock price volatility.
 
 
 
Option Pricing Assumptions
 
 
Grant Year
 
2013
 
 
2012
 
 
Stock Price Volatility
 
 
127.46-135.98
%
 
 
123.48 –128.54
%
 
Risk-Free Interest Rates
 
 
1.09-1.75
%
 
 
..093-1.32
%
 
Expected Life (in years)
 
 
5.00-6.25
 
 
 
5.75-62.5
 
 
Expected Dividend Yield
 
 
0
%
 
 
0
%
 
  
Expected volatility is based on historical volatility of the Company’s common stock at the time of grant. The risk-free interest rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected life of the options. For the expected life, the Company is using the simplified method as described in the SEC Staff Accounting Bulletin 107. This method assumes that stock option grants will be exercised based on the average of the vesting periods and the option’s life.
 
The total fair value of options vested during the fiscal year ended December 31, 2013 was approximately $519,000. The total fair value of options vested during the fiscal year ended December 31, 2012 was approximately $506,000.
 
The following table summarizes information about stock options outstanding and exercisable at December 31, 2013:
 
 
 
Options Outstanding
 
Options Exercisable
 
Range of Exercise
Price
 
Number
Outstanding as
of December
31, 2013
 
Weighted
Average
Remaining
Contractual
Life in
Years
 
Weighted
Average
Exercise
Price
 
Number
Exercisable as
of
December 31,
2013
 
Weighted
Average
Exercise Price
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$0.41 - $2.60
 
 
2,374,514
 
 
8.16
 
$
0.93
 
 
1,349,579
 
$
0.83
 
$15.00 - $29.80
 
 
27,909
 
 
4.58
 
$
17.82
 
 
27,909
 
$
17.82
 
$34.20-$96.00
 
 
7,711
 
 
1.38
 
$
51.49
 
 
7,711
 
$
51.49
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Outstanding
 
 
2,410,134
 
 
 
 
$
1.28
 
 
1,385,199
 
$
1.46
 
 
The number of new options granted in 2013 and 2012 is 237,315 and 1,547,550, respectively. The weighted-average fair value of options granted in 2013 and 2012 is $0.56 and $1.03, respectively.
 
 
45

 
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 9 - Stock Plans, Share-Based Payments and Warrants (continued)
 
The following table summarizes the option activity for the year ended December 31, 2013:
 
 
 
Shares
 
Weighted
Average
Exercise
Price
 
Outstanding at December 31, 2012
 
 
2,294,714
 
$
 
2.14
 
Options granted
 
 
237,315
 
 
 
0.64
 
Options exercised
 
 
-
 
 
 
-
 
Options forfeited or expired
 
 
(121,895)
 
 
 
3.27
 
Outstanding at December 31, 2013
 
 
2,410,134
 
$
 
1.28
 
Exercisable at December 31, 2013
 
 
1,385,199
 
$
 
1.46
 
Vested and expected to vest at December 31, 2013
 
 
2,350,688
 
$
 
1.29
 
 
The aggregate intrinsic value of stock options outstanding at December 31, 2013 is $0 and of stock options vested or expected to vest is approximately $0. A stock option has intrinsic value, at any given time, if and to the extent that the exercise price of such stock option is less than the market price of the underlying common stock at such time. The weighted-average remaining contractual life of options vested or expected to vest is 8.1 years.
 
The aggregate intrinsic value of stock options outstanding at December 31, 2012 is $793,000 and of stock options vested or expected to vest is approximately $768,000. A stock option has intrinsic value, at any given time, if and to the extent that the exercise price of such stock option is less than the market price of the underlying common stock at such time. The weighted-average remaining contractual life of options vested or expected to vest is 8.9 years. 
 
As of December 31, 2013, the total remaining unrecognized compensation cost related to non-vested stock options amounted to $727,000 and will be amortized over the weighted-average remaining requisite service period of 2.3 years.
 
Restricted Stock
 
The Company has issued restricted stock as compensation for the services of certain employees and non-employee directors.  The grant date fair value of restricted stock was based on the fair value of the common stock on the date of grant, and compensation expense is recognized based on the period in which the restrictions lapse. 
 
The following table summarizes restricted stock activity for the year end December 31, 2013:
 
 
 
Shares
 
Weighted
Average
Grant Date
Fair Value
 
Nonvested at December 31, 2012
 
-
 
$
-
 
Granted
 
398,227
 
 
0.73
 
Vested
 
(264,770)
 
 
0.71
 
Forfeited
 
(58,007)
 
 
0.88
 
Nonvested at December 31, 2013
 
75,450
 
$
0.66
 
 
 
46

 
NEPHROS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 9 - Stock Plans, Share-Based Payments and Warrants (continued)
  
Total stock-based compensation expense for the restricted stock was approximately $157,000 for the year ended December 31, 2013.  For the year ended December 31, 2013, approximately $109,000 and approximately $48,000 are included in Selling, General and Administrative expenses and Research and Development expenses, respectively, on the accompanying condensed consolidated statement of operations. The remaining expense related to the restricted stock awards issued to non-employee directors of approximately $77,000 was recorded to offset accrued director’s fees that were incurred prior to December 31, 2012. Any additional stock-based compensation related to non-employee directors will be recorded to stock-based compensation expense. As of December 31, 2013, there was approximately $4,000 of unrecognized compensation expense related to the restricted stock awards, which is expected to be recognized over the next six months.
 
Warrants
 
The following table summarizes certain terms of all of the Company’s outstanding warrants at December 31, 2013 and 2012: 
 
 
Total Outstanding Warrants at December 31, 2013
Title of Warrant
 
Date Issued
 
Expiry Date
 
Exercise Price
 
Total Common
Shares Issuable
 
 
 
 
 
 
 
 
 
 
2013
 
2012
 
Class D Warrants - Lambda
 
11/14/2007
 
3/10/2017
 
$
0.40
 
 
8,806,575
 
 
8,806,575
 
July 2009 Warrants
 
7/24/2009
 
7/24/2014
 
$
22.40
 
 
33,629
 
 
33,629
 
Shareholder Rights Offering Warrants
 
3/10/2011
 
3/10/2016
 
$
0.40
 
 
2,264,817
 
 
3,057,190
 
March 2011 Lambda Warrants
 
3/10/2011
 
3/10/2017
 
$
0.40
 
 
2,782,577
 
 
2,782,577
 
 
 
 
 
 
 
 
 
 
 
13,887,598
 
 
14,679,971
 
 
The weighted average exercise price of the outstanding warrants was $0.45 for December 31, 2013 and 2012. 
 
Following the closing of the rights offering in 2013, Lambda Investors’ existing warrants to purchase 8,806,575 shares that remain outstanding were amended to expire on March 10, 2017.
 
The following table summarizes the Class D outstanding warrants at December 31, 2013 and 2012:
 
 
 
Lambda Investors
 
Other Investors
 
Total Shares to be issued
 
As of December 31, 2011
 
 
8,806,575
 
 
447,197
 
 
9,253,772
 
Exercised in 2012
 
 
-
 
 
(352,034)
 
 
(352,034)
 
Expired in 2012
 
 
-
 
 
(95,163)
 
 
(95,163)
 
As of December 31, 2012
 
 
8,806,575
 
 
-
 
 
8,806,575
 
Exercised in 2013
 
 
-
 
 
-
 
 
-
 
Expired in 2013
 
 
-
 
 
-
 
 
-
 
As of December 31, 2013
 
 
8,806,575
 
 
-
 
 
8,806,575
 
  
Class D warrant holders elected to exercise 352,034 of the outstanding Class D Warrants in 2012. As a result, 190,326 were exercised pursuant to the cashless exercise provision of the warrant. In addition, 161,708 warrants were exercised resulting in proceeds of approximately $65,000. 
 
 
47

 
NEPHROS, INC. 
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
Note 9 - Stock Plans, Share-Based Payments and Warrants (continued)
 
Warrants exercised during 2013 and 2012
 
In connection with the 2013 Rights Offering, the Company temporarily reduced the exercise price for its warrants issued in March 2011 from $0.40 per share to $0.30 per share. The Company determined that this inducement was a modification of equity instruments and, therefore, an incremental fair value of the inducement was determined using the Black-Scholes option pricing model.
 
During the period that the 2013 Rights Offering was open, warrant holders exercised 14,879,708 warrants, issued in March 2011, for 687,793 shares of common stock, resulting in gross proceeds of approximately $206,000 to the Company. The incremental fair value of the inducement recorded in the year ended December 31, 2013 was approximately $14,000.

Additionally, during the twelve months ended December 31, 2013, 2,254,500 warrants were exercised outside the period that the 2013 Rights Offering was open, resulting in proceeds of approximately $42,000 and the issuance of 104,206 shares of the Company’s common stock.
 
An additional 374 common shares were not issued as a result of warrant exercises for the year ended December 31, 2013 due to rounding.
 
Shareholders exercised 23,720,667 warrants, resulting in proceeds of approximately $438,000 and the issuance of 1,096,313 shares of the Company’s common stock for the year ended December 31, 2012.

Note 10 – Stockholders’ Equity
 
On March 4, 2013, the Company filed a Registration Statement on Form S-1 in connection with a $3 million rights offering (the “Rights Offering”).  On April 17, 2013, the Company’s Registration Statement on Form S-1 related to the Rights Offering was declared effective by the SEC.
 
The Rights Offering commenced on April 17, 2013 and expired on May 17, 2013.  All of the Company’s stockholders and warrant holders were eligible to participate in the Rights Offering on a pro rata basis based upon their proportionate ownership of the Company’s common stock on a fully-diluted basis.  Pursuant to the Rights Offering, the Company distributed to holders of its common stock and/or warrants one non-transferable subscription right for each share of common stock, and each share of common stock underlying a warrant, held as of April 4, 2013.  Each right entitled the holder to purchase 0.18776 of a share of the Company’s common stock at a subscription price of $0.60 per share.  The Company rounded up any fractional shares to the nearest whole share.
 
On May 22, 2013, the Company completed its Rights Offering which resulted in the issuance of 5,000,000 shares for gross proceeds of $3.0 million.  The aggregate net proceeds were approximately $1.4 million, after deducting the repayment of the $1.3 million February 2013 senior secured note, plus $46,800 of accrued interest thereon, issued to Lambda Investors, LLC, the payment of an 8% sourcing transaction fee of $104,000 with respect to the February 2013 senior secured note and an aggregate of $100,000 for reimbursement of Lambda Investors’ legal fees incurred in connection with the February 2013 senior secured note and the Rights Offering. Those payments totaling $204,000 are reflected as amortization of debt discount.

Note 11 - 401(k) Plan
 
The Company has established a 401(k) deferred contribution retirement plan (the “401(k) Plan”) which covers all employees. The 401(k) Plan provides for voluntary employee contributions of up to 15% of annual earnings, as defined. As of January 1, 2004, the Company began matching 100% of the first 3% and 50% of the next 2% of employee earnings to the 401(k) Plan. The Company contributed and expensed $46,000 and $49,000 in 2013 and 2012, respectively.
 
 
48

 
NEPHROS, INC. 
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 
Note 12 - Commitments and Contingencies
 
Manufacturing and Suppliers
 
The Company has not and does not intend in the near future, to manufacture any of its products and components. With regard to the OLpur MD190 and MD220, on June 27, 2011, the Company entered into a license agreement, effective July 1, 2011, with Bellco S.r.l., an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of our patented mid-dilution dialysis filters (MD 190, MD 220), referred to herein as the Products. Under the agreement, Nephros granted Bellco a license to manufacture, market and sell the Products under its own name, label and CE mark in Italy, France, Belgium, Spain and Canada on an exclusive basis, and to do the same on a non-exclusive basis in the United Kingdom and Greece and, upon our written approval, other European countries where the Company does not sell the Products as well as non-European countries (referred to as the “Territory”).
 
On February 19, 2014, the Company entered into the First Amendment to License Agreement (the “First Amendment”), by and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011 by and between the Company and Bellco.  Pursuant to the First Amendment, the Company and Bellco agreed to extend the term of the License Agreement through December 31, 2021. The First Amendment also expands the Territory covered by the License Agreement to include Sweden, Denmark, Norway, Finland, Korea, Mexico, Brazil, China and the Netherlands. The First Amendment further provides new minimum sales targets which, if not satisfied, will, at the discretion of the Company, result in conversion of the license to non-exclusive status. The Company has agreed to reduce the fixed royalty payment payable to the Company for the period beginning on January 1, 2015 through and including December 31, 2021. Beginning on January 1, 2015 through and including December 31, 2016, Bellco will pay us a royalty based on the number of units of Products sold per year in the Territory as follows: for the first 125,000 units sold,  €1.75 per unit; thereafter, €1.25 per unit.  In addition, the Company will receive a total of €450,000 in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. In addition, the First Amendment provides that, in the event that the Company pursues a transaction to sell, assign or transfer all right, title and interest to the licensed patents to a third party, the Company will provide Bellco with written notice thereof and a right of first offer with respect to the contemplated transaction for a period of thirty (30) days.
                   
License and Supply Agreement
 
On April 23, 2012, the Company entered into a License and Supply Agreement (the “License and Supply Agreement”) with Medica S.p.A. (“Medica”), an Italy-based medical product manufacturing company, for the marketing and sale of certain filtration products based upon Medica’s proprietary Medisulfone ultrafiltration technology in conjunction with the Company’s filtration products (collectively, the “Filtration Products”), and to engage in an exclusive supply arrangement for the Filtration Products. Under the License and Supply Agreement, Medica granted to the Company an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale and sell the Filtration Products worldwide, excluding Italy for the first three years, during the term of the License and Supply Agreement. In addition, the Company granted to Medica an exclusive license under the Company’s intellectual property to make the Filtration Products during the term of the License and Supply Agreement. In exchange for the rights granted, the Company has agreed to make minimum annual aggregate purchases from Medica of €300,000, €500,000 and €750,000 for the years 2012, 2013 and 2014, respectively. In the year ended December 31, 2013 the Company’s aggregate purchase commitments totaled approximately €532,000. For calendar years thereafter, annual minimum amounts will be mutually agreed upon between Medica and the Company.
 
In exchange for the license, the Company paid Medica  €1,500,000 in three installments: €500,000 on April 23, 2012, €600,000 on February 4, 2013, and €400,000 on May 23, 2013. As further consideration for the license and other rights granted to the Company, the Company granted Medica options to purchase 300,000 shares of the Company’s common stock. The fair market value of these stock options was approximately $273,000 at the time of their issuance, calculated as described in Note 2 under Stock-Based Compensation. The fair market value of the options has been capitalized as a long-term intangible asset along with the total installment payments described. Other long-term assets on the consolidated balance sheet is approximately $1,894,000, net of $356,000 accumulated amortization, and is related to the License and Supply Agreement. The asset is being amortized as an expense over the life of the agreement. Approximately $214,000 and $142,000 have been charged to amortization expense for the years ended December 31, 2013 and 2012, respectively, on the consolidated statement of operations and comprehensive loss. Approximately $208,000 of amortization expense will be recognized in the years ended December 31, 2014 and 2015, respectively. In addition, for the period beginning April 23, 2014 through December 31, 2022, the Company will pay Medica a royalty rate of 3% of net sales of the Filtration Products sold, subject to reduction as a result of a supply interruption pursuant to the terms of the License and Supply Agreement. The term of the License and Supply Agreement commenced on April 23, 2012 and continues in effect through December 31, 2022, unless earlier terminated by either party in accordance with the terms of the License and Supply Agreement.
 
 
49

 
 
NEPHROS, INC. 
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 
 
Note 12 - Commitments and Contingencies (continued)
 
As of September 2013, we have an understanding with Medica whereby we have agreed to pay interest to Medica at a 12% annual rate calculated on the principal amount of any outstanding invoices that are not paid pursuant to the original payment terms.
 
Employment Agreement
 
On April 20, 2012, the Company entered into an Employment Agreement, effective as of April 20, 2012, with John C. Houghton (“Employment Agreement”). The Employment Agreement has a term of four years, ending on April 20, 2016. The Employment Agreement provides that Mr. Houghton’s annual base salary will be $350,000. Mr. Houghton will be eligible to receive a target discretionary bonus of 30% of annual base salary, as determined by the Company.
 
Contractual Obligations
 
The Company had an operating lease that expired on November 30, 2013 for the rental of its U.S. office and research and development facilities with a monthly cost of approximately $8,000. On July 25, 2013, the Company signed a one year lease extension for the same office space which will expire on November 30, 2014 with a monthly cost of approximately $8,000 beginning December 1, 2013.
 
Rent expense for the years ended December 31, 2013 and 2012 totaled $108,000 and $109,000, respectively.
     
Contractual Obligations and Commercial Commitments
 
The following tables summarize our approximate minimum contractual obligations and commercial commitments as of December 31, 2013:
 
 
 
Payments Due in Period
 
 
 
Total
 
Within
1 Year
 
Years
1 - 3
 
Years
4 - 5
 
More than
5 Years
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Leases
 
$
108,000
 
$
100,000
 
$
8,000
 
$
-
 
$
-
 
Employment Contracts
 
 
788,000
 
 
350,000
 
 
438,000
 
 
-
 
 
-
 
Total
 
$
896,000
 
$
450,000
 
$
446,000
 
$
-
 
$
-
 
   
Product Recall
 
On October 30, 2013, the Company filed a Current Report on Form 8-K announcing the voluntary recalls of its point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications.  As a result, the Company has recalled all production lots of its POU filters, and also requested that customers remove and discard certain labeling/promotional materials for the products.  In addition, the Company also requested, for the DSU in-line ultrafilter, that customers remove and discard certain labeling/promotional materials for the product.  These voluntary recalls do not affect the Company’s dialysis products.  The consolidated financial statements for the year ended December 31, 2013 include product revenues and cost of goods sold adjustments of approximately $216,00 and $110,000, respectively, reflecting estimates of the financial impact of product recalled to the Company.  This recall and the related circumstances could subject the Company to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact the Company’s sales and revenues.  The Company has fully reserved the recalled product and will destroy the respective product by April 20, 2014.
 
 
50

 
NEPHROS, INC. 
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 
Note 13 - Concentration of Credit Risk
 
Cash and cash equivalents are financial instruments which potentially subject the Company to concentrations of credit risk. The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash and cash equivalents.
 
Major Customers
 
For the years ended December 31, 2013 and 2012, three customers accounted for 86% and 68%, respectively, of the Company’s sales.  In addition, as of December 31, 2013 and 2012, those three customers accounted for 97% and 88%, respectively, of the Company’s accounts receivable.

Note 14 - Subsequent Events
 
On March 24, 2014, the Company announced the completion of a rights offering that resulted in gross proceeds of $2.1 million and the issuance of 7,140,822 shares of common stock. A portion of the proceeds was used for the repayment of the $1.5 million note issued to Lambda Investors LLC in November 2013 in connection with its loan to the Company, plus $61,000 of accrued interest thereon. The Company issued a total of 7,140,822 shares of common stock to the holders of subscription rights who validly exercised their subscription rights, which represents 77% of the total shares offered in the rights offering.
 
On February 19, 2014, the Company entered into the First Amendment to License Agreement (the “First Amendment”), by and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011 by and between the Company and Bellco.  Pursuant to the First Amendment, the Company and Bellco agreed to extend the term of the License Agreement through December 31, 2021. The First Amendment also expands the Territory covered by the License Agreement to include Sweden, Denmark, Norway, Finland, Korea, Mexico, Brazil, China and the Netherlands. The First Amendment further provides new minimum sales targets which, if not satisfied, will, at the discretion of the Company, result in conversion of the license to non-exclusive status. The Company has agreed to reduce the fixed royalty payment payable to the Company for the period beginning on January 1, 2015 through and including December 31, 2021. The Company will receive a total of €450,000 in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. In addition, the First Amendment provides that, in the event that the Company pursues a transaction to sell, assign or transfer all right, title and interest to the licensed patents to a third party, the Company will provide Bellco with written notice thereof and a right of first offer with respect to the contemplated transaction for a period of thirty (30) days.
 
 
51

 
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
 
There have been no changes in or disagreements with our accountants during 2013 or 2012.
 
Item 9A. Controls and Procedures
 
Disclosure Controls and Procedures
 
We carried out an evaluation under the supervision and with the participation of our management, including our President, Chief Executive Officer and Acting Chief Financial Officer (CEO and Acting CFO effectiveness of the design and operation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”), as amended for financial reporting as of December 31, 2013. Based on that evaluation, our CEO and Acting CFO concluded that these controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported as specified in Securities and Exchange Commission rules and forms. There were significant changes in these controls or procedures identified in connection with the evaluation of such controls or procedures that occurred during 2013 based on the resignation of the former CFO and the CEO expansion of duties to include acting CFO.  These changes were considered in the review of the internal control structure. 
 
Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the rules and forms of the Securities and Exchange Commission. These disclosure controls and procedures include, among other things, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Exchange Act is accumulated and communicated to our management, including our CEO and Acting CFO, as appropriate to allow timely decisions regarding required disclosure.
  
Management’s Report on Internal Control Over Financial Reporting
 
Our management is responsible for establishing and maintaining adequate internal control over financial reporting.  Internal control over financial reporting is defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, the CEO and effected by the board of directors and management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: 
 
· Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
· Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of our management and board of directors;
· Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
 
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2013.  In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) (1992) in Internal Control-Integrated Framework.
 
Based on our assessment, our management believes that, as of December 31, 2013, our internal control over financial reporting is effective.
 
Item 9B. Other Information  
 
Not applicable.
 
 
52

 
PART III
 
Certain information required by Part III is omitted from this Annual Report on Form 10-K because we will file the 2014 Proxy Statement  within one hundred twenty (120) days after the end of the fiscal year pursuant to Regulation 14A for our Annual Meeting of Stockholders currently being planned to occur in May 2014, and the information included in the 2014 Proxy Statement is incorporated herein by reference.
 
Item 10. Directors, Executive Officers and Corporate Governance
 
The information set forth under the captions “Proposal No. 1 – Election of Directors”, “Corporate Governance” and “Section 16(a) Beneficial Ownership Reporting Compliance” in the 2014 Proxy Statement is incorporated herein by reference. 
 
Item 11. Executive Compensation
 
The information set forth under the caption “Compensation Matters” in the 2014 Proxy Statement is incorporated herein by reference.
 
Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
 
The information set forth under the captions “Stock Ownership of Management and Principal Shareholders” and “Compensation Matters” in the 2014 Proxy Statement is incorporated herein by reference.  
 
Item 13. Certain Relationships and Related Transactions, and Director Independence
 
The information set forth under the captions “Corporate Governance” and “Certain Relationships and Related Transactions” in the 2014 Proxy Statement is incorporated herein by reference.
 
Item 14. Principal Accounting Fees and Services
 
The information set forth under the caption “Proposal No. 2 – Ratification of Selection of Independent Registered Public Accounting Firm” in the 2014 Proxy Statement is incorporated herein by reference.
 
 
53

 
Item 15. Exhibits 
 
(a) Documents filed as part of this report:
 
(1) Consolidated Financial Statements of Nephros, Inc.
Report of independent registered public accounting firm.
 
 
Consolidated balance sheets as of December 31, 2013 and 2012.
 
 
Consolidated statements of operations for the years ended December 31, 2013 and 2012.
 
 
Consolidated statement of changes in stockholders’ equity for the years ended December 31, 2013, 2012, and 2011.
 
 
Consolidated statements of cash flows for the years ended December 31, 2013 and 2012.
 
 
Notes to consolidated financial statements.
 
 
 
 
54

 
(b) Exhibits:
 
EXHIBIT INDEX
 
Exhibit
No.
 
Description
3.1
 
Fourth Amended and Restated Certificate of Incorporation of the Registrant, incorporated by reference to Nephros, Inc.’s Registration Statement on Form S-8 (Reg. No. 333-127264), filed with the Securities and Exchange Commission on August 5, 2005.
3.2
 
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant, incorporated by reference to Nephros, Inc.’s Quarterly Report on Form 10-QSB for the quarter ended June 30, 2007, filed with the Securities and Exchange Commission on August 13, 2007 (SEC File No. 001-32288).
3.3
 
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant, incorporated by reference to Nephros, Inc.’s Quarterly Report on Form 10-QSB for the quarter ended June 30, 2007, filed with the Securities and Exchange Commission on August 13, 2007 (SEC File No. 001-32288).
3.4
 
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant as filed with the Delaware Secretary of State on November 13, 2007, incorporated by reference to Nephros, Inc.’s Quarterly Report on Form 10-QSB for the quarter ended September 30, 2007, filed with the Securities and Exchange Commission on November 13, 2007 (SEC File No. 001-32288).
3.5
 
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant as filed with the Delaware Secretary of State on October 26, 2009, incorporated by reference to Nephros, Inc.’s Registration Statement on Form S-1 (Reg. No. 333-162781), filed with the Securities and Exchange Commission on October 30, 2009.
3.6
 
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant as filed with the Delaware Secretary of State on March 10, 2011, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on March 16, 2011.
3.7
 
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant as filed with the Delaware Secretary of State on March 11, 2011, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on March 16, 2011.
3.8
 
Second Amended and Restated By-Laws of the Registrant, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 3, 2007 (SEC File No. 001-32288).
4.1
 
Specimen of Common Stock Certificate of the Registrant, incorporated by reference to Nephros, Inc.’s Amendment No. 1 to Registration Statement on Form S-1/A (Reg. No. 333-116162), filed with the Securities and Exchange Commission on July 20, 2004.
4.2
 
Form of Underwriter’s Warrant, incorporated by reference to Nephros, Inc.’s Amendment No. 2 to Registration Statement on Form S-1/A (Reg. No. 333-116162), filed with the Securities and Exchange Commission on August 26, 2004.
4.3
 
Warrant for the purchase of shares of common stock dated January 18, 2006, issued to Marty Steinberg, Esq., as Court-appointed Receiver for Lancer Offshore, Inc, incorporated by reference to Nephros, Inc.’s Annual Report on Form 10-KSB for the year ended December 31, 2007, filed with the Securities and Exchange Commission on March 31, 2008 (SEC File No. 001-32288).
4.4
 
Form of Class D Warrant, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 25, 2007 (SEC File No. 001-32288).
4.5
 
Form of Placement Agent Warrant, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 25, 2007 (SEC File No. 001-32288).
4.6
 
Form of Investor Warrant issued on July 24, 2009, incorporated by reference to Nephros, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, filed with the Securities and Exchange Commission on August 14, 2009.
4.7
 
Form of Warrant Certificate, incorporated by reference to Nephros, Inc.’s Registration Statement on Form S-1 (Reg. No. 333-169728), filed with the Securities and Exchange Commission on October 1, 2010.
4.8
 
Form of Warrant Agreement between Nephros, Inc. and Continental Stock Transfer & Trust Company, incorporated by reference to Nephros, Inc.’s Amendment No. 1 to Registration Statement on Form S-1/A (Reg. No. 333-169728), filed with the Securities and Exchange Commission on November 8, 2010.
4.9
 
Form of Subscription Rights Certificate, incorporated by reference to Nephros, Inc.’s Registration Statement on Form S-1 (Reg. No. 333-169728), filed with the Securities and Exchange Commission on October 1, 2010.
10.1
 
Amended and Restated 2000 Nephros Equity Incentive Plan, incorporated by reference to Nephros, Inc.’s Amendment No. 1 to Registration Statement on Form S-1/A (Reg. No. 333-116162), filed with the Securities and Exchange Commission on July 20, 2004. †
 
 
55

 
10.2
 
2004 Nephros Stock Incentive Plan, incorporated by reference to Nephros, Inc.’s Amendment No. 1 to Registration Statement on Form S-1/A (Reg. No. 333-116162), filed with the Securities and Exchange Commission on July 20, 2004. †
10.3
 
Amendment No. 1 to 2004 Nephros Stock Incentive Plan, incorporated by reference to Nephros, Inc.’s Registration Statement on Form S-8 (Reg. No. 333-127264), filed with the Securities and Exchange Commission on August 5, 2005. †
10.4
 
Amendment No. 2 to the Nephros, Inc. 2004 Stock Incentive Plan, incorporated by reference to Nephros, Inc.’s Quarterly Report on Form 10-QSB for the quarter ended September 30, 2007, filed with the Securities and Exchange Commission on November 13, 2007 (SEC File No. 001-32288).
10.5
 
Supply Agreement between Nephros, Inc. and Membrana GmbH, dated as of December 17, 2003, incorporated by reference to Nephros, Inc.’s Amendment No. 2 to Registration Statement on Form S-1/A (Reg. No. 333-116162), filed with the Securities and Exchange Commission on August 26, 2004.
10.6
 
Amended Supply Agreement between Nephros, Inc. and Membrana GmbH dated as of June 16, 2005, incorporated by reference to Nephros, Inc.’s Quarterly Report on Form 10-QSB, filed with the Securities and Exchange Commission on August 15, 2005 (SEC File No. 001-32288).
10.7
 
Manufacturing and Supply Agreement between Nephros, Inc. and Medica s.r.l., dated as of May 12, 2003, incorporated by reference to Nephros, Inc.’s Amendment No. 1 to Registration Statement on Form S-1/A (Reg. No. 333-116162), filed with the Securities and Exchange Commission on July 20, 2004.
10.8
 
Manufacturing and Supply Agreement between Nephros, Inc. and Medica s.r.l., dated as of March 22, 2005. Supersedes prior Agreement dated May 12, 2003, incorporated by reference to Nephros, Inc.’s Annual Report on Form 10-KSB, filed with the Securities and Exchange Commission on April 20, 2006 (SEC File No. 001-32288).
10.9
 
Form of Common Stock Purchase Warrant, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 2, 2006 (SEC File No. 32288).
10.10
 
Form of Registration Rights Agreement, dated as of June 1, 2006, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 2, 2006 (SEC File No. 32288).
10.11
 
Addendum to Commercial Contract between Nephros, Inc. and Bellco S.p.A, effective as of January 1, 2007, incorporated by reference to Nephros, Inc.’s Annual Report on Form 10-KSB for the year ended December 31, 2006, filed with the Securities and Exchange Commission on April 10, 2007 (SEC File No. 001-32288).
10.12
 
Registration Rights Agreement, dated as of September 19, 2007, among Nephros and the Holders, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 25, 2007 (SEC File No. 001-32288).
10.13
 
License Agreement, dated October 1, 2007, between the Trustees of Columbia University in the City of New York, and Nephros, incorporated by reference to Nephros, Inc.’s Annual Report on Form 10-KSB for the year ended December 31, 2007, filed with the Securities and Exchange Commission on March 31, 2008 (SEC File No. 001-32288).
10.14
 
Lease Agreement between Nephros, Inc. and 41 Grand Avenue, LLC dated as of November 20, 2008, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 20, 2008 (SEC File No. 001-32288).
10.15
 
Lease Agreement between Nephros International LTD and Coldwell Banker Penrose & O’Sullivan dated November 30, 2008, incorporated by reference to Nephros, Inc.’s Annual Report on Form 10-K for the year ended Deecember 31, 2008, filed with the Securities and Exchange Commission on March 31, 2009 (SEC File No. 001-32288).
10.16
 
Amendment No. 3 to the Nephros, Inc. 2004 Stock Incentive Plan, incorporated by reference to Nephros, Inc.’s Annual Report on Form 10-K for the year ended Deecember 31, 2008, filed with the Securities and Exchange Commission on March 31, 2009 (SEC File No. 001-32288). †
10.17
 
Senior Secured Note dated October 1, 2010 issued to Lambda Investors LLC, incorporated by reference to Nephros, Inc.’s Registration Statement on Form S-1 (Reg. No. 333-169728), filed with the Securities and Exchange Commission on October 1, 2010.
10.18
 
Form of Registration Rights Agreement, dated as of September 30, 2010, by and between the Registrant and Lambda Investors LLC, incorporated by reference to Nephros, Inc.’s Registration Statement on Form S-1 (Reg. No. 333-169728), filed with the Securities and Exchange Commission on October 1, 2010.
10.19
 
Amendment No. 4 to the Nephros, Inc. 2004 Stock Incentive Plan, incorporated by reference to Nephros, Inc.’s 2011 Proxy Statement (Exhibit A), filed with the Securities and Exchange Commission on December 2, 2010. †
10.20
 
Employment Agreement between Nephros, Inc. and Gerald J. Kochanski dated April 1, 2011, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on March 31, 2011. †
10.21
 
License Agreement, entered into as of July 1, 2011 by and between Nephros, Inc. and Bellco S.r.l., incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 27, 2011.
10.22
 
License and Supply Agreement dated as of April 23, 2012 between Nephros, Inc. and Medica S.p.A., incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 26, 2012.
 
 
56

 
10.23
 
Employment Agreement dated as of April 20, 2012 between Nephros, Inc. and John C. Houghton, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 26, 2012. †
10.24
 
Non-qualified Stock Option Agreement made as of July 3, 2012 by Nephros, Inc. and John C. Houghton, incorporated by reference to Nephros, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, filed with the Securities and Exchange Commission on November 9, 2012. †
10.25
 
Senior Secured Note, dated February 4, 2013, issued to Lambda Investors LLC, incorporated by reference to Nephros, Inc.’s Registration Statement on Form S-1 (Reg. No. 333-187036), filed with the Securities and Exchange Commission on March 4, 2013.
10.26
 
Registration Rights Agreement, dated February 4, 2013, by and between Nephros, Inc. and Lambda Investors LLC, incorporated by reference to Nephros, Inc.’s Registration Statement on Form S-1 (Reg. No. 333-187036), filed with the Securities and Exchange Commission on March 4, 2013.
10.27
 
Security Agreement, dated as of February 4, 2013, by and between Nephros, Inc. and Lambda Investors LLC, incorporated by reference to Nephros, Inc.’s Registration Statement on Form S-1 (Reg. No. 333-187036), filed with the Securities and Exchange Commission on March 4, 2013.
10.28
 
Intellectual Property Security Agreement, dated as of February 4, 2013, made by Nephros, Inc. and Lambda Investors LLC, incorporated by reference to Nephros, Inc.’s Registration Statement on Form S-1 (Reg. No. 333-187036), filed with the Securities and Exchange Commission on March 4, 2013.
10.29
 
First Amendment to Registration Rights Agreement, dated as of May 23, 2013, by and between Nephros, Inc. and Lambda Investors LLC, incorporated by reference to Nephros, Inc.’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 13, 2013.
10.30
 
Amendment No. 6 to Nephros, Inc. 2004 Stock Incentive Plan dated June 14, 2013, incorporated by reference to Nephros, Inc.’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 13, 2013.
10.31
 
Senior Secured Note, dated November 12, 2013, issued to Lambda Investors LLC, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 14, 2013.
10.32
 
Registration Rights Agreement, dated November 12, 2013, by and between Nephros, Inc. and Lambda Investors LLC, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 14, 2013.
10.33
 
Security Agreement, dated as of November 12, 2013, by and between Nephros, Inc. and Lambda Investors LLC, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 14, 2013.
10.34
 
Intellectual Property Security Agreement, dated as of November 12, 2013, made by Nephros, Inc. and Lambda Investors LLC, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 14, 2013.
10.35
 
First Amendment to License Agreement, dated as of February 19, 2014, by and between Nephros, Inc. and Bellco S.r.l., incorporated by reference to Nephros, Inc’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 25, 2014.
14.1
 
Code of Ethics and Business Conduct, as amended on April 2, 2007, incorporated by reference to Nephros, Inc.’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 6, 2007 (SEC File No. 001-32288).
21.1
 
Subsidiaries of Registrant, incorporated by reference to Nephros, Inc.’s Annual Report on Form 10-KSB for the year ended December 31, 2006, filed with the Securities and Exchange Commission on April 10, 2007 (SEC File No. 001-32288).
23.1
 
Consent of Rothstein Kass, Independent Registered Public Accounting Firm. *
24.1
 
Power of Attorney. (included on the signature page)
31.1
 
Certification by the Chief Executive Officer and Acting Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *
32.1
 
Certification by the Chief Executive Officer and Acting Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted  pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
101
 
Interactive Data File. *
 
*
Filed herewith.
†
Management contract or compensatory plan arrangement.
 
 
57

 
SIGNATURES
 
In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
NEPHROS, INC.
Date: March 28, 2014
 
 
 
By:
/s/ John C. Houghton
 
 
 
 
Name: John C. Houghton
 
Title: President, Chief Executive Officer and Acting Chief Financial Officer, and Director (Principal Executive Officer and Principal Financial and Accounting Officer)
 
POWER OF ATTORNEY
 
We, the undersigned directors and officers of Nephros, Inc., hereby severally constitute and lawfully appoint John C. Houghton, our true and lawful attorney-in-fact with full power to him to sign for us, in our names in the capacities indicated below, the Annual Report on Form 10-K for the fiscal year ended December 31, 2013 of Nephros, Inc. and any and all amendments thereto, and to file the same with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
 
In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
 
Signature
 
Title
 
Date
/s/ John C. Houghton
 
President, Chief Executive Officer and Acting Chief Financial Officer, and Director (Principal Executive Officer and Principal Financial and Accounting Officer)
 
March 28, 2014
John C. Houghton
 
 
 
 
 
 
 
 
 
/s/ Arthur H. Amron
 
Director
 
March 28, 2014
 
 
 
 
 
Arthur H. Amron
 
 
 
 
 
 
 
 
 
/s/ Lawrence J. Centella
 
Director
 
March 28, 2014
 
 
 
 
 
Lawrence J. Centella
 
 
 
 
 
 
 
 
 
/s/ Paul A. Mieyal
 
Director
 
March 28, 2014
 
 
 
 
 
Paul A. Mieyal
 
 
 
 
 
 
 
 
 
/s/ Daron Evans
 
Director
 
March 28, 2014
 
 
 
 
 
Daron Evans
 
 
 
 
 
 
58

 
EX-23.1 2 v367659_ex23-1.htm EXHIBIT 23.1
Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  
We consent to the incorporation by reference in the Registration Statements of Nephros, Inc. on Form S-8 (Registration Statements No. 333-127264 and No. 333-148236 and No. 333-188592) of our report, dated March 27, 2014 (which includes an explanatory paragraph relating to the Company’s ability to continue as a going concern), relating to the consolidated balance sheets of Nephros, Inc. as of December 31, 2013 and 2012, and the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows in the two year period ended December 31, 2013.
 
/s/ Rothstein Kass
 
Roseland, New Jersey
March 28, 2014
 
 
 
EX-31.1 3 v367659_ex31-1.htm EXHIBIT 31.1
Exhibit 31.1
 
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND ACTING CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, John C. Houghton, certify that:
 
 
(1)
I have reviewed this Annual Report on Form 10-K of Nephros, Inc.;
 
 
 
 
(2)
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
 
 
 
(3)
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
 
 
 
(4)
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
 
 
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
 
 
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
 
 
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
 
 
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
 
 
 
(5)
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
 
 
 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
 
 
 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Dated:  March 28, 2014
 
/s/ John C. Houghton
 
John C. Houghton
 
President, Chief Executive Officer and Acting
 
Chief Financial Officer (Principal Executive Officer
 
and Principal Financial and Accounting Officer)
 
 
 
 
EX-32.1 4 v367659_ex32-1.htm EXHIBIT 32.1
Exhibit 32.1
 
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND ACTING CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report on Form 10-K of Nephros, Inc. (the “Company”) for the fiscal year ended December 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John C. Houghton , President, Chief Executive Officer and Acting Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
 
 
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 
 
 
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated:  March 28, 2014
 
/s/ John C. Houghton
 
John C. Houghton
 
President, Chief Executive Officer and Acting
 
Chief Financial Officer (Principal Executive Officer
 
and Principal Financial and Accounting Officer)
 
 
 
 
EX-101.INS 5 neph-20131231.xml XBRL INSTANCE DOCUMENT 0001196298 2012-01-01 2012-01-31 0001196298 2012-01-01 2012-12-31 0001196298 2013-01-01 2013-01-31 0001196298 2013-01-01 2013-12-31 0001196298 2013-03-04 0001196298 2014-03-25 0001196298 2012-04-01 2012-04-20 0001196298 2012-04-20 0001196298 2013-05-01 2013-05-22 0001196298 2013-05-01 2013-05-31 0001196298 2013-05-17 0001196298 2013-05-22 0001196298 2013-05-31 0001196298 2013-06-26 2013-07-25 0001196298 2013-06-28 0001196298 2013-07-25 0001196298 2013-11-30 0001196298 2012-12-31 0001196298 2013-12-31 0001196298 2011-12-31 0001196298 neph:ClassDWarrantsMember 2013-01-01 2013-12-31 0001196298 us-gaap:SalesRevenueGoodsNetMember 2012-01-01 2012-12-31 0001196298 us-gaap:AccountsReceivableMember 2012-01-01 2012-12-31 0001196298 us-gaap:SalesRevenueGoodsNetMember 2013-01-01 2013-12-31 0001196298 us-gaap:AccountsReceivableMember 2013-01-01 2013-12-31 0001196298 neph:BellcoMember 2013-12-31 0001196298 neph:MedicaSpaMember 2013-01-01 2013-12-31 0001196298 neph:MedicaSpaMember 2012-04-01 2012-04-23 0001196298 neph:MedicaSpaMember 2013-01-05 2013-02-04 0001196298 neph:MedicaSpaMember 2013-05-01 2013-05-23 0001196298 neph:MedicaSpaMember 2012-01-01 2012-12-31 0001196298 neph:MedicaSpaMember 2013-09-01 2013-09-30 0001196298 us-gaap:CommonStockMember 2011-12-31 0001196298 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001196298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-12-31 0001196298 us-gaap:RetainedEarningsMember 2011-12-31 0001196298 us-gaap:RetainedEarningsMember 2012-01-01 2012-12-31 0001196298 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0001196298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-01-01 2012-12-31 0001196298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-01-01 2013-12-31 0001196298 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0001196298 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0001196298 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001196298 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001196298 us-gaap:CommonStockMember 2012-12-31 0001196298 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001196298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-12-31 0001196298 us-gaap:RetainedEarningsMember 2012-12-31 0001196298 us-gaap:CommonStockMember 2013-12-31 0001196298 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001196298 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0001196298 us-gaap:RetainedEarningsMember 2013-12-31 0001196298 neph:BellcoMember 2011-06-03 2011-07-01 0001196298 neph:BellcoMember 2011-12-18 2012-01-15 0001196298 neph:BellcoMember 2012-12-18 2013-01-15 0001196298 neph:LambdaInvestorsMember 2013-02-04 0001196298 neph:LambdaInvestorsMember 2013-11-12 0001196298 us-gaap:MinimumMember 2013-01-01 2013-12-31 0001196298 us-gaap:MaximumMember 2013-01-01 2013-12-31 0001196298 us-gaap:NonsoftwareLicenseArrangementMember neph:BellcoMember 2013-12-31 0001196298 us-gaap:NonsoftwareLicenseArrangementMember 2013-01-01 2013-12-31 0001196298 us-gaap:ScenarioForecastMember 2013-01-01 2013-12-31 0001196298 us-gaap:ScenarioForecastMember 2014-01-01 2014-12-31 0001196298 neph:LambdaInvestorsMember 2013-01-01 2013-12-31 0001196298 neph:LambdaInvestorsMember 2013-10-14 2013-11-12 0001196298 us-gaap:WarrantMember 2013-01-01 2013-12-31 0001196298 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-12-31 0001196298 us-gaap:WarrantMember 2012-01-01 2012-12-31 0001196298 us-gaap:RestrictedStockMember 2012-01-01 2012-12-31 0001196298 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0001196298 us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001196298 neph:ManufacturingEquipmentMember us-gaap:MinimumMember 2013-01-01 2013-12-31 0001196298 us-gaap:MaximumMember neph:ManufacturingEquipmentMember 2013-01-01 2013-12-31 0001196298 neph:ResearchEquipmentMember 2013-01-01 2013-12-31 0001196298 us-gaap:ComputerEquipmentMember us-gaap:MinimumMember 2013-01-01 2013-12-31 0001196298 us-gaap:ComputerEquipmentMember us-gaap:MaximumMember 2013-01-01 2013-12-31 0001196298 us-gaap:FurnitureAndFixturesMember 2013-01-01 2013-12-31 0001196298 neph:ManufacturingEquipmentMember 2012-12-31 0001196298 neph:ResearchEquipmentMember 2012-12-31 0001196298 us-gaap:ComputerEquipmentMember 2012-12-31 0001196298 us-gaap:FurnitureAndFixturesMember 2012-12-31 0001196298 neph:ManufacturingEquipmentMember 2013-12-31 0001196298 neph:ResearchEquipmentMember 2013-12-31 0001196298 us-gaap:ComputerEquipmentMember 2013-12-31 0001196298 us-gaap:FurnitureAndFixturesMember 2013-12-31 0001196298 neph:FederalAndNewJerseyMember 2013-12-31 0001196298 neph:ForeignMember 2013-12-31 0001196298 neph:FederalMember us-gaap:ResearchMember 2012-12-31 0001196298 neph:FederalMember us-gaap:ResearchMember 2013-12-31 0001196298 neph:TwoThousandPlanMember 2013-12-31 0001196298 neph:TwoThousandFourPlanMember 2013-12-31 0001196298 neph:TwoThousandPlanMember neph:NonEmployeeStockOptionsMember 2012-12-31 0001196298 neph:TwoThousandFourPlanMember us-gaap:EmployeeStockOptionMember 2012-12-31 0001196298 neph:TwoThousandFourPlanMember neph:NonEmployeeStockOptionsMember 2012-12-31 0001196298 neph:TwoThousandPlanMember us-gaap:EmployeeStockOptionMember 2012-12-31 0001196298 neph:TwoThousandPlanMember neph:NonEmployeeStockOptionsMember 2013-12-31 0001196298 neph:TwoThousandFourPlanMember us-gaap:EmployeeStockOptionMember 2013-12-31 0001196298 neph:TwoThousandFourPlanMember neph:NonEmployeeStockOptionsMember 2013-12-31 0001196298 neph:TwoThousandPlanMember us-gaap:EmployeeStockOptionMember 2013-12-31 0001196298 neph:TwoThousandFourPlanMember 2012-12-31 0001196298 neph:CeoStockOptionsMember 2013-01-01 2013-12-31 0001196298 neph:MrKochanskMember 2013-01-01 2013-12-31 0001196298 neph:RightOfferingMember 2011-03-31 0001196298 neph:ClassDWarrantLambdaMember 2013-12-31 0001196298 neph:ClassDWarrantMember 2012-01-01 2012-12-31 0001196298 neph:ShareholderRightsOfferingWarrantMember 2012-01-01 2012-12-31 0001196298 neph:ShareholderRightsOfferingWarrantMember 2013-01-01 2013-12-31 0001196298 neph:RightOfferingMember 2011-03-01 2011-03-31 0001196298 us-gaap:MinimumMember 2012-01-01 2012-12-31 0001196298 us-gaap:MaximumMember 2012-01-01 2012-12-31 0001196298 neph:ExercisePriceRangeOneMember 2013-01-01 2013-12-31 0001196298 neph:ExercisePriceRangeTwoMember 2013-01-01 2013-12-31 0001196298 neph:ExercisePriceRangeThreeMember 2013-01-01 2013-12-31 0001196298 neph:ExercisePriceRangeOneMember 2013-12-31 0001196298 neph:ExercisePriceRangeTwoMember 2013-12-31 0001196298 neph:ExercisePriceRangeThreeMember 2013-12-31 0001196298 neph:ClassDWarrantsLambdaMember 2013-12-31 0001196298 neph:JulyTwoThousandNineWarrantsMember 2013-12-31 0001196298 us-gaap:ShareholdersEquityMember 2013-12-31 0001196298 neph:MarchTwoThousandElevenLambdaWarrantsMember 2013-12-31 0001196298 neph:ClassDWarrantsLambdaMember 2012-12-31 0001196298 neph:JulyTwoThousandNineWarrantsMember 2012-12-31 0001196298 us-gaap:ShareholdersEquityMember 2012-12-31 0001196298 neph:MarchTwoThousandElevenLambdaWarrantsMember 2012-12-31 0001196298 neph:ClassDWarrantsLambdaMember 2011-12-31 0001196298 neph:ClassDWarrantsOtherMember 2011-12-31 0001196298 neph:ClassDWarrantsMember 2011-12-31 0001196298 neph:ClassDWarrantsLambdaMember 2012-01-01 2012-12-31 0001196298 neph:ClassDWarrantsOtherMember 2012-01-01 2012-12-31 0001196298 neph:ClassDWarrantsMember 2012-01-01 2012-12-31 0001196298 neph:ClassDWarrantsLambdaMember 2013-01-01 2013-12-31 0001196298 neph:ClassDWarrantsOtherMember 2013-01-01 2013-12-31 0001196298 neph:ClassDWarrantsMember 2013-01-01 2013-12-31 0001196298 neph:ClassDWarrantsOtherMember 2012-12-31 0001196298 neph:ClassDWarrantsMember 2012-12-31 0001196298 neph:ClassDWarrantsOtherMember 2013-12-31 0001196298 neph:ClassDWarrantsMember 2013-12-31 0001196298 neph:ThreePercentEmployeeContributionMember 2003-12-01 2004-01-01 0001196298 neph:TwoPercentEmployeeContributionMember 2003-12-01 2004-01-01 0001196298 neph:LeasesMember 2013-12-31 0001196298 us-gaap:EmploymentContractsMember 2013-12-31 0001196298 neph:LambdaInvestorsLlcMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2013-02-04 0001196298 neph:LambdaInvestorsLlcMember us-gaap:SeniorNotesMember 2013-11-12 0001196298 neph:LambdaInvestorsLlcMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2013-01-05 2013-02-04 0001196298 neph:LambdaInvestorsLlcMember us-gaap:SeniorNotesMember 2013-10-13 2013-11-12 0001196298 neph:LambdaInvestorsLlcMember 2013-10-13 2013-11-12 0001196298 neph:RightOfferingMember 2013-01-01 2013-12-31 0001196298 neph:TwoThousandPlanMember neph:NonEmployeeStockOptionsMember 2013-01-01 2013-12-31 0001196298 neph:TwoThousandPlanMember us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0001196298 us-gaap:RestrictedStockMember 2012-12-31 0001196298 us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001196298 us-gaap:RestrictedStockMember 2013-12-31 0001196298 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001196298 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001196298 neph:SterisAgreementTerminationMember 2013-01-01 2013-12-31 0001196298 neph:ClassDWarrantLambdaMember 2013-01-01 2013-12-31 0001196298 us-gaap:SubsequentEventMember 2014-03-01 2014-03-24 0001196298 us-gaap:SubsequentEventMember 2014-03-31 0001196298 us-gaap:SubsequentEventMember 2014-02-01 2014-02-19 0001196298 us-gaap:SubsequentEventMember 2014-03-01 2014-03-31 0001196298 neph:LambdaInvestorsMember us-gaap:SeniorNotesMember 2013-12-31 0001196298 us-gaap:SubsequentEventMember 2014-03-01 2014-03-21 0001196298 us-gaap:MinimumMember neph:FederalMember 2013-01-01 2013-12-31 0001196298 us-gaap:MaximumMember neph:FederalMember 2013-01-01 2013-12-31 0001196298 neph:MrKochanskMember 2013-06-01 2013-06-15 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:EUR neph:Warrant iso4217:EUR neph:Product iso4217:USD neph:Warrant xbrli:pure <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Note 3&#160;-&#160;Inventory</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The Company&#8217;s inventory components as of December 31, 2013 and 2012 were as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Total Gross Inventory, Finished Goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>527,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>581,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Less: Inventory reserve</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(365,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(269,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Total Inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>162,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>312,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Note 12&#160;-&#160;Commitments and Contingencies</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Manufacturing and Suppliers</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company has not and does not intend in the near future, to manufacture any of its products and components. With regard to the OLpur MD190 and MD220, on June 27, 2011, the Company entered into a license agreement, effective July 1, 2011, with Bellco S.r.l., an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of our patented mid-dilution dialysis filters (MD 190, MD 220), referred to herein as the Products. Under the agreement, Nephros granted Bellco a license to manufacture, market and sell the Products under its own name, label and CE mark in Italy, France, Belgium, Spain and Canada on an exclusive basis, and to do the same on a non-exclusive basis in the United Kingdom and Greece and, upon our written approval, other European countries where the Company does not sell the Products as well as non-European countries (referred to as the &#8220;Territory&#8221;).</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">On February 19, 2014, the Company entered into the First Amendment to License Agreement (the &#8220;First Amendment&#8221;), by and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011 by and between the Company and Bellco.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> Pursuant to the First Amendment, the Company and Bellco agreed to extend the term of the License Agreement through December 31, 2021. The First Amendment also expands the Territory covered by the License Agreement to include Sweden, Denmark, Norway, Finland, Korea, Mexico, Brazil, China and the Netherlands. The First Amendment further provides new minimum sales targets which, if not satisfied, will, at the discretion of the Company, result in conversion of the license to non-exclusive status. The Company has agreed to reduce the fixed royalty payment payable to the Company for the period beginning on January 1, 2015 through and including December 31, 2021. Beginning on January 1, 2015 through and including December 31, 2016, Bellco will pay us a royalty based on the number of units of Products sold per year in the Territory as follows: for the first <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 125,000</font> units sold,<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.75</font> per unit; thereafter, &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.25</font> per unit. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font> In addition, the Company will receive a total of &#8364;450,000 in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. In addition, the First Amendment provides that, in the event that the Company pursues a transaction to sell, assign or transfer all right, title and interest to the licensed patents to a third party, the Company will provide Bellco with written notice thereof and a right of first offer with respect to the contemplated transaction for a period of thirty (30) days.</font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></font><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">License and Supply Agreement</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">On April 23, 2012, the Company entered into a License and Supply Agreement (the &#8220;License and Supply Agreement&#8221;) with Medica S.p.A. (&#8220;Medica&#8221;), an Italy-based medical product manufacturing company, for the marketing and sale of certain filtration products based upon Medica&#8217;s proprietary Medisulfone ultrafiltration technology in conjunction with the Company&#8217;s filtration products (collectively, the &#8220;Filtration Products&#8221;), and to engage in an exclusive supply arrangement for the Filtration Products. Under the License and Supply Agreement, Medica granted to the Company an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale and sell the Filtration Products worldwide, excluding Italy for the first three years, during the term of the License and Supply Agreement. In addition, the Company granted to Medica an exclusive license under the Company&#8217;s intellectual property to make the Filtration Products during the term of the License and Supply Agreement. In exchange for the rights granted, the Company has agreed to make minimum annual aggregate purchases from Medica of &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">300,000</font>, &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> and &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">750,000</font> for the years 2012, 2013 and 2014, respectively. In the year ended December 31, 2013 the Company&#8217;s aggregate purchase commitments totaled approximately &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">532,000</font>. For calendar years thereafter, annual minimum amounts will be mutually agreed upon between Medica and the Company.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">In exchange&#160;for the license, the Company paid&#160;Medica&#160; &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,500,000</font> in three installments:&#160;&#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> on April 23, 2012, <font style="FONT-FAMILY: 'Times New Roman'"> &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">600,000</font> on February 4</font>, 2013, and <font style="FONT-FAMILY: 'Times New Roman'">&#8364;400,000 on May 23, 2013</font></font><font style="FONT-SIZE: 10pt">.&#160;As further consideration for the license and other rights granted to the Company, the Company granted Medica options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 300,000</font> shares of the Company&#8217;s common stock. The fair market value of these stock options was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">273,000</font> at the time of their issuance, calculated as described in Note 2 under Stock-Based Compensation. The fair market value of the options has been capitalized as a long-term intangible asset along with the total installment payments described. Other long-term assets on the consolidated balance sheet is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,894,000</font>, net of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">356,000</font> accumulated amortization, and is related to the License and Supply Agreement. The asset is being amortized as an expense over the life of the agreement. Approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">214,000</font> and&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">142,000</font> have been charged to amortization expense for the years ended December 31, 2013 and 2012, respectively,&#160;on the consolidated statement of operations and comprehensive loss. Approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">208,000</font> of amortization expense will be recognized in the years ended December 31, 2014 and 2015, respectively. In addition, for the period beginning April 23, 2014 through December 31, 2022, the Company will pay Medica a royalty rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>% of net sales of the Filtration Products sold, subject to reduction as a result of a supply interruption pursuant to the terms of the License and Supply Agreement. The term of the License and Supply Agreement commenced on April 23, 2012 and continues in effect through December 31, 2022, unless earlier terminated by either party in accordance with the terms of the License and Supply Agreement.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of September 2013, we have an understanding with Medica whereby we have agreed to pay interest to Medica at a 12% annual rate calculated on the principal amount of any outstanding invoices that are not paid pursuant to the original payment terms</font>.</font></div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="left"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Employment Agreement</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">On April 20, 2012, the Company entered into an Employment Agreement, effective as of April 20, 2012, with John C. Houghton (&#8220;Employment Agreement&#8221;). The Employment Agreement has a term of four years, ending on April 20, 2016. The Employment Agreement provides that Mr. Houghton&#8217;s annual base salary will be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000</font>. Mr. Houghton will be eligible to receive a target discretionary bonus of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>% of annual base salary, as determined by the Company.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><strong>&#160;</strong></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Contractual Obligations</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company had an operating lease that expired on November 30, 2013 for the rental of its U.S. office and research and development facilities with a monthly cost of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,000</font>. On July 25, 2013, the Company signed a one year lease extension for the same office space which will expire on November 30, 2014 with a monthly cost of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,000</font> beginning December 1, 2013.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Rent expense for the years ended December 31, 2013 and 2012 totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">108,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">109,000</font>,&#160;respectively.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;</font></font> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> </font></font><font style="COLOR: black"><font style="FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><strong>Contractual Obligations and Commercial Commitments</strong></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The following tables summarize our approximate minimum contractual obligations and commercial commitments as of December 31, 2013:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="39%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%" colspan="14"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> Payments&#160;Due&#160;in&#160;Period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="39%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> Within<br/> 1&#160;Year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">Years<br/> 1&#160;-&#160;3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">Years<br/> 4&#160;-&#160;5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> More&#160;than<br/> 5&#160;Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> Leases</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> 108,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> 100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> 8,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> Employment Contracts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> 788,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> 350,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> 438,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> 896,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> 450,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> 446,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> &#160;&#160;&#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font></font></font></font></div> <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"><strong> Product Recall</strong></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On October 30, 2013, the Company filed a Current Report on Form 8-K announcing the voluntary recalls of its point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> As a result, the Company has recalled all production lots of its POU filters, and also requested that customers remove and discard certain labeling/promotional materials for the products.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> In addition, the Company also requested, for the DSU in-line ultrafilter, that customers remove and discard certain labeling/promotional materials for the product.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> These voluntary recalls do not affect the Company&#8217;s dialysis products.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> The consolidated financial statements for the year ended December 31, 2013 include product revenues and cost of goods sold adjustments of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">216,00</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">110,000</font>, respectively, reflecting estimates of the financial impact of product recalled to the Company.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> This recall and the related circumstances could subject the Company to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact the Company&#8217;s sales and revenues.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> The Company has fully reserved the recalled product and will destroy the respective product by April 20, 2014.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> Note 14&#160;- Subsequent Events</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"></font></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt">On March 24, 2014, the Company announced the completion of a rights offering that resulted in gross proceeds</font> of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.1</font> million <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt">and the issuance of 7,140,822 shares of common stock. A portion of the proceeds was used for the repayment</font> of the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> million note issued to Lambda Investors LLC in November 2013 in connection with its loan to the Company,</font>&#160;plus $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">61,000</font>&#160;<font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt">of accrued interest thereon. The Company issued a total</font>&#160;of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,140,822</font> shares of common <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> stock to the holders of subscription rights who validly exercised their subscription rights, which represents 77% of the total shares offered in the rights offering</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"></font>On February 19, 2014, the Company entered into the First Amendment to License Agreement (the &#8220;First Amendment&#8221;), by and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011 by and between the Company and Bellco.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> Pursuant to the First Amendment, the Company and Bellco agreed to extend the term of the License Agreement through December 31, 2021. The First Amendment also expands the Territory covered by the License Agreement to include Sweden, Denmark, Norway, Finland, Korea, Mexico, Brazil, China and the Netherlands. The First Amendment further provides new minimum sales targets which, if not satisfied, will, at the discretion of the Company, result in conversion of the license to non-exclusive status. The Company has agreed to reduce the fixed royalty payment payable to the Company for the period beginning on January 1, 2015 through and including December 31, 2021. The Company will receive a total of &#8364;450,000 in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. In addition, the First Amendment provides that, in the event that the Company pursues a transaction to sell, assign or transfer all right, title and interest to the licensed patents to a third party, the Company will provide Bellco with written notice thereof and a right of first offer with respect to the contemplated transaction for a period of thirty (30) days.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Note 1&#160;-&#160;Organization and Nature of Operations</font></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Nephros, Inc. (&#8220;Nephros&#8221; or the &#8220;Company&#8221;) was incorporated under the laws of the State of Delaware on April 3, 1997. Nephros was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced End Stage Renal Disease (&#8220;ESRD&#8221;) therapy technology and products. The Company has two products in various stages of development in the hemodiafiltration, or HDF, modality to deliver improved therapy for ESRD patients. These are the OLpur MDHDF filter series or &#8220;dialyzers,&#8221; designed expressly for HDF therapy, the OLpur H2H, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy. In 2009, the Company introduced its Dual Stage Ultrafilter (&#8220;DSU&#8221;) water filter system, which represents a new and complementary product line to the Company&#8217;s existing ESRD therapy business. The DSU incorporates the Company&#8217;s unique and proprietary dual stage filter architecture.<br/> <br/> </font></font> <font style="COLOR: black"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: black; FONT-SIZE: 10pt"> On June 4, 2003, Nephros International Limited was incorporated under the laws of Ireland as a wholly-owned subsidiary of the Company.&#160; In August 2003, the Company established a European Customer Service and financial operations center in Dublin, Ireland.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 47000 579000 935000 122000 312000 162000 109000 125000 1403000 988000 16000 7000 2109000 1894000 3528000 2889000 1070000 1073000 1318000 0 321000 365000 707000 703000 3416000 3499000 707000 0 4123000 3499000 0 0 12000 18000 96847000 100526000 76000 74000 -97530000 -101228000 -595000 -610000 3528000 2889000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> Note 2&#160;-&#160;Summary of Significant Accounting Policies</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Principles of Consolidation and Basis of Presentation</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nephros International Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">These <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> consolidated&#160;</font> financial statements were approved by management and the Board of Directors and are available for issuance as of the date of the audit opinion.&#160; Subsequent events have been evaluated through this date.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Use of Estimates in the Preparation of Financial Statements</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> consolidated&#160;</font> financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> Certain prior year amounts have been reclassified to conform to the current year presentation.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Going Concern and Management&#8217;s Response</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The accompanying <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> consolidated&#160;</font> financial statements have been prepared assuming that the Company will continue as a going concern. The Company&#8217;s recurring losses and difficulty in generating sufficient cash flow to meet its obligations and sustain its operations raise substantial doubt about its ability to continue as a going concern. The Company&#8217;s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company has incurred significant losses in operations in each quarter since inception. For the years ended December 31, 2013 and 2012, the Company has incurred net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,698,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,262,000</font>, respectively. In addition, the Company has not generated positive cash flow from operations for the years ended December 31, 2013 and 2012. To become profitable, the Company must increase revenue substantially and achieve and maintain positive gross and operating margins. If the Company is not able to increase revenue and gross and operating margins sufficiently to achieve profitability, its results of operations and financial condition will be materially and adversely affected<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">.</font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> </font></font></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> T</font></font></font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">he voluntary recalls of point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications announced on October 30, 2013 and the related circumstances could subject the Company to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact the Company&#8217;s sales and revenues.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>On June 27, 2011, the Company entered into a License Agreement,&#160;&#160;effective July 1, 2011, with Bellco S.r.l., as&#160;licensee (&#8220;Bellco&#8221;), an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of Nephros&#8217; patented mid-dilution dialysis filters.&#160; This Agreement provided the Company with payments of &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font>, &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">750,000</font>, and &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">600,000</font> on July 1, 2011, January 15, 2012 and January 15, 2013, respectively.&#160;<font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman">On February 19, 2014, the Company entered into the First Amendment to License Agreement (the &#8220;First Amendment&#8221;), by&#160;</font></font> and <font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman">between the Company</font></font> and Bellco, which amends the License Agreement, entered into&#160;as of July 1, 2011. As&#160;a result of the amendment, the Company will receive a total of &#8364;450,000&#160;in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. See Note 12, Commitments and Contingencies for&#160;further discussion.&#160;&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt">On February 4, 2013 and November 12, 2013,&#160;the Company issued senior secured notes to Lambda Investors LLC in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million, respectively.&#160; <font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman">As of December 31, 2013, the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million note is outstanding. The $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million note was repaid on May 22, 2013.</font></font>&#160; For a more detailed discussion of the terms of the senior secured notes, see Note 6, Senior Secured Notes.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman">On March 21, 2014 the Company completed a rights offering which resulted in gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.1</font> million. See Note 14, Subsequent Events, for further discussion.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">There can be no assurance that the Company&#8217;s future cash flow will be sufficient to meet its obligations and commitments. If the Company is unable to generate sufficient cash flow from operations in the future to service its commitments the Company will be required to adopt alternatives, such as seeking to raise debt or equity capital, curtailing its planned activities or ceasing its operations. There can be no assurance that any such actions could be effected on a timely basis or on satisfactory terms or at all, or that these actions would enable the Company to continue to satisfy its capital requirements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Cash and Cash Equivalents</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company invests its excess cash in bank deposits and money market accounts.&#160; The Company considers all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash equivalents.&#160; Cash equivalents are carried at fair value, which approximate cost, and primarily consist of money market funds maintained at major U.S. financial institutions.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accounts Receivable</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="BACKGROUND-COLOR: transparent; FONT-SIZE: 10pt">The Company provides credit terms to customers in connection with purchases of the Company&#8217;s products. Management periodically reviews customer account activity in order to assess the adequacy of the allowances provided for potential collection issues and returns. Factors considered include economic conditions, each customer&#8217;s payment and return history and credit worthiness. Adjustments, if any, are made to reserve balances following the completion of these reviews to reflect management&#8217;s best estimate of potential&#160;losses.&#160; <font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> There were no allowances for doubtful accounts at D</font>ecember 31, 2013 or 2012.&#160; <font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> There was no allowance for sales</font> returns at December 31, 2013 or 2012.&#160; <font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> There were no write offs of accounts receivable</font> to bad debt expense during 2013 or 2012.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Inventory</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company engages third parties to manufacture and package inventory held for sale, takes title to certain inventory once manufactured, and warehouses such goods until packaged for final distribution and sale. Inventory consists of finished goods and raw materials (fiber) held at the manufacturers&#8217; facilities, and are valued at the lower of cost or market using the first-in, first-out method. The Company&#8217;s inventory reserve requirements are based on factors including the products&#8217; expiration date and estimates for the future sales of the product. If estimated sales levels do not materialize, the Company will make adjustments to its assumptions for inventory reserve requirements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt">In March 2014, the Company requested the closeout of its October 2013 voluntary product recall.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> The Company has fully reserved the recalled product and will destroy the respective product by April 20, 2014.</font></font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Patents</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company has filed numerous patent applications with the United States Patent and Trademark Office and in foreign countries. All costs and direct expenses incurred in connection with patent applications have been expensed as incurred.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Property and Equipment, net</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Property and equipment, net is stated at cost less accumulated depreciation.&#160; These assets are depreciated over their estimated useful lives of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> three</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> seven</font> years&#160;using the straight line method.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><strong>Impairment for Long-Lived Assets</strong></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company adheres to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 360 and periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. An estimate of the asset&#8217;s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its carrying value or its estimated net realizable market value. There were no impairment losses for long-lived assets recorded for the years ended December 31, 2013 and December 31, 2012.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Fair Value of Financial Instruments</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturity of these instruments.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Revenue Recognition</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Revenue is recognized in accordance with ASC Topic 605.&#160; Four basic criteria must be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company recognizes revenue related to product sales when delivery is confirmed by its external logistics provider and the other criteria of ASC Topic 605 are met. Product revenue is recorded net of returns and allowances.&#160; All costs and duties relating to delivery are absorbed by Nephros. All shipments are currently received directly by the Company&#8217;s customers.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Deferred revenue&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">was approximately $703,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,414,000</font> on the accompanying consolidated balance sheets as of December 31, 2013 and 2012, respectively, and is related to the License Agreement with Bellco. The Company has recognized approximately $1,756,000 of revenue related to this license agreement to date, including approximately $711,000 for the year ended December 31, 2013, resulting in $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">703,000</font> being deferred over the remainder of the expected obligation period. The Company amortizes the deferred revenue monthly over the expected obligation period which ends on December 31, 2014. This will result in expected recognized revenue of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">703,000</font></font> for each of the year ending December 31, 2014.</font></font> <font style="COLOR: black"><font style="FONT-SIZE: 10pt">Total payments of approximately&#160; $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,459,000</font>, including the &#160;final payment of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">791,000</font>&#160;&#160;received in January 2013, were related to&#160;</font></font> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the License</font> Agreement with Bellco.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>&#160;&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Shipping and Handling Costs</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Shipping and handling costs are recorded as cost of goods sold and are approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33,000</font> for the years ended December 31, 2013 and 2012, respectively.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <b><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> Research and Development Costs</font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Research and development costs are expensed as incurred.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"> </font></strong>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Stock-Based Compensation</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company accounts for stock-based compensation in accordance with ASC Topic 718 by recognizing the fair value of stock-based compensation in the <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> consolidated</font> statement of operations <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and comprehensive loss</font>.&#160; The fair value of the Company&#8217;s stock option awards are estimated using a Black-Scholes option valuation model. This model requires the input of highly subjective assumptions and elections including expected stock price volatility and the estimated life of each award. In addition, the calculation of compensation costs requires that the Company estimate the number of awards that will be forfeited during the vesting period. The fair value of stock-based awards is amortized over the vesting period of the award.&#160; For stock-based awards that vest based on performance conditions (e.g. achievement of certain milestones), expense is recognized when it is probable that the condition will be met.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Amortization of Debt Issuance Costs</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company accounts for debt issuance costs in accordance with ASC 835, which requires that costs paid directly to the issuer of&#160; the notes be reported in the balance sheet as a debt discount and amortized over the term of the associated debt.&#160;Debt issuance costs of <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">399,000</font></font> for the year ended December 31, 2013 are associated with the senior secured notes issued to Lambda Investors LLC&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">on <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">February 4, 2013 and&#160;</font> November 12, 2013. Approximately $257,000 of these costs were amortized as of December 31, 2013 and are included in amortization of debt discount on the consolidated statements of operations <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and comprehensive loss</font>.</font>&#160;There were no debt issuance costs for the year ended December 31, 2012.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Other <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Income (Expense), net</font></font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Other&#160;income (expense), net, <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of approximately $33,000&#160;</font> includes&#160;approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> of other expense&#160;for the year ended December 31, 2013,&#160;primarily due to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">36,000</font>&#160;related to&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">foreign currency losses and</font> approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,000</font>&#160;related to <font style="FONT-FAMILY: 'Times New Roman'">the <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">May 2013 rights offering&#160;</font> warrant modification. Other expense was partially offset by other income of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17,000</font>, which consisted primarily of a refund of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,000</font> received as a result of the Steris agreement termination.&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Other income (expense), net, in the amount of approximately <font style="COLOR: black">$14,000 for the year ended December 31, 2012 is due primarily to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,000</font> in write-offs of old vendor invoices which are no longer due, offset partially by approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,000</font> of net foreign currency losses on invoices paid to and due to an international supplier.</font></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"> </font></strong>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Income Taxes</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company accounts for income taxes in accordance with ASC Topic 740, which requires accounting for deferred income taxes under the asset and liability method. Deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable in future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">For financial reporting purposes, the Company has incurred a loss in each period since its inception. Based on available objective evidence, including the Company&#8217;s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2013 and 2012.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">ASC Topic 740 prescribes, among other things, a recognition threshold and measurement attributes for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company&#8217;s income tax return.&#160; ASC 740 utilizes a two-step approach for evaluating uncertain tax positions.&#160; Step one, or recognition, requires a company to determine if the weight of available evidence indicates a tax position is more likely than not to be sustained upon audit, including resolution of related appeals or litigation processes, if any.&#160; Step two, or measurement, is based on the largest amount of benefit, which is more likely than not to be realized on settlement with the taxing authority.&#160; The Company is subject to income tax examinations by major taxing authorities for all tax years&#160;subsequent to 2010.&#160; The adoption of the provisions of ASC 740 did not have a material impact on the Company&#8217;s consolidated financial statements.&#160; During the years ended December 31, 2013 and 2012, the Company recognized no adjustments for uncertain tax positions.&#160; However, management&#8217;s conclusions regarding this policy may be subject to review and adjustment at a later date based on factors including, but not limited to, on-going analyses of and changes to tax laws, regulation and interpretations, thereof.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Loss per Common Share</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">In accordance with ASC 260-10, net loss per common share amounts (&#8220;basic EPS&#8221;) are computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding and excluding any potential dilution. Net loss per common share amounts assuming dilution (&#8220;diluted EPS&#8221;) is generally computed by reflecting potential dilution from conversion of convertible securities and the exercise of stock options and warrants. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following securities have been excluded from the dilutive per share computation as they are antidilutive:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,410,134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,294,714</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,887,598</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,679,971</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="54%"> <div>Unvested restricted stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>75,450</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Foreign Currency Translation</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Foreign currency translation is recognized in accordance with ASC Topic 830.&#160; The functional currency of Nephros International Limited is the Euro and its translation gains and losses are included in accumulated other comprehensive income. The balance sheet is translated at the year-end rate. The statement of operations is translated at the weighted average rate for the year.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Comprehensive Income (Loss)</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Comprehensive income (loss), as defined in ASC 220, &#160;is the total of net income (loss) and all other non-owner changes in equity (or other comprehensive income (loss)) such as foreign currency translation adjustments. For the years ended December 31, 2013 and 2012, the comprehensive loss was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,700,000</font> and $3,235,000, respectively.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Recently Adopted Accounting Pronouncements</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"> </font></strong><font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: black; FONT-SIZE: 10pt"> There were no recent accounting pronouncements that are expected to have an effect on the Company&#8217;s consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Note 4&#160;-&#160;Prepaid Expenses and Other Current Assets</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Prepaid expenses and other current assets as of December 31, 2013 and 2012 were as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Prepaid insurance premiums</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>70,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>78,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Security deposit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>34,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Prepaid expenses and other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>125,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>109,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"><strong> Note 5&#160;-&#160;Property and Equipment, Net</strong></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Property and equipment as of December 31, 2013 and 2012 was as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>Manufacturing equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3-5&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>599,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>602,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>Research equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>5&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3-4&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>7&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>39,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>39,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>Property and equipment, gross</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>734,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>737,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>Less: accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>727,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Depreciation expense for each of&#160;the years ended December 31, 2013 and 2012 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,000</font>,&#160; including amortization expense relating to research and development assets.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> During 2013, the Company sold fully depreciated equipment totaling approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,000</font> which is reflected as gain on sale of equipment on the consolidated statements of operations and comprehensive loss.</font> During 2012, the Company agreed to sell its manufacturing equipment to Medica for approximately &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,500</font>,&#160;or $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55,000</font>. All assets at the manufacturing plant were fully depreciated as of the date of the sale. Approximately &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,500</font>,&#160;or $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55,000</font>,&#160;is recognized as gain on sale of equipment on the consolidated statements of operations and comprehensive loss&#160;for the year ended December 31, 2012.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Note 7&#160;-&#160;Accrued Expenses</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Accrued expenses as of December 31, 2013 and 2012 were as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Legal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>149,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>90,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div>Accrued Product Recall</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>60,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Directors&#8217; Compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>77,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Management Bonus</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>81,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>39,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Travel</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>84,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>36,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>365,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>321,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> </font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"></font></strong>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> Note 8&#160;-&#160;Income Taxes</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A reconciliation of the income tax provision computed at the statutory tax rate to the Company&#8217;s effective tax rate is as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="3"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>U.S. federal statutory rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>35.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>35.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>State &amp; local taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Tax on foreign operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.78)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>State research and development credits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.09</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.06</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2.29)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(38.71)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(38.35)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Effective tax rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Significant components of the Company&#8217;s deferred tax assets as of December 31, 2013 and 2012 are as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Deferred tax assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Net operating loss carry forwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,029,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Research and development credits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,096,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,054,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Nonqualified stock option compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,801,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,701,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Other temporary book - tax differences</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>408,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>441,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Total deferred tax assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>30,334,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,917,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Valuation allowance for deferred tax assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(30,334,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(28,917,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Net deferred tax assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: black; FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black">A valuation allowance has been recognized to offset the Company&#8217;s net deferred tax asset as it is more likely than not that such net asset will not be realized. The Company primarily considered its historical loss and potential Internal Revenue Code Section 382 limitations to arrive at its conclusion that a valuation allowance was required.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font><font style="COLOR: black"></font>&#160;<font style="COLOR: black"> </font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">At December 31, 2013, the Company had Federal and New Jersey income tax net operating loss carryforwards of $87,292,000 and foreign income tax net operating loss carryforwards of $8,305,000. The Company also had Federal research tax credit carryforwards of $1,096,000 at December 31, 2013 and $1,054,000 at December 31, 2012. The Federal net operating loss and tax credit carryforwards will expire at various times between 2014 and 2026 unless utilized.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> </font>&#160;</div> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt">It is the Company&#8217;s policy to report interest and penalties, if any, related to unrecognized tax benefits in income tax expense.</font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> Note 9&#160;- Stock Plans, Share-Based Payments and Warrants</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Stock Plans</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">In 2000, the Company adopted the Nephros 2000 Equity Incentive Plan. In January 2003, the Board of Directors adopted an amendment and restatement of the plan and renamed it the Amended and Restated Nephros 2000 Equity Incentive Plan (the &#8220;2000 Plan&#8221;), under which <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 106,538</font></font> shares of common stock had been authorized for issuance upon exercise of options granted.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">As of December 31, 2013 and&#160;2012, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 831</font> and&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,053</font></font> options<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, respectively,</font> had been issued to non-employees under the 2000 Plan and were outstanding. <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> During the twelve months ended December 31, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,222</font> non-employee options expired.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> The remaining outstanding options, all of which are fully vested, will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">March 15, 2014</font>.</font>&#160;As of December 31, 2013 and 2012, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,003</font> and&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,230</font></font> options<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, respectively,</font> had been issued to employees under the 2000 Plan and were outstanding. <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> During the twelve months ended December 31, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,227</font></font> employee options expired.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> The remaining employee options, all of which are fully vested, will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> March 15, 2014</font></font></font>.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Board retired the 2000 Plan in June 2004, and thereafter no additional awards may be granted under the 2000 Plan.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">In 2004, the Board of Directors adopted and the Company&#8217;s stockholders approved the Nephros, Inc. 2004 Stock Incentive Plan<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">. During the year ended December 31, 2013,</font> the Company&#8217;s stockholders approved an amendment to such plan (as amended, the &#8220;2004 Plan&#8221;), that increased the number of shares of the Company&#8217;s common stock that are authorized for issuance by the Company pursuant to grants of awards under the 2004 Plan to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,500,000</font></font>.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">As of December 31, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,360,059</font></font> options had been issued to employees under the 2004 Plan and were outstanding. The options expire on various dates between April 27, 2015 and March 24, 2021, and vest upon a combination of the following: immediate vesting or straight line vesting of two or four years. At December 31, 2013, there were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,407,318</font></font> shares available for future grants under the 2004 Plan. As of December 31, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 715,692</font></font> options had been issued to non-employees under the 2004 Plan and were outstanding. Such options expire at various dates between November 11, 2014 and November 18, 2021, and vest upon a combination of the following: immediate vesting or straight line vesting of two or four years. <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In addition, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 331,550</font> options were issued in 2012 to the Company&#8217;s CEO per terms of his employment agreement and are outstanding as of December 31, 2013.</font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">As of December 31, 2012, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,316,628</font></font> options had been issued to employees under the 2004 Plan and were outstanding. The options expire on various dates between April 27, 2015 and May 23, 2023, and vest upon a combination of the following: immediate vesting or straight line vesting of two to four years. At December 31, 2012, there were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 19,904</font></font> shares available for future grants under the 2004 Plan. As of December 31, 2012, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 637,253</font></font> options had been issued to non-employees under the 2004 Plan and were outstanding. Such options expire at various dates between November 11, 2014 and <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">December 31, 2023</font>, and vest upon a combination of the following: immediate vesting or straight line vesting of two to four years.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font> <font style="COLOR: black"> <font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Share-Based Payment</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Prior to the Company&#8217;s initial public offering, options were granted to employees, non-employees and non-employee directors at exercise prices which were lower than the fair market value of the Company&#8217;s stock on the date of grant. After the date of the Company&#8217;s initial public offering, stock options are granted to employees, non-employees and non-employee directors at exercise prices equal to the fair market value of the Company&#8217;s stock on the date of grant. Stock options granted have a life of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> years.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black">Expense is recognized, net of expected forfeitures, over the vesting period of the options. For options that vest upon the achievement of certain milestones, expense is recognized when it is probable that the condition will be met. Stock based compensation expense recognized for the years ended December 31, 2013 and 2012 was approximately&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">418,000</font> or less than $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.03</font> per share and approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">443,000</font> or less than $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.04</font> per share, respectively.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Gerald J. Kochanski, Chief Financial Officer, Treasurer and Corporate Secretary of Nephros, Inc., resigned effective June 15, 2013. The Company agreed, in consideration of Mr. Kochanski providing certain consulting services to the Company, to extend the exercise period of his outstanding vested stock options from September 15, 2013 to March 14, 2014. This modification did not result in any additional compensation expense. In addition, as a result of Mr. Kochanski&#8217;s resignation, 90,945 stock options that were granted to him were forfeited on June 15, 2013. Of these 90,945 stock options, 25,000 were granted during the twelve month period ended December 31, 2013.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the below assumptions related to risk-free interest rates, expected dividend yield, expected lives and expected stock price volatility.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%" colspan="6"> <div>Option&#160;Pricing&#160;Assumptions</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>Grant&#160;Year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="51%"> <div>Stock Price Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>127.46-135.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>123.48&#160;&#150;128.54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Risk-Free Interest Rates</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>1.09-1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>.093-1.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expected Life (in years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>5.00-6.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>5.75-62.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expected Dividend Yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Expected volatility is based on historical volatility of the Company&#8217;s common stock at the time of grant. The risk-free interest rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected life of the options. For the expected life, the Company is using the simplified method as described in the SEC Staff Accounting Bulletin 107. This method assumes that stock option grants will be exercised based on the average of the vesting periods and the option&#8217;s life.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The total fair value of options vested during the fiscal year ended December 31, 2013 was approximately&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">519,000</font>. The total fair value of options vested during the fiscal year ended December 31, 2012 was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">506,000</font>.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table summarizes information about stock options outstanding and exercisable at December 31, 2013:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 91%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="39%" colspan="8"> <div>Options&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%" colspan="5"> <div>Options&#160;Exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"> <div>Range&#160;of&#160;Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%" colspan="2"> <div>Number<br/> Outstanding&#160;as<br/> of&#160;December<br/> 31,&#160;2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life&#160;in<br/> Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number<br/> Exercisable&#160;as<br/> of<br/> December&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>$0.41 - $2.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>2,374,514</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,349,579</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>$15.00 - $29.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>27,909</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17.82</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>27,909</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>17.82</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>$34.20-$96.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>7,711</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.38</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>51.49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7,711</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>51.49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>Total Outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>2,410,134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,385,199</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 13.2pt; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The number of new options granted in 2013 and 2012 is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 237,315</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,547,550</font>, respectively. The weighted-average fair value of options granted in 2013 and 2012 is $0.56 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.03</font>, respectively.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt">The following table summarizes the option activity for the year ended December 31, 2013:</font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="3"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Outstanding at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,294,714</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>237,315</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Options forfeited or expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(121,895)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,410,134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Exercisable at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>1,385,199</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Vested and expected to vest at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2,350,688</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The aggregate intrinsic value of stock options outstanding at December 31, 2013 is $<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and of stock options vested or expected to vest is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>. A stock option has intrinsic value, at any given time, if and to the extent that the exercise price of such stock option is less than the market price of the underlying common stock at such time. The weighted-average remaining contractual life of options vested or expected to vest is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.1</font> years.</font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The aggregate intrinsic value of stock options outstanding at December 31, 2012 is $</font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">793,000</font> and of stock options vested or expected to vest is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">768,000</font>. A stock option has intrinsic value, at any given time, if and to the extent that the exercise price of such stock option is less than the market price of the&#160;underlying common stock at such time. The weighted-average remaining contractual life of options vested or expected to vest is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.9</font> years.</font></font><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">As of December 31, 2013, the total remaining unrecognized compensation cost related to non-vested stock options amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">727,000</font> and will be amortized over the weighted-average remaining requisite service period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.3</font> years.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black">Restricted Stock</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black">The Company has issued restricted stock as compensation for the services of certain employees and non-employee directors.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> The grant date fair value of restricted stock was based on the fair value of the common stock on the date of grant, and compensation expense is recognized based on the period in which the restrictions lapse.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes restricted stock activity for the year end December 31, 2013:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average<br/> Grant&#160;Date<br/> Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Nonvested at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>398,227</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(264,770)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(58,007)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Nonvested at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>75,450</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.66</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Total stock-based compensation expense for the restricted stock was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">157,000</font> for the year ended December 31, 2013.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> <font style="COLOR: black">For the year ended December 31, 2013, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">109,000</font> and approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">48,000</font> are included in Selling, General and Administrative expenses and Research and Development expenses, respectively, on the accompanying condensed consolidated statement of operations. The remaining expense related to the restricted stock awards issued to non-employee directors of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">77,000</font> was recorded to offset accrued director&#8217;s fees that were incurred prior to December 31, 2012. Any additional stock-based compensation related to non-employee directors will be recorded to stock-based compensation expense. As of December 31, 2013, there was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,000</font> of unrecognized compensation expense related to the restricted stock awards, which is expected to be recognized over the next six months.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><strong><font style="COLOR: black"> </font></strong></font></div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Warrants</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table summarizes certain terms of all of the Company&#8217;s outstanding warrants at December 31, 2013 and 2012:</font></font><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><strong><font style="COLOR: black"> </font></strong>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="100%" colspan="15"> <div> Total&#160;Outstanding&#160;Warrants&#160;at&#160;December&#160;31,&#160;2013</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%"> <div>Title&#160;of&#160;Warrant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%"> <div>Date&#160;Issued</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%"> <div>Expiry&#160;Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div>Total&#160;Common<br/> Shares&#160;Issuable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="32%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Class D Warrants - Lambda</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>11/14/2007</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>3/10/2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>July 2009 Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>7/24/2009</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>7/24/2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>22.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>33,629</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>33,629</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Shareholder Rights Offering Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>3/10/2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>3/10/2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>2,264,817</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3,057,190</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>March 2011 Lambda Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>3/10/2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>3/10/2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>2,782,577</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>2,782,577</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>13,887,598</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>14,679,971</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The weighted average exercise price of the outstanding warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.45</font></font> for December 31, 2013 and 2012.</font></font><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"></font></strong>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Following the closing of the rights offering in 2013, Lambda Investors&#8217; existing warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,806,575</font> shares that remain outstanding were amended to expire&#160;on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">March 10, 2017</font>.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table summarizes the Class D outstanding warrants at December 31, 2013 and 2012:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Lambda&#160;Investors</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Other&#160;Investors</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%" colspan="2"> <div>Total&#160;Shares&#160;to&#160;be&#160;issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>As of December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>447,197</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>9,253,772</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Exercised in 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(352,034)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>(352,034)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Expired in 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(95,163)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>(95,163)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>As of December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Exercised in 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Expired in 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>As of December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Class D warrant holders elected to exercise <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 352,034</font> of the outstanding Class D Warrants in 2012. As a result, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 190,326</font> were exercised pursuant to the cashless exercise provision of the warrant. In addition, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 161,708</font> warrants were exercised resulting in proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65</font>,000.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Warrants exercised during 2013 and 2012</font></font></strong></div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In connection with the 2013 Rights Offering, the Company temporarily reduced the exercise price for its warrants issued in March 2011 from $0.40 per share to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.30</font> per share. The Company determined that this inducement was a modification of equity instruments and, therefore, an incremental fair value of the inducement was determined using the Black-Scholes option pricing model.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">During the period that the 2013 Rights Offering was open, warrant holders exercised <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14,879,708</font></font> warrants, issued in March 2011, for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 687,793</font></font> shares of common stock, resulting in gross proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">206,000</font></font> to the Company. The incremental fair value of the inducement recorded in the year ended December 31, 2013 was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,000</font></font>.<br/> <br/> Additionally, during the twelve months ended December 31, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,254,500</font></font> warrants were exercised outside the period that the 2013 Rights Offering was open, resulting in proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,000</font> and the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 104,206</font></font> shares of the Company&#8217;s common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">An additional 374 common shares were not issued as a result of warrant exercises for the year ended December 31,&#160;2013 due to rounding.</font></div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Shareholders exercised <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,720,667</font></font> warrants, resulting in proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">438,000</font> and the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,096,313</font></font> shares of the Company&#8217;s common stock for the year ended December 31, 2012.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> </font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="left"><font style="FONT-SIZE: 10pt"><strong>Note 11&#160;-&#160;401(k) Plan</strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company has established a 401(k) deferred contribution retirement plan (the &#8220;401(k) Plan&#8221;) which covers all employees. The 401(k) Plan provides for voluntary employee contributions of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font>% of annual earnings, as defined. As of January 1, 2004, the Company began matching <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of the first <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% of the next <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font>% of employee earnings to the 401(k) Plan. The Company contributed and expensed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">46,000</font></font></font></font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">49,000</font> in 2013 and 2012, respectively.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Principles of Consolidation and Basis of Presentation</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nephros International Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">These <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> consolidated&#160;</font> financial statements were approved by management and the Board of Directors and are available for issuance as of the date of the audit opinion.&#160; Subsequent events have been evaluated through this date.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Use of Estimates in the Preparation of Financial Statements</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> consolidated&#160;</font> financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> Certain prior year amounts have been reclassified to conform to the current year presentation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Going Concern and Management&#8217;s Response</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The accompanying <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> consolidated&#160;</font> financial statements have been prepared assuming that the Company will continue as a going concern. The Company&#8217;s recurring losses and difficulty in generating sufficient cash flow to meet its obligations and sustain its operations raise substantial doubt about its ability to continue as a going concern. The Company&#8217;s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company has incurred significant losses in operations in each quarter since inception. For the years ended December 31, 2013 and 2012, the Company has incurred net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,698,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,262,000</font>, respectively. In addition, the Company has not generated positive cash flow from operations for the years ended December 31, 2013 and 2012. To become profitable, the Company must increase revenue substantially and achieve and maintain positive gross and operating margins. If the Company is not able to increase revenue and gross and operating margins sufficiently to achieve profitability, its results of operations and financial condition will be materially and adversely affected<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">.</font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> </font></font></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> T</font></font></font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">he voluntary recalls of point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications announced on October 30, 2013 and the related circumstances could subject the Company to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact the Company&#8217;s sales and revenues.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">On June 27, 2011, the Company entered into a License Agreement,&#160;&#160;effective July 1, 2011, with Bellco S.r.l., as&#160;licensee (&#8220;Bellco&#8221;), an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of Nephros&#8217; patented mid-dilution dialysis filters.&#160; This Agreement provided the Company with payments of &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font>, &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">750,000</font>, and &#8364;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">600,000</font> on July 1, 2011, January 15, 2012 and January 15, 2013, respectively.&#160;<font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman">On February 19, 2014, the Company entered into the First Amendment to License Agreement (the &#8220;First Amendment&#8221;), by&#160;</font></font> and <font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman">between the Company</font></font> and Bellco, which amends the License Agreement, entered into&#160;as of July 1, 2011. As&#160;a result of the amendment, the Company will receive a total of &#8364;450,000&#160;in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. See Note 12, Commitments and Contingencies for&#160;further discussion.&#160;&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt">On February 4, 2013 and November 12, 2013,&#160;the Company issued senior secured notes to Lambda Investors LLC in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million, respectively.&#160; <font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman">As of December 31, 2013, the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million note is outstanding. The $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million note was repaid on May 22, 2013.</font></font>&#160; For a more detailed discussion of the terms of the senior secured notes, see Note 6, Senior Secured Notes.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman">On March 21, 2014 the Company completed a rights offering which resulted in gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.1</font> million. See Note 14, Subsequent Events, for further discussion.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">There can be no assurance that the Company&#8217;s future cash flow will be sufficient to meet its obligations and commitments. If the Company is unable to generate sufficient cash flow from operations in the future to service its commitments the Company will be required to adopt alternatives, such as seeking to raise debt or equity capital, curtailing its planned activities or ceasing its operations. There can be no assurance that any such actions could be effected on a timely basis or on satisfactory terms or at all, or that these actions would enable the Company to continue to satisfy its capital requirements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Cash and Cash Equivalents</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company invests its excess cash in bank deposits and money market accounts.&#160; The Company considers all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash equivalents.&#160; Cash equivalents are carried at fair value, which approximate cost, and primarily consist of money market funds maintained at major U.S. financial institutions.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> Accounts Receivable</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="BACKGROUND-COLOR: transparent; FONT-SIZE: 10pt">The Company provides credit terms to customers in connection with purchases of the Company&#8217;s products. Management periodically reviews customer account activity in order to assess the adequacy of the allowances provided for potential collection issues and returns. Factors considered include economic conditions, each customer&#8217;s payment and return history and credit worthiness. Adjustments, if any, are made to reserve balances following the completion of these reviews to reflect management&#8217;s best estimate of potential&#160;losses.&#160; <font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> There were no allowances for doubtful accounts at D</font>ecember 31, 2013 or 2012.&#160; <font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> There was no allowance for sales</font> returns at December 31, 2013 or 2012.&#160; <font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> There were no write offs of accounts receivable</font> to bad debt expense during 2013 or 2012.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Inventory</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company engages third parties to manufacture and package inventory held for sale, takes title to certain inventory once manufactured, and warehouses such goods until packaged for final distribution and sale. Inventory consists of finished goods and raw materials (fiber) held at the manufacturers&#8217; facilities, and are valued at the lower of cost or market using the first-in, first-out method. The Company&#8217;s inventory reserve requirements are based on factors including the products&#8217; expiration date and estimates for the future sales of the product. If estimated sales levels do not materialize, the Company will make adjustments to its assumptions for inventory reserve requirements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">In March 2014, the Company requested the closeout of its October 2013 voluntary product recall.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> The Company has fully reserved the recalled product and will destroy the respective product by April 20, 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> Patents</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company has filed numerous patent applications with the United States Patent and Trademark Office and in foreign countries. All costs and direct expenses incurred in connection with patent applications have been expensed as incurred.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Property and Equipment, net</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Property and equipment, net is stated at cost less accumulated depreciation.&#160; These assets are depreciated over their estimated useful lives of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> three</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> seven</font> years&#160;using the straight line method.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Impairment for Long-Lived Assets</strong></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company adheres to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 360 and periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. An estimate of the asset&#8217;s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its carrying value or its estimated net realizable market value. There were no impairment losses for long-lived assets recorded for the years ended December 31, 2013 and December 31, 2012.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Fair Value of Financial Instruments</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturity of these instruments.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Revenue Recognition</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Revenue is recognized in accordance with ASC Topic 605.&#160; Four basic criteria must be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company recognizes revenue related to product sales when delivery is confirmed by its external logistics provider and the other criteria of ASC Topic 605 are met. Product revenue is recorded net of returns and allowances.&#160; All costs and duties relating to delivery are absorbed by Nephros. All shipments are currently received directly by the Company&#8217;s customers.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Deferred revenue&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">was approximately $703,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,414,000</font> on the accompanying consolidated balance sheets as of December 31, 2013 and 2012, respectively, and is related to the License Agreement with Bellco. The Company has recognized approximately $1,756,000 of revenue related to this license agreement to date, including approximately $711,000 for the year ended December 31, 2013, resulting in $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">703,000</font> being deferred over the remainder of the expected obligation period. The Company amortizes the deferred revenue monthly over the expected obligation period which ends on December 31, 2014. This will result in expected recognized revenue of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">703,000</font></font> for each of the year ending December 31, 2014.</font></font> <font style="COLOR: black"><font style="FONT-SIZE: 10pt">Total payments of approximately&#160; $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,459,000</font>, including the &#160;final payment of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">791,000</font>&#160;&#160;received in January 2013, were related to&#160;</font></font> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the License</font> Agreement with Bellco.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Shipping and Handling Costs</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Shipping and handling costs are recorded as cost of goods sold and are approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33,000</font> for the years ended December 31, 2013 and 2012, respectively.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <b><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Research and Development Costs</font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Research and development costs are expensed as incurred.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Stock-Based Compensation</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company accounts for stock-based compensation in accordance with ASC Topic 718 by recognizing the fair value of stock-based compensation in the <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> consolidated</font> statement of operations <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and comprehensive loss</font>.&#160; The fair value of the Company&#8217;s stock option awards are estimated using a Black-Scholes option valuation model. This model requires the input of highly subjective assumptions and elections including expected stock price volatility and the estimated life of each award. In addition, the calculation of compensation costs requires that the Company estimate the number of awards that will be forfeited during the vesting period. The fair value of stock-based awards is amortized over the vesting period of the award.&#160; For stock-based awards that vest based on performance conditions (e.g. achievement of certain milestones), expense is recognized when it is probable that the condition will be met.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Amortization of Debt Issuance Costs</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company accounts for debt issuance costs in accordance with ASC 835, which requires that costs paid directly to the issuer of&#160; the notes be reported in the balance sheet as a debt discount and amortized over the term of the associated debt.&#160;Debt issuance costs of <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">399,000</font></font> for the year ended December 31, 2013 are associated with the senior secured notes issued to Lambda Investors LLC&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">on <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">February 4, 2013 and&#160;</font> November 12, 2013. Approximately $257,000 of these costs were amortized as of December 31, 2013 and are included in amortization of debt discount on the consolidated statements of operations <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and comprehensive loss</font>.</font>&#160;There were no debt issuance costs for the year ended December 31, 2012.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Other <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Income (Expense), net</font></font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Other&#160;income (expense), net, <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of approximately $33,000&#160;</font> includes&#160;approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> of other expense&#160;for the year ended December 31, 2013,&#160;primarily due to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">36,000</font>&#160;related to&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">foreign currency losses and</font> approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,000</font>&#160;related to <font style="FONT-FAMILY: 'Times New Roman'">the <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">May 2013 rights offering&#160;</font> warrant modification. Other expense was partially offset by other income of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17,000</font>, which consisted primarily of a refund of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,000</font> received as a result of the Steris agreement termination.&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Other income (expense), net, in the amount of approximately <font style="COLOR: black">$14,000 for the year ended December 31, 2012 is due primarily to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,000</font> in write-offs of old vendor invoices which are no longer due, offset partially by approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,000</font> of net foreign currency losses on invoices paid to and due to an international supplier.</font></font></font></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Income Taxes</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company accounts for income taxes in accordance with ASC Topic 740, which requires accounting for deferred income taxes under the asset and liability method. Deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable in future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">For financial reporting purposes, the Company has incurred a loss in each period since its inception. Based on available objective evidence, including the Company&#8217;s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2013 and 2012.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">ASC Topic 740 prescribes, among other things, a recognition threshold and measurement attributes for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company&#8217;s income tax return.&#160; ASC 740 utilizes a two-step approach for evaluating uncertain tax positions.&#160; Step one, or recognition, requires a company to determine if the weight of available evidence indicates a tax position is more likely than not to be sustained upon audit, including resolution of related appeals or litigation processes, if any.&#160; Step two, or measurement, is based on the largest amount of benefit, which is more likely than not to be realized on settlement with the taxing authority.&#160; The Company is subject to income tax examinations by major taxing authorities for all tax years&#160;subsequent to 2010.&#160; The adoption of the provisions of ASC 740 did not have a material impact on the Company&#8217;s consolidated financial statements.&#160; During the years ended December 31, 2013 and 2012, the Company recognized no adjustments for uncertain tax positions.&#160; However, management&#8217;s conclusions regarding this policy may be subject to review and adjustment at a later date based on factors including, but not limited to, on-going analyses of and changes to tax laws, regulation and interpretations, thereof.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Loss per Common Share</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">In accordance with ASC 260-10, net loss per common share amounts (&#8220;basic EPS&#8221;) are computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding and excluding any potential dilution. Net loss per common share amounts assuming dilution (&#8220;diluted EPS&#8221;) is generally computed by reflecting potential dilution from conversion of convertible securities and the exercise of stock options and warrants. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following securities have been excluded from the dilutive per share computation as they are antidilutive:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,410,134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,294,714</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,887,598</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,679,971</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="54%"> <div>Unvested restricted stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>75,450</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> Foreign Currency Translation</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Foreign currency translation is recognized in accordance with ASC Topic 830.&#160; The functional currency of Nephros International Limited is the Euro and its translation gains and losses are included in accumulated other comprehensive income. The balance sheet is translated at the year-end rate. The statement of operations is translated at the weighted average rate for the year.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Comprehensive Income (Loss)</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Comprehensive income (loss), as defined in ASC 220, &#160;is the total of net income (loss) and all other non-owner changes in equity (or other comprehensive income (loss)) such as foreign currency translation adjustments. For the years ended December 31, 2013 and 2012, the comprehensive loss was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,700,000</font> and $3,235,000, respectively.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Recently Adopted Accounting Pronouncements</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="COLOR: black"> </font></strong><font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: black; FONT-SIZE: 10pt"> There were no recent accounting pronouncements that are expected to have an effect on the Company&#8217;s consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 269000 365000 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 90000000 90000000 11949824 18082043 11949824 18082043 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company&#8217;s inventory components as of December 31, 2013 and 2012 were as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Total Gross Inventory, Finished Goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>527,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>581,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Less: Inventory reserve</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(365,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(269,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Total Inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>162,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>312,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The following securities have been excluded from the dilutive per share computation as they are antidilutive:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,410,134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,294,714</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,887,598</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,679,971</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="54%"> <div>Unvested restricted stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>75,450</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt">Prepaid expenses and other current assets as of December 31, 2013 and 2012 were as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Prepaid insurance premiums</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>70,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>78,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Security deposit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>34,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Prepaid expenses and other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>125,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>109,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt">Property and equipment as of December 31, 2013 and 2012 was as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; WIDTH: 95%; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="56%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: left" width="12%" colspan="2"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="24%" colspan="6"> <div>December&#160;31,</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="56%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="12%" colspan="2"> <div>Life</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="11%" colspan="2"> <div>2013</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="11%" colspan="2"> <div>2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="56%"> <div>Manufacturing equipment</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="11%"> <div>3-5&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>599,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>602,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="56%"> <div>Research equipment</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="11%"> <div>5&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>37,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>37,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="56%"> <div>Computer equipment</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="11%"> <div>3-4&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>59,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>59,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="56%"> <div>Furniture and fixtures</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="11%"> <div>7&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>39,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>39,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="56%"> <div>Property and equipment, gross</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="11%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>734,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>737,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="56%"> <div>Less: accumulated depreciation</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="11%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>727,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>721,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="56%"> <div>Property and equipment, net</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="11%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>7,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="10%"> <div>16,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Accrued expenses as of December 31, 2013 and 2012 were as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Legal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>149,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>90,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div>Accrued Product Recall</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>60,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Directors&#8217; Compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>77,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Management Bonus</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>81,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>39,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Travel</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>84,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>36,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Accrued Expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>365,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>321,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">A reconciliation of the income tax provision computed at the statutory tax rate to the Company&#8217;s effective tax rate is as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="3"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>U.S. federal statutory rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>35.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>35.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>State &amp; local taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Tax on foreign operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.78)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>State research and development credits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.09</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.06</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2.29)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(38.71)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(38.35)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Effective tax rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Significant components of the Company&#8217;s deferred tax assets as of December 31, 2013 and 2012 are as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Deferred tax assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Net operating loss carry forwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,029,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Research and development credits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,096,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,054,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Nonqualified stock option compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,801,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,701,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Other temporary book - tax differences</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>408,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>441,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Total deferred tax assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>30,334,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,917,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Valuation allowance for deferred tax assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(30,334,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(28,917,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Net deferred tax assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the below assumptions related to risk-free interest rates, expected dividend yield, expected lives and expected stock price volatility.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%" colspan="6"> <div>Option&#160;Pricing&#160;Assumptions</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>Grant&#160;Year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="51%"> <div>Stock Price Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>127.46-135.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>123.48&#160;&#150;128.54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Risk-Free Interest Rates</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>1.09-1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>.093-1.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expected Life (in years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>5.00-6.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>5.75-62.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expected Dividend Yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The following table summarizes information about stock options outstanding and exercisable at December 31, 2013:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 91%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="39%" colspan="8"> <div>Options&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%" colspan="5"> <div>Options&#160;Exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"> <div>Range&#160;of&#160;Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%" colspan="2"> <div>Number<br/> Outstanding&#160;as<br/> of&#160;December<br/> 31,&#160;2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life&#160;in<br/> Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number<br/> Exercisable&#160;as<br/> of<br/> December&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>$0.41 - $2.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>2,374,514</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,349,579</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>$15.00 - $29.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>27,909</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17.82</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>27,909</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>17.82</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>$34.20-$96.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>7,711</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.38</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>51.49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7,711</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>51.49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>Total Outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>2,410,134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,385,199</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt">The following table summarizes the option activity for the year ended December 31, 2013:</font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="3"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Outstanding at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,294,714</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>237,315</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Options forfeited or expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(121,895)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,410,134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Exercisable at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>1,385,199</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Vested and expected to vest at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2,350,688</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The following table summarizes certain terms of all of the Company&#8217;s outstanding warrants at December 31, 2013 and 2012:</font></font><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><strong><font style="COLOR: black"> </font></strong>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><strong><font style="COLOR: black"><font style="FONT-SIZE: 10pt">&#160;</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; WIDTH: 100%; BORDER-COLLAPSE: collapse; MARGIN: 0in" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 10px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="100%" colspan="15"> <div> Total&#160;Outstanding&#160;Warrants&#160;at&#160;December&#160;31,&#160;2013</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="32%"> <div>Title&#160;of&#160;Warrant</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%"> <div>Date&#160;Issued</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%"> <div>Expiry&#160;Date</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="12%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="25%" colspan="5"> <div>Total&#160;Common<br/> Shares&#160;Issuable</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="32%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="13%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="11%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="12%" colspan="2"> <div>2013</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="12%" colspan="2"> <div>2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="32%"> <div>Class D Warrants - Lambda</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>11/14/2007</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>3/10/2017</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>0.40</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>8,806,575</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>8,806,575</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="32%"> <div>July 2009 Warrants</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>7/24/2009</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>7/24/2014</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>22.40</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>33,629</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>33,629</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="32%"> <div>Shareholder Rights Offering Warrants</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>3/10/2011</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>3/10/2016</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>0.40</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>2,264,817</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>3,057,190</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="32%"> <div>March 2011 Lambda Warrants</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>3/10/2011</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>3/10/2017</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>0.40</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>2,782,577</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>2,782,577</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="32%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="13%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="11%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>13,887,598</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="11%"> <div>14,679,971</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The following table summarizes the Class D outstanding warrants at December 31, 2013 and 2012:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Lambda&#160;Investors</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Other&#160;Investors</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%" colspan="2"> <div>Total&#160;Shares&#160;to&#160;be&#160;issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>As of December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>447,197</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>9,253,772</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Exercised in 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(352,034)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>(352,034)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Expired in 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(95,163)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>(95,163)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>As of December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Exercised in 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Expired in 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>As of December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>8,806,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The following tables summarize our approximate minimum contractual obligations and commercial commitments as of December 31, 2013:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%" colspan="14"> <div>Payments&#160;Due&#160;in&#160;Period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Within<br/> 1&#160;Year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Years<br/> 1&#160;-&#160;3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Years<br/> 4&#160;-&#160;5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>More&#160;than<br/> 5&#160;Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Leases</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>108,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Employment Contracts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>788,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>350,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>438,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 10px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>896,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>450,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>446,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1127000 1029000 680000 711000 1807000 1740000 737000 898000 1070000 842000 632000 826000 151000 223000 3620000 3110000 4403000 4159000 -3333000 -3317000 2000 0 0 94000 0 257000 55000 3000 14000 -33000 -3262000 -3698000 27000 -2000 -3235000 -3700000 -0.29 -0.24 11223878 15624999 0.68 0.88 0.86 0.97 3 3 581000 527000 125000 1.75 1.25 300000 500000 750000 500000 600000 400000 300000 532000 273000 356000 142000 214000 208000 0.03 0.12 P4Y 350000 0.3 8000 P1Y 8000 109000 108000 1421000 10000 95630000 49000 -94268000 10501477 -3262000 -3698000 27000 27000 -2000 -2000 2771000 5000 2766000 5000000 503000 2000 501000 248000 1000 247000 1448347 791999 443000 443000 652000 652000 14000 14000 273000 273000 12000 96847000 76000 -97530000 18000 100526000 74000 -101228000 11949824 18082043 2 500000 750000 600000 1300000 1500000 P3Y P7Y 1414000 703000 703000 1756000 703000 703000 2459000 791000 33000 30000 399000 53000 14000 36000 2294714 14679971 0 2410134 13887598 75450 78000 70000 21000 21000 10000 34000 9000 42500 55000 42500 55000 P3Y P5Y P5Y P3Y P4Y P7Y 737000 602000 37000 59000 39000 734000 599000 37000 59000 39000 721000 727000 90000 149000 77000 0 0 81000 84000 0 70000 36000 8729200 8305000 1054000 1096000 0.3500 0.3500 0.0536 0.0522 -0.0078 0.0040 0.0106 0.0109 -0.0229 -0.0300 -0.3835 -0.3871 0 0 25721000 27029000 1054000 1096000 1701000 1801000 441000 408000 28917000 30334000 28917000 30334000 0 0 9000 9000 142000 214000 443000 575000 0 14000 82000 210000 0 -39000 55000 3000 -7000 -26000 -1006000 -820000 147000 60000 -4000 16000 0 904000 59000 0 -1318000 -680000 -711000 -1547000 -3583000 8000 0 659000 0 55000 3000 -612000 3000 0 399000 503000 248000 2800000 0 2771000 0 1300000 503000 4120000 34000 -8000 -1622000 532000 1669000 18000 2000 0 77000 1318000 0 791000 0 273000 0 106538 4500000 2053 1316628 637253 7230 831 1360059 715692 2003 19904 2407318 331550 P10Y 443000 418000 0.04 0.03 506000 519000 1547550 237315 90945 25000 1.03 0.56 793000 0 768000 0 P8Y10M24D P8Y1M6D 727000 P2Y3M18D 0.30 0.45 0.45 8806575 65000 161708 23720667 1096313 2254500 104206 14879708 687793 352034 438000 42000 190326 1.2348 1.2854 1.2746 1.3598 0.00093 0.0132 0.0109 0.0175 P5Y9M P62Y6M P5Y P6Y3M 0 0 0.41 15 34.20 2.60 29.80 96 2410134 2374514 27909 7711 P8Y1M28D P4Y6M29D P1Y4M17D 1.28 0.93 17.82 51.49 1385199 1349579 27909 7711 1.46 0.83 17.82 51.49 2294714 2410134 2350688 1385199 2.14 0.64 1.28 1.29 1.46 2007-11-14 2009-07-24 2011-03-10 2011-03-10 2017-03-10 2014-07-24 2016-03-10 2017-03-10 0.40 22.40 0.40 0.40 14679971 8806575 33629 3057190 2782577 13887598 8806575 33629 2264817 2782577 8806575 447197 9253772 0 352034 352034 0 0 0 0 95163 95163 0 0 0 0 8806575 0 8806575 0.15 49000 46000 1 0.5 0.03 0.02 896000 108000 788000 450000 100000 350000 446000 8000 438000 0 0 0 0 0 0 229000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Note 13&#160;- Concentration of Credit Risk</font></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Cash and cash equivalents are financial instruments which potentially subject the Company to concentrations of credit risk. The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash and cash equivalents.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Major Customers</font></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">For the years ended December 31, 2013 and 2012,&#160;three customers accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 86</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 68</font>%, respectively, of the Company&#8217;s sales.&#160; In addition, as of December 31, 2013 and 2012, those&#160;three customers accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 97</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 88</font>%, respectively, of the Company&#8217;s accounts receivable.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1300000 1500000 0.12 0.12 2013-08-04 2014-05-12 0.08 0.08 104000 120000 50000 75000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Note 6&#160;&#150;&#160;Senior Secured Notes</font></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> &#160;</font></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black">On February 4, 2013, the Company issued a senior secured note to Lambda Investors LLC in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million. The note bore interest at the rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% per annum and was scheduled to mature on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">August 4, 2013</font>, at which time all principal and accrued interest was due. However, the Company paid amounts due under the note on May 22, 2013 with the cash proceeds from the rights offering that closed in May 2013.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> In connection with the note, the Company paid Lambda Investors an <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8</font>%, or $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">104,000</font>, sourcing/transaction fee. In addition, the Company paid Lambda Investors&#8217; legal fees and other expenses incurred in connection with the note in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> as well as Lambda Investors&#8217; legal fees and other expenses incurred in connection with the May 2013 rights offering in the amount of $50,000. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></font> <font style="COLOR: black">Those payments totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">204,000</font> are reflected as amortization of debt discount.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black">On November 12, 2013, the Company issued a senior secured note to Lambda Investors LLC in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million. The note bore interest at the rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% per annum and was scheduled to mature on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2014</font>, at which time all principal and accrued interest was due. However, the Company paid amounts due under the note on March 18, 2014 with the cash proceeds from the rights offering that closed in March 2014. In connection with the note, the Company paid Lambda Investors an <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8</font>%, or $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">120,000</font>, sourcing/transaction fee. In addition, the Company paid Lambda Investors&#8217; legal fees and other expenses incurred in connection with the note in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font>. Those payments totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">195,000</font> were made on November 12, 2013 and are reflected as a debt discount which is being amortized over the term of the senior secured note. Approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">53,000</font> is reflected as amortization of debt discount on the consolidated statements of operations and comprehensive loss for the year the ended December 31, 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">On March 21, 2014 the Company completed a rights offering which resulted in gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.1</font> million.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> <font style="COLOR: black">A portion of the proceeds was used for the repayment of a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million note, plus all accrued interest thereon of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">61,000</font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> See Note 13, Subsequent Events, for further discussion.</font></div> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"></font></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0 1358000 0 121895 0 3.27 10-K false 2013-12-31 2013 FY NEPH 25225704 NEPHROS INC 0001196298 --12-31 No No Yes Smaller Reporting Company 10181000 0 0 0 0 0 0 340220 0 206000 14000 1222 5227 2014-03-15 2014-03-15 0 398227 264770 58007 75450 0 0.73 0.71 0.88 0.66 60000 0 39000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black">The following table summarizes restricted stock activity for the year end December 31, 2013:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average<br/> Grant&#160;Date<br/> Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Nonvested at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>398,227</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(264,770)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(58,007)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Nonvested at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>75,450</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.66 <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 109000 48000 157000 4000 142000 17000 15000 50000 2017-03-10 2100000 1500000 61000 7140822 225000 225000 1500000 1300000 2100000 18000 4000 1500000 61000 2014-12-31 2026-12-31 -90945 374 53000 204000 195000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="COLOR: black">Note 10 &#150; Stockholders&#8217; Equity</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="COLOR: black"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black">On March 4, 2013, the Company filed a Registration Statement on Form S-1 in connection with a $3 million rights offering (the &#8220;Rights Offering&#8221;).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> On April 17, 2013, the Company&#8217;s Registration Statement on Form S-1 related to the Rights Offering was declared effective by the SEC.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black">The Rights Offering commenced on April 17, 2013 and expired on May 17, 2013.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> All of the Company&#8217;s stockholders and warrant holders were eligible to participate in the Rights Offering on a pro rata basis based upon their proportionate ownership of the Company&#8217;s common stock on a fully-diluted basis.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> Pursuant to the Rights Offering, the Company distributed to holders of its common stock and/or warrants one non-transferable subscription right for each share of common stock, and each share of common stock underlying a warrant, held as of April 4, 2013.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> Each right entitled the holder to purchase 0.18776 of a share of the Company&#8217;s common stock at a subscription price of $0.60 per share.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> The Company rounded up any fractional shares to the nearest whole share.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black">On May 22, 2013, the Company completed its Rights Offering which resulted in the issuance of 5,000,000 shares for gross proceeds of $3.0 million.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> The aggregate net proceeds were approximately $1.4 million, after deducting the repayment of the $1.3 million February 2013 senior secured note, plus $46,800 of accrued interest thereon, issued to Lambda Investors, LLC, the payment of an 8% sourcing transaction fee of $104,000 with respect to the February 2013 senior secured note and an aggregate of $100,000 for reimbursement of Lambda Investors&#8217; legal fees incurred in connection with the February 2013 senior secured note and the Rights Offering. <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> Those payments totaling $204,000 are reflected as amortization of debt discount.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 3000000 0.18776 0.60 5000000 3000000 1400000 1300000 46800 100000 104000 EX-101.SCH 6 neph-20131231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Organization and Nature of Operations link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Inventory link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Disclosure - Interim Reporting link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Property and Equipment, Net link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Senior Secured Notes link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Stock Plans, Share-Based Payments and Warrants link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - 401(k) Plan link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Concentration of Credit Risk link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Summary Of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Inventory (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Tables) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Commitments And Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Organization and Nature of Operations (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Summary of Significant Accounting Policies (Schedule Of Securities Excluded From Dilutive Per Share Computation) (Details) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Inventory (Details) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Property and Equipment, Net (Schedule Of Property and Equipment, Net) (Details) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Property and Equipment, Net (Details Textual) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Senior Secured Notes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - Income Taxes (Details 1) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 144 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 145 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details 1) link:presentationLink link:definitionLink link:calculationLink 146 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details 2) link:presentationLink link:definitionLink link:calculationLink 147 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details 3) link:presentationLink link:definitionLink link:calculationLink 148 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details 4) link:presentationLink link:definitionLink link:calculationLink 149 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details 5) link:presentationLink link:definitionLink link:calculationLink 150 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details Textual) link:presentationLink link:definitionLink link:calculationLink 151 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 152 - Disclosure - 401(k) Plan (Details Textual) link:presentationLink link:definitionLink link:calculationLink 153 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 154 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 155 - Disclosure - Concentration of Credit Risk (Details Textual) link:presentationLink link:definitionLink link:calculationLink 156 - Disclosure - Subsequent Event (Details Textual) link:presentationLink link:definitionLink link:calculationLink 157 - Disclosure - Revenue Recognition link:presentationLink link:definitionLink link:calculationLink 158 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 159 - Disclosure - Warrants link:presentationLink link:definitionLink link:calculationLink 160 - Disclosure - Comprehensive Income (Loss) link:presentationLink link:definitionLink link:calculationLink 161 - Disclosure - Loss per Common Share link:presentationLink link:definitionLink link:calculationLink 162 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 163 - Disclosure - Concentration of Credit Risk (Tables) link:presentationLink link:definitionLink link:calculationLink 164 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 165 - Disclosure - Loss per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 166 - Disclosure - Basis of Presentation and Going Concern (Details Textual) link:presentationLink link:definitionLink link:calculationLink 167 - Disclosure - Revenue Recognition (Details Textual) link:presentationLink link:definitionLink link:calculationLink 168 - Disclosure - Stock-Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 169 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 170 - Disclosure - Warrants (Details Textual) link:presentationLink link:definitionLink link:calculationLink 171 - Disclosure - Comprehensive Income (Loss) (Details Textual) link:presentationLink link:definitionLink link:calculationLink 172 - Disclosure - Loss per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 173 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Warrants, Private Placement and Shareholders' Rights Offering) (Details Textual) link:presentationLink link:definitionLink link:calculationLink 174 - Disclosure - Basis of Presentation and Going Concern link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 neph-20131231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 neph-20131231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 neph-20131231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 neph-20131231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accrued Expenses (Details) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Accrued Expenses [Line Items]    
Accrued Legal $ 149,000 $ 90,000
Accrued Product Recall 60,000  
Accrued Directors’ Compensation 0 77,000
Accrued Management Bonus 81,000 0
Accrued Interest 39,000 0
Accrued Travel 0 84,000
Accrued Other 36,000 70,000
Accrued Expenses $ 365,000 $ 321,000
XML 12 R54.htm IDEA: XBRL DOCUMENT v2.4.0.8
Concentration of Credit Risk (Details Textual)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Concentration Of Credit Risk [Line Items]    
Number Of Major Customers 3 3
Sales Revenue [Member]
    
Concentration Of Credit Risk [Line Items]    
Concentration Risk, Percentage 86.00% 68.00%
Accounts Receivable [Member]
    
Concentration Of Credit Risk [Line Items]    
Concentration Risk, Percentage 97.00% 88.00%
XML 13 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Plans, Share-Based Payments and Warrants (Details 5)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Class of Warrant or Right [Line Items]    
Outstanding warrants at end of year 13,887,598 14,679,971
Class D Warrants [Member]
    
Class of Warrant or Right [Line Items]    
Outstanding warrants at beginning of year 8,806,575 9,253,772
Exercised 0 (352,034)
Expired 0 (95,163)
Outstanding warrants at end of year 8,806,575 8,806,575
Class D Warrants - Lambda [Member]
    
Class of Warrant or Right [Line Items]    
Outstanding warrants at beginning of year 8,806,575 8,806,575
Exercised 0 0
Expired 0 0
Outstanding warrants at end of year 8,806,575 8,806,575
Class D Warrants - Other [Member]
    
Class of Warrant or Right [Line Items]    
Outstanding warrants at beginning of year 0 447,197
Exercised 0 (352,034)
Expired 0 (95,163)
Outstanding warrants at end of year 0 0
EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!LLG4[(@(``&XA```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,VEUKVS`4!N#[P?Z#T>V( M%7VX:TN<7NSC2/"[ M@4*65MM0LB;&X9KS4#74FY"[@6QZLG*^-S%]]6L^F&ICUL3E?'[!*VY7,#$/75B:FI/S!UJ^ZS!X[Y&GE M]$YHVB%\2#$8/]AA?/+W!H_KOJ>M\6U-V:WQ\9OI4PR^[?AOYS>_G-ODQXL< M2.E6J[:BVE7W?=J!/`R>3!T:HMAW^73->]/:I]Q'^D\O!SY=Q)F#C+]O*GQB M#@F20X'DT"`Y"I`<%R`Y/H+DN`3)<0620\Q1@J"(*E!(%2BF"A14!8JJ`H55 M@>*J0(%5H,@J4625*+)*%%DEBJP215:)(JM$D56BR"I19)4HLBH4616*K`I% M5H4BJT*15:'(JE!D52BR*A19%8JL&D56C2*K1I%5H\BJ4635*+)J%%DUBJP: M15:-(FN!(FN!(FN!(FN!(FN!(FOQOV2-:9I-?/K\][_I5.:-<6J(NX["F4<@ M^Z)O=6Z,I_I']&GN?_8`+VL?RY&FXK?>#2&=#_!T^BX\'0`85\^&5(A\;.GY M","A4?ISQW2VX/2&KV;Y-)Y>J*D^T)M/IR66?P```/__`P!02P,$%``&``@` M```A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G M:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-` MZ^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$` MYZKC[EL"``#7(```&@`(`7AL+U]R96QS+W=OZ3HM-W+=ITA]B5YZL^F'?YC(< MUO6A7;RVZUCK=#JKA[_7.&YZ68JUZ.A_+J]Q?O5ZOM(C[UB^_[ MV.5_O*/^V0^O:1-C+HNVPSKFQHU3J3X]$9L4S:[^CYP2#ZZ<.R1'9V0Y.D-R M[)XLQ^Z1'!6R'!4DQSQ9CGDDQRM9CEIE!.8,L)2`Y[ MK^!6L?,8IK&PB2R0R,HFLD(B"YO(`HFL;"(K)+*Q,]E@*AO[E!L\YIY-9`^) M[-E$]I#(@5TG!U@GAZO6R6G3#G'Y-0_E6I**$;Z5[A?3R*[86P5W2MA(%HAD M-@(A`=FA@9$1=F@$QD;9[J#0'93M#@K=P=CN8-`=C(T<@\SQ;'?PT!W\5=UA M[."FOJ>-A%"5>MV7-I?L6SE-.P/GW"6I0=$AP1=IT>8&S8V0N35]@< M%LAA87-8((>5#3Z%X#-ZZL#<,?8I-WC,_57!-T+W#+]QZ@^'<;."[>$*/=RS M(>@A!`.['`VP'&4'!\:&G<(BY>.N_'Y\[M^0>IYMB-XZ`B!71B'L3"N+_Z. M,/\-``#__P,`4$L#!!0`!@`(````(0`ZXVA$B00``'\0```/````>&PO=V]R M:V)O;VLN>&ULE)A=<]HZ$(;OS\SY#XSO3\$?!)))TB'@3IEI@:DY[:5&L05H M8DM4EALXO_ZL3&-6%O6$*R)@7^V^>G8MW_7[ M9;IC!2T_R#T3\,E&JH)J6*IMO]PK1K-RQY@N\GXP&-ST"\J%=U*X4^_1D)L- M3]E,IE7!A#Z)*)93#>F7.[XOO1]RKY?34L<9URQ[ M\(:PE*_,>D-5^Z>*Y_#I;3@(O?YC4^1*]3*VH56NUU#>FSKX%41!<&.^::SX MSMEK>0XRR][A!Q>9?#5?!6N/S2J$!%[KCW[P3._@\\%@T+SWF?'M3K^]"?)] MI%\["/O4KSU1E_?F")F(C,1"^21RK M3)>+9/EE/INLXQEYFGR9+*8Q23['\3I!$L,;I!%H`14;*R+F*I=TR1::6P3H!V]AU85PIFC`+.C0GQSXKOS4@@"V9E'V(- M!]:$"2X525@*%H*54L-X.S?+#8;+=Q@%LU0%86^5X$AHY<8UW^%R#B.V8&1- M#_9^F!_?P3#1,GTAJYR*DB0[JM@3+6'[%3V:RO'NF"#?`;'6VM MX\.MX#O\10/_E`/>#Z/F.ZQ-95%P;7(\'?94PH`26WC.<*O\$4;-=UB#L!0T MU`E]`'<*9\8U^<;+%Y3,".,'0[=W68)8>0"![FFWX"=Y]QV#R,7.,AUMYV5`J8P M<"C\<]^9G+`GF,+34Q*/PW;W7*@(DQ@X).(FNA",F0P<)KM["=LQQE0&%Z@\ MPVT>OA;5[B4,Q[>"6UN!ASH3K;>PVU2;K#"6'Z0V=V=M`/Q2&=L568`^^E)P_Y M;0]98QVK+H=CIXLN6(P[(70`MMK(C8XP_K!HC=-+T033&F'L8?&>^#4[Z(K" MC;TA;(Q/)7)1[7PR8DPBC"HL6NETCP7,?(3/%Q97"4%L4UJ$#Q@65PE![%G( M\L@AM[LTB&V$QGAP1RZZG69#;",4X0$.BZM*@]A&:&P).0A?N-"<>XDAG2&& M&1:MA)J[#8IV2,3=-'1X;MT1,'JWUN8.PYVW)*NEAIAA6+2JZ+HGD1EV`R,\ M=!%NW91L4Y#.+6[Q84UPOSXZ^)&:TCR%7\_FQ=R3:LO[;_\[>/P?``#__P,` M4$L#!!0`!@`(````(0!5BB\5L00``-81```8````>&PO=V]R:W-H965T&ULE%A=CZLV$'VOU/^`>$_`?!,EN;JPVO9*O5)5M;?/A#@)6L`1 MD,WNO^^8<3`V-RG9A]VPIV8YZZ[KRRK#8_ MT2IKE^Q,:X@<6%-E'5PV1ZL]-S3;]S=5I>78=F!565&;F&'5S,G!#H6K;\>: M-=FNA'5_$"_+;[G[BTGZJL@;UK)#MX1T%A*=KCFV8@LR;=?[`E;`93<:>MB8 M7\DJ=3S3VJY[@7X4]-J./AOMB5U_:XK]'T5-06VH$Z_`CK$W#OVVY_^"FZW) MW:]]!?YLC#T]9)>R^XM=?Z?%\=1!N7U8$5_8:O_Y0ML<%(4T2\?GF7)6`@'X M;50%;PU0)/OH_UZ+?7?:F&ZP]$/;)0`W=K3M7@N>TC3R2]NQZE\$$9$*DS@B MB0OL1=Q9.I%/_.#_LUC(J%_@2]9EVW7#K@9T#3RS/6>\!\D*,M]6ACR&M=Y; M*JR1)_G*L_2Y8!4MU.=]&P9KZQTDS04D00CLB`%"5$1Z0_!*`+N!(BQ".( MIF?Z"*%0@R3SJ7'PQH1U#U4*(XT:0L*^RL1V8C6<*F'BR(4II*#MYY/B8(V4 M]M0$(1ZV'M$[:QP-(GM@K%`*GJ'$P2JE4=I^3R0("5"GT)-/[<.I$H[L.SJ% MSY#B8(V4ID2"$-0IBK72IN-HZ-ZAQ%]J(\=XW.HA&@\<&5>)<;^=3PS=62$FMY/0"S%(S".^9FDI4>*> M+055B7'#G4\,[5DAIKE`0A"#Q!:N2S3FJ0YP[U%[RN7Y@4KW"DV31&"PQV2E M1"7'-G^O[9]R>3*U^5A[:B(P2&D1:YLU5<+R7K6$3[D\F=I\+'>3Z*VQD\OJ M")W&05]N8Y734S9/ICX?RPH(3F.C7SC^I*O&\7M*/67T!$UZW.RQ)D8B,*)\ MHTX66MU\GI]IB2RNHI7SE,7W:-7B]:Y)!.:V!8/)FUH#.(%46Z6FV3P_W\\X M/$_M/I9]@N5T$".$DX]'W93HO4.@`Y69;UT]6M---WN!P"%W_D MQKP!G'OG>4>S^YFZ36T_UMH\Z3-OS+@_%RY@8)1-)2AB$@F(8N5'VK5::>T] M,)/Q]'V@]UH"DS77#)N13YL>\%'/)'SZ'F$(O/ZCT>"`1'&\QNFSHLV1IK0L M6R-G%SXZ$Q!D^"^.]0F,]?T,;`T!F*K/V9%^SYIC4;=&20]PJ[T,P?H;G,OQ MHF/G?OK;L0[FZ?[C";X_H3"LVDL`'QCK;A=\WAR^D=G^!P``__\#`%!+`P04 M``8`"````"$`DXD2C.@"``"O"```&0```'AL+W=OM]T2%9+Q?HM#'R*-]R2O6[Y;HQ_>'FQQY M4I&^(BWOZ1*]4(EN5^_?+0Y!+!O:$>GS@?9PI^:B M(PHNQ2Z0@Z"D,H.Z-H@P3H..L![9A+FX)H/7-2OI/2_W'>V5#1&T)0K\9<,& M^9K6E=?$=40\[H>;DG<#1&Q9R]2+"45>5\X_[7HNR+:%NI_#&2E?L\W%67S' M2L$EKY4/<8$5/:^Y"(H`DE:+BD$%NNV>H/42W87S38&"U<+TYR>C!SGZ[,F& M'SX(5GUF/85FPS3I"=AR_JC13Y7^"@8'9Z,?S`1\%5Y%:[)OU3=^^$C9KE$P MVPD4I.N:5R_W5);04(CQHT0GE;P%`?CK=4RO#&@(>3;_#ZQ2S1+%J9]D.`X! M][94J@>F(Y%7[J7BW2\+A<+!IXI!Z*78#B'Y+Z=A,P1D)3<-+!-DC MMYG[Y+5E,M/6*,-1@3%VD8V#)%D4CA''#DJ\WD[#4[L_,V([9YG4V(6X2,=/ M-L3&)9+9F'#<8,F/W?1FBF%+7EYZ>M#4<3)W:\L<'7/L=, M=M/PU&VZ+2QCW68X'S?'JCG`S'%WS++_,=/PU"QW%]7:,M8LQG'L3)QU&R-1 M7H396-^QTP?>Z'5RW=SJ05/+8F)I&6MY\Q=-A[GL6;B>E^=7PZY?/-V::\O8 MW3O=MF_?LWVS9XY])0]D1[\0L6.]]%I:P[[`?@9+5M@3QUXH/IA7\)8K."G, MQP9^&%!X/V,?X)IS]7JAS[333XW5;P```/__`P!02P,$%``&``@````A`!J^ MA>FD`P``2@T``!D```!X;"]W;W)K&ULE)=1CZHX M%,??-]GO0'@?`1$%HTY&$?8F=Y/-S;V[SQ6J-@.4M'6<^?9[2H6QU2O,RS`> M?_SI^9_3%]889)[1:VM[(M2U<930GU6%I__J9/(6VQ06J$U MPRAO;BH+9^RZ4Z=$I+*5PIP-T:#[/:M69D/D M2L1>3_531LL:)':D(.*C$;6M,IM_.U24H5T!>;][$Y2UVLV'&_F29(QRNA0@;3=8GB_M%^\>1K:SFK1^/,OP6=^];_%C_2<,I)_ M)Q4&LZ%,L@`[2E\E^BV7(;C9N;D[:0KP#[-RO$>G0OR@Y[\P.1P%5#N`A&1> M\_PCQCP#0T%F-`ZD4D8+6`#\M4HB.P,,0>_-]4QR<5S:_G04S%S?`]S:82X2 M(B5M*SMQ0 M')3;(KTE_*!;JN8(;(OACDA8@9KQ<`*NHUC^M!+Q+W$MI=(>HGT$:%Y!.?P M<(\DO+1A4W;Y!]'$\$@QCSSJ)6)%S)JC-YR-(QB:]*=L-<)W`](NXEMKU$H@CEL^=&TQL74YT()M>$YI$< MF(TWKP_CVN,WD[S)],K846O%!$TO3*9^:)PJ&^U[:!2C'V/U_0.OM[U$TDO` M#"LSN?\4Y9.:4=6T4F)VP!M<%-S*Z$G.GS[DUT6[T?AE(E_:1GSMS6&VN(W' MWAP&"(@[W0TPRM;H@/]&[$`J;A5X#X]R1W+J9&H85A\$K9O9:4<%#+'-OT?X MS8)A:G%'`.\I%>T'^8#N5]#J?P```/__`P!02P,$%``&``@````A`!A9=C&Z M`P``N`P``!D```!X;"]W;W)K&ULE)==;ZLX$(;O M5]K_@+@O8#Z2$"4Y*O1T]TB[TFJU']<$G,0J8(2=IOWW.X,#P:9ETUPD?+R\ M/)ZQQY/-M[>JM%YI*QBOMS9Q/-NB=JDK7][R%6V6LMI7#NKW'@Q\.+*=//#]7M);*I*5E)H%?G%@C>KN MRMJ7<_.0\ZH!BSTKF7SO3&VKRM<_CC5OLWT)XWXC89;WWMW)Q+YB>`D>=B=//W<9^*.U"GK(SJ7\DU]^I>QXDI#N"$:$ M`UL7[T]4Y!!1L''\")UR7@(`?%L5PZD!$NM\+*^1I:P<+)UIZ`0&YM:=" M/C.TM*W\+"2O_E4B/'N>M14(PHF$MD2]0%\![8 M?..]4T40#1*-!"(T)L%HA9_.IIX('X)Y,P((5^'@KR"5)AQI%KHBG5-HC&`R M9IR/%HJW-@1@"$X4K_0W)TI#?+]+K*??33^[JS%!C.YG0K'!1(QH)$H#[QZX M#44ZI]#8%CK;?3G%A_XOITHSQSBGT!B7.N-\3E&LQR_P`SUKB=+T.25.`.LU M'GUT>6K*H7B%WNUS6\@:-6ZBH]HR3XUBD]K(::(T-^IE=&.`(__[@[FTS2<" M3:/1QE^A1;%)&^M!2Y1FG/\H-C3I5+/P;BM,XR.P^=T?SDZM$T9D4I+1$DK8 MS#*Z^GPLT?FP?(_2?=]"(JKHSU?'J^ACB*Z`IK,2G1/+_8AS?EH2M3F,*^1T M-5U%MXGI+T-C[J9331!^O.1T6JS[]].J74*G-4@2HD0W6B^>+AQ#M')&Q0$/ M5]\?;GN83@QI^@(QJO5Y&OC&*DF@0S3G:109(FPC3='",RN3:A15!U31]DA3 M6I;"ROD9FT#&PO=V]R:W-H965TZ16JJI>GC%>VRC` M6D#BY-]W=F>Y[&(,=AYL8W\S\\UE/\BLOW_FF?%!RRIEQ<8DEF,:M$C8/BV. M&_.?OU^_+4VCJN-B'V>LH!OSBU;F]^W//ZTOK'RK3I36!G@HJHUYJNOSRK:K MY$3SN++8F1;PRX&5>5S#97FTJW-)X[TPRC/;=9R%G<=I8:*'53G'!SL8R>O9\T]ZN18'^3>FEZGTVJA.[_%JF^]_3@D*UH4^\`SO&WCCTQYY_!<;V MP/I5=.#/TMC30_R>U7^QRV\T/9YJ:'<`&?'$5ONO%UHE4%%P8[D!]Y2P#`C` MJY&G?#2@(O&G>+^D^_JT,;V%%82.1P!N[&A5OZ;Y;M!N)SAQ49&(L&7N(ZWZY)=#)@:B%F=8SZ#9`6>F\R01YOK6*J0 M(W?RQ+UL3!AWR**"_GQL%XZ[MC^@IHG$/",&7EL,:1$VL&DI`8T^I>M%;B)S M,(_,B\ZI/.,7_3`=$26,IX;AF?NC/6W"<2/H7B^)A>.U:2`#Q/A]3(M0&`"D MGRAGX,%LWDZ8&VU,R+(MX\+Q6__(`#$+T0C7)P[Q.H3"`/*]GP$WTAD$&@/$ M1((!L=QE^[,2?O%(>&ZDAU^T_K$`B,$"$&\9D"AJ$0J#\!$&W$AG$+;^D0%B MF@+X'4$E/+]!]$[?[&&E M$]`;+T'RS'NA'Y`.HLP<>4CXA)5&@CC:T$N0TGPRU@0N4KTFS*P%M])H.+KX M$`0U8Q!U`JT6XB'UX_?]`8.NWW(<$-0(D!\%83$)H83%4"%4^_` M`R5"4(@WP*X^2O+N70HHT/KH=U.%@R=!4H0ITKZCA]$.8L-)H#&1(@K`7 M)+268Q2X7-VMA"ZWTBGH.B1!T\UX2`KY/R\#"KH*2=!T%30AO'T(W:$`>L$@ M>P0IAZ2H#DD-"V;\'>H/U.PLMC`[5L/F1WP\ MP::/PB[#L0!\8*QN+OB.JMT=;O\'``#__P,`4$L#!!0`!@`(````(0`?KD%- M[P,``!0.```9````>&PO=V]R:W-H965TH+G:ENU1(,K.2+/2:K679PQM&P5H1.,X^?NIHH!`V^/@?;$-??IP MZE1175Y_?2MR[977,A/E1F>&I6N\3$2:E8>-_L_?SP\+79--7*9Q+DJ^T=^Y MU+]N?_NR/HOZ11XY;S1@*.5&/S9-M3)-F1QY$4M#5+R$E;VHB[B!R_I@RJKF M<=IN*G+3MBS?+.*LU(EA5<_A$/M]EO`GD9P*7C9$4O,\;D"_/&:5[-F*9`Y= M$=\^4NU.&M0 M-?!,6<58@VP%S'UDI&.(]5>A0HQ(\H@L&QW*':*0D)_7K<_@S5:>>XEPO`$R40(.C96@ M6^XOZZ!7A)L@XR,![D(UAS#N".,/"MHPHEN(B48@434Z4/&W7<--&QV,&$SR MV8<'9"1A_#:]MKUT`S7%$2'@\X-EB&*B$3P;:[RM#<&J-L6=D#"=-B=P5/'1 M&,`\-_`\Z[HT_QYI"%:E!0,OV488M[7MXYF4U'[M4\.">U0A>*K*\=6"(PP9 M]L!LME@JZ8X(,2.9>,J-6LCM9")XJLUG"\4QPG3)=)G%'$5]-$$HI3@IM.4] MVA"L:ELJV@A#VI@#W7>I(")"S/"-P5LYW[@6K:BSE7H*.U#_'GB6OU#,C3K( M''W8CT>)Q6[W>2=AU,4GK<16.GW8@9;42XR+1M*MSQ&)S?M^D=3RIR*58R%D M!"*1EJ&^0E&W/D,3S7&J)..&`;4.=#W>'X?_1QG%/N1_BGP*\;PX+,)-7\8'_$=>' MK)1:SO=`:1D!)+^FJ9XN&E&UD_%.-#"-MS^/\.^+PSAI&0#>"]'T%_B`X?_< M]B<```#__P,`4$L#!!0`!@`(````(0!LN:>"0@,``.4)```9````>&PO=V]R M:W-H965TI&WJ! MZ]`ZXSFKMZG[Z^?C:.HZ4I$Z)R6O:>J^4NG>+C]^6!RX>)([2I4##K5,W9U2 MS=SW9;:C%9$>;V@-3PHN*J+@4FQ]V0A*\C:H*OTH",9^15CM:H>YN,:#%P7+ MZ#W/]A6ME381M"0*^.6.-;)SJ[)K["HBGO;-*.-5`Q8;5C+UVIJZ3I7-OVQK M+LBFA+Q?PAN2==[MQ<"^8IG@DA?*`SM?@PYSGODS'YR6BYQ!!EAV1]`B=>_" M^3H,7'^Y:`OTF]&#['UWY(X?/@F6?V4UA6I#G[`#&\Z?4/HEQUL0[`^B']L. M?!=.3@NR+]4/?OA,V7:GH-T)9(2)S?/7>RHSJ"C8>%&"3ADO`0#^.A7#K0$5 M(2_M_P/+U2YUX[&73((X!+FSH5(],K1TG6PO%:_^:%%XM-(FT=$D!OKC\\B+ MIDF8C/_OXFNB-L%[HLAR(?C!@5T#:\J&X!X,Y^#<9:8Y3KG^*U7($4WNT"5U M8;M#%A+Z\[Q,ILG"?X::9D?-:J@)3<6Z4V`K`._$")GW&=^N>H>"8D3!+B#; M2M\`[Q-;9*T[5,1G>(,$*G0]"8JAT[V%D^G87'JE-3<]C:587U(8;&!R/1N* M4Q<2/Q=ET#"M":.H;6C@]8K25G9]06"0P1Z_G@S%-MG$JIK6=&2)%\%YV/O$ M#R.[Q79$/.[I@R#J1QCLX_>PH]AFGUKL6M.QWW@&1Q"$#Z/8C%B;$:.)-YD9 MGW$_Q("?F/#X#$.=D[ MA"[SH=CBN[$WB-9T?*/`"^RB6@HX28T4#+S9>_!0;.'-`JM\6M/#BZ<3^S!\ M0Q,G_*UL\B/+^M^RN<\GC?/SV`(=N0+?U&Q);5TBEI`9:!-X'7 M7>@QK2\4;]I1M^$*QFO[=0<_IRC,A\`#<<&YZBYP@4/W`VWY%P``__\#`%!+ M`P04``8`"````"$`3@S/:`1.L`D:V MT[3_?L<^:0).5Y$;`CDOKY_SVF`6MR]UY3TSJ;AHEB0O MAYN4>$K3)J>5:-B2O#)%;E>?/RT.0CZIDC'M@4.CEJ34NIW[OLI*5E,U$BUK MH%((65,-EW+GJU8RFMN;ZLJ/@F#JUY0W!!WFL7N1[6O6:#21K*(: M^%7)6_7F5F=#[&HJG_;M32;J%BRVO.+ZU9H2K\[FC[M&2+JMH.^7<$*S-V][ M<6%?\TP*)0H]`CL?02][GODS'YQ6BYQ#!R9V3[)B2>["^28,B+]:V(#^<'90 MG7-/E>+P1?+\&V\8I`WS9&9@*\23D3[FYB^XV;^X^\'.P`_IY:R@^TK_%(>O MC.]*#=,=0T>FL7G^>L]4!HF"S2B*C5,F*@"`HU=SLS0@$?IB?P\\U^62C">C M*(W#>`IZ;\N4?N#&DWC97FE1_T55>/1"E^CH,@;\8ST:[.(CDNWPGFJZ6DAQ M\ P)BJI681AG-P?K\EZ,5H[XS8W@*P"N;A>16GT<)_ANRRHV9]J7$4FTO% M.#Z9^,!U@H.6A\,9,21+O`[<^.1K&UBC9M+13/N*S4>*'AL,-)S-B)<$O$]L M47+N&=E0D]A8P\DL"`('K2LPY7.]!P;=#0`;K,/Q MU-S9H4<&:WTXF1'WR>)TTD]DC9J))3NG@5180^HD^6]:TVN8C+C/%"6IPX0: M'#<-N^,B%]9=YEY.R35,1NPRS1PFU"#3^)V5A?4/F-O@]8<0.4^K,SQHU M[IB8$=:.&4ZZ&?9RFEW#9,0N4^CDA)IC3F:I]^N;;MTLJ7.]QP5[T15A6;5# MEKAD1Q&^'<;3N#LV9M971+V5AW2XO^';OZ4[]IW*'6^45[$"GMQ@E,`C(W%W MPPLM6ONVWPH-FY(]+>$KA,%6$(Q`7`BAWR[,_GGZKEG]`P``__\#`%!+`P04 M``8`"````"$`%$4BHW<%``#R&0``&0```'AL+W=OY:=%_8NOSJ+^JO54]*UNDF*0W(I"[K5?]):_[[[_;?-1UF]UF=*&PT4BGJKGYOFNC:,.CW3/*EG MY946\,VQK/*D@8_5R:BO%4T.;:'\8EBFN33R)"MTKK"NIFB4QV.64J],WW): M-%RDHI>D@>>OS]FU[M7R=(I(ENV3-SU94U_)T'9^*LDI> M+M#N3[)(TEZ[_7`GGV=I5=;EL9F!G,$?]+[-*V-E@-)N<\B@!-7R MC*4&.))\MO\_LD-SWNKSYZ*?/_.$0Z*2YB=2+P MOQ,A]FQAV<[35U3FG;V,LO/`L\==N@Y:!B.3.R,+^BX70:JT%C M#AVC-L/@QK;]Y"5-LMM4Y8<&R0_6U=>$#26R!L&^@[B=0Y?]JL>@JYC(,U/9 MZC!JH3-J2+/WG>V0C?$.J9%VC,L9>!V8Q:@(_@+PVRZOPP6_.4! MYF]O^5YF/#G@=X4$M^;#T[59%DQ@P@>,([D>36!B-2.X!9/1=+<8++C%`X); M,N/)`;\K-!@#S,O4LQP?XS@[) M`"5"E(@X87?[+T?>I<;B]XO5+><%CPFD[W236UIV69J!W0Y2V8PC'H[X.!+@ M2(@C48?<4MJ4-H^QBA#]9OOQT12B3FK"=^_"7.U(9PVW@Y1^8>1SP<\7$D MP)&P0[B9#EO_Q-4OPC5B0:-=0@<-T6VVY1^YS4[A^`))^$%!<'TA[_PZ2.DZ MU^$MM6!*O&NK-ZBPH[UDA-]]V95GI66O`AP)ARIN^RMIAHQP)%8BHN=@R=AS M9$9AM#R#KX;>Y+MLPB&EURCBX2I^AW0#_='>+,"1$*\HPI%8B8B.LQ/0*,L1 MQ_EY2_L^8>FO+87QB]E`W?M[=LS_+9"X1K6G`%\+,NF_\`J&'ZM MV?T/``#__P,`4$L#!!0`!@`(````(0"K-!WP;0(``#`&```9````>&PO=V]R M:W-H965T\\)A\7B2#3IP;81J"YQ$,4:\ M9:H4[:[`OWYN[J88&4O;DC:JY04^ MVB"B>4,M^#>UZ,R'FF1CY"35;_ONCBG9@<16-,*>O2A&DLU?=JW2=-M`W:?D MGK(/;3^XD9>":65492.0(\'H;S-WX#OFM4\HKN&_M# M';]RL:LM['8&!;FZYN7YF1L&@8),E'H;3#5@`'Z1%.YD0"#TY/^/HK1U@2=9 ME-S'.=!HRXW="*>($=L;J^2?P"3.TT4C?=>8@/GW[VF43K,D&Z%"@B%?WS.U M=+G0ZHC@S,":IJ/N!"9S4/YW0>#"L4\.]E/`K(%-."RS+%Z0`R3'WIG5+9,. MB?4M,J92RZZOH!58.Y[3#XDUO\C!MY@H?'>'%Q@ MT+YX2R=7*Z\"\Q!B31_B^"K9]0"8)GU@X`S*&^_,P=?.IL-,5H')O;.[29[U M5_:YK@=$FL_ZQ,`;'/?QWAQ\[6UVY2TP(;4DAUOQ.K4^,$D&0'`6FCXT14=W M_)7JG6@-:G@%NQ5'#Z"@0\N'@56=;X*MLM"K_K&&FYE#A\01P)52]F/@+I7+ M7;_\"P``__\#`%!+`P04``8`"````"$`4"^3])("``#:!@``&0```'AL+W=O M\_*<,56);E/B']_O+BXQ,I9V%6U5QTO\P@V^7GS\,-\I_6@:SBT"A\Z4N+&V MGQ%B6,,E-9'J>0`PT^=XJ+H6C-\J MMI6\L\%$\Y9:X#>-Z,VKFV3GV$FJ'[?]!5.R!XNU:(5]\:8823:[WW1*TW4+ M>3\G$\I>O?W@Q%X*II51M8W`C@30TYROR!4!I\6\$I"!*SO2O"[Q33);%9@L MYKX^/P7?F<$S,HW:?=*B^B(Z#L6&-KD&K)5Z=-+[ROT%P>0D^LXWX*M&%:_I MMK7?U.XS%YO&0K=S2,CE-:M>;KEA4%"PB=+<.3'5`@!\(RGNJV8#(#9Y=9!O7YXH1(RPT9'R_@$Y<8O`^L*63M]P#6]!,?7FG,7R.R$;SE\/Y$1>_7W^1$7;/SSN9SXF&LZKL&PO=V]R:W-H965T MD'6FUVH]K M2IP$%7`$M.G\^SWF..`/:LC<-$WRL8NM(1OCJPJD@;>5B>OOE0T.;0'%;D7S.>15R19Z6*%=36E M!CL>LY0^L?2MH&6#12J:)PWPU^?L4M^J%>F4 MN?3;@7\$!WO&T<]M!_ZLG`,])F]Y\Q>[_DZST[F!=A.X(GYAZ\./)UJGX"B4 MF06$5TI9#@#PURDR/C3`D>2C?;UFA^:\=<-H1I;ST`>Y\T+KYCGC)5TG?:L; M5OR'(E^4PB*!*`*OHH@?S18!63[<4R445>#U5B68!0_$)]$XBX?7U=KTE#3) M;E.QJP-C#\CK2\)'LK^&RMR?$%S&J^D<^\PP<(H7>>15MBY,&CB\ABZ_[PA9 M;+QWZ$PJ-#%JX&^G\57%_J;@#06\CA%\DQF'>W=#X6*.PGO)V6+\0#YOH)W7 M5(2DDR@DX)!,E"R>DKX^0J%E(FJ@C:!5[FT)AA"(RHYV-B[M,E@:OHJ M"IT/RZQLH1VO56M\_E(]=RQ$,F!_1?'(2K%2S]P.BWFR5D*_=TPEQI5<)C4[;XD!T MVB91^>!"9;YIL>;SH\9FLQ#)3O8F"4ZL,RQ1.>\*$'Z;I\UH,]N$"%=JLEK) M:['`DS,DFL/]>Q]_*IT6(A-=--.$$&U-B7T4#5LD,&T2E5.+E8F\0`3PMYQ(9+YS)5\ M0/1)QP,>#)-7\E:M9;9Q=RU$,F%_%?6\!_@&J&9-4*$61,._%JQ"%0V M+6E&W!M(F$C_P1+8XD.,0IM$Y?NIA`FF)(P0R5WN&R@X)R=,<%?"M&IU%`[T M&,/C=C\AWRP(NL\%JH<_E2W!4+:$ZHUK+$16#R=G"W]8),_D:2M.>]18M@B1 MC=,J4?P,[\J65JWVVOR5($0R'XFTIU[[`5$_8%5"+5LF.LF/TD@CX^D2BF32 M'@+'96B3J)Q\E;\[8T+,!OAKN7\4(BOGY(P)H8S,:5\E6[7FHY$Q0B3SF7<3 M`Z+>;-7)NS(F-#.&1'WEMHVQ$,F$FF1OE:A\6LY,')&8$R.=MH6)&)$VB^,;(CX\5>T^[39K'H-VNZ7[`O9*+LF)?D^J4U;6 M3DZ/<.A\MH2Q6N%N"[YIV*7=:WAA#>R2M/^>85>,P@/Z^0S$1\::VQO^^+_; M9]O]#P``__\#`%!+`P04``8`"````"$`&)$PTQ@#``!4"0``&0```'AL+W=O M';`!*N`D>TT[;_?-4XHA)9F+TFPCP_GG'OA9GW[7)76$Q62\3I"KNT@ MB]8ISUB]C]#O7_J,E+RF$7JA$MUN/G]:'[EXE`6ER@*&6D:H4*I9 M82S3@E9$VKRA->SD7%1$P:788]D(2K+V4%5BSW%"7!%6(\.P$M=P\#QG*4UX M>JAHK0R)H"51H%\6K)%GMBJ]AJXBXO'0W*2\:H!BQTJF7EI29%7IZF%?;TL6_/A%L.P;JRF$#672!=AQ_JBA#YE>@L-X=/J^+<`/864T M)X=2_>3'KY3M"P75#L"0]K7*7A(J4P@4:&POT$PI+T$`?%H5TYT!@9#G]OO( M,E5$R`_M8.[X+L"M'97JGFE*9*4'J7CUUX#<$Y4A\4XD,U!_VO=L;Q&X0?@Q M"S:*6H,)462S%OQH0=/`/65#=`NZ*V`^.S,Z.J_O606/FN1.LT0(NAU<2"C/ MTR8(YVO\!)FF)TP\QKA#Q/:,T`%JVJ2W@$%O)QJBZ(M^NPQG;1JLM9U98[,` MW)U8[T+(&.$'0T@R"1F(]?]'K`8/Q)J%OMC9DBZ$-#!T&X[/C;#&.#F7)@$.\[Z.]/ M.-"3^^*]^/%#H`]=.)B_)F0<&(QI$G\4\+:_';Q1`+/_=@"F!&:*F9=\1<6> M;FE92BOE!SVA/"AMM]H-SSM?OQXOUF,8JNT(PMT&#+6&[.EW(O:LEE9)ZHX-X)QS=;Z`&^/N_]#F'P```/__ M`P!02P,$%``&``@````A`-#)QXSQ`P``&@X``!D```!X;"]W;W)K&ULE)?;;J-($(;O1]IW0-S'G,&V;(\"479'FI%&HSU<8VC; M*$!;=#M.WGZK*,!TVVNSN4@"_5/]U:&+8O7UHRJ-=]:(@M=KTYG9IL'JC.=% MO5^;?_WY^C0W#2'3.D]+7K.U^FM5-L5MOMQ97YJL@:+OA.SL"<1:#7/B^LA066-JN\``\P[$;#=FOS MV5DF3F1:FU4;H+\+=A:C_PUQX.??FR+_7M0,H@UYP@QL.7]#Z;<<;\'#UM73 MKVT&?C9&SG;IJ92_^/D/5NP/$M(=@$?HV#+_?&$B@XB"F9D;H*6,EP``OXVJ MP-*`B*0?[=]SDO@2RK3S:KA9P.J!O84QQ1KT%F"Y=XSXAA\_2]7P4)KC:,JDEZ!J0"\@1$\'S/>CGJ/@F)$ MP2P@6TPWP/;`YFK[7BN\8)`H)!"AZ20HADR/-@[=Q6"7X$CCCS6J(KFG4-C` MR'0V%*]-<'P(2NC9ZLXQ:<(VG:X7>ZE#91D89.A[>8NVZDH9'@=F@5-`>.PCAR]]E:M0[G MJWO'G8CHGMS0CR*-/^DD4_BP+X\R^X"/NKC:6K23&#LDZOB"N6WKT>L44_"P M?8_PIG47AYJ^BAGJ820184:!/^IO='`[*U,HL8]KE#XTI`?!I.ZO4FJABAT2 M13-*M3X'$'JZ%<0(D=7XUC%?S MR?CU8,\BS8D$!S[P=`JD]@J96)&WWB7ZO."0J(_D7',BZ=:G0&KO$H2<4)#T M.E`BZ6NM)891'"/50X;:L<)1_5$D:12G2;5BS9XEK"R%D?$3CMDNE/IP=_@$ M>'9QZ-/NQ_AI@/>M80$F\V.Z9S_29E_4PBC9#DQ"PB&_#X!O,`9#)1Z'!,P$``!X%0``&0```'AL+W=OP1#;+=1B'V2?B>X+1@(AF.@P+BS_?1(:_4 MDO`1N23(WMX//T*2'$#B-8JCXJL4594D;$UV*YJ34U4.JV-Q'T@*9=R?"VH[Z@UMI5M6Z[S,^_$3[F5_^5 M?$^.HRS:S*,40[)AF.@`O!+R1M')AA9!8ZW6>E@.P#I3-G@;O,?%/^0XQM%N M7\!HV]`AVJ_6YLO'>0@)!9F&85.ED,00`/PJ242=`0D)/LOK,=H4^XYJ.@W; MU4T$N/**\V(844E5"=_S@B3_,0B=I)B(<1*!ZTD$&0W#LY'M/*%BGE3@6JE` MT,^J6"<5N%8J?Q`+]+U,BW-6,=RGT^*>1!`=U3].+CH/T24QIO5T,*A*#+KT MR30:+M*;IBL=:HW9IG2A'Q1!MYV1HP(S&X++#P%=)U"+*E?^8VXY._([0X(3 MJFHL":!UW*81!]=QT)M[0.<'YZ87ITQ>*+/"&28I8*%+"1H^'4-T^9% M!B>1JU"$QPSKA"@RJB."R+A.B"*3.B*(3.N$*#*K(X+(O$Z((HLZXE@.G[=E MG1$>M*H3XH/6=>3Z01J8[NP\6&QJSC-AIMU>^2JCT5;4:'0EI,[KB05]5D!- M5#&^R`Q.S)5''$OH[?`!9G2+,?F\CA]@)K<8B]>9/L#,;C'"_)@_P"P>8):W M&)>/>?4`L[[/<):!!92SS'VK4!I>A]>#;#3Y`'N,@:7ULF[Q1%]*^%)B("6& M4F(D)<928B(EIE)B)B7F4F(A)9928B4EUO<(SE8P_$_8BM(=%5Q[L8SE\:;I M,>:>K:2$+R4&C+#9RU+7D1#%4*HPXA4<)*R!8ZG"1*(PE2K,KA7,IJ7K?"[G M4H6%E%A*B9646-\C.#O!Q]@3=J*T:"=QE6(,!'"Q')^DOI3PI<2`$2<[(<\2 M7D!#J<*(4S`\75`82Q4FO()E"IF82A5FO$(MAKE482$EEE)B)276]PC.3O!1 M_H2=*"W8R19F5(\Q5KENZ`U+^$#H\]7"9Z+/UXJ-!]?5AM$0'#"LJK]U\J@B MZ!X"@N-]/JYJOVT_J8B;[:=5[;?M9Q5QL_V\JOVV_4)*+*7$2DJL[Q&<>V`/ M^X1[*"VZ1]B"]1CCE.Y!IN>Y=E-X\?09]\CD1RW&;35=XSN`:,4U'_'0; M2NI'U_6&ZQFV*WR=CJ7$A",,Q_*0H#&])DS==E%3F&VS:\+S=,=VA0DWEQ(+ M*;%DQ&E.\Y-F=:<.CK;HB+/1M"P(_])!YB-VPGE/=2"S5J]O(]:L&>KE_NH!1LW*-?.0G#P=0AV>!%DNRC- ME1AO(02]08\_,G9TQFX*Y=\]G'!BV"_J#8"WA!35#7W`^&PO=V]R M:W-H965TFZ9:6A9/CK2(^8Q5M(25/:N+N('+^F#QJJ9QVCY4Y)8]G_M6$6>EB1:6 M]10;;+_/$OK"DE-!RP:-U#2/&^#GQZSB%VM%,L5<$==OI^HI844%)G99GC6? MK5'3*)+E]T/)ZGB7@]\?Q(V3B^WVXLI\D24UXVS?S,"MJZ>?FTC\'=MI'0?G_+F'W;^DV:'8P/A]L`CX=@R_7RA/($=!3,S MVQ.6$I8#`/PUBDP<#=B1^*/]?\[2YK@V'7_F!7.'@-S84=Z\9L*D:20GWK#B M%XI(9PJ-V)T1!^B[=7MF+SSB^?>M6$C4.O@2-_%F5;.S`:<&WLFK6)Q!L@3+ M%\^0H_?U*U?!1V'D65A9FW#M6L4:+&,)Z42Z2&HE,I^HP9-C2;!B2V7$58/9B739H)7( M?*)63^?#RJXOP01%6CZ=1.83Y7K$-RU?"19Y>,M0S*X2MA-IXXQV;DMD3G!W MS*G/62+4ZCF\BC.*;N='9T%=E)D>ZA'B^]<5DYJRG4A]+=:W+Q9EIH=Z`\&R M+L?Q*E]1=#M('9E.(O,I_>%.'&\T!C=0RAQ!D38?=!*9[Z'>0+"XW\G72W<8 M)8OL0M39N>V"S*=TB8GY>JM=#&VHJ\NZ?D'&#<-U`Q(.89``[8<:1JN^EZB= MZ'92=(MX.K7]U7ZH5;1JE4Q-UT[T!1DVFXY,TV-A$GR@MK5J%4S-V4[T!=BE M.XBY9_BZ@F'$F1)'KH+6!QK1/.=&PDYB7K3A*TY_MY]EG]M15KF_A1FW'0BM M?@%&S"H^T!]Q?_<\3F_\!``#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<; M```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=U MBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3 M.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT M81C+RSPA,S*A/D%#3=+; MRHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI> MU?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/T MZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_ M^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT M,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81B MIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#UO5D"53,+ M2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0 M%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1J MCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU7 M69O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD M/M)Z+_NH9IR4Q>Q,O91&\ M\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3 MV63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@) MJ=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]E MR43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO M:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45% M],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_ MJ/"9_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<7JN('NK/2+=O[RR;!U_]S=&`Y\LG8]6P_@K??8\S>>H:]\=I)M]8;]_D7/ MUDU'C21(;;N?=INSI:NO=$#\\&TS.`EE*4J]O+J[:/C>OJ#!5"?!V-] MF<@.W^3$V^;2/7^<\^ M?J/V$C5()OB@7.9YOU0L?%P@>7"Q(_NGK_[WG_^>#7_^J(1@8ZAG.X<9RE[, MQLWUVG4R4H9#H)PQ?_7)<;\X&OL,`@NH8E^[N?9_4S[K%AP9,"%+UW(])8"( M`:["(XYN&]$W%KIE/G@F^]I:MTWK)3H\9`?"((N_9YO@\A!1I.&P>AX8FL2F M2P:#V#1B1[!--IBDLX/E-NF_[+&)Z)I4ZVK#']$56E%NES!=^;C(<=A&5^HK MI,=[?)BKF@;Y:-#O,UJQPSI2-EOT0=_!E%U,#F;92!MI4Z&6D5C,^XTI'&DB MJ:Q0J+V>OCD8G>*5%5D7I^%#C0`VX,2R:,+0+1G?4XW]'2).#ES0NO%8*)4D M_7#H9;GQWK0-7WEO?%%^=&W=8<3BHA9^NX=K,@F\PXE/TWL^WFJ;D(87@B]& M?LB4#Q2:EI6UF!/6.,&1FVOH=@/#CI M+X-AV#SPG>"[EKEB*!X78;,66[NXN-,6=Z%>A(P718%035M,.Q!Z=SM;B$>Z MF,U$"QUJ\"=8Z.L)^Q,L5(/_+81Q&J?+L2B0J3PE,-E$K7\^G#\3@D^2&.:--9&<\&F[L)HRF/8`((9J/+V<40@/3'EZ&J@R(8`8#I9'(Y M&*;!L(GFL(@22O(H0 M2/+J5'`&GDKW*D(@R:L(@22OAJM2`L]I(SDG]+ MSH3K4'#)::X&3^;R$R@C2Q,1-Y&*KC2D66_,9A/CZ;@_'4^&%]&$39!JVUB9 M6SMO7:I[;UP"C8S;:L,1ATZJ)`Z';'FLQ[P0NX_SC-#5H:KS\I3]C!:>4Y=6R&_Y,;&[9#]A=WQ'DLKSLC;67'"'BLKSN"U MD<9-XETB/%VZ8.EY#Y(=OLG7F\$`1=&)"9Z=)!CG)[9Z&UTOX$YW^\VM%(^L M!@GURA6W#4@)]SG-^.46OP?2CK=%N2+G\H[T)*97BD>F-W9Y'27O[;,1\W M?I'QP.Z]BH,:7("#N@R/2`2PV),@`"?(0,#NYXHY@/"4@0`FT0D""-`,`<`I MB8HVXV"`LAG$0*82]'>E$G),8B51V:&51>D7])=8J9'TVXIFE&\AT#.:X4T) M@%8JBU*LK!2#W`XC+:,`WI10H$'5%5/R!D4Y7QHA*.D"AHP12`-EC(B+2I1S M06<&H)R16X%]"`H*EHID0P`X4B`@1PPDU5]8A4S3\D!2!<;1(*D$8PBD!A]P M3&!/D`HI"0/@D3(J4$"2BG%`&A`$61D21<-05HK$&&3ER,P5[(<2D@-R*"M# M8D_(2I$8@ZP5ZZD#HIF32`K.3V:/D531W!&.)E" MRG=4M8334\E?VL,S"7^,@73]_<&\\P%XTN`SZO M6QE8@2G3#ZOKJE)'N7!^6F#A\'0%$966A[/ZRI7YG5%:Y4M0RA%BXNU\+7+N(.@ZYE`!:R"8]B M*'4XI;.1^SGI12T(SJR4WCS<_:5-@R+.&MVX\I"8:&1$>!\71UI"5N`L>6)6 M%)38T>YZS7$-Q(.@:S`044R0R"['6S^P"TL]3L9M`_FH0:.X)4P?I(`(C(QR MO-U&1@,S)-$>AW([P(6]V=&T0HQ=KCE.X?BOTZM*G<_A00MF'W8^A^OUX96+ MGB+4\3FVG-;XJD$@OSTD]2@/MWZNE-(>GI85*-^3T"%EB]V"P=\?-F)=Z,PB M!_=$0J>"]".S`H=.4YS"=\]:1EHJZ`>R*A<[)6X*Z<9AT! M\5\X:<&YLNVB!_HHO/4\!+W'V!YKFVX4GZ['_V00 M.7@)OS0>`'W'-9AS.`&LO>U;!=P3:7PJK#B&H,9!`FDTRQER(=C&'>?)3FS3A%2^[%7!/)$E2*RK& MN8!**C1&X&>2IQ0C.;@G$B,T[>6L$%Y(.6.D:&!6P#U>TCOM!IH4OT)`5==+ M&DUB.-V.RL=A\?%.L@:04Y.*@1$>]_TB&'5QTY,K$/5'$]=Z0&NN25T[9M2$ MZZ-&73#P:%@?YV('(9G6!WC7<0_!&\N8W\+[@7.A3*MOH\3;!&"7JV^_;/W` M7+]P_,044W9\B(J<6.%#K@09%;A'1GI1Z)R6%?C!7/P/@^)Q!5>Q2^:N#3R1A[R74%=3_P0JB51>Z$ MZ;M@F4+"H\C"9Q+"4PC1GBYT1Y?TF86*H]NP'=ZP_P?E3'F]9+&2+G6SEN)A M:UJP3R>[$LN>)[F$YM*U;Z.#\0,`RV2EM2E\2BR2!2.XKJQTKC%DSQA%LH#D MNK)`?31O&8&U2!9L=U-;5KK6/F)/@,UPC6&MKRZN='EP1+F?<'(_WN='UGDA M7,QD'EQ85N9'EGHS&YG)=65E?@3'85E@;,$]C&S(^4^PDG][L9E4;\D#/B(RF9[^`5XHC-7G@XBJ1D M7J-1/N*,\DA*YB\:WV/.^(ZD9)X">N!Z+PI[5F\JCCI]PBGNSZZ;MG-''3%P=H2&QA^;IM81`V='8FA29?T3CYBWSF:;>HCF4E:Z>42\,YU/ MQHI&#F5X""!Y)+TWMH&GI_%'A]20DYCW;/>^5`9-$>%F?+L]XWO8K"\AD?7[ M:.RP.0@/\+]N`T0C.PL)84O8/$+NS0"VO(V]2<SU7\+-I"&8XF_]8'YV@U#$7,U>OV.[=,,HAHT?(=V\\V'G9_A7V7KF7/W7 MW>UT]N9.&YY=]F\OS\8C8W(VF]R^.9N,%[=OWFBS_K"_^#=09EN.?_4\&,_5 MIR#87/5Z_O+)L'7_W#:7GNN[Z^!\"9M_N^NUN31Z_L:#I.(_&49@6[UAOS_K MS7JV'NZ["T*N?`N^Y<7&QN`_9,?F*GH3P0^WY@78L&=M8D3/9QMB?F!*;OX/ M``#__P,`4$L#!!0`!@`(````(0"]]ZOO8V$``+)$`0`4````>&PO9Y^\'F'?8*"CC,D#)$G6H4N)40];!5E)5JI'D M!$$P%Q2Y)3&F2(:'*BM706/>8*X:F`$*?3U/4?,F?I+Y_;]OK7U8>U.28R=I MH!O=;A6YCM_YM#Y^^2_?WXVR]_EL/IR,?_UL:V/S69:/^Y/!<'SSZV??7IZL MOWR6S1>]\:`WFHSS7S^[S^?/_N75?_TO7\[GBXRYX_FOG]TN%M-??O'%O'^; MW_7F&Y-I/N:;Z\GLKK?@G[.;+^;36=X;S&_S?'$W^J*[N;GWQ5UO.'Z6]2?+ M\>+7SW:Z>UO/LN5X^.=E?N@?O7BY^>S5E_/AJR\7KXXF_>5=/EYD!^-!=CQ> M#!?WV>G8-^#?OG9UN;Z;],/#X#.P"!T,NK=I-]^=MT;S1L+%;N\RV?# MB>`ZR(YZB]7C3H;S?F^4_2'OS;(3,#)O[-,&R&*;,#WLUK[`R1_2-2]G/=%B M=G%_=S49I=]^]O;XW3?IAX%`#B=W=]#&Q6+2_ZZ37=SV9OD\.ULNC)I9E#;V]Y=`QJVX_G917;Z]G#%"H=0Z@Q`G4)TWV>_S>_3<9]M;FYN M;>WO=?=?IE\=+FPXT0DBL&!9/?9Y/)[.%H6O16[00 MR!_R54O8^MDA]'O3X\.+H^/LJ\.7A^\/3S.+KXY/KZ\6"5)3L?9Y>UD.4<.SCO(J5$^ MGV>3Q6T^^S"'U\.'14RW<8Z`Z]Y\GB_FOVQ\W9O?9FR8]?5'_N?E M\'UOE(\7#0@>]$V*SK-9WL\9=#5J4.WI^#TS`6PGLZ,#S,F'WK@/1TRNL[7M MO=VLM\@0B/G=%5".0M&V7^ON[;=]V[C/NUD^[0T'6?X]"F#.TCJ\`2GKUZZ: MWO1RLH!='A[S;H9:F2'WM:B`,96XZV3CO('?,^$E%+$?0UR#K MW8E*_]);H#O:S^*3T^\BF8^&O:OA:+@8YDVL7>3CX626S7.NPU;CR2+/IKU[ M(:4XRR"_6F0#I*DTG2%@:ZN\ MV#6=Q[JS)2>+6$J_/\JO'L5Q.*@"FS2E5]/QC?KBWQV MEX65=/5!LETZR6GC@54EYH<+W=H)[A"-CP3"B`$]V?.W0L!6]_-TW<\^??ST M,?W0=,7M9#1`U'VFHPW[PT6#,:'S`**YZY:U#>0Y6)YE<.@R_U6VVT'"Z_^R MN:N=WG)Q.YD-_R+B6\5G*,_NKR"8.&OY'>*"C!50?=MU/^ M;2?=>MG9?-GM;.YLVQFWMCK[._N=E]V=O_4"J?CI=J!!B=;%\'T^NF_<[6`P M@`%!]O+-%T-,M<^? MIL[R[_OY=.$64C;H+7H_1L-5-$NI5-)+OWU4"J8S&CQ6<->C(QLL]]09SG!/ M'5WAR71*G>E6GKP^[-%CMPYO/W/KT(<.7+6(+BXQC-XO7EW?OS-\=N+T]\=9Z_/+E::3&_S!>QK*J1%@DX&RW[Q?<.B M<=TF.S*LT!CAC(?R7SGB<(*#BH*YF4P&\VR.4$_1]/5L@A5WUYO=#!MFP!G& M!O8!)XAZLG&)\WR.)]1W&VW`34<3LTG2;8[R*8;9T*P-8_:'S(\+C'9V[60H M,$XP\@F#N^'8G!))PG1]!X6LH_J!TW&O==OKV>0N"V,GXP983\?HYQS`M4O$ MXNL`E'2+K_'I,WRN.8:J8%_8:>G`@XH%YE9`Q2)*![L]YR?*GH>M&PI=]#;B MBNVS^RWROI,103U-=OVCF?* M0`ZA#O-'C<\[V55OCG\BY3X8CI98I>D>O^=DMV:M$IWIW>2U^9CMI4GPA,5J M.J-@'?[VF[/71\?G%Y]EQ__]V]/+/V3/CXY/3@]/ M+U?J$H-%>O@@@,R>RO[XQKR*1MRCHK_?!?U]Z/I[]92*(G>R8"?8*RKR4U/D M3YJ.G2OK;N78KWHC.4C!WBH"10UO.XSK1*O'[;O5X^L'=JINR!81SG),S&QD M-N,-?#7_0A0FAVW\(-VVH*("H#8J/?X^G_7EQL*Q'WHSA3X:7-0V)EXYW?'M M9&PNJYE%ZQ`Z5BS$+Z?0."L=KZ"$@9K];0X"2APHA]8=ML4DPYN7L89`+KR< M=)T5&&MX5H]@K#'^0C:\&V?93$PIIQD/P.0T*B@]QV/C5\&M"@<)X=FP+_XW MD*1[/#1VU?J_=]QF=T1WH?U67*R`X7:Z_R,P;(QO%T!F81P>7'R3G;P^^_U* M4Z)4QCWY`N9XIPT*?ZVTAS*9J4KBJT9KER@QEK M"AP:G;:&(AH'2E2<^QWM@04X9OU!ENE((8^6%@FMLX@TR&/$$A$_'&-U68`@ M/6QAQ6NM?-8T,B)/#X.!D"X0-3]1C>D$]2]9\C0XO999LE*F"2TM=LIS!#W2 M<9Y_CI_E?R7H;(^I%?=,SU_&)AX*HH6=GL<]/Z]O6O'J&D24AG/ MO07Y&'Y=7,3V>WB?_`EZOK)VRU'2]5M149YI-7T=HS_Q_[@!P8=;B"7/\%[< MN#&"EEBS/QZ(>VMWQ*+)@:S.DT]>XW!5D!VCFD30>"PBX9CWN'KI[1^82S9N MU:P+Q6I-"",E%03&)"-4K.%VZFLB\URK2&ZV[FIQ=H9DB][W30(Y3XP'HTKX M!`U(IF$!6T9)U4B?@'^%JIN65WN@.3W<>9&!:%TAQJ?3:2>]88B="@QU!7]0/_R8?8+:DDS$MCHA'D,MYHI'QM!A9X`3CX0N%YRQY9C)`H84&5Y[-;GKC MD%0PX?Z6#)CC-=@O+7JL.JF3$;HF3C$D!&?^)S3T3NH8:6H?`)H@N*"<"SXT M*IIG?SRX4L*ROVAX6&\M^/WIX_JGC]6=GGR\M_GTEB!)AU0FJ?+G/_SU?X=/ M?OCK_\E$?;=YQH=R:4C%\>'G.!!S,>5D1HS?DBU+LJ`^_ZFER-'>7#D'F'I#3OKH:][-LQP13J'I#:,$8( MX.#UOQ>./1W.*9%,Y[E"S$=X2-*(@L+QQ?F1W5:9IMZ4!?+^[7@RFMQX?HJS M*;XUWR!KF+.C@2=#H6:+#Q.=W+X%3B0,R+TOB4]I)X-.)9*D`0(69168[#WN M`9I%"AT!_YNCDXYL>7S$>(61;I0-\8@G[\4RX702%#HR87)R5GAW=B[N(KAK M@[/7T^4L>W/$DJB4$3$@!,5,^1-F*UO5O02R`G""@,]/ZR>8;4"LE'9O[?HH(?8P2@SOG'D(D1TMPZOC]5F`- MUQ9VCRZ^#:0L0$1XW,_AMT[VX79(R(],IW,F](57\<%HCH-'R4["/&`944OA M!Z<5G,-9?OCKO\T!'L0J[6*8B:BZ6N+C`E.G'$Y2929NG2SB%3.V._O!/KDE MZP>ZG)%4/+X"E4.H5"*ID4@Y&V=4M.39C@I:-K<[!>=9O&]L),>"KX1N9EA.L_?$"`P6P03AS,'!4S"!^('P"4\= MJ3@`)@JG;,#C8GE'5-@.>`&EF[.LXB//LPMG[Q#3RB^FNJAER&/BN6OB^6_? MLBV/^8[81'\(,1H#-=7*5P0?[:NJ?DGO<@FM];BR"2]=&H\ZJ"=04((8O$1- MQ*XXJ2Y3-'6II&P=S88?,:!31992Q2/$)RHY&(W`(K@,9[-3VE8B.0OA!K<1 MD4MV[RK/QUD^@GHA98X.!91709HV\,_-$8[EF'S`KJT7_D"T/.M-@[S%#[GK MC1'D9I[;88#A5Y/>S*S!HR&^)448KJ$D>WOO>\.1V5N2884?`-<$H&$*F&4H M1NCA_F,R3TD%<&9.=`$K81Y#UIGR+,"T[31#)*Q.NTI8'2,``,$S'UF:CJ0C^@.L1:I M.61%5.O05]+2L:G#HLWU+R2ZN1'7&25Q!-!ZV4P>!,*ZBAK$\5WONUPR)5S9 MA=5\>11*KV6(X1=+2GI3*U5&+7QY($EK2X M1#H'!>G;5/'=1G#2I*;7TP,)@3%79F-BVJJ3#9:*5%9N83`%.)/!!C)M(5T! M?)8C"`B6'>GT"F\"(G@,S2_]KK01)0Q02@$SD>`A)3G$IH4B"%A.4@&@DA:A M^A'WM@(I:4(H0JB.2C%6CMCLJ:M5([H&H7X]T=$/">SE,PP*(/&F8#?3J>>4 M"R"DFBDRL<\J4;:*M\L+<"@H6L@G"H`4$3`#PH)&AV812EP,C;YD+ZF]&SLM MG^FT-4O0S@I4R#IIL1#7=[K!6NV#"B()XY`#-"-AOM07,MXJ7J+(F(I:LV\S/Z\[,'JF,!,M=H0!(U$+D6O[LB( M4C'@S"$Y:JV94RU/W?RL'64,TL(1X-NU[<[>/L4TE`N)!OAG=X^Z&BJ(!(BR M_D7F$5:TU;PT%Q=H73Q*3!&$91S*KXPI)*E?L]DEVIYV&PA8%K>A`75W39F- ME;1IA0CN.VA.\/:(3!!'9O$%8I/XP)N8!%/ MTF,5G]9L1E2FD92I4+BAL;=6>6`]SA;9BJ.Q0#Q9O*&J_*B9%!-%$0G"*C2C M#4I!#0\X>EP>X*!49*C=?""7DV*FH%OR02+D9BIWOW2URM_ZWW?\9_X7E991 MG[_Y[(M77_;Q-(T2[RC(W](GLQ-$CP^Y'-ZAA-[BDYQ/L$;T[77O;LB6OH(^ M^,(67;P"=^^+"E\$$K+>3(\IH@M3XUK^5?;\W=FWGQNNW!U9-X\&&16=)O@Q MI%-0$%/57^$BB($6$((ET&4B83`7XFF,#I6/C3]XAD5D):=0N\K';2/7N",6 M(0HXG/67=Q)7JE9U!843\:>HF2/Q@3W4S/"."\SD?"EXBW2=*SHLV;3$'I@[ MVYP<'6B09V1F^8W*0JF-Q<*R*CW5=08_[Z['IP7.<*PQ+$V3AEU-DGO\6NB- M&C@@%<157B-$+ZO[PF[*NX,J[R#9L24'D+#($%\+=P7@'\2064=V?FX&B=CZ M-TL0ZD\7^*]93%]1.M*?9!<;LXW1!H;"_--'3YI2"RJWUK^79VO^^"EXN@_9 M6:L?'8(Q4%YSMW4I3A3*Y/JR60&M12^L>L*N`)4MKP&,V1F$)'JS[Z@_@VLU M6\#1LD7@Z-\4A=!M!]D=17M6_8!TQ>C@/')+W.&>R[RXE,U:@$!;>\"_"CB[ M^]1#XD:\U-_M>O5E)^/O%[M>XVBGX=][H3*3+>M`_`W7D->WY8\^NC8A^7`[ M$:R182P8[^J[N M`8Z@>Y4O/LB[J>ZGSQW7,5K!,P;JUFU08Z,.>JRDO$\?W?>H0@8C$5*2(2T; M4;C4;K:F_)SZ9SWU@95RAZ MW]D@E)!G;[UN6$'9A^J+,60_?;Q>SMAI9E;_TD*2$&^SNKA**A9J"=+N+<$Z M*[N7S2`9"*_KY%&RR2^$6P@$IY7E%@9[W;N[&O0P#I3WDG?Y^O4A3&N7#ZX3 M.'"_1>!;V]K8AO6H,^/J@A(?[,8/&O0-\C6I8>8XVJM3O=8=AJV4)KG96]L1 M.R6W$)*,:EX+&/SOLVZXN]A>=E:/2"'29D!`BRR^>U0.6QU'X(%J)>S]'VW` M(2@<$;G'`R`'7RVSEBC?Q2M0Y,30==FZ8SM%1/0MP&=>8)84@@2B=!XQ,1[L MCJ")[*!KW8VM".@JE4$,%5_^V'QY%Z\ME.6V0?G([1+*DYDW5CR4ZG'Y**1, ML%Q3)\64U?72LA*E66@(? M0HC<'C^0R;MHTH`!U^[L([[,B$S(3E2=(,2#:E99)0D.:5H9*X'\X11==V0I M@8AQ#`>=%:LG^V`>/1D,9?6J4@58(77=7Q6\;6W<3L$[5.$%N$K*SQNLKG21!H*^#O8W1P7=V%)LN>*J,F M3G2SH%Q1IAU%``JJX8'?XCX"M!'O2!$M7@I@Q\](<%A%`^%K98%XC$&""+F( M@8[=8B:?B1)>T"!Y[-$H0+?'4B'X@3#"<)'`B6N)WL";W4`DA(%MH$*$&5`J MGUFJ!?N)"#UTA.(K,IZ%DIXB*KZW`R6&-C# M9B4JZ<0HDL(%5#B^5:M'N!52.PA6$TPL&7)F95!'=;.$J?`<%(3"NA[FI!#C M'I$F(E]:S&0R@QA,$*A8THV>W@!,]"CO#+KMW`1G#@`-D4U>5`$#VL4 M[!'3ODZ0LQQ:&>.%GA@/A=6C M!H;D(&:120.5X!54+"A"C;$6B'66HY7 M:+&Z[,!EAM+I>JS*9%,T_@)B"67KH91MZMLH<&$U*)2:7IE@,.+3[DJBQF,% MR6-08XJGX'Q1(]_>!PZ!!,"!X\'=]1!W_G._"_B1RJG?&$HV5^*7][E./!$M2LJQZBX M!%EDDJIJ,R[R,F68P_6KY%HVIX04*&QH.D$:"4?[%]=MP8@4O3@R"=#?5+.4"./?2OC&(8TQ21I3"=1$S?61"JKD5$44L MF&`WR>5K^V`VBK,%7K/TJ!D@A8_EPPG`8PB,%N.N[D,!2==#23N-^[VSP$,C M:7O)>D$368T&`0BV'RM@I-*,J=O(-C(DNZ5M`-XS9=]F90HS. M\I@YH,6?G"B-I!(+)+NE#F+ERL"RA%'\&!UZ_)K)<&+-36X[6IFV"!(,>Z-< MI0F3:C'S,4:,O6%J?5?]KCI4MDTY5(%80G3F&JF"`Y[U=^:5]QK8=N#6WT$% M6I"=&A)B2(!B`-#')38VHBZL9!1$FO2(JER""2%K#=J?*__I@>Q/'TL1H:HH MRR=8Q#((AU1VGQ+4&\YD))KHM4+@U^PPP//5N_QT?)5:>@,Y7^:%!P-*TNF" M6.6`G.\`)4DS<`E;5Z1=S+%U@8Y/R5&X?F(,38;=X1$NM7FA3/2M9U-Y MCZY*A#)<9XN;=BI]`<.">V!5#"(BZA#5LJWS.42Q]Y^7F&H$6=U_`FR*GR-$ MY!EB)OKG`%>V9*Q#L)NW3A2RQZ28BJ%^]D@QOD;*R%E^(VF%#Y>`8N MM7*[#3E^(H?R=[*A=-,3KPO'NCO%ZYNARG#AVR19P1^5N@;S9R4/4L<6SHXF M/.(AM!JI?$@4WH"DN8RLM9EPY@W^;852!AP83`D,&GI#W M&N[1N/NYQ#_KG".S*->2AYO>-0Z!,"79&*5>#,8-U*H.+%YF2AT)3:93TGEO M#%#DP:B"(A5CVX"R5#+GY^Q0RF#"A90@+?FTTR09%:%AN*"J&Q:KD/C_YQ M>_.!366NP*D>(%SW>OB]J!\_+(AJH>A7)FF>#]]_CL0T5S>F_0U`ZA;$,'Q1 M!1,;24HRE*P?3:;BJ@*M`T'5?^)B$!NM.+>#46ED>N+%V`N+!O/]CK%(?^.\ M[P&QW!**:54@V3<%(9`1Z8*N=#,/Z1?8`(XUK)D]#VHVJ&"RF$)QKH!]8SXQ M-C,+5U(T6SBN0GQBEN$?(3_M9N:"2),$!$DV]J[FD]F5WR/DNMRRF]^ZG81D M8EC0Y6;T6I)$D6T@N."3H/\"7$TUQ)A!&GXCLTA7M-B&)("=,ZLTT[2D,QJ+ MKKV@H+,H+=CJ[)">TC\EA@&E&!KU-S9S08Z>UY_K'N']JS5MDVLA:*5R:-MP M(K^]GCAPM\[`75""MFNDGZJIR[H\EWM0D!:XD>XO;[75>;&[YQ*N0?/R=F=R8J('1$D!ZJM< MG]`R)'>6#;8LYU.83I0,*+6X+'1[XUE6[X205QT6"&H7DE^5<0QK/$G[YL4ML%3S\76L>U+/PE_-IKT_IQ#1$`YZ]RIZT^^SFZM?/3DX@#_[G M)Y1=>/N`:LZZ!D'X>*W;V=G=%R%6257()]MH49LP6Y14FPP5[AL%*P,)NI2( M-447,]GRT8DYHRTJ_!*3E?\IP"\P/BR(RNPM`*F4<%P@RZ=7Z5[RN&9A5 ML:I1P"6(BU9'88GJ_@3.6<`]'^FSN,##!MZ+K9?2N5&F":\BC8IQ"G,]M+1& MUW2FA4`LE,#,,B=HV-2YRD85,"CEWTU(KB[?M'GN06:(LPHO2Y>WN2C(-_M;VY.$,?B%^PY'$\]H!=R:*'& M2JZBK,!8&"W2RT-NQ,)*X55ZH2+\O.9NJKB,M**]3](\7:T\]FAX;;Z*J0B[ M&-XG]G"MPI'`(>6P+(*R`J8UY#J552X1_+L`O6(KVY=PGLK,)"X=AA8MB1ED MB.@ZMP+R`=G`0`BJI]#?'IX1Y!XBCK`L-D_4UF44BP:[U:6B^O=+FX]1I^'J M$36U=.HY"V3P^QV5^3\,).TCZ'1PIB7(*Y=A96^6'`!J1 M5>-G2\`4SR$280`F! M$RE$Q1!<7^J+F@TL$Y@8A:X5XUDNIH-Q5D$W+@Q=EMS&@WDFBGJRJN;"]`:9 MY'8,7MO>-XW_)-/31$!EZ2(@W58(`UJM@HCKMQ4+??H(RUB`$99+UM\WADE6) M0(:<%Q-;NMY!*T2^).Z3Z>YX5J<;\[TAWFQYHZ2BBILBJ(F-D-:KA-$W,H=Q ME&/R>*=*LN*\*UQT3<186MU!$*#;A.:6$6V4'"(F@@W(`6D#6(%KQ5)8+M+ER$%_!HKT(^PD_R!?PB'MFWO M3OP3$-N53!<^RYLA!E+4^.L#=K4<^7K,D=,T#]4U'D`_I!(G%D%V62N>):6N MX"8$S_HB68-]B0RPD.P30@_7UHB'P[>2#@Q>;&;B6^<%"9$H]36@+9ZEQN+E MAD8Z==:Z;&N1`/^WJYZ`$.NKP$86(&F/#[[8P3E+-$_08K(:A)O"4Z^M"D4! M,\.O\AMVN?B`C'JGD,,NHCNUN8)[16]'`N"X,@?\.:#B_%`OCS+19JIH+C,0 M5@T/4D86[Z$JS*(/,EN77E3&.J2V64"#2"LI60040M;&`]7@H[9B):DAWY2W M>H3O2E.X$6*.IJ`.K<"JG;9X#HU2(^=3`XJRI*GX/`&\Y6ZNN,U86])Y@-*' M>M:\]OJF!]DJ81.>^[AY%U_[L#4`CR]^W">!(HNT1S:QIPJ'WU)KC.]7]87V-+>%2F&$*6!8$)=@% M2)D-BPDC`R;FTV.^`FU-@&\V`#(CRH5$<]'@PL[S8GK14,]F6M;%;>TB%(K\ M(F:%":K@[*HC8&ZE`9UMPZ`B@PW4E<%:6`BYE,\)Y5X)9<@[.,=%MPJ?;O19 MI'?S`7C-FI,G"`G+D'`S@[>W\"H6H!FYHJ2/DAH#\[@WA52I+@&2BI=EZJP2 M7E'!5U:+@P="0"N&[.`"`*X:'0DDCHD>GQ)(-;27/,OI531F`652"[HQD62U M]8/&U0YB';TS=4&IQVT@!BYQ7G$?+H5^FQ/`D>6=5&"DJ&0SAXE`6^(RI M6F7\1`D?K,.D:9?W\1URI&FNY%EE.V4%%%(G[71J\)@O`;6E@Y=3L8W>+%?Y M`^SQX"BZ<]&20-B08D,.D"XC?>/O&*$,'O$@#2`"KWYDFDU!$E7_/@Y>LVQM[JSN*25>QG$AO0%6L1(45B9#'0M2K;,ORV7T,#3<[J@*L M9F>W,)1%,8Y*I]E5!#8#D%LM$^JBJ*+05/!7Z>0G$#S``M]0)49PO2I3/6U" M9=R(L(ANS_LN8B9"E>4$INK[7EGIB/"KWCAB7'N+ M)C1JC-DY4P2(R62^![&S?'+=D*BOI<_08Q+NB%!OY9UJS%,6-6503W9V]S;7 MM[!D)-M-+VH=9)G6F:OS96`@2OMXCB1]W<^.WUU8&8N^E=A3_UH9W0/*XPW4 MQ6)1*GM$027G9>\T;ZEI/""*=7&4#];IV6`-;\N039SES?0K[TL,3!22AR"4 M:NNGL4"5T[BD42>AQ^Z&+O67W7&2W=;^P=7B?>'IL@-!]>+X"183@\J:^_L[ M9AB)>XDF10+^KX7UR+/?BK!J2+N.8%%MU58-`+I=%/RB>0A)%66^E86J56!6 MF$RU@;_A5T&*X((!(TP[BOTN0?5;E@G;7:BG:#0.;[0TO+"N6*%7:TIMOW?? MK1$S_M9>``!3-,&#'4[7DQ7;$S<(W636K5(N:#!`YM00CG%@V&4@YY)P(QUC5"0=Z6`6%R*$@*"&% M^HXWG/SM+64;G'Y9"['!2:QC+!1F8Z%49G-KZ5ID3M7"=CL%1RWTB_Q;[)/T M1J=%8?M1V7WQD1YZV]:DJ9B9+LE5HU\5S'^B)N90"S?8Z&K.\U`(5'Z21R,9 MY>\VFC\M5#6G&B>PA[;^BP;%,3NJ`_-R_:_U*PCII+7T@]>8V[\D?!E/#V6T M-0/V_'4Q+%WE77C9>5S]'2@/=[E,YO&S.?GI1!_CWSW6-FO',/(W;Q4GAC"B MZ]7`T:8WH,40B#"3K0I[#U>*BWX4VCY]Y(5Q>N5X#ESL\&IS2I7(D(8'Z4A[ MN"K90QVO6F6DWQOPT@_A4)0\DW3:2G4W!M&JH9WL'>^'N'YUQF/8V`W8^-&[ MV39%+?D3>$2!UM4L\IJ<8GJQ-]7V!*M_DF)[G4N8V$T7.(])\>*=3^(1JBU6]J"X-6JN@!FA M$WH8F*L_1665)6A>?N$!8&R+X`+(AL)+(`9B@8/0_:)<#?-?X*FYU85I9:*F M8EN)!YO:?8,&AI:DEOBI7\:2#59W29,9W'K43OGX2GIRA=C=U M:^AVU$6#W.`L6]LU2\'K&:-87-@]ZJM/37)85JT)4<""Y:C+JP0O_JVZT#2G MV+X]9S$P%]6[?V\X/REQU@QOMC4::/(06>2GFQ][GS[^\-?_]>GCXTM3KV1= M#-)T;IU,0CZX1V"KT5-"H<*V+#',:<@CCZ1N?`2-RL!:M<&#>PMCO/#L2O%L M"V)8',XIQCP!"&&K^PMS0'E:O[PS-2"C5;\AK`:Q1L-6!0ZE8,9[5]"0F\;( M7X3,BU[)V\OORK%@&F2959\7FVMM$D@;61$R$B%*/EO,0(TH_#J>+"M3-'81 M3F!IRM"CPHM6C8WU"!ZIH&9#:*7H82>I3.#&@>W1G#EK,>6IV-UI\U67%M:V M=9Q9*JR!&)($+W]AL="UK4U+K]'N@(KU/LS^A7D9>N[!^:D&;RFOJ0$@71Q3 MEE=<-V#:VK1(&+F%5!A-4()7I4,;2+3:V[1XBT@W%6H)B6I0\D%2BO__\V\= M89REN`ADW#C.!BZBL^E_BB+(2VOF6-2@%DINK>MD9*Y83:)74R6]:V49 MD'(!O$K!Y-FX64%2)^N_@RC:+7NL7`96^AE%D0@K-.I!'/TS!)%^!,MF)3ML[7NEAQDUUFH!8=JH MBC+]I>!%G6/J/!)4%D:,/Q`(#(6N*PKW\16*PK$6W9P:2FN[;H2FYN>#K"I] M:KJ+[$CQVN-'FJ"U4)ZMMB+CD]CA,D_:`[E(BC=FS__].R\5,>-'!/W/5>Y_ M0$X`R0G8@_U;&`RR2I:J>I;[))PHJ=_[\SV,I M-E@YW4>K)A"1B$W"OYJ,EPU_/&YON0),YU7K7,X(KZ\\5FM`Z+2H MB?H1[L?+$/W$%1`J4CH$8T]X0_?NAI;_XR#.&*$\1 MO61/O?Q(/HB^$3!C2479^U+Y4O,B$'O0P:IPJ;<_R@?;?>G?37Y$4!?E*PC>C+\!"TA3NM?!^Z;FWK[\23E. MNO!QT1$T0B4=4?T%`T$^1*,#@JH0;BLN>I3/+$NX&@E%%9N.YZAY1V=D` M.B(4EK^PFC'!E51G,VY=!.3DDE1C/RO@R(_7T?^)]P9JOE5-IUIP)7)KC&6E M`#0^JE3374TFWV7K5I51*8-+9WF,O`6DZ<`6))LZ>,)4`>X)PPY:Z[I4$F>_ MC"#.#>^A8;M0Q9ERGY)ES:W$?H^5KEGC"$TW[/L3@K%7J\42&P\9!%+$G:ZU M/(-_P9HB65Y+IV9@3B3"?IEM#XG5$<(:U4;!*\TWE^&E%!(P M)*CM<0M90!:7]/*2$20/@JG7"C0I[%!=U=JYN>(%R;A8U;KY9[(LVBVI\BUC M57>W5.C5C?I;&E^=!&DIR*J#]&\H6*`%7T6*"Y%MO!I955IY[>6+3G??.IB; M71S%XX]>IK.]69CGA3+`^)E/*&`J3UN(5/ MRB<>[F`A+JQ>,"6XQ:M32->3VE4Q'BJT=45S:B[&*I1^Q-/>Q8BB:U"^Y_:T'K,Q.Q3AQ/'X[ MB4*#BN3T9J2"++9,+`#1*$O%D94[)7=.*IU2')W(//#RF:Y^B$D3VWX_)N3B MU3X"L`X$6F,U6$&6B_T[:'C%Y,-W8P9+E-JR!YK(/T5M*%1-$]/;#[[95=H/ M632FMGOHV-Z2VB.FG@W9VMSK[&Z_C+^(S4'ZE;(OXUW3/*%V4ITX8%5H.3P6 ML]+1:@E4J#$B>T5FLJ4=Q<%J;^#31\^2O-S>TE7QB!!,N]OA>214"LB*Z@?U MF*:031VU0UP*+E(="*7TH\F]FE7[/867`@`&0HL/5"K3BB2-AL+<(Y!L[_17 MOM'E9^\ZW6ZWME\\IFP3!,<@5GMZ)P$E="I;QL%$I53$$AMERT+S;(R>$JIG M45448;ZZWQW:GN^PQ0/@Y-86_"*\LQW@B;#?II^$MYU[`CS_,;#TGV/A$444I$KGSO6MECZTHUI]Z M]D;Q_>J=5[#&G\=LH%' M(G6!(&53Z1:REIJCC/>*1W5!ZCV^=TWXP:=F:)JT>XZ59G(Q-NBB<-7.58HK ML_%0:(!8\1>=J2PWM9K((EM9/4E-CA452ZOD&!6Q6C@LH+;!$G`+&9^&-MLB MO/6MX6_']('&[5@6%I710.8*)I44H:\<,FZ_(/H6H1;)/1%H86/17U.@77*7 M*(F#(8/TB(;,``52&C+^4Y[AIRYVC:!#>`_RP[BAO;HVL`ER[MHCYGY)A3JZRSJ_:8Y)/KV9KC;X*[Y@,C^SB4;A5T/]5ZGF1$Y;K#[C M!,2CW966&YLO.MLT!0CX+]_\2#N%)U`!<2WH8HMV-=3)7B!<]_:[!?1:$/*` MEGD0*1?J;9Y@I6)>UK%2QJUC>WLAH?S4D@K_!-P@F,IG_]N42>WN%AK%D1/4 M,6)2"J@M/G1X?&;Y9(70#0^XBT'^NWE4O,/4G:44JZH3B0'--=R")W(=>6&X M;FNOL]=]62"C!2TR%9[COW]OGD-B/<)S7K`2>6YKO[./OOAY&8XM M]K:Q2DHK[T>:=7]OADO([!^/F+IUHJ3,JR=&+I#*/_%'IQX+6OP#XB;5RU9B M)"W^:AU0*U)7[^S'#R']BK(/9<"\ZL!BF^KW9OL(F&M>6XUO*-<(/9I-[T0+ MC@4*^_Z$3KCQ5S(,]KBWD<;2\5S M?M9JIMK#,FK:JI%CIE[,$DJ!:)"=$A5G!JDN&K]X\J7#LN'J$L`__\TI;P/> M`14_^;(7U0\'\C*U@@KWO MX1C,N#)LHRNJ/+2\O7GZ.N#37C@T.QI^^KBV0_6#HBA8918@,_)>V]S`)2V? M-)F6GY)U*BLV=W8\7=Z8MU/.JSNP#?W_M;))@^PW&]EO)WVX:O[=D)^(HNU. MM>?JF77\GG5X>>0=@;UUY>&$I^F6N"(JK5=]/,V'#&K^DVT??EV]2.V89QC\ M\^UZL-P+/HGE^6\:JTUFD8![,ZN<$MF@]]XRG&-?($+>ZE>ACXJ6HG4IAGVL MIL[\*H:[2*6@*6A25E;5D!(5XE#5F=T*XR[T>[W^.U>[H<<,JX?@@WD%*D*Q M]H/5AA^(.G^S"G>HNP8W5M!=A]S:*2VK=Y!`JTA/:<]0@8Z*:[X"Z@:Z3 M[6]V]G=VDSL8CZ4"^W9XY_9I8&%NCDN4X.O,G!FXH&U=(%$I,(D2<>`%ON*3 M:NQ(9"I9`#[8*3$CMK8;U'K)?)."Z@)F8MQKM+V9F&TFV22'2D^![?#:,\IV M'U$V5&_M,":E(QKRGF+%^^@K>L?QG%;O*H/(K\29:8SRW?JUNK<7%9IB#,1? M(13M+:D([WY(?_+*%VJZ"CKYIACKU&;:K])SK`&.,SO(IX\H;)U8@:[B=*GH M_EJAQD\?_T"@(OW*U8(6R;/?%1W.TE%;W1<;.WOK6]N[&_LOFU]N;^R05J>J M=ZO[OH MK02=AD/?_,8CN]V-S4*6JOMJ:E6+Q`D M]KU3G3_Y\[=G;1N8,G.>5`:1]Z;Z_6D3L@4?%$0:#0;M5=/B^J`VR@-TX:HZ M9\F!,A%7E=P.1@Q*_;KU5?DLF1BYALI35H28R*UHY0;549.,U#_A0``]%$UL-B%W\3L74K&'#S[TE#_FD;NJF MQRXID;8HGNY<1+E('JK?#C()$]TZA`SME])##8C]1'<5/77-ZQ+1/`%;!H)M M:(A&[86+1'J)G2T7Y(",=E.&+<86^M M+6/Z:>4P=#EK"#WM$J^63B5X9"F?[?2+WUNWD[PAC@[\A7(Z_-QZ-:,ETB\. M^7&X&47U.!KI5Y*HZNB6?BXETKC$*C!5@-Q^]W3UN)#KM0;8L8MWMJA7X<(G&S2 M&7,#840X;]N4N<7UD'5=0C?;6QXR)A"X\T+!P,0J-[Z-;\R+?A%U2^P&; MW3W;G1JNIP+$^?TA"-7C2XA`->JD` M6CY_I/\L_&QM0\\'KHUN:XJ<^'4>8@<-OH@#*I8M*1M/0S86*X5'V]D:O%BA M\2>-_YT[%36;#]]!"N%)\R5E>S<$@.DL9"8G81CU,2G,X@>D:A/4VU+):_[3 M/:B\^MR@I,![H=+C29F5:`4TT$%M/H%*V1PTQBC/1]16R?W[[`:R1.%BX83: M#9PR#SJ9BR8#*!@I$:D>$)(]9,FQZDEUA])Y%HV&L)!;T4&5+]6JSIO%I=:6 MK:C#N!9M<&.9HL;/C!*3&BR,3A:/W/DPN%[R>[EBG6;[MY\7H]8DD<;I'AX0 MF?TTO+[8LP#%?W#L\E-9_VST[@?TQNAS64Q^T)Z0<=/83;:2PFIE2Q!J&8!2 M,UJD^LB\6[A%0=1`:6/ M-1=^R+@,XW4WME=0]3D"#;=2GOB%O)I4SHKJHUM@D@+_E;%HK3C-+X40J4$A MJJ$BS`-YQRA0$7.VV[8'F17;U-X>#[#H0%W9-DX@$[CF(]3'2][4!$KP)&J! M!T]7_7_VSFVWCB,[PZ_2%PHD`Q1'/$B4)X`!6I0,C251$*48@T$N*)*2Z:$V M!1[&UB!705XB=\9U,#8Q#$".*QN:OKL&K5.A\& M!Q%-E3T1XE68%`<+!9P1+3P824NE[9&#`=4[_'AYPHG&@#O#WM,MN\O$N_?F"N M:E`ME?M`[Z&.N''/ZW^+ZE0_;;O!6TX3@E9RU:<#TF=14=:Z;ZALJ#0'?;I[ M3'E!JAG+$$S06<`6"L=OK\JJ"65_AS1J*`+CC0@-GZ(_99L@K#L*FY$%N4TA M<_X>AF@B+T0Y>EJ=[KH@RN43[9^7A?[STE/I\G'2I,4J8.TX\?98[>BR`56/ MR/;#R&)*'C2S1UB"UXPPI)L\;YXTP<"[0ROT)'(7!YTX0F(Q(FG6 M$X0%)Z<+^+'^#(>4?QT*7`$FEU^>YI& MY_5OCZ5O?6*A$49A-/67GSDV5M#Z0]\VC,RSSW5Z7SH,)P'/PZXG^ M<$UA%(+GOLQ#ZQ&VE$<&=J_4;I5^P.'IGOS&O3[`?2.E_J>-U+,+(9*+BQIS5M&%77_(P+!DUQ84;.K?(/<'-`;_>=(60&F MP80P5LH@%[?^,>$BKX1P0#R("#,/UQXJ8'H'CY,7N#1"Y!1S>"@B0E-@HX@2 M;XXP`)`KQ_!B*&$7._&T>FE:4)QY5CI0PHA1*,X_G?K.'`0@GXDK!"G4`RRE M:N;W0.V$Q&HT\%:6M=$W,DX'-^HUP^8`?W&K4V,PL;"Q&6J82 MD:X4$V#QOV'[JK_3L1.L7Y!P!,:!:9W*638>@8! M74/;"%?9ND\L_M9V>E(EYJ5I$EE(EV9L+[ERB;K#I;I%IHSY91-5(,FEB+05 M;JN1J1D[TA#WAJ=BK!H2^ZW\QALD4N_<>YA^5<$2GF":Q32O\*!SG7C8O0Y, M*Y(\\#RF^K+SZ?H9P[LA6I)I4_W9T_%J*_9-18&'KJ34$N`4FDX,^O61+H3# MI^7#7B216CEQ`1,L4BZ$<<:"<)M37Z25&NZ$K!CM,NWYWCKY`/E/+O\%<\95 M)=;M_:+=6H4J1ZUQMF)1FB:UR)5,LB9-K2-I7E6KL*:J#GWT@!5L[&P47"#[ M5JHB/Q-5H5D0A%MULUJDV$CO75ONWVXHZU[OJ0_-,UOAQN[#Q#(2Z!:(3LX+ M^A>2++$=G5(>[GPY0#PL?B-WX.G[#\BWPW:5N`?8A[">/:,FT?=(:@7@YE!U MTSU5NDFA1ER:4,P-)):EZKY@&V+O1&PRICVX&A2.P#)*8 M2;#9)"C4(NH3\)L'+1J$[]HV?QNXA&B42*EH<$+(1`V4U3VK MQKK$FQJST)#=W(?-MHR-9SZ0L9RPUQWJQ#QXL)-6OJQP=0Z(6Z$1([XW4+1, MSRT(:,A3G&T.CLN.:?I!>RH9Z.)4MR-7KB;4!\68E$[W0I71EJ0J$E-(9(C; M`&,);G]BD?U$E3V&"A&T."R%(U5,[1#-7^V491-`6B0V("4)TOF+?G+=P=T- ML5@4^D$1+TJ0;*5J2HW(>T?KD%I3L1SE`\K@PKX\"V1CQ\.]!ALS;%YA4X7V MK.6JM8QV')\N!4_8E(B+SACB(YMY>C\RB5T6I<*8`.,--&Q-V0=M^M?)/ M<2"=N:ALCNL#\OF M#D6Z5?WB,%KGN.W34FC8`SW@^3W*S6@F*V!]2=O2)&0%/6^(B4[N76`^W4UE M[YG[U/H[O*SDJ6IC@XLE7D_6:)HA2+@@4YOZFJ21:WW/L^]9DV#[.TA,P(8Q M"U6^6]P%3Q>7!$M'.,1;-8CQF+4+*9CV8"V2S84.IB[IHMN-IW_W'$[W:AVF MQ4G])%9)T33,YB@0[TFW_%BM67QM)>RBTCO9\^\7!GYX&FH;ZB M".]2T*-=,93://F8V)T(+F,*Y*L'I3`5AOBXQ*]6-(_T"4DNPTL%OA^)'F(I76)U_V%I=P:H M(<[T2\YF\J_QO=B86$LKB]S:6K^7Z(W@KL?:.VZ5R(\VC(W@V2,';UGM294<<^U&K\G?UVXT7(@*C[BDKL!& M#U5(&U$37M=!$9L/;WGI+HGS:[UQ\:"B(&2VDHXP M#L%VM2UI9(5/$C;IX05)C*(!YN^3\>5SJQ/6C'G[WL:=/W]A69;U3WI:6+VD*%`PS<&9NYN:W)C_QH;54YK9PVM@DIZX_'S@#:30*[D?=O%A M+L=B_G417+%V3R^VW7HNK.`+DRY6L]8M[AP[DG$6*1`FEOV`+NH7X_7F%-#I M\N!?Z-^$BD7L>OI"4H-3?#9@]!-R!-YOW/\G>R(4>(4@08$67"'8SX'8NW3` M9,1.10\L*U$)T-IT`L!;HC86:E5$=UM0`(RU:37DW>D%1&WKGPRW[_=_-TLS M]67!X;S)M'YZ,,4!ARIJ/@V43)P;YN_>#CW[)+G?VG9?#:AO#TX#^1=H9[S+ M\1`BSD1O(-T.0.>31T".0R%[4)%C!!.G!]^@?-?&IN';C=8>%DW75@^NU1$0 M;*FW62/K`@5#'QR?@S'Z#]%&_CNX@EA1)--RS^=%?6I(/3R,.Q.+`>=$N!U, M1[Q)KUNUWGWGQ.\]A:'25>X_@_MVS_>P!MG*S_>LY0>OP7/J75P#N4JTX@Z@ MU-H6FZ#'$PQ7GN78MQ?5#ZU]SLJ9J/F")6O];]HM4S4=`B6A6] M'3P,;?:)45FK%V-\A2M^%J]E-R=5)V6P&NS%85#'=`.IRE$)`?W=D2@Y$ZUR M@R-CLPR/I[J0+5]*HF6MTU0;'Q*+?I=.(`R;BL0HGEFNV]IL MFAM'3G__?>U$WMQPQE.M[`6NX#HLZF#(-PHNP:_!RM!O1Y:R5H,*$.@.?J2: M%X+HWLE"%&2-/'_*Z6$WHRD,97O`X6^QG!ZN=<]Q3QW14/'KB\._GH*_I+,M M#@V*NJ@7Y`@0`ZC-C&_WW?6%1O12@B)]%8+P@;KNHE8<0JT8>>4F=%CPHOB" M9*Q+U>0323UC8?0@K8@"J?0XD3+(I_X2SR69A_1$X=(278I!9X&3H.?P62,\ M75W'YM/#DU3EN7-B(H`4`[0M1:,-X'MQ_HDJ6323BVJL_*_IHHPM]I,-1V$I M1%(Y74C($7$9R#3$,R?B\HA*93X^N^>A4($\:8\>HW=DT("DTO' M&@1,]2':UY`\>U&)":".H!/+E&\&7,"NT_?H"!#=JTC7H&0K?&?48B.RVGQ* M34-8?D=C!^4JV8SZY9\U7U2Y6?-?-_M?59$=K2FG^@V?I`5-8&=6_VV.9BJ" M\$7-(Z+`//N]_HB;@I(K%N#A:#,P<.D\U?M3$:@S(E13_213-*WD-;>:=9J> M=NI"-8V3_>&WQM\#=_C:O2<1L>T5MU,>HQ^NVDK_IN14X.'X!:C`H9Y*O)>$ MTPA!Q,KHGLU^$LHC*"OFPNNZ5(JCDF:3><7D?K-JL+J,&O;H>U76D3W>%7A@ MT@:O6?(2S301P&2T@J+H^&D7=B\?76/HL1"%-3%*GKZ,&W;S`%G@`S/-KL-_ M.OI8JORHGBOI7#(]>P'LLA,E)9F#81W+B:G:("_XSM:]+\AG_-2&$/_R\RK_ M5_//1'*U;1.)Z8R6F&`]=C\9$[T`1]VL9/Z[KIULO2_.#=&)BEE5=754185=R:)>RA]0FDT128(Y$SC,PQ M7XH#-8$I;>,_3<#'RN59T/HSSI-WLO_A0[DX+*:Y.CGZ?G%^=OY>_C^1_1^B MP:*C1X%Z9M,LOLP;N'-$)`?12::3.;8B)SWIM_HRA-X$'S"+Z(K%>ZHT:U$` MUDN4)MHC9"BHZ+V;!1+I&YFQ%*/G[DY<6->0TC6T@>)HPRW$BPQ-)#\=+(CY M%SYWM0&3%5U)K)L(,`[#+#*J(G2,9IL^(9S+(NC(,;H?SR_.CG_$"(`$EMNM M&A95A%\-NB.Y?^BA&Y&0QC"]2D7QH>&%J)HA@6P1 M@`1"`74P,/W9.?_8L4L7XTT.`(RL9V0&CET2?:%`&@C7D&(.99$/=!3/XI.: MX[#?WF:7S,PP7C6;"3@XV]MR6YXQ4O5N2K8*..).<,2$J994$0:+TGZQ7=DO MQ'X%R5G_;0WJ=K>B(MF489P:XCVTW;+)^UOF&?72%E`DC`:8"GRKK)'EA`!* M$C$]0[(SQ)]['F-F>7_0[JLTNR!$R.>12[NR@R.GVTTO1^W.I98B>%?$98FMZA0GU MS"]C0D'"S2X0,?D@P,X:180/'-V\9*Y56,"&DZP^+8O/,,G8J)PQ-!+7NKD3 MB3L2BGC,D0/.O^,/2UZ(-:PM9T?7+C@@N`Z2IE_(*;L9I.-`7MNH6RL$2=;@ M^8WF#>HYOU4)T:/#CZ=<.XF\(+O$LK/SQ?N[IBI"C>`>YOI#+%-Q;/W6YL^@+6#86<4RT3(R0QIQE/4N6M!$)R4'H1^;+N@^*H*279P;7OA).2AK3 MY=JCUD/"=OP1.MY7=]GTH!$)E-2(V8@PB[X1-A09+=18>WF,O%QZ'4YP(#Z, MK=2S(B9K2"A1;L:@+LTS>U.B;+9,Y'IX/(&/?7]F5;UO3W0OZMP@)9?-EQ*` M$L4K@JV15@2EN3-LV_+0BOO#,U2<-X&CT6T']&J;Y<:-&YC"M9.@L$Z=I8@F M"MPE913BA/+T3F9\_BGLDTAB>J@F&&/+ID_*8_H#4IVHE2GP9C&PA^:>2$TG MORIV:\F./+R+:_\!@](8@ M!?&.EX;VT#0B-`="$?M_NOC+.>1(9C0YV;&^+C`\F3)?X\`Y/!!H(AR&S<>0 MHI$,'ELE:+.#KJ#W>3QV]12&>M^B&YNR]#Z`TB!;/+L\HWDA_G#^_:)[I*Z& MV!>O`,P=%)NQ^:39./$=^]72CM'I0\3M2SC*WGHA`5VU MEM+V3!*/6Y4-2B]=GL1$R.`Y)K:N=^57^>>3(ERFL/R8<;&P&FK&M^JK8U3E MGI&5=E$91,IP5#!43R3H57/OC^3CQ-0@<7P?/8M, M6UZFE'33!_PX9@4W.VSB&.Y>\8U>?CQDN^YLMEOV@TM&J<^]?9/=(CHD6VOF MT>X":*M@O0*,G\GEX2W<`,PO4HKH85K*E]C[K$"U;)6BV2:W])Y_Y9LX:-^ M8?UK=I;;8\Y7'2;4-K'V982,D#)UK8R1!551S"18;UUNY+92"Y$9?^11U8,] M8*-*PKCZ:MO\ZO?KT<]QJ_SR,\1O4?]RWZ=OJ,8S$8;FKP6E3M2G&>/85:_S M,DQYKT;[EO'.]X^NSM\B0B22,Y35WD7,Z",E0?)V7ITHHE!O]HEB11_>_9:K M6N#6M+IO(A)]4`AT&97%;LO<^.

%$PVMQU=U[NO_G";GGOX`V<_R[)JX7! M3ZYJAEFD`/$_ICP1G@=7PM![:YAEK]C)2QNL`=>C^KJ7?",Y"EQ;WKLPP(KL3,,'0`\MH\28H:; MZ*VO$X#3T1%P?H5M"L8P-6ZOO>-C>=H0J[Q`6L$LC,_G,(3RP$P%%RH44^*` M\.F+SF1EJ0>5L9DI3C*&4OKY(JI5')U>'%U_D$@M`98H`LZ051[&)51A5N*? M3Z7`F!-6.4A@(=JU/H6W_C:>[.UJ4-A\3M[+&D*@0!<-#%QD^/X4F4+= M)0Z/Y6&E$A+%]^U,Q>;MAI'>V)G+(@[[P):\-SU"[STB:>4BM8S([S*!2'.8 M>(!5Y@K%T.#40S^#DB,-Q-#M,3E-/77"XL4M/$(WI.6-"BK69!*J6HS='XQ= M&J*_I79"PQF6K*9>X3JHLM$ZI301+<)6@2!Z28%`19:3"TX?L4ZA*((DGR8Q MH#R*824N=)U;U0]=5D_X<@PUIS().B?_;WM!^1PN3RUBDVZQ2*!>8TX#?ZS> M3_Y6^/'6G"/82=6DBK-CKKIF44*I8-M8,UZ?6R'1EBR+:,B&@?O'@NY%\(1B MIQ>F5\D6`EY!I_,.Q\#67/WSPQ]`[D>)5->W#>\RM)JSC6S9!:'<;F+1<5=& M3U.)]54H#R<4*7_X0`KJD1`Q).9($4WY:45N.)7`TN1;X`RT<"SCGF?A:^MX M;=BXHL9UB*PWR0:C/T#D!S$->C5GYVB>0WX#1GOTNC<'QF()$YP(7Q]2C)0N MYMJ0?;@,+&GM(OL#WM4G.(3#@7P$6?M/CZ%L*>W,[@##_/`N>UKZT`Y]F<@FJ\6$`=8Z5D-7%J;O M;!G*?OMJL#N:X69"N>2;*E?3WW\+BT.&VX4E1'\[]7V$;0`:V?/*.*3?PN)$ MXX(62&@+DB@HH2U98#/H^7\Z+.YU\19-5$2(_"WV*U$GLV9+&!_$1''GO\5^ MC<5^'9B-ZA.%:KJR/_:N2WB2'5[B.E52!D:+^+>F0OHWV#;>NPIPX<)#W]C] MO_^&B_Y__N-OY,I93?#+JIB;&0?W4A1^J*Z(AR/>[1T*TZ90#ORTV^'F1%[1 M\Y8T9R8#[47JWKC+%\Q8*FL.A5AQH&GG;L_ABFR(H=00!IC46[K2MZFK$?YE MN'>4V>8PQ2(7)(B[&J5[T9,T(0A[`(]RWHI#O+$Z=S(TU>?8\( ME!>:GC=LZ3!%TY!JW2%UT`@*F=A"G@^BF2XD+RRN0'(7VK@80Y!W?HIO@?7<2%*BJRR>>:.!F'`'_ MEX;!,NT&CS/E)064)]I\Y3J@1Z%ZVQQ81B;+Q1#%Y>Z=G6$^P$>-X\![8ID-< M$PN"6.8[FZK,==E/V@>N8&'QBH\6\F<$)"V!#<7U4M.%8PF1>D:A7(`B1#G0 M]<=WU)0A54HRZ6]8`.^L<.(\FA01]PS4AWFI_&K:]3SV"!Z8#DS$HY22+V%7 MX4YPU176:V;;G9BMW4:$=VKYQQC:/LJN1`(,L253"\/Z+U1+-V]]:F")`_5' M]4:>+F#.*"J'/TF0F#CR*T@R%O`SFIM*;`>U^L^ZE_*EFSB/)>Y`B2QV7:_@ M@?5B)5)++/2$2@J@5SC=LGS^)?>GJ)]I!" MY[K=(EP:M;<<%RZ[;IUG5?YYK7%)7&#Y>:^BQJ"]5I-R;0_/;=V6PT8N9CL5]5),6(KNQ1;K,F[ M$VBZ?T$:]NE?'4GUL%Z`C!"88'LVM3,;O.WL\^AQS>243;":>"!545<1'UDC?A!\M.M=$]EPAWV3U6V&"] MTIN#O>[.K084,/3U7(BR_J;\L2DR&"C03=TP)M3U3GU\D16VZYEKT^V26<(. M6\]B2Z1,IOK'QV]>$8GT[__5'!D;VSJIR.,;P[#)CU%^I)ZRKD4QN6M;0C4$ M)"?5LQR<+%30]P66ULO)&0[DL;WLTWK`996L<\R?`CGR<+[,%N288`XI)2S_ M.?YQS%I3T[R0!O?N"E)8B#@%[9SZ[ODA@;#D6T[^'OF84[\;NJ46@S74W!`Y M.7?Y;8.J1!2M=_>^`9/<.[I)UFP5Q.3;F/2B*DM<,-Z]54^HY'X#3^3 M03[B)K1P_75@X,(PT`WK]9#'X5RFK,_E"=Y3U&`JQ]2C;N]XE&_S]V@N4/]= M8L9[8K%,Q>_&/RD\]BC^2$AO4V";UD,]I:=3`O?1)YP>_\J;DA#$PB:O^]=2262OL]][=D<33"CS]T#EJWJA]/?;72F2(98!M?,'5 MIYK?T(PZ6=XZ6(RL2OB]=CS4.XN;G=ZL?[UF:I@_^CS)K%XT6%>!):'OJA]= MC='#PCYY\"1S7S:^^S<<]O.RQ^W[XYQJE:F7B"TH51X#O?P@4D>I28A%,P%H M\LPS0UUB++IY!H/<7XJ'[[]*A7E*-Y"H?JOXJ)"PCP1"R%\9W&KUTZA4V M>H:B+J9HGW'#IYD;SC[2AG/FS!=T9QP:%OYHQ390%J[(/*_/U4Q`:*DLD)_, M(U*/?HGUPN?1G5Q2J MD`;OD;UQA"GN,CGZS,:;S%WU67J#GNR`B6M-CR)AAI@80NSFMC(Z:;$(1(746FGH"Z7=)DB\H_/,'A8RR\0G;4Q+&IG[/!'UJ0'^*6>"$ MT0@"9!(><=H7GQ#R$'N.6_S'*AK1DK/CYN948,II!)W*05G?K8MO(EP(^RO8 M5Z=P1&AM-L3CU&/;VJ/7R]U^X#RHHWJS&:;:`9LQXL'4B.#:W9<3`S[S2#,8 M6EJ%Q2W3@W:$8,RZF%T'^ZBW7`R+\8_.;-1P3E\6]6`]^KU)[9K-B\VKMM#GNAZ?R-GS;U*>CV2-D49^DY\8ID3C!'LR M(_T")S]NG-RI;^'D%Z5CKFD*-S*=&Y6GGHZ]1==>:U1%-*=7H[W6]B>+)9@0 M]CR:#(%7AFY_1YV6&#.4?^XEWV\NN90=DC5X"1F=^F2IW!%,H*5X!K/VSY][ MRF7*[+U9-SW%PO$_1_&#^@I5D.+;\R-\7)=_GL2U`K4)!<#JAG%F"I-*!WJ# ME\Y*<&;@B4:'G9JC0M^5QX61:VK:XAC.U-H7.KF4)ZU3`M#O,%2SJ94>/=X? M#)PV:!Y0O0]0S+8Z!IMDJIR>)%L79*`OVQ_'EY.GH@'J/3/+3XZ`5DA/\86<\35,K:03C\\YT!:\GJQB4??I;[1A>J`OE/`6?.Q@:H% M!X9.'N[EZ5'[QO2# M4:VW'T9'']>/-[='1[Y9%"Z!P8U:O9H^R-D2F!(D'-6FKBVW"NY/KY(.A%(B M2RL37:8A;!"GY_Z2ICMB:P_U*K>3\2R9U[J-<5M"8GS$I&E!'G)Q_9-.V'AI MJ9ZB$B*]QEKPZ7H[0S.\B0[D56NUT$Z:-Y?^GHTYC2XRRNLGU=/A#N0-2D.U MBR1>U/MN=Q%-)Q1\0OPU/#0L#WT<;#W'<.7R[$F@DNY7?X45&<20?^2LT*P\ M]E:EX/53_4TBJA,R2_7SJ!QH%QNDCNT5!L[1^(_,2Q/"&E4;(95K>AEF"I$N M![@54G)E20KM>UJ0??^)2.C^T>%\LHA?IZG^?3CF5,4F!0[4`)G4@>DY()75 M8CF\@D&^Z:0FYZL=$W*3DZ4$T53(>=\2-/%(G<^9%$=4`HPE:"0WBDK(IXP;3%^\TZ%Q[XY/3Q=5H73M@W%Y@94.[,MI-?!=9 M_@XTD%Q)HLUE+YU$=2CGIQB&-UUZ9*DE<`#3!==;'WCXP6&=>L\+7FF2JDE; M;LA6+UKIJ&FJ,M M(_REZ/YDVDSTK-Z]Q>NF"H#UC]3>(:X\2E#6/UKX=BHH5O](Y5#"HZ/`8?UC MU/VT=@63".)K;UE<=V/0*P\M3_3PT'.HT!-&;U7B?D7O0D$])$A2M()Q2C+& MKCQD7IU M*Y13'[5=WX$Z4M1Z^:>05<'ML[[U=,O/^C0I1_B9$LQ#RJBW_)+X&A*>K29- M/+]Z"%+-]8=4?[P(;FG&%;^)%+A!,N=P/4)4>]\&\4#8Z1\ZX M7O.;C=[3JX3?(U$+3LHD#!?9$,30?:CW'#0/_I)ZH:B6GO4N*.J\KO*5(GR\ M^5-?QG6:'C^78DGBM)4IG*#'5EP1L8\:6I9(-[;_V^[*K3?XQ.TAS'Y",RU7 M8Y>L]DK`FMB)1X)';D*]5DG"9)X:DK`<-#05IQ-9=)<==2\G(K_+(=9&D?"[ M#?.5UWL9'WF7:)(_CEEPQH9O=W>[^RL,?Z[(Z]?2,B9&%S@HD,C5/VU2\T*: MDSR$"<38(TZ'M_6H+P[7"CXU5(9?[P^_7H''\,62$F6.(*^\D.&*IU!A.T*& M)T46R(Y$OC+/87+F)C4LH5U6?VJ8-%_,P6&HJR>ZUH8+'D28@K3Y4G3_W>7E MU5?_*P````#__P,`4$L#!!0`!@`(````(0#Q<4O72@,``)$*```8````>&PO M=V]R:W-H965T&ULE)9=;]HP%(;O)^T_1+EOOH!`$%"5=-TF M;=(T[>/:)`ZQFL21;4K[[W?LDP9B6@:]H,3G]9OG'!]L+VZ?Z\IYHD(RWBS= MT`M=^U-QNL6+#:L8NK%F+I.GO?7=DR?>?!RHSJ"C8>-%$.V6\`@#X=&JF M6P,J0I[-_SW+5;ET1[$WF0:C$.3.ADKUP+2EZV0[J7C]%T5A9X4F46.$_006S3K)&"?P`>DDT5*2GBM&DE_B`US-"YM MI+%&R>5'@T,`*`PQP#GBZ/%2Q>L^LSCN,\+7XR2J:G<*+:PTN-H%"?] MW`'2^!HD+;:0IKTM(J$$D<*QO588A<]#3OW\`1:T\^65TF(+:];;(A9*$E.I M\-/-:!A.WPT/H.)KH+38@CHL`4*A)#90D\#\65SG%`.TZ35H6CQ$FP;#%Z]1 M,C9H5BQ].S;`T0?6T6YPOM&UV,()+1R4O(WS=FR`DUR#H\46CM7&:Y2\VTWO MA@=0(6R/EQ?)J"TLJXO7G08;*L&&LA?OO&8(:.WIYU+^:GFSFJ$'` M`/"` MK*G8TI16E70ROM.G>P0_JWX4;Q[K<`['")SXUG@*-Q(S[OY,X-P@"1I.T>G>D'6FU MVLMS.AB(FF"4I)ONO]]RRF"[PO5EIJ&.*\>GRJ>(9]\^ZZWSP9NV$KNYRT:^ MZ_!=*9;5;CUW__G[Y6GB.FU7[);%5NSXW/WBK?MM\>LOLX-HWMH-YYT#&7;M MW-UTW7[J>6VYX771CL2>[R"R$DU==/"Q67OMON'%LE]4;[W`]Q.O+JJ=BQFF MS3TYQ&I5E?Q9E.\UWW68I.';H@/^[:;:M\=L=7E/NKIHWM[W3Z6H]Y#BM=I6 MW5>?U'7J_LVD>I*ZWF/4"_5OQ0VO\[;0; MA7B3T!]+^14L]@:K7_H*_-DX2[XJWK?=7^+P.Z_6FP[*'<..Y,:FRZ]GWI:@ M**09!;',5(HM$(!_G;J2K0&*%)_]_X=JV6WF;IB,XK$?,H`[K[SM7BJ9TG7* M][83]7\(8BH5)@E4DA#8JW@P"B8QBY/;63QDU&_PN>B*Q:P1!P>Z!I[9[@O9 M@VP*F>7.0M#G_,Y@2W+-=[FH7PKH%LKQL0C#F?XK-[ZP"(`P)H'KXD@PB&CL/$S( M@Q$2&1""R*\A+&J0Y'YJ$CQW89>GHH1C0@TAX[ZH\3BUH[D9C?12BQ%T]/V, M))@PFMC/S!`2]8Q80+O(C*:7&BBQ*X> ME,V*AW&@"VTK)\WV[O9B:,VFJT:DJ3.%`8\ZV9NNFN*&:U(?:YN=-&*#W8VJHFU;K$BS9PPQBI4_)NV8 MT_@E8M*/#6)WRH8N;A$DLF3R]Q:<&2J+T@R#1TV97FS+1@;!#=F&$R`BS9XQ MR^03TI*Y'0ZT(]JTR!"X06OH_K&N1J]'QDR#A]^9MA/G)*Q[P:;UT`!@PPD0 MZ_TJ6J;)AU%*U,Q5#BQC&%TTW8>F`!N.@9B.`86YT%SF(!C[%]0*R"2X7L0> M;1MM3*J4*@*N8VRBTIP- M[[BAH$3;O[-C:K4!8DR"!))?A=CTSDR$,?C.#9K#B1#K#L)C$9QW?+2V"T&; MFC1O0SE9XO3F6UR`EF^Z+AU&F<+@P3!L57'##"JJ#Y5-3GJS0>Z&7NCD%BEB M$YE\W872'V>5'P>#JIJ(-)E<>E<)R$"X\VP,!T-"';C/?!Q78W)R)W2DU*5%-,H2#J.0[TSF]U#TR$83@?ZOI0I#';3 M4\+T@Q4US*'B<:JMQB9&IL.=-1U.B40;:D\@@RLFV7?X?4[?XKU6QJ99(*\GR/>YO.^2WWNG`%PW[8LU M_UDTZVK7.EN^@I3^2!I4@Q=6^*$3^_Y6Y%5T<-'4_[F!BT4.UQ_^",`K(;KC M!_F`TU7EXG\```#__P,`4$L#!!0`!@`(````(0!P=GX9WP,``.D.```9```` M>&PO=V]R:W-H965T>$%!5('+(\ M8Q^-J*X5R>KKJ20U.N20][OMHJ35;AX&\D66U(22(S-`SA0#'>:\-)B;7N,[2?[(2@]LP3WP&#H2\ M2"V6D^%]` M]DU*B#@WD1F,_O;>,9R%9WOS/U!Q;RI^I^+XANU:$S1,D55C4H`8VJYKL;T^HJ?,7@3*<[PV') M&1%X=,9=+N0![R-H=AHWQ8'+Y_K[5F<>\$`R/H%E!O M='LE$2B)4$E$2B(>(R2/YK)'?#.=P0=K?&?AC38ZK,Z[#\NE7.8[P?C-SNKX MOFU9EDSL'XG>N^#QG*8E(V4L\1D@>\=/GPV=YO((X+'OD+7HUL!/,F$=*(A"$ M\&@^K,%0\3Y2]A"/$9(_RS_QA\.R/[[?7V&"&?-'201*(E02D2"$QSZ<[19. M[SP0CVE('L&I6BJB:=M1TTIVRW/[U72#QNQ2(X$:"=5(=$-LQQ7;H\-7K[P[ M\@L&+X'?,,(U<8,0A^,"UR>\QWE.M81<^.U@!N)=M+NYO+C\0-B+[^P5'&6' M\8#?='C<[!K`1:-")_POJD]92;4<'Z$KR_#ABU.+JXIX8*1JCNH'PN"*T?P\ MPY42PP'",@`^$L+:!]Y!=TG=_@(``/__`P!02P,$%``&``@````A`)1%74D- M`P``E@D``!D```!X;"]W;W)K&ULE)9=;YLP%(;O M)^T_(-^7KWR01"%5DZK;I$V:IGU<.V#`*F!D.TW[[W<.3B@X'6&*W&X^ M?E@?A7Q4!6/:`8=:Q:30NEEYGDH*5E'EBH;5<"43LJ(:#F7NJ48RFK:+JM(+ M?7_N5937Q#BLY#4>(LMXPNY%ZJ&XAX,5N!\ MKLQP=+7^JU2H$4WNT"4FL-VA"@7Y/&VBR%][3]#3Y*397FJ"H6)W5F`4@-[?D9!,:)@"LBV-2?`NV,+K?M>*B:S3C(@@0[U2;!;$]A-XT2X"'0] M@"BR2M\:S;2GF7<$;1F[,<6`$4SZC.-L*(X)-*!K3A19[=D:S;2-=6)1O7UM MP`,[_'H>%-L\UCVW1@-W[ICM7HTI!FSS(=MU>>*B]_(TFC'&,<6`,1HRCN>) M8KM_TV%F6Z,)PK!-U'<7=OMLP7S1.0S(<+SUWAWC9"BVR5Z?,O.H&LU8U\84 M`[;ED.VZ9''1>\D:S1CCF&+`""/K/QK8JNT.VMF>1*_A+J,N._,>N5`L['3- M HF(R9SM6ELI)Q`%''.Z:[FPW?N]"?.%:Y[U M8O M````__\#`%!+`P04``8`"````"$`\>'WQV$#``!`#0``&0```'AL+W=O)$YIJ7OJ^ M3'):$CGB-:W@EXR+DBAX%%M?UH*2U"PJ"S\,@L@O":N095B*/AP\RUA"GWCR M6M)*61)!"Z(@?IFS6N[9RJ0/74G$RVM]E_"R!HH-*YCZ,*3(*Y/EMVW%!=D4 MD/<[GI!DSVT>6O0E2P27/%,CH/-MH.V<%_["!Z;U*F60@2Z[)V@6HP>\?`PQ M\M_`AO,7#?V6ZJ]@L=]:_6QVX*?P M4IJ1UT+]XKNOE&US!=L]A8QT8LOTXXG*!"H*-*-PJID27D``\.J53+<&5(2\ MF_<=2U4>HW$TFLZ",0:XMZ%2/3--B;SD52I>_K,@D]&!)&Q(X+TAP>$HG$_Q M-+K-XMN(3()/1)'U2O"=!UT#FK(FN@?Q$IAU9F.HS^7,("6]YD$O,DL!+6$[ MWM:S*%SY;U#"I,$\MC%'A`_BAPA`=7@$>A%$BKQC!..9$X'%3$XPT0%Q%@'0 MG$;0G;L&QPBXC\K1^,!KZO-H,3-3F?DB"H+@`#@3AMCZ"VNP*SPY\%IABXF, M\&0*NE>$H>OZ"VNP*SQUA"VF$9YQ+*934T_^$UMUMY0&NYISI\`6TZ.9%^?*_0RM%]VRD\7TB`##_.B?O$&[ MV;N&:D"VOV;S^=7&QLX\ZRZ\0;O:KJ<:D-4>=Y@*.Y/LAK8=3^>#Q+65H8Q1 MXZMQ1]Z#9AB^-,1<9S6@SC;'>N#T[G.#=LOMFJL!=F6\MC M%K37OGYP86>\W?"8G5DW/&9!5OMZUN&@J6;0;JN[#FM`G:T>#AIH!NW*N@YK M0/9ZXIZ9]@YLKX@UV=(?1&Q9);V"9M"XP6@&9A+V!FP?%*_-57##%=Q&PO=V]R:W-H965T3"+ZG.GU*41`57Q#PY2Z3MKM3D\0NM:=GOOVSD8VZ-X2_]C,7 MD_3VYQ*0M=C`TGSZWS]OKS=_K[>[E\W[XZUQ5[J]6;\_;[Z\O'][O`T#^X_& M[EU\[Y^O/UWO;O]W^?__N?3K\WVK]WW]7I_(R*\[QYOO^_W/Q[N M[W?/W]=O3[N[S8_UNWCDZV;[]K07_]Q^N]_]V*Z?OAR>]/9Z;Y9*M?NWIY?W MVR3"P_:2&)NO7U^>UYW-\\^W]?L^";)=OS[MQ?+OOK_\V*71WIXO"??VM/WK MYX\_GC=O/T2(/U]>7_;_'H+>WKP]/[C?WC?;IS]?Q7K_8U2>GM/8AW]DPK^] M/&\WN\W7_9T(=Y\L:':=F_?->Q'I\Z[[YM?SO;ER_#E?2TVMWBCXK?@S\WFKYBZ7^(A\>3[S+/M MPULPV=Y\67]]^OFZ]S>_>NN7;]_WXOVNBE6*U^SAR[^=]>Y9;%(1YLZLQI&> M-Z]B`<3_;]Y>XGU#;)*G?PX_?[U\V7]_O"W7[JKU4MD0_.;/]6YOO\0A;V^> M?^[VF[=Y@@P9*@EBRB#BIPQBEN\J9K7>N"9*6481/],HE>NC5&04\5-&,<2J M-ZI&M7;%&HEU/VR6VC&*:=XUJM5*K5&_?+O4913Q,UVCQO511*X>EJ5YBO(; M6]<0NU;R3L?[6/(NFI7KE\8X[C'B%QFG;%[_/AGI3F.DVSFLUVG>F=42M?L?D:ZYQCBS4_7ZOJ\-,0N MDRS,:=\QFM;9._X;F]A,WW'S__6.F^D['J>SW#:_L5+I^V2>DK/\ M.RN59J=YVL27[\;W234^%/?.T_[I\Z?MYM>-.&2*+;W[\10?@(V'.'):UI,B M?"ST']5Y4>#C**TXS..M6$11PG?BZ/3WYUJU_NG^;W%`>9:FG36&*JQ4Q$>/ M.&PG&4B.`?%`-QTX?YV&&L7.&NUUG%2DK]-+!TYA*TUM\=W$G*^B%K:?BC3L M0!\8Z@.>/C#2!\;ZP$0?F.H#OCXP2P9.FS%(!T[KJZU+F(IT7:)TX,.GS%.1 M/F6A#RSU@94^T)([TFE16W*W.1N1N\EAY%[LQL=]6:2]LB_G3TW273;6\2Z; M+FX['3BMH:GN6596E*LJZ23$$)4G3H**43&T+=N50DF5IAK%SAIM41P4O:RH MU;0H;M9HHI\5^BH/LD0+,D3A987^,J,LT5YFC&*"8HK"1S%#$:`(LT+?(%&6 M:!MDGA5ZD$66:$&66:$'666)%J35RA(]2DLFH*@)QX.('D9FX#DY"Z,4`W'H M5XI!?&`KBPE&<5&(GZ44!7W`T@ MGBFKK^5>8/IYIJ+&&>09K0`.\TQ-C>-=8$9Y1CLDC_.,-AN8Y)BRMEM-+S#^ M!6:68^K:^Q5<8,(+3'2!F5]@%GE&VW^6%YC5!:;5N@2U+T$R#<\+0:U^6FRE M$HAI_&]4@OA92B70!RQ]H),,*)5`#AU+@ZT/./I`3Q]P]8&^/C#0!X;Z@*FZ<"I/-=JVL3%SS%UK?+-4I.6RR`=.`^LI7IX@8ER3%U+]?D% M9I&:=`&7^L`J'2A8XE;K$M3.0?HRM^2>IN[LIQ53=G9QJIK9V2MBL/BP%S]+ M'![/#EB5AE;\VXD1RWL\.FMEW4+10=%%8:-P4/10N"CZ*`8HAB@\%",48Q03 M%%,4/HH9B@!%B")",4>Q0+%$L4+1:C'AK&L5IIU2&\25J$QMX"EQ_*S'6S%_ M/^5]7:\-B2FJ#2@Z*+HH;!0.BAX*%T4?Q0#%$(6'8H1BC&*"8HK"1S%+1.UP MU<0HU:IE;1X?8(@0181BCF*1B&1!*]52_)]Z=K/$&"L4K1:3-A.KB"BE05R; M5DI#\70AUGI)T,X#VXE)MI-9,4I&62L:EB+,9J5N:**3B(*RTD5AHW!0]%"X M*/HH!BB&*#P4(Q1C%!,44Q0^BAF*(!%R'RN53N=_A[L'X?G#=;.LY6F4QH\O MU#;*VGGZ_/S)9JFJQ5ZD3SX[*FIE`,7J_"6,KBRTE MT>KBYG/S=&:0W)M1$JU6KIMG*Z,4`7%OXXHB$&N]"&AG!.W$%"2PA:*#HHO" M1N&@Z*%P4?11#%`,47@H1BC&*"8HIBA\%#,4`8H0181BCF*1B/2`5ZJ7#2U5 ME^?":#9+VN%NA:_1:C'AG&L5)IU2$<0-X2LJ0JSUBJ!=QVDGIJ@BH.B@Z**P M43@H>BA<%'T4`Q1#%!Z*$8IQ(I+]NUPVJE7M>#K!$%,4/HH9B@!%B")",4>Q M0+%$L4+1:C'AI&M915&4DA"W=UU1$PY<+PI:86Q+5%05\DA=FRYU\I`Z*^LR ML9DX3'I,7"9])@,F0R8>DQ&3,9,)DRD3G\F,2<`D9!(QF3-9,%DR63$1+39Q M!C_>%F2;:+IA8Q4:M6:(6Q?7U(R8:S6CH1UMVG%[J$!UV6?3R%R'L511*6=$ M1XJ"+=%E8C-QF/28N$SZ3`9,ADP\)B,F8R83)E,F/I,9DX!)R"1B,F>R8+)D MLF(BZD62:059(NH%FS0?\^.H]2+N%M*[4OE.1=SIG:D;VG6=MD250]THW>D7 MC2S]<>TDK7-\_,,K/UTF-A.'28^)RZ3/9,!DR,1C,F(R9C)A,F7B,YDQ"9B$ M3"(F:M&,S.#L%11$M=PM7E*1XJ"+=%E8C-QF/28N$SZ3`9,ADP\ M)B,F8R83)E,F/I,9DX!)R"1B,F>R8+)DLF(BZD62C@59(N88;-)\S(^CU@MA MKJD7,=?.20S]=D?\T3"!Y#7@LK@$K-T5M11A5"OUS&6TCB3YJW`HG5TFMO)" MS5*SHBV)PS%Z3%PF?28#)D,F'I.1)/(-BN_>JY>'QAQCHL0H-QNFJ5WCGG(0 MG\F,2<`D9!(QF3-9,%DR63$1M2+)LH($$;6"39J+^7'46A$W:IW/+2[[,$'\ M"4^]9C2T&\EMB9KR?*0:3R'._M/2UE*X^+R]%JXC'\]?*5D]L.W,YB@.DQX3 METF?R8#)D(G'9,1DS&0B2?J6G_6M']Z@*8?PFS]E,[QZ1\F>Y>)S<1ATF/B,NDS&3`9,O&8C)B,F4R83)GX M3&9,`B8ADXC)G,F"R9+)BHDH&6F2?9@EHF2PL0J-.KN(F\+TDL&?^8J_\25S M=I*YHI'3<-;0SG)S<1ATF/B,NDS&3`9,O&8C)B, MF4R83)GX3&9,`B8ADXC)G,F"R9+)BHFH'CGYIF:)J!YLM'G'GEUX] M+KC7FC2,J1,.K1^K'7\ME"@Q\C3$K(OK&L>%.)QC6%(HI4,E'29=)C83ATF/ MBDQ&3,9,)DRD3G\F,2<`D9!(QF3-9,%DR63$1W\W$S9ZY&:DF M6ZLX(=7:$;>+G4\ZBB^(FDEWF3+9T#_FUI8H;>S2;WA:\'A'>UP[$^H>'_[P MO,YFXAQ)_*'#TIW67-;3'M9N[KC'AS].Z]D_Q;8W9BJ$=C=L2 M%58,[$GK<)0N$YN)PZ3'Q&72ER0I![5L%]6`8PR9>$Q&3,9,)DRF3'PF,R8! MDY!)Q&3.9,%DR63%1-0+3"-1+]A8A4:M%R*KKYEAQ%R?86C'P+:9H"0O3+,: M?SV0/L-0B/@NCE*MIMU.Z<@P0IZ^<4L-TV5B,W&8]"1)5LFH-.K->DF[L^-R MF+X:IF9D@@PXR%`-4JJ(;:=N%D\3S5K9T&:!(WZ=,9,)DRD3G\F,2<`D9!(Q MF3-9,%DR63$1%2-)I((D$16#C55HU(H1MX1=<^-B_^PQ*B MJA2LA,6DPZ3+Q&;B,.E)(J<&C;KH/5-SU.4@?28#)D,F'I,1DS&3"9,I$Y_) MC$G`)&02,9DS63!9,EDQ$?4"4TW4"S;%^:C6B[@O[(IZD;21G=>+6E,[P+5- M[#6SF'28=)G83!PF/28ND[XD2=DI5\V2_F6#`PXR9.(Q&3$9,YDPF3+QFIX)R=N./ M^%7&3"9,IDQ\)C,F`9.02<1DSF3!9,EDQ404"V[H3%.Q((W$'9*B.&JQB)O` MSHO%97WB9M([IA8-[82^+5'!DEI,.DRZ3&PF#I,>$Y=)7Y(DX<6W`91-;7XV MX"!#)AZ3$9,QDPF3*1.?R8Q)P"1D$C&9,UDP63)9,1&%@WLY+TA'43B*XJB% M(VX"^XW"D?2.J85#[_>,_X#DL=_3K->-S#'1DB3W8VN=XX.G:R9:AG69V$P< M)CU)Y,PIYYL]7`[29S)@,F3B,1DQ&3.9,)DR\9G,F`1,0B81DSF3!9,EDQ43 M43*XB[-]@3EE8EZR*24C[@972D9QM]:!J_=*1.>W>AFP+5'1'(-)ATF7BZLE[1F[[9$A?6BJ+WLT`+?X2A=)C83ATF/ MBM%>*,XIJY1>A)RC(ABS#G&@LF2 MR8J)J!:81*):L+$*C5HMXAXP_>(%?^:LG+2.B44Y]F(8^A]2:DLD:WT]V]9H M*:*2]X7B4A14GBX3FXG#I,?$9=)G,F`R9.(Q&3$9,YDPF4HBS]-*V>]]]161 MFSC+H8A,*1M(^= MSS+J^M]X:Y<3E.Q.V2N`EGR\H+!TF'29V$P<)CTF+I,^DP&3(1./R8C)F,F$ MR92)SV3&)&`2,HF8S)DLF"R9K)B(LI$D6D$BB;+!IC@AU;(1=X/I92.^:@IE M(VDB4\N&_M&2,G::64PZ3+I,;"8.DQX3ETF?R4`2>5YN-O22/.08'I,1DS&3 M"9,I$Y_)C$G`)&02,9DS63!9,EDQ$74#,TW4#3;%Z:C6C;CIZ[QN0+U(>L34 M>J&U2;3+"4K^.IIV[]52'JQG9[0="0IJ9Y>)S<1ATF/B,NDS&3`9,O&8C)B, MF4R83)GX3&9,`B8ADXC)G,F"R9+)BHFH%$7-FO(KMRXP:3KF9YM:*?2F3Z@4 MV6;/6-U:+^LP/I*B^4\Q=);'X9ATF/ MB_U>I:SO9[UDO[)$HF21LZR_M%6Z_CPZ9:+-D?I,.DRL9DX3'I,7"9] M)@,F0R8>DQ&3,9,)DRD3G\F,2<`D9!(QF3-9,%DR63$15>."=L\+3'%")E7C M?O=]O=YWGO9/GS^]K;??UM;Z]75W\[SY^2[NF\8SA./HS7;]]?&V93RT*K?W MF?&V\6`9.>.N\>#GC;?-AW9>',M\L/+&.^9#YS!^?UR@W>=//YZ^K;VG[;>7 M]]W-Z_JK6.3277S5=OOR+?YP3/*/_>;'XZWH&ULG)AMCZHX%,?? M;[+?@?#^"E44->K-(`][D[O)9K,/KQ&KD@%J@!EGOOV>0$"O_[I M^9_3TNGJ^T>>&>^TK%)6K$TRLDV#%@G;I\5Q;?[]5_AM;AI5'1?[.&,%79N? MM#*_;W[]975AY6MUHK0V0*&HUN:IKL]+RZJ2$\WC:L3.M(`G!U;F<0V7Y=&J MSB6-]TVC/+/&MCVS\C@M3%18EH]HL,,A3:C/DK><%C6*E#2+:^A_=4K/5:>6 M)X_(Y7'Y^G;^EK#\#!*[-$OKST;4-/)D^>-8L#+>91#W!W'BI--N+J[D\S0I M6<4.]0CD+.SH=MPR8#?Y3&GA[BMZS^DUU^H^GQ M5$.ZIQ`1#VRY__1IE8"C(#,:3[E2PC+H`!R-/.6E`8[$'\WYDN[KT]JHPY9*FD;Q5-16G58'>=RH0^GQ*IK,G(IJU*G#N5,9/V^*V(G#^$GFT*Q8FJLF[']?Q9E6R MBP&#"5)1G6,^-,D2E+N$8WKZ$KA7`9!Z+O+"5=8FS`*0W`K*]GWCVO.5]0ZE MEK2,APP<>\99N"*SO6:(2/@=P6N/OSJ0;X3RC6APPX*H^]"AOH:AWZ[Q+D(. M\PB[]WIX@XQ)$ZY#H$#%KFY;8A#P6"3\*PTR$XG@FI`,":_?XMH+426Z9B9? MG14\@='RN"<,RB,MX6N)0$N$2+A-04_LYD_,9J32$#R"^7+H$9]6G+O? MD6Z,\4:R5]*0\9"!?O1^RO6D)7PM$70$G\GL$9F[[@S]:(Y2_L*.OMNG2$4( MOL$70O9M`E]Q]=S$&\F^3<3,>=;O'M\-,N@(%)#2$G9/ M[[:/.N*J`X)#\)$:.J1VAL.R,X[D##(J9[2$C\2L&3G36R,GT&J$6B)2$8)' M?#DN?=3U5<0;R5Y)1>`AH_)*2_A(H%A`07J^)ZX6HEC1!ZYLSFMK3HVK8J2L=0 M0X$$>I50CT1*1'2,+U,'CFFJ"Q>UHE/2PM'_Y_;W^UWHU[&S7Y2_P`V M@\[QD?X>E\>TJ(R,'J"I/7)A`5SB=A)>U.S<[#WL6`W;0,W/$VS[4?B/WAX! M?&"L[B[XAE6_D;CY#P``__\#`%!+`P04``8`"````"$`YZFI(%(#``#-"@`` M&0```'AL+W=O[G&)N$-K7,%(3EF)!'RRG"22TK;2`Q>T_*M`_HE*D00G MDA%D?QH/G&`^\2?3#[",3RRP;IO*S11<):=Q)T$"K9:,'BWH.$B8UTCVKQ\" M2VN+$M$9]3^?P"!)\B!9(ANV"EC`H;8OJUG@+]T7*$AZPL1]C(%8MPCIOJ1- MVL"9=KR8Z;2;%B.+#YHZ8>#UI;#K=6[SEV"9?[MRW`;.*P?ZNNL^8C31(8F" M0((7KA@TFV&,I@BZYOV*)%A39`;69B!1`3W=D2YI"WLW7:9=#TS?HF(KF)V`PA-)VP:SZN4TZ*;"A^IV$6 M&"IBA?&#H-E0GN,;1JP58,"(Y"9B,X309$YUF<-EE&!3GK%Q8X69->+&4\_S MC")JXXO>>*+&!]1OAA":MIFN[7VM*B>9&N>ZAEAA!G)(V+@ELI/<@K?0(]UD6[U\;#2![W1CSV0[B&^O$$7B?7XG$0QM=XUD$( M!ZR\D[H%X#51HQW^CMB.5-PJ<`ZI>&PO=V]R:W-H965T2K4<[GVK4/U\:0Q!J5E)C)S+_?W72C=C?I%[T9)^1A`?+: MP,+P\/?OW;;WJSA4FW+_V#<&HWZOV*_+E\W^[;'_GW^[?]WU>]5QM7]9;Q)[]Y M+0^[U9'\>'@;5A^'8O52S[3;#LW1:#KM]\5$VUW;I+N=WJ\//SXZ]UN?L@)9XWV\WQ3UVTW]NMY\'; MOCRLGK=DNW\;D]6ZJ5W_H)3?;=:'LBI?CP-2;LA65-WF^^']D%1Z>GC9D"V@ M;WOO4+P^]G\8\WQL]H=/#_4;]-]-\55=_+]7O9=?WF'S$F_V!7FWR7ZB>^"Y M+']2&KS0263FH3*W6^^!_-![*5Y7G]OCO\HOO]B\O1_)[K;(%M$-F[_\L8MJ M3=Y14F9@6K32NMR2%2#_]G8;&@WRCJQ^UZ]?FY?C^V-_/!U8L]'8(+SW7%1' M=T-+]GOKS^I8[O['D,%+L2(F+T)>>1'#&$Q,:W9W394QKT)>FRKFP)B,IE>L MR837(.M^KF'>689U394IKT)>SU6N?5-FO`CYI/$BYNS:S;GG-3C\^MI-AX]#'^1R*^Y6:AFB\93C362ZOAM1@I=H!IIA4-5S,83<6TB;DRCCO_$ MF!C2,^$\&%HCZ7/H=S!! M8YI1-I0G1,T$S9+B#B;I8%+5*!_&3#7*EN=Z(^Q<<@HG[%QZ@C$FYS+Z@Q.= MBSCA6"0-IPMFR*JN$ M$"]RRGI#O.A%#X4`2-H!>$QF`FG9R'S:_/'T-I!(^@B*%(H$BAR*#(=4+(%&W975YQZS-% MM92IB?317#"CRQ04-A0.%"X4'A0^%$$C6*9,.5/-K[_/%!0Q%`D4*109%+E. M")DBC24A4]U.LNA<&T?B+U;18< M:>/&ZFB(C:LXF+B8>)CXF`28A)A$F,28))BDF&2_"8$@;-TAL7,7!Q,7$P\3'),`DQ"3").:$96G: M#+N(&C)^L77\9L-I%O)C$F`28A)A$F.28))BDF&2:XD0,_.VNP?U;-(5J"7%8,&1 M9BA98F)SPH=Y\F5U)6Z",";"J0([A.+%>)CXF`28A)A$F,28))BDF&28Y%HB MINVVFP?D>[O*I8$EWPWE2)LV?/.`5^%I&]VUI`T6)CXF`28A)A$F,28 M))BDF&28Y%HBQHT<#J\XAIJ4RX.:?$G`D39FK(Z&V+R*05[KBX*!_!UF!R_' MQ<3#Q,@27?">5( M$Z%E"[&FTBTNNP5)?6('$Q<3#Q,?DP"3$),(DQB3!),4DPR37$O$I)$\".-9 MMU8'^9J).JY)25EPI$TH[`W?WZJ6B(XC9N"UD<#$>+Z)961^3`),0DPB3&),$ MDQ23#!/ZM#F:A?:WCH6,/4V./BF6QW5:]=?E)GQ1'AY#3U--3['Y, MZ`.?I.D+8[ZLGY\B3;>-.7F\ENH]8TX>F*5.#XTY><"5.CTE3\^KIP]/"R`/ MK_M8O17)ZO"VV5>];?%*5GE$_D2\WSNPQ]^Q'X[E1_V0LN?R2!Y;5__WG3RF ML"#/]1H-"'XMRV/S`UGP\/3@PZ?_`P``__\#`%!+`P04``8`"````"$`MP M?,Z,QX.S^OI>Y,X;KV0FRK7+)K[K\#(5NZP\K-WO?[]\>70=J9)RE^2BY&OW M@TOWZ^;GGU874;W*(^?*`892KMVC4J>EY\GTR(M$3L2)E_!D+ZHB47!9'3QY MJGBRJU\J*DU2\3Q1H%\>LY-LV8IT M#%V15*_GTY=4%">@V&9YICYJ4MVC-FCZVU6=8!^9/PB>^>./(K+ M+U6V^RTK.40;\J22[5\\YZGB.\BN&Z9^W0[[4:?NCX_,JSPU'!2#,(`T9CN?N(N4PA#3#6))@A M:RIRH(!?I\AP/D$8DW>M+MNIX]J=SB>SA3]E`'>V7*J7#"E=)SU+)8I_-(@U M5)HD:$C@>-'/@_M)I@T)'!L2%MRMY*$A@6-'\ID-3X>DCG:1XO%<$P-7LAFG6L=41"C8`T=4&`2;XADIK%!#9G59/K#YE+B+]/.^.RI]"&%(7]PC'<%$.BG%4$/ZTABIQE+1D0VAZH<0AOJG>]0CF*@G`X<: M8J@G-1W9$$(2#R$,]0P^)?K!QT8TA7O#2:C?(C[(LA(VF+X1HC)J(/.Z1()9 M$,#'`4EF/$AC6L'&-7H>,=WF^DLG(Q4:-IB^A8`N0#@VZ)A@:PT(;-;9T!F270#<]77 M?-;8-%>(:0&B=8<%1)NU$)#E)F0:8V3A.GBM+[J!(9!X$&):P*XW/@NZ1QI9 M(&M.B!_^8'/8@HVQ+`Q!3`O8_<9;T+W2L&"M2'8_#4C)1\S&6!:&(*8%;('C M+>B&V;RF M%#Z%X&89619UZV`^>V2^?PV6MJ`WN7K;5?#JP".>Y]))Q1DWK0Q>[>YVN_!F M>]P]@/WL*3GPWY/JD)72R?D>7O4G"YC&E=X1ZPLE3O6F;BL4[&3KTR/\W<%A M0^5/`+P70K47N/_N_D#9_`<``/__`P!02P,$%``&``@````A`-(I_.HT`P`` M6`H``!D```!X;"]W;W)K&ULE%9=;YM`$'ROU/^` M>`]?!F,LXRAVE#92(U55/Y[/<)A3@$-WYSCY]]WE;.+#+79>$@.SP^S,VGN+ MV]>ZLEZHD(PWJ>T[GFW1)N,Y:[:I_>OGP\W,MJ0B34XJWM#4?J/2OEU^_K38 M<_$L2TJ5!0R-3.U2J7;NNC(K:4VDPUO:P)."BYHHN!1;5[:"DKPKJBLW\+RI M6Q/6V)IA+J[AX$7!,GK/LUU-&Z5)!*V(`OVR9*T\LM79-70U$<^[]B;C=0L4 M&U8Q]=:1VE:=S1^W#1=D4T'?KWY(LB-W=W%&7[-,<,D+Y0"=JX6>]YRXB0M, MRT7.H`.TW1*T2.T[?[[V?=M=+CJ#?C.ZER>?+5GR_1?!\F^LH>`VY(0);#A_ M1NACCK>@V#VK?N@2^"ZLG!9D5ZD??/^5LFVI(.X(.L+&YOG;/949.`HT3A`A M4\8K$`!_K9KA:(`CY+7[OV>Y*E-[,G6BV)OX`+VDXO4?#>HZ MZDF"`\D$U!^>!TXPB_QH>IG%U8JZ!N^)(LN%X'L+I@;>*5N",^C/@1D["T&3 MUM'W^K]6H4#NM06#]YXC)E$/,92`0]UXM M3F/"$\S`MO48PM`&)*?:,,D)3/JX6U@$N)/W1\'`GI7&C&D<0Q@:8;(^KA&+ MAC[.!CYJS+0;O2#T/7\2FHBU@0B2,/;?$8;&J:EQW#\$#[1Y@[%>:D-?E$NSR$6#7P,AQEKC,[8G\QF<90,(&L# M$D[C)(G?TS!4)J;*\901/%27F/.UTI@Q!\<0AC8?OK8?M["KNI3S`30F6L/O&OS_4^O0BUWNNIF)+U[2J MI)7Q'2[I`&KZN_T!XB[`E3&XO\*#17X\/HSX?(O````__\#`%!+ M`P04``8`"````"$`.<*8U&D"``"C!0``&0```'AL+W=O%>*)&:G=D=[FI]\Z(Z\@S&2MT7-$TFE$`O="7[IJ`_OC]< M75-B'>\KWND>"KH'2V_*]^_6.VV>;`O@"#+TMJ"M<\.*,2M:4-PF>H`>O]3: M*.YP:QIF!P.\&H-4QZ:3R9PI+GL:&%;F$@Y=UU+`O19;!;T+)`8Z[C!_V\K! M'MF4N(1.2ACY4_PF#V*OIAO("OAE10\VWGONG=)Y!-Z_"V9UB0 MKVM5[>_!"C04:9+IF(;0'2:`*U'2=P8:PE_&YTY6KBUH-D]FBTF6(IQLP+H' MZ2DI$5OKM/H50*E/*I),#R3X/)"D\R2?SA;7%["PD-%8X#UWO%P;O2/8-*AI M!^Y;,%TA\]L5818>>^O!!<6FQF0MWL)SF2^G:_:,UHD#YBY@<(V8-"(8BD9E M5+MC M/@AQ)V[ERSSRAU(#!M?HZ#PBSDK%7KK<40\N*-H86?/E+/(&Y8#)QYO^V]XP M+*&7%)@&/D#762+TU@]"BC'Q-,[H;3:.6?R`,S+P!KYPT\C>D@YJ#)TD"]0U M8-G^/X>RU_`P``__\#`%!+`P04 M``8`"````"$`<+-0#L8'``!\(P``&0```'AL+W=O7RV6[:KDS,'->0OB\:[F\:M?5//[Z_7R:?,O**B\N3U-MMIA.LLN^..27 MMZ?I[[^YOSQ,)U6=7@[IJ;AD3],?637]]?G?_WK\*,JOU3'+Z@DI7*JGZ;&N MK]9\7NV/V3FM9L4UN]"5UZ(\IS5]+=_FU;7,TD-3Z'R:ZXO%:GY.\\N4*UCE M+1K%ZVN^S^QB_W[.+C47*;-36E/]JV-^K83:>7^+W#DMO[Y??]D7YRM)O.2G MO/[1B$XGY[T5O%V*,GTYT7-_UY;I7F@W7T#^G._+HBI>ZQG)S7E%\9DW\\V< ME)X?#SD]`;-]4F:O3],OFI7H^G3^_-@8]$>>?52#_R?5L?CPROP0YY>,W*9V M8BWP4A1?66AP8(@*SZ&TV[3`?\K)(7M-WT_U?XL//\O?CC4UMTE/Q![,.ORP MLVI/CI+,3#>9TKXX407H[^2='?JB/3U-C-3/7"T.C\,E+5M5N MSB2GD_U[51?G__$@K97B(GHK0I\C(I\4--J"RZZ@OIH]F.9R];"FVW]2DJXV M]:;/]I:Z,=.6BQ6K]B?E5FTY^A3E;KSCNBU)GVU)DKM94E3[; M@MKFTSK25=XF+!NXW[?:HG7M2?_<5TU-M"+[Y[:*:J+]V#^WU73.\Z])9SNM MT^?'LOB8T!A!]:VN*1MQ-(O)B43F;=FE]L\RFU*:J7QA,D]3LIJ2MJ+N^.U9 M7SX\SK]1%]JW,5N,T>2(G8A@_87)VBIP5."JP%.!KX)`!:$*(A7$*D@&8$Y. M=G92&_X_[&0RS$YAQ%:`@;^*=R)"%+%5X*C`58&G`E\%@0I"%40JB%60#(#D M'64?>&=07QP?4T7FL5(T>DJ9MY&]V;8QU&A=>J[DD%T7TOD'Q`'B`O&`^$`" M("&0"$@,)!D2R4D:U\%)-CO=V:F9#(T+=)O.-NS5/,CXS-LNI/,6B`/$!>(! M\8$$0$(@$9`82#(DDK=DH^3MY]G)HAL+Q:-O.3&H$_2FF@LE&[L@4$!](`"0$ M$@&)@21#(ME#"YL[[&'1LCV6L=* M]O`EW8RM[.MCOO^Z+6CDH?%ZQ#:#EFY\0<=$9-=:LNR[(1";$[/9>#4Z#A`7 M2GFUKU<1OD93X*W5) M+`H.$[\K*)[7P2@7D=0B\EHD)76[S^)) MO=;'AO.NGJ(&(6I'J!T+Q+-ZK6O0I(DD)-O.MC/_W':^*9)L;]$PVY?@>ABPQ:-_ZYAJ,'1_(YQ@K6[5U4G\>`'/:B1W;91>0A\A$% MB$)$$:(842(AR3^V4[C#OR9<3K86#3)KA\A&Y"!R$7F(?$0!HA!1A"A&E$A( M-DO=)+(93#=G-'O?><)-6R^UT[9(R4-ES[?KH[H\1.0@O6('_S@:G*;PE^C\K>,Y*]^R778Z59-]\D%.?>'[L,'][ MO]4V%NLLY*UZ15_0B_UF*017V"O_Y@6Y>F5IT7'^B)9IT:'U"%]9=%H[PM<6 MG4F.\`>+#N-&N$87:,C$*_;&HH,QY-[&HO,IY'049+&#'KQ"!SL6.[O!*W0P M8[&S%[Q"OXWXTIS0J3Z1@:/^Z63LB,[6L.@5U(C^DO2;`O/N#O3;AVOZEB5I M^99?JLDI>Z6F7S1GDB7_]03_4K=S[4M1TZ\>FFGW2+]RR>AE\(+U[]>BJ,47 MNO.\^]W,\Y\```#__P,`4$L#!!0`!@`(````(0"*52]Z[0(``(8(```9```` M>&PO=V]R:W-H965T7S^7!7D2VDA5 M)33T`DI$Q54JJWU"?_^ZNUI28BRK4E:H2B3T11AZO?G\:7U4^M'D0E@"#)5) M:&YM'?N^X;DHF?%4+2KX)5.Z9!9>]=XWM18L;1:5A1\%P=POF:RH8XCU&`Z5 M99*+6\4/I:BL(]&B8!;V;W)9FQ-;R,O9/(20D_&*O*OPX5MER.)6I9X+-EF:SM?\$J>,MYL9AX-EAP@[A@VBG#&KCE1&,RIA;W,J-"_1EHO,RDX_((#BA M\.PV'\WG':]3=IAI#_.*&!@$R'B#"(8:#*7?YM:!1DC#H1HOC>!&NDMN&X$^ MZ>5AT>5AX'+^$2D$#Z7:B.N__O%8#'FQY:)EB/UUX9#BPJ%&&X$CT[.S/&\' M1_;H?D#P4*J--+-HD*;5D!?M3,*5=]$-KAM*M)&AF]5Y-R&4<+R=!CT4.X6: M230P%&*C]S*%CE8@=V&"M.-A\MK)#1&H#GIY$?S'$/9]3_6"6CLE^FHN-$5] MY\=-?3<42Z'WXHLH"D.X.N!$CV#,=='NMMDV!7X;G\9;=POYW2]P"]1L+QZ8 MWLO*D$)DP!EX"ZB[=O>(>[&JAA3`5:`LC/_F:P[WO8!1%^`AR92RIQ?<>?&PO=V]R M:W-H965T?M4T]U`=SG6.#LW<>:;ZA_JKZ(I]RP_?RO/VE=2-T5U M6>G6Q-0UFM'_M>94O45UL?^CN!!P M&^I$*_!<52\T--E3!(L-M#KL*O!7K>W)(7L]MW]7;S$ICJ<6RNU!1C0Q?_]] M1YH<'`69B>U1I;PZPPW`OUI9T-8`1[)OW>=;L6]/*]TQ)Y9K3B%:>R9-&Q94 M4=?RUZ:MRO]8C,65F(;-->"3:]BSB3L!$9>+P"<7L29SSW.G\]G[[P0B MNVS@DXM,'[X1>#(Z#?C\]1M9VAZ%3EB&VB]C_"&RE!O1%8;`49FR59M1818 MLE-!H()0!9$*8A4D*DA'0#+"^1@CJ`QL!5*3V'+F&QX#)>D[:2J';/N0WAU$ M`D1"1")$8D021-(QD4R"/>8CNH7*P,,(E^D-P(\2"W+NN=2']"XA$B`2(A(A M$B.2()*.B>02;**22[=?*6);H=&=&2*)#2,.=.K('D?ID#Y(+-LA$B`2(A(A M$B.2()*.B93[]*'<:;2<.R..T^\D6T1VB`2(A(A$B,2()(BD8R(E.GLH41HM M)\H()#HNLJL4N0_JBXQ(@$B(2(1(C$B"2#HF4NYT!AZ_4.\W.(V6K_>]*IR*8(-')%H)$M'+DV&\!,2]D7@R&@]P3+1!C%P\)NM#,MY;6=#`%" M.95D9)OHP/7^9\2BX8H?'$%S#ATP4SI@*Q9VWY3X0,D6VG+KS)36X0MMJS/2 MF:3+E:*DG+7M*9[0$OV8@'XX6HT\9BR(-7 M]LA+=>CB4?;0@3N,`J'E=<9-<28A7A1A%&.4".EI?^>I%"6[0J>T!UQA0YWD M"D=RARF-LJ5C&FW-<8?U"X7#`8_RX)TQ.&PK[[,0:T48Q0(-7R<2(6]VIL]F M-]IG?)NR4710>\`H-M?!%45R&XLA3S9J+C\N6QXEM0];:`]:@8AB[3.W4":A MB!C:,,(H%FB03CCR8._^>0U2L;"3EXVB4]T#1K$A4#**H:FT%\P6JE%\X;BC M.!I*'M##&.@[CY7LBQHV%1$W M.HJ.D&.C?FF`LM@@*OG'D?1$SM%9"X\:-QI#[F!#P.5=EJ!#=W2Y84-Q`X-. MA%$L=`;I1"`F37-62SX\@%"X?] MQ5'>%X&(FG=;M3/U4-(AUHXPBH70W?WZIKF#> MS0$?CFC%A`_;#3*9H=$CP4ZBV<%D2>HCV9+SN='RZI6>,D-SKY<]9D?@FZD/ MWS_A+:3RF0_?S6[PN0]?93#?+7R8\&]PR_3IO(Q_`\.P3^==_!LXEG^R;_`- M/:Z_Q6T?CMRPSL;QX9@)\R?7?V*[MYJTZ\.)"UZP\7PXC0!N]`O@F/Z:'?'4=)C+:MP'9WNO_]%D529/$X3MS3\S#N?"H>B8=%LG2Y_>/' M;COXWAR.FW9_-_1'WG#0[-?MXV;_?#?\SY_YS6PX.)Y6^\?5MMTW=\.?S7'X MQ_W?_W;[UAZ^'E^:YC0@A?WQ;OAR.KTNQN/C^J79K8ZC]K79TY&G]K!;G>C/ MP_/X^'IH5H]=H]UV''A>/-ZM-ONA5%@I$ MUW]\V;P>M=IN_1FYW>KP]=OKS;K=O9+$PV:[.?WL1(>#W7I1/>_;P^IA2_W^ MX4]6:ZW=_0'RN\WZT![;I].(Y,;R0K'/\_%\3$KWMX\;ZH&P?7!HGNZ&7_Q% M'<;#\?UM9]!_-\W;T?KWX/C2OA6'S>,_-ON&W*9Q$B/PT+9?16CU*!`U'D/K MO!N!?QT&C\W3ZMOV]._VK6PVSR\G&NZ(>B0ZMGC\F3;'-3E*,J,@$DKK=DL7 M0/\?[#8B-'JY&X;>:!)$TYE/\8.'YGC*-T)S.%A_.Y[:W?]D ME*^TI$J@5.A7J\2C:.J%UXB$2H1^E4@0CV91-(EG4[J4"Z>?J);TJUI&HV`6 M^5$L^G"A(1WM>D^_^I33D3_Q/FH7JW;TJ]I-+=,NG'"J&M*O/N$G^T@3MKM4 M^E4M_4]=ZERUHU]]QD^U\RD596:(G)2#?MG5L4RM+E/3U6EU?WMHWP8T_2EW MCJ\KL9CX"R&KTE+V2I4O@B9NR'UG]+Q2#/M^WW@1[?C[S0[UBIF MB3$^CTATA)@*0C9U0>:"W`6%"TH75"ZH+3`F6WIO:,;\#F^$C/!&]VJI@666 M8X2.T$U2%V0NR%U0N*!T0>6"V@+,")KUO\,((4-KF)TDLX#W?*EB:$CZ3(IY M2-*'].X`R8#D0`H@)9`*2&T39A(M<+_#)"%#DY%.TQN`4TD&A9=3F;133OJ"3447N0 M)\X@]T'](`/)@.1`"B`ED`I(;1/6=RI:KNB[B.9]E\0>9"`ID`Q(#J0`4@*I M@-0V81T591'KJ:R11J+P/;ULUE^7+4U16HO/C'Y(M9"JD(0*=Z`3OAM.K#Q7 M*!+MJ(;R?&?&IR9`9T.&*%*@ZTCHB.3Z,(V`=2JGK"A0M]0- MY6BXNI4^_)XN=TP45U[DF4*\(S/7M3[* MN*:0G6<217+"T+TX5\E%U4:GC]]+B&XE*%24;X1+W3#J3+OQ1E/G`BL=\9XT M=TV47U>X)JLU.H7N_-*7R,FU.>]O8J)TPU0CDQ&90BK7Z'G7W+/_*!;ZH8J\8)1X(QQI2,^EWBB)+1-^[6M4A:6S$N)>#[. M/34!UB4:\36OKFS/R+'2*I$Q'R3(EF'J!J"'Y[I_K M(*->("HUNGC"2D?)&H%>N04^G+#60=T)N:'7%>`!%N`:\;QR[FP3'67GE=(R M6W:FHB(Y&WUO'D-?]:`+BM6[6728W2I2D=N:)=8I> M+8IW@Y=W*Q'A)J%$8EA,+LV=JBU1#>F:],1+-3(3+]-(9IP_\W#\ZY@SR24*2-50@RU![M]>(YYPS%Q,=9>><:+FM-W[(,U4B6I&;QE( MY*29<\.>Z"ASW:E"L7$N4V@JIV;HA2%.GQRE"D0EJE=:7<[-8#:G5'.7S9I) M<:M$Q6M;]6M%A%!QZBF%>*(Y=YY)H**,7:E"+-%DE$JTF_6C+A1!/*8K-*XHXKHZ94\9@H MN*=#^0)1J=#E,U8J:LI6;_>,M9&WK\OLB\Q\JC\OF_^YF\%.AF>P0O0>\OQE M=/>WB8GJMQI$&:(<48&H1%0AJAGB]IR[20BB$6VC5W[^(=Y$.W-<(;IG,@Z% MGON`P409AZ26=;.5852.J$!4(JH0U0QQAZZ[/Q!O:UT;)&*)$GK.34NB&EJO MM5-$&:(<48&H1%0AJAGB-M`@PB+V:XDBE)RI))&3*.X=E#A,#:VL2!%EB')$ M!:(2486H9H@[=%W!+]+!M4$B*P42%66A%%&&*$=4("H158AJAGB?1;EM;VV7 M*ZD0"W:%Q"GZ32;TW+M&$V76"*E%#37*,"I'5"`J$56(:H:X#6XY_H$-6'?3 M-Z@B&[K.2&GY2:G\4&_7')Z;I-ENCX-U^TU\+DI[_OUMC^6WK,LPHH]9NT

24>R2D([0]G#LB/HWMWAY#FX".!&?;A'2DJY.AS82.=-USC\0+ M^HKDS/FG"_KHX@R?+>B#A#-\OJ#W]V>X3PWH`>FY(]2$GAGBD<3W%N*=.AY) M`W\AGESA$7HLM1!/GO`(?6/\Y:Q;9/"Y^"79>S9>F'M.?[+X(K]A=JTES\]: M3GG2I*,GH'21-LH/\:EG^<5*/SA_:$WUL M3*LX?2Y*7Y&UL MK)W;0:'[IE@G%LFPO,.JRF.=*_;,7*LEVE:T)#I$NMW]]OM' M`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`V M[V@S2BT6WL*,)L;M,@=5#NH<-#EH<]#EH,_!*@?K'&QRL,W!+@?['!QR<(S` M&\DS:*3^\Y_0R+@Q&OGHOO,@B#;.!/$6OL@R!U4.ZAPT.6AST.6@S\$J!^L< M;'*PS<$N!_L<'')PC$`BB'HG!-%M_3NW6=]'3"G=4),^9I)UL,1K[8$J0"J4$:D!:D`^E!5B!K MD`W(%F0'L@E`>I`5R!ID`[(%V8'L00X@QY@D6IAE@S/$.)FG:C@4]P.B)5%%5!,U1"U1 M1]03K8C61!NB+=&.:$]T(#HF*-7"9(EYQCZ>7>@V?N;4UJSI9)W&H;37C"ZS M7A.LAFY#5!'51`U12]01]40KHC71AFA+M"/:$QV(C@E*E3/I9*SL?)2O-9K%F52Q)5%%5!,U1"U1 M1]03K8C61!NB+=&.:$]T(#HF*)7'I)%GR&.SSD2>.!$]K;LOS"Y&K@501:N: MJ"%JB3JBGFA%M";:$&V)=D1[H@/1,4&I%B:-C+4PNRD_-C>S"6DBD\M1TUXT MR>=F@Y4?"I=F7RD5LR*JB1JBEJ@CZHE61&NB#=&6:$>T)SH0'1.4*F?RT%BY M9^9F-FU-Y(DS6=>+@)9FBRW7`JBF54/4$G5$/=&*:$VT(=H2[8CV1`>B8X)2 M+4P>&FOQX[W(9K2)3$.2&]^+IGDO&JQ"+P*J1D`U44/4$G5$/=&*:$VT(=H2 M[8CV1`>B8X(2Y<;GK1.R676VD[P(5H,\1!513=00M40=44^T(EH3 M;8BV1#NB/=&!Z)B@5)Y\Z>#I06[,]0&'TJ7E4;Y#&:R"/-:7"GI4T:HF:HA: MHHZH)UH1K8DV1%NB'=&>Z$!T3%`JSWGK`V.N#S@4I98+HB511503-40M44?4 M$ZV(UD0;HBW1CFA/="`Z)BC5PB3I_Y%[T-BF^_$]R*%LD,MW*8.5[S)+HHJH M)FJ(6J*.J"=:$:V)-D1;HAW1GNA`=$Q0JMQY2P=C+ATXE/2B.#NVCR;1JB*J MB1JBEJ@CZHE61&NB#=&6:$>T)SH0'1.4:G'>TH%Y5E.3XZ2K#(L"\70MW\MT M!2/%ED0544W4$+5$'5%/M"):$VV(MD0[HCW1@>B8H%0>D]+'@]PS\P&[`I#( M8]'4W-53UR;G/,.U35$3URYK/?FV^=08:$E4$=5$#5%+U!'U1"NB-=&&:$NT M(]H3'8B."4JU,`EFK,4/YU-CFZHF,KGL50-DM+:7[[.Z@I,@YI*H(JJ)&J*6 MJ"/JB59$:Z(-T99H1[0G.A`=$Y0J9Q+,6+EG.JC-1Q-Y7(H:`K\8`RV)*J*: MJ"%JB3JBGFA%M";:$&V)=D1[H@/1,4&)%I/S7HOZ(#T3%!J3SGY;;F6BT7+\]O4I\,.+&>-\Y\U9V8K9[,:A MZ?CT+L?XNU'(C7]EZN*,JV"E,Z9]_+S4;L+4SB&3R4>1R:YY$:S\ M-2^)*H=FFMI$OK(5E3H4#%:%*-NJJE[^C&THZ%'GT%4R[QUGB6D?"CYQQE6P M0I3/R]`FS-`\TC0]BDP^/P]6_@*71)5#LV1@G603F)H%&Z*6J'/HRMPEAL%J MDHW;/0NN$I2V4I,QOGP"/;$)9CR!=BAMI9-LS%H$JQ`_ZRMJ1I6S4BLU0Q_B M-A0(EU]HG8.5/U/+DW<.J746SM2'`D^<:16LT"KSA+)P']>JPW`C9]8X<5EC MW/='Z(#T3%!B7+3\W+,DWF:8SH417E!M"2JB&JBAJ@EZHAZHA71FFA#M"7: M$>V)#D3'!*5:G)=03IE0.F1FJM']+)OZ+8*5[Q=+HHJH)FJ(6J*.J"=:$:V) M-D1;HAW1GNA`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`JV#E?:WI:^-1HK6X0X!"OOZ^A106JS8G%&1[<+'$E'MRB1VJ)$:H>2JD^SJE?3 MP/"O*TVA!M67!'JSW1@06/B54R,35-\(S[U- M)]E]<)5ZOKRXR6ZZZ^#&=]L-T=:[L9N# MLED=C\&-ZI@VB/-6>6947"U\P'C:L M+ZV-^7!6SDKIMVDE\_DHR_QJNFF(6H?T7()Q,[J8H)&XRPBUZ?VI)>B0G3R/!M=3+-FO&9U-D1;?[;O7>B.9?:^S),U/#BK[]?PF+A.AXSSEK9F M?+K$H:@_+(B6#EV%>4?ET'5X'[!FP8:H];Y"*^IHU7NK<,:50]$9URRX(=KZ M@J'[[FBU=RBZQH,O&*[QF!1,M<@7FGZLOW+]R3RM8Q8ETE$]NSDN@I7OG$N' MKD.D*X_<6#<=Z;E`W.:'\WE/#9VW#NE9'V_5T:KWYWNR"ZR\E>U<(WWX/7V; M>TW/&Z*M=V,O;C31Y^-OLMZ^8[&]+_9D'0_>RM=QF@V8Q\1SVC*D7#+3RUO& M?]__(7V+3]-&3^&8VWJV..50O*U#M"2JB&JBAJ@EZHAZHA71FFA#M"7:$>V) M#D3'!*4:F?6:EZ\>F><4B8X(2>>L3YIGLK!L2511503-40M44?4$ZV(UD0;HBW1CFA/="`Z)BB5Y[PEBRN[/I%T M%8NBX6_AK"*T)*J(:J*&J"7JB'JB%=&::$.T)=H1[8D.1,<$I5IHNG+.L&7, MLQ'1(JU0^4ZP,`_#RRI>:?4HF7U>93M(5;#ROFJ/PO)EXU'B*]]6:(.5]]41 M]1YQD=,\?GY.9%QJ&;*#=RQ0*-AZE8,3=T*`F#M4H:B$-Q&(!JYRLJV'B4A"'?FVR#50@# MW/?>JA"&_TA:=L6TS*$D.M8JNLBEL]*K;+[Z%5'M4%2P"59A>6.2;^>UPAW9;QD@XM%Z2+35;8ZM/`%0]M9.G03]@DJA_2D M[VDI?V4K3T3XY61K//(W(X_FR M5$^+$`BH12:#&:YF"YNZ4NCI\:AN*41=1[9EC:Y&&=+8GWB.0U>GF?\ M6/"8?LPMRAI@=LD+9Z45/=_:E@[%PYY#?M@KKM714^-04@6LB[?!RE>A.>19G,+J^NLQ7=FIX: MAYYKN/9\LO)5Z%S!T'"S=+]/3I8&UTSKX\6??"#P+??IIT:-%MD$R*$HK5T0 M+8DJHIJH(6J).J*>:$6T)MH0;8EV1'NB`]$Q0:E&9KH?:_2,%C8[B%<=]$$# M(T^Z*'25-T)SH0'1.4:F$R ME[BKG.X5/_+3,GK^#B.:15DORL;:A2L8C7M+HHJH)FJ(6J*.J"=:$:V)-D1; MHAW1GNA`=$Q0JER>.#[3BY@@FO<3["#GAZ\%T9*H(JJ)&J*6J"/JB59$:Z(- MT99H1[0G.A`=$Y1HH6<4TU[TM!8G\S0/=2CM*O-LT701K+QB2Z**J"9JB%JB MCJ@G6A&MB39$6Z(=T9[H0'1,4"I/GOD^(P]37#UKD]]PB)9$%5%-U!"U1!U1 M3[0B6A-MB+9$.Z(]T8'HF*!4BSR1?D8+9LQZG.>DA?X,RRR3>;Y0&*Q"5QD* M>E31JB9JB%JBCJ@G6A&MB39$6Z(=T9[H0'1,4"I/GI<_(P^3[FN+].4S'^4% MT9*H(JJ)&J*6J"/JB59$:Z(-T99H1[0G.A`=$Y1J81+7>&[VC!8N(8^VI?0@ ME[O#QUTE7P(.5EZQ)5%%5!,U1"U11]03K8C61!NB+=&.:$]T(#HF*)4G7PEX M1AYF_-<613/?!=&2J"*JB1JBEJ@CZHE61&NB#=&6:$>T)SH0'1.4:G%>QG_- MC-^A;`*6;P0$J]!5AJ4"CRI:U40-44O4$?5$*Z(UT89H2[0CVA,=B(X)2N4Y M+^/7KJ89MN(%&8>2KN(6`<)XMZ151503-40M44?4$ZV(UD0;HBW1CFA/="`Z M)BC5(L_XGQFVF-:;U],ESTUXTGI!M'3(O+T2IFEX#(0%ZV+!_)F/)ECY;M`\VQ!L@M5P@8FO]`+S%"Y?=G_1YN4- M,SN'DNNV5A%:.BM]B]K7M6+!.EC%UYWMY37!ROMJ$U_I=9N5S0.W9YRW7 M(W7:T`_GV6[2(ECY2BT=,@^4#06QG5VQ8.U0\BU=['DU+W+?)N[3R)@\XXS( MV+0DOJ?<6)1N#\[S':Q@%2+C"MJ]P,G-]3C?2:Y8JB9J'-*3:68#]?(B_QQF MFY1)+_^\Y$![[&@8#J4-(]_C\`6CG6>']-+P:8]^?#6=YRM5%8O51(U#>B3- M77^6Q;=)F?3Z\]GWCPT(G)1KT]=$*FL5^:)UL`JMPLWF[2;FWV;7EY=96ZI8 MJB9J'!I:1;X5VB9ETJCD\^`?BPJGQS<.)8WE.E^?#%8A*K:@ONIG))[/IOGS M>A4+U0%%0T_^=F_CK(;6$^WLIT')9Y]Y4%ZV9:L-:W0AB_B*@':RSQJ+S%?3A[ODY#H;QQ:N8*3FDJ@B MJHD:HI:H(^J)5D1KH@W1EFA'M",,D#)GG`)`^8Y`&3/&"2!TSRQ"R3Y[RD9G3)K,:S="4S_]*%AD!;-%)' MBH%),3`I!B;%P*08F!0#DV)@4@Q,BH%),3`I!B;%P*08F!0#DV(QRQ0[+P\; M73(1\TSW03^V21YK%S')`R9YP"0/F.0!DSQ@D@=,\H!)'C#)`R9YP"0/F.0! MDSQ@D@=,\L0LD\,,D#)GG` M)`^8Y`&3/&"2!TSR@$D>,,D#)GG`)`^8Y(E9)D^>KSXW@6!F.KJT+%UHSK^B MI`XUF'D5I1B8%`.38F!2#$R*@4DQ,"D&)L7`I!B8%`.38F!2#$R*Q2Q3(D^2 MGU."V?#HTK),B6S=5TH,9I$2`PNS0#UCG[Y&)7$&,U]4X@PL+IHM<$JOP77)_P+%H2E[+6+MH>4!]S"QG1TKEGD9UDA)TT@S]I!CL)!":! M4%8"#7:Q0-F2IP0:S"*!P"00F`0"DT"6V?:B<%!H,G:OLV1?I-5AX5]++N>*ZWFATYH+$R3Y;D/!, MK6+(>"?7^0JS/96*AFG'6FX^O+;%AN M!IM0KHU8J"JVR/K+.V;(Y-&GS%W/-GG6MM4/-U-N,DT6XQ<49GY5BBM;5$S MNSUI=GDYRD8J:3VX]^6D=59N=(W-UMJ:N=V)\?B"8@^.?*4D M-IC$=LSN_DST;G+6!R0UBDEJ,$G]G"L)'1?+A#8)^3E"VP0^21)&CB6=^B9? M!QX%,Q\;">V*NDX]O;S*?R!50@_N?3D)G94;3_.W_=6I44Y"#^QIH:W9$YUZ M\./K))W!I+-E_DNQVB^\'F63(BF-@E(:3$HGSB:7L_DH[T[2.BZ8:6U2^5CK M'YL12?M\)V#D6-;7LSN.^KHM&O4]-0'G;NCKI2:`74!`;V M=!.P9L-.)+OZX"=J`I;I%SH]4Q-PS+XI/)Y?CV?Y1KN:`)RI"<"9FL#SSM0$ M8F=9$S#+!?^!)F!7'70B?YWO1OHQF5.S"/=0Z0TFO<'4Q<&DKV7J@_XC/(;TL<`D#YCD`9,\8)(' M3/*`21XPR0,F><`D#YCDB5DFCUE(.$<>N_"0RF-9UJ&R.[LZU&`6=2@P*08F MQ<"D&)@4`Y-B8%(,3(J!23$P*08FQ<"D&)@4`Y-B8%(L9IEB9BGA',7<`D#YCD`9,\8)('3/*`21XPR0,F><`D#YCD`9,\ M,4OE,<^HGB//R3Y+\1W+.E2V:K$8!;/0HUE=OL@TA*>G*RLX[E)1P*"F#8>PP6\*0 MO,'..Y2^<"A]@V'L,,NOI'FP\PXE>NPP"[[)>>/@/S/?-BL5V6.G(\_2X&4+ M+=4HUK&S+-8F6STGUBZ[35JT9>8L0T/%@KYB/9CY5J!8@RG6 MEFFU)KC#"QN*-HHJVF"*MF/V+8>_36;CR_R7'Q1N%%2XP13NYYTIW''!+-PF M&XW#_8/CBDUJT[N!8W&+GUYBY=8\+FPZ2]+B+8M_WV;D[^Z!J20;XDPSP M)QD<]241K(V]SDP$DSC&(CPWOMA$,XVV95F; MSWJ>VOQ@%K5YR_2]4,_4YBW3AQO-'LGWQA&.G67A-HG@.>&VB6,:;LN23^1-+[,&I'"[HJ$!:8@!4[@M>^83 MI]XLZBL*.-PIX"]QIX"CJ`(.IH"_Q)U"'A?-0FXRN3CD/SC,&#=YFF!9\B7( M:;X+*R6LF?J';^12PK)H15U*6&8^8_W]MJK!'NZD!-Q)B9>XDQ)P)R7@3DJ\ MQ)V4B-UE2IBD[3^@A,W]TCYA6=8GF+"YHDF?L"Q:*Y<2EKFU\N\-07`F'>!, M.C@[\TS/]W65$/`G(>!/0ECV5.4D0^PLE4&/]SPMPPM7WD]^LA[A6)(X:_,S M?>9K,0IFH4>0506[NL":`FL+K"NPOL!6!;8NL$V!;0ML5V#[`CL4V#%EF9(F M:8L[U#,W[XE-\I*>XUBF6#8'EV)Q?OCAU;>WKY<%)L5@)\7`I!B8%`.38F!2 M#$R*@4DQ,"D&)L7`I!B8%`.38F!2+&:98B;3.T[D7FM1G>BPI-, M1L2SO+M<*/%N6;+4?_*;OJ4X(I/X*"OQP20^F,0'D_A@$A],XH-)?#")#R;Q MP20^F,0'D_A@$C]FF?@F%SI'?)L[I=W5LN35JNEEMLR@[CJ810,LF!0#DV)@ M4@Q,BH%),3`I!B;%P*08F!0#DV)@4@Q,BH%),3`I%K-,,9,XG:.82[22#F69 MSN*ED#Q@&DW!)`^8Y`&3/&"2!TSR@$D>,,D#)GG`)`^8Y`&3/&"2!TSR@$F> MF&7RF$3K''EL8I9V*,M,(Q@F9]/\9XZEV&#F591B8%(,3(J!23$P*08FQ<"D M&)@4`Y-B8%(,3(J!23$P*08FQ<"D6,PRQ4R>=HYB+J]+.I1E:8<"DSQ@D@=, M\H!)'C#)`R9YP"0/F.0!DSQ@D@=,\H!)'C#)`R9YP"1/S#)Y3/)VCCPVV4L[ ME&5IAQKA\=C)8!9U*#`I!B;%P*08F!0#DV)@4@Q,BH%),3`I!B;%P*08F!0# MDV)@4BQFF6(FSSM',9<7)AW*,DU;O10:[\#4H<`D#YCD`9,\8)('3/*`21XP MR0,F><`D#YCD`9,\8)('3/*`29Z8I?(H23]+GI-]EE,[EG4H+&8',Z_B,,D#)GG`)`^8Y`&3/&"2!TSR@$D>,,D#)GG`)`^8 MY(E9)L^9";3>.*(\CIF7=L*<+W]`?S'R9647=:E0V$.)1BC5""4;H70CE'"$ M4HY0TA%*.T*)1RCU""4?H?0CE("$4C"!F80F0SZGA]F,.IED3.,L^[0<);G` MU,/`)!:8M`*35&!2"DQ"@4DG,,D$)I7`)!*8-`*31&!2"$P"@4F?F&7RF'3X M''EL^IS*XU+J)*D:88M*FZRFWGW\.'NJT:X2_-A MK)]_.O637T93FU"G@ED6K2F^>?C][NYQ^?[Q_<\_?;G[]MO=XN[SYX=7'^[_ M-!Y'^GWHB+_Z=O?KV]?OU*QN3VU+(^-09C@V-<=.9\"QR5S'E)>4RDVNS;'3 MC@W+W9ACI\UC')M>FO.=AFX>&YECI_DNCXW-L=.G[G%L8GQJHZ)83^/3SJ%9 MSL1%*X/%!"@>,S[U M+'GQF-%(#S(7CQF-[-8PZC(R&NEYS4*Y&QVR7T-!J4L3:?N:,X^92.N#2`6/ M^A"/.596[]*HH-=EB^6,"GI5JW#L6L7T1?_2$172Q^1+1Q1D?=J\=$0AUE>U M2T<48'WCN7#D1N'5Q_`*1^8JHU^"*AU1&?W24.F(HJ[?O2DM9#RF#>3/O;'(?-8CW5$ MN^@%;V-%5!N[A2-F8"J/2Q-=3WE4,@-K>5R=Z#SE474L;WI4M%"#L:*CYQA+ M1Q0=^^P#KE31T0-BI3+25/>LTA&U>#WM43AR&MB*949F6"NV@Y$9U,K>%)WO MC&B*3GD\&TL%/?]=J)N*%'4;J81-+_+8C!1IO=]<\#52I/4V;.F((FUOZ_!F MAK=2I'\9W?Y2]J4"I7,8F4M9;[KOF'!8^:+%<9G27\] M!S2^U>,FI8CJ89+QK9X>*1W3@R'C6ST)4CKV3H_:FP92;(=ZSML<*RFK;^W? MFJ^6\PK>Z2-#YLJ+T3=1D4$I8N:S0+>G+\C0ISY1,K\]?4F&Q\PW@125HD_S M;:#;TY=E6,Y\$.CV](49'C,?!KH]?56&Q\R7?VY/7Y?AL7>*RKMB5/0#";>+ MXA']3L*M^;P\O54Z8KXRSR/ZB81;\P,(I2,W.E)J/?HH_ZWYY'ZAS,U(1TKG M.4[5C?29;Y9Y=S6]?7=5ZDD+'5D4CRQUI"H>J76D+AYI=*33`\VL07,UTY%2 MWV^NKG2DU/Z:*\E:/$^O\_3%(SO%8%>,P5Y'#M/2>?;3N8Z4HK.?7NM(2;G] M]$9'2LKM9Y>W!WT\@3'8ST8Z4M)GK;JMBTJ M];98ZXUJO2W6>J-:;XMUZU2WKGBDUY%5L=:]:KTJUKI7K5?%6O>J]:I8ZUZU M7A5KW:O6JV+=EBI3%=_;)N-F=83B:W53%G;76D*QY93F=2H=2#-SIR M*!Y9*#J+)6V;B]&2[UX>>?_GC_V]WF_;?? M/GU]>/7Y[M?3IO]@/B^@4'_<_C_1]:]'C]ZN_WC_JX^.F?O]^]_WBG MY^`NS0_<_WI__^C_1YWZS5_WW_YQ6D#Y^7\$````__\#`%!+`P04``8`"``` M`"$`<4B=V"L%``"$%```&0```'AL+W=OBGMCV[AM%D)U*FS82>206_ M'&A=IBU\K8]&49\FCV7I&JY2$V* MM(7Y-Z?\W`BU,KM'KDSKI^?SMXR69Y!XS(N\?>M$=:W,W.18T3I]+"#O5\M) M,Z'=?4'R99[5M*&'=@)R!I\HSGEEK`Q0VJ[W.63`;-=JHE)?CRU4.X99,02<_=O/FDRWY9+8P;0O"M4?2M&'.)'4M>VY:6O['@RPVJ4%DVHO`IQ"Q)\O9S)DO M%_>K.+T*?/8JUN=%X')=/O#9BWP^G46O`9\_/Q&XP;J)P.=G)V+P&G4E]],V MW:YK>M'@/H(J-.>4W966N](U46M>F:'Z[Q4?"L9$'IC*1H=Y05T;Z-B7[=0Q MU\8+=%G6QW@XQI(C=B*"]0&3]540J"!40:2"6`7)"!A@PN`$=-H7.,%4F!,B M!T^`D35*VB)"#/%5$*@@5$&D@E@%R0A(:=M?DC93@?M<:@"EO%X?`_X/73)7 MK!A"!B\0"1`)$8D0B1%)QD1R!!X67]`(3`5N*KC*D"V^)WB0_9$E0\A@"2(! M(B$B$2(Q(LF82);`HV]LR>V50#P,6'"7N9BQQXD-+3CR8JK4?@@2PWQ$`D1" M1")$8D22,9$2G7\F418L)\J);0^W_PX1'Y$`D1"1")$8D61,I*Q@U;F_?"Q8 MSHH3R&IA$9`=Z-+8` M(U^@*=_7F);2^<$U8#!`H*NYD4"#C/+\BZ\!0B81J).1+6&[F+L[W6+12NX] M@J8;E78FEW8G!E[W,WZ/IE)/V`MY8""BK,ZTA0G_Y(@02T=BT(?2L8CB1BZ6 M2#J1I&7;V"[H?MOXG@G6<%$1S^)H*C\+U6W,-4H,]#$*!)KQQK)0(J&(N$X@ MPB@6:/Z>3B(B;O01VP6-#/FI9PO;Y*CMU2.YO90NV8F!X_;B`QUG\#SHHQSN MD^W<\&FXFO`[$H.N.K%`W"=FM]*3B30?N7'8UNB7?>+[*[B*F*9G<23UD_KF MM+L&B7%^CQQ8":^W+[X+N;JS[#H#7K]1RB'6CN[2CD74BFN;*Z2=2-JRG6P# M]H&=/^CYO24-SA#$FL8.)=2^XZBK.K\B/^;@[[PEJ8]D1XJBT3+ZS(XPH!;; M]8#Y^8HW=V$K!5:K?.'"SN,&7[JP=F/NKUQ8Y6YPRW39HH%_@47"9>L`_@7. M?!ZF-[C'SH)N\:D+;WQ8Q[-=>/'!_,%Q'_B9DIJTX\)K`1[@S5S810,WA@%P M!G1.C^3/M#[F5:,5Y``&F]T^I>:G2/Q+VQ?WD;9P^M/5^02G?03>^,T)U.]` M:2N^L`L,YX?;_P$``/__`P!02P,$%``&``@````A`-U7]@8V!0``&ULK)C;;J-($(;O5]IW0-S'''U" MMD=QS%&[TFHUNWM-<-M&`=H"$B=O/]4TC>DN;Y3,Y";$GXL?ZJ^B*??JVVM9 M:"^D;G):K75K8NH:J3*ZSZOC6O_G>W"WT+6F3:M]6M"*K/4WTNC?-K__MKK0 M^JDY$=)JH%`U:_W4MF?/,)KL1,JTF=`SJ>";`ZW+M(6/]=%HSC5)]]U)96'8 MICDSRC2O=*[@U1_1H(=#GI$=S9Y+4K5M$=:W,O/A8T3I]+"#O5\M-,Z'=?4#R99[5M*&'=@)R!K]1 MG//26!J@M%GM<\B`V:[5Y+#6[RTOL5S=V*PZ@_[-R:49_:\U)WH)ZWS_1UX1 M3!;3J3M;S$'FD31M MD#--7FY:6__$HJ]?B*G:O`L=>Q;$FKCV=+RRXZD=5W%X%CKV*]?E;@(^X-GH).#X\_>Q[$7@^,G[,'B)NHKOTC;=K&IZT>`Q@AHT MYY0]E)9G0:>(6O/"#-7_O^)#U9G*/9-9ZY``.=]Q7>,!GFC1KC,8`!^E'B0\YY+0\C@$B(^ M(@$B(2(1(C$BR9A(+L$2*KET^YTBEA46W9DADMARXD"G#O;8CJ-TR!`D3MLA MXB,2(!(B$B$2(Y*,B93[[%.YLV@Y=TX<9UA)'A#9(>(C$B`2(A(A$B.2C(F4 MZ/Q3B;)H.5%.(-%QD5VER$/04&1$?$0"1$)$(D1B1)(QD7)G0_#XA?I^@[-H M.7=.QD5&9(>(CTB`2(A(A$B,2#(F4J(PA$B)\LEAPB:\]I1G3UL*3RBL4#<, M<&!"X',#$Y'S[TDWWG8Q#SWADV8W%G#BP+@R6@24<<,?@D1_!(B$B$2(Q(@D MG,!$#,J2)6R`^G5/.A79%(%&K@@TLJ5'KMT-8+9I*>NB?PT8/,$R(4;1]40V MVH&R\MJ.KP%".9%D9)O8P/7Q9\1BX8H?/8+F''6`.BB($Y?#@KGKD2VWSEQ> M6GP1975&3NVY:9IR2("U0XPB(?3NY6(1Q>LV75CH.;-!RQ=HWAEZY\RF*,4`*X4814+I*AX+ MM.#B]FR)Q!-)2?:/#72_[A]347JT1W*/+E7_^JAQCW+DP#(S:F[4HSS*-;NL MK1GLD:`>1=HAFRO9?5XO%_7H_R&2.NN[CE^2[&OPW;DGJ(WD@1=%H&7UF.Q9PCYO5@/EVRG;F MP2@#?:_RN0>O^1M\X<%;$?/=TH.7Q0UNF1Y;>O$WL*YZ;.G$W\`6S[U]@V_9 MUL\M;GOPZPWK;!T/?K%@?N]Z]WP+24W:]6!XQR=LIQX,ML"-X038\CFG1_)G M6A_SJM$*<@"#S6X`J/FF$?_0]L5]I"WL]71U/L'F'H$?^.8$IH4#I:WXP"XP M;!=N?@```/__`P!02P,$%``&``@````A`"*C;DB>%@``M(L``!@```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`E""?H,&"%T&?T50L1F=/V;0;*PF;]/ M,>J2PTBZL"&;0\A!'9`6Q(%T(!XD@/0Y,2+INOLK1(K-Z&+4RQP$X*4T!*V> M4ND00I+Y]# MT%BM`6E!'$@'XD$"2)\3D[ON#C-RC]$V]X&L[-!8%5?'(>B0.T@+XD`Z$`\2 M0/JHVWN`RGZ_:S(_1!TR!VD!7$@'8@'"2!]3DSNT0SG]]BGQWR, MMKD/1/T^IK4!:4!:$`?2@7B0`-+GQ"0J^V(2C69B>?Y*%\1,.Q$;LAH,I!C[ MYT7_'X)&H1J0%L2!="`>)(#T.3&R1%]E='EZ`.S#;?8)Y4.`J"%JB1Q11^2) M`E%OD,TYFJJ?'_2+P8/IMC=VW?N$BBXOS<`4-59LB%HB1]01>:)`U!MD98B6 M:H8,@P,S,@S(=#U0LP!JB1Q11^2)`I$^=>ZOT>%]V9RC19J1\^"H3,X#*F;[ MR^)JCQY)LX2BIJX':AGEB#HB3Q2(>H.L#-$#S9!AL$QJ;\SF_2*YJ`EMB!JB MEL@1=42>*!#U!MFPN(BPS%/2"AE63)S-]5.2R&BHH: MA6RFBB-JB1Q11^2)`E%OD)4H6J1G)3)^6"N\JY?EUU_B!K[N5D`M42.J"/R1(&H-\C*$(W3 M#!D&GV5DR*U7ZGJ@9@'4$CFBCL@3!:+>()MS=$5YSO_"C#`8+*/'P7-EP^*J M6'C:+`Y1T[``:AGEB#HB3Q2(>H.,1,MY]G`?;NUA0KE'(&J(6B)'U!%YHD#4 M&V1S+NWARX?%DM8Q(6L=KXJEILT4=1@61"V1(^J(/%$@Z@VR$D6#E5\Y3]\H MEH,?RZ^.A+([X8:H(6J)'%%'Y(D"46^0S3GZMSSG%W^"U#.1TCXD5(R*6(.B)/%(AZ@ZQ"\USEDJXRH;T]LDV7YNV9`4>#%FU>=.23 M]=H0-40MD2/JB#Q1(.H-LCF7;BP.N(O5JTME,G/-8DFGEE`QXLH5NREJ&G'P M\\OGH<&+&3D.]BPW+>5:YO(0-8T*H)91CJ@C\D2!J#?(*A0-5*[0 M,Z-B\%M&AF3!\LD"J%D"M42.J"/R1(&H-\CDO)IGU/;AUJ@E9#_!7I7+F%/4 MH>N)6B)'U!%YHD#4&V1E*+W;TUT?GU(5'^03RN\31`U12^2(.B)/%(AZ@VS. MI1E[N5^-JUJE'@,J[A/E4F>JJ*AI6!PJCJAEE"/JB#Q1(.H-LA*5WNV984&# M%O./]F%*<$/4$+5$CJ@C\D2!J#?(YCS/C<7KONSZ`459IS6MJW*I,U54U-C/ M#5%+Y(@Z(D\4B'J#K`SSG..*SC$A*3TFN"%JB%HB1]01>:)`U!MD:)`U!MD=MT6IP=+DM2JB8$,J5SBEJZOKD#J09&9+ORR<$H&8%U!(YHH[($P6BWB"3\UGI#J-%.)?YF?DY ME@72YS3E&',4'4$CFBCL@3!:+>(*O//-MX1MN84#X=$#5$+9$C MZH@\42#J#;(Y1W_V\]?!V6#G\NL@(3L=K,I/#%/4U/7)&F;3`:,<44?DB0)1 M;Y"589XU/*,U3,AT/=QBPZB6R!%U1)XH$/4&V9Q+:_CR3PQGM(T)%3-"N<(] M14W#(OG-:5YM&>6(.B)/%(AZ@ZQ$\VSC&6UC0ES+/"O=V=,?1O;AQ9R;EN"R MY8D4)1\\R8FHEE&.J"/R1(&H-\C*.<]OG=%O)52,JG*%?(J:9(`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`N'4]2H3$/4$CFB MCL@3!:+>("O#/-=X2=>84'9'V!`U1"V1(^J(/%$@Z@VR.<]SC?$G$L7C@H2* MJ[Y<.)RBIJY/KC'S!XQR1!V1)PI$O4%6AGFN\9*N,2$^E;XLS=G3G\;WX<5- M)AFIZ1'T)D5E]YV&J"5R1!V1)PI$O4%6SGEVZY)V*Z'X5H.L#*7->KKKK^BF M$LHN\0U10]02.:*.R!,%HMX@F_,\ZW1%ZY1082/*=<*!#U!EE]YMFL*]JLA+)L-D0-44ODB#HB3Q2( M>H-LSO,\U14]54)V.EB4"Y)3U-3U0UMF.@!RK-@1>:)`U!MD99CG_ZX&LY<_ MB$O(='VRA)-W;AC5$CFBCL@3!:+>()MSZ?]>.AW0&%XE?Z=9(*O//&-X16.8D!D3R1CF8P*H945'U!%YHD#4&V1R M7L\SAOMP:PP3*J:#()MS:0Q?.!VLZ1@3DACY=%"N.4Y1TYA(CG&Z6EI&.:*.R!,% MHMX@J\\\Q[BF8TPH_[!`U!"U1(ZH(_)$@:@WR.9<.L:G/R"M:0P3*J:#897S8JZ!K7!_.7WR;*Y<0I:AH5AXHC M:AGEB#HB3Q2(>H.L0O->9R<4IW.3(^R%B(B3N*" M25PPB0LF<<$D+IC$S5DA[CR7MCBE31M9X5G*!)&ED])%:8!D4Q;=GNN,*6/.*4/IO3!E#Z8TL]9 MD7[IW>+4],*-CT]I[!:)V;EI6:Y\9F'98($#U.4#)K7`I!:8U`*36F!2*V>% M6J7K>V[VH+=;G"9#-CGW385IL"!.Z8,I?3"E#Z;TP90^F-+/69%^:>GB8%F< M[S<=?/Q\>_/;^UT$U3.75CI<*1VY=$JKMQB9F5-3W/085*H,3)M\Q;.:],W. M8NE$&ATBQJ$DC="2-`*31H>ZJ?5B34Z*'2+&UJ58WE*A6&D(GQLPM'V+T\3T M1^H.AU0ME^4*\B%L??C*CM0:JFH[V_'=2I_$%H."9[I9KHJU!@F67G-J3(*! M23"\@"1*;#F\P')]=KDH7D":Y8T5FLVSB(M3>L21Q>U(,\V*WM1U-U35SJ*C M/M(L,3-))W:^3VFQNKJZ/"]_12+1T)I$`Y-H>`6)EMC%\`IG%Y?K]671QU(M M;\VJMC_1(O\=S3,C+9V`D:_1+Q*+VTMFJA57V&8,T\;0DVIC MC/%JNCP_.R_F?9UE,81D3>DP"S"=9@&FXRQ2\](D>[<8:5/5/&Q:8BEDG.D^ MTPD:5L;!D1H[8$[:2&?$D4DSU)5(8!()3"*!220P'?J1LR+]:!WGC*+!:MKT MD_W4GZQ?RM6+Q7@.QW0?U`$HAZKCR)(B8%($3(J`21$P*0(F17)6*!*MXQQ% M!JMI%4GVJ(Y-88!(+3&*!22PPB04FL7)6B!6=8R[6 M$%[]0S,CA4P MC14PC14PI0^F],&4/IC2!U/Z.;/I[X_VZ&[^>0\5H7IW"RF ML+'S=0S98";-RA29#B)#G$XB`]-19&`ZBPQ,AY'EK%`DVK0YB@RVSBJ2K-XT M3RI],*4/IF/8P)0^F-('4_I@2A],Z>>L2#]ZLCGI#Q[.II]\G6[9V8`H/E9) MD4-8-B#`I`B8%`&3(F!2!$R*@$F1G!6*1)LV1Y'!UEE%!I:MC`\GJ`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```` M`/__`P!02P,$%``&``@````A`)8!/PVV!@``QR```!@```!X;"]W;W)K.[D^ZDT^D> M7M.$-&B3$`'=[G[[&S/&BX=@D[YH$N;'X/G/,$SC/GWZ=CE/OF9EE1?7YRF; M>]-)=MT7A_SZ]CS]YV\QVTXG59U>#^FYN&;/T^]9-?WT\O-/3Q]%^:4Z95D] M`0_7ZGEZJNO;;K&H]J?LDE;SXI9=P7(LRDM:P\?R;5'=RBP]-"==S@O?\]:+ M2YI?I^AA5X[Q41R/^3[CQ?[]DEUK=%)FY[2&]5>G_%:UWB[[,>XN:?GE_3;; M%Y<;N'C-SWG]O7$ZG5SVN]_>KD69OIXA[F\L2/>M[^9#S_TEWY=%51SK.;A; MX$+[,8>+<`&>7IX..40@99^4V?%Y^IGMA+^=+EZ>&H'^S;./JO-^4IV*CU_* M_/![?LU`;0A.7O3.%DT&_BPGA^R8OI_KOXJ/7[/\[51# MNE<0D0QL=_C.LVH/BH*;N;^2GO;%&18`OR>77)8&*))^:UX_\D-]>IXNU_/5 MQELRP">O656+7+J<3O;O55U<_D.(*5?HQ%=.X%4YV8P^=ZG.A5=UKA_,6>"M M'[A^H'S`:QL$O!VY>`BS40!>VY,?5V"MG,!K&T7H6L$"4]%DEJ=U^O)4%A\3 MN%U`[.J6RIN/[PPS&7Z/\4TFN<K1&4&M5H"3?/_;)O)9$G MF9*L5]I]HUJ$2'/#-@=B>H#3`PD](#H'C#5#B7?7;%^KA)^GX*J3&[I89#9- M-X6J])/:D:P](X8BN<18&_GJK930BAKMP?,02IA&OM5], M#S+P6ZM"B!B)-6KBK3P6;#:F$^YTDC@)82,,":"MC)=`PM"!.^$QCZP^0@:N M/RB!D^!.(G$2PD88"D`+&Z^`A,TB"']T`*P!1###LZ6_)ITF1KM%(.XD$B[^Y0\R12!>3_N,%0!F:"I23@UY` MM,9[%S#BEW-FYUEF[WD2IG&3UA,AH[._)#TQ1KLM^TXB<1+"1ACQPQ0P/GX) MD_@9Z>H''72NX+WK5!7S2;8M):[V6TJ3AA(XR8&3R(QP?=T#1J MLKI(09:TQ@I1G3\(MLN`W!;<[25Q(\**F$+(@69T]3,$FT>]""LB"F`'(4Z`HQK?PP'*%,($FFDH+8!$G.LS8-A M<(U@AR,>$FT>]""LB"F$G)@Z0MC[(,/YRA2`/@85A`+,5B%MA(:=UA%75KQ; MPO66WBN)LK8-=C;N11"/WKB&T]=XU3!GD'-61P=$6<>HRPZ?S(4.H'1`W_2\T M;+-;,^EPY<-2+HD;$5;$E$&.5N-EP$',D(&1!ATQA%`&?[,A`U6L[&J.-&=! M3DY>$^>)/OE>@G%8M")&\/Y#TV)#TR<$F?,B!5GR%RL$]5EYS0]1P>TE<2/" MBIA"/#0M^O>F1=+W(@5AELE?$K$V#F:1NY'$C0@K8DH`13W^1O`E36N!]@,% M66L!_6`M+`//]XE4W.TD<2/"BI@Z/#0N^O?&11)"I"`U+P>D4F+#3)H%-XQ^ M;U34YL%"$E;$#!TR]4`)2)J6`%E^Y"-D+0%$L`0V(0OI=^7<[21Q(\**F#H\ M-"[*S9*>#N39'RD(2V"](N98FP?3R#4BG_L]#XDV#WH05L04X*$QT>^/B8S> MQI&"4`!&_B"(M75P]5PC,G[J(-'600?"BICADPG1/AKY=R9#NA\0*0CW"V9K M^M52;-@9Z1#RJ=C@4%LB+S"L,Z8QWS_QR7,T!^:"F%WM5?Z/JGM2$'6 M%M`='-G6V_H>_7J%N]TD;D3N!\L5WU\,*H'[O;@K>,G*MRS.SN=JLB_>Y5[N M"K[UU4=QGSEBN\B7F[+D>,QVL(75/\[9#G:R^L<3MH,-K?YQ(?>QY?&%O@!L M(]_2M^R/M'S+K]7DG!UA:=Y\`ZVHQ(UH_%`7MV;3[;6H80.Y>7N"?QC(8)/2 MFP-\+(JZ_2`OH/\%X>5_````__\#`%!+`P04``8`"````"$`R[D3#+= ME^9F.XHS&AC-[D@[TFJUEV>"<8S&-A:0RDCAU*`Y5U>LK/+BM''4;.%,LE-:;//3R\;YY^_/TY4SJ>KDM$T.Q2G;.#^S MROGP].LOCV]%^:W:9UD]@0RG:N/LZ_K\,)]7Z3X[)M6L.&GK,3O5F*3,#DD-_*M] M?JXNV8[IF'3'I/SV>IZFQ?$,*9[S0U[_;)(ZDV/Z\.7E5)3)\P&>^X?RD_22 MN_G027_,T[*HBET]@W1S)-I]YO5\/8=,3X_;')Y`EWU29KN-\U$]Q'[HS)\> MFP+]FV=OE?7WI-H7;[^5^?:/_)1!M:%/N@//1?%-0[]L];_@XGGGZL]-!_XL M)]MLE[P>ZK^*M]^S_&5?0[L#>"+]8`_;GY^R*H6*0IJ9&^A,:7$``O!SXJ[,W<5J""\G66.C)H'_)34R=-C6;Q-8&K@GM4YT3.H'B#SY2\YK M>-PT6/)9\GM&B$$^KA(=C^VH\J_T4[N=D!(?"CW,35\DN8EYBA"#W(*EZ'9L M1WW?J`ZKUYIS&^:DP9*3Z%&$&.34*9<=7+2%9H04")A=K6%I0\DQF''L" M77HHPC$+KZ[T4`D_N$$+%9N)A4E,K!!#K`(Q=W%SPXV#84.9UTK+L#59-TBA M:-NDE*?:+A`K!.%M/='<6-G1:Z2T_%JDQLF70M'FY#HENRB[-M*IF>B&>DPI MD/HT,,N!UTR+L$7O1LU0LCDM<>-((8@Z*00M9E'394Y*ZZY%:F3-4*VA**V> MJXZ7Z^T8+-HAT1^$<)Y"]F\4KZOWGI0P96OZRC4S13W%<(A;)]C=TE M^ZI']ZWM"RT$6]JG88<8"RO_6F-[M/^VEZNN^/N"0$08FG9E"D.%8^I_I6IW MB;_J47]/W#8BT."TC3`!5YC`N/707"7V0)YI#/:50$,,!R%L[ESA"B-Y=MU! M=19&D_JB_X$48A9=+\RVA-/3Q]-:]8V"=,R5#K* M0"TW<\A)W640;H]!6!MH(F4[0(>4'9R&UOKEM-YE#V[7'I1O)(#HV0;0F34[ M>&VGY`I[&"EN/3;AF[T8D;,]H$/.#DY#97:!K';:1L>O@P8MO,&7[D6@(6\8 MA'!^/=YP^[7/Z_$&2PFP?`1"+7&72[&>8XH/BJ_W+F]HKI)29]8&L1CUG<,.>TM):/M@;OIH$2!VYK5??GT4$:A?8XDB MYNF'<)["*V[P0_GGNB(&/_(1A.4S4T7,[*#U:L%)"6\8MV;]'H^P=F40(\FA";#*R6\>(A]!2,[,8B2] M'L,(I6'H+4[S?9/^CJY#SPXNU^9:SNY==@'GG)VW,.N$A3J+(#RBZ;"S@^[2 M*#FRPU-0/"0\9N5+%F>'0S5)BU=]PJG@*ZKVOWCZ&L'I:W-4.6\#CJ'/_ZN7YXQ,A8VI6T51W/\1LW^*GX_"D;E-Z:AG.+@-"9 M'#?6]BDAAC5<4A.HGG?PI5):4@M'71/3:TY+'R1;$H?AC$@J.CP24GT/0U65 M8'REV$[RSHX0S5MJH7[3B-Z<:)+=@Y-4;W?]`U.R!\1&M,*^>2A&DJ4O=:$&+P73RJC*!H`C8Z&WGA=D08!49*4`!Z[M2/,JQ\]1NDPP M*3+?G]^"#^;=,S*-&KYH47X3'8=FPYC<`#9*;9WTI72O()C<1*_]`%XU*GE% M=ZW]H8:O7-2-A6E/P9#SE99O*VX8-!0P03QU)*9:*`"N2`JW&=`0>O#W092V MR7$R"Z;S,(E`CC;07,,)A#^_6X8^/!JMY; MW2@+N^$?&_@5<)A$&("X4LJ>#FZ+SS^7XB\```#__P,`4$L#!!0`!@`(```` M(0!@8A3ZNP(``'X'```8````>&PO=V]R:W-H965T&ULE%7; M;IM`$'VOU']8[7NXQ<8Q,HZ<1FDC-5)5]?*\7A98!5BTNXZ3O^\,:Q.(W92^ M(!C.GC-G9AA6U\]U19Z$-E(U*0V]@!+1<)7)IDCISQ]W%U>4&,N:C%6J$2E] M$89>KS]^6.V5?C2E$)8`0V-26EK;)KYO>"EJ9CS5B@;>Y$K7S,*C+GS3:L&R M[E!=^5$0Q'[-9$,=0Z*G<*@\EUS<*KZK16,=B185LY"_*65KCFPUGT)7,_VX M:R^XJEN@V,I*VI>.E)*:)_=%HS3;5N#[.9PQ?N3N'D[H:\FU,BJW'M#Y+M%3 MSTM_Z0/3>I5)<(!E)UKD*=V$R4T84'^]Z@KT2XJ]&=P34ZK]9RVSK[(14&WH M$W9@J]0C0N\S#,%A_^3T7=>!;YID(F>[RGY7^R]"%J6%=L_!$1I+LI=;83A4 M%&B\:(Y,7%60`%Q)+7$TH"+L.:41",O,EBF]C+WY(K@,`4ZVPM@[B924\)VQ MJO[M0&&7E./J4KMEEJU76NT)]!O0IF4X/6$"Q.=S@200NT%P2F$>0<9``9_6 M83Q?^4]@FA\P-PX#UU=,C_!!M%<&M>G*"$9EK`JF*[+HJ_W(0)#_]K7>-&79&0X'JN^/U,('DL=(E$WM\.)68QY.S=+J,+[ M`GAJ+'"(P`@-O%R=]X++=_+W@>"QE(O,3JPLQ[1H9;&8T!@\-U8X1(9?0A@O MSYN![?8?;CKT6.P0&OAQV\ZME%KH0GP2564(5SO<9!$LB3[:;]E-U]JW\5FR M<=O7[]_`]FM9(1Z8+F1C2"5RX`R\!0RC=OO3/5C50IZP`Y6%O=?=EO"?$[`H M`@_`N5+V^(`;NO]SKO\```#__P,`4$L#!!0`!@`(````(0",3'6X%`X``(1[ M```9````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`MBW;V<3@<7'Z\ZCXO0NX7Z/(M2^_X>;DJLXC? MU1)]/-,&%\ULMO;&BM M6B^:6+C_8VZNJ[D1?Y1I?F-N>J):]@N5_U&FT:Z/WV5Z51'D?[SE.;H*JDW5 M>[<'7QZ[P?."*1;J;8-W7S?G17GO6PM]L5M\_K19_SP13;!8LNWK(F_0M9M\ M$E4[453UH>7X5<,A6HP\RY]YFMM3L?%%F[`5K=W?GP?7EY_._Q8MU$-I[IK, ME6SN*Y,W2'EB70T85>!M2IJ!MUFOK:*D M,M6$4S60%8%]IW`N=KC#7BEELWRAQ/ZV*H*2MX5C=*%@^%7Q=#K2_/;5`WRG3F*$(4 M$8JX+H::LF:3!M-3UEO:9)2&(:N;MV66RE$<84GEF'<"?=%WMI=E_BZI+(N` MJ/E#X5I;MOH/1.QBC@S$[F%'=#"^4]3AN,LK^974P=@D!N(J M\+;5:ULBZ6#2#B9K,-I;`R`5BCB=D0JEO3O+M50@1>!=@:@!70T8:L!4`R,U M,%8#EAJPUG#C:41J?>Q0Z M"@.%B6*$8HS"0F&CF*!P4+@HIBAF*#P4/HH`Q1Q%B")"$:-(4*0HLC8A%:2X M4B@59'NCG.O;4W$BJW`E$GO M4MSQ4,[:1CB=,0H+A8UB@L)!X:*8HIBA\%#X*`(4*:HE2)W;K&_%UR10Y[RLGP76':2A*%CL)`8:(8H1BCL%#8*"8H'!0NBBF* M&0H/A8\B0#%'$:*(4,0H$A1I(2[W'8.X?EQK\[.V%%(]BGM>OU&/^;O4>E2[ MR,*TU2,*'86!PD0Q0C%&8:&P44Q0."A<%%,4,Q0>"A]%@&*.(D01H8A1)(4H MJNUJ7V[R=?X44V1M0JI'35P!_XV"W+]-KD*,++ABXOX20IDZR5R)6: MWV=^/XJA_:12*VY+OS^K'/:4BS=W)6JMT")/"]$YB\'$9#)B,F9B,;&93)@X M)2GV(:WIN,GE+%,Y2[]A5YQQ%H^)SR1@,F<2,HF8Q$P2)BF3K)7()9K?C#ZB M1(M[UW*)*O?G[O(Q<.+8MZ7^[IGH3`PF)I,1DS$3BXG-9,+$8>(RF3*9,?&8 M^$P")G,F80,9]I1A#E$C4NX=QPU(Z842)BF3K)7(99K?ASZB3(O;UN_+5.LK MBWFG%:BU3)'HG,4H27EV<)'W!_+9@2D),6QL4",CGLZ8B<7$9C)AXC!QF4R9 MS)AX3'PF`9,YDY!)Q"1FDC!)F60E:=QUY0(5971,@>9=Z##OK*R[O*/>-!Q M+A*=LQA,3"8C)F,F%A.;R82)P\1E,F4R8^(Q\4O2V%/LKRT&*.8\F9!)Q"1F MDC!)F62M1"[0?*3"$05:#&R0"U09L7>7?XJ*"A2)7F8IMFQO,+RN-9L&3\AD M,F(R9F(QL9E,F#A,7"93)C,F'A.?2U4FT;'K%O/^_+/&4+>UT_3-5+T7+$;#`QF8R8C)E83&PF M$R8.$Y?)E,F,B/%MZ+!R<7W,Q&)B,YDP<4I2+*VX!*`N MK"N!_G7]Y&#*4YDQ\9CX3`(F:'M^HQGZF87C\? M*">?I(YX4F,F%A.;R82)P\1E,F4R8^(Q\9D$3.9,0B81DYA)PB1EDK42N4C5 M$44=^]+ZR**A^L5*=ST<-G3/1&=B'$C#F:;9]N+H\.*O3T.96$QL)A,F#A.7 MR93)C(G'Q&<2,)DS"9E$3&(F"9.42=9*Y/(4/9W4AW8LS_QM:H#B=J')_3J`XB& MM4^SE*BU/'&,D ME<=9?"8!DSF3D$G$)&:2,$F99*U$*M'\"_NE*[GM![M[KES!':AC<4M4;MO] M&%FEF[TO24L5ZTP,)B:3$9,Q$XN)S63"Q&'B,IDRF3'QF/A,`B9S)B&3B$G, M)&&2,LE:B5RBOS>NJ-\PKFB@CO\K44L=WC/1F1@E*8\?KZ[JGX\Q#UD:+OB. M#B_^\OK66)Y$/@&U2[&8V#RA"1.'BOU[K$><8\S$8F(SF3!Q MF+A,IDQF3#PF/I.`R9Q)R"1B$C-)F*1,LE8B%^COC2@23UNM#5D8J-_+6:+6 M0L5!1SIG,9B8)2F^<[[AFXHXQ9B)Q<1F,F'B,'&93)G,F'A,?"8!DSF3D$G$ M)&:2,$F9Y`\M_O6H@:).BX<2%X\9?5YNOBWOET]/VY.']8_\@<-YQW.('AZ& M_.?^(<1*_$Z[$0\`%8^?4>*&=B,>ZEF/C[4;\1#.>MS3;L03+NOQ6+L1SZP4 M\?/#!,0SD%\7WY;N8O-M];(]>5I^%;-\<98_:'A3/$6Y^&>W?MT_//7+>B>> M?KS_\[MXVO52/$CKXDS@K^OUKOHGG\#A^=F?_P<``/__`P!02P,$%``&``@` M```A`,/?->;G`@``@@@``!D```!X;"]W;W)K&UL ME%;;;J,P$'U?:?\!\5YN(4F#0JITJ^Y6VI56J[T\.\:`5<#(=IKV[W?&)@B2 MM*4O(4R.S_&9&8^SOGFN*^>)2<5%D[JA%[@.:ZC(>%.D[I_?]U?7KJ,T:3)2 MB8:E[@M3[LWF\Z?U0)[RM:LIHH3[2L@5]R(6NBX546 MOFHE(YE95%=^%`0+OR:\<2U#(J=PB#SGE-T)NJ]9HRV)9!71L']5\E8=V6HZ MA:XF\G'?7E%1MT"QXQ77+X;4=6J:/!2-D&17@>_G,";TR&U>SNAK3J50(M<> MT/EVH^>>5_[*!Z;-.N/@`-/N2):G[C9,;L/(]3=KDZ"_G!W4X+NC2G'X*GGV MG3<,L@UUP@KLA'A$Z$.&(5CLGZV^-Q7X*9V,Y61?Z5_B\(WQHM10[CDX0F-) M]G+'%(6,`HT7S9&)B@HV`)].S;$U("/DV3P//--EZLYF7A@'"T`[.Z;T/4=& MUZ%[I47]SV+"CLER1!T'/(\<"V^^#&;A^R2^W8^Q=TU50A*=-',9K_PD21SO,K<7`9X\)>X0/HKTRJ$U7 M1C`J8V9Q*[,#`)DND$$0PW& MTJ>YM:`)TM!4TZ41;*3[Y'81."5]$>/P%9>+CT@A>"S51>SI&[;'2S@."Q5!P^0\``/__`P!02P,$%``&``@````A`#T>Q#_9#@`` MA5<``!D```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`O)+C5[*S_U"\EK'WB!RZZ!_-0-!F_O0,.K MKJ'\?-.>R7AJ]DQ^ZA-N>3:2/M"53G:4]W(>/VJ0OLOQ' MO]CAO9OHDJK_Z"9OW#_I!>W^F>[PD_W3W6!B^L&5Z80'JJ1Z>OM:@Q[QQMW4 M76-B^L9/=E/WB8GI%&_<3=T[)H/N<7`WS]IAVHSZU>W^]M.'U^V/$SF52@5W M+[?JQ#Q9J&QZO+<'J3\#_-4)0$:^RO)9I?EX*NUE;._DK/7[I_GTXL/9[W*F MN>MB;A@SL2.6.D*=5E3:E0N>"[X+@0NA"Y$+L0N)"ZD+F0NY"X4+I0N5"_4` MSJ0\?8UDR/P_:J32J!KIHWNCP11MZA1$1^@F*Q<\%WP7`A="%R(78A<2%U(7 M,A=R%PH72A-U.G]R!.;2B/G M1GF9OB`\L[5!LT-5ZT/ZJD$\B`\)("$D@L20!))",D@.*2`EI(+40[&J)@6R MJG9X1*GHICCZH-ZT,I.!.RC7E3W(EGV0;K:">!`?$D!"2`2)(0DDA620'%)` M2D@%J8=BU4*N8XZHA8JV:]'*;-9_X"PA*X@'\2$!)(1$D!B20%)(!LDA!:2$ M5)!Z*-:!E\O!(PZ\BK8/?"O.(+AV!D$?U`\"B`?Q(0$DA$20&))`4D@&R2$% MI(14D'HH5BWDDO:(6JAHNQ:M#`K(3W"5R*Y)*U*3X8?$>V=\]$']^(!X$!\20$)( M!(DA"22%9)`<4D!*2`6IAV*52:T>6'4Z_(G=A-O5Z&@X1$@KDD?R20$I)$6D MF)204E)&RDD%J215I-HBNQ9J`NE.YB\$CQPQ:GW'&3(=V6-F=NZ,&1/5#QJ2 M1_))`2DD1:28E)!24D;*206I)%6DVB*[;FJ>.:S;3\90.RV5.8D^RC=J54TJ MYI0'RRM]E&ZX,@TU>22?%)!"4D2*20DI)66DG%202E)%JBVRRZ/FF$>4IYV2 M6N5IR;XBF[F++6J2J8HX[>NZ(GDDGQ200E)$BDD)*25EI)Q4D$I21:HMLLNC M)I-'E*>=>TH^W>-OU#)Q.WHT+4DKDD?R20$I)$6DF)204E)&RDD%J215I-HB MNQ9J,CFLA;IJFUVK6T5'?PBU\U*K3BTY9[F9^R'41^EJKM2ZCUU@C^23`E)( MBD@Q*2&EI(R4DPI22:I(M45VZ=1T=%BZGWP(M;-7JSS#"6VS?K]4]T+L`[\B M>22?%)!"4D2*20DI)66DG%202E)%JBVR:Z&FH\-:J&'T=R[DVFFM5:1NIBN? M-6:%;#9WQU`?9<80R%/WK>SJ^J2`%)(B4DQ*2"DI(^6D@E22*E)MD5TW-9L= MUNTG8ZB=_%KE:6FN/ISLU&H&=D3J=L)FI>[F<$WN;GB"5A.01_))`2DD1:28 ME)!24D;*206I)%6DVB*K%M/CYKQ-N#WG[6@F%QZ#4>C<,%V:J'X4DCR23PI( M(2DBQ:2$E)(R4DXJ2"6I(M46V>5QI\&'1^&4L]V.I#SZP"])*Y)'\DD!*21% MI)B4D%)21LI)!:DD5:3:(KL6QTUMIYS::E(7G8.QXMX5'83IFJU&S!LQ?\2" M$0M'+!JQ>,22$4M'+!NQ?,2*$2M'K!JQVC:[7FH.^O:/F6D[91U^S'0T7,XC MK4@>R2<%I)`4D6)20DI)&2DG%:225)%JB^Q:J&GI$;5H9[%6+5IR)DSN[=!I M'V5&#LACE$\*2"$I(L6DA)22,E).*D@EJ2+5%MGE49/*(\K3SD&M\G334K/@ MLU03975);6A%\D@^*2"%I(@4DQ)22LI(.:D@E:2*5%MDU^*XR>N4D]>.G"4Z M]Z:IB3)#I9OBFHIYC/))`2DD1:28E)!24D;*206I)%6DVB*[/&JB>,10:>>5 MUE#!5',Y!:U('LDG!:20%)%B4D)*21DI)Q6DDE21:HOL6APW1YURCMJ1\ZGB MWC\U46:HM+D&EP8>HWQ20`I)$2DF):24E)%R4D$J216IML@NCYI_'S%4VNFZ M-52Z&;Q9X%Y.02N21_))`2DD1:28E)!24D;*206I)%6DVB*K%NHKG4?4H@FW MY_D=V4-E[MXV-5']4"%Y))\4D$)21(I)"2DE9:2<5)!*4D6J+;++<]P\7WT] M4RZMAD.E(Z<\[FU3$V7*T^8:GLD8Y9,"4DB*2#$I(:6DC)23"E))JDBU179Y MCIOZJRLOMSPMV==D<_>V:==0?ICR]`TU>8SR20$I)$6DF)204E)&RDD%J215 MI-HBNSS'S?35&''+T])@$"R[J`&M2![))P6DD!218E)"2DD9*2<5I))4D6J+ M[%JHZ?;;/_35LK%;BW["/E@DF[NW1KN&LB-Z7*Q('LDG!:20%)%B4D)*21DI M)Q6DDE21:HOL\APWTY]QIM_1X,`O22N21_))`2DD1:28E)!24D;*206I)%6D MVB*[%L?-]&>ZH/89V?8Z;ZL\XU=R]RF M+]#DW+FV]DR43N:/)`M,F$DVGSLWY$(3I9-%(\EB$V:2S>;.!#DQ43I9.I(L M,V$'DN4F2BN.N8G2R8J19*4)&R2[<(9$9:)TLKI/-E)>M79PQ+5)N]0P*-O-K*/!W51- M[1,$FC_UU62BO(ZNFR<6--]8\'64:1AH,@U#-HQTE&D8:S(-$S9,=91IF&DR M#7,V+'24:5AJ,@TK-JRM*&NHS8];D&C"[1FO)AE=_4ES?N'.>'64&6@K3<.& MTYG3Z;TNZN*\^1/PR?GUN7M"]G4BDSO0=#!WZ.:6U$[/CG0BDSO6=#!W8N?F M7J^B+N6:L#_@TZES&5'H7"9]J>E@^NI-Z6N32T:\W:/<-93V M[__?7:G]?=C<_7:SE=V6H)'O4,RDR,VH_#SGTDI'ZNYF_[[G%^[<74>9`;'J M2*XP]-G)TW35]*JK:];'9Z)`MS*)0DUMHMG%6!=JWXK<]M,O'^M6)E&BJ4TT MGW&/TBYDD"C3K4RBO*-+N0SJ#]-(]\!.E-)ITTLG5\^=N'Y_B1.#S]S!FW*'7527>S[: M8[IW9_8[?E/NQ,D]YWZG78A\%4WWQNQ-N?,NZG)XR$?Z%7:]?%/ZZDWIZRY* M'BN"KJ:6CH87%6Y7^W7[\E>G';D+W)]WVA6HX<7&O"4UF>^[S/S"70@Q4?JX MKD@>R2<%I)`4D6)20DI)&2DG%:225)%JB^Q/B^/6J>9\'Y7$^#IHWQ20`I)$2DF):24E)%R4D$J216IML@NCUIX&HZJD0_MX>A1 MX<[E84LR>O2!7\Y!*Y)'\DD!*21%I)B4D%)21LI)!:DD5:3:(KL6[CJ5.L/] MO;^$F7,-JR/G+.>MI_?IMO5P_/NY.[K;?U;/T+M1U9,_M@_YN MYI?RI+_F4M'=,ILMU,T$*2JVS&5+\[+824/Y)M+MGD;#.V M1;))WQ_9,KU:J"^?C&VYEBW-I8"[!]/WLJ6YQ'&WS,YEKYOI/[;(VR-%IKY6138Y.>W6/+7)TY#P[EDUJ M*E^3&MDRD6SR%>>Q+9)-_FQK;(MDDS\B&MLB59`_4QG;(L>ZO9S$7LNQEB_5 MC[21PHW635*-5FTBF>2OU$K:9Z^;']4N4?*%6@4>VW(M6\;:R!+Q0JTCLHTL%"_4,O#8EFO9,M9F M-;N4+:/O1K+=C+:1A?W%KK)U^UVKW^1ES[K'Z#[ MZ7\```#__P,`4$L#!!0`!@`(````(0`^9Z=G_@4``/<7```9````>&PO=V]R M:W-H965T,X0D:$*(@)G9_?<]QC;&/MGI9+LWR^:9XQ?\GH-]\.KSU_JLO99M5S67 MM6[-3%TK+T6SKR['M?[7E^C34M>Z/K_L\W-S*=?ZM[+3/V]^_67UUK3/W:DL M>PT4+MU:/_7]U3>,KCB5==[-FFMY@;\_C9'HWNVI;Y?AA4GPW;-!=& MG5<7G2KX[4JKAU7JXN/R-5Y^_QR_50T M]14DGJISU7\;1'6M+OST>&G:_.D,\_YJN7G!M8 M\X/Q8(#29K6O8`;$=JTM#VO]T?(SR].-S6HPZ.^J?.LF_]>Z4_,6M]7^M^I2 M@MN0)Y*!IZ9Y)J'IGB`8;*#1T9"!/UIM7Q[REW/_9_.6E-7QU$.ZYS`C,C%_ M_RTHNP((RT3@RD2LV7(^=Q=+[^-/ M`I'#;.#*1!9W/PB\&8,&7'_\01Z8"%SO?1"#9FA(>)#W^6;5-F\:O$60A.Z: MDW?2\BTH%)YJFIDQ^=_+/22=J#P2F;4.LX.\=E"PKQO76ZZ,5RBR@L5L<8PE M1^QX!*DH(ANH(%1!I()8!8D*4A5D$V"`+:,W4'H_PQLB0[SAL]IR(,RR%2-X M!!\2J"!40:2"6`6)"E(59!,@&>'\'".(#"P%DR*Q/67F6Q8#*1DK::&8,X:, M[B`2(A(A$B.2()(BDDV)9!*L,3^C6H@,O(QPF]$`UWN0+=C2(.<]E\:0T25$ M0D0B1&)$$D121+(ID5R"151RZ?:6PI<5$CV8P2>QI<29VF-[KFS/;@SBPP)$ M0D0B1&)$$D121+(ID>:^N&ON)%J>.R4P=SZM'2(!(B$B$2(Q(@DB*2+9E$@3 M]92)TDUE1O;<_E05S]N&;O\WDN_`YD&W%"(BSY\15\R?$=J###L&)0[L9./K M8SMSN3[",8@;&2$2(Y(@DB*240*]$BA+EI#6&.^S=UI"1&1+&)E8PLC$$DI< M>]B6;=-R%#?&OX]N((T8D60<139[4%46\G3\.U?-IAJ2-]#/2-[<*`OH^7A= MD&C9!$9`7^3<4W*^8T$/8_$$E-ARJ7B*.2S(&LRSW`?3-.6("`G'B"0?N54J MW8K<2+E3-M65#"2-VQT.#N&RA0S-8=V>>*CNO"S*%N468!1R+9*RU\T"3R3" M@V*,$HQ2+KT8LYA)4;(KI*^;OG/OUY5%VT#8>7G%;CF2*TLID1V/FI061Z+I M"QF:PPHA'+:5G2OB`X56C%'"D9!/N;PYF.YYN'KXH$%:-HKT?7<81=M$R2B* MYK)1R@?`SJ)14ODP)$P/>10MGZ6%9A+Q"%&&,48)1T(Z96@.+]+W138X(5*U5%;$G<6B1"4$'`FMD*'W MTQ[Q@4(KQBCA2,BG'+&"=5'!9CSB1D619G%JU`^U2N1L1MD3.9+>R"7ZX&8# M18$$;*`K;`@YHA-TR(JN[('\;D(GQBCA.D(ZY8A*DU5+D. M=K%2[5$DUYZ'O&-18C:!19$KO3:.LE^$/&HY+-7.8HXF';&0R4H98Y1PH7=O ME_(H=CL;+ZB9I"U[#-JCQ[!6J^7YI;G".O6?IT-$16DX*)J\$?0TDAY.U65[ M+'?E^=QI1?-"3AIA]]JL1DR/0;<+'[Y!8,E0>.#YT)K?X$L_'!8Y)3Y9^M"N MXG@X9GVT;_`M.7Z]Q6T?CE"PSM;QX=@`\T?7?Z3'N,H#;5T?OJ#Q@.W&ULK%K;;N,V$'TOT'\P M_!Y;=U^0N(AU%UJ@*+;MLV(KB;"V94A*LOOW'6I(B>0XOFQW'U;QT__9MOQN]%W535H>'L3DQQJ/BL*FVY>'E8?SWE^AN/AXU;7[8YKOJ4#R, MOQ?-^+?5K[_2WV>3.ICL4![CQ7]3YO MX6?],FV.=9%O.Z?];FH9AC?=Y^5AC`S+^AJ.ZOFYW!1!M7G;%X<62>IBE[?P M_,UK>6P$VWYS#=T^K[^^'>\VU?X(%$_EKFR_=Z3CT7ZS3%\.59T_[2#N;Z:3 M;P1W]X/0[\M-7375'\:/YC*SYN/I MZKX3Z)^R^&BDOT?-:_41U^7V]_)0@-K03ZP'GJKJ*S--MPP"YRGQCKH>^+,> M;8OG_&W7_E5])$7Y\MI"=[L0$0MLN?T>%,T&%`6:B>4RIDVU@P>`_T?[DJ4& M*))_>QA;T'"Y;5\?QK8W<6>&;8+YZ*EHVJADE./1YJUIJ_V_:&1R*B2Q.0E< M.,.K%\Y<^-^^@[IN^$V:VICJA:^L&"YRF@#'0AU(-*!6`<2'4AU().`*5"5MXV]=R\W5=85UQHO-M6#QP M26$D:OR(.%+\B+C,Z7UE&::M)D+0WQ>*A02)$/&PK&&K3HR(U$Z"B#D3[6BS M5BIS*$JP6EM>7D]$#,6!")E9JR%S1%Y8H:10H_1[(Q%EP)%%GRDA(I[516!K M#!&_"^M_/^E8C0EIPMU0?ITTO4"JZ`2ESPTZ,6M5)T0L=5J8:3KU1KU. M''$&G1!Q%YU.[L32>CKB]R&V,TH1V@01S^&TMJ9M>H%6T8J5:3>(U9FK:@E( MC6*NR358]7H)2$HL#KDX-HR)-A='_+YW/K=P$HZ!<)32C$,\SV"3OC#D?]IZ'PES MM<.T)(II.PF'>.)!.YI/>HE9U9`5B#=HB/6DHB&'E$`1#CRQ+,FEM;'J;"X+O%8Q2B+]D.K(2L(M3F/0VH^+K1= MES]8#5HBER7G(T*>AX/-GL-664WLB!.Y2M>114(T-W`G'/)PAK@#;K)47.)6 MLY`5E_]?4"Q1H66AR]KDD!+A0M/!'ZR$8R`@.3F1RU.X+#(Y:Y46.%+(WD?RUX*G17L2W6$!>+B'A\+6T4QA+K.5ON(U8:TC\1KD.O? M*V"-R?*C7V\=LFDT>24*(?16VD3G#S9#M_5N`@JI542AF$()A5(*90JD"L9* M2%FP\Y4BE*)D.D!(W1HMM/K%YX[2)B*@4$BAB$(QA1(*I13*%$B5`<;++3(P MN%]*,%J@L M-UD"05=+4[[V(L$75L-S!QSR!N5"#LUP:-J&;=/A$U&JF$()94\%.XY-:[Z` M5-.GS4RA4J4Z77#?FFA]N2T6I[7%(371M!VQ+ZP&N0(.*8F&7#S1[CZ3D+^J%\*O]CMFM&F>F-G(V!OO+KO83RXL?:6\&T#1H"&/YK>\A%/ M=&AWUG"';>ZHS]JLFJ9W MX!#*HW4"7\/AE.Z3A];VVH)#*Z?L[25\^CS![RP?04-Z8^TLX2O@"=Q=PA/W]]?#J\&EQ?'[W>/G^Z_?WE_^3__ M2/^VN+QX?KG]_NGVV^/WX_O+?Q^?+__^X;__Z]V?CT^_/W\]'E\NR,+WY_>7 M7U]>?JRNKY_OOAX?;I^O'G\GA]L7^N?3E^OG'T_'VT^-TL.WZ]%@ M,+M^N+W_?NDMK)[>8N/Q\^?[NV/\>/?'P_'[BS?R=/QV^T+M?_YZ_^.9K3W< MO<77*S)W[1N*?5Y>+Z_)TH=WG^ZI!\[M%T_'S^\O/PY7 MA\7L\OK#N\9!_WM__/.Y\_\7SU\?_\R>[C_5]]^/Y&V*DXO`;X^/OSO1XI-# MI'P-VFD3@=W3Q:?CY]L_OKT<'O_,C_=?OKY0N*?4(]>QU:=_Q\?G._(HF;D: M39VEN\=OU`#Z[\7#O1L:Y)';?[V_'%'%]Y]>OKZ_',^NIO/!>$CB%[\=GU_2 M>V?R\N+NC^>7QX?_\T+#8,H;&0O27]49OT2.K M3:/I+^N-KT:+Z7#Z6HVSH$E_6?---M.W54CSK&DJ_0V*"W'O"=3V6)^.AY#'@WN?[C:Z9O: M.Z0!Y&N5D30T=_FV.GD(N;G"/7UC'O^\H!68XOG\X]:M MY\.5,\;+A&]UNW#\;-V@!<-9^>C,O+\D?5H2GFFQ^^>'R6+\[OJ?M$#=!9D; ME!EJB8@EW&KDS,86)!:D%F06Y!84%I065!;4%JPMV%BPM6!GP=Z"0P=<4WC: M&-'$^2MBY,RX&+%W;QA(T$8F("S!*K$%B06I!9D%N06%!:4%E06U!6L+-A9L M+=A9L+?@T`$J(#2K(2`36B_ZKZT\1YP67475')EHA]\$&1H)[42::9&H%6F# M`B0!D@+)@.1`"B`ED`I(#60-9`-D"V0'9`_DT"4J1K3P0XSR"' M+E%1HP"IJ)V>44ZZ"0X[]<:3<3=-H/*\7Y/=N7VZ"]?[^]^OWGTB5?/Y!C3WLOO MR)P1'8]`)A(/(+$G<_K3+G?CD=FF):T0!S8%D@')@11`RD"DB94GM(VGNI23 M:*_YGSO)&=%.\J1Q->]DQR.[+0IJTLS8D\FHV?J.!D.S]TW:\M9EH:+F!*") M6`8D;[7T419.@\G)ZT]YMD: M.E%;U0I1;6IHNOSZ#-NKXFI*(H4 M.EBDN,8<41'0C*[RG1H7NL92%$4*:JQ$"KSLTJ5NZGIZ`+N3"S."&=$4Z;1S MJ=L9B13W.4:4!#2E]4ILCT0R[5HW1L%JE(I%@Q1I0$1*/4K77@MYZ:8*QD:#9'5`1$ MH[.GIE(4Q-%04R52,"I=0G*&5YVXF?L>X8+MSK*4Z5\]J_&[;Y/3F,7EIJF- MTM5328W(2&B[6_OFNI:@5(HH0Y0C*A"5B"I$-:(UH@VB+:(=HCVB@T)ZYKDM M]QECQ._0UT0[1$=%-+A<1OS,\+C]_$J/-VM?3,)(GT0'A70LW/[_C%B$=*%[D0I(ML21.VUWBVYG_Q[05&VXQF9- M3$2*U[L4488H1U0@*A%5B.J`.JU?BY1..D;(U,>W: MBQ3;.C#"Z+O#@#.BWXCKS6]`/(7FLV(L6VMHRDCSM&R_:RN$=T8-03U_-. M!49X*A"0BJN74G$-2-J9!,6%H)21=#`+R`31[`YRD6)G%6BK9"0U5HAJ1M*( M-:/%3\Y[-R+`]6\9B9D=(ZE_C^C`J"=8YQTVN(,:M^_M7&T#4L'R4BI8`4D[ MDZ"H@@6*69`RP3*S)!R[`;;AA)IA(ABA$E`2V:9P2;##1%J0Q1CHH%2I6(*E2L M46J-:(.*6Y3:(=JCXD%)J8VI>^#PG*T)GKDT%MY?SM0-CZG9+4=!BG;(',08 M41+0=.#7C_%\,AT:2RFJ98ARMC1O+"VNAF;G4J!.*4BN72.;+E;:\N!J:2ZZ MM9CAKJX1;=B,[^IP/%E.YV8!V*+:3M")-N[9N._]X,H^+S$B!)$*:(,48ZH0%0BJA#5 MB-:(-HBVB':(]H@."NE`GG?Z,<;3CX#TG=FIF1>12$EXO*W.S=H$I5)$&:(< M48&H1%0AJA&M$6T0;1'M$.T1'132X7$G#-UY=CJA=D&P4]BCCI>C(-5!,:($ M48HH0Y0C*A"5B"I$-:(UH@VB+:(=HCVB@T(Z%K2`GQ,+)VZ64X^FOQS)RI)R+%$RIE)`4R,[9W?G)6%/,%HI)1CQO.2[#'F&`'I-S@ MI90;`I)V)D%1N0$4,Y'JN,'>K<J*;FY\$Q0Y*`^HH9B+5\8Z]P9&+%)LO$)7*O%Y%7/;37='M9NU-S[J/G14S MA3S2:??,Y,L1*\K8B0-:RLEI$M`DG-:-EI,YG-:AI8PMT::NS23@F"T7*?%@ M:'MXFIQ^$*HWZ*6J3/O391.G_/G&S6](2B2'NQE[I$^[9N8,*`I2G00W#F@I MRWS"R/U:@4Z[QO/QT!R;I6@H"XA:P)[*$16,PH.D5S-PGN^(;Z)R'@58.^_T M]J(1UZ,N(#/JS,%IQ(K2D5@4N6])0.J)XM'(]"9%6QG:RA$5;S)?*O/:6?TY MSYF_4IFT&0_W^R8@,]!,OZ,@U1UH`2T["7A`M/ZX@?:WX6BX6-J1AI:R@+HC M#5'!R(\T>L^`2=1*95D[S^89O[3LT<]-[+(7D!F`ILL1*W8'H+?57?:"%`V! M9I;VGEZ@I:RO";CLB10'O@BH/9:TYQ*EJDS[TR8&C3_I?16T]+I?3/&J]_:? M3TTP=PB(AIRLY^.9.9B(1(H[%@>TE,.;A%$XW^@[/$G14A:0FAL]OO5M[PS? M@A7]6*5S6=/L4E6F?6LW^LZWH[E,]%]P+B8#[F#97<+ITM=>+,L5E9X,3I);A[OQX.I@MS!E7BI:R@-3NV MXO_Y]=K]^-QL@`+"PRJZ>]!7Y=F'58V=YO(G$9M8/]\$*7?DTL;5C+U(9-BE M,:($48HH0Y0C*A"5B"I$-:(UH@VB+:(=HCVB@T)Z[-C,XI7M"J80$X]K<9B92$IU5DE*!4BBA#E",J$)6(*D0UHC6B#:(MHAVB/:*#0CH\;A?? MG=JOA,=O^KNW(B8>47C8RQ&B&%&"*$64(G@W*0MF4A)![NV=`?_DBR!#HCLWB"@3B+ MVYJ@5"I2W7Z;C",3*;:5*UNZWV[_^O:5T\TVL_EAI':3<[OO$"EN5!S0K'M% MA*0[0<4T(/?`='LIA,VGV=X)FRJ96K>3#W22=%HZ]NSY0RYF M*$C:3VX[V5T\K)\XD7]E5CDS9J/@$>::[J43/56>G6LV=B#7-./S)DB=S#5% M1L:PW]J1&J,$I5)$&:(<48&H1%0AJA&M$6T0;1'M$.T1'1128\<=BJA`GAXC MC;@>(P'I7-,^0QJ)%,Q42K;"=V]<1HAA1@BA%E"'*$16(2D05HAK1&M$& MT1;1#M$>T4$A'8OS,@FW[3>7MH#CH-CQ%)!7453=*8B10KYH(ZBE-SC%J(%"N6B"I!'5OV$=!:I-C6&M$&T1;13B$= M1)MNV0WCF](-]\XJ&UN/.B<+49!2@02I!*72@#JV,I3*4:I`5*)B)5+=>)B$ ML18IB0>T?H-26T2[@+PG=#S^DO1OAND?HX$<]43,Y&YZS&C0V2DS$[&44<=: MQDS$P" MZGGSR3@4E3$Q:1-#5E%+0F MH\7`K*\9BXA6+DAF!)QT%4&*!K-S[>#*&"[%"G>B"HB.T!C5C'RW%HO!;#HW M*_D:+6U832QM&9VPM%.6],RSJ?,KH<44>>:1/F%9FB!%(L4NB`,:#OS[ZBBP M0[/Z)*B56JWA`FXFH%8NZ&1H?5?HNM',FA'&MNTK]Z(2RXQJ1N%`<3P;F8&^ M9@G90FT0;1G]U,Z.)1H[.J[V?.*5N/J3`I4W!41=EOWATASI1?0SI^8:*-,H M9L23;S"SKW=-6$2T4D:L-9K81S(S%A&M7)`TLF?*^D;^?,I")RHQ+&'U4N&@ M=$0'I8NA.1)6/S2YJ6QH@\R`C(SV5PY M(I%BS\1LJYW)&''42JU6SR*-6KF@4Q$/4F$FXR(M5K@354#TO#.CFE%XW&:^ MH(_1V(BCI0VKB:4MHQ.6=LJ2CK@]!/FUB./9R#P@F5$1HAA1@B@-B"89^R]# MJ1Q1@8HE2E4!T4.P;+X.*!Q&T^_TZ&,_2W,)6:.I#9K:&E.3V7RYM+ML!]!Q/3`)JMHBZ2GL`X*L\^P!Z[K-YJKE=Y2=V,;H)0B?/GT6& M`Q0C2A"EB#)$.:("48FH0E0C6B/:(-HBVB':(SHHI.-HSQ-<'%__Y,K<'R)T M#V\F"[,5O6$AFN5M<$W6'XF,A"W8EE0E0:D4488H1U0@*A%5B&I$:T0;1%M$ M.T1[1`>%=-A<$MP]E_[5Z>>3:=IX28@F"[-?O'%O[:>3AM/SKY610`)*Q!)+ MI8@R1#FB`E&)J$)4(UHCVB#:(MHAVB,Z**0#:8\>3F^4YWC&$)"^_V,?QH]$ MBAT?(TH0I8@R1#FB`E&)J$)4(UHCVB#:(MHAVB,Z**3#<][1@_N^ASF2"ZC[ MK"&B&%&"*$64(F(\4Q+F8FUC)&Q9K;W>4>,K17,Q%K)R%@S MF]&J(\;6:F8]6SR7<';]_^:==-!>\Q<72*1XD;%`75.K!)& M)\Z94K24L9J<6.6,O*4)_>9P:=Q>H*&2M<10Q<@;6HZFX_GQ;M7@V>STM1,4.4,_('1W\;3T<#^W:6 M@F5DM)2(*D8G+-4L@X=0]"ZBCHF2K=)3^<7KAH#,DH`H>W:GJKU'W2E:RM!2 M'I#[\_-(%6BK1%M50*=:52M+VL,J^W[=PS[)[AZO+CQR3[ZT?9D,S&")@E3W MI8N(DH#<`W*MK9ZU(S1"!EZ&MO(WV2I0L414O8%30(>RW%`G4/")"!W]^R4\\%6AK;R-]DJ@E2G727: MJMYDJU:VM/-=\MCN/G[9^3X%5<[WR(Q\<_,K6@1%&:UQ0)TCP"2@\$O>GZPM M8"E#2SG7-S@YB0H6DV:5:*P*Z%2S:F5)>UZEI#V>?]MIX@)3U8`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`O65+*FD+S[T!9*5^[Y(C\YH2"5]\:&O M(U!)7WSHQ?Q4TMMW&>1^DJ65-+7:OH&R\I]8:5'AUKM M/LC15S*BDKY6TW<(J*2O;?3-J%716T*?CEJY#T-A/?19(2KI:S5]A6;EOC'3 MHT.M=I\DZ2L944E?J^FS"U32U^J8XN.^V8'68M)Q'XC`$OK2UBKM+:$/;JW< MY[10AS[&1"5]/:5O]ZS_;C]WXF7:[](M%2A6>[K^X--/_ MXR6\4?>WQY>7QP?:$%,.>KS]='QR`B3\^?'QA?]!55__^?CT>[.C_O#_`@`` M`/__`P!02P,$%``&``@````A`,''%E-Z!P``PB```!D```!X;"]W;W)K&ULK)K;DZ)&%,;?4Y7_P?(]*H**U,QLC1>\WZA-\LPH MCM2J6,#L[/[W.4U?@/Y7[WPT?4XWW1OMPO/[<_7/K^X?=K62I/YYYQ^C<_!<_1DDU2\OO__V]!G%WY)#$*05 MCW9'H*3G]2B2W"F_[./XI.?TI_Q>SVYQ(&_RX).QWJST6C7 M3WYXKG(')[['(]KOPVTPB+8?I^"<`S3GYEIM7+:.I/W%W)3E$GZ,X MW,W#GBNFNU:J],P M#9)7WH(D=4-F6:UL/Y(T.OW-18:PXB9-84)786+8-;O5LMIVAUQN1)HBDJXB MLEMKVBVCU6:WOQ%HB4"ZREO>=T>RS1Z8KB*P\+PW;M@6<71]K*4=$4C7QUI* M0S1K*5T?:FE7Q-'UL98:5'V\&%@9BD3?UZN&JB/Z\5!K#5D\[,>#[9758^3E MTZQUC$;7_)>RHQ$IGC2OG^9]A<<&%^^DO(+NK%E#UA#[(1[5NJ^]LHB,O(JH MY3?*U9#5PW[?09,-<7IG-E2.:.S\'SEB-BQ'LG=[ M$N1):Y93UI<*&3+0P5`'K@Y&.ACK8**#J0YF.ICK8*&#I0Y6.ECK8*,#KP!* M":$9"1)BTK1Z_;TLQPB+HC=P<8PTV^4.[PD-58(:2)JDKR0J*4"&0%P@(R!C M(!,@4R`S(',@"R!+("L@:R`;(%Z1E')$,RCDB$WO#TYLS(;F1KJ-2HAE:<.D MQT7FK:PIB)V8Y769YD/652(8-@`R!N$!&0,9`)D"F0&9`YD`60)9`5D#6 M0#9`O"(IY8+6,0_D@JG+N>"$R`+($ ML@*R!K(!XA5)J>-I&?A`QS-UN>,YZ73SCA<:6LC+7`PXZM(^HC"Q6>61,E0B M&>8"&0$9`YD`F0*9`9D#60!9`ED!60/9`/$XX7U62@:M:1](!E.7DR$(;8!D M'_8ERD?&@*-2-HQ&0\N&$DDG%YU&2E3,:ZOL-%8BZ31!IZD2Y4ZFU2T[S91( M.LW1::%$-YR62B2=5NBT5J+1)IRP)I?12_3^07J8NIU>08GHE M*J27(TJO;-$0B(MA(R4J/JVV'APKD?2>H--4B8I.'2V72B2=YNBT4**BDUUV M6BJ1=%JATUJ)"DXMK>8W2B2=/.F$N61''`\D,Y.7LRE1=J:7;4'[$O'S-;XK M9?>AP%PU%"H[.\_+`ET,'$F4!XXQ<")5^1VG$N6!,PR<2U4>N)`H#UQBX$JJ M\L"U1'G@!@.]DJHTKMB9T2.YX'M?6F?+//`]UKW)6JOKB33*O:<2W?2>E;VQ MU7-IDSLO)+KIO!2J-BT(58[D7%4*YHMAN'(^J M:NPT,#V$VV^]B)I-Y7!ESV!2DL5!%=_3EPJ-HV9IT]#2]GA]=H))@[Z9#XB! M0&9;%>U0HDY651T;\^.BT4A&Y49CB;B1V;I60M"BJ8S*C682<2/+Q!;-A:3P M:`L9E1LM!6K32NE6>4"CUNBUNV>"TFA3Q9W>2^%JEWL\BO3#C1]?9?]YBY[3ZCH90.EQLXJ;I7:U^CRJVF' M/G.I>8=!]\A<<1]F$PFT?>:#IUVHD_/=.B(#?FKY;SR]8]^`\NATQT, MZ+4<.FFXPML.;821SVV'5I_(%[9#.X4KO.O0JA/YRG9H[8E\;3NT3[C"NPZM M.9$/.@[M&I'W;*=W3=^WG?XU/K`=6ONCCVL[M`-`/K(=VJU=X5V'5O[()[9# MZW_D4]NAO=H5WG5FF;ZN$DE?D"_^>[#PX_?PG%2.P9Z*KY&]9V/^#9K_D8K" M?XM2^G:/D'``#__P,`4$L#!!0` M!@`(````(0"J8=?)C@(``*$&```9````>&PO=V]R:W-H965TJ*L'X@V)[R3L;2#1OJ07_32-Z\\8FV1@Z M2?5NW]\P)7N@V(I6V!=/BI%D^6/=*4VW+<3]G&24O7'[PP6]%$PKHRH;`1T) MCE[&O"`+`DRK92D@`I=VI'E5X'62W]]BLEKZ_/P6_&!.WI%IU.&S%N57T7%( M-I3)%6"KU,Y!'TMG@LODXO;&%^"[1B6OZ+ZU/]3A"Q=U8Z':4PC(Q967+P_< M,$@HT$3IU#$QU8(#\$12N,Z`A-#G`J<@+$K;%'@RBZ;S>)(`'&VYL1OA*#%B M>V.5_!-`B7)`?BZ[Z`$PZ[=N`"0SN"C('\ M/:VR-%Z2)PB:O6+N`P:>`R89$`1$!V50&Z_LP$[99<6Y`&1\H`X,M3B7/H86I`-HA#3TQ7AI M!_;20Y*#9;XXB3%+)]>CG/V/E`.?2[U:4M^LIVTR/^?U0Y-!W=\OH+MU+O!J M@;X9&C-+L^NQN(4[>B@<^%PJ6+)C*&$EA+F37-?\$V];@YC:NW%/89(&Z[") MUCX5_]JS?.V'@`P?8$/TM.;?J*Y%9U#+*Z",HSG43H<=$PY6]>`E[`EE83?X MUP9^!1R&*8X`7"EEWPYNBPT_E]5?````__\#`%!+`P04``8`"````"$`];"P M@78&```(&P``&0```'AL+W=O5JH_&JI)?LG)?7)Y6ZC]?O$]S5:F;]+)/ M3^4E7ZG?\EK]O/[SC^5;63W7QSQO%%"XU"OUV#176]/J[)B?TWI47O,+_'(H MJW/:P-?J2:NO59[NVT;GDV:,QU/MG!87E2K8U4/5W**GT\P;B_ MZI,T8]KM%R1_+K*JK,M#,P(YC784CWFA+3106B_W!8R`V*Y4^6&E/NAVHD]5 M;;UL#?JWR-_JP?]*?2S?_*K8Q\4E![X*@L89:>VT&_JJ4 M?7Y(7T[-W^5;D!=/QP;2;<&(R,#L_3B,Q*!9>@0FJH_=?U9#9;:J]0KUD7L\$QNABQ91&D.(FL(P-7 M!IX,?!D$,MC)()1!)(-8!LD`:.`DMQ-2\SOL)#+$3F;$AH'>7T/RCD6P)HX, M7!EX,O!E$,A@)X-0!I$,8ADD`R!X!]6'O#-A&;R]@+'*(ZU@J1I4GC%9B-YL MNAA(&B_/J1BRY2'MSR$>XN(BXB'B(](@,@.D1"1")$8D61(!&_!1J%* MWZ].$MU:R(:^H<043+7DA9`'L68.(BXB'B(^(@$B.T1"1")$8D22(1$DT MQR)[WI1TUW6CT$RXT]+[+Q$17>O(I'<-$8<2R^`Q+B(>:N530E;FP;(P$9>% M@`>QI.T0"1&)$(D122C1VX$)1I*##-[*W&DD$1&-[,C`2$0<2BQQ4DMW:)<' M,4L\).13,C':+90QUDW)5OX[T]@AC1"1B+2";? MJ$K8Z+.R)-&BFQT!_;YX+&F46Q[$^N,@XG(R%)*JT.-!3,BGQ!"*UY1VJD$7 MI+=9L!:+\7@LYF&'A$-$HH]<*NZ":,*G8S@S2Y=*AL)"*G08A%#P[^>B#1>3 MT2%#K%M+'.NVCV(N.ABY/1HF1-IF>7T4T_(Q"A@BA?2Z-F?(E!V+Z&\*(481 M1C%#T^]))RRBE18-)[O^X0KS`\/I(0'V3VRL&W(4)!-"+'^I_+9]%&OH8.3V M:&BXM#WS^BBFY6,4=,@:=Q5_PW#>R,Y+TNK4(>DPI>.#=L^BHW9PWT4T_([9+;/A-K;>,#0C%;G MC84'ZX0814RGEXX9FG]/.A%TQ#S``O$;\D!4I`6H0\)\F,J[87("H;.&>>=@ MY&+D8>0S!,%F3E!1;IC,?V9/,0H8FB@'G-&DSJ[L9PE+*95%ZTG M!Y%?GP+T.`.788/>P`:*F"I.@:FT,]CV4:RA@Y&+D8>1WR$=5C\F%G"V:,MR M9MQ:ZWE/6;,0JT=/&8/;/;F1S`P=)381I$3KR8GFUZVGYR+!^@X-JWZ" MG.=!;-0..<*+\\#%R,/([Y`)6XE^UX5V/5W4I#,+6;7#RB%&T88KZ45UAG?O3D"![&H_6(HL'9@CYNIX],SWGUE&_STZE6 MLO*%/$J'K*Z7'-/G_)N)#4\/(&DRMVPX(]_@4QL.AY@[,QN.8YC[,QM.19@[ M9)63\6E5D[Y`WBK[)H%^:+K&/90-O(-H<'^&- M4P[/BL&PO=V]R:W-H965TTV)DZ`"CH`V[;_?,38$>[)'Z=G>E.;) M^(5Y9XSMK+Z]EX7V1NHFI]5:MR:FKI$JH_N\.J[UO[X'#PM=:]JTVJ<%K9:5S!:^^1X,>#GE&MC1[+4G5X#DB_S MK*8-/;03D#/X@^*8EEZ\9FU1GT=TXNS>A_ MK3G12UCG^]_RBH#;4"=6@6=*7UAHO&<(!AMH=-!5X(]:VY-#^EJT?])+1/+C MJ85R3R$CEIBW_]B2)@-'069B3YE21@MX`/BKE3EK#7`D?>^NEWS?GM:ZO=2U M9]*T09T(7#_Y'`:O3%?H;=JF MFU5-+QK,'JA!=-GY??@:I:M&-%']$.V*MBI(%!!J()(!;$*DA&0C'"^Q@@FL];A[]`DMJ-D M[HL8*,D0-%/,&4(&=Q#9(1(@$B(2(1(CDHR)9!*\8;ZB6Y@,3$:XS6"`.W=E M"WP>Y/S(I2%D<`F1'2(!(B$B$2(Q(LF82"[!*U1RZ?92TK]66'1G1I^$SXDS MML=V%'N>AJ!^V!:1'2(!(B$B$2(Q(LF82+G//I4[BY9SYP1R[]-Z0F2+R`Z1 M`)$0D0B1&)%D3*1$YTJB?%&9L!6W/>79BT^AMZ%Y;Q3?@<6#+RE,1,Y?$/>: MOR!\[]&M&)PXL)(-T\=VIO+TV0U!O9$!(B$B$2(Q(@DGL$<"9]5D MK"%Y`]L9R9L;;0$[K;XO6+1L@B"@/ZJYNFJ(H.70/%M.;+E5YDJKB""K,V]J MSTW3E",")!PB$MUSJU@$\3I-%Q:Z53(6EAQD.S?)PI^:<9V*;*U`MOR^7<@6 M//51US;<"N3,!K]W/9IW7CXXLRG*,,!*(491KW05CWNTX.+V;(G$$TE)]H]M M`?_W]+28BN*?0')O+E7_1-2H.866`R4?-;7:G2+*-;NLK1FJZC]^2GVCY M0:[`=QSJ^X\$6%/-'UWOD/P6H-W`]V(WA`?[4 M@YT*<&,8`$?W0$CR.$" M``!Q"```&0```'AL+W=OZD>=,FY(<#0Z(26QK2Q[^NTY#73GFQY`U]RJ6IF8*D*7[>*L\QNJBM_$@1S MOV:BH8XA5F,X9)Z+E-_(=%?SQC@2Q2MFP']=BE8?V.IT#%W-U,.NO4AEW0+% M5E3"/%M22NHTOBL:J=BV@KB?PHBE!VZ[.*&O1:JDEKGQ@,YWCI[&O/27/C"M M5YF`"##M1/$\H9LPO@XGU%^O;(+^"+[71[^)+N7^JQ+9=]%PR#;4"2NPE?(! MH7<9FF"S?[+[UE;@AR(9S]FN,C_E_AL716F@W#.("`.+L^<;KE/(*-!XDQDR MI;("!^!):H&M`1EA3_:]%YDI$SJ=4[+EVMP*I*(DW6DCZ[_N8]A1N,V3;C.\ M^\W>;!%,0]!ZA\1WCMBX;IAAZY62>P+-`I*Z9=AZ80S$YP.!"!"[07!"H9G! M5PW9?UQ'L_G*?X2,I1WFVF'@V6/"'N&#:*\,:N.5$8S*F%)TY=H9CF4FYV6F M'Y%!,-3DR/EHMNAYG;+#1$>8EQ0,`@3(^``1##482K\0.VD'&B$-_3!>&L%6 MND]N9X'CT11A$"?T[7@K!0ZG.8L_L@'2G66TVB6'^%%\)"WLPP*,@_.AQ`":GP,%CT4.YA. MHPCQ`MH7>6N#+ZZO+]O+>UFC.ZZ-4$V&HR#$B#=, MY:(I,_SKY\W%!XR,I4U.:]7P##]P@R]W[]]M3TK?FHISBX"A,1FNK&U30@RK MN*0F4"UOX$NAM*067G5)3*LYS;M%LB9Q&*Z(I*+!GB'5;02:IOC^T%4[(%BH.HA7WH2#&2+/U2-DK30PV^[Z.$ MLD?N[N4%O11,*Z,*&P`=\8F^]+PA&P),NVTNP($K.]*\R/`^2J^B$)/=MBO0 M;\%/9O2,3*5.G[3(OXJ&0[5AG]P.')2Z==`ON0O!8O)B]4VW`]\URGE!C[7] MH4Z?N2@K"]N]!$?.6)H_7'/#H*)`$\1+Q\14#0G`%4GA6@,J0N^[^TGDMLIP MO`Z6ZW`1`1P=N+$WPE%BQ([&*OG'@Z*>RI/$/0G<>Y+%:BX)\0EU_JZII;NM M5B<$30.2IJ6N!:,4B,\;`B<.NW?@#$-30ZX&=N%NEZSB+;F#RK$><^4QDXPP MJP$Q40;(?(,.#'LPE7ZRY*4]:(8T--5\:0?NI(?B]A$X)J,Z).==KMXBYS9Q\&!IUI]Y(P;4!\3 M.S=)N`G`_NM'SJV;:O219W[^T8,P%">ZKXMUZ*E:'TJ>MLQ6_\\GJ1[/[3)\`6&9DM+_HWJ4C0&U;P`SC!80T=J M/W;]BU4MY`FC4UD8E]UC!;]'#J,A#`!<*&4?7T"9##_6I>X00``'T2```9````>&PO=V]R:W-H965T&;`VVJK(./S=%JSPW)]GVCJK2^U%3:/*_?18 MTR9[*"'O%]O+RNYO>DE(<3QU4.X99,02\_>O(6ES6TA`[`_T95 ML*$!CF0O_?-2[+O3VG3GD]EBZMH0;CR0MHL*)FD:^5/;T>H?'F0/4ES$&43@ M*43'ZT M(Q:O45_R,.NRS:JA%P/F$52A/6=L5MK^G6F(6O/*R.K_K/A0=29RSU36)O0+ MZMK"B'W>>(O9RGJ&498/,0&.L=6(K8A@0XK)ACK8Z2#20:R#1`?I"%A@@G0" M1MHG.,%4F!,BAT"`JS6.EK:($$U"'>QT$.D@UD&B@W0$E+3=3TF;J<`\'PT` MQ]/*&PPQX+\<)7/-"ADBO4!DATB$2(Q(@D@Z)HHCL%A\PD!@*C"IX%=DMMY" MRS?@0>Y;EL@0:0DB.T0B1&)$$D32,5$L@:5O;,GMG4`L!BRXSUST..#$'7OA M>*Y6>QDDFH6([!")$(D121!)QT1)=/Z11%FPFB@GD*C(88M(B,@.D0B1&)$$ MD71,E*Q@UQF7CR_R$[:/=JN7?>('-L4GCI3QY&G=VMHRZ&H3 M1QZLC]=YBR;@T-!;]B,#[FHHY0AKQZ+5F]J)B+KCVM,[I)TJVJJ=[*3VAIW? MZ!GFW7]>49B*-C\YZJO.?Y'?B?D%J2+-D6Q)6;9&3I_8?1LUGBX\&&'NL&7/BSZF,=+'Q9RS.&R?^_#R?\Z.Y,^L.19U:Y3D`&9-^_VUX:\/ M^(=N*-0#[>#:W]?L!*]Y"%SUIA,XC!PH[<0']@/RQ='F7P```/__`P!02P,$ M%``&``@````A`/^W8UT%&0``+Y<``!D```!X;"]W;W)K&ULK)U=;]NXMH;O#W#^0Y#[W41V$L=!VXW8^L8YP,'!^;C.I&X;3!,7 M26:Z][_?+R5*XN+#<2JC-Y/IPT5:ZR5%O:)LZOW?__'X[>3/W?/+P_[IPVGV M[OST9/=TO__T\/3EP^G__D_YM^O3DY?7NZ=/=]_V3[L/I__.__]O[ M'_OGWU^^[G:O)VKAZ>7#Z=?7U^\W9VW7WJ*CU^.UN[Q[OGW/[[_[7[_^%U-_/;P[>'UGUVCIR>/ M]S?-EZ?]\]UOWY3W/[*+N_NA[>X?:/[QX?YY_[+__/I.S9WU!\JQ^O`3_?_+R=?^C>G[X]!\/ M3SO)K8YR7?#;?O^["VT^.:3*9ZA==EWP7\\GGW:?[_[X]OK?^Q_U[N'+UU?U M]Z52/CT^O7# MZ?+JW>7J?)DI_.2WW":/#VY_^/E=?_X_WU0YIOJ&UGX1O0WTOD.?N99WT==E^=WKW'&U>G_VIX;9O8_9,":S$=LAPHTI MUVP>@R(&90RJ&-0Q:&+0!N!,LHS::.S]"FU<,TZ;(:O-`":Q%I$00\10)8]! M$8,R!E4,ZA@T,6@#8(30.?4KA'#-:#((!DFVBH;`QL>H2\:1=!6),X:,ZH`4 M("5(!5*#-"!M2(Q(FG!^A4BN&9V,^IA1@&QU8278]$'+0RJ-(:-*(`5("5*! MU"`-2!L2HY*F4J-2^J(R3"LNNA-C2&+3DZ5&ZE_+LQV#AFHY2`%2@E0@-4@# MTH;$Y*X+Q8S<7;3-O2?+Y3B3;$%RD`*D!*E`:I`&I`V)270U*U$7;1/MB1(- M._G2G@/;,6CL9)`"I`2I0&J0!J0-B#P@GIX@+MHFWM/PDX&R4$*D!*D M`JE!&I`V)"91N989B;IHFVA/HDZ.Y_HQ:.QDD`*D!*E`:I`&I`V)R=TYI1G) M=^$V>X\NW+ELFW9N)!Q`QSJRWM5$%Q)XLC[JX)4D&V/&3B`JB$JBBJ@F:HA: M@ZQ@SK6$@AT^X[+>Y$B7(9N-1]%%)9)J.T4-%7.B@J@DJHAJHH:H-N/LZ,V+D:%'B9G*7?_#IH^=J7H?X;IYU/GB*M)YDWFWH2<9T`%44E4 M$=5$#5%KD)7!68H9,O0.Q,@0FI)NI6";`>5$!5%)5!'51`U1:Y#-V5F),&=W MKBPNWQTQ4?6FQ,@Q^I3IU,BNS^-1,49-HP*HR(!*HHJH)FJ(6H.,0HMYEJH+ MMY;*H^!BM27*B0JBDJ@BJHD:HM8@F[-S5O&H..[ZM>A-6C@L/+(.^SI:<-E. M4>.P("J(2J**J"9JB%J#K$3SW-V"[LZC97T=4X[VC$?Z-I&J:N!?G0<,#U40'*&540E40544W4$+4&63E33NYJ M^6YZ\/'3/GHQFKEAX&P\BN:A971YFJ*&BCE10502540U44/4&F0E<@8J/"?? M&!:]WS(GGK=@TQW&=@&4$Q5$)5%%5!,U1*U!-N?8J!UM6A;TQ2<9;J@I;* MHW"B(LJ)"J*2J"*JB1JBUB";<\I272JSF5_`NZ"?\LA.4^MX67B*FL;$:,0& M5#"J)*J(:J*&J#7(ZC//3UW03WG$:>KB%_FIKIW83RVCVYF-CSKHIZ:80?B< MJ"`JB2JBFJ@A:@VR?3'/3UW03WEDIZE8JNT4-'6$WGD[@^GF[=U_*1CBAJ4R8D*HI*H M(JJ)&J+6("O#/$_DG$.TGN`11]5ERGJX'WK,M!Y=._'U;QVM[V]\U,'KWQ0S M]87W(L%Z`J-*HHJH)FJ(6H-L7\SS(I?T(A[9ZU\LU7:*FF3HVPJO?XPJB2JB MFJ@A:@VR,L2^Z?!L=-FO"(6SD4?A]8\H)RJ(2J**J"9JB%J#;,ZQ]3EZ/>&2 MKLBCZ/(7/PJ9HJ91X5W1]$BI8%1)5!'51`U1:Y!5:)XKNJ0K\B@Q4:7,QS$3 MU>@\P@M";-0O^ZC#$]48,_4%4#&U-$251!513=00M0;9OIAG12YI13R*)JI( MJNT4-228$Q5$)5%%5!,U1*U!5H9YMNF2MLDC,U'U40'*&540E40544W4$+4& MF9ROYMFF+MS:)H^BV2A^##-%C5U/5!"51!513=00M099&>;9IBO:)H\X&UW] M(MO4M0/;%#U;V/BH@[/1%#/U!6T3HTJBBJ@F:HA:@VQ?S+--5[1-'D6S4235 M=HJ:9*!M8E1)5!'51`U1:Y"589YMNJ)M\BB8>K9$.5%!5!)51#510]0:9'-. MV:;COEAT1=_D4313Q<]AIJAI6-`W,:HDJHAJHH:H-928J9PE M"9<-CGP.<]5;&_L<9AT]7-CXJ,,S%4Q2/E4;NJ<@*HDJHIJH(6H-LGTQSS== MT3=Y%,U4D53;*6K(.2B;/`IG(Z*>.&Q6CHQLZ=[/RUDQG_OBT9'$> MK>)OIZBA8DY4$)5$%5%-U!"U!EF%YAFX%0V<1V:NZ*,"E#.J("J)*J*:J"%J M#;(YQV[-N?PCOD&RHHWSR,P4%U>QFYVBIC'1MQ6<6P6C2J**J"9JB%J#C#[7 M\YQ=%VZ=G4>T-->Q6SKR!JMK!Y8F6FW=^*B#EF:*&?N"J"`JB2JBFJ@A:@VR M?1%[P,./CJY[-Q8^.O(HLC215-LI:I+!.[O@&R2,*HDJHIJH(6H-LC+,):8IYT=^P3.R=>]K MS#.R11:O2ONHP],4'%(^51NZIR`JB2JBFJ@A:@VR?3'/-*UIFCRRTU0LU7:* M&G+.B0JBDJ@BJHD:HM8@*\,\T[2F:?+(3%-]5(!R1A5$)5%%5!,U1*U!-N?8 M-+EIZK@?`:QIJ#R*9JIX67J*FH8%#16C2J**J"9JB%J#C$39^3Q'U<=;2S4P M3E;9^2\R57U#L:O*HM7>S1!V<+X*@L8N2;`BP:V#!E*7T M^[B`Y0FF`8$XI0^F],&4/IC2!U/Z(8O2_T6N*SNG[1I8-)O%W^D.PH*10N>5 MB)-4B)-48)(*3%*!2:J015+-,V#9.1W8P%*SVB_R8-EYTH1%B\.:U4:'-=VZ MQ\N(05#0,V/%@6D0@ZEGP-0S8.H9,/4,F'HF9%'/S+-CV3G]V,"B62V23:=U M7U5A0_8ZK<&D")@4`9,B8%($3(J`29&018K,< MT@=3^F!*'TSI@RG]D$7IITS:40^)]>H;?'=@8-&\QK,'GDQC!4QB@4DL,(D% M)K'`)!:8Q`J9%6ON/NZIC=P],V.%+,_(M&>Z/&BM^?/7Q4EPU[MNL2/*V.9_'J>!`VS2M3U8%)+'>TL5A@ M$@M,8H%)+#")%;)(+&>DPI6"PTO&F=^JW2KBS=CT@ZWM$!>,'XT5Q"E],(T5 M,*4/IO3!E#Z8T@]9E+XS4F'Z[N9OI1=[S?Z]:.862:+O)`TLFE?BY?0@;!@7 M$BNT>-T&KQ(+3&*!22PPB04FL<`D5L@BL9R5"L5Z:ZSTUDLM#FEM,K^G>\(O MN9^^F=:/?-"7=0WA+C!:,-:1]&[N\%W@%#2DH)X9*PY,/0.FG@%3SX"I9\#4 M,V#JF9!%/>.LU)R>Z:V7[1EOQW2R!/-:))M.[#%LR%Z*@$D1,"D")D7`I`B8 M%`&3(B&+%'%6:HXBO?6RBG@[-HU?I0^F],&4/IC2!U/Z8$H?3.F#*?V01>D[ M*Q6F?_RB5N;W?[?2C%8M&"R+>`%^J&JO`F/580!)+3"I!2:UP*06F-0"DUHA MB]1R7BI4ZZV)K?=>5A'OQZ;["`T6,`T6,*4/IO3!E#Z8T@=3^F!*/V0V_6XK M]S#]?N;M-DI^_?IP__MFKQE!'B(ARU*O1>RN3K>9WQ'>J#*P;K[W[S086/^6 MS?Z-B)YI8U+WED5]FSM:?=(;:+SAZ][RV;6D5]#T3!/C,)3T#AHPO81FK.M; MC]9?]4Z:,6)H22^E"5N*%'.&*E0LH8PVIIZDZ0V8E<8S#:1;TIS7S8-.JDV5@UT,PSUU-_?LR6 MU]>KRW7DSB0:6I-H8!(-GR#1/+OJ/T&O#UVOX[=#2K6PM4@U9\?FJ-;;-ZM: MS]R6V(%JT1DFU7Q5,]+`--)\<]==3JO+B\MHWI=DJ";)P"09F"3SS6N^"HZ6 M(RVL&FDVTZYUOZ9'CO6I?N=Z=568:+3HH-=XC;9O"HN"U'=C MT#"Z->+!U'=@ZBPP=1:8.@M,G06FT1RRJ&><89LSFGN#9T?S:/HF/18+*C*& M!8J`21$P*0(F1<"D")@4`9,B(8L4<1YNCB*]Y[.*A#YPN,B":4"`*7TPI0^F M],&4/IC2!U/Z(8O2=Z8L3-^=3,>MU?C][*TRH^<+QPK6:LQ6^,,U=JPZC!^) M!2:QP"06F,0"DUA@$BMDD5C.PH5BO>4Z>LMG%>E9XOZ[VQ0^;/W8>JP6;9R687M:'.+VM#TROZP/3^_K` M],*^D-F><8L(CWMFGU""9%P*0(F!0! MDR)@4B1DD2+.TH2CZ8VQZM*.5\\\"^X>E7X?%S`-"#"E#Z;TP90^F-('4_I@ M2C]D4?K.G83I'S^ON<5#*-,S5S2>.XL%UFI\52O66'48/Q(+3&*!22PPB04F ML<`D5L@BL6;Z-7TCFXKT+#6O.3L2=X5;2YNY(6#F]Z*W\]HR\KZ:UT;[,_4- MY[4Q:.@%#6,P]0R8>@9,/0.FG@%3SX"I9T(6]8PS+J%V;YW%O=$Q5YQA.WN= M+--8C673B1UZ)'\-)I,BB),B8%($3(J`21$P*1*R2!'G9>8HTGL?JXCW0^%2 MT;"E_<0T(!"G],&4/IC2!U/Z8$H?3.F'+$K?N9,YZ?=NQJ;O'8[.V&!`8.'# M;\0?_/Q"BHQ5A]-&BH!)$3`I`B9%P*0(F!0)6:3(3%/F]\NWBL"4G;U\W>U> M\[O7NX_O'W?/7W;;W;=O+R?W^S^>I)D;H`$_>=Y]_G!ZJQ/Y1O_I;M_'.GV9 MFY5NNC-=NK'LRI5=N<4DEJUB M^Z5DF3L6W4PDR]RQR#NS3)*<.UVZ2P/S.U<].3O6DV:9*^ML)NLM7%EWMK)L MZXCA=TL>B,JW3=HN943T]K7*ZZ'E'ZC@SIXL>!B3+G"Y:^DZ6 MK5U9JH]N]>4<':<>UJ7JJ:S[]DZRS!V+OL>2+'/'HB]Y),O@[#:FRS/61 M'O@GRUP?Z?EVLLSUD1[^)LM<'_4G8:3U[=JEKF^\)JJIR'V)/%6BO/6]ZE2) MLM:WCU,EREE?NF6)/CYSQY`>"BJ35.F4SUW*^G(DV]SH2X.N+#4L57;ARE+= M?7LM.?1[J$2+*G&_0TR52`W]-"]5(C7T`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````#__P,`4$L#!!0`!@`(````(0#16/ODC00``%,0 M```9````>&PO=V]R:W-H965TLRK\T;]\V?P;:DJ39M6Q[2@%=FH[Z11OV]_ M_65]H_5SF M]?/+]5M&RRM(/.5%WKYWHJI29FY\KFB=/A60]YMAI]F@W7U`\F6>U;2AIW8& M&FQB&JFW7G4%_Y>36C-XKS87>PCH_ M_I97!-R&.K$*/%'ZS$+C(T,P6$.C@ZX"?]3*D9S2EZ+]06\1R<^7%LH]AXQ8 M8N[QW2--!HZ"S,R<,Z6,%O``\%>Y7ES#'T ME?4)C56O`:__6\.`(G!/6#7Z?!].1^,&=_7RTC;=KFMZ4V`1@(7--65+RG#9 M3PR5XKZ*VOU;Z:!F3&7'9#8J+%^H2@/S[75K._I:>X4YDO4Q>QQC3",.0P2; M$$S6DX$O@T`&H0PB&<0R2$9``UN$-S!QOL(;)L.\&;+:#^##+%,R8H@8AG@R M\&40R""4022#6`;)"$R,L+[&""8#*WDT20Q'F@+[/@9*(F;20C)'A`AW$/$1 M"1`)$8D0B1%)QF1BDOTU)C$96(SP,\(`&[G$@ZS_V1EX\(&H9YB/B(!(B$B$2(Q(@D M8S+)??&IW%GT-'=.+%/L)`=$/$1\1`)$0D0B1&)$DC&9).I(B?*F,F,=L[WD MV?.>\N9]I_@6-`_>4IC(-/^>V!_Y]X0?(;J.P8FE=SW(U`UKNGGXXOMA:@1( M(T0D$J-89P-5:<+%XOM!-1EK3+QA1]QQP[WC`9QQ!A-8]-2$GHQ;K6E*N^BA M#UH)ISQ.S.[8UOGK]\3@3MD&>&5/S0J03(A(A(3CGIA>6+84#^_)ZP2KUO#6L*1<;64[$$Z(2(1 M4HY[LN#*]L)9K>3]/1GK3/QA1[1/&-2%3QWJD0D35#08TY26R6$8.)I!&/F# MUK++Q9G;<^G,%^!!(4811O$@#4Z,'E.>1Q\#QU%S4:>I=^R<]_C2@_N1/+MZ MU$T<+LUO0/Q$79+Z3`ZD*!HEHR_L=@./MUT+S*]>GN/")@3S3.*1X\(V@CE< MU7;=CB_%[]D5[D[\WG3A'(=U]I8+9Q?,=[:[XU=!^0=L%]HX'K"?N]#B[O"% M"QT!N":$X$IW3<_D][0^YU6C%.0$INA='ZCYI9!_:.D5S(*+'6WA,M>]O<#E MG<`50)]!TSA1V@X?V`^(?P=L_P$``/__`P!02P,$%``&``@````A`*>?6H^0 M`P``"PT``!``"`%D;V-0&UL(*($`2B@``$````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````G%??;]HP$'Z?M/\!Y7T-[F\A;L^^Z^\_TD^+S;%(,M:".4''N7 M%T-O`#)3N9"KL? MVMKRQO=-MH8--Q=X+?%FJ?2&6_RI5[Y:+D4&4Y55&Y#6OQH./_BPLR!SR-^5 M1X5>H_%F:\]5FJO,\3,_TWV)A,-@4I:%R+A%+\-O(M/*J*4=Q+L,BL!O7P;( M+H<L+NPV'@MW\&2<8+B%!QN.2%@EL3K\I?2C60-8$_@HT!S6GVW9]K>X M#D>C6@*_NI).0\,$+[H<4V$+,//E@FM+4!Z-VIQK%@WCAM`ABFPB,J^3.XGLRAFR6T2D+]-XEJ#CG5=XHDA:F>L5E^)/G;0,*Y#- MN*TT,+5D\Q)(2%)M-ESOG4@B5E)@N6&BL4F6J4I:$G(GMUB+2N_)VX6&D@L, M\`ZKV8"I>&?2T:_ZY$Z8J=S8"VGX`42K.ZY@!]5!8Z>7_, M'G1"5RAQH$(:O\/>M0&6\MT)+8E5V2-;%%P:EJRYAB]8ECFFT]ZQ)'76D+4J MZ'EXVFDDMD=ILA'5&FD>,%-:,7&&SQ19Z`B$S%-=-`F!((PVY ML.R[,(\D(*D>#/RNW&O'+JBTVN^0*6SXZ'3BFLSE"55]B41CCIF$S_^`G854 MW)]0M.*G44-DE+-$FGF9+'V4VCG3)]>?.C3U=M1=H^Q$G9'4^\N>-M-?]U>D MG7[,>Q+S'.(I6"Z*3^CSOI-)K M!1D=6THG2W%MJCCN+L?VZ':)9C+WYRG]_/T8.AGZ,==G#X!9W:%TX)=&:XP#-#S+_ M7KBU_V?SWR:\O+X8OA_B1M\Z"_RG'H(C./P+``#__P,`4$L#!!0`!@`(```` M(0`F!\/B-0$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**```0`` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````"4D4%/PR`8AN\F_H>&>TM9 M%U-)RQ(U.[G$Q!F--X1O';%0`FBW?R_KNCJC%X_D?7EXOH]JL=-M\@G.J\[4 MB&0Y2L"(3BK3U.AIO4Q+E/C`C>1M9Z!&>_!HP2XO*F&IZ!P\N,Z""PI\$DG& M4V%KM`W!4HR]V(+F/HL-$\--YS0/\>@:;+EXYPW@69Y?80V!2QXX/@!3.Q'1 MB)1B0MH/UPX`*3"TH,$$CTE&\';-GNS?7)MYO*_P[ MJZ08[*APP`/()+Y'CW:GY+FXO5LO$9OE9)[F13HKUZ2D!:'S\K7"I]9XGTU` M/0K\BWA]1CP!V.#]\\_9%P```/__`P!02P$"+0`4``8`"````"$`;+)U.R(" M``!N(0``$P``````````````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+ M`0(M`!0`!@`(````(0"U53`C]0```$P"```+`````````````````%L$``!? M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`).)$HSH`@``KP@``!D`````````````````N10``'AL+W=O\#```4#@``&0````````````````"K M)```>&PO=V]R:W-H965T"0@,``.4)```9`````````````````-$H``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`$X,W*+P`@``'`D``!D````````` M````````2BP``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`%`OD_22`@``V@8``!D`````````````````PS<``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`-#)QXSQ`P``&@X``!D`````````````````KT,``'AL+W=O1Z'!,P$``!X%0``&0`````` M``````````#71P``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/MBI6V4!@``IQL` M`!,`````````````````2U$``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"+0`4 M``8`"````"$`/B9&+$8.``#HE@``#0`````````````````06```>&PO&UL4$L!`BT`%``&``@````A`)^^#0Y+$P`` M[*@``!D``````````````````MP``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$^<80B&"@``/5$``!D````````` M````````\O<``'AL+W=O&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`-(I_.HT`P``6`H``!D` M````````````````/`&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(I5+WKM`@``A@@``!D````````````````` M1!4!`'AL+W=O&PO=V]R:W-H965T`0!X;"]W;W)K&UL4$L!`BT`%``& M``@````A`(3+U"'+*0``M_,``!D`````````````````-2D!`'AL+W=O&UL4$L!`BT`%``&``@````A`"*C;DB> M%@``M(L``!@`````````````````!EX!`'AL+W=OP$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$+I7-P``&0`` M```````````````3B`$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#T>Q#_9#@`` MA5<``!D`````````````````?)D!`'AL+W=OG9_X%``#W%P``&0````````````````", MJ`$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)B\\=?$&@``D(P``!D````````` M````````D+&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`/6PL(%V!@``"!L``!D``````````````````=T!`'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`(PN9-J\`@``M0<``!D`````````````````W>L!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-%8^^2-!```4Q`` M`!D`````````````````)`T"`'AL+W=O XML 15 R55.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Event (Details Textual)
 12 Months Ended 1 Months Ended
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Mar. 21, 2014
Subsequent Event [Member]
USD ($)
Mar. 24, 2014
Subsequent Event [Member]
USD ($)
Mar. 31, 2014
Subsequent Event [Member]
EUR (€)
Feb. 19, 2014
Subsequent Event [Member]
EUR (€)
Subsequent Event [Line Items]            
Proceeds from Issuance of Common Stock $ 2,771,000 $ 0 $ 2,100,000 $ 2,100,000    
Proceeds from Other Debt     1,500,000 1,500,000    
Accrued Interest Issued To Investors     61,000 61,000    
Shares, Issued         7,140,822  
Upfront Fees And Connection Of First Amendment         € 225,000 € 225,000

XML 16 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Plans, Share-Based Payments and Warrants (Details 3) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Class of Warrant or Right [Line Items]    
Shares, Granted 237,315 1,547,550
Weighted Average Grant Date Fair Value, Granted $ 0.56 $ 1.03
Restricted Stock [Member]
    
Class of Warrant or Right [Line Items]    
Shares, Nonvested at December 31, 2012 0  
Shares, Granted 398,227  
Shares, Vested (264,770)  
Shares, Forfeited (58,007)  
Shares, Nonvested at December 31, 2013 75,450  
Weighted Average Grant Date Fair Value, Nonvested at December 31, 2012 $ 0  
Weighted Average Grant Date Fair Value, Granted $ 0.73  
Weighted Average Grant Date Fair Value, Vested $ 0.71  
Weighted Average Grant Date Fair Value, Forfeited $ 0.88  
Weighted Average Grant Date Fair Value, Nonvested at December 31, 2013 $ 0.66  
XML 17 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies (Schedule Of Securities Excluded From Dilutive Per Share Computation) (Details)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Stock options [Member]
    
Summary of Significant Accounting Policies [Line Items]    
Excluded anti-dilutive stock options and warrants 2,410,134 2,294,714
Warrant [Member]
    
Summary of Significant Accounting Policies [Line Items]    
Excluded anti-dilutive stock options and warrants 13,887,598 14,679,971
Unvested restricted stock [Member]
    
Summary of Significant Accounting Policies [Line Items]    
Excluded anti-dilutive stock options and warrants 75,450 0
XML 18 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 19 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Prepaid Expenses and Other Current Assets (Tables)
 12 Months Ended
Dec. 31, 2013
Other Assets [Abstract]  
Schedule Of Prepaid Expenses And Other Current Assets
Prepaid expenses and other current assets as of December 31, 2013 and 2012 were as follows:
 
 
 
December 31,
 
 
 
2013
 
2012
 
Prepaid insurance premiums
 
$
70,000
 
$
78,000
 
Security deposit
 
 
21,000
 
 
21,000
 
Other
 
 
34,000
 
 
10,000
 
Prepaid expenses and other current assets
 
$
125,000
 
$
109,000
 
XML 20 R50.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Details Textual) (USD $)
 1 Months Ended 12 Months Ended
May 31, 2013
Dec. 31, 2013
May 22, 2013
May 17, 2013
Mar. 04, 2013
Dec. 31, 2012
Stockholder Equity Note [Line Items]            
Authorized value of rights offering         $ 3,000,000  
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right       0.18776    
Class of Warrant or Right, Exercise Price of Warrants or Rights   0.45   0.60   0.45
Class of warrant or right issued, shares     5,000,000      
Class of warrant or right issued gross value received     3,000,000      
Class of warrant or right issued net value received     1,400,000      
Repayments of senior secured note 1,300,000          
Repayments of accrued interest on senior secured note 46,800          
Reimbursement of legal fee 100,000          
Amortization of debt discount (premium) 204,000 53,000        
Debt Instrument, Fee Amount $ 104,000          
XML 21 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes (Details Textual) (USD $)
 12 Months Ended
Dec. 31, 2013
Federal [Member]
Maximum [Member]
Dec. 31, 2013
Federal [Member]
Minimum [Member]
Dec. 31, 2013
Federal And New Jersey [Member]
Dec. 31, 2013
Foreign [Member]
Dec. 31, 2013
Research [Member]
Federal [Member]
Dec. 31, 2012
Research [Member]
Federal [Member]
Income Tax [Line Items]            
Operating loss carryforwards     $ 8,729,200 $ 8,305,000    
Tax credit carryforwards         $ 1,096,000 $ 1,054,000
Operating loss carryforwards expiration date Dec. 31, 2026 Dec. 31, 2014        
XML 22 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
Property and Equipment, Net (Details Textual)
 12 Months Ended
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2012
EUR (€)
Property, Plant and Equipment [Line Items]      
Depreciation expense   $ 9,000  
Proceeds from sales of property and equipment   55,000 42,500
Proceeds from the sale of manufacturing equipment, amount recognized in other income   55,000 42,500
GainLossOnSaleOfPropertyPlantEquipment $ 3,000 $ 55,000  
XML 23 R52.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Details Textual)
 1 Months Ended 12 Months Ended 1 Months Ended 1 Months Ended 12 Months Ended
Jul. 25, 2013
USD ($)
Apr. 20, 2012
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Nov. 30, 2013
USD ($)
Mar. 31, 2014
Subsequent Event [Member]
EUR (€)
Feb. 19, 2014
Subsequent Event [Member]
EUR (€)
Dec. 31, 2013
Bellco [Member]
Sep. 30, 2013
Medica S.p.A [Member]
May 23, 2013
Medica S.p.A [Member]
EUR (€)
Feb. 04, 2013
Medica S.p.A [Member]
EUR (€)
Apr. 23, 2012
Medica S.p.A [Member]
EUR (€)
Dec. 31, 2013
Medica S.p.A [Member]
USD ($)
Dec. 31, 2013
Medica S.p.A [Member]
EUR (€)
Dec. 31, 2012
Medica S.p.A [Member]
EUR (€)
Commitments And Contingencies [Line Items]                              
Number of units under first tier royalty receivable               125,000              
First tier royalty per unit               1.75              
Second tier royalty per unit               1.25              
License agreement product purchases in year one                           € 300,000  
License agreement product purchases in year two                           500,000  
License agreement product purchases in year three                           750,000  
License agreement first installment payment                       500,000      
License agreement second installment payment                     600,000        
License agreement final installment payment                   400,000          
License agreement options to purchase shares                         300,000 300,000  
Purchase commitment                             532,000
Fair value of stock options granted to Medica     0 273,000                 273,000    
Other assets, net of accumulated amortization     1,894,000 2,109,000                      
Accumulated amortization     356,000                        
Amortization of Other Deferred Charges     214,000 142,000                      
Amortization expense, years two and three     208,000                        
Royalty rate     3.00%           12.00%            
Employment Agreement term   4 years                          
Employee Agreement, annual base salary   350,000                          
Employee Agreement, discretionary bonus percentage   30.00%                          
Monthly rent expense         8,000                    
Lease extension term 1 year                            
Future renewed monthly rent expense 8,000                            
Rent expense     108,000 109,000                      
Upfront Fees And Connection Of First Amendment           225,000 225,000                
Sales revenue     1,029,000 1,127,000                      
Cost of goods sold     $ 898,000 $ 737,000                      
XML 24 R47.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Plans, Share-Based Payments and Warrants (Details 4)
Dec. 31, 2013
May 17, 2013
Dec. 31, 2012
Dec. 31, 2013
July 2009 Warrants [Member]
Dec. 31, 2012
July 2009 Warrants [Member]
Dec. 31, 2013
March 2011 Lambda Warrants [Member]
Dec. 31, 2012
March 2011 Lambda Warrants [Member]
Dec. 31, 2013
Shareholder Rights Offering Warrants [Member]
Dec. 31, 2012
Shareholder Rights Offering Warrants [Member]
Dec. 31, 2013
Class D Warrants - Lambda [Member]
Dec. 31, 2012
Class D Warrants - Lambda [Member]
Dec. 31, 2011
Class D Warrants - Lambda [Member]
Dec. 31, 2013
Class D Warrants - Other [Member]
Dec. 31, 2012
Class D Warrants - Other [Member]
Dec. 31, 2011
Class D Warrants - Other [Member]
Class of Warrant or Right [Line Items]                              
Date Issued       Jul. 24, 2009   Mar. 10, 2011   Mar. 10, 2011   Nov. 14, 2007          
Expiry Date       Jul. 24, 2014   Mar. 10, 2017   Mar. 10, 2016   Mar. 10, 2017          
Exercise Price 0.45 0.60 0.45 22.40   0.40   0.40   0.40          
Total Common Shares Issuable 13,887,598   14,679,971 33,629 33,629 2,782,577 2,782,577 2,264,817 3,057,190 8,806,575 8,806,575 8,806,575 0 0 447,197
XML 25 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2013
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 2 - Summary of Significant Accounting Policies
  
Principles of Consolidation and Basis of Presentation
 
The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nephros International Limited.  All intercompany accounts and transactions have been eliminated in consolidation.
 
These consolidated  financial statements were approved by management and the Board of Directors and are available for issuance as of the date of the audit opinion.  Subsequent events have been evaluated through this date.
 
Use of Estimates in the Preparation of Financial Statements
 
The preparation of consolidated  financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates.  Certain prior year amounts have been reclassified to conform to the current year presentation.
 
Going Concern and Management’s Response
 
The accompanying consolidated  financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s recurring losses and difficulty in generating sufficient cash flow to meet its obligations and sustain its operations raise substantial doubt about its ability to continue as a going concern. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
The Company has incurred significant losses in operations in each quarter since inception. For the years ended December 31, 2013 and 2012, the Company has incurred net losses of $3,698,000 and $3,262,000, respectively. In addition, the Company has not generated positive cash flow from operations for the years ended December 31, 2013 and 2012. To become profitable, the Company must increase revenue substantially and achieve and maintain positive gross and operating margins. If the Company is not able to increase revenue and gross and operating margins sufficiently to achieve profitability, its results of operations and financial condition will be materially and adversely affected.
 
The voluntary recalls of point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications announced on October 30, 2013 and the related circumstances could subject the Company to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact the Company’s sales and revenues.
 
On June 27, 2011, the Company entered into a License Agreement,  effective July 1, 2011, with Bellco S.r.l., as licensee (“Bellco”), an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of Nephros’ patented mid-dilution dialysis filters.  This Agreement provided the Company with payments of €500,000, €750,000, and €600,000 on July 1, 2011, January 15, 2012 and January 15, 2013, respectively. On February 19, 2014, the Company entered into the First Amendment to License Agreement (the “First Amendment”), by  and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011. As a result of the amendment, the Company will receive a total of €450,000 in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. See Note 12, Commitments and Contingencies for further discussion.  
 
On February 4, 2013 and November 12, 2013, the Company issued senior secured notes to Lambda Investors LLC in the principal amount of $1.3 million and $1.5 million, respectively.  As of December 31, 2013, the $1.5 million note is outstanding. The $1.3 million note was repaid on May 22, 2013.  For a more detailed discussion of the terms of the senior secured notes, see Note 6, Senior Secured Notes.
 
On March 21, 2014 the Company completed a rights offering which resulted in gross proceeds of $2.1 million. See Note 14, Subsequent Events, for further discussion.
 
There can be no assurance that the Company’s future cash flow will be sufficient to meet its obligations and commitments. If the Company is unable to generate sufficient cash flow from operations in the future to service its commitments the Company will be required to adopt alternatives, such as seeking to raise debt or equity capital, curtailing its planned activities or ceasing its operations. There can be no assurance that any such actions could be effected on a timely basis or on satisfactory terms or at all, or that these actions would enable the Company to continue to satisfy its capital requirements.
 
Cash and Cash Equivalents
 
The Company invests its excess cash in bank deposits and money market accounts.  The Company considers all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash equivalents.  Cash equivalents are carried at fair value, which approximate cost, and primarily consist of money market funds maintained at major U.S. financial institutions.
 
Accounts Receivable
 
The Company provides credit terms to customers in connection with purchases of the Company’s products. Management periodically reviews customer account activity in order to assess the adequacy of the allowances provided for potential collection issues and returns. Factors considered include economic conditions, each customer’s payment and return history and credit worthiness. Adjustments, if any, are made to reserve balances following the completion of these reviews to reflect management’s best estimate of potential losses.  There were no allowances for doubtful accounts at December 31, 2013 or 2012.  There was no allowance for sales returns at December 31, 2013 or 2012.  There were no write offs of accounts receivable to bad debt expense during 2013 or 2012.
 
Inventory
 
The Company engages third parties to manufacture and package inventory held for sale, takes title to certain inventory once manufactured, and warehouses such goods until packaged for final distribution and sale. Inventory consists of finished goods and raw materials (fiber) held at the manufacturers’ facilities, and are valued at the lower of cost or market using the first-in, first-out method. The Company’s inventory reserve requirements are based on factors including the products’ expiration date and estimates for the future sales of the product. If estimated sales levels do not materialize, the Company will make adjustments to its assumptions for inventory reserve requirements.
 
In March 2014, the Company requested the closeout of its October 2013 voluntary product recall.  The Company has fully reserved the recalled product and will destroy the respective product by April 20, 2014.
 
Patents
 
The Company has filed numerous patent applications with the United States Patent and Trademark Office and in foreign countries. All costs and direct expenses incurred in connection with patent applications have been expensed as incurred.
 
Property and Equipment, net
 
Property and equipment, net is stated at cost less accumulated depreciation.  These assets are depreciated over their estimated useful lives of three to seven years using the straight line method.
 
Impairment for Long-Lived Assets
 
The Company adheres to Accounting Standards Codification (“ASC”) Topic 360 and periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. An estimate of the asset’s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its carrying value or its estimated net realizable market value. There were no impairment losses for long-lived assets recorded for the years ended December 31, 2013 and December 31, 2012.
 
Fair Value of Financial Instruments
 
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturity of these instruments.
 
Revenue Recognition
 
Revenue is recognized in accordance with ASC Topic 605.  Four basic criteria must be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.
 
The Company recognizes revenue related to product sales when delivery is confirmed by its external logistics provider and the other criteria of ASC Topic 605 are met. Product revenue is recorded net of returns and allowances.  All costs and duties relating to delivery are absorbed by Nephros. All shipments are currently received directly by the Company’s customers.
 
Deferred revenue  was approximately $703,000 and $1,414,000 on the accompanying consolidated balance sheets as of December 31, 2013 and 2012, respectively, and is related to the License Agreement with Bellco. The Company has recognized approximately $1,756,000 of revenue related to this license agreement to date, including approximately $711,000 for the year ended December 31, 2013, resulting in $703,000 being deferred over the remainder of the expected obligation period. The Company amortizes the deferred revenue monthly over the expected obligation period which ends on December 31, 2014. This will result in expected recognized revenue of approximately $703,000 for each of the year ending December 31, 2014. Total payments of approximately  $2,459,000, including the  final payment of approximately $791,000  received in January 2013, were related to  the License Agreement with Bellco.  
 
Shipping and Handling Costs
 
Shipping and handling costs are recorded as cost of goods sold and are approximately $30,000 and $33,000 for the years ended December 31, 2013 and 2012, respectively.
 
Research and Development Costs
 
Research and development costs are expensed as incurred.
 
Stock-Based Compensation
 
The Company accounts for stock-based compensation in accordance with ASC Topic 718 by recognizing the fair value of stock-based compensation in the consolidated statement of operations and comprehensive loss.  The fair value of the Company’s stock option awards are estimated using a Black-Scholes option valuation model. This model requires the input of highly subjective assumptions and elections including expected stock price volatility and the estimated life of each award. In addition, the calculation of compensation costs requires that the Company estimate the number of awards that will be forfeited during the vesting period. The fair value of stock-based awards is amortized over the vesting period of the award.  For stock-based awards that vest based on performance conditions (e.g. achievement of certain milestones), expense is recognized when it is probable that the condition will be met.
 
Amortization of Debt Issuance Costs
 
The Company accounts for debt issuance costs in accordance with ASC 835, which requires that costs paid directly to the issuer of  the notes be reported in the balance sheet as a debt discount and amortized over the term of the associated debt. Debt issuance costs of $399,000 for the year ended December 31, 2013 are associated with the senior secured notes issued to Lambda Investors LLC on February 4, 2013 and  November 12, 2013. Approximately $257,000 of these costs were amortized as of December 31, 2013 and are included in amortization of debt discount on the consolidated statements of operations and comprehensive loss. There were no debt issuance costs for the year ended December 31, 2012.
 
Other Income (Expense), net
 
Other income (expense), net, of approximately $33,000  includes approximately $50,000 of other expense for the year ended December 31, 2013, primarily due to approximately $36,000 related to foreign currency losses and approximately $14,000 related to the May 2013 rights offering  warrant modification. Other expense was partially offset by other income of approximately $17,000, which consisted primarily of a refund of approximately $15,000 received as a result of the Steris agreement termination. Other income (expense), net, in the amount of approximately $14,000 for the year ended December 31, 2012 is due primarily to approximately $18,000 in write-offs of old vendor invoices which are no longer due, offset partially by approximately $4,000 of net foreign currency losses on invoices paid to and due to an international supplier.
 
Income Taxes
 
The Company accounts for income taxes in accordance with ASC Topic 740, which requires accounting for deferred income taxes under the asset and liability method. Deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable in future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities.
 
For financial reporting purposes, the Company has incurred a loss in each period since its inception. Based on available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2013 and 2012.
 
ASC Topic 740 prescribes, among other things, a recognition threshold and measurement attributes for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company’s income tax return.  ASC 740 utilizes a two-step approach for evaluating uncertain tax positions.  Step one, or recognition, requires a company to determine if the weight of available evidence indicates a tax position is more likely than not to be sustained upon audit, including resolution of related appeals or litigation processes, if any.  Step two, or measurement, is based on the largest amount of benefit, which is more likely than not to be realized on settlement with the taxing authority.  The Company is subject to income tax examinations by major taxing authorities for all tax years subsequent to 2010.  The adoption of the provisions of ASC 740 did not have a material impact on the Company’s consolidated financial statements.  During the years ended December 31, 2013 and 2012, the Company recognized no adjustments for uncertain tax positions.  However, management’s conclusions regarding this policy may be subject to review and adjustment at a later date based on factors including, but not limited to, on-going analyses of and changes to tax laws, regulation and interpretations, thereof.
 
Loss per Common Share
 
In accordance with ASC 260-10, net loss per common share amounts (“basic EPS”) are computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding and excluding any potential dilution. Net loss per common share amounts assuming dilution (“diluted EPS”) is generally computed by reflecting potential dilution from conversion of convertible securities and the exercise of stock options and warrants. The following securities have been excluded from the dilutive per share computation as they are antidilutive:
 
 
 
2013
 
 
2012
 
Stock options
 
 
2,410,134
 
 
 
2,294,714
 
Warrants
 
 
13,887,598
 
 
 
14,679,971
 
Unvested restricted stock
 
 
75,450
 
 
 
-
 
 
Foreign Currency Translation
 
Foreign currency translation is recognized in accordance with ASC Topic 830.  The functional currency of Nephros International Limited is the Euro and its translation gains and losses are included in accumulated other comprehensive income. The balance sheet is translated at the year-end rate. The statement of operations is translated at the weighted average rate for the year.
 
Comprehensive Income (Loss)
 
Comprehensive income (loss), as defined in ASC 220,  is the total of net income (loss) and all other non-owner changes in equity (or other comprehensive income (loss)) such as foreign currency translation adjustments. For the years ended December 31, 2013 and 2012, the comprehensive loss was approximately $3,700,000 and $3,235,000, respectively.
 
Recently Adopted Accounting Pronouncements
 
There were no recent accounting pronouncements that are expected to have an effect on the Company’s consolidated financial statements.
EXCEL 26 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`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`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O M'!E;G-E#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%C8W)U961?17AP96YS97,\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I7;W)K6UE;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E!R97!A:61?17AP96YS97-?86YD7T]T:&5R7T-U#I7;W)K5]A;F1?17%U M:7!M96YT7TYE=%]486(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DEN8V]M95]487AE#I7;W)K6UE;G0Q/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=OF%T:6]N7V%N9%].871U#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M'!E;G-E#I%>&-E;%=O&5S7T1E=&%I;',\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I%>&-E M;%=O&5S7T1E=&%I;'-?5&5X='5A;#PO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-T;V-K7U!L86YS7U-H87)E0F%S M961?4&%Y;65N=#(\+W@Z3F%M93X-"B`@("`\>#I7;W)K6UE;G0S/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K7U!L86YS7U-H87)E0F%S961?4&%Y;65N=#4\+W@Z M3F%M93X-"B`@("`\>#I7;W)K6UE;G0V/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H M965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I.86UE/D-O;F-E;G1R871I;VY?;V9?0W)E9&ET M7U)I#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-U8G-E<75E;G1?179E;G1?1&5T86EL#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O6QE#I!8W1I M=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0 M&UL/CPA M6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G M92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S0Y-F8U.&-A7SDT9C!?-&,P95]A-#4P7V,W96%A.#ED8F8Q-@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T.39F-3AC85\Y-&8P7S1C M,&5?830U,%]C-V5A83@Y9&)F,38O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)V9A;'-E/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^1&5C(#,Q+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UB;VP\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO2!# M;VUM;VX@4W1O8VLL(%-H87)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO2!#=7)R96YT(%)E<&]R=&EN9R!3 M=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO3QS<&%N/CPO'0^ M)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO2P@;&5S'!E;G-E'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO'0^)SQS<&%N/CPO MF5D(&%T($1E8V5M8F5R(#,Q+"`R,#$S(&%N M9"`R,#$R.R`Q."PP.#(L,#0S(&%N9"`Q,2PY-#DL.#(T('-H87)E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.39F M-3AC85\Y-&8P7S1C,&5?830U,%]C-V5A83@Y9&)F,38-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-#DV9C4X8V%?.31F,%\T8S!E7V$T-3!?8S=E M86$X.61B9C$V+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,"PP,#`L M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.39F M-3AC85\Y-&8P7S1C,&5?830U,%]C-V5A83@Y9&)F,38-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-#DV9C4X8V%?.31F,%\T8S!E7V$T-3!?8S=E M86$X.61B9C$V+U=O'0O:'1M;#L@8VAA&-E<'0@4VAA'0^)SQS<&%N/CPO'!E;G-E M'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M2!T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`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`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO2!A;F0@97%U:7!M96YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%SF%T:6]N(&]F(&]T M:&5R(&%S2!T'0^)SQS<&%N/CPO3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E2!A;F0@97%U:7!M M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2`H=7-E9"!I;BD@:6YV M97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO M6UE;G0@;V8@9FEN86YC:6YG(&-O&5R8VES92!O9B!W87)R86YT2!F:6YA;F-I;F<@86-T:79I=&EE65A M'0^)SQS<&%N/CPO M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N(&%N9"!.871U6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3F]T92`Q)B,Q M-C`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`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!O9B!3:6=N:69I8V%N="!!8V-O M=6YT:6YG(%!O;&EC:65S/&)R/CPO'0^ M)SQS<&%N/CPO2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<^(#QS=')O;F<^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!A;F0@:71S('=H;VQL>2!O=VYE9"!S=6)S M:61I87)Y+"!.97!H2!A8V-O=6YT3X\9F]N="!S='EL93TS1"=# M3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)B,Q-C`[/"]F;VYT/CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QS=')O;F<^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/E1H92!P M2!W:71H(&%C8V]U;G1I;F<@<')I;F-I<&QE65A6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C M:R<^/&9O;G0@6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@ M1D].5"U325I%.B`Q,'!T)SX@8V]N2!W:6QL(&-O;G1I;G5E(&%S(&$@9V]I;F<@ M8V]N8V5R;BX@5&AE($-O;7!A;GDF(S@R,3<[2!H87,@:6YC=7)R960@;F5T(&QO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2X@26X@861D:71I;VXL('1H92!#;VUP86YY(&AA2!A;F0@861V97)S96QY(&%F9F5C=&5D/&9O;G0@3X\9F]N="!S='EL93TS1"=#3TQ/ M4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O M;G0@3X\9F]N M="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^/&9O;G0@2!R96-A M;&QS(&]F('!O:6YT(&]F('5S92`H4$]5*2!A;F0@1%-5(&EN+6QI;F4@=6QT M2!C;VYS=6UE2!A=71H;W)I=&EE6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M3X\9F]N="!S='EL93TS1"=#3TQ/ M4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O M;G0@2UB87-E9"!S=7!P;&EE2XF(S$V,#L\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N)SX\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N M)SY/;B!&96)R=6%R>2`Q.2P@,C`Q-"P@=&AE($-O;7!A;GD@96YT97)E9"!I M;G1O('1H92!&:7)S="!!;65N9&UE;G0@=&\@3&EC96YS92!!9W)E96UE;G0@ M*'1H92`F(S@R,C`[1FER6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#M&3TY4+49!34E,63I4:6UE6QE M/3-$)T9/3E0M4TE:13H@,3!P=#M&3TY4+49!34E,63I4:6UE6%B;&4@;VX@ M36%R8V@@,S$L(#(P,30N(%-E92!.;W1E(#$R+"!#;VUM:71M96YT3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA M8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^3VX@1F5B2XF(S$V,#L@/&9O M;G0@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^ M/"]F;VYT/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@ M2!W:6QL(&)E(')E<75I2!B87-I6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QS=')O;F<^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V9O M;G0^/"]D:78^(#QD:78@&EM871E(&-O2!M87)K970@9G5N9',@;6%I;G1A:6YE9"!A="!M86IO6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\ M+V9O;G0^/"]D:78^(#QD:78@2!P6UE;G0@86YD(')E M='5R;B!H:7-T;W)Y(&%N9"!C6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQS=')O;F<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^ M/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!E;F=A9V5S('1H:7)D M('!A2!C;VYS:7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@ M2!P2!R97-E6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO M9F]N=#X\+V9O;G0^/"]S=')O;F<^/"]D:78^(#QD:78@6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@2!H87,@9FEL960@;G5M97)O=7,@<&%T96YT(&%P<&QI8V%T M:6]N6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQS M=')O;F<^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!A;F0@17%U:7!M96YT+"!N970\+V9O;G0^ M/"]F;VYT/CPO6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@2!A;F0@97%U:7!M96YT+"!N970@:7,@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@ M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!A9&AE6EN9R!V86QU92!O9B!I=',@9&5P2!T:&4@;&]N9RUL:79E9"!A6EN9R!V86QU92!T;R!D971E2!R97!O6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\6QE/3-$)T-/3$]2 M.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B M;&%C:R<^/"]F;VYT/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@&EM871E M(&9A:7(@=F%L=64@9'5E('1O('1H92!S:&]R="UT97)M(&UA='5R:71Y(&]F M('1H97-E(&EN6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\6QE/3-$)T-/3$]2 M.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/"]F;VYT/B8C,38P.SPO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^ M/&9O;G0@2!H M87,@;V-C=7)R960@;W(@&5D(&]R(&1E=&5R;6EN86)L93L@86YD("AI M=BD@8V]L;&5C=&%B:6QI='D@:7,@2!A2!I&EM871E;'D@ M)#F5D(&%P<')O>&EM871E;'D@)#$L-S4V+#`P,"!O9B!R M979E;G5E(')E;&%T960@=&\@=&AI2`D-S$Q+#`P,"!F;W(@=&AE M('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,L(')E'!E8W1E M9"!O8FQI9V%T:6]N('!EF5S('1H M92!D969EF5D M(')E=F5N=64@;V8@87!P2`D/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M5&]T86P@<&%Y;65N=',@;V8@87!P28C,38P.R`D/&9O;G0@ M&EM871E;'D@ M)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2`R,#$S+"!W97)E(')E;&%T M960@=&\F(S$V,#L\+V9O;G0^/"]F;VYT/B`\9F]N="!S='EL93TS1"=#3TQ/ M4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O M;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO M9F]N=#X\+W-T3X\6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2`D/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE3X\9F]N M="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CPO9F]N=#XF(S$V,#L\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL M93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O'!E M;G-E9"!A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQS=')O;F<^/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQS=')O M;F<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=#3TQ/4CH@ M8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M/"]F;VYT/CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@86-C;W5N M=',@9F]R('-T;V-K+6)A2!R96-O9VYI>FEN9R!T:&4@9F%I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@1D]. M5"U325I%.B`Q,'!T)SX@8V]N2!E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQS M=')O;F<^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF%T:6]N(&]F($1E8G0@27-S=6%N8V4@0V]S=',\+V9O;G0^/"]F M;VYT/CPO6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2 M.B!B;&%C:R<^/&9O;G0@2!A8V-O=6YTF5D(&]V97(@=&AE('1E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)SL@1D].5"U325I%.B`Q,'!T)SXD/&9O;G0@2`D,C4W+#`P,"!O9B!T:&5S M92!C;W-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)SL@1D].5"U325I%.B`Q,'!T)SYA;F0@8V]M<')E:&5N65A6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(Y+C=P=#L@34%21TE..B`P:6X@ M,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@ M3X\ M9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^3W1H97(F(S$V,#MI;F-O;64@*&5X<&5N6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)SL@1D].5"U325I%.B`Q,'!T)SYO9B!A<'!R;WAI;6%T96QY("0S,RPP M,#`F(S$V,#L\+V9O;G0^(&EN8VQU9&5S)B,Q-C`[87!P2`D M/&9O;G0@'!E;G-E)B,Q-C`[9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R M(#,Q+"`R,#$S+"8C,38P.W!R:6UA2!D=64@=&\@87!P2`D/&9O;G0@2!L;W-S97,@86YD/"]F;VYT/B!A<'!R;WAI;6%T96QY("0\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B2!O M=&AE2`D/&9O;G0@2!O9B!A(')E9G5N9"!O9B!A<'!R;WAI;6%T96QY("0\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)SL@1D].5"U325I%.B`Q,'!T)SY/=&AE2`\9F]N M="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/B0Q-"PP,#`@9F]R('1H92!Y96%R M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R(&ES(&1U92!P2`D/&9O;G0@2`D/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\6QE/3-$)T-/3$]2.B!B M;&%C:R<^/&9O;G0@3X\6QE/3-$)T-/3$]2.B!B;&%C:R<^(#PO9F]N=#X\+W-T3X\6QE/3-$ M)T-/3$]2.B!B;&%C:R<^/&9O;G0@&5S/"]F;VYT/CPO9F]N=#X\+W-T3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`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`[/"]F;VYT/CPO9F]N=#X\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE3X\9F]N M="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^05-#(%1O<&EC(#"!R971U"!P;W-I=&EO;B!I2!T:&%N(&YO="!T M;R!B92!S=7-T86EN960@=7!O;B!A=61I="P@:6YC;'5D:6YG(')EF5D(&]N('-E M='1L96UE;G0@=VET:"!T:&4@=&%X:6YG(&%U=&AO2XF(S$V,#L@5&AE M($-O;7!A;GD@:7,@2!M86IO65A M28C.#(Q-SMS(&-O;G-O M;&ED871E9"!F:6YA;F-I86P@"!P;W-I=&EO;G,N)B,Q-C`[($AO=V5V97(L(&UA;F%G96UE;G0F M(S@R,3<[7-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQS=')O;F<^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@"!S;VQI9#L@34%21TE..B`P:6X@,&EN(#!I;B`P+C5I;CL@5TE$5$@Z(#@P M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U325I%.B`Q,'!T M.R!/5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@ M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3,L.#@W+#4Y M.#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O M;G0@6QE/3-$)T-/3$]2.B!B M;&%C:R<^/&9O;G0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V9O;G0^/"]D:78^(#QD M:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@ M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQS=')O;F<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9F]N M=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE3X\ M9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^0V]M<')E:&5N2`H;W(@;W1H97(@8V]M<')E:&5N65A&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O M;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQS=')O;F<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG3X\6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQS=')O;F<^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\T.39F-3AC85\Y-&8P7S1C,&5?830U,%]C-V5A83@Y9&)F M,38-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#DV9C4X8V%?.31F M,%\T8S!E7V$T-3!?8S=E86$X.61B9C$V+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R3QB6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<^(#QS=')O;F<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^ M/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V9O;G0^ M/"]D:78^(#QD:78@6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$ M15(M3$5&5#H@(SEE8C9C92`P<'@@6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^-3@Q+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S$R+#`P,#PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'!E;G-E6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<^(#QS=')O;F<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2 M1TE..B`P:6XG/B`\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M("8C,38P.SPO9F]N=#X\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y M96(V8V4@,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S@L,#`P/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXR,2PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S0L,#`P M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3(U+#`P,#PO9&EV/B`\+W1D M/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^,3`Y+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!A;F0@17%U M:7!M96YT+"!.970\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@@8V]L'0^)SQS<&%N/CPO6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/'-T6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF M;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2!A;F0@97%U:7!M96YT(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"`R M,#$R('=A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E. M1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)' M24XZ(#!I;CL@5TE$5$@Z(#DU)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S M93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO65A6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO65A6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M'1U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO2!A;F0@97%U M:7!M96YT+"!G6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S,T+#`P,#PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^-S,W+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U M<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9F]N M=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE3X\ M9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^1&5P65A6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!S;VQD(&9U;&QY M(&1E<')E8VEA=&5D(&5Q=6EP;65N="!T;W1A;&EN9R!A<'!R;WAI;6%T96QY M("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B2!A9W)E960@=&\@&EM871E;'D@)B,X,S8T.SQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^ M/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N M/CPO6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQF;VYT M('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQF;VYT M('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2`T+"`R,#$S+"!T:&4@0V]M<&%N>2!I2!P86ED(&%M;W5N=',@9'5E('5N9&5R('1H92!N;W1E(&]N($UA>2`R,BP@ M,C`Q,R!W:71H('1H92!C87-H('!R;V-E961S(&9R;VT@=&AE(')I9VAT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T-/3$]2.B!B;&%C:R<^5&AO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPGF%T:6]N(&]F(&1E8G0@9&ES M8V]U;G0N/&9O;G0@3X\9F]N="!S='EL93TS M1"=#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/D]N($YO=F5M M8F5R(#$R+"`R,#$S+"!T:&4@0V]M<&%N>2!I6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6UE;G1S('1O M=&%L:6YG("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B65A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J M=7-T:69Y/D]N($UA6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\T.39F-3AC85\Y-&8P7S1C,&5?830U,%]C-V5A83@Y M9&)F,38-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#DV9C4X8V%? M.31F,%\T8S!E7V$T-3!?8S=E86$X.61B9C$V+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QS=')O M;F<^/&9O;G0@6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V9O;G0^/"]D:78^(#QD:78@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@ M,3`P)2<^(#QT86)L92!S='EL93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E M(#!P>"!S;VQI9#L@0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!- M05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L M;&%P"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^ M(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^.3`L,#`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,SDL,#`P/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^.#0L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S8L,#`P M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S`L,#`P/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L M93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO M6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="<^(#QS=')O;F<^/&9O;G0@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QS=')O;F<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^($YO=&4@."8C,38P.RTF M(S$V,#M);F-O;64@5&%X97,\+V9O;G0^/"]F;VYT/CPO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S M='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^/&9O;G0@"!P2!T87@@28C.#(Q-SMS M(&5F9F5C=&EV92!T87@@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E' M3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L M92!S='EL93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@ M0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@ M5TE$5$@Z(#@U)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9, M3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5S/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!O;B!F M;W)E:6=N(&]P97)A=&EO;G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXQ+C`V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^*#,X+C6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(&1E9F5R"!A6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO M9F]N=#X\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X M('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^-#`X+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`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`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V9O;G0^/"]D:78^ M(#QD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\ M+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPGF5D(&9O6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@ M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@'!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M'!I65E65E(&]P M=&EO;G,@97AP:7)E9"X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;B2!V97-T960L('=I;&P@97AP:7)E(&]N(#QF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2 M.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^ M/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@28C.#(Q-SMS('-T;V-K:&]L9&5R28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!T:&%T M(&%R92!A=71H;W)I>F5D(&9O2!T:&4@0V]M<&%N>2!P M=7)S=6%N="!T;R!G'!I3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL M93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^07,@;V8@1&5C96UB97(@,S$L(#(P,3(L(#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG'!I6QE M/3-$)T-/3$]2.B!B;&%C:R<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B,Q-C`[/"]F;VYT/CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O M;G0@3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9F]N=#X\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M3X\9F]N="!S M='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^4')I;W(@=&\@=&AE($-O;7!A;GDF(S@R,3<[6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2 M.B!B;&%C:R<^/&9O;G0@3X\9F]N M="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/D5X<&5NF5D('=H96X@:70@:7,@<')O8F%B;&4@ M=&AA="!T:&4@8V]N9&ET:6]N('=I;&P@8F4@;65T+B!3=&]C:R!B87-E9"!C M;VUP96YS871I;VX@97AP96YS92!R96-O9VYI>F5D(&9O65A&EM M871E;'DF(S$V,#LD/&9O;G0@&EM871E;'D@ M)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@ M2P@=&\@97AT96YD M('1H92!E>&5R8VES92!P97)I;V0@;V8@:&ES(&]U='-T86YD:6YG('9E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O M;G0@'!E8W1E9"!D:79I9&5N9"!Y:65L9"P@97AP M96-T960@;&EV97,@86YD(&5X<&5C=&5D('-T;V-K('!R:6-E('9O;&%T:6QI M='DN/"]F;VYT/CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C M,38P.SPO9F]N=#X\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V M8V4@,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@"!S;VQI9#L@0D]21$52+5))1TA4.B`C M.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C M96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^,3(W+C0V+3$S-2XY M.#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`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`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT M('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S='EL M93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^17AP96-T960@=F]L871I;&ET>2!I2!Y:65L M9',@:6X@969F96-T(&%T('1H92!T:6UE(&]F(&=R86YT(&9O'!E8W1E9"!L:69E+"!T:&4@0V]M<&%N>2!I M&EM871E;'DF(S$V,#LD/&9O;G0@&EM871E;'D@ M)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^-"XU.#PO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^ M)B,Q-C`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`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,2PS.#4L,3DY/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/&9O M;G0@6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$S+C)P=#L@34%21TE..B`P:6X@ M,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@ M3X\ M9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^5&AE(&YU;6)E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(Y+C=P=#L@34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN M.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@ M5TE$5$@Z(#DP)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U3 M25I%.B`Q,'!T.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z M(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,BXQ M-#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,3`E/B`\9&EV/C(S-RPS,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!I M6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^,RXR-SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2XR.#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5R8VES86)L92!A="!$ M96-E;6)E6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!E8W1E9"!T M;R!V97-T(&%T($1E8V5M8F5R(#,Q+"`R,#$S/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C8V-F9F-C.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+#,U,"PV.#@\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2XR.3PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S='EL93TS1"=#3TQ/ M4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE M(&%G9W)E9V%T92!I;G1R:6YS:6,@=F%L=64@;V8@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG'!E8W1E9"!T;R!V M97-T(&ES(&%P<')O>&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CPO9F]N=#XF(S$V,#L\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE3X\9F]N M="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2 M.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG65A3X\9F]N="!S='EL93TS1"=#3TQ/4CH@ M8FQA8VLG/CPO9F]N=#XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\ M6QE/3-$)T-/3$]2.B!B;&%C:R<^4F5S=')I8W1E M9"!3=&]C:SPO9F]N=#X\+W-T3X\6QE/3-$)T-/3$]2.B!B;&%C:R<^("8C,38P M.SPO9F]N=#X\+W-T65E65E(&1I6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG65A6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/ M3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN M.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@ M5TE$5$@Z(#DP)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U3 M25I%.B`Q,'!T.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T3Y4 M;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!F;W(@=&AE M(')E&EM871E;'D@)#QF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65A M6QE/3-$)T-/3$]2.B!B M;&%C:R<^1F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S+"!A M<'!R;WAI;6%T96QY("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;B2`D/&9O;G0@65E(&1I2`D/&9O;G0@"!M M;VYT:',N/"]F;VYT/CPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T-/3$]2.B!B;&%C:R<^(#PO9F]N M=#X\+W-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QS=')O M;F<^/&9O;G0@6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V9O;G0^/"]D M:78^(#QD:78@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG28C.#(Q-SMS(&]U='-T86YD:6YG('=A6QE/3-$)T-/3$]2.B!B;&%C:R<^ M(#PO9F]N=#X\+W-T6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O M;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO'!I6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@ M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,R4^(#QD:78^ M)B,Q-C`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`P,#`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`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24^(#QD:78^,RPP-36QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24^(#QD:78^,BPW.#(L M-36QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2 M.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE('=E:6=H=&5D(&%V M97)A9V4@97AE6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QS=')O;F<^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V9O;G0^/"]D M:78^(#QD:78@6QE M/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$15(M M3$5&5#H@(SEE8C9C92`P<'@@"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$ M,3,E(&-O;'-P86X],T0R/B`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^.2PR-3,L-S6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M-B4^(#QD:78^."PX,#8L-3&5R8VES960@:6X@,C`Q M,SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D M/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO M9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^."PX,#8L M-36QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^("8C,38P.SPO9F]N=#X\+V9O;G0^("8C,38P.SPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE. M.B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG&5R8VES92!P&5R8VES960@&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T3X\6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@&5R8VES960@9'5R:6YG(#(P,3,@86YD(#(P M,3(\+V9O;G0^/"]F;VYT/CPO3Y);B!C;VYN96-T:6]N('=I=&@@=&AE(#(P,3,@4FEG:'1S M($]F9F5R:6YG+"!T:&4@0V]M<&%N>2!T96UP;W)A2!R961U8V5D('1H M92!E>&5R8VES92!P2!I;G-T3XF M(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE3Y$=7)I;F<@=&AE('!E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG&EM871E;'D@)#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE3X@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3Y3:&%R96AO;&1E6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!F;W(@=&AE('EE87(@96YD960@ M1&5C96UB97(@,S$L(#(P,3(N/"]D:78^(#PO9&EV/CQT86)L92!B;W)D97(] M,T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D M/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!.;W1E(%M! M8G-T3X\8CX\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA M8VLG/DYO=&4@,3`@)B,Q-3`[(%-T;V-K:&]L9&5R3X\8CX\9F]N="!S M='EL93TS1"=#3TQ/4CH@8FQA8VLG/B`F(S$V,#L\+V9O;G0^/"]B/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C M:R<^3VX@36%R8V@@-"P@,C`Q,RP@=&AE($-O;7!A;GD@9FEL960@82!296=I M6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/B8C,38P M.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE3X\9F]N="!S='EL93TS M1"=#3TQ/4CH@8FQA8VLG/E1H92!2:6=H=',@3V9F97)I;F<@8V]M;65N8V5D M(&]N($%P'!I2`Q-RP@,C`Q M,RX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B28C.#(Q-SMS('-T;V-K:&]L9&5R6EN9R!A('=A M6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C M:R<^3VX@36%Y(#(R+"`R,#$S+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@:71S M(%)I9VAT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6UE;G0@;V8@=&AE("0Q+C,@;6EL;&EO;B!&96)R=6%R>2`R,#$S('-E M;FEO2`R,#$S('-E;FEO6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0T],3U(Z(&)L86-K.R!&3TY4+5-) M6D4Z(#$P<'0G/B!4:&]S92!P87EM96YT6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO M='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1L969T/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/'-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^ M/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!H87,@97-T86)L:7-H M960@82`T,#$H:RD@9&5F97)R960@8V]N=')I8G5T:6]N(')E=&ER96UE;G0@ M<&QA;B`H=&AE("8C.#(R,#LT,#$H:RD@4&QA;B8C.#(R,3LI('=H:6-H(&-O M=F5R2!E;7!L;WEE92!C;VYT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2`Q+"`R M,#`T+"!T:&4@0V]M<&%N>2!B96=A;B!M871C:&EN9R`\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'0@/&9O M;G0@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA3X\6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9F]N=#X\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M3X\6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I M;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!H87,@;F]T(&%N9"!D;V5S(&YO="!I M;G1E;F0@:6X@=&AE(&YE87(@9G5T=7)E+"!T;R!M86YU9F%C='5R92!A;GD@ M;V8@:71S('!R;V1U8W1S(&%N9"!C;VUP;VYE;G1S+B!7:71H(')E9V%R9"!T M;R!T:&4@3TQP=7(@340Q.3`@86YD($U$,C(P+"!O;B!*=6YE(#(W+"`R,#$Q M+"!T:&4@0V]M<&%N>2!E;G1E2UB87-E9"!S=7!P;&EE2!D;V5S(&YO="!S96QL('1H M92!06QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^(#PO9F]N=#X\+V9O;G0^/"]D:78^(#QD:78@ M6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@2!A;F0@8F5T=V5E;B!T:&4@0V]M<&%N>2!A;F0@0F5L;&-O+"!W M:&EC:"!A;65N9',@=&AE($QI8V5N2`Q+"`R,#$Q(&)Y(&%N9"!B971W965N('1H92!#;VUP M86YY(&%N9"!"96QL8V\N/&9O;G0@2!A;F0@0F5L;&-O(&%G'1E;F0@=&AE('1E M2!T:&4@3&EC96YS92!!9W)E96UE;G0@ M=&\@:6YC;'5D92!3=V5D96XL($1E;FUA2P@1FEN;&%N9"P@ M2V]R96$L($UE>&EC;RP@0G)A>FEL+"!#:&EN82!A;F0@=&AE($YE=&AE2!W:6QL M('!R;W9I9&4@0F5L;&-O('=I=&@@=W)I='1E;B!N;W1I8V4@=&AE3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3&EC96YS92!A M;F0@4W5P<&QY($%G6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I M;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!F;W(@=&AE(&9I2!! M9W)E96UE;G0N($EN(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!G&-L=7-I=F4@;&EC96YS92!U;F1E28C.#(Q-SMS(&EN=&5L;&5C='5A;"!P2!T;R!M86ME('1H92!& M:6QT6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2X@26X@=&AE('EE87(@96YD M960@1&5C96UB97(@,S$L(#(P,3,@=&AE($-O;7!A;GDF(S@R,3<[6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V9O M;G0^/"]D:78^(#QD:78@2!P86ED)B,Q-C`[365D:6-A)B,Q-C`[("8C.#,V M-#L\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B2`T/"]F;VYT/BP@,C`Q,RP@86YD M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<^)B,X,S8T.S0P,"PP,#`@;VX@36%Y(#(S+"`R,#$S/"]F;VYT/CPO9F]N M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/BXF(S$V,#M!2P@=&AE($-O;7!A;GD@ M9W)A;G1E9"!-961I8V$@;W!T:6]N2`D/&9O;G0@6UE;G1S(&1E2`D/&9O;G0@F5D(&%S(&%N(&5X<&5NF%T:6]N(&5X<&5N2`D/&9O;G0@F%T:6]N(&5X<&5NF5D(&EN('1H92!Y96%R6%L='D@2!!9W)E96UE;G0N(%1H92!T97)M(&]F M('1H92!,:6-E;G-E(&%N9"!3=7!P;'D@06=R965M96YT(&-O;6UE;F-E9"!O M;B!!<')I;"`R,RP@,C`Q,B!A;F0@8V]N=&EN=65S(&EN(&5F9F5C="!T:')O M=6=H($1E8V5M8F5R(#,Q+"`R,#(R+"!U;FQE2!I;B!A8V-O6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE2!W92!H879E(&%G6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1L969T/CQS=')O;F<^/&9O;G0@6UE;G0@06=R965M96YT/"]F;VYT/CPO9F]N=#X\+W-T3X\9F]N="!S='EL93TS1"=#3TQ/ M4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q M-C`[/"]F;VYT/CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@07!R:6P@,C`L(#(P M,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!%;7!L;WEM96YT($%G M2!W:6QL(&)E("0\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2P@87,@9&5T M97)M:6YE9"!B>2!T:&4@0V]M<&%N>2X\+V9O;G0^/"]F;VYT/CPO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T-/3$]2.B!B;&%C:R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)T-/3$]2 M.B!B;&%C:R<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^0V]N=')A8W1U M86P@3V)L:6=A=&EO;G,\+V9O;G0^/"]F;VYT/CPO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^ M/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!H860@86X@;W!E2!S:6=N960@82!O;F4@>65A'1E;G-I;VX@9F]R('1H92!S M86UE(&]F9FEC92!S<&%C92!W:&EC:"!W:6QL(&5X<&ER92!O;B!.;W9E;6)E M2!C;W-T(&]F(&%P<')O>&EM871E M;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S M='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^4F5N="!E>'!E;G-E(&9O65A3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[ M)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9F]N=#X@/&9O;G0@6QE/3-$)T-/3$]2.B!B;&%C M:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO M9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^5&AE(&9O;&QO=VEN9R!T86)L97,@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E' M3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L M92!S='EL93TS1"=C;&5A6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\ M+V1I=CX@/"]T9#X@/"]T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B!4;W1A;#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0G/B!-;W)E)B,Q-C`[=&AA;CQB6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T M9#X@/"]T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B!,96%S97,\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0G/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T9#X@/"]T6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0G/B!%;7!L;WEM96YT($-O;G1R86-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`W.#@L,#`P/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0G/B`F(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`X.38L,#`P/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G M/B`T-3`L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0G/B`T-#8L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/BT\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@ M/"]T9#X@/"]T6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G M/CPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@ M0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/CQS=')O;F<^(%!R;V1U M8W0@4F5C86QL/"]S=')O;F<^/"]F;VYT/CPO9F]N=#X@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@1D].5"U3 M25I%.B`Q,'!T)SY/;B!/8W1O8F5R(#,P+"`R,#$S+"!T:&4@0V]M<&%N>2!F M:6QE9"!A($-U2!R96-A;&QS(&]F(&ET2P@2X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;B2!A9'9E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!! M<')I;"`R,"P@,C`Q-"X\+V9O;G0^/"]D:78^(#PO9&EV/CQT86)L92!B;W)D M97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQF;VYT('-T>6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O M;G0@'!E6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M("8C,38P.SPO9F]N=#X\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^ M(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S='EL M93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^1F]R('1H92!Y96%R2P@;V8@=&AE($-O;7!A;GDF(S@R,3<[6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(&%C8V]U;G1S(')E8V5I=F%B;&4N M/"]F;VYT/CPO9F]N=#X\+V1I=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD M:78@6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^($YO=&4@,30F(S$V,#LM(%-U8G-E<75E;G0@179E;G1S/"]F M;VYT/CPO9F]N=#X\+W-T6QE/3-$)T-/3$]2.B!B;&%C:R<^/"]F;VYT/CPO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE. M.B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@ M0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/F%N9"!T:&4@:7-S=6%N M8V4@;V8@-RPQ-#`L.#(R('-H87)E6UE M;G0\+V9O;G0^(&]F('1H92`D/&9O;G0@2P\+V9O;G0^)B,Q-C`[<&QU6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0T],3U(Z(&)L M86-K.R!&3TY4+5-)6D4Z(#$P<'0G/F]F(&%C8W)U960@:6YT97)E2!E>&5R8VES960@=&AE:7(@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%2 M1TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^3VX@1F5B2!A;F0@8F5T=V5E;B!T:&4@0V]M<&%N>2!A M;F0@0F5L;&-O+"!W:&EC:"!A;65N9',@=&AE($QI8V5N2`Q+"`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`P:6X@,&EN(#!P="<^(#QF;VYT M('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S='EL93TS1"=# M3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M5&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E M;65N=',@:6YC;'5D92!T:&4@86-C;W5N=',@;V8@=&AE($-O;7!A;GD@86YD M(&ET2P@3F5P:')O6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)SL@1D].5"U325I%.B`Q,'!T)SX@8V]N6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE('!R97!A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)SL@1D].5"U325I%.B`Q,'!T)SX@8V]N2!A8V-E<'1E9"!I;B!T:&4@ M56YI=&5D(%-T871E'!E;G-E2!F65A6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D M/CPO='(^/"]T86)L93X\6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF M;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S='EL93TS M1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^5&AE(&%C8V]M<&%N>6EN9R`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B<[($9/3E0M4TE:13H@,3!P="<^(&-O;G-O M;&ED871E9"8C,38P.SPO9F]N=#X@9FEN86YC:6%L('-T871E;65N=',@:&%V M92!B965N('!R97!A2!I;B!G96YE M2X\+V9O;G0^/"]F;VYT/CPO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^ M/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!H87,@:6YC=7)R960@ M2!H87,@;F]T(&=E;F5R871E9"!P;W-I=&EV92!C M87-H(&9L;W<@9G)O;2!O<&5R871I;VYS(&9O65A2!M=7-T(&EN8W)E87-E(')E=F5N=64@2!A;F0@86-H:65V92!A;F0@;6%I;G1A:6X@<&]S:71I=F4@9W)O M2!I2P@:71S(')E2!A9F9E8W1E9#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)SL@1D].5"U325I%.B`Q,'!T)SXN/"]F;VYT/CPO9F]N=#X\ M+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT M/CPO9F]N=#X\+V9O;G0^)B,Q-C`[/"]D:78^(#QD:78@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@1D].5"U325I% M.B`Q,'!T)SX@5#PO9F]N=#X\+V9O;G0^/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@1D].5"U325I%.B`Q M,'!T)SYH92!V;VQU;G1A2!I;7!A8W0@ M=&AE($-O;7!A;GDF(S@R,3<[6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O M;G0@2!E;G1E6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG28C,38P.SPO M9F]N=#X\+V9O;G0^(&%N9"`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N)SX\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N M)SYB971W965N('1H92!#;VUP86YY/"]F;VYT/CPO9F]N=#X@86YD($)E;&QC M;RP@=VAI8V@@86UE;F1S('1H92!,:6-E;G-E($%G2`Q+"`R,#$Q+B!!2`Q.2P@,C`Q-"P@ M86YD('1H92!O=&AE6QE/3-$)T9/3E0M4TE:13H@,3!P=#M&3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#M&3TY4 M+49!34E,63I4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P M:6X@,&EN(#!P="<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`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`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L M93X\6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<^(#QS=')O;F<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT M('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@3X\9F]N="!S='EL93TS1"=# M3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M5&AE($-O;7!A;GD@:6YV97-T2!C;VYS:61E2!L:7%U:60@:6YV97-T;65N M=',@<'5R8VAA6QE/3-$)T-/3$]2.B!B M;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!I;B!O2!A M;F0@8W)E9&ET('=O6QE/3-$)T)!0TM'4D]53D0M24U!1T4Z(&YO;F4[($)!0TM' M4D]53D0M051404-(345.5#H@6QE/3-$ M)T)!0TM'4D]53D0M24U!1T4Z(&YO;F4[($)!0TM'4D]53D0M051404-(345. M5#H@'!E;G-E(&1U&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T3X\6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^ M/&9O;G0@2!E M;F=A9V5S('1H:7)D('!A2!C;VYS:7-T6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T2!R97%U M97-T960@=&AE(&-L;W-E;W5T(&]F(&ET6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2!!<')I;"`R,"P@,C`Q-"X\+V1I=CX@/"]D M:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T'0^)SQD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(%!A=&5N M=',\+V9O;G0^/"]F;VYT/CPO6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`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`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE. M.B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!A;F0@97%U:7!M96YT+"!N970@:7,@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z M(#!I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B M;&%C:R<^/&9O;G0@2!A9&AE6EN9R!V86QU92!O M9B!I=',@9&5P2!T:&4@;&]N9RUL M:79E9"!A6EN9R!V86QU92!T;R!D M971E65A6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\3X\6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6EN9R!A;6]U;G1S(&]F(&-A6%B;&4@86YD M(&%C8W)U960@97AP96YS97,@87!P&5D.R<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^ M/"]T'0^)SQD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^4F5V96YU92!296-O9VYI=&EO;CPO9F]N=#X\+V9O;G0^/"]S=')O;F<^ M/"]D:78^(#QD:78@2!I3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@2!I=',@97AT97)N86P@;&]G:7-T:6-S('!R;W9I M9&5R(&%N9"!T:&4@;W1H97(@8W)I=&5R:6$@;V8@05-#(%1O<&EC(#8P-2!A M2!.97!H M3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CPO9F]N=#XF(S$V M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE3X\ M9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CPO9F]N=#X\9F]N="!S='EL M93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^1&5F97)R960@2`D-S`S+#`P,#PO9F]N=#X@ M86YD("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;B65A2!A;6]R=&EZ97,@=&AE(&1E9F5R2!O=F5R('1H92!E>'!E8W1E9"!O8FQI9V%T:6]N('!E6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O M;G0@6UE;G0@;V8@87!P2`D/&9O;G0@6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@ M6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQS=')O;F<^/&9O;G0@2`D/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO M='(^/"]T86)L93X\'0^)SQD:78@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)SL@0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C M:R<^/"]F;VYT/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<@86QI9VX],T1J=7-T:69Y/CQS=')O;F<^/&9O;G0@28C.#(Q-SMS('-T;V-K(&]P=&EO;B!A=V%R9',@87)E M(&5S=&EM871E9"!U2!A;F0@ M=&AE(&5S=&EM871E9"!L:69E(&]F(&5A8V@@87=AF5D(&]V97(@=&AE('9E'!E;G-E(&ES(')E M8V]G;FEZ960@=VAE;B!I="!I&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\ M='(^/'1D/CPO=&0^/"]TF%T:6]N(&]F($1E M8G0@27-S=6%N8V4@0V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J M=7-T:69Y/CQS=')O;F<^/&9O;G0@3X\9F]N="!S='EL93TS1"=#3TQ/4CH@ M8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M/"]F;VYT/CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@86-C;W5N M=',@9F]R(&1E8G0@:7-S=6%N8V4@8V]S=',@:6X@86-C;W)D86YC92!W:71H M($%30R`X,S4L('=H:6-H(')E<75I2!T;R!T:&4@:7-S=65R(&]F)B,Q-C`[('1H92!N;W1E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)SL@1D].5"U325I%.B`Q,'!T)SY&96)R=6%R M>2`T+"`R,#$S(&%N9"8C,38P.SPO9F]N=#X@3F]V96UB97(@,3(L(#(P,3,N M($%P<')O>&EM871E;'D@)#(U-RPP,#`@;V8@=&AE&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T'!E;G-E*2P@;F5T/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3X\6QE/3-$)T-/ M3$]2.B!B;&%C:R<^/&9O;G0@'!E;G-E*2P@;F5T M/"]F;VYT/CPO9F]N=#X\+V9O;G0^/"]S=')O;F<^/"]D:78^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@&EM871E;'D@ M)#,S+#`P,"8C,38P.SPO9F]N=#X@:6YC;'5D97,F(S$V,#MA<'!R;WAI;6%T M96QY("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@1D].5"U325I%.B`Q,'!T)SYF M;W)E:6=N(&-U&EM871E M;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<^=&AE(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@1D].5"U325I%.B`Q,'!T)SY-87D@ M,C`Q,R!R:6=H=',@;V9F97)I;F'!E;G-E('=A&EM871E;'D@)#QF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T-/3$]2.B!B;&%C:R<^)#$T+#`P,"!F;W(@=&AE M('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3(@:7,@9'5E('!R:6UA2!T;R!A<'!R;WAI;6%T96QY("0\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B2!B>2!A<'!R;WAI;6%T96QY("0\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L M93X\'0^)SQD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26YC;VUE(%1A>&5S/"]F M;VYT/CPO9F]N=#X\+W-T3X\ M9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`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`[/"]F;VYT/CPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL M93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^05-#(%1O<&EC(#"!P;W-I M=&EO;G,@=&%K96X@;W(@97AP96-T960@=&\@8F4@=&%K96X@:6X@82!C;VUP M86YY)B,X,C$W.W,@:6YC;VUE('1A>"!R971U"!P;W-I=&EO;B!I2!T:&%N(&YO="!T;R!B92!S M=7-T86EN960@=7!O;B!A=61I="P@:6YC;'5D:6YG(')EF5D(&]N('-E='1L96UE M;G0@=VET:"!T:&4@=&%X:6YG(&%U=&AO2XF(S$V,#L@5&AE($-O;7!A M;GD@:7,@2!M M86IO65A"!P;W-I=&EO;G,N)B,Q-C`[($AO=V5V97(L(&UA;F%G96UE;G0F(S@R,3<[ M7-E6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO M='(^/"]T86)L93X\'0^)SQD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@"!S;VQI9#L@34%21TE..B`P:6X@,&EN M(#!I;B`P+C5I;CL@5TE$5$@Z(#@P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S93L@1D].5"U325I%.B`Q,'!T.R!/5D521DQ/5SH@=FES:6)L93L@0D]2 M1$52+51/4#H@(SEE8C9C92`P<'@@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^,3,L.#@W+#4Y.#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@2!46QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C M:R<^/&9O;G0@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U M=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R M/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0^)SQD:78@ M6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^0V]M<')E:&5N3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9F]N=#X\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M3X\9F]N="!S M='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^0V]M<')E:&5N2`H;W(@;W1H97(@8V]M<')E:&5N&EM M871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2X\+V9O;G0^/"]F M;VYT/CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W M:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL2!!9&]P=&5D($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\ M+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQS=')O;F<^/&9O M;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9F]N=#X\+W-T3X\6QE/3-$)T-/3$]2 M.B!B;&%C:R<^(#PO9F]N=#X\+W-T6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A4 M86)L97,I/&)R/CPO'0^)SQS<&%N/CPO M&-L=61E9"!&'0^)SQD:78@6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QS=')O;F<^ M/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G(&%L:6=N/3-$8V5N M=&5R/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T M.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52 M+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;B`P:6X@,&EN M(#`N-6EN.R!724142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E M.R!&3TY4+5-)6D4Z(#$P<'0[($]615)&3$]7.B!V:7-I8FQE.R!"3U)$15(M M5$]0.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+5))1TA4.B`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^-S4L-#4P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!$:7-C;&]S=7)E(%M!8G-T M2P@0W5R'0^)SQD:78@6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P M)2<^(#QT86)L92!S='EL93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P M>"!S;VQI9#L@0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)' M24XZ(#!I;CL@5TE$5$@Z(#DP)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S M93L@3U9%4D9,3U6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^-3(W+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\ M9&EV/B@R-CDL,#`P*3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T M.39F-3AC85\Y-&8P7S1C,&5?830U,%]C-V5A83@Y9&)F,38-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#DV9C4X8V%?.31F,%\T8S!E7V$T-3!? M8S=E86$X.61B9C$V+U=O'0O:'1M;#L@8VAA'0^)SQD:78@6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V9O;G0^/"]D:78^ M(#QD:78@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$15(M3$5& M5#H@(SEE8C9C92`P<'@@6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S@L M,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR,2PP,#`\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^,S0L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M,3(U+#`P,#PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^,3`Y+#`P,#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO M='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78@ M6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO M9F]N=#X\+V9O;G0^/"]D:78^(#QD:78@"!S;VQI9#L@34%21TE..B`P:6X[($)/4D1%4BU, M1494.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@1D]. M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#4V M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=. M.B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=. M.B!L969T)R!W:61T:#TS1#4V)3X@/&1I=CY-86YU9F%C='5R:6YG(&5Q=6EP M;65N=#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$Q)3X@ M/&1I=CXS+34F(S$V,#MY96%R"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U714E'2%0Z(#0P,#L@0T],3U(Z(",P,#`P,#`[($9/3E0M4U19 M3$4Z(&YO"<@=VED=&@],T0Q,"4^(#QD:78^-3DY+#`P,#PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@ M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U714E'2%0Z(#0P,#L@0T],3U(Z(",P,#`P,#`[($9/3E0M4U193$4Z(&YO M"<@ M=VED=&@],T0Q,"4^(#QD:78^,S6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D]. M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"<@ M=VED=&@],T0Q,"4^(#QD:78^,S6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L M.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$Q)3X@/&1I=CXS+30F(S$V M,#MY96%R6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@0T], M3U(Z(",P,#`P,#`[($9/3E0M4U193$4Z(&YO"<@=VED=&@],T0Q,"4^(#QD:78^ M-3DL,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4 M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@"<@=VED=&@],T0Q,"4^(#QD:78^ M-3DL,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4 M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/ M5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]2 M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/33H@ M(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/ M5%1/33H@(S`P,#`P,"`Q<'@@"<@=VED=&@],T0Q,"4^(#QD:78^,SDL,#`P/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=2 M3U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@ M;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=. M.B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%, M24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L M.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5. M1#H@(V-C9F9C8SL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@"<@=VED=&@],T0Q,"4^ M(#QD:78^-S,W+#`P,#PO9&EV/B`\+W1D/B`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`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4U193$4Z(&YO"<@=VED=&@],T0Q,"4^(#QD:78^-S(W+#`P,#PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P M,"`Q<'@@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D]. M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU2 M24=(5#H@-7!X)R!W:61T:#TS1#$P)3X@/&1I=CXW,C$L,#`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`\9&EV/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C M9F9C8SL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4 M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ M(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@0D]21$52 M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%, M24=..B!R:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$P)3X@ M/&1I=CXW+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P M,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE M/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&5S(&%N9"!!8V-R=6%L3X\9F]N="!S='EL93TS1"=# M3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M06-C'!E;G-E6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V9O;G0^/"]D:78^(#QD M:78@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@ M(SEE8C9C92`P<'@@"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^,30Y+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^-S6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!E;G-E"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0G/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV M/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA"!$:7-C;&]S=7)E(%M!8G-T2!2871E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^02!R96-O;F-I;&EA=&EO;B!O9B!T M:&4@:6YC;VUE('1A>"!P2!T87@@28C.#(Q-SMS(&5F9F5C=&EV M92!T87@@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4 M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS M1"="3U)$15(M0D]45$]-.B`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`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXQ+C`V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^*#,X+C6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T3X\ M9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^4VEG;FEF:6-A;G0@8V]M<&]N96YT28C.#(Q-SMS(&1E9F5R"!A6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N M=#X\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O M;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO"!A M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!E;G-E/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M-#`X+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52 M+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!3:&%R92UB87-E M9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^)SQD:78@6EE;&0L(&5X<&5C=&5D(&QI=F5S(&%N9"!E>'!E8W1E M9"!S=&]C:R!P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4 M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+4Q% M1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@5TE$5$@Z(#DP M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U325I%.B`Q,'!T M.R!/5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@ M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^ M,3(S+C0X)B,Q-C`[)B,Q-3`[,3(X+C4T/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M0T],3U(Z(",P,#`P,#`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`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D M/CPO='(^/"]T86)L93X\6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#!I;CL@34%21TE..B`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`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^-"XU.#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^ M,2PS.#4L,3DY/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0G/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV M/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T2!/9B!/<'1I;VX@06-T:79I='D\+W1D/@T*("`@("`@("`\=&0@ M8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@ M5$585"U)3D1%3E0Z(#!I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P M,3,Z/"]F;VYT/CPO9F]N=#X\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@.3`E M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+5-)6D4Z(#$P<'0[ M($]615)&3$]7.B!V:7-I8FQE)R!C96QL6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO&5R8VES93QB"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U M<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXH,3(Q+#@Y-2D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@ M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/ M4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXQ+#,X-2PQ.3D\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^,2XT-CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4 M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(L,S4P+#8X.#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)W=I9'1H.C$P,"4[ M('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D M9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0^)SQD:78@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS.3@L,C(W/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@U."PP,#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1% M3E0Z(#!I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2 M.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1C96YT97(^/'-T6QE/3-$)T-/3$]2.B!B;&%C:R<^ M/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5TE$5$@Z(#$P,"4[("!415A4+4E.1$5.5#H@,&EN)SX@/'1A8FQE('-T M>6QE/3-$)T]615)&3$]7.B!V:7-I8FQE.R!724142#H@,3`P)3L@0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S93L@34%21TE..B`P:6XG(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\='(^(#QT9"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2 M1$52+4)/5%1/33H@(S`P,#`P,"`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`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S M;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@ M;F]R;6%L.R!415A4+4%,24=..B!R:6=H="<@=VED=&@],T0Q,R4^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E, M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#,R)3X@/&1I M=CY#;&%S6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@ M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H="<@=VED=&@] M,T0Q,R4^(#QD:78^,3$O,30O,C`P-SPO9&EV/B`\+W1D/B`\=&0@"<@=VED=&@],T0Q,24^(#QD:78^,"XT,#PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L M.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#,R)3X@/&1I=CY*=6QY(#(P M,#D@5V%R6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U7 M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@ M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`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`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`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`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`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H=#L@4$%$ M1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$Q)3X@/&1I=CXS+#`U-RPQ.3`\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@ M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4 M+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=. M.B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E' M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E, M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D]. M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU2 M24=(5#H@-7!X)R!W:61T:#TS1#$Q)3X@/&1I=CXR+#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@ M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H=#L@ M4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$Q)3X@/&1I=CXR+#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`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`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5. M1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=( M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT M.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3$E/B`\9&EV/C$T+#8W M.2PY-S$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A M8FQE/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#!I;B<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^ M/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\ M+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED M.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S M;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS M1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/B`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`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^ M.2PR-3,L-S6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q-B4^(#QD:78^."PX,#8L-3&5R8VES M960@:6X@,C`Q,SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD M:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^+3PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^ M(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD M:78^."PX,#8L-36QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!& M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/"]D M:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA3X\9F]N="!S='EL93TS1"=#3TQ/ M4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE M(&9O;&QO=VEN9R!T86)L97,@6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@ M,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^,3`P+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6UE M;G0@0V]N=')A8W1S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^,S4P+#`P,#PO9&EV/B`\+W1D/B`\=&0@"!S M;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^-#4P+#`P,#PO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P M,#`P,"`Q<'@@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'1U86PI/&)R/CPOF%T:6]N($%N9"!.871U7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N(&]F(&1E8G0@:7-S=6%N M8V4@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO#PO M=&0^#0H@("`@("`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2`H1&5T86EL'0^)SQS<&%N/CPO2P@1FEN:7-H960@ M1V]O9',\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'!E;G-E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)SQS<&%N/CPO M2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M2!A;F0@97%U:7!M96YT+"!,:69E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG-R!Y96%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M2!A M;F0@97%U:7!M96YT+"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG-2!Y96%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S,@>65A'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@4&QA;G0@86YD($5Q=6EP;65N="!; M3&EN92!)=&5M2!A;F0@97%U:7!M96YT+"!G'0^)SQS<&%N/CPO2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M2!A;F0@97%U:7!M96YT+"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG-"!Y96%R'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S<@>65A M2!A;F0@97%U:7!M96YT+"!G7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO2`Q,BP-"@D),C`Q-#QS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N M/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO2!R871E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XS-2XP,"4\&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C(R M)3QS<&%N/CPO"!R871E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XP+C`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`@("`@("`@ M/'1H(&-L87-S/3-$=&@@8V]L2!;365M8F5R73QB M'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO69O'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'!I'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'!E8W1E9"!,:69E("AI;B!Y M96%R'0^)S8R('EE87)S(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N/CPO'!E8W1E9"!, M:69E("AI;B!Y96%R'0^)S4@>65A'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS M<&%N/CPO&5R8VES86)L92P@3G5M8F5R M($5X97)C:7-A8FQE(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,X-2PQ.3D\'0^)SQS<&%N/CPO MF5D M('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N&5R8VES92!0&5R8VES92!0 M&5R8VES86)L92P@5V5I9VAT960@ M079E&5R8VES92!0'0^)SQS<&%N M/CPO&5R8VES92!0 M7,\&5R8VES86)L92!A&5R8VES92!0&5R8VES92!0&5R8VES92!0 M&5R8VES86)L92P@3G5M8F5R($5X97)C:7-A8FQE(&%S(&]F M($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XW+#&5R8VES86)L92P@5V5I9VAT960@079E M&5R8VES92!07!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M, M:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'!E8W1E9"!T;R!V M97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,U,"PV.#@\ M'0^)SQS<&%N/CPO&5R8VES92!0 M'0^)SQS<&%N/CPO&5R8VES92!0'0^)SQS<&%N/CPO&5R8VES92!0&5R8VES92!065A'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^36%R(#$P+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^36%R(#$P+`T*"0DR,#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M&5R M8VES92!0'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES960\+W1D/@T* M("`@("`@("`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`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XG."!Y96%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7,\'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R M8VES92!O9B!W87)R86YT'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES960@56YD97(@0V%S:&QE'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!I M'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^36%R(#$U+`T*"0DR,#$T/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.39F M-3AC85\Y-&8P7S1C,&5?830U,%]C-V5A83@Y9&)F,38-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-#DV9C4X8V%?.31F,%\T8S!E7V$T-3!?8S=E M86$X.61B9C$V+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!%86-H M(%=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T.39F-3AC85\Y-&8P7S1C,&5?830U,%]C-V5A M83@Y9&)F,38-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#DV9C4X M8V%?.31F,%\T8S!E7V$T-3!?8S=E86$X.61B9C$V+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQS M<&%N/CPO&EM=6T@96UP;&]Y964@8V]N=')I8G5T:6]N+"!P97)C96YT86=E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2XP,"4\'0^)SQS<&%N/CPO M'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#0V+#`P,#QS<&%N/CPO'0^)SQS<&%N/CPO65R(&UA=&-H:6YG(&-O;G1R M:6)U=&EO;BP@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO65E(&-O M;G1R:6)U=&EO;G,@;6%T8VAE9"!B>2!E;7!L;WEE'0^)SQS<&%N/CPO3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.39F-3AC85\Y-&8P7S1C,&5? M830U,%]C-V5A83@Y9&)F,38-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO-#DV9C4X8V%?.31F,%\T8S!E7V$T-3!?8S=E86$X.61B9C$V+U=O'0O:'1M;#L@ M8VAA#(P86,[*3QB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO2!P97(@=6YI=#PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO#(P M86,[(#,P,"PP,#`\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO6UE M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!R96YT(&5X M<&5N'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA6UE;G1S($1U92!7:71H:6X@,2!996%R/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XT-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@0V]N=')A8W1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N/CPO6UE;G1S($1U92!7:71H:6X@,2`M(#,@665A M6UE;G1S($1U92!7:71H:6X@-"`M(#4@665A6UE;G1S($1U92!-;W)E(%1H86X@-2!9 M96%R'0^ M)SQS<&%N/CPO6UE M;G1S($1U92!7:71H:6X@,2`M(#,@665A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`\'1087)T7S0Y-F8U.&-A @7SDT9C!?-&,P95]A-#4P7V,W96%A.#ED8F8Q-BTM#0H` ` end XML 27 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Plans, Share-Based Payments and Warrants (Details)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected dividend yield 0.00% 0.00%
Maximum [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock Price Volatility 135.98% 128.54%
Risk-Free Interest Rates 1.75% 1.32%
Expected Life (in years) 6 years 3 months 62 years 6 months
Minimum [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock Price Volatility 127.46% 123.48%
Risk-Free Interest Rates 1.09% 0.093%
Expected Life (in years) 5 years 5 years 9 months
XML 28 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Plans, Share-Based Payments and Warrants (Tables)
 12 Months Ended
Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule Of Fair Value Assumptions
The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the below assumptions related to risk-free interest rates, expected dividend yield, expected lives and expected stock price volatility.
 
 
 
Option Pricing Assumptions
 
 
Grant Year
 
2013
 
 
2012
 
 
Stock Price Volatility
 
 
127.46-135.98
%
 
 
123.48 –128.54
%
 
Risk-Free Interest Rates
 
 
1.09-1.75
%
 
 
.093-1.32
%
 
Expected Life (in years)
 
 
5.00-6.25
 
 
 
5.75-62.5
 
 
Expected Dividend Yield
 
 
0
%
 
 
0
%
 
Summary Of Information About Stock Options Outstanding And Exercisable
The following table summarizes information about stock options outstanding and exercisable at December 31, 2013:
 
 
 
Options Outstanding
 
Options Exercisable
 
Range of Exercise
Price
 
Number
Outstanding as
of December
31, 2013
 
Weighted
Average
Remaining
Contractual
Life in
Years
 
Weighted
Average
Exercise
Price
 
Number
Exercisable as
of
December 31,
2013
 
Weighted
Average
Exercise Price
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$0.41 - $2.60
 
 
2,374,514
 
 
8.16
 
$
0.93
 
 
1,349,579
 
$
0.83
 
$15.00 - $29.80
 
 
27,909
 
 
4.58
 
$
17.82
 
 
27,909
 
$
17.82
 
$34.20-$96.00
 
 
7,711
 
 
1.38
 
$
51.49
 
 
7,711
 
$
51.49
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Outstanding
 
 
2,410,134
 
 
 
 
$
1.28
 
 
1,385,199
 
$
1.46
 
Summary Of Option Activity
The following table summarizes the option activity for the year ended December 31, 2013:
 
 
 
Shares
 
Weighted
Average
Exercise
Price
 
Outstanding at December 31, 2012
 
 
2,294,714
 
$
 
2.14
 
Options granted
 
 
237,315
 
 
 
0.64
 
Options exercised
 
 
-
 
 
 
-
 
Options forfeited or expired
 
 
(121,895)
 
 
 
3.27
 
Outstanding at December 31, 2013
 
 
2,410,134
 
$
 
1.28
 
Exercisable at December 31, 2013
 
 
1,385,199
 
$
 
1.46
 
Vested and expected to vest at December 31, 2013
 
 
2,350,688
 
$
 
1.29
 
Summary Of Restricted Stock Activity
The following table summarizes restricted stock activity for the year end December 31, 2013:
 
 
 
Shares
 
Weighted
Average
Grant Date
Fair Value
 
Nonvested at December 31, 2012
 
-
 
$
-
 
Granted
 
398,227
 
 
0.73
 
Vested
 
(264,770)
 
 
0.71
 
Forfeited
 
(58,007)
 
 
0.88
 
Nonvested at December 31, 2013
 
75,450
 
$
0.66
 
Summary Of Terms Of Outstanding Warrants
The following table summarizes certain terms of all of the Company’s outstanding warrants at December 31, 2013 and 2012: 
 
 
Total Outstanding Warrants at December 31, 2013
Title of Warrant
 
Date Issued
 
Expiry Date
 
Exercise Price
 
Total Common
Shares Issuable
 
 
 
 
 
 
 
 
 
 
2013
 
2012
 
Class D Warrants - Lambda
 
11/14/2007
 
3/10/2017
 
$
0.40
 
 
8,806,575
 
 
8,806,575
 
July 2009 Warrants
 
7/24/2009
 
7/24/2014
 
$
22.40
 
 
33,629
 
 
33,629
 
Shareholder Rights Offering Warrants
 
3/10/2011
 
3/10/2016
 
$
0.40
 
 
2,264,817
 
 
3,057,190
 
March 2011 Lambda Warrants
 
3/10/2011
 
3/10/2017
 
$
0.40
 
 
2,782,577
 
 
2,782,577
 
 
 
 
 
 
 
 
 
 
 
13,887,598
 
 
14,679,971
 
Class D Warrants [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Summary Of Terms Of Outstanding Warrants
The following table summarizes the Class D outstanding warrants at December 31, 2013 and 2012:
 
 
 
Lambda Investors
 
Other Investors
 
Total Shares to be issued
 
As of December 31, 2011
 
 
8,806,575
 
 
447,197
 
 
9,253,772
 
Exercised in 2012
 
 
-
 
 
(352,034)
 
 
(352,034)
 
Expired in 2012
 
 
-
 
 
(95,163)
 
 
(95,163)
 
As of December 31, 2012
 
 
8,806,575
 
 
-
 
 
8,806,575
 
Exercised in 2013
 
 
-
 
 
-
 
 
-
 
Expired in 2013
 
 
-
 
 
-
 
 
-
 
As of December 31, 2013
 
 
8,806,575
 
 
-
 
 
8,806,575
 
XML 29 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2013
Income Tax Disclosure [Abstract]  
Reconciliation Of Income Tax Provision At Statutory Rate
A reconciliation of the income tax provision computed at the statutory tax rate to the Company’s effective tax rate is as follows:
 
 
2013
 
 
2012
 
U.S. federal statutory rate
 
 
35.00
%
 
35.00
%
State & local taxes
 
 
5.22
%
 
5.36
%
Tax on foreign operations
 
 
0.40
%
 
(0.78)
%
State research and development credits
 
 
1.09
%
 
1.06
%
Other
 
 
(3.00)
%
 
(2.29)
%
Valuation allowance
 
 
(38.71)
%
 
(38.35)
%
Effective tax rate
 
 
-
 
 
-
 
Significant Components Of Deferred Tax Assets
Significant components of the Company’s deferred tax assets as of December 31, 2013 and 2012 are as follows:
 
 
 
2013
 
 
2012
 
Deferred tax assets:
 
 
 
 
 
 
 
 
Net operating loss carry forwards
 
$
27,029,000
 
 
$
25,721,000
 
Research and development credits
 
 
1,096,000
 
 
 
1,054,000
 
Nonqualified stock option compensation expense
 
 
1,801,000
 
 
 
1,701,000
 
Other temporary book - tax differences
 
 
408,000
 
 
 
441,000
 
Total deferred tax assets
 
 
30,334,000
 
 
 
28,917,000
 
Valuation allowance for deferred tax assets
 
 
(30,334,000)
 
 
 
(28,917,000)
 
Net deferred tax assets
 
$
-
 
 
$
-
 
XML 30 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Plans, Share-Based Payments and Warrants (Details 1) (USD $)
 12 Months Ended
Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Options Outstanding, Number Outstanding as of December 31, 2013 2,410,134
Options Outstanding, Weighted Average Exercise Price $ 1.28
Options Exercisable, Number Exercisable as of December 31, 2013 1,385,199
Options Exercisable, Weighted Average Exercise Price $ 1.46
$0.41 - $2.60
  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of Exercise Price, Lower Range $ 0.41
Range of Exercise Price, Upper Range $ 2.60
Options Outstanding, Number Outstanding as of December 31, 2013 2,374,514
Options Outstanding, Weighted Average Remaining Contractual Life In Years 8 years 1 month 28 days
Options Outstanding, Weighted Average Exercise Price $ 0.93
Options Exercisable, Number Exercisable as of December 31, 2013 1,349,579
Options Exercisable, Weighted Average Exercise Price $ 0.83
$15.00 - $29.80
  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of Exercise Price, Lower Range $ 15
Range of Exercise Price, Upper Range $ 29.80
Options Outstanding, Number Outstanding as of December 31, 2013 27,909
Options Outstanding, Weighted Average Remaining Contractual Life In Years 4 years 6 months 29 days
Options Outstanding, Weighted Average Exercise Price $ 17.82
Options Exercisable, Number Exercisable as of December 31, 2013 27,909
Options Exercisable, Weighted Average Exercise Price $ 17.82
$34.20-$96.00
  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of Exercise Price, Lower Range $ 34.20
Range of Exercise Price, Upper Range $ 96
Options Outstanding, Number Outstanding as of December 31, 2013 7,711
Options Outstanding, Weighted Average Remaining Contractual Life In Years 1 year 4 months 17 days
Options Outstanding, Weighted Average Exercise Price $ 51.49
Options Exercisable, Number Exercisable as of December 31, 2013 7,711
Options Exercisable, Weighted Average Exercise Price $ 51.49
XML 31 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments And Contingencies (Tables)
 12 Months Ended
Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]  
Contractual Obligations and Commercial Commitments
The following tables summarize our approximate minimum contractual obligations and commercial commitments as of December 31, 2013:
 
 
 
Payments Due in Period
 
 
 
Total
 
Within
1 Year
 
Years
1 - 3
 
Years
4 - 5
 
More than
5 Years
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Leases
 
$
108,000
 
$
100,000
 
$
8,000
 
$
-
 
$
-
 
Employment Contracts
 
 
788,000
 
 
350,000
 
 
438,000
 
 
-
 
 
-
 
Total
 
$
896,000
 
$
450,000
 
$
446,000
 
$
-
 
$
-
 
XML 32 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Organization and Nature of Operations (Details Textual)
 12 Months Ended
Dec. 31, 2013
Product
Organization And Nature Of Operations [Line Items]  
Number of products in development 2
XML 33 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Organization and Nature of Operations
 12 Months Ended
Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Nature of Operations
Note 1 - Organization and Nature of Operations
 
Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. Nephros was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced End Stage Renal Disease (“ESRD”) therapy technology and products. The Company has two products in various stages of development in the hemodiafiltration, or HDF, modality to deliver improved therapy for ESRD patients. These are the OLpur MDHDF filter series or “dialyzers,” designed expressly for HDF therapy, the OLpur H2H, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy. In 2009, the Company introduced its Dual Stage Ultrafilter (“DSU”) water filter system, which represents a new and complementary product line to the Company’s existing ESRD therapy business. The DSU incorporates the Company’s unique and proprietary dual stage filter architecture.

 On June 4, 2003, Nephros International Limited was incorporated under the laws of Ireland as a wholly-owned subsidiary of the Company.  In August 2003, the Company established a European Customer Service and financial operations center in Dublin, Ireland.
XML 34 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies (Details Textual)
 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended
May 22, 2013
USD ($)
Jan. 31, 2013
USD ($)
Jan. 31, 2012
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2013
Warrant [Member]
USD ($)
Mar. 21, 2014
Subsequent Event [Member]
USD ($)
Mar. 24, 2014
Subsequent Event [Member]
USD ($)
Mar. 31, 2014
Subsequent Event [Member]
EUR (€)
Feb. 19, 2014
Subsequent Event [Member]
EUR (€)
Nov. 12, 2013
Lambda Investors [Member]
USD ($)
Dec. 31, 2013
Lambda Investors [Member]
USD ($)
Feb. 04, 2013
Lambda Investors [Member]
USD ($)
Dec. 31, 2013
Lambda Investors [Member]
Senior Notes [Member]
USD ($)
Dec. 31, 2013
Steris Agreement Termination [Member]
USD ($)
Dec. 31, 2014
Scenario Forecast [Member]
USD ($)
Dec. 31, 2013
Scenario Forecast [Member]
USD ($)
Dec. 31, 2013
Nonsoftware License Arrangement [Member]
USD ($)
Dec. 31, 2013
Maximum [Member]
Dec. 31, 2013
Minimum [Member]
Jan. 15, 2013
Bellco [Member]
EUR (€)
Jan. 15, 2012
Bellco [Member]
EUR (€)
Jul. 01, 2011
Bellco [Member]
EUR (€)
Dec. 31, 2013
Bellco [Member]
Nonsoftware License Arrangement [Member]
USD ($)
Summary of Significant Accounting Policies [Line Items]                                                
Net loss       $ (3,698,000) $ (3,262,000)                                      
License agreement revenue paid year one                                             500,000  
License agreement revenue paid year two                                           750,000    
License agreement revenue paid in current year                                         600,000      
Senior notes issued                     1,500,000   1,300,000                      
Estimated useful lives                                     7 years 3 years        
Deferred revenue       703,000 1,414,000                                     703,000
Licensing revenues       711,000 680,000                         1,756,000            
Recognition of deferred revenue                               703,000 703,000              
Cash payments received     2,459,000                                          
Receivable related to license agreement   791,000                                            
Shipping and handling costs       30,000 33,000                                      
Amortization of debt issuance costs       257,000 0           53,000 399,000                        
Other income (expense)       (33,000) 14,000                                      
Adjustments to liabilities and foreign currency losses       36,000   14,000                                    
Comprehensive loss       (3,700,000) (3,235,000)                                      
Allowance for Doubtful Accounts Receivable       0 0                                      
Allowance for Doubtful Accounts Receivable, Write-offs       0 0                                      
Sales Returns and Allowances, Goods, Total       0 0                                      
Interest and Other Income, Total       17,000                     15,000                  
Other Expenses, Total       50,000                                        
Upfront Fees And Connection Of First Amendment                 225,000 225,000                            
Debt instrument, face amount                           1,500,000                    
Repayments of notes payable 1,300,000                                              
Proceeds from issuance of common stock       2,771,000 0   2,100,000 2,100,000                                
Other Income Write Off         18,000                                      
Foreign currency transaction loss before tax         $ 4,000                                      
XML 35 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes (Details)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Income Tax Holiday [Line Items]    
U.S. federal statutory rate 35.00% 35.00%
State & local taxes 5.22% 5.36%
Tax on foreign operations 0.40% (0.78%)
State research and development credits 1.09% 1.06%
Other (3.00%) (2.29%)
Valuation allowance (38.71%) (38.35%)
Effective tax rate 0.00% 0.00%
XML 36 R53.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Details) (USD $)
Dec. 31, 2013
Commitments And Contingencies [Line Items]  
Payments Due, Total $ 896,000
Payments Due Within 1 Year 450,000
Payments Due Within 1 - 3 Years 446,000
Payments Due Within 4 - 5 Years 0
Payments Due More Than 5 Years 0
Employment Contracts [Member]
  
Commitments And Contingencies [Line Items]  
Payments Due, Total 788,000
Payments Due Within 1 Year 350,000
Payments Due Within 1 - 3 Years 438,000
Payments Due Within 4 - 5 Years 0
Payments Due More Than 5 Years 0
Leases [Member]
  
Commitments And Contingencies [Line Items]  
Payments Due, Total 108,000
Payments Due Within 1 Year 100,000
Payments Due Within 1 - 3 Years 8,000
Payments Due Within 4 - 5 Years 0
Payments Due More Than 5 Years $ 0
XML 37 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 579 $ 47
Accounts receivable 122 935
Inventory, less allowances of $365 at December 31, 2013 and $269 at December 31, 2012 162 312
Prepaid expenses and other current assets 125 109
Total current assets 988 1,403
Property and equipment, net 7 16
Other assets, net of accumulated amortization 1,894 2,109
Total assets 2,889 3,528
Current liabilities:    
Senior secured note payable, net of debt discount of $142 1,358 0
Accounts payable 1,073 1,070
License and supply agreement fee payable 0 1,318
Accrued expenses 365 321
Deferred revenue, current portion 703 707
Total current liabilities 3,499 3,416
Long-term portion of deferred revenue 0 707
Total liabilities 3,499 4,123
Commitments and Contingencies (Note 12)      
Stockholders' deficit:    
Preferred stock, $.001 par value; 5,000,000 shares authorized at December 31, 2013 and 2012; no shares issued and outstanding at December 31, 2013 and 2012. 0 0
Common stock, $.001 par value; 90,000,000 shares authorized at December 31, 2013 and 2012; 18,082,043 and 11,949,824 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively. 18 12
Additional paid-in capital 100,526 96,847
Accumulated other comprehensive income 74 76
Accumulated deficit (101,228) (97,530)
Total stockholders’ deficit (610) (595)
Total liabilities and stockholders’ deficit $ 2,889 $ 3,528
XML 38 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Plans, Share-Based Payments and Warrants (Details 2) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares, Outstanding at beginning of year 2,294,714  
Shares, Options granted 237,315 1,547,550
Shares, Options exercised 0  
Options forfeited or expired (121,895)  
Shares, Outstanding at end of year 2,410,134 2,294,714
Shares, Exercisable at end of year 1,385,199  
Shares, Vested and expected to vest 2,350,688  
Weighted Average Exercise Price, Outstanding at beginning of year $ 2.14  
Weighted Average Exercise Price, Options granted $ 0.64  
Weighted Average Exercise Price, Options exercised $ 0  
Weighted Average Exercise Price, Options forfeited or expired $ 3.27  
Weighted Average Exercise Price, Outstanding at end of year $ 1.28 $ 2.14
Weighted Average Exercise Price, Exercisable at end of year $ 1.46  
Weighted Average Exercise Price, Vested and expected to vest at end of year $ 1.29  
XML 39 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Operating activities    
Net loss $ (3,698) $ (3,262)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation of property and equipment 9 9
Amortization of other assets 214 142
Non-cash stock-based compensation, including stock options and restricted stock 575 443
Warrant inducement 14 0
Inventory reserve 210 82
Amortization of debt discount 257 0
Noncash interest 39 0
Gain on disposal of property and equipment (3) (55)
Loss on foreign currency transactions 26 7
(Increase) decrease in operating assets:    
Accounts receivable 820 1,006
Inventory (60) (147)
Prepaid expenses and other current assets (16) 4
Long-term receivable   0
Increase (decrease) in operating liabilities:    
Accounts payable and accrued expenses 59 904
License and supply agreement fee payable (1,318) 0
Deferred revenue (711) (680)
Net cash used in operating activities (3,583) (1,547)
Investing activities    
Purchase of property and equipment 0 (8)
Purchase of intangible assets 0 (659)
Proceeds from sales of property and equipment 3 55
Net cash provided by (used in) investing activities 3 (612)
Financing activities    
Proceeds from issuance of common stock, net of equity issuance costs of $229 2,771 0
Proceeds from issuance of Senior Secured Notes 2,800  
Payment of financing costs (399) 0
Proceeds from exercise of warrants 248 503
Payment of Senior Secured Note (1,300) 0
Net cash provided by financing activities 4,120 503
Effect of exchange rates on cash and cash equivalents (8) 34
Net increase (decrease) in cash and cash equivalents 532 (1,622)
Cash and cash equivalents, beginning of year 47 1,669
Cash and cash equivalents, end of year 579 47
Supplemental disclosure of cash flow information    
Cash paid for taxes 2 18
Restricted stock issued to settle liability 77 0
Payable related to license and supply agreement 0 1,318
Receivable related to license agreement 0 791
Fair value of stock options granted to Medica $ 0 $ 273
XML 40 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
Prepaid Expenses and Other Current Assets (Details) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Prepaid Expenses and Other Current Assets [Line Items]    
Prepaid insurance premiums $ 70,000 $ 78,000
Security deposit 21,000 21,000
Other 34,000 10,000
Prepaid expenses and other current assets $ 125,000 $ 109,000
XML 41 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary Of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2013
Accounting Policies [Abstract]  
Principles of Consolidation and Basis of Presentation
Principles of Consolidation and Basis of Presentation
 
The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nephros International Limited.  All intercompany accounts and transactions have been eliminated in consolidation.
 
These consolidated  financial statements were approved by management and the Board of Directors and are available for issuance as of the date of the audit opinion.  Subsequent events have been evaluated through this date.
Use of Estimates in the Preparation of Financial Statements
Use of Estimates in the Preparation of Financial Statements
 
The preparation of consolidated  financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates.  Certain prior year amounts have been reclassified to conform to the current year presentation.
Going Concern and Management’s Response
Going Concern and Management’s Response
 
The accompanying consolidated  financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s recurring losses and difficulty in generating sufficient cash flow to meet its obligations and sustain its operations raise substantial doubt about its ability to continue as a going concern. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
The Company has incurred significant losses in operations in each quarter since inception. For the years ended December 31, 2013 and 2012, the Company has incurred net losses of $3,698,000 and $3,262,000, respectively. In addition, the Company has not generated positive cash flow from operations for the years ended December 31, 2013 and 2012. To become profitable, the Company must increase revenue substantially and achieve and maintain positive gross and operating margins. If the Company is not able to increase revenue and gross and operating margins sufficiently to achieve profitability, its results of operations and financial condition will be materially and adversely affected.
 
The voluntary recalls of point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications announced on October 30, 2013 and the related circumstances could subject the Company to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact the Company’s sales and revenues.
 
On June 27, 2011, the Company entered into a License Agreement,  effective July 1, 2011, with Bellco S.r.l., as licensee (“Bellco”), an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of Nephros’ patented mid-dilution dialysis filters.  This Agreement provided the Company with payments of €500,000, €750,000, and €600,000 on July 1, 2011, January 15, 2012 and January 15, 2013, respectively. On February 19, 2014, the Company entered into the First Amendment to License Agreement (the “First Amendment”), by  and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011. As a result of the amendment, the Company will receive a total of €450,000 in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. See Note 12, Commitments and Contingencies for further discussion.  
 
On February 4, 2013 and November 12, 2013, the Company issued senior secured notes to Lambda Investors LLC in the principal amount of $1.3 million and $1.5 million, respectively.  As of December 31, 2013, the $1.5 million note is outstanding. The $1.3 million note was repaid on May 22, 2013.  For a more detailed discussion of the terms of the senior secured notes, see Note 6, Senior Secured Notes.
 
On March 21, 2014 the Company completed a rights offering which resulted in gross proceeds of $2.1 million. See Note 14, Subsequent Events, for further discussion.
 
There can be no assurance that the Company’s future cash flow will be sufficient to meet its obligations and commitments. If the Company is unable to generate sufficient cash flow from operations in the future to service its commitments the Company will be required to adopt alternatives, such as seeking to raise debt or equity capital, curtailing its planned activities or ceasing its operations. There can be no assurance that any such actions could be effected on a timely basis or on satisfactory terms or at all, or that these actions would enable the Company to continue to satisfy its capital requirements.
Cash and Cash Equivalents
Cash and Cash Equivalents
 
The Company invests its excess cash in bank deposits and money market accounts.  The Company considers all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash equivalents.  Cash equivalents are carried at fair value, which approximate cost, and primarily consist of money market funds maintained at major U.S. financial institutions.
Accounts Receivable
Accounts Receivable
 
The Company provides credit terms to customers in connection with purchases of the Company’s products. Management periodically reviews customer account activity in order to assess the adequacy of the allowances provided for potential collection issues and returns. Factors considered include economic conditions, each customer’s payment and return history and credit worthiness. Adjustments, if any, are made to reserve balances following the completion of these reviews to reflect management’s best estimate of potential losses.  There were no allowances for doubtful accounts at December 31, 2013 or 2012.  There was no allowance for sales returns at December 31, 2013 or 2012.  There were no write offs of accounts receivable to bad debt expense during 2013 or 2012.
Inventory
Inventory
 
The Company engages third parties to manufacture and package inventory held for sale, takes title to certain inventory once manufactured, and warehouses such goods until packaged for final distribution and sale. Inventory consists of finished goods and raw materials (fiber) held at the manufacturers’ facilities, and are valued at the lower of cost or market using the first-in, first-out method. The Company’s inventory reserve requirements are based on factors including the products’ expiration date and estimates for the future sales of the product. If estimated sales levels do not materialize, the Company will make adjustments to its assumptions for inventory reserve requirements.
 
In March 2014, the Company requested the closeout of its October 2013 voluntary product recall.  The Company has fully reserved the recalled product and will destroy the respective product by April 20, 2014.
Patents
Patents
 
The Company has filed numerous patent applications with the United States Patent and Trademark Office and in foreign countries. All costs and direct expenses incurred in connection with patent applications have been expensed as incurred.
Property and Equipment, net
Property and Equipment, net
 
Property and equipment, net is stated at cost less accumulated depreciation.  These assets are depreciated over their estimated useful lives of three to seven years using the straight line method.
Impairment for Long-Lived Assets
Impairment for Long-Lived Assets
 
The Company adheres to Accounting Standards Codification (“ASC”) Topic 360 and periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. An estimate of the asset’s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its carrying value or its estimated net realizable market value. There were no impairment losses for long-lived assets recorded for the years ended December 31, 2013 and December 31, 2012.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
 
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturity of these instruments.
Revenue Recognition
Revenue Recognition
 
Revenue is recognized in accordance with ASC Topic 605.  Four basic criteria must be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.
 
The Company recognizes revenue related to product sales when delivery is confirmed by its external logistics provider and the other criteria of ASC Topic 605 are met. Product revenue is recorded net of returns and allowances.  All costs and duties relating to delivery are absorbed by Nephros. All shipments are currently received directly by the Company’s customers.
 
Deferred revenue  was approximately $703,000 and $1,414,000 on the accompanying consolidated balance sheets as of December 31, 2013 and 2012, respectively, and is related to the License Agreement with Bellco. The Company has recognized approximately $1,756,000 of revenue related to this license agreement to date, including approximately $711,000 for the year ended December 31, 2013, resulting in $703,000 being deferred over the remainder of the expected obligation period. The Company amortizes the deferred revenue monthly over the expected obligation period which ends on December 31, 2014. This will result in expected recognized revenue of approximately $703,000 for each of the year ending December 31, 2014. Total payments of approximately  $2,459,000, including the  final payment of approximately $791,000  received in January 2013, were related to  the License Agreement with Bellco.
Shipping and Handling Costs
Shipping and Handling Costs
 
Shipping and handling costs are recorded as cost of goods sold and are approximately $30,000 and $33,000 for the years ended December 31, 2013 and 2012, respectively.
Research and Development Costs
Research and Development Costs
 
Research and development costs are expensed as incurred.
Stock-Based Compensation
Stock-Based Compensation
 
The Company accounts for stock-based compensation in accordance with ASC Topic 718 by recognizing the fair value of stock-based compensation in the consolidated statement of operations and comprehensive loss.  The fair value of the Company’s stock option awards are estimated using a Black-Scholes option valuation model. This model requires the input of highly subjective assumptions and elections including expected stock price volatility and the estimated life of each award. In addition, the calculation of compensation costs requires that the Company estimate the number of awards that will be forfeited during the vesting period. The fair value of stock-based awards is amortized over the vesting period of the award.  For stock-based awards that vest based on performance conditions (e.g. achievement of certain milestones), expense is recognized when it is probable that the condition will be met.
Amortization of Debt Issuance Costs
Amortization of Debt Issuance Costs
 
The Company accounts for debt issuance costs in accordance with ASC 835, which requires that costs paid directly to the issuer of  the notes be reported in the balance sheet as a debt discount and amortized over the term of the associated debt. Debt issuance costs of $399,000 for the year ended December 31, 2013 are associated with the senior secured notes issued to Lambda Investors LLC on February 4, 2013 and  November 12, 2013. Approximately $257,000 of these costs were amortized as of December 31, 2013 and are included in amortization of debt discount on the consolidated statements of operations and comprehensive loss. There were no debt issuance costs for the year ended December 31, 2012.
Other Income (Expense), net
Other Income (Expense), net
 
Other income (expense), net, of approximately $33,000  includes approximately $50,000 of other expense for the year ended December 31, 2013, primarily due to approximately $36,000 related to foreign currency losses and approximately $14,000 related to the May 2013 rights offering  warrant modification. Other expense was partially offset by other income of approximately $17,000, which consisted primarily of a refund of approximately $15,000 received as a result of the Steris agreement termination. Other income (expense), net, in the amount of approximately $14,000 for the year ended December 31, 2012 is due primarily to approximately $18,000 in write-offs of old vendor invoices which are no longer due, offset partially by approximately $4,000 of net foreign currency losses on invoices paid to and due to an international supplier.
Income Taxes
Income Taxes
 
The Company accounts for income taxes in accordance with ASC Topic 740, which requires accounting for deferred income taxes under the asset and liability method. Deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable in future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities.
 
For financial reporting purposes, the Company has incurred a loss in each period since its inception. Based on available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2013 and 2012.
 
ASC Topic 740 prescribes, among other things, a recognition threshold and measurement attributes for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company’s income tax return.  ASC 740 utilizes a two-step approach for evaluating uncertain tax positions.  Step one, or recognition, requires a company to determine if the weight of available evidence indicates a tax position is more likely than not to be sustained upon audit, including resolution of related appeals or litigation processes, if any.  Step two, or measurement, is based on the largest amount of benefit, which is more likely than not to be realized on settlement with the taxing authority.  The Company is subject to income tax examinations by major taxing authorities for all tax years subsequent to 2010.  The adoption of the provisions of ASC 740 did not have a material impact on the Company’s consolidated financial statements.  During the years ended December 31, 2013 and 2012, the Company recognized no adjustments for uncertain tax positions.  However, management’s conclusions regarding this policy may be subject to review and adjustment at a later date based on factors including, but not limited to, on-going analyses of and changes to tax laws, regulation and interpretations, thereof.
Loss per Common Share
Loss per Common Share
 
In accordance with ASC 260-10, net loss per common share amounts (“basic EPS”) are computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding and excluding any potential dilution. Net loss per common share amounts assuming dilution (“diluted EPS”) is generally computed by reflecting potential dilution from conversion of convertible securities and the exercise of stock options and warrants. The following securities have been excluded from the dilutive per share computation as they are antidilutive:
 
 
 
2013
 
 
2012
 
Stock options
 
 
2,410,134
 
 
 
2,294,714
 
Warrants
 
 
13,887,598
 
 
 
14,679,971
 
Unvested restricted stock
 
 
75,450
 
 
 
-
 
Foreign Currency Translation
Foreign Currency Translation
 
Foreign currency translation is recognized in accordance with ASC Topic 830.  The functional currency of Nephros International Limited is the Euro and its translation gains and losses are included in accumulated other comprehensive income. The balance sheet is translated at the year-end rate. The statement of operations is translated at the weighted average rate for the year.
Comprehensive Income (Loss)
Comprehensive Income (Loss)
 
Comprehensive income (loss), as defined in ASC 220,  is the total of net income (loss) and all other non-owner changes in equity (or other comprehensive income (loss)) such as foreign currency translation adjustments. For the years ended December 31, 2013 and 2012, the comprehensive loss was approximately $3,700,000 and $3,235,000, respectively.
Recently Adopted Accounting Pronouncements
Recently Adopted Accounting Pronouncements
 
There were no recent accounting pronouncements that are expected to have an effect on the Company’s consolidated financial statements.
XML 42 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
Property and Equipment, Net (Schedule Of Property and Equipment, Net) (Details) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 734,000 $ 737,000
Less: accumulated depreciation 727,000 721,000
Property and equipment, net 7,000 16,000
Maximum [Member]
    
Property, Plant and Equipment [Line Items]    
Property and equipment, Life 7 years  
Minimum [Member]
    
Property, Plant and Equipment [Line Items]    
Property and equipment, Life 3 years  
Manufacturing equipment [Member]
    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 599,000 602,000
Manufacturing equipment [Member] | Maximum [Member]
    
Property, Plant and Equipment [Line Items]    
Property and equipment, Life 5 years  
Manufacturing equipment [Member] | Minimum [Member]
    
Property, Plant and Equipment [Line Items]    
Property and equipment, Life 3 years  
Research equipment [Member]
    
Property, Plant and Equipment [Line Items]    
Property and equipment, Life 5 years  
Property and equipment, gross 37,000 37,000
Computer equipment [Member]
    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 59,000 59,000
Computer equipment [Member] | Maximum [Member]
    
Property, Plant and Equipment [Line Items]    
Property and equipment, Life 4 years  
Computer equipment [Member] | Minimum [Member]
    
Property, Plant and Equipment [Line Items]    
Property and equipment, Life 3 years  
Furniture and fixtures [Member]
    
Property, Plant and Equipment [Line Items]    
Property and equipment, Life 7 years  
Property and equipment, gross $ 39,000 $ 39,000
ZIP 43 0001144204-14-018633-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-018633-xbrl.zip M4$L#!!0````(`*MS?$1VUD0?*?8``&>]#@`1`!P`;F5P:"TR,#$S,3(S,2YX M;6Q55`D``X&_-5.!OS53=7@+``$$)0X```0Y`0``[%UM<^*XEOZ^5?L?='-W MWJH@P88D'=(]M_+:DVD24@F],W>WME**+4"WCR3;8!N;D#3& M-JBK>P:P+.D\Y]$Y1_*1_/%O+R,+/1'&J6-_VM%V&SN(V(9C4GOP:>=K[[+^ M80?][==__[>/?ZG7T6=B$X9=8J+'"3K'+NXQ;'SCX?U(V]5V]Q%\T`_KUYC5 M]8;60O^MZ6U=:^L?_@?][^WU_Z&+^QZJH^?GYUT3:G!E#;N&,T+U>MC.*>;0 M!M3SY^E=!^F[6G#MY9%9M"W^BZ#;-F_;9#S\M#-TW7%[;T]4*7Y@CJQO#UIO M:GI3VPD*6]3^%BLL*MIUV`!*-II[XO(C-!P6%U=-.KTA6OA@S[\X+3I7]7-3 MEM6.CH[VY-5I44[3"D*EVMZ?UYU[8TA&N$YM[F+;B/6%+NA[LCSE3DO7#A?= MX9<(;S#)F!%#J#;SGJ,]S`SF6&2OCPVW3E[&%K:QZ[#))7P/*S(C&%Z>7$E MY09J/Q'NIM_B7TNYR<;4X.GWR$OB%BU^"Z=&^@UP(:VX.V89Y>%*R@T>KP\P M'D_OZ6/^*#4;7$B1XL5:P)\_.Q%2>RY;0!NXN@.C%Z&/8B"TN:3X'>DC.3#: M[F1,/NUP.AI;@K_RMR$C_4\[8C#7PU&\^\+-';0'%?E&XLRQ7?+BHGMBN&![ MI(&`)GP38007*=#YMJ$]P%]!G9X#'YK^9[]+TSN([5)W$OPV_96:XO<^)0S) M;I.8F"'D9U=?=GYMP`C6C@[THP\?]Y(WATWM)=J*]6!,&'7,9`]@7#,73"WY M->1^0POKF5T+JXJ(8\9N:FJSQLW@EFB7(HV'/P48!G6_!JRF;R&P\#=?8)L1 MQC:K"&SS/<`V\V=L,\+8;0(V+\:>\*[=:#XT6E4"U(^:W`!.^-N:5A]<61TR M^KY`IE4]9%H"&7T_!V2`+#._+(A39??1>H]?;D%TD]=@K!J@$1F0W&U2-3K4&81&8VFE9I_P\>](/03!T&05E5$$J:J8.Z?O!F,W48 MB>56;:8`V0]5`C1..8#S0UZ#L6I4BR-SF$_\+Y#1M(=FH[+(:%J]F4>8*I&I MVH):+("/K3/DA4PU.;,.9+3J(:.M`!GQ7."VG]VK0US_3''P_W MV"+\CCP1VR.?'859Q*KTLV)5TF M1@51JZP/@.+4.C'D$W1`SB#T"3]:1!$K3JPLA!2M%O@[9;$J:+'*Z@SCU%(6 MJV(6JV2TBL_W'DZ)91F.CX1):(<,L'4A1:TF74"&]IP0,NR.2KH^*JQEIIIA M*JZ)20U\/\;;H-Z$L&JPIR4$-/VH5Q&CB+CUO0D-S9R"B_WPL8T>9ADI8A1E M,?;?:C$:>B2Y*K^T`]]B*&(40XSWYJ/D93%2%E`4,;9^">0H8C&.PH>/BAB% M6(RC]UB,H\@SU[QFFMK#F3,:.;9\&)+Z`.CBGQZ(#:7&C@U?>34Y,O<0*%VL MV:I&`I1"9J:K>%*X%`=.3).*]1MLW6)J7MEG>$Q=;"D^3->N%@&TX=PP#&_D M66+'9-<=$B8@8F0H@'PB5[;AC(CB262-4JWT5)!":J&H&@M%E:!6/`93UJG$UJFL,54BC%?6J7K6J634 MBN](5%:I9%9I_7LOE5FIBEDIA!MJ&E_I:7P1G%%+UV5=NBY@9[^*,,H;8:SI M#`.UK%+!"&-]W%`1QJ9$&&OCC(HP*A!AY+CO\."A(3>(:/+PMT:0E:7VE*YQ M64L3YZPUICL^EEO6TL019(T\EK7`.&@?0DIH#]J^/Q51E%@K)<2LXL/;*"&7 M1[4\3C*<4D*/4$+M/%_SXO<[*-',C1+R",?9MM,.'CV:^$J^_,5AL2CBG#RZ M5^"QF"?@J"8SPI@@319)D%3Y"XH58AM+5W\VI:8KE9=-Y=)AY!$>9AQ+06TZ M\D91E=]A>T"JK>F(".%/,4%53L8B2N"7+:%$5%!%B34FQ M=)TLW29KF77@)&"&H;I+1[QTE,5KKMCQJ(E_H1+[,YD9K/&BMD#%JZ:>B-ESKCCW".,^ M^-6?@2TG75@Z$ZK"GEF5:L-&!L&4;2JA;:H&=>X@`<(FILG(3R5,IP"@J M+8B0E)NKK)LK:QR5/`9)V:K2VZIJ4.D:VUX?&Z['J#T0X(Z33T5NF0,-NI-; M"P*)$]N<%CJ=CN<-S2)80O+PR.$%**[F@9[*;"@/V55^Q'?3..^AI<@N@@2" MF3%\+\^K2^7ER96!D>+5X@/%QIY+F`H6WDZZR$[7-`Q5J+!!+-_(**$:+%=Y MG4NR_-)C-H70BH`J+^F+^,15F)#&Y6RD%,%23CM9R4QKPZE5HNE-,0?BJ/E) MZ>T.O#2?&NZ.K3>"&"EBJ%+`4<;*6BCRJ&GFL\:`<%7E4*?)8&S%4 MY%&YR&-MW%"11T4CC_4QA)B$80NDOB'/OQ/&R21KYW3UF)"]H3A3[`W7ML,( M'=A;H>&HJ)NL53TD-'8]CVQ017BRLA>\W>%3U^#4FA>13JLQ; MH^9+QV/;J.JXW)NL;EV<>Y.RO2(V:3UYQLR<.A9E!E[EQ7M:C8$<-+M0-YL< MYZQD$["R9,M;LO>T7+D]7$7P^'O,JR*M,K/5,K/;R%9E7@M<#E'1:SG(6@VS MNK8YM(I>2Q\(5-F\KHW'*GHM%VF5F>GSF!3B6H`V MS?7DI%N8\_/@'$__M.HH%>3E;C^XWF42GVK38(%(OKO)0F3#0LJ,@TICXBLJ M)+$HR).4]632.'?NAYB1H6.9Q(>2AY94T4G0:3EX%,,6O?M(,:RR#"M9-`R1 M,&D0BV;5)?'\.>/-3S(DIK#)@C\4"J/R5GWCNT&'T7\3\ M:H.WCRR0BD5Q?CJ9K[W:5,L%#.G=%NA!14IOXF_OV5'\+0%_IWI0_'T;?X>, M*`M<"@;/-*$XG);`HF*'DC*W@-BAD`PJY?Q+2L`"G'])"*B\=UDH6(3W+N1$ MM^@#0C[_^#RR'A^D,,H[-H!)64+-/S?E&_P,/4&'WSUK$DE1O*$V"4%03Q(D M,UY%:+,),C]TMMM:9!?:!C9W`5\%&-8.-M1%$!1L5"#;6Q@85;&Q"L+$FNF@JV*A$L*$50X>N M.R1,L:&=BI/)<4C0IV M4I5@4.*T#>7;*N';2I:IMQ2;E&\KIV^K(I<4C9+H5R,8%L0W+NC8%LHQ6/?E<8R&81]=E1-,V;IDM@K$B:XE`[!//PY>0" MR3-G-*+N2*:IV6;WT:(#N0NGHH[4]Y&+99)EHCALF/],/5A>=%P.$6S$XZA+ M:E.7=.@3,:]LZ,*`/EKDA'/B\M/)-?Z'PS8@KGJ3D/&#W%.`VT"^-,"5M0(+ M(9?/K^PGPEV'\8YE^.+-OW;YX9[8U&$WCDMBE.HX]L!-OL/YWGODY)^>L-A/ M)'XJ7N)2=8\,SWZA?!:HV51Z#\W3@(\DF2:UM=K&,[684:#0L=0`%]W*R_9J M#V!^?>V_]=E7S#^LI:\\W/;A-5,I)'U`'793[@NF3I M(QD<4F]/+L?+$DO\6L\*LEJ]%;2T1*_<6T'+3/]$&M@=1$^,&BXQ)5Z91KRZ MG$V(,3V]/DWP#_O<^L_!P3RP+IDJ?B4T8 MMDYL\\0<49O"W=BE3^3B19PP&E\TN[(-9T2FL[&.8\@\@6I3:*%0LZ6L-X"5 MZP2A)!0OLQ7,'AE$'`T#VCLG3\1RQG))P5?=DC3?`I.ZU'A8`DLU"DHY"NY= MJ(R?#!B1ZNT1!H8,)R?*8D'_"GP5\T2A:A,Z31;_58NO0*%XM.P&1O76Z7*\ M=;K4/`I?UMF2+^O4959%:RO2'RJ9"=!ZSWLZY4UZ'ID`,NLR?,>KHDV9:!.9 M[K;B[VE=Y717CY@/_4$[4CPH&P^2YN/-VSK\F[2C_+V/,B/EI\\[O<\Z%E83 M62N+9TZ;G8+VZBPK%:O5+@Z4-@UM/0O!BBS8A:LNH_^O]>4;EE#LM M73ML0XGWU_T``OOOK4FT(I5/DEH0M][`E(%AF!PDV;5TUZ*`)VM,:?"@3K8Y7VEX-2+Y$AA>?+U["!XBY($@5+\N!.4`#T19,X*O,#P#A"7J MOF6.Z1E)S<0D#HI\QQ#*4?UK'$!%J7_LS=F>^)@6!9;2SL>_U.L7EGPXC.Z) M(9X,U^M^T5FVA)A/.FQR3KEA.:*N'MCV4\LQOJ'`T-^1?F;0NB.[?(FASM1U;&\=G_U M7Q=^4\?3;E#;_S=V9_5SESGV0'P5W_H@\[2Y;J=[UT:/%C:^[:052+0CRXB% M&M3\$8_&QW_5#AK']=G'*=BBGCU145AI_$N\1WL`P-K`^&[QT4S<5Z1]WT3QQ@\SB5W\:)&P\=/N MW?G%7?VTV^MUK]OHKT?D\<`@P@`C[EC4/$9!B<[%92_U>@3=:8-'C1^F-P*H MG9/;>^BU`=K'8TZ.4?<_+^XN.]T_VNB)XP(JT.BA/\!X8""0_F1(_:SBU1XY[+U#BLL@)+/`YCSF2^-YG#5-.B MPU2?0T9$-5NGW,O'Q+SW&Q MA3XSAW,T71FH(7%V*1\2$WUV').O4>'O$[TRUNK[-/N60?V*]/_Q#J&9R-5/ ME_KVY/S\ZN9S.(O:#U?9WHA$,$T.9%L',HUY:/;UPQK<7WI6;#CI-UR\K1G3 MQ8SA#]JVC^&2A"]]^2>O\*5#.&_/`A?$""?LB12E]Z6%+>&DI&3:7C\`"TSA M.Q!X=RCS)COW<_-@7QBZ7Q3CMT`\-:`+'-`Y#6#]X&CK!W!)0I5UK+3$LR^V M-#1]=4`W84";CBV^_2%F,>O)H--ZV?33^:T,]&/;/8Q5-W'O67RH<-\[>F! M2K'W3HJ7!D)7B&U0PE>13:U7*9LZ3,7[A\==VI],M9%'Q(&CX:8@Y1D"L98#K$_T+!4I[0!520ZZ# M1E/J$"2JZWJ@AQT:_>S9!^J',]==JLG#859DY142WH!:,+&J(PU(1#L^?K"'2[XM= M1D\$JK$F2`MK>18].`5W;3CH?I?M6KLU:!9=N=B:U!\QATIYP'XAS9",')/" M-4Y]:20>7-1K8!`ZE+2&^@Z371Q%1U,-OK)OQ`T'%L<0;T"U#H@\QJX0PQ31 M8=VDEGQ].)HVUJ<6R,C1S]?G"+"I`3`(D/FE!OCU"1/2@^Q#@`%T`YH3;0?; MY0#HKS:$-/*W""8W9#QD#D<#L8T,[@]@F.$7UVC8>;_G4#;6!O)D$T+=SK.- M;#R"&RS\2"S?XUW(NP5Q)+8U=`FM&E`&6AU0;P3AP!B+KHO"V,8F%CH'59`7 MP_(DPJ`.RFNR!/3,]/G"H2%9$NAIUQ.%0YY^%>]<-M$7P-UT1K*&SP"#(5AJ MUI`'A)0Z>&;4!2T@/`9%/F$+>`>W,W3A,6=,H#.&XXEWN\-@>!90QT@X'2/S MV(`^GL6/&2,NZB$S"/IMR9"C]W`ELX M/9$#O6NOC=-[G@AH;4&"(LZO#'_ERSM823 MDUO@HKYLN:9V5QHVIE,2W7J,>]C'+P766D;??-\D+2!,1D68($K*FH MP*_,\0;#Y&9`7=M%O12%8HN+RJ'A`.>I805;_"3A!1@SFG(`>G`O)D'WS\0D M,)$])[;P:N!*'?:,_0Q92[J4+PXC&)PT>:%"OZ<,_XN".SD;4AO['@S:N"'" MNX@;>'IW^QZ3_D=X(VH*]P*:&?F')"AK$K6S1A\L^(C"P"2`,UB#"">Y8(\,1J`$#!(X4B`4'G)/`#,J$B43"%$J??78MV4`O9*H`5O4<>R#L5RX\9G2`^]N2M M@*+8^"Z'[#0FX(YE"NG01`310:`RHV-D]^H4B[ZDQTI=C*;O3Y=,I^/7[ZSH M8&T=YB*PF,V#UDKMO[9[N!]O2*`M9#L6:,+X[(-MJ>77O)[1_.YJ59@%ZQ7$ ML:9)Q6"/6UQ)7`:\%B,8P\`3CZ"!FA$@6OL-00M!2V_<9Z*K?4)X8!UL_\`& M?_*4:N"'V.J+*GV_]O_MO6MSV\BQ,/S]5)W_@-?/YLEN%<7E_6(GJ9(M>^/$ MME26-OON^\4%@4,)61!@<)&L_/JWNV=P)0B`)$`,2*1.3F02Q$SW]'WZ0N78 M8-T37Z3H9%\>!;D1OP:#'12*P6]38'7LQ10X MA2!.`_TGQ.="^'@.V?CPC6[C1[;[DG(^8M^AL`%4^^X)2'B=RU2;`:)P297O M`O'&I82%\UKYSV`K:S@Q?S<4[%VM#15=HBB<*&947^"2Y-=A;\J/P]Y/RD)] M]#6P)T9]X5IP M<2_7MFXH@R$IQ$%F6#2+.#:\VDQ*BKBX7,5\9@M=4Y7;[KI[V55^C+R'?Q-W MBA,!UA4]8OC!TWC(E.+%Y*"$$=6T$*K&;!?CAQ@GM6G24!AVYLM0E"^^'6HQ M`X\!#IF+-@E^#6X0X)TI'KXH\CJ7:8^F95@/+\(,^K=G)NR@M`XV:1OZ$5N3 M\'BT(91_+*`0_,+W%I+XXTZR^:`^,$5/A$D=?EK4'>R!'ZZ/NI0W1V/#66?> M\<_8CQ8G_+78%H3!(\+K@67B>/?!-Q1;QH/L(%I6E@N?+7#JGW[OX=_D)[L/*QT?;! MHF`.DAK(AX07TL7)=WT%#P*I587]X6`#&UWE`Z`#M`@`IMH")U$O7Q!H0*\K MO'IQN*]U#W3L(;^AV.3T3XUR^M!56)!141@2$&?,X*E54T M1J#JB_#1J#V!_ZXLFM1)E3D4SD!]1D,O#(.X\772D3N._+,VC='=UHP28NE; MGFS9JVG[#PI!H>$S]W&'\J`.49C9J8VOJA3(@&TV&*J<##CJZ^ M\K<%F]4=O#3#E`A08YK'XW.PN05S-+"*R8]3*,MP($Q(&LQ[\9:\&\0*'#,= M?38&`LC1G+M'_::I:QVDA_Y?OJ"J&);Y<$%V)%BC(!NQ92)&/S'Y`[\+/1X> M/(Y('_]>)[+OKG)-9!>^E5[E^+J5GT^_,YJ,4 MJ]%DY*Z4NM9P/$FA`TWS5OY)KRS;U?^K"PL@.&'`B3&L5,.?QT/DAZ7BP MY"'SEXIS15U'8Z05O.L4PF$9T(4:ONJR0H;H;Z(<`0HE6KEG/-HT%H'R,4.( M2/\1[T]YUDWD``)$Q8WL;5:SWW@V;G%W0I#2*-WQYX!3!MA:B.TP2Z:<7HR+_%-0U= MFM,S)([%U3P>B!_=H2LFVUOSN%(BWP)EK%,L!'"W0\"`M"P#X;S8M/4$U6): MN\?O"7G&9=9!>2;@!>A%M2F]TA5#PGD.!M-YY@->CU&(2],L>T&J(50^A>'< MP:>1O2`DX7<=6'B17E94[AIU7P@=FAE?_%WI[[@D&KUE:Y=S`/#B(OJ%0B]XS^P(.+#2E/_B3'^\@,1>Q)X4B`MXU M-7V-$3L*A)!LP81MSPWVH9M/%O`4OSFG>WC,+*)K_*3`L<"C`-8U@J0>XLQX M@":#ZR+><_64$G3DKN#Z[?UJ;5@<`_)>N[4U$U5=PO7R+^%,)8U&HO4)/+,S M^482"O^P'DWE75?Y.VI4%U@Y>M&62GO1;''2]6E/\;A^8`8L,1->W(\P+@JL M!(B3C)?%$FZ4SW:XW7A`F M21X1>1L75PE!+&6:2\GJ"LM0;97?-%[?PY+<`VTU5L.Y)@_L>+;V`K62B#^` MK#<8BAH2WN#QZS8W&K]83\)]ZXF81W!A#$*?YX]BTO"OW=LNWMWKO+:*6B]2 MRB95$3+P^*TU3TD`Y\@`IQ]+J5"WJU."9^8A1-P*)"!2<:;N<%:1P#Z`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`*:S.5AK7AR#=#U_A,MVZI,BA]%)IRB=/F;>;` M-N-8PCGT'%I$EF'@+'ED%QRO:UAN@`(`6A'@=0AXU7!P9/M_/.:X\%,:7JS! M&5LKQ(#-5M83'T>,4]Q5>Z%HS'950(JAWC-`VR$^QNR]%W*L/#4=!P]\B<-#986.`V`-4NEPP$ M:00__$6S07_Z!IZ"?;\XNG/H&$8NFVYJW`D(Q-5A)LSPX5L>[_W>"SG';FJ'J*P#61J`TQG!Z MHJ/2L2C/B3#U>7^!"H4:`MFSUXL)(%S*1Z[J-EB_'K-)Y\I<*GBR?X M)1*,0-HV[G)40U"B3Y9'8Z^HKEAZAO%"(^;M)^;C4IRM?]BX21J]OF!H:;V( MIWPZ"IX#W%VN;=T`[N/SV%,&0:?YO13NH!F:]Y:]8#;-L!0XH$##:SXUDYZY M,-07RW-?+_7O;/$F=Q9F\'X[^&L1;";ZIQW^Z0<3_O*SYUP\J.KZ=63"[Z6Y MP`)5>#T#YF#.%:@!PW(\F]VQ[^Y;P]+^^-O__L___H^B_,7_]:UW[Z#*,=WW M3_B*X$$:"PO_^,J6?WUUT^M_@_]#R75G]0??AOSO5XJ^`%(`4M(7WX:O_I8P M\@+3;.W"?T7TC--!,@K4X1]TE%ND&Z7,R$WVJ/FX>7[X?-@OELN4?G3.C!*B M6.$XSO%X$AY#R19TF=C8MN]2K7T1[Q,V_0X#?@_VB8_IT]0"9?G^,'A*GU4; M],U@Q,5LPL3E3I`0YAI\:C`R_]&DX;%X5/%+V#/Y2:HK'`GNXSS8EN/X*C'. M1OB&$ZY2)OT-XSAN,@I%X'(;)IF>\14X`,"NA!NFUEF-V:$ M"=RJ@!@_JWMS?_"V4B5O0/EQ.MI@@PH(BSC+IX)'<+O0K885P4IW-%M?$\D( M*?7\:"E/*CB"8**R[\S6=(>+-=U.>[XC['!@131HT8V;3O_DLR#A-P01Y!\7 M>,2\<:D8PTJ.$=MHY92\;#M-*,L*:P?H`0W\@=W;'L94^O,T)4SC^CCO8Z3#E\L%F%-90?L0G?2]QT'N3^%'P3?_-3QWTME"I MW3/WF3$S80(LE+?@!VF6SQ(JOL.AAS:6[<1WJQ([_L,#GN.!E'ZQI8[BOMYX M-NIO5TE':](2\O>FJ`@L:3!PMYBP!0#HE2\=-@_#?;0M[^$Q&5<:]+G\3AXH M11;9=UA8X/F.V;9.D0(-E".B]_YEVU)6$*NZ?68+!J[:%3-7JOU'!S2K_:R^ M=&`]TX!W=Y1_6C93.\IG]EW'\WUKJ__5C8[R[E$WU2`>\H6ALL$?..G;77HV M!33`H'G2P:]73#B9E6[J*V\E8A.N:C\P5P0W.@JXC!@T=%17=Y8Z!D\Q)M!1 M5![CP'"HS:*VDJ_BA7DIK`(,CT0>,@0R7`Q)FA?L.Z#!P:`"!OL\I[L1L`A/ M$E#J@2''0U7?X3/;>E$-]T41AAC^+T45XB9'&(D%^K.0JA]TTT1;&';U#]7D M7$V4/PZ(`/'*CP@?W$(2_@(4*['A&81#*':$5_#O<#)Z(U*Y$2?>>FDCURP9 MX#S%R+82_%M57343F8<#X.(U)R'/W!Q&@; M?0W*F*XP2#O#ZKIK,'$2OD5E18EH`8"XI/91C,$WNHT?V>Y+7"[0^8A]^P*" M4/T,#`LO0#K7.66!O;;DUR-\%XBW)6&`;`7^,Q$*\W=#01WPNB@@&843"4_U MR8[H7X>]*3\.>S\I"_7%*1@N:UCL;&OT*QDFN[8?5%/_+]VBO0MN`.`?E^;B MAAMT],_KY0<_,GT;W`BDA.%VCJZ-&AE=NR\ML,;C:JGCFZ-G0_SP!:2S35[T M-1`TO_G,B;G=5V59%C8B]PLW9MG(E1O,V^[A`T"+W,?O1PUL#:#-2D$3T**6O;9LDHZ>N6#\EX;Z'%P\$5?C/ZX8 M?(P*"HB.WRP,.Z#6YM.N(O9`KUQ:'MT`@GWUR,`">$3AOF2.0W>P`(&CZ2`C M=,?E%R[,!(W/T.]4ETO=T&DK),G?68:WNM=5Y5=3)T/%I:NB!:@SPUKCY8Y* MD;7W\!;8Y0-3OC*\Y@7I@U-E8EAZ?_OU*@8]JA-U#2]DVJ-I&=8#MU"#V]4- M4\=]MH)O4;$^J:`Y/`=-HP?NIHN-D2(6FO>1K:R%3O?7G"T[>#A_O_K04>`+ M(!8?)`,AQ%LJ4(3`ZXP/4GT.+*YRMXI<@@4-"2 M9W25%H&?KH__B]=H44(!2P'(%=8#4QEDNF/P%?%E8@>=R"I_'_P=K1O.XQ0`&!YT#^DAP%E<>G#D__U_#9('8Z5_=_IH@?7S"Q]>+`VHK)5RA MDAG.KZ@T4-8`L*XZD.`1,Z M6U_FF3JH;9]&@?T8[67A\:OX!^:#@R:C#E2-&H%L&']T>_+OC,RLW>Y!]G$S M"\2FP*__AP<8IKAZ#V2-+V4^HL%IJB*IXY.^TDEDY(NSCW@QC>8CGNWSHV48 M+Q?6,](NQJ]T($W`:-Q?ZD8R4H$8+[T'D.QB/[$0@X/&ENX\4O3PO0='Q(!5 MWHE<%;1#GM"*Q>7#JWPKT-9@[2%4*#>N/'@1"`JQVY.YMBW;HDQ:K.]4YS%N M95XZUV9@70YBUN7X%7(4?^[7VZM7(,8T?07ZZ:^O+H:O_C::@C\8N7&&5^^X M7-R8G60O-Y[.<]>[U#30K*[SE5Q91.\O>#GD)^`5!7R:O9/YTQ MCJU9]A[[(-+WWR/>EI@8"?K"BF-MGKVC83^^H^@:>ZX?QTB_EX.22?$-7*,F MNG07.J@S21P,L@CD_&.F]D3*<.K=A>.Z>=(6-"HT0UEK5G2_A(8RQ') MT[VW%Z&S+Y:I[4I-.0)ZD,%CX7*'[BF!JSR!/)N/=M\3_[XX8O)D\'B01N,[ MKQH'?9`C>`>SV;S(JD)%W?#8[JXB9I`K=Y%<4U1B?+V#=Y7`39X`[DV'A^^* M:&EGA.7)Y&%_EK6UZ*+E["^!NAQYO??.,,?ADZ[>ZP;EPNZ,MQRI/03QDT!; M^HIE;"V!LAR!/9QL6*[%MG;%E@R^6'SEF;\[HRQ'8$][<562OMS!FTH@*T=B M3Q,F2;%-'4)8>=)[E#`(\L_M`%H:YDCUX6@^WW$W"0SNH?F'.4(^AY"V*]I] MMI;`5XZDWV=7$9061U&.6!_U!\-MY[;?^@D\Y(CM++K9B!]LSV(OCH\-^QJSTC64. MVTD"[ARANMM.WE%P?!^$Y(C21"PBN-2)#:HQHVJ+SZ: M[U1>W5D4+:,<\3F?S!)1O2TK'KZQ!)YRS>3>>##9:V>:YJT\2FW@9J&U6MOL MD9F8L_/1U*P5^V0Y#OBHU\L[]7MQ5.:(V>DD:6GMLHWJH$C@/4=83T=E0O&5 M8=TI6[Q7;4Q?-7$SZO1UW$S$S0*L? M@JE=@RQY*Y>XTS@6Q[L&9G;=Z:W^8.I`B1CPXRXXT.F-9>AH*^V?UC3N-S*O MJ9*JP4%J=M.MMUJ)B]C(&2CA(2C^*R"PP"Q-S8.C@W M:X,GH,2NG7E&NHJY*/!5]`;Z3.CJG/+G,-=&U32>K8$R)+^KA5\$X(J?>J(3 M1;*H0>>U45BYGTPFR)BX["B/ZA-3[K'V@QGP M(E,5Q:):E+I3TD:.+2PJ.\SSI6&'E=(6+$;]VZI[4IF"BANH%\L3S_&$1=0' M7CCC%S:\M;`3#V:,ZC;3J#"5LJ[PET^J;E"6$J;Z!>6_:L!8"Y%L2DSG@1>L M6&O=)'H.>2727X!*&V(L\:0:'D_V%]4B+G8HP?>66Q.537FU*>;F:HB3L#_&O#O'%^Z`OD,@POL%2=YY$B-\'J7-*F#O7FC/RZ+MMMLDZ?HSU"GEN2X"$ M7J%'3KGX:NA]K4.3^H&9S%;1\H'OV=H-:[A_-2DIEXB0A/OE"BA=4ZG=FXY% MWQ'%X5KPKS]8I.D5S])UO-6:FSQ4NQ;ID&93NT',M5T%=IG*,SOPIT;D;L?O M#L>S1WDYO;CU<+?\)BRCC&BC-$QU(BVO8AO"'\4:G+'O:RR*@U\L/-MOB8#D1G!VEXO>=:*\'-`#Z MF_J]^2<0JF!0^@86#V)=*O7VXK045.2)RT?Z]3KB=AU3/U?5#;CT#J=G)#]; M9=^^>./%OU@H']]9X";8/&3S.5`>?1@B0`4DG2LT#!&T*!&05/BHV"Z.($ELUSJFH>- M%;`]&-E?9$$X'GZA4U8/5J8LJ1(/#"O&7`I16?=P.J+8"-_DP"FA*J?OPCHD M6]7!JL`0EJO"I@%R'"("EM*]Y?$7<3/I16CVW>'*C[R)CKA^`(ZB89%NL(3C M%34`$,TLA#T$MIKGXD6MJ.?'JCG1$-A]:0-B)RD7HB6Z.L\U`]J.W!L)YH&] M1*@<_L54[5'YCZ?:5`.J8Q@*_Q\Y'%WL8AZT-':V]C1&/L([U,VNW\%63!9L MH>R&?0T+T[I31)%![*S$%;8&,1R=.I5&THJXN#( M`2UWPC\(&RPB)M;':G.=R@_CVUAAX28"O5?M!-!U`0OQS0.=Q^UYN-M?$M&>^+B'2#I*V_,Q]" M$L,=DLF^PP@D%D%BO-@4Y"X_'JZ3[EG4HR3(@V[)W-,&M5B"GLV3NRMW9ZXCHR%YNG^#W`U.+ MTH5*N6NS\-AB#*>__F-':4DUI)YF61\1(O:,Y$VTLV>&1?M&"[;9K M=XTN=H$+?R)>=2@A`J44B(1D#QB_?1SEV((U M:(>3:<)I,(`O;ZEB/Q/@CPY:1W\PLI/(BU4-\O8279!`;(CV<[#\2E]<+'3# M(]LG6%N(V.B],LVR"!M!BJ9TBX0_CQV->$]#)]%'L$P:&/?2YH54M-ATG+88 MXK>B!2K7$8DGC_6*TA)2>]M6[S':/AJZ9N-WH*@ MIS1=C&]$ZL;HG?'*,1#5(6!^,UN\=/6H[5LW30F=ER=## M,"Z"_*D,Y<\*2XZ4$"MM576UR^Y+AW>(3`3H.D<8MY&8C8%7`.C3HC/%[R". M0P2T_#/->_3%\6?P<0>"WK.B8.$Q?J">Q"O+QK:*KDHS-D,Q&LQ.8/8J2)A, M8Y6.XOBR>X*^%CUQ*Y[`C]/\9UG$D`1QK.UQA..:CV*PD-#(,8M#3!)BBY0I M0GXCRVUCA(XV.2AJ0X`VV!@+QGV\-'M!0NKQ(L%TZ(; M<9N2NY-7XK'0WM*CSM7A19!_-Q&YS\ZZQ=9"NS3M_L4S_=L7__8I_:(\>?TD M;`JQ.VJ)S_MWZI25%]K"&U[`/?-3''E'W(6UQG$4HOKCB82SA\:W@T+Z#\H9 ML,2M^X+=NQ@_9:(4DE=]=S!C#I4!/DL#DPW5Q#H3K`=YXD%5^)'&5,=_(H2$ M5P>#&^89$=0D/!,.S3%P"H2H#GP;(#[RD>UXO9>.'?/B$JE&(5R@E&U,G M51P?0-$;?O+8KUB\_9G>SL2Q)*+,?C8!XIO>_<+Q+0KN!5[Y85<6;ZOTQ75F M)#;OQ6U6UNGG4%(;78HHX!]8BOVD&FW50B,MG5WR=73RX1T2\.R[QAR'JV/8 MP[UJ_@&ZD'(NN)9?629[$9'_H#`R'KF/FL:FH],@.QQ7\PC&,>@M0P?*6HA5 MN>I>>V!=T_T$!=LL,*-U,27>$W>5Y&/9#-O9F^XCJ3<#=QKDF_D%`OZ[1#-[ M@H2%M!S=ZKO$=Q2&TU3;QFQYT)=+5;=QSI['@L!F./J0]32PWBHG\/"W[Y2_PU`_-J][48GBIMPT*['#8:ZU53+PM((_0H'#/M= M+96P:7OOOG+U^O?_UR=2&>I:)US(\VW722B$KM8'*9!IZ3[@I_ M`KT",4(A]8;$E[O)POR8CQG.=`E+!T3%E:Y1]IO-GG3V[`1K^3K&=[$HV9KR M/,BGPVQ.[OJI"Y#DJA9,C:`!*#RA)K@]QAC'VL*[:)Z%9Q@"`@IV^WDMH'/0 M6_N@\H)I7XFQ19`&S>`S:Z5K82(?^)*4Q>IO.PZUF+L7OAYTH,S_A#-YB!@C8XC$L+X?7+V>+3K;G?YV.6 M?KU$R".%?[']WN,(.;^:C>=*"9Q%$A`HD38K\!VAPH^?+W\!:C-!);Y1(I]? MWMU=OOO[9V()1[,!A-C77]_?O+^$KVRV9JH;^^KF^O;CW<=KY)X_P?^)M#+R MK^D>SK2B!(#G3KGS2\^(='-PE:L8VV\DM5HVSVF5$4I*Y0V!)!@I.RNNP@4Y M$["-@D^<(HX>1!I<\L)2_^SL=%U%1I^ZX.$;4>CIEWG&(6Y-*YF5Y2ZJL2GN M=?OBX,7!3!3I#,TS33LX2IR!F0\TGR^*4OCP>2Q\B[YVP1UUG)GX:'EHI%*@_<&R%G@SX>J& MORA?9DGAAP48:;9^[P4MRG#UKA)0K^_N.WSZK%'8[RXU(' MY?L3AT71HGQB%0KXE0@^?X1B#-X[W` M^67\+ZP:7#'W$;L;;*L(#%'H6YC14#]M@R>2XMA>82"'\Y]Y\@'B*N;#BQ=OH0LG_Q4(\8N"0QZ!$T4>T_E^6DA%& M32UBE8L6KZ",=+:@/DB9\)_V54>;4"]K0GVU5MYNM%=D8.3'(&%B(]$6V0D8 M6:1R8RL8AG()V!W9T:^4(5L]+-OQQWSR\IVCM%=)%K2"YV@$0L&OWL'=L&!2 M+58; MJ@1I;Q1/V](G@4DIDR:6).)L;EX"%"^2##+KXRW*;L2C($WO;'7!T+!5KC%5 MB(DR)335&("A4#0(9VQWJ6LKFL)^/FJDB#XYW_H4HU3^>$WBHF"V9@>;9T@GM$^.H&H6X;&S9[&SQPQ.:@M$ M\0<*.5#ZA1H."\$\$1"ZNF@@&,L(P;1#T=^1$NK%@QA'>.*3X74[XM][#L.; M&@.3-'?OP9ECCU`:R<:M0:E+.%@;'U^"NJ>$2`FC-,`V*C50HI8#(C[3/,4A MK^3-98LC984?O08^%,@?P2S3;;J#QB#7)_CXXI..?BR?D9LFOYMYEJUDSS7. MU05>L%($-#+(Y18+M51[XV[:$6SM=4T93GH\:!_- MXO!;OV./$48E)7ZK60P:\R3Y6,\3W<2?NI$2!_3@CU-*/U?0_V"3U,$F8+^\86Y/L(4%\K+@Y>Q[SI/[(NE0'@F M%L4@MO"*(%$JX2>V\#[\/#H/+&80B_%MBBQ\T;%_;:/VPV(@;XTP!CV3.ZAH MJ;VBJ%I(005\&NPXP*\>LC@!P&LP``AZ+[XU#B5@A_\$[T;XCD&=PV,KICI4 MG1;$^2F[DAH?,[Q6B1:'T\OC521!SF0PD2.^??#4XIC-?0]L*MC+?SR+^DCP MNPY`(R<>GAW$Q.>?Q&A*]$[#S7(!GD3J]E^CE6Q=G')3T\[*^/D M5-HI>K\?D-O_Y;-I.,'AHPD0>'*.<&CMWH2A$TB_R$0"S:]M2=8#=-)RRB(? M^ETY>#]*FF,?1A6CY0`11;'@2IJ\NT>0WQ>H>/UBAIRPNL!U.7GB!!Q"X01. M>N-HQ.^#Y=E4GZPI&N;O@K?#F_[>4X0+_@?PF\I!8D1V)3,@C_S?294`;S1U8_ZTT]^Y8#??IT0I3H6/O;"J[IWNR-J M&H6T49206)V`C/UNKJ#Z_4P/GJ@&/KH9DB8Y^.82G2H*%_"R2^I*8(!C]0#D MK&M!T8J=Z!L6\!,.GXT$$E4!:!5$]1))(=@ M1JY3/.]8]CV'1_1_Y#>RSB._1!"UE3P(1(DTU*'-OZC% M=@8O6ZN&@KJCMAN)S%"4P6)7;,E(9@OBS6NLM:>!@M4S$>,=R.^':6]XA`;^ M_ZQI1+'/<.E%C[%^C>9L`TL]%[PT+A(L`*O?,?1QOY"V]\KRM6I"R=\F,35J,L;[(IFF=164S?#]T5. MVE\<#:_XV93M,%1Y5O�VJB:DUQ/CY5X7%NHBKC1>58%=2B--K'.(;HB`0L MMU-89S2>I[0:CF?S1WJ)4DF$7\I:+3E,Y_W-(TQI7!I8$4"\?C-B+@HH?!U* MH$*==VOPS]/!C\CF^`[3!75U(8':>\76&6B1-^^W#35M>?$M>!MKOQ_]W^'_ M&7QBH7-*8?O6.4\%.W;VC_[9"Q?69J$+K#JB9&XI2O7`REX$1785:K5A2J/] M\B>$I1BJNTWP2K8VKE(*M)5I=5:FW>]CL.17?^'\5T;E7_R6'\C(HB#0-DE\ MWR`Q=!I!F_PK@,@)+B(G&,K3K741S3(9FOGB<[LIWL&R39G2%_FU-+=TK:WN M6MH?%V\IH0X#8"!,U-.Z&VX-]?Q<9#_-AGI[$$7P%$LM0A'95\_3_@SOCOR0 M9=#\(DS'`4,_Z]44YBHA:A.?8AZ3F,%`[<14V#*6%:W7US9[%,/;,$\SMGZR M/6L<-UM'/2+.8+>\^\DSY8:3XH^4Z?`4U[=X_A>WVJ-%G3OX+\+,V)6U8(:( M.-/??D\-'N?6S35O`"#ZPXK!ES2_*=*=@VJ21+^^:,^1(&C-]TN9O=@Z`-:F MRWG_^C318NAH`)L)21R9IJ:%C7)%KHQ8B&&T$1(!*#YH/\8?S0],C- MPH`IQR$][C>H![I?,BI^%5W*\"?8&!?_CMX1;*=G\5JG6 M!'1BVDG*.VFK^(HP\1E>!'M>$2>&W0^5'UGWH>N/1?8IW>_+L](-'!)D,N>G M3M"5+9Y=0E?D.N6I@_]]+WK2^Z4`F^.2F5M[QMQ)&5B-56:MS;7#BR^Y@`BD MVA6V2?P(0I;8N8V3GK7Y13TS=9\8N([;8GG-AN-.,-LHJ@7YKVCJ5I#8(Y(- MJ,4NZL&(VB']2!/E*/T/:UWX91Y^$4MYP"B#RK?H%]3PD.VFRJ-DZ["NR!*% MQOC;B,J[2H%VYTKC=)8K-YX[W[RDW1[=W1[[8R7AZ4)C0($.6AHI%!.NZ:QJK`UWG:9 M/D_YOZ5$*CZ:P/Q,^?$]]\5^*M+>Y8AF8,Q"&LR[4_BLXFFYY]JUBX@J.@F; M$P:+$D:G%*+;S!@35]5;M+30GM$)X-5=S8]3KN91ZQ++"61$4N&*9*.&CX?C M@41A8)4Y!I.,Q+EM^7"''FW0C8W2^[47OU(<;;`82BL$/"6K.@WP'4DY2,0>.:BZHV--YDZR!@E?U*D/@MG\18+:YQH M?CJO_4KTLRJ#%*ZCQY.4ML+_#6>GQW&4*_=_X+Q0R`ZGQB`>BYQ/M?*I/]L\ M$X"7IGQ<^%,^,!_K"3;,^W%;5+ M6%)9U38I2+=,`@J*C""&J::**P/\6LRDM3#%VO&P$26S[4[ZR-O9^ZM[4U]BXL`1>I("?=8=3;"+VK81LW'L@7A6.Q MMWI4D18TVR(59.A^";L_%^0J];=^_K2XK/4-"_B23#QLZ4_-U-"08JNU96,D M-FP9Y@B=;%!=(S-5S0]P>GQ@.;S'IFYQH@'(NG+6.Q8/2-D2YD MX?C4,-%BHPF,GP>`BXG1Z4O>/(">$MU)(TC!KM+RJL"6!?<#^X.8[L/IA=\Y M48*$9V-+-2<^K>(QDMP*_@+OD6?RS!&14N'HR*4Z799I;,V=M+=^ND3064ZQ M@JP6OYE%LM8N+0G'GQ,)M,K-R4YD:",P@8'Y%H[(G%AA4PU#_P.-7O<1#$O3 M?_1+=D2W2CY>U>73NEADI%2*9HB^+/D*:O3IIRTA@=+D<[IV MPYEC.'DV3#CCO1CYYZBS%2UUH):O1T73C5B3#<`#8L##7#6L^U85]]FZ<%RV MYCXLRAFJ5A:<\TE2RD=]6//Y$) MQ2?&)UZK"W('B4L_2C0:AS=S^XQ>#O*TE]R&NA`9F^'(M2?=H35%CQDDT85. MV0&\?Y(:3%NC_J!:<(.=VKTE>JN=PI`QTKT*LR"+5JO%ITL%1BH.QXW,>T,4 M%6"=OUO/H%#MSK;1R``,$"S'CLT>5%MH;\Q;!""U%[_U<.1$^>!EGA80[`AU M'A@4B$8^$V_[6+V.`D*-D&_H*YU+'B!N\^+!XO6.JO$BYF[3O?XC]L8B@QG! M--1G!QG_P<]FY2-48%V0NZXJAE>CP&76LJWV,TZVVJ_9`9A/:'J#R8VL#C:" MBAD,.E=]'M\,(GA$X;&"<-Y5&T6>/W1_O6\(>'[F]M8 M%WOJ2P;JPW-Y^S)`FDY"/7BY;U?RI'0K6`CSY=$09;;C=R_CAA-;7*C8=OXA MFOT?W1[(:L_%#O0+OV"=?0\Z(*%O9>%$*IU&T'*;J`MGE`'@_>?YJS%0)QI#,VD4C4H MR=/+3Q]_^?+Z$UOBG-$-`?O;QZN[O^/CO3^%2W/A(Q9_>_WUZOW7B[?7=W?7 MGU\K_V?.[B<@'L$P4,C2?J.()SZ]_W"7^OW&J>)_N^/(\C.TK,1KX#`_7=[< M`@S8^%1=.VR#)]XHU_]Z__7#I^O?7BOH/5"_5/'SN^N;K$U^_?C+W]-VF6O# M^<=D`"(CF+)]-/W]/7]S?[#^'OE^X7\?.0O%H,/@0-W]_@F@,K'*R8B?;M+6 M2D$#8.'NX[O+3_Z+@41<:R4>_$WL:-2#W9,)^]=7X]&?8A26+@3(Y/^.LU*(*WE^_^^#?7%Y=??SRBV]PC?TXTHXH$::]`/(8*.IMXFC0 M&?5[G?YP)#V!G#C]GSAXY\?>-;'S8#[J3/MGS=V6S:&<]GTI_QB9/PB8-W@AQ:$4>..I/I MO#.?]J4_T].W'O;V$G-1DV9-_$J-26A,B>/:>M@'[ISMR+,$K[CP&ATK[I&/ M@Q1A-AUW1N->>[XM>*<$7G'NG$C-G1Y=Y MW[/A1AG)TC,UT<$B>+NU5,0T8.5CK,?%)U'(H/,6X.\]F_?$P"+!Z):H=I!7 MY8J60LF^BIKFK3Q>*R0&),?:&O)J&MY".]Y05`]7PCHC-Z@YN6"P')8C\U]M MZ]V>^GL__U?Q\W_Q/;%&++6WK:Z204\N_?T4.TY4]N)W,<[S>PQBX<9/TJF2 MDZ/4FA7+NQ2IJ_R(0ONG#J:R+]B2:C]A'U3`,>AU(CI8J`&7)N&*=DJQ=_B# MZH6,-RWSPGHV4=J+8CMI-R-KLV1=5/I("P M2S,2=JU+W.RQJZ2,'B^3(X>=:6_;G,%A9S"DGF@2COAK=5W=$J35=3N\^"O# MC%]@WDNLG@9)^NV\-2_OC;__[/__[/XKR%_]7U./TDAK\7.F. M!L:/9[/@::0D%_[QE2W_^NJFU_\&_X<&U)W5'WP;\K]?*?H"CD,%.V7Q;3QX M];>$3)"X*KZJ4.`7RV7**)2M%^&?-S:C]J*BJ3L/F_!&LSRZYRK\-*332*<> MURL1P.8)09\L690LA8,FR-+O`I8Q3X5Z%?/Y*XXHM79DJH1N..5*59$<+#C/ MJ4%N=LGQL4L&HY?`DW')%_QU`G->U9Z#8;3:<[P!NB\_0Q2`(#V;$ST\"[)E MR]H/46*VW*7HZ0C-`MKS;<[Y[E.#W\SSE2P5O1JY[/LUNNEX-N45K&VVTKV5 M_"7Y1Z\L:7S-[@][`'TFE?C3\+:Q"431TGRS:;X>&I^=.XU+HM++*R1,4^FW MO''CB[)@U!RZK@.7MT3TQ,$[E1KU0;].>27O^9XX>$TMX&[)51+U6JW'S&=- MG[$1M6_'P/L+RZ-,EOHQ4$,L<4>\2.ROEQE^[`_&Y^X@M:S3.-:IAU5Z\W-GE1I: MGC3MOXJ2RRI96@E8H06L=*Y@C,S_I2W9VAR.=M)2L(*G9 MIWLZD)P3G4HUW/0D=7Q5PTU3%/]GU?26JN9Z-C8O"H()=07T94@@:,&3`+P4 M^(87D0`M=84\`3A/XAA/O@I*BK2$\;S6N]:6Z,\*O)/GZ5IX>-(;G#L/2V)6 MESAV-\6L_LH<,%"TQ_HM:AE29%KP)``O!3Y9[.GV$$^V@O%(A3[3<\]";,$[ M/?`DRAENN;&)-FZUH6/L5^^YS*[?QI7!K6G!DP"\U*CQ2!(KMSW&D].CQRUG M'[?QWQ:\DP-/HDAORXU-M'*KC>1^\&Q3=SV]-D!)Q,1/CLZ]+/!KR6PR7C\):C3]K>KC:JG%[;,MI0W-(%F$\*OI,`K\341"USGT:"\K3>Y`T9J%T2,[O:L/8G MYCBO%573O)5GJ"Y;X!`6FVFZZNJ6>5@N>!."=.GQMV.OTPE['"6Q/!V>? M77DVX+4L+AF+5\72[4`F.6SN>D+;)FLSIUOPVL"VY,=7QR2$)I3M2S,)0:ZH M^+F'T?VA7?[]/^;\]Q]>5+:@_\ M_48=2#W2H3*PKR(7&_[`/&5IV0I3M4?%6H9H<1^90JG3"C,7;)$W2^&',DDM MS&[SCZ(3;DS13'34GV%X":>^?3QR_N+()#2QZD2AY"ID9QDMXEWBX5"X:;G"1\ORH`S/H M#C#&TF`:[@EX]T$%N@,.P+"<>%_\%L:L8)1'.(_ M/G93`P38[!$847]BBF$Y"1Z+H&P01YGZ8#-X.S"MPPQ#T>'UJ_1^K/C,9[;0 M-94D5QR#G,)GP\FHU)DSHT%GO%TDP2Y*/;GQ>./HNLHE8(6++45U"75Q_*QQ M));RS&R60GE\'@[^"`_1_QL/'%Y\%@B,K$;TKUD/IO[?(S!`N"Y2JZ]6MVC5 MP2XJJ3E#WG89VY8<^7:I:98'R+Y17_#%\&OXQ/;8XI.NWNN&[NHL;7+<[M/? M1HV<_A8?N7:PROR"P]\BU7.1X6\"[6WR_BX1-1KZS9$#&[C@3,9/S<=21(0SP5EI2\6>*P2)6@T M89J9(MD0LPJ/L>_<65H2JV7O MXK%VM?`T5_G*--6HS9PI7'C23-$G+W@2UD+FXR!UFEHCZJ9:\FW! M*X<[I>7$]CPELBF.$PFYTFVFN98MDGUF@_[T#66V,=.IM8F(#-:E#."=8"?_ MX[18N)#^:$^<9-E<7Q63?6!LI"5MY;IR3_@ MH)ER3(9^((V)6^PEQV;-Z/=RXN1[XN"UW-DT\U\&RI7$P*C.KLPR,#YBNA%S MY._&U$S1U3I(ISWUJ"7?LP"OYC`@4BEIJ.PY9*!3']BX=.ZT_8(KH(%N/4C6X_@V?B46P0? MN]=LU(J=E%TA7V?CW/X@VNEP6%9'SOU!JB`NW?#C.ODNG=N),X73]FR]>1H$ M*=P?';/)_+$@ETLFG0,/[WBQ71;/#2=VG*0'-2J)S MJ_63[]3O.,UU:=E,?S`C8UOK-KI.5..>@@=Q="]Y)^G5ZXY:CZ&E83E$4`I] M_MCK3F<_U7UV$E"H)/KU&#ZMS1RFVMHC3=M=L"=F6'R0NF:SA>ZV[FWK&C33 MO>UW>_.Z3U<"4=;2<(/<6Z#9UKV51OU6Z]XVHSR^F=JUD6Y`HUS9'X?=7J]U M%5HJED,(I5'HH#N8MQ0JC3:MUIG]EVIX/.=]*Z-(XNTC$PW%+Q-)HZ&K]W?<;%5MUVV8GJJ#E M2$O)*7]Q6 M?;>-#YI%M;>`8GVI:RHF9%BKM64RTW7\O@IIC1$6;,ELFRW(RE8=A[G4%@%^ M<<4TMKIGMC+L=Q2L>Z:4#ZPW552;M;T3JN"B2RE[)_#>4"?;/&%?X^%PNR"M M=V@M1K'4]J^,E?C]:)N(05EM(II]?*<#R4D1XC&+MNH\OI.+BJ9IAZM-<^UU MW?ZR'#Q;_T&6V""VB=D69<:`&G3Z)T[<)PY>R[LM[YZR-5+>E7R:-?*%N7Z= MK?F@&);C*)IJVR]8A/NLV@OYJX&:*=XJ31DKVIR^(9WG=Y)=@VFG-ZAUK'A+ MN6"$4L/:K5NI&!YB6Q;JJ-G]Q9KFJDU0:=LUTK`W@-RE>K.Y)2ZO"F M7FP9VKO>"H'T9\X>"U/U\C3%?%P:,.<-0]+8L147V@CD<$B@_&Z M=]NTQCMT1>L`*FLG=_1FQR?17DXNICEQ\%J9('F+R5K#/Z(=J`N?ARU38G:<]TL_Y+YYUPZ`O M[W%0)8`%ZW>5NW!996WK*]76X46:93KZ@N&2NNLHC[KC6K:NJ0:O8\=BM+7E M,M/5X:./V.')A#^^LB=F>OB^!5-NL4$YP#^<#6![*]WE\Z818M6VL74Y;!%? M#FMIAN?@L[1M-15YSP"PS?[CZ;"G;C;354+HE5#=8-Z=HH`KM27HUD::.4_' MK(C,W^4(/:GQ7P:JT[=[Z6YV!>U$V1H$P$+YP("M@%>0A7"7_V"VPUX4W=2L M%>_F;V[I&^&WC<#VHS_,IIW!?(#Q#7J3/]=]Y]=TAKTQOB4N"%3#L6*[#0;; MXIMYZ6G*VX*:/F3M]`ZI/P1E1FG/#/@V_%530,!W;-T#23CV?:W;)%R>0)99 M'D@<(HE[YCZC\(5E1J)9ZV"B>*;!X+6>JW-YF$W94M.?DL'.>_)G$>7\D;30 M-NVU!@-4>T&A;[.U9<.SJ"R8XW(=PD!MN#IS.HJ^A$]>.O"8H;I<,7IF5%'" MH=\SDRU19>@Q2A>%2MU->>ƄKM8*]MVR@+6J2*C!`)N-KWL65GKDPU!?+ M]L\2:WV6KP?COX:Q$03_1/._S3-_[^\K/G7#RHZOKU1P+G3OU^I3L: M4+IGLSOVW7UK6-H??_O?__G?_U&4O_C/AH]<+]]%*K:^!TJ7!?^\94M__KJIM?_!O^'_'EG]0??AOSO5XJ^`.)0084O MOHTGK_Z6H/Z`BM@D(5ETX=_*/U33PUH:>$R8E6\ML'JH&3T8/!HX:$[P7G`#59!`"VH5 M@D((52XH!_JW:'B_-O`I^LZ$A]'3H\\O\8?TC@5X=/2S18%-*C_BCWWE/^B] MH4?QF^"S_IN?.J#500$KSX\Z6)-ELU1I49U^;](9#V?;"55Q4-R3V0N*>P6N M*B^D1J.9?'S5.\H#*HE4"U1V M<[2X!#U/"7"Y?6)$B!'T?CKEAB9GPWZ<9F,+2LM[X-6.AQF<)QAF5T\F;2UT M-YPUGZ1GO'3BZP2LC+S+/1+3,B_8:FU8+PS>SB492KU`U)'0?`8'1P$/`D2G MB5Y"MP*O2[GR;'2*<77P:PT0PB"$W$='X<([)1)1KH#L#`:#.+ZBR`FD&O?& MN50KC=K2Q0B%#FRV4G43,1,Y`'\W'8PG(B]R[8.#6I:>8;PH3Z#FV*(3"R"` MF"YSTY\I?-(?TVF,8AM/B/P`N@RYH50@+C":-&RBP)AV!L.>G`*C%18E'_88 MY,XTXZPE$D#)K=0I?4KEMPQ1MOT?K5U["#VLS5;>'.AN(-UO^'9](G MHPZ/W#^"M%.7+H@:TU(PAHJ<@;,Y#S_6@90"_P@_7:MI[BT94.1BNZM)`(V\:C%V48!]VHGGUAJKU5O<;5 MQFY`Q4([8&+0+3_%[QZVQ+ZN'^)Q<#6GHU?$!#$\;24D`0QUN<[Q^>DU8FCSKC7"TKF M6@UX'J)KBX;J0$%5\]"HL_EK15RNV MT&$-^@W%`K`,PE8Q=U,Q=#/R!?SXV<+OEY9GDP!WNLK6K`X`@V"5]J@'G5%O MVAGV"T2QU2=5-^A^'`7VTG,]F_DR.>6@`2N-(_PI^"N3^6`_LL^(^V62_BWJ MY@3M1Q)3XK3_!=0[8;//L[`9"Z[4U/AI;QL,G:?V M6QO@%&V`DH.S9=L`_4EG,LA2#++9`"_*8$CR;UB]_`,89[+JI4PW2VKLW=`UKJ1B&8#MQ%\"_4(A: M+YV$6$O1P$(^D#C%"BJ%1U6UFI]A_,I4(F MEA5`%=,W^"]1'^##M%M0LG1/$OUB9R1$AWLXY+"4CPF<3\(RH-^-O8SOU= M/ZI8-@9*9DG/EFDA]!,N9*BLRK1GMM9FE??B8]6Y5H862;+'#Y9=4B7%[R6A MW_/"&JSO"2MQ.KPL:TEE-YK++WF63$>G`40)6+%<:/E&X!K.WEKXW:I;)@U`\U^*>*2L6")M[LBS21B!%WX\>DG^_MS5_)DC1HK)5NKK[ MKJ]`PADO(5'\4"87C?JSC=LG-,RINHUT4ZG+];K)5#&,FY$[R6-C49#+77HT M&AX9TM$62./)8#FE@[*7HB5DSX$%7NG5A^6N<2(F;HZK6*,^J#HH\PL6^2Z4 M?W25?UH:,*[SA]Y1WH'<7RH?=%,U-;1IKY=+,#-M(`#,40`=8Y.`>6?9.%O& MI3X#-G.Q,@;T1"S;@_@3H`0)S<`D)C[E&4DB=VV8J'K&\#[H-]T,^A\$09#/ M=F27J%F>=`KZ^XH)?^`9I/``Y">RC.-N2X=L[N\N$VDLH1T=*$B\;HC>*/#$ MP(05O[2M%0"]=D6T2("";Q>)>2,>/T+@J#_$0@<4HT?P7)#$3L^\Y]E7^JWFO,Q^-$["08DYZ:(_ZBG\F[`KX MU#*3YW9-Y@1@+^V]\!`5M<=?O4A/@O7QOT65-R1>5:)MG]%-ZK2""Y5Y,7>^ M)QRXP$P-(L&<'M$^10-YI0KZWO"!%<_QR?4M@G5QJSU:!N9C\=>@^XT/`'\S M`^Q9H&1\]IX9UC-V?/%6@LDB%?6V[OQQL00I%Y;AHPP5QC09\W"L(/A`1KWH MS%A$OC!`>O+80/`19SJ*`RA/%JRB&[J;9@BU3MQ^O,'[77VBYEJ;S/+;QZN[ MO^/CT29>W+84BR<;FLW9_03.JA=V!A-/?'K_X2[U^PAV@P7G:)^*'P)2/UW> MW,*N-B'DS^]0@8! MB@6BG&R@XII$=8B0&R[;HZ5@@3S?X]AE0D5+TNZ>79F/TZ;\\!-.DUJ_H$43 M8N=WIMIG54M5#7++0.G%0SXG2!W(> M?ZM_2]>_]0\!V;?+=!**>7E!:\Z M`^W@N52[R>EN;W[1[T[')WG$M0ED>0GWQ,&K?EY<-7P(;#@$/ASN$]:2_TC/ MF@\E,8S*LQ'3#*/W?F[*)ZP1^5$W>:*V_$-@FRF`Y05/XLC53@)YW.WU+B;= M06V&D;Q'W(+79/"J#T!5Q9#3\<5DT&T9\G3!D\14JC:&%)A*5W[*[^^8\GO. M)O)9@G21[M6;NL9PF>1&/%6_X[;_ZK861Y^U[^WNK::U2^2DEX.6)E MUWDV5PH<@+!V#\L2>1\,RXQ.?8\\4;0=O&BYX0(.(GU]:$1*>A5B;&W\Z:_= MVZY?]OW"ZQ%I]"\OYDY=@-IS\()>W(Z-#1HL7DP=5$A&*AJ7++4OR<93\>&- ML,^P-M/15VMX1(HY-KF:L>9W^):+K!WO%C9K\X7[0)86W)"`]2*]14R8VO*Z? MFZJQ7(_//X?V)$CM*-`_M*/`43L"U%F_-1A*$DV3+W!6Y[$,Y]%*P=F6"G\G MA.\ZE&#MH=7%2[&V#./\0WL?JIDS.;3Z;D*K$95?5?.!A;!;RXW#I9.]MW^F M7U)]Y)D<=0-ZAXRSR[&_T.C"Z/E%I6R`!=6)/A(E`=]NC'X/)F3XP)ZM#5IR M*.7X^]G'_QO#FS.VB)[>)8^$13_ZZD]HCG[X#LQF6]5<3S6B'V,6:8@OW8Q^ MATU,CEEPTQ)#!<30"GWIA?YP5Z$?M=*V"_W(OP*Q'SR-0C_R0"OV92*(0;F< M'^NZ=BY\WS2[?M2&0,X+DHPLJ,I!&;6GPJS;G[2GVSSP?CACFNUUY\>\HVEI M5@;P&DF\*>YSOS,]NDX;J6YZ'[N2 MD9\^[\Y.L^Z_?IDE+WC5=Z@XDJ,^[<_WQ,%K)/FF>#RC[KBV827R MGJ[\X,EE+QZ79OO3[NPT>TN?.-&>G\1-<=-;@Z&IX)V-S$V!_>QEKB1.^I'O MTH>C[J!W\<-\TNVU=^D$WG$F:)\,`JJ/45;CUD\[TWZ_I?@S`Z^1$?4T#ZD[ M/,T1I&/0_;C?';77G^<`GFST74VLH+5"6D$N&:$?)]QP]H)< MDG!#>9$7:0JNI8LLR01>`R;+2PF^+-7>+7'+`%Y-U+N3J]2>GVS@M;)W/_!; MXF[!JXIZ]_9V]J9F6>KB&W+]G0?YI!0W=T5FW M)SJAL>RQ?T@]C3PVZ[`_[`ZVC2E.!:>!@Q[K'4QLTE@/'-UKPC;]N9\T_IJ/ MU:9APSC[DR;TZDZI%*0,AM/.L#^.4Q*N5NHJ_[O6'6]BMC[!U8PO\'Z08: M1GIOV0MFTV!0L2^2RJ]Q<.D;/H_VPE!?+,]]O=2_L\6;W`&CP?OMX*]%L)GH MGW;XIR^Z$VP;,-O:A?\*3(X9U9%10[1W1=XW*;/L\:JYPTP/IHV&,R[TVV:[S0'AG-[KN2! MQ[US>UW(NWQV8R)*M)[7GNR7#7*HI7CGS^VX?53`CV@-MSH'&QK(--U#1 M#F1L8C;!<21X)*]`4=T-ZZ>VYA4R!'OD"',>/YFNO1VH*,%VT!G,1YUI.YY` M5M%9(LOLT_;HY)!PJFTE2A4*W?.6!Y*87=4U!DLUN^)1X[K.7X8D7IG/-(W/ MHS;,".[%OKSNIS9:1@7@,K2LI=, MQT0\RP:+9*W;;72EME:`"*ZD= MNAKVU*3IN24W)*3MM-I)FB\Z1R;D[`,FK[3)RA M952>D9AF"8F,="KIDI1%#:.-$YQ8G.NE7C"36LJ^J]U;7(JGR5 MDO#RIFVF5U4S/?7AP68/JLL4W71MW71T+>P=Y[B6]D?00<[*N?>E3G*[D=)V M$BJ+'./]\\@]V0#LB;LN/"$O[KD`2.IZ;5O?]17@R'@IMT%>?'-=Y3*V,>51 M=9*GTD',J^:+\J`_,5-Q8;F.HB\)+M@S]@ICWUT&VW,?55?\FY<]*&OLE4+0 M>]IC?"4`TV`.]B!33?K12K7_8&[X$_S,,Q?,-E[P^#5KM8*?\7?`.O1&W,R6 MEH0V6ZFZR7\)`*F:ZZF&8NC+6(O"[',H$_'*K-N/$P9V6'.Z.>S?8%D0[GV[ M7I8?BK*;]E4O%0>!5(Q13UF$/)T/.V"=RBSDII/9QA8E%W4ACYR6S)OO+O.: MW:"Q1DETGF!?.DC<&Z9AASC-I4EA(5]XILTTZ\'4_PM4#^RU9J:C$I-J%M"_ MS0Q5\(-IF1>"4^)235U9GBD>*E=J#:;I@O59-PSEGN'*MDL[MX#A";X,$6"S M_WBZHX-"@46?4-*L87&+Y'2I3#[H#G=G\H81X9%LF5WV[+BV93X4@N`KT#'H M&B3:6Z3ES=.(OZPA8&4ZT<>'J%AT`!7W.Q`\:&:0">(X'IR+'1Z14/=.7#[Y M?9D%,Y/0TYCM`K%OX#1"?`<9[U4%YQNVB^//X2LG1-,5&$71KS^`*15^^R^TJ M:'N4RY&]<5`6UK[%>F?=UD4F\&KND]V2]^F1MR1ZK,2"MA0]]DO;[KFN4HP2 M8$YKT#&?=0;GW:/C+,%K*KWVNM.SKIJ51,M4ZRWQ4J%S-B9V9MIZX$MKV3:8 MC#K3::^VEFWR'M^)@R>14[.K2NF?\VE*HE*J=5P^^&U5S]EXD*-U:$5Z9XQ9 MI-.V4^BY@==<3Z:^6EP93E,2M5/CO4_;XD#.@OU:8N?3<61X=_D%'N<7D M124M32\">WEK*(G759W^?4?%&I1-><'3=5/S>OW\RM1\X@JKROKCE/J,9+(G M2TGW/$KJ=7*-C<3.#P5VVJD4?[UY>GU+A6N.-@L!%=7&&DO-\!`%0(ZWP./` MWQWE%V8R&R@0]W2Y6.FF#@0&M/?$?-KC"?9?F0,XU![I'U?LB1G6>H55@?Y3 M':1-+*V#GQHO'3_K7-4TGO@O*O06^#`2N4GJ7>64#/]#+Z.*/683[3N\X"\L M[O%Y(5*PE,H2ZK-J+X(B`U'6M%D<@(M568^9PCC(K)B>;R_XQJSETF$NXLC& MK?I;X^0^&_2G;QQEB24.5'KYS/@A>K8-#Z]M'8G;VLR#ZBJ7YHN"`AS1F"5= M$J5?*3CRR["BN\X35K!^1GD:P%"QS!IM(AYVL[T*;C>ZZHCR"=V)E9(*'(GW M![5J)OL.,.G?E15LY3&M0*S1S4$JK3!/KQ>I$ISM!Y&RO9V*MC;`291JI9/$ MT>ON@O?O`%P1?)5*W7%L_J;:F$WC;*>8-'S+4WI2"'OG6>5<'=%4)FQS"JC\ MXD67V2MN@(!Z%65_HD`RIORC72^>!:&G-P5"LPR5?TJ9U4GT&<@B/)ZQ7[Y@ MKJWL>7^`2CW":F5F*95PR:CGG-U/-(:.OQ\^%$]\>O_A+O7[M%HZ'BPYJ)@N M$=;M#:H/]Z(EBD4(PFI-C(8*_PP,`."3]1H MI9"0E^$G(#C#?^3>(N3X:D18]UG(#V7M$;&NEM/,J MN1MN@DL%V9 M2GRF@W'T3#=MEH3)\HY:NN#W?JVR*%J/"6.Z-3N74]_/I"KC3KORQ(0T:ZJ6 MVWOY\A#VSH&L/ILD1=6VAR8WH[5GUL`S.Q^)TK@SK?30I#/N=CG77>SY(^>D M-H)CS^GPC]F(ID[6KL^"KRA5,\UN?V>HCJ-<*7Y\6;E0/JFK^X5ZQ$-N2(ZQ M='6U*=9AO_]S?_3SH->KK5?#N9Q?!7.]4LYS^'._!\?9;X^S@>"=;,I_"JR] M[J@M2Y$$O`:XKG4/5RS3YYUU9KU)9SP=-X9`6OIOZ;^E_U-T%LLKV4YS%O_A M&2\*.!=S)9:5?*:EZ55Z&27"E^)53'\>D)-8V\C@]OA*.+[^J#V^YH$GEU-8 M(J@IL`X&-7J%+9'*)T)+HM8*8F\I2!@..Y-!JR+/#;R6?$_E?"7QR:J]P*-$ MRT?+6#!;^8JDZRC7RR6SL:2N;B]-!L>\N7=Y_MW/6;<=;?[Q97=".LOCDQ\\ MN;RT]NJNI='&6+D5)DBDA1@ZV$E^UB9(G!UXIT+!PTYO/.WTYV;0HA>[?GM:PUNFQ1V?C5*THU2DZ*,J3_LS&;3SGA>V[S% MEHU:-FH^&XTZD^F\,V^G98=_QP;<+0YN+1^.98@M'_U'XR;MI.Z\G2:R`]PX MFN.9H9#!.;)/S%8?<,89[[V+X[0TYH_B2!V[@5.K2IU35>:[>MW1>/MITL2^ M[3-#4J92G>S,D.#].P[5J&=(2,TL\R&<9`-)E/U..S M!>/LC@/JU!6?%0E[8]AM/3H&P2QUESSEI=\CCIS&=IK#E?60VMFHH?(`+96H M,X5S:89,SA0KFE8E^N*5/J&J'Z0-/=)K''W*;V/1EB,V);32@)>2^WEH62RB9-Y9S`>=J;38\XTD8[>);%BRTLG M3[-B_2FD"W&14]N)RY`U?Y;@-:+<+T4C7[1'>6;@25?\GD*5/P['@TYO./JI M/;XS`T\ZZDRQZUKJE,>NJS8Z^9X26&JWZF2PXVNM"&XR`B1R;IMA&3;YL,\> M`=+5M*59E_-QIS\9UJ:^FWR^9X\`Z0@\S4!M"5P6^[3:N&/Z[7D;?90$O-._ M7SD>2F2\/6_IO:7W(])[&ZN7!+R6SBN]-V_ENCSV:W7MRHO.'@MY9[LT9XX>(VDW!2[\:PI5Q)[L;HNQ?GW\[59BS+X"VW' M;NGNYROLV"V3WF[RX9\]`EKJ/^/#/WL$-)+Z9;)\93A\22S?XT9*TV_^VWAI MVUVX[2[X7;*W5M_WNL,!Y/XWJB[.`LRA-:> M[7B(,<`0=5A7G4>#P58C8PDL[(EKF3Y8`L==Y:.I8#];%[XK>^>3?F?:FR5V M'HQ!B(/`<2?ZO\-N-<86Y->K:_C7=WVENLQX*7=PPB3>TKT#RFJ79NG^/T@+ M43OD>\L&@J7&P&)[)/]?8^OD-[S_]86AO@!)O5[JW]GB36Z#X>#]=O#7(MA, M]$\[_--7$@FA$+#RVL4.QQPE'!M)/=CA'W246\2>DC9\(0)[>6N4)<=VD5H[ MSF_(DV&!:`A)>^'17(-8\_(<,HMO*J2ZX`R.C2F0$IIEFB"'488\Z^XC21&" MZ2L?X'`M!CAT>%]W:[56S1?%9:NU9:NV#LQKLX6GH1Q_W!B8@H-%=!J.XDM6 M:F^*PH"/-L!.F,K2ME;*#SB675DSFX]@0)E7JE3H=8>]N,P*UNHJ=Q'0%LQE M]DHW"2(5A.^CCAH!85PQV`L.>E&5E;70E[JFND+XLO]XNOL"S\$9>_B<@T1! M2+,9H(%UX-_PM6;36U1#6:JZK3RIAA?,E4DL$MF(Y_A3-MXBV5[<:J!$`7AK M3>LCLO$!V!0SNE68$(59KU)#IN@NKCAK(K[@D'4K.,ETTB9L6VL&PFO#1@G8 MO6SCMCQ]/.K,IO,-E9RNGSNI'-@A1BUU5Z6^;#*;=J;S809\8FP+,))FK5;` M$HYK:7]TXO;'@VV!\70D*Z3,=PW`808K)@-^82$*&<8%6F%A8S,-+1PB"OSJ MA:FVPD?<;,[I(/'7#+0!9V1BC23EO?US0+#^WY?"2TC93'CTF?<'VD:IU>`&CP<;ADYE&M.^@ M7\4'NDE[5OW>J`.,7TCH17@_,D[+B0G#UBXH-Z`B@H3B_3O$D0ZABLO0K0>I M/IR.@B/FM$`\:UJNK^;5,("!=.*;-SY7.Z3X,V1^>&[$X@N/#'/;\BARDN)6 M;_HT=1XX35UHD"TW&':F@UYG,ID6$-`UR=7AK-F"M=_IS2>=8;^8.5E$LN8Q M462*9I,"37_YV7,N'E1U_?I*=W"ZHV>SZR4B@YD..;Y?F0$4MGAG.:Y#K/96 M!?:Z45_(`;YCW]VW!N#G;__[/__[/XKR%_]U-_![^/6EN:"Q-S?POOI;!:&L$BX%,JX"JI>0P5BS(GN-!].^6"Y3^OU0NE^$?XYZ_1__^$FY M,50S+=IU["E^E=UGR#V9LM(!R7Z,[!'L"N:@I-"=1S0S%''X"P;&/]:K(*O: M^KU'\:F0NY4U4(?R(PI+7YP.XI3C?]I_\Y/R_*AKC_"J)U3?X(PI;+4VK!?& M'.[A1G['KT(6PJ)YL@P/_%[[)?A%;$,DV;TUFC+EFNSQFX<_D2HV30],-=`, M)LADD"84V5MB6(_NE^"1?ZCP".R5-`58_;%(ZSU[`.A`DVN/J.A+=C%ZFQO& MQ9>Z[;BEKC5,+(060ZFPC+>`8H+"*'6EP>8Z`9'YI^S'8R($&@\R!]2(S`.H M8-]1J<(_I`VFR/JN44YH+$/5(N++M8WGFZ:Q*-P+KHC(:E_CCIZ]N@$PQ=HS?['FM>03L-'Q"<[W6G*II7!VA8:$%I`!:",P3<.-U ML%O`R',9O\\$PC$\$0#&GWKX8=Q%)A*B"]]'RS!>%.L9;R\=[][1%SJ8.!U` MR/K1MASE(S"O;:HBD/5)7^FP;C=R$WX)YIZ.#VG^J_TE*=A@J^"#:MR8>U2? M0!8R9BK,@!>9!()N1D""QW:1M*U'TA0:WCEE;(OU&*7^+=A,9PH*N%*X[0F( M[OX%+'53?>"^CA\5>VNI]H**F4`%:CC6E[["+`?U2=4-TN64*N&'S]2`L7!' M_M^JM]!=Q5KK)M%SR"NWP&#L/QZNR9YH6Q&6P%L_X@@7&,][>.0)#?C>TS0^ MLHR&I('QJ\.NE^^!+#%2ZNQN4LQ;D\)]`TA$"@W1**Z1P8)8JW:0(?,A8)_; M@'U:PT(>S;/-2EC'C[%><!DVWM_C]VSM MAMD-OYIH:G`B)#%[N0+^T_":[#^>CF'_B`@'/WZE_L$PV"6(FR0WR.G5FAL? M=`>N+I<@V.GU@"W+)K=^%5A(\#P3AHNAJ_>ZH;NZ>-4B\()X\@H!0LHC]3<= M1=RX1_5"&J8Z@?9);`A_9*.6\,0.1.C!B24Z\!\13NFJOZM<:B[&L?B5$XI* MS\#=XV4_1J?@*<(VY?*YCY83P5FWU-C!%G)YQVQ7I6LP'30IW<3X)Q`J0U"_ MF.NM+W6>=RYH*4BP]FP;<4^_7D<3/%@B7H`D'0MKQP@:9"V(4WP4)(D3J+OE4M=` M@[Q00B8I:5(SCH=?Z"A]L4]?;=F MMOC*5C'['",.K@J;!LBQU!+4Z3W(6GJ8Z](7(?YWARL_4+*P>`J.B)=0\&*! M5,6_)ARO,%G.S\P12I.JDH!,A&('+\W#O2"8[DZ1XC9^T1BY$+U1!8+QZ/+4 M@?6HN@!^+Y@']A*A"J:=#3_`J`'^/[)*N\J'2$;*UD35R)V$ MNVTK)@NV`$19ZFW)L#.9;\DE*GF=P60S&31Q#Q,OF$NB`]E9""NLR[,<'7\6 MD53$P9$#6NZ$?Q`V%DAD8OVU;2UULMSBVU@!]?&4;M5AO@4?%70&C[X"6>CP M)?V]0LE!1K&_8YX"C]^)S6+5B&H_Z*8#*(C'7+WA.53*69*4?2=<@5T*8B\VX$0#UT,I$"80@.&'/`8,><:3"2*('@@ M!WZ\N?[U)^*\J]M?03Q<&+K)%.!C6UWJAHLY.YX8=/!H.6L=ZU">D645%P2) MRT/DZ[4AJNB0WTT++1X0)J9RK;D6"1%CRT`0E'2J:;FO>"J6?QOQX!(C# M?_N!F*!4$>P\0]57`(#M)\E2CL8]I6&`X0L[Y;+VP]4E/F3AI36L\^#!2A9@ M0/7<1\OF01N>D[127R+R1H>5XJO&+$9'-83YZP=>&AY/*->M;U()EQ'"H;95/NH:!/>7RP6;DF42R^<._&.E*M`W^X1DB M!PU?3+'5MT`SFJ7<=NVNT<74M?!W!G\[B(%((A]_/IK#1V6O'X'U7R[N,3D8 M6!19'O@+I,@CPS):^`YS#NCJ&"`P'6Y:V60I+#P-@YF^/05GXBV!USQ>D@RF MQA^,C`YR"8'/\+7BCCG"@\H:1(:)4F.E+RX6NL'S$H.UA;R*WJG=H?\5H,Y/ M+UPDG&/`T5JD.U-PG"\YG(Q*S7$:]WHI]FM%BTW':8M1OEXU"TY2H$,-$*?' M($ERS//I:4>)#X?)Y*J89,E@KC<9,J`(<^;^'ACW`[NW^6;GM-E1!O.2,J(< MS$N@K85_%;'!T1N9M(D?Q3GQ_J50,YJMJ9E'Q-<];8C"&ZQ`E_-(]2G68H!OY/E)(1=?Q/I8[FQ$SL)D8BC$5C@WMGKAL M&`D6"UX->L-;@P\)"%LRYE]S;?1E2)QN!WQ38TEU700TY2*L59WLIQ1R\RTH M;M_$?TOB5GTA8\/R:\.%HSKJ@BIE"L_]'W00TI7N!DT.,+K-;ZTTG>=?AX`M M/9L6PVLNSW'B>0MG&O:1&^SRPOU1F3>*&/%?K"<>!T%:(JD=8B0>?Z`21H>9 M>*/G8#@9`U(6WL*B,%17]PM5^6@^,8=R:CY]>N??\8J+8&"\\-*SU)A2OQM/ M:`>[PC#\',J25QJGKK15U=4NN[!-1)`B_ M"0-I=VZX\%C,9A>44IEBT.VG,D74A@!M$$E9?/_$$U;0QTNS%R2DSKUM@_.( M=]YATRMPX4V,TIL672_;E-B:O%^.Q&M\."ND_Z`+>$E?8"W;O8C!2-!;35`J@=C!'"94!%?W#FEA/B3GV MF'/SQ".4\".-J8[_1`@)J<"L@\&-\PV)S'H>585GF;A1054&/@V0'WA)][Q6 MQ,8/L2#$G[[#@[<_T=B:.)1&R]:_F$=_T[A>. M;XX''Z_\L,N47P?$TG?MFWMJF==9Z6,;I5W`;I?F`O_G/?SJ237P)`^M\9KT MVYPS]PTBE3OF^$<$O3E4U^:6-5+5ACJ.7&&'Y"3[KF&G8-)JL(=[U?P#5`KE M`7!EN;),]B("Z$%M53P`'BM7QMY?H@K_$6Q,$/\&L;M8E6O`M0=&*H7Y*69E M@36J8WW72L6(/==.J)=M%C11`]5`/8V#'"@_L]E_%VJ`>V$5L)"6HUM]E_B. MHEF::MN8Y@MJ)^Q^%\0'PP8Y`)SC\N#8VH9/J*Q0W""&J*6'844_KX*_ M?:7^&X#XM7O;C60K8"-0W>7=!DZTSJ:(!$^*_3M;73"_+OA24-U7"I;B"OS7 MNXO]02OVL6VA7R$9(K25^(V6^.'Q)9\].L):O9'Q7A3*` M2;:1;X0IAMR%`@GQ'T\%,>#?LQC@E?$LC^`6%F,%:POO='EJF&$(""AH["=; M@-)!K^>#RHLN?2U&<1">F\O@,VNE:V%V&<@!2JWTMQV'FM_U1EX/RM#A.2+H M@'(T/UNV^PC:P8&U+\/$WXZB8SN8EPZIIY6ZX+WT&+J3(.95@\.XM!!>OQ!' MQ';"B!]/P"/,TJ^7"'FD9"FVWWO0S$$=#D_@$3B+7.13=F=6`#E"A1\_7_[R M'J>NF"PZ5>7B\N[N\MW?/Q-+.)H-(,2^_OK^YOTE?&6S-5/=V% M(_?\"?Y/Y#J1GRJ:&48)`,^=$KJ7GA&I"'>5JQC;;V1:PL]X$S8)H:3\TA!( M@I%2AN)Q-$'.!&RCX!.G^`P&(-+@DI?$^6=GI^LJLOK4!0^#B!*U6,O]`.)3 MM*T*F4E)VPIOPDR410=[T<,FF5-'F@`18%`P;8.G M'@)&EL(4Y/9?,"1"&+-1:$#GZ*+JG2(25"H=5('[^8CB4H!G^`I[5;R-KB#\ M7RS$(P9[8D90(>8C6O\O2\DAHL+S6.&8Q0O8(M7GU#4D$_XV.-YF2M>@JH7. M#(>,)-(=D42!.41"+=X6,.1U8"$D<3_YGRR]L!)!<):H2#A*6X%DC1[X'4;` M:'Y!`NX&Z\+$]DAL(P>#ZPW6P(MXRL_6"9Z[?U$NUS;(\4%/Y-DUCKY#DW6; M]>E;J29;/[Z^H31L$20\V$P=-`E5D"H<[W)S(QX%P42N)=I=.*@%LQAXW05:$@S`4,C7M'5LL7Q)I?^. MZY?N8_.RH%U,6"*<%D),V5JD)9G?[#92:'Q:?GRNL-MHB6]CFH;[@IV"77#\ M\49EC?;;P4)RW"0A>21?WL/26+4QH,< M5O)1Z6I:U31OY?&JTP5;@QC415>HV&TY9C:)IEV4LRL>1,?SB9&[J-L1AQ!< M>@QB&Y@'5O:\%'[%OA%0+74)!VM9XTM0MX,0*:%;#VRC4L,3*A$6#GWK/^YB M7Q?5$(4URTE``DB/Z'(CN,(J`N\5:-@X&78^?(6JUQ4>^'`4X:3'X]?1JWN_9S!V.V"4C^]W1L3X*<\PCG5?T$W\J1O) M[\;L*^IU%@P=Q;B.KQ11T`I=R;.[>(#97/".$=A=@7*G:?0+/DW!5(I_QQ?F MFC8 MVZC7L9+"6R.,08M/'*]+5_:J2/E.005\&NPXP*\>LC@!P!/8`0AZ+[XU#B5@ MA_^$\1G3U*,)'ULQU:'2GB#D33EUU*>3X0U#M+*67AY/P0_GQ/JMW./;!Z\P MCMG<]\"F@KW\Q[.H")^'_6E&.*6@J#PPQC\7B1)^9VS"1.H/53'K,'B4HR*Z MNRW[>%*!VL&%YG2.G.(R[='4,2;9B5P.J$J$;`)*#FVX#4J*3WGA752=\!SY MR<$[UQ;M9+EQ,[*)<47,4`]715/59GAM0(PDD"*.)W[I'J$KT<4+-<@&>8YL[*Y0*R=-K@_P^;_P-*Z70=/KC^%@^'V3'*L99M=L3QY1K?S+ M9\RPQ7@$W:?CT1^I>.SH,MOX2)=WI(5:?_+QMOR,S(4IU+'SLA=>F[G8Q MU#0*.=,0?-Q%$L3J!&3L-W@$C>QG2O#D*7"6S9`TR=,VEVB"D]_.J]ZHMMH` M#^G,_/7L,XC=SI$:1N/QE`B"O69 M\F]GL2C[9?O,/46+L0L:F!_'Z8]H9' MZ.G=[XSZH]2N@?YTPO3!AJ+*!OB)T45=>JNB+<-:>5JK[D0E5&J'N6CSS.Y& M"EG$&$C@KM^9CFF<;61(3WPQ6%PTWE348#64(O!(+'"5.)1^GUX;C>YL"^YT M1+<8ZA]AEGMLJ<1QSW"I8'*X?UD*V\`ZVP6/BU%@[_M:-*$(&G\$XXEB(?(5 MSB[Z+^/E9(L$*_#"8QQ.Z2^T_;VB6IAZ"<*'25R-NKQ-J&CY1\T!=3-\7^2D M_<71\(J?3=G7H%6>5?S@D)JH5DZ)R;J,IX43E6!35:C'9CC2$Z(@'+ M[7?4&8TWQSYW$AGFD8Z(E*;O%Q)62P[3>7_S"%/:+P96!!"OWU*5BP**(X<2 MJ%#_T-+N5HNC(1W\B&R.[S!=4)]D1"G/88I;;G+'\Z38A#N-CPGV0CU%*5X,:&\&9AW&);?P*^N ML.[,HA#">WX9LNO-@_-7')'IS;-KUP MW\@@1Y-#-?F!_\@)+B(G&$KWK240E27$MB\^W=S@`H)^T\P',GR+^5`8-8'G M*.QQ367%\)J/IH9]8IX8IKWLF[$R;50WQF/9_"YHZ@O"O!)%?6OP-_P:8JOP08]!`(+NC_P7X0II2MKP0P1(::__;X,/"ZMFVM>\"[::8K9=30U M)M+A@S:-^*(,C,]TLIL5@J#VO39;I_W1ENV]"7/'T50[8$6,K44TTU M-"QU$@W'8D3#S9<($(E9T4'B+7YH>N2N88"3XY`>]]MB`]TO&56HBIY.^!/L M(XI_1V/ZV^E9O!8GAXEX?^3N(/ZJ($^9@$[,6$AY)VT57Q%F#,.+8,\KXL2P M5YSR(^L^=/W)ICZE^[U=5KJ!HTE,YOS4"7I8Q;-!Z$I;IP1O\./O12=L/X=^ M<^(I+CFG!>+A"KNS?01I17S1 M!B[/VHZA5GVZ3PQ<66PQ86;#<2<831)5)_Q7-#0GR&@1M^S4V1,52D1^DZ*A M@5"4]X;5%OP6"[^(W?6CHZWR+?HE'3R&NJD[*/DWK&RQ1!$O_C:B.ZY2H-VY MBC?=M"DWP#K?O)W<'F[='FVU8\@(^DRD3N<2D[NV#.G*F.8XIP^Z30TI+BO[!/$MFM3RG-&$Y(U3LLA[ MB:6Z!,9W"--16>_*:2&!?C=4$7A:YR':5):MA.G8"I5P(V-&?4RY%3KF#G:A/[ M^M.4C$/N3XG^OBPZS08W@Z,"/'-1]<;&FTP=9!>2"Q:?H7V+11A.-)>9UPDE MVBN500K7T>-)2EOA,H;3@N,XRI7[/W!>*&2Z4C<'CT7.IUKYU)]MG@G`2_WX M+_Q^_)A3]`0;YOV$+:KQ"B>#@Z&./0-P,"?.4!(T'S(!4'^%`*0E^B^I!&>; M%*0;#@$%!1,0PU1_PY4!?BVF,%J8CNMXV*F0V7E>Q4G>(A=R)S:CK?CHG?K] M8+>C45UU`=53]P>V!E2%KG*1"G(N@T>]C7BJ&G:'XM%94083 M>ZM']35!#Q\2DH;N%^3ZG?>O4G_K9ZF*JRQ?]<&79(30=&=-M,5GJ[5E8W@M M[$3D"*UA4)46,U7-CUIY?(@LO,>F)E2BC2S*3FQ4RWON\.10+'V*OC'2W"B< MQ1=>0V]TFO!O27$Q,[`]B?@:G%WZ10-?' MGHV=FIQX[_K'2-(>6+2\]9;)[]7%A;.CFV)`-/ZQYF[$6_\R.6A8I5C!G;]? MFI^L'$I+4?!GC@&MXHU_CCI;T5)'UOAZ5+00B+4,`#P@!CS,Y,$J5E5QGZT+\.G7W,M" M.4.UEX*S`#=;]A=][2W^WC(9M3*,@-N)F`S^9N--"G7NJS\S:N%K17KSA0U% M_`Z0M-O(%K9+(,*3`T3$!^EZ:\0\R#TW*@%A5Y;A^9=>?DP)L,!P/!&VLH-5 M_))=V\*9QRP8M+@!/:"1H(\<;B?6%Y!:\:GV`Z;^A+&`>V:R)>Z+6UC9$'$Q MR5\'8LPU(H6&PM(@T\(#TPJ[2VT;N8R]J'E&&,W]"0F&?5?]"`F94'S\<.*U MNB!W'->,/TIT9H8W<_N,7@[RM)?^O!N, M&LPSHK:#6G`MF=J+(GI5F<*0,=*]"G/$BM8$Q6?-!$8J#EJ,3%1"%!5@G;]; MSZ!0[1$^1!/?M<;[`AU'A@4B$8^ M=6K[X*J.`D*-D&_H*YU+'B!N\^+!XE5EJO$B9KC29>TC=OHA@QG!--1G!QG_ MP<_UXU,@8%V0NZXJ!J&BP&76\E3O6M,C&,E(QWO5-E'EW#";LM0.#GBT$QD. M+?>6I9"D62_^A'X*^"N`J3II`&#E_M&.,]OMH*%,/4: MK7:<1"X:5W$KDRTN5&S]_1!-)(]N#Q2;YV(7\(5?0\V^!\UOT!$-AH,O=&Y` M=N&,\F"EQ'OJ1B-^%(.>/@00D_"#FG\`$]&FJY`H(L1T;HHD;.Q'6=K6"K4' MP.D$Z?;X+U='-%%*';?D@ES^[\S6="=,A1=%!XX_*13O+IUN$ZM>*=<_F'P> M@3TZ-DJDPQ'B>%MS1"5.U(,#Y2?)T2]L&BJT$)W5`/G^XZ_KCQT$[R][&EQA M*5>I9`_$&:;M,[M4*X7DZ>6GC[]\>?V)+5-Z-KQ1?OMX=?=W?-R?1!Y:HV+Q MM]=?K]Y_O7A[?7=W_?FU\G_F['X"XA&,+X7*>.+3^P]WJ=]OG"K^MSN. M+#]#^U:\!@[ST^7-+<"`/2_5M<,V>.*-XWQY>Z4:\=--VK,I:``LW'U\=_G)?S&0B&NMQ(._B1V->K![77W\\HMO<(W] M6-V.*!&FO0#R&"CJ;>)HT!GU>YW^<"0]@9PX_9\X>.?'WC6Q\V`^ZDS[9\W. MDA@O2_I/5<;+;R+.5]=!%X:NF8*MO,-KCN3R8=[;,-E)5/6'G=ELVAG/9]*? M\8F3\(F#=X(<6A%'CCJ3Z;PSG_:E/]/3MQ[V]A)S49-F3?Q*K3EH0H7CVGK8 M4NR<[OK-5TU%YH]-+-R[3"6>#3?*0Y:>J8G> M"<';K:4_LU3Y&.NN\$D4*.B\\?%[S^;=&+#X+[HEJ@GDU;:BF4VR"9ZF>2N/ MUP"),:ZQ'G2\2H8W#HYW?]3#E;!^R`UJ22X8+(=EQOQ7VSI6I_[>3U55_%15 MF^;*1UJ`G&;EQ-YR.ZD`WD5/K]1>=M,FR?LCU5C$L*WX_>BP*N`GZ81_6P50 M+MCO4N2D\B.*V9\ZF">]8$NJPH1]4'7`H->):$TAN%V:L"E:[\3>X0_`%E+9 MM,P+Z]E$^2S*SK`\_C\>]I3X$<3C=MDMWO>3XGC8>LC9[/`351B14KXN]7+? MM4)PLX6IDC+2.!7!^S:+ZTQ[V^:J#3N#(?7/.H>19D5E?U)G`*(O@\XF-R"7 M+"S@)!HH27?,6MVQ0;9?F<8'SE]B73!P5G@&2OP0&J-*RJY@E*+PXD`]LP-. ME#S(]I&8!2;ZQ=M'VT27T5Y'ZQ@U\D8G_L0UOT$#+U<'E;1GOU M"NP=#=2[X?SUU<7PU=\&DSEHW6AI^+8E2]E<7-_,>MF;&T[&>V[NQA9==2C= M^4:UK^U;)-P%_I+Y0;K"6)SUXQO]!N[Q-WI%=,NPXUZWU^N'&RZVC=(WG\#R MH+[-TR/.)6_-\5\:Q540X\/(IGG9:W2W'[]\>/6W,0_7;]MQ\ M0&]4P!]Q033 M_K)S7D`%%4!DQC9OM4>V\`QVO0RL6'Z+X-ZAX[!_T&;>I(#_9LN"$B\[[[9X MLKJ/<`IZ6B;C_4ZV3Z"B5O5\8I4C6G,X,G7.:/BUL%0=+((%YSD]*]H6%?LE M74_:%A7-[`PP&$4[`TPV0(_*SC,YQOK2Y%L^/'4^W*4BMNTD+H>'I[USYV')3%?RNL+D&:^?&*.\SHT7#`M%3-- MZCIW&9H$[.N42';:QT=`ABC<`P/'Z53SXW!""=D_M11_!N"U#%TC0U?$P(/) M_.P96!)3Y1B1EL!4.6?3-)>AA\#0"\NCZ]OZC[D&%VU'O)Q)9*8_&9R[5W`I86.U5;FI9^GN;-:9P\U0:4^I6-+UU>UKL M961,V6TP!.V]F'SVP;96[\(!9]?+9,.E`Q)HI:UZKKES0CN8KA0TMH/IVL%T M9Y?UVPZF.R"\*/D\L#:=L+F0G!0AMOF"#8UBMX/I)`?O_"9721&&;@?3M>"U M['TRL>1V,)T\QDL[F*[!@DVN7*%V,%U+PBUX+8>V@^G.QGIH!]/5;D>>)7CM M8+K3/M\6O":#UPZF:\;1EIH*QO&S/67K?&;>E9^[M3T[[!KGIHB,LDO'8:YS M:-O$>2.SODIL`GACL[6J+V@\@$DSQ\Q@MAA'M*(2IMM>B6VOQ'/JE7CLK(=8 M?=>X9!NE3F#.*V%E,(PFK(RW]DL,4;!?X\1FGNCA@9R6+6L_1(G94K+VB>WY M-N=\]TDC;.;Y2A9-KT8N^WZ-;CJ>38.0US9;Z=Y*_JS"HU^.-3[M2,[.9%(D M$TY[C2AD;6G^-&B^'AJ?G3N-2Z+22VS&EZ+214SY15FPM>7H;ET'+F^6RXF# M=RII=H-:FX?*>[XG#EY3<]!:]M^K4?/W<_+K$_FY-_8UIK9[LN-H<(/ MS,7[_WCZ>H6-7O?.Q0=DR)J,GY);OIF(76I2/LG,1VV!#'S5:1/P2P8K MDEW_1LDX]%C"?>FI[V'2_3@[Z3X_U3^6RI^=]U]YPOV&(LY6YD75=+JAD#0G MPNKK20F&KQR@E&'"5P9)NK=6%+)!=@JG/&`V]<#R(YXQ6*=%8!5MIH/JB%'T M$">E5D2$Z;3HL4W33_=6G7\]JO7C9.C`G"%TD4G%="[QDK$A>'FY6#F?=QXOLM] MW+D1_8F#U_*T9$#OQ\.3WBZS2D^2R.4QJV,9!N6:U5^9`P:*]BB%15T2G+** M[1:\?2UJB>SI]A!/$[SCF,;#:()C94MBX MM;LU+7@2@)<:-1[)8^6VQWB:X!TK`'SNL:,6O!8\64*Y+3?*8^56&,G]X-FF M[GHX+<%<*$O]._[=1LI:\*2+YD[EL7//Y!!WS,=K$7#$B'#=VOE,6.#$P6LY MO`($M!S=='N[PJAR>CEU1WFP+:<-W;7@21=@/BGXFIVZV$QM+3=^CF.N3W=J MYWEN''3BX,G-`"U^ZK#VI[4GD=3.,?*8^Q6&US\QQWFMJ)KFK3Q#==D"!X;8 M3--I\/0Y>WLM>!*`=^KP-5-=-3LZ)S=^CF3O#^I6[S)ST(F#)S<#M/BIQ=[? M:7#127*,//9^#>%]D[79XRUX;7"_:<=7>VPJVI2_?`0UH'7!7G@YDI5_[B&\ M\P5/-E/#O0GYRX(,@:)-'0<1?Y0B>08BG"`Q:6FV1Y;?-+5>]W0 M79TE!ECL,8ZBW^QQ%'YO_G][CJLO7U(G+>PUBD&@.C),+G<=-/T8ZQN\VO+A MJ?/A+C,+HVQ:8DO]TSG=TX'DG.BT:$O]II^N)/.[RQMEGJ9;?)?K$WM0C2,> M['X@-D8J'7:"-4P1/LZ(8!\3(G M*.U,%;FHR;)B;FQKX6FN\I5IJE&;.1-+SCH]T2-4)N>K(.7WP0IU23-[S M;<%K,G@9W"DM)[;G*9%-<9Q(R)5N,\VU;(2>]2YW>2UJ4, MX.6>;G/,BH-]IYV$V87T1WOBE'OBX+6,N2=C3G?)/3Y)\I7$PMC;N#S(XOBL MFNH#PW1$Y:UE>D4;AYVDJ2D#>"16R'V%S!%7K`9T5Y9XX>"UC[ALXW*6A^DF2KR1FQ'%2 M+*[=1V:?L]&X;^&89&=\?`2,FEXS#7 MN32W]T78HY?!4-9>!INEYFE%]I7U,KB%U^I+75,Q%<):K2V3F:[C=S1(:TFP M$"=%]JU*9X4-">`75TQCJWMF*\-^1\$SH&0+K/145)NU70M*!DOBK@5<1IUL MVX)]U?;A&CFM96`MYJC4EJ>,-?#]:(.&05D-&II]?*<#R4D1XC'+I>H\OI.+ M1Z9IAZM-<^UUW9ZJ'#Q;_T&6V!>RB7D.949?&G3Z)T[<)PY>R[LM[YZR-5+> M97B:-?*%N7Z%J_F@&);C*)IJVR]8_OJLV@OYZW":*=XJ3=8JVI.Z(0VG=Y)= M@VFG-ZAUFG!+N6">CWNS< MG:VS`:]E<*U,D+RY8ZWAG[.6`1G-'!O? MPW"GOH-^^T*3K1]?WSZJ-GNK.FSQ+I(A?&G;JOG`L!SI[4OXR(WZ@A]=8HWS M!U6W,<;$8$%O14G&A_>$./8I9"IVJ.?V_U@8]]# MW5$8++M27;"5X5/L?+C`H9'P-'_"<[!<'3]_BZM?`/U8!H`M7K.V=:17964M MF`'\YC[2L_?,L)[1\/9/6;&908NX%@A*YX^+I=&8O(%X;^!(MC]5OP$4]9QXTPYE]@X''B8X??L)I4NL7M&A"[/S.U&..YSPO\56)KQICX6DE M;65EAKADH77BH)X3I>_3M[;65KRM_I7E,NYH_0_3-/(M^>XWY+O_*_#=I;^B M/?'12+..NO$RK-.OM*U[D?,"+G(_^10Z. M09,_U:J94EY>\*HST"KL$90FI[N]^46_.QV?Y!'+/V>]Y$Z&47DV8IIA]-[/3?FD+YGRHVXJ+TRU'?EK#YHI@.4%3^+( MU4X">=SM]2XFW4%MAI&\1]R"UV3PJ@]`5<60T_'%9-!M&?)TP9/$5*HVAA28 M2E=^RN_OF/)[SB;R68)W*B$D^9NDM"YKRX^-:F;4\M]Y\U]&$=[A)2Y!#4[) MI3.G\=Z-PB2?:OZ<>-V?.W]VL(+NSQND$KYX:Z&2_-6359<]^N65FU6:Z8O2 MI\ZEYSY:MOY?MOC5!'11,ATOXK@Q5--Y^_+^.[,UW6&48/<5MWE(H>6X+;3< M7FAI8<,T*I7DI6_>:J7BT3B*;BY1[O*V:O=`LDITR(ZCP">.JYI(J**PD0Z- M7J.ZRA73V.J>V2S#>;3>8+:E3M`)X;L.)5A[:'7Q4JRX_MG^B49@6=RU`VH0!YG%W5]\=#HBYY?5,H&6%"=Z"-1$O#M MQNCW8$*&#^Q9(-F20RG'W\\^_M\8QM_8(GIZET_,5A]B//V5K53=%'K7__`= MF,TV.&V>:D0_QER4$%^Z&?T.2Z&/F;;;$D,%Q-`*?>F%_G!7H1^UTK8+_4CJI*_V5*1)9*^N9"K-B_NA MUQWUE0OEAT%W(O\0Z,9(EX:`5_W0\@K2V5-\Q4%G.!UUQOW3;%'34O")47"* MMS#K]B?MZ38/O*)3>DZ19GO=^3'O:%J:E0&\1A)OBOO<[PQ'\\YX.F^/N'G@ MG8W438&]UYV=M=25Q$VOKEXWU4WO8V\3\M/GW=EI5@_6+[/D!:_Z.MK3 MSKQ7F\J5]WQ/'+Q&DF^*QS/JCFMK>2[OZIJ'U!V>YB"SLQ?716U0V:3T<>A^W.^.VNO/ M,T(\3;CA[02Y)N*&\R(LT!=?2199D`J\!\VFE!%^6 M:N^6N&4`KR;JW:JS_I M[DM\7NH>TTLGLDXO31FPN3F-LKKII:G/E#7F]Y1?'&@(PG?ZZW-&P[KP-1\# MJZB"SN%QFSY_8:JM,."UQ>XC8"L?G.I3YF#>G2*Y'G7>[NF-C.TU:F3LOK9' M^0;51)9\)ZE]ARTYNE+-0QP)'KF9 M551WP_JIK?Q?!G=9CD#1\=.1VOAJ12F*@\Y@/NI,VP;OLHK.$EEFG\8Q)X>$ M4RW,+U4H=,];'DAB=E776BG5[.(!5^7!5DUAF9]K&J3,9YK&YU$;Y@1D88TX M2A.&PVEGV!_733`M/[3@2I(;6#=[[\2^O>ZD-EM&!MZ5Q)8Y<@A)V#),Q`]K MLV9DL&8;>:K-$6?'30>]J/NHY3O:,Z/D,P.W9=P38%Q)C)!Z`BI+RUXRW64+ MQ;+!(EGK=AM=J:V9FMP.6&E=UN3`2(H8_+$_Z'=F\_%/+0SNA%I^5?7>4VTEEMO8:WNK ML&OWD=GIKRVM1]BT[1&6VG$IIXV5QFQ7A5VYS%XYBK6$?1CX/]C&"L])-5^X M:)@-^M,W\$3D-OE9M;'>T$EU&,BUP)8/.0VO&MM2*JMO%F_G$H#@N+9E/A2" M6-G<=^37VX6TM`"5>H3Q=4U M`>NEAR M\!/5#?_VA5'X"4BE\!^Y\8R<"%"U*,[/(SWX$(8IO9SO=!=,@@!'UG(#V07M M7FDHK007ICE'VD\9EG.ENI$3_>@X7N'D]?8093G$]UAT\!*1;7BH[2%*?(B# M['Z(05^\``6[=,5KS[2.,QV,HV>Z:;,D3!9PG%:6B=_[C0]%$\R8,"8?_%Q. MO223JDBNYF%H&15!"UGA6=947;QP("B5<+4D9T8AZ$Q5VQZ:=(<6![0]L^:= MV0D#FI`H$IE$9W-H$MCS.V3'R$K([>$?UHWG;7K#8INO0@OUVY_9ZB. MHUPI?GQ9N5`^J:O[A7IDE[8"<"523R6!EV_1]_L_]T<_#WJ]HF7/<@%X]N(R-7/"=^/')[/0=2)0[6P:#0;U>7TNDYPG> M?M0Z''8FA8O7Y`+XQ,_SQ,%KR;7I/E>%%VZ4&/EH&0MF*U^14!SE>KED-M:7 M2>"%U>YXRPI>\;N;?B/A:X]/'%_15D!RP7?BQR>S%]9>O;4T>@;@[1DRZ`PF MH\ZL36AHP6L(Q0X[O?&TTY^?M8R5QQ6K\/KKLVIKC]BRHR]R'F5PP&KWPF4% MKQD.6'M\C\$I@"PS5: M!)6.H/W,Y_ZP,YM-.^-YT9$?+=LTBBI:!%7#-J/.9#KOS*=GG4:6,7:C\>,F M=AX.<>0Y$]^H)\R5?Q?ZF3J+>PXN?>NJ+ELQTZ5'KIXHE/[S_6WO>G M]]$(JRZ*)MO43PXMM;?47A`EDTV*7==2ISQV7;7129I37+]5)X,=O^\EQ-DC0"+GMAF689,/^^P1 M4([^KI:R?YR/._W)L#;UW>3S/7L$2$?@:09J2^"RV*?5QAW3;\_;Z*,DX)W^ M_VUB])."U=%[IO7DKU^6Q7WU37A3XB*.M+MX:OT-U*:?O/?QDNSA$"TU5_]&*CS$FE'!$D<(#BI?(*6BUHN:CP7G744KN6> MEGN:G?L@`Q=E=`9>'-S],VA/FMID./8/0O6Y=!Q^9YFNK6JNIQK7]X;^0#_] MH#N::OS.5/NSZGHVO,1?>PXG^P7-9^P=O-H--:X-[S/[!3MA`6+$\6U'7 M:]OZKJ]4ERDKW=17WHH.0!R?8@7GYU#G8,U:K3"Q!K["/W47VSO#5^D^Y)%[ M#,?0/9AWIRALVL;#QVX\S"79B70>WC*RK+Z.D-'>F,.Y).D)N:"L],5B8R[" MM,),!`WD$K./=RQ1>='>I&;X]PUH)4O^/J7E M'.5^XP/E@+KE12EY$8>FY+XRP%^MNR(3>D^JC$Y.H[+4?D' M()RGA3DZ'0M3QK1Z.2YX)!ECU.\UY51:^FKIJZ6OEKY:^JH;DI:^9#R5EKY: M^FKHJ=3GH%64NY+FM7UBJL..Z7+O!UMCQ,CQTHY^*%>DU)UOMI,LZO=F'7B] M].?:DFU+MC&R[;5D6S]X+=GN1K:MK)4`O-,AVFJ(5/X*C99`6P(]N1-LEB]= M7F5WFB_]?K4V+$JG5/RZ@]H\Z\*0'D4JM1T<3K^#0XK(F\YJ-1U;'FAYH'8> M&(YK]?E;'FAYH'8>&`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`C@4E$QM(>B,U1#.-QW(8NM(U2-Y^%\!P%,BQA[S1IY8ME6G%)NC_#Y[E/ M<2[+7KZ4S68A.%_A'+!;\-P/T=.C''5S,1Q,XBHGMN`^N\E`U2A'N5P,)PDG M/7,WA$DJQFV[4B)^O,M4V09LY-.'1+US!.H1N>R_8(,(X2:O<;",QO M].KHO@>P[5YW,`_WG+.17I#OL>[;WOWQA>%K+%Y1/HD0?VQ<.15==+ M^NFUYSJN:F(LZ/!CB"IC!]_N1.'X^.4#7:\,AK/I+`1FO]U5"F/6D M#$;S^;QL&-]9)K9?MTET?=6=/^#\\0-X8[_(:7U+NR_Z3`/,/`=7V%C@[0YR`9W4!&BIYSG,`W,^W0U,DZT?7_L\_5G]MV6_`ZL" M%*"]AQT^'F5LKP=>V%]^SEAO_RUER+SQN(PM18-!IFO9+W2#%-_-);B36Q&3 MX5O#)L:S_D9`+%QF[TTD49'A(^,F$@9\^B9BR/H5WN;\:BZ8_4&W'?=.9_97 MZT4UW)>0V+/V]^TM,PS-XORP8/HG]J`:[TU7=U]2:'^6?9+]`3<_=]YA#+3D M8\`R^([RH(CJX/>_?OWVFVJ#3>\F&+G?G8X%*%MV%-OU+8/]+2K<]J17<-L# M?]O;MA3;M\AON'RP&4-/YL:V%I[FWGBV]HA-5S^:F&IS;18*6'S[S!:ZIMZN MU8(P]>,P)26#X-T]6Y6`-\@$;[P[>+#1?!TO#N` MN-5,$(D9/YI@]!H&O8?/ADR`-PI5)?P]&'+#;E?P1ON?WY9M9H+&&387-CBZ ML3BZWN`;@K?/T8TS89MDP;9MGSGG9JI&+FSCD"P1R.%^L$TR81MEGUOJ-C-! MNU[3P.<[RR=F\LP*F4H[@S;-=R`SQ>:6O6[DV5GFPQVS5_Y3[X+AU9%N/J.1C/3IX.>,E?+)-1*S3&;IG]!&AR(H&^#ZIN?P8' M@+G_4@T/A[QSO/V"*K>8Y[\S^!GQ_1X&=X?AJ98,SL95G*9Y*\]0,>80NQ>C MJ.D56S+;QD'W&S=S6<;O-..*`)7].)Z!M,,>4D/2\1\%SP/B'O9)VIAF7"F@ MZ3M*"2]G;J&T36>X7M.,"P,DJ;3[K4*;%F8QO)I]TI\P`<1'[I.,QU MHB\1%TXT-0_L%PRA;]HCF823$=E'*'JSD#$.VU,,/-]+`0K<`_-9?CB%"7J^ MWQM9I^#Z\XB2G'\;]O82-],LMYQVV!_D[#!L)1FH%Q3(V:98+XVY)J_^=C/Z M72RWY;5Y2U^:IJ<:MZJAVB^;Q+5UZ6R7?!@U87,6S=O@E>YH-D/R@X??6J;G MA-&@'3:;M878]H-<)1J]\1DV]VB`PVZF9[00]_9]2DSL-UNM M17@W;\VX#8;/O/_NXHV19::0W>3;8.(SR?3;8)RRM1FL?]/WR6[SC3MA!/YD MSZJ19A[1<6[;0[9>V0$]L0ULV'/X&Q!S^#S(A'T3)F;9"J7?B^<(IJYZR-8R M).XL6TOT>[/=MW;K6MH?CY:Q8+:#22ENBF`)]M-/[">OL&,TB(<<-Q<[;#O? MT""V3/I1--Y]ZX(@7>O(+M:(*"W-`1L[Q:D%ZU$%PN%CH)*^-&U4&A MOU/7.IS6OM#DI%?-QY-AU0"%1NVV!(1]@X_J8.^L&Z"(?7)(Y^7DB%4"C?2HK%`^S_,*@MIS M*6KIS?/RX(IE^ITG*JLD\;RL/PG.A4=/4<%S;7OEV:!:P`G6K06%1DD5;IN!F(*-<8NX/I M9'($O'#KLW8**6`Y\QO7'(3D@)/JYVQ!ZSO+?`*O@B+A_&\7X\FW3,/&(SIS M2/*$@FCW>X5!+\?*'B=J04O=;NVX.)QNX"V[%#J>&/I*E4>#7H[O`&[K:2%S MN_(>]/+L]5%*%.)D<%$&7^;%/T\9?27S95XMZVA:.S*YULU]^[&4PJ1`&&XT MF@U'TURT%83L*'@JG4D+I!--Y_U8-4JY:(I0VIVUA6WHU?>8[8*P@*_(T^D9 M@.?HKI_OPK?QE6G6@TEO(7K?PR++L>QHJV?B@; MM7E=O4:AUU\BI'5B,(&`'&_C&`C8HM>_,HH5WUD\DQB[OOG91'LJV+R6E_%, MU_UV=2S(RF:$/$N_1-3L==%?AG&>U]"SGQ*R*2]5H?0CRXELSR>S-/>L5("J MNM(9Y/47G4ZJA:R<%(!!7G?2B_ET7&WJ3QG.6EZOTO[.>3&[05`NW^1U).WW M>N-!I>15X5WH(*]/Z714+60E,4Y>&].+/G#IH*)\K#)T3:RIZ=:F(O/1?!;M MD)*5CU5P\Z4P_+C`YF>]V:`W&F9O/E:1+2HOG8]FI+7O[C9KK(VI>&>R-"-1 M"YZZB7RY%N/R@3[E.C=$ZE\.Y16#V*]3W>L\TS;X&X0;10? M`\+[,Q^B_K?^F#/#3A!EE])E%N:F;;`X1#QMP\7?;8%J$(%JIQ+XP6">"55F MS>JV36ZV)S9UR_YBN;("1 MV9IU#"SM%W"F[&FG[0(;`-8/WFZ6HL;MCHMO-];F\=)?W78TC,^ZJZJ:^\512,KZKYP%)V/WCUMYOA[^'N"FRALEVKWXON&G3KS?2P7?NE>ZFC M,C):I0RR^KM2J6.B;#"QT/[[R),&W[Y8IF,MW6=0<#Y_8YSC@3@\3M.Q-2-/ MW;VLT_"=X7>CO.PEN[67!7%B&]E-:G;?QNT)P)$)LV) M[306;#7!VUD]:7MTRQH:+YE+;SHD^GH-/M[?57.!`PW\+-FU9;MTG;!?F^]! M5K=9K(Q-Y*45VD6I>\_P3;*:P?J-A0[=^Z']R@^QR;):P2)\\SC95].&O=_[ MUA_Y8)5B:F;UC:4.(#M#Q2MG,;;#PSFQRY-/NGJO&Y26`$>>R#O'VI^">1CB MMF5/+S_9?G;#W(J4`.\/R#$1DH`OI\)^4BI\`7&`U;C`1J@@U\/L$SZYB"U0 M_N.9>*Z@GF1/W!VZW+SWVZY@I(?W58E2`O_DH[E@W_%2AN(R?F`LW50JT@@7 M?.'1M!\)694";WU(/)"%BE1=CB;3^7S:/QF4?07Y:NN:RQ:'Q!AC;7BWH*[7 M8)S%)77IO!IK[[N-5T=]6+O)O%JFNHOU"=[&J\/9;#J>STX&927QZC`?==/Q M:%PUO][8;$UQ5,<#0M!V""V-L^W6Z2SAK<77.6`?"9MDG!?OV6D?5VQM.3J< M&/69$L'E'9"2;0`.-B8:;BYVZ(Z2Z,DVV?;9$9EV`I&BV\KNB,H.NB2ZD6Q? ML92])5&6'349IG1:*[2WZ&#(W7WX279\9)X\QV"IK,@-G]CT6=4>=9/9+]%H M]!X[S&X!/,*6TNGQFXQM'&_WV3&2Q,"N'7=/+E'!WW!!+6)Q_\7F=Q%?:@^X MLAO[BE,I;8,R0)RMF<:1`N4R(2[_BLGTE@`2Y0,&+XG:&UM7>AN8N#M5^P$Y!-Y8&,VZ?,/@8QS^0AYL/!+D['<]%] M4P*P/WC@@``'8VN^#_IW_,LYB)2GO<-OTK?^9+<9)(.<'L+3X31I+F0L6]XF MRQ&<"5"S#:-);U`/J.7*R9S.Q'6=YZ&R(P%DCF6T<<-Z'"#+EQ39,8%A+7`F MO,QI3H)(PLT\UB8KD2`YLY+F]9Q'V1(D.Z11CP0YW/I(`)D=&ZE'@E1@:\QR M)AP<`F>D5"$:IX&_#29ZHT7OP[>^O+BUDM.9>IJ(`I:UP1H`3PC9G";7TT2K MQK(!YT6>FF9[;`$/+YGC4-$-)BJ)("'E1>YPDMEFRCR2-EU@W1+WF41\7N+I M_."-1LNL=XX_9[7#1L*8;FPO9;G#=Y7$6K9-4'Q'$8+&)VD\`-O].B.K$W4O M?IF.RR0_P@DLFS,]*R&CEO7MIEKUK:'I/HRTF:G!RRQV``!-@'[U3; M?EE:]K-J+W+,'+:`WQDX(XH]_X/9#GLI5FZ3U;(8B70*T,:@V;J_LB#AB5\% M=Y^M3&;#7OQRIOCN[]3O[VRVT-WH4]OF?D0]5GX0L?+(OI.^72Z:Y0=4O_!*G'>'EC:D! M5_*&PZZ`"U,V/)S+&WMX]SNG6%/%(2/'<'L/C!K'>MJD`]\;#R6X`;]O=$2#=?K3#6#O;+9`.!O5! M*E1([(DK'5L#@\+5D\Y*@;,=QOK/ID!\`2#WIK/=0,[;YA%!SSKL0>YA]T8[ M\G$5D`=ZP/'US1['/,R%M=_;D84W]U4I=%DGF36NT(=N7@=T7RQSP;!I`+:1 M%(X&F>&'"';/,W'6;T?J4-" M+X=S2MAMS1A)'G].O&#I/HS-:;A^PP M/\%A=WM]D-/U>'N9TK8]E+CO##-]D#=0^N!]DV"-_O!P7.>T*^Z/4J8T9NR@ MI!UG83EO2EX_I;9NAQU':L$Q)R=[`'T69G<<8I&^[D&[R\!B9M-!G.TU'>^P M.][5TS(UU7D,>LWGM+_/0%UFB\%AF'6P;<5#MI6%LQW&$A3:&C;%,?%NZH.^ MM-`+L9_$<(=W8(`^[$%TPYP&O;-!N,6\U"1D M;S[.Z@4HB#%WU4.WEX7&'*5SD4@S+;S'7U3=Q)#%M7FE.U3132T!N%FP!QKS M)K[&Y4WFZF5L-0NE.1IFN/].MP\S]E_SJVDSU<`"T3UPG-?7/F[E[[*9"@#) M.(&L/GY\=/2D-$AH*`JX^E>,_^]'\U+3,"?$"=ON[7X46>W]1*?T7AR&(OLH M<>]9V,_1D14K?NB_C"XX%3.PY=V+.-&?+D>7+V&L6?G,TWR0/NSMM5;25 M2`2^P`CFV89[BO.LUGQ$(Z,<&(ILJU+@L@XH;R)-'N>6`]PGRWS`%+F0B=(3 M4`N=5X[ZS01G^T:*"Z0;]05_B,[71H+K'N#DJ.AY+X_^BNRK4NBRZ"]'CR@GZS'Q@3K]W]V,8Y>CTT]_?83F4`99S4.%?- M#\48GL/AVG[X[<)-N M;.M)7[#%VY=?'>K;XM_H7N)-.T_1+R51(:L=&J>F<<*,.6R'1X$WZP3SC(CA M>#:L$%Y@,-%1]E+[CZ?;K&"U8*&SS+$A$JWM"N^D=!BRSJ>XT5`B`!]-5S4? M,*5L7^,TJS$<'\TZS\9^<@ME[3D+USDZ_Z#M;G2H*I'0LWK*I01V=MA+^6!D MX'^2H\F'94&Q183Q!ND5*)6LGG1PDZS\)FC9@>C9!_<_7:*_:LQ$^)ZR4=R^6X]EN#ML>N\>]A98@Y8 MT:T4`R$R3G$/VMA!V>:M7M9V,U`]S5&Q@^FT7P#5&9O^RM8!D_(3R2"*#,1F MM31+(#9]R8,VEH7"O+O;Y)"]8MO;HC\".5>V,L_J,)8FU`[;WU&@S3JT'"TX MZBHL`$SZ:]-7`#L._P?M/&>P/H#(BGI>/,T:SRJ>>@& MCP1PU@GGW5[/*@4X_9<\L2`9+=KC-'/T^D5_,HB;WKOLIP)8L@XJ1]N/A^5" MDI'7]R>3^<;64L*3?ADQCH3=_:RS>GVE#&-/K+??=C*.*ZM9%UD, M178C9L_%1E5$ITG?6;?,=0WF7RJ\[(&V'+4<3L`KOHNRMY^%YAQU'&T!M0\( MN]SPT-5B6&QTR.U:5N,M;BQMDO/^^SL&L%EG6#R_ZTA@AM>L&^_;-R*:U12, M"'6>=U52>'/5PYEUF(=<<^\,(O%U6"OTBV4M<"#=%\MD_F`I9C_I&G,B&4D? M5-W^K-I_,!=K%,`MXUFUSB_HQ^^3]975THQ[A\-0"I6\VQHPD77Z^6Y]E4@( M=8QU+X]Q=UM=F:=#@O,.:MWYN,AY%&):6#)0W>/EB>O0/N"LQX&XT3 MX01YD2=H^=IS'1=P`4*.+YG9NPSX)65V7JQ=+KT\Z.RU'Y46F`TWZ(V'):!Y M&Q;J17,)\PD/H/,"X^7`$IQ,!F4("3D/X!`ZWQ';HWQL3X;304OM1:E]!]R/ M\W$_'0S+$.]#K-4*/)JS_)U4W,"[QP;+)]\Q4I_L2[ZA7Q#FVFW_L]&K\Z3`N#%% MC/M['%QV#ZYQHGJXJHW7C*`LFLB9(M:?UX>@`VQ)TM6.OTY*,[(BQ-,O8L&- M1]-RE.;VG=>'G`S"Z1>QRH9@E(W/`3??/MO_M#";RODC:I#=Z2Y6-8!_IC_I M"T\U-@VS?@'#;-Z;C\X#C26XNPGT%@B_#\;E7#+5A=[?F/[P"&+U\HG9Z@.C M+Z]`>0?B=0_1E[`WOZV9_8VVE+`9^MTR0P`[PB4G6K.$YK@@6GO=\>1DT!H) M['PT75LW'5U+06!&=\A13M/:Z7Q8*@MOW;$,J$G25.')@(W!"K<2L?P/_`S, M];NS\*/(^IT-41-0FR3(;)="6JP>[-9D;20A M=+^RE:J;5,('&P/$@6V(\:0]7-P!X/1F]GN_]WDPNBK;4RL#I,8A.T.!#_H< MV9\GC4#U^W@V7CJ_?;&H3A?>3GW\[RQ7-9(-V[]8[N_,Q3DE#R;F344CT,4E M0TY#ZN0,Z*/L_F@H$R$/RQ8?X7/[4"`&L0>_#S_W9U='0%7JKC=*30S5<:Z7 MHHKVVOZ*U.H7T][8.I9-BB\=\6T*U?2&?FG*-WKD&N>3`9''!E[BU#KD'^[S MX>XM$VMB-CV_9+ON;V('&Y9V-"-E'TBJP<96<9]T(;:!%8T82`A6DJPG,H$5 M7`(RS;-YI:-J&%@*N0N$W^C=5^(GG]35_4*-$G/JTBF$7"#G9#;K3<;3/-04 M!ZM8.;;_JR)&2QP9^Z`AVV*?;&^0LKGAV+6+_Z%/.(6*!PX'IT!^17_2G_9F MXDIF8YN'`Q'?T;!`N'LPG`YZD\FTNCWQ<,BC92R8H$5?#^R/ZV&!6#6./1KV MAZ4"EJ'&AT62L@?CT3BH.:E@2Y7@NDB^[HV;5SQ?X@M[IJ^2XK1"$`MD[$YFT^D\&N(M!,). M@+]#N]1V=&SXS?^F49BAECJ*0!X6R*L=C@>]X:@@,G+!*H@DBECDONP+`VJX M7/S;VS;NHK;Q7%V%?YN(U$1F1'%*'>0B=3HJXUKT!)!:G%*'>4@=CN>/#S;#"Q\& MRL"M0J*.,E`ZICS*7F]>1EI$40`EQ6AQ(AUG$RE@M#\LH\BG:0C=6Y1F)2P+ MA/;**%%K.$*+4VA6[K1`Z+2,'+V#$+K/)626W"Y\);T+:_>UF_/O\EM#EB:#'Z?G`>:]I5SXQX1TSGBJ#`IC3%G8?+[L#Y**MN=6+7Q,0Y MGZQG9O._])5>J#ORM\VW7)LL%HW??X=O7S;?GL+=13.U>]U1;E.([:.>TJ%$K][6$_4GI%_1H]@\A[WE)))*-MX:3CJ#G+E7@,.ZM?UNHDB;UKP MF`;=256GE,!<`T[IZ")O5O24YMU9>TPU2KUY0=TTSXV]-^"4_!RX2';USGG, MDR*94J,^_"[W"JAT*"1$G@0J8U*L6AE\Y?;$Y%`?DR()_3SX/YNW15GRTQQ?'$^QV]OOH=A:(FR/O3[BR9 MNB0)BD_I^(^N7Y/C9+<2P+C?'26]5$F0?!175GR#771WCK1-BU3N#6?C_KSJ M.,`F%!(B3P*M."T0M^D/1_/QM#TQ.339M$#U_%53X'2U"-$V@H> M6%FZ;G.Y+%VW@QN7G!>=X<9ME)_4!%Q3$"V#0BJ:U-'KSJIRT\[G=(^NO`J' M8"ITP\[H>(^OZXI&6:ITL\HXX'WR8C<;;^8/@$N@K\@8G\$<'*TRJE6W[;?6 M&4IQA,S*R]V0""'Y+01WQE.AC(EQ;S(K<6YE43#*1E^$OW?&4R%_MU"$XH#] M5LA@69*NN!R:#0OG;%8DB;+@V!E]SB$=MS-06*0@8U8\XW^R"RK+@TD^:DRB ML+C'5]%8WF.B;^?^LOMBM:BG!5@M41@>!EZ%JJ0DK!:_9"ZE.<9N<*0V"(*S M$,V/PC/`"0.\*U'QEIG.9L],VC/OKR3F?M`O-OV&V8SF4TXO^OV+_BC1_"=[ M@V7#]`_/>(E,/_RBF\Q_ZYZ-VV9S`FY^`?`-Z@5N\T#V.JYY#R&"L^H-+_K) MEH?'A>BS:FN/D?-Z;[`G9G)23#VWPC#VRX$QWAHKZ-D:^2%(0MU^N=JH]ZR* MV>8#@FP:@VR7;58#7_F,-Q\2H*,8X]4/:%E,."+H)I(=8W4,.2Z);*OJD5TB MAQ;NKRUW-_1*F#II8:7C9C"0'SEE"8)DT+6QU%*=[$CF?]6*HHAT*AR3&1>: M4#Z:3.?S:3\'ALCZ9>ZW-/DW+C)$O%@3_:I`+5VNC8O-_)Y$??&C0ER.L!KW M"N2O#'OC:7^>QXE5`5J5$!KW"B2"#*:SP7@ZK07T86*[!?J-]X>SV336D?*8 M^RU1X!1H)UZGP*G`D!KW"DPJJ4_@E&4=C6-#Q;?>J4Y&LWY-7%>AP"ERG5RC MP.F7Q\!%IG_7RP/Y+&G M7!Q$W@6LIORI`@5!JQU1!S!'`1.KEK$@U2%K/SP5L.T:B*=X76]YW%?`.FP6 M]V4AZ@#N*V!1G@Z>]D-1`6NT=!0E1JFL=3O^NB/KL@)6Z>88M8U-5PC<_APP M*&"&SD&>;$ZN.R9\^X%6P.X\#F@52?E!`:.S>KJL1C(/BMF/-<*V'U@%S+T= MP*H@"'[`D14PT>H*D99Q=-)'W$H[R-VLHAIAW`^\`A;-P0=YQ9:ZBSCS?>>6^N-AHA="HG'H:!Z;4%AH$V7N/.-$8J.!4W8^J6SGXJ3LSZJK M/?HMDOSOTP@,0"!P>@".#UIO](U*LL0/_-./OHNS("JL[(W$?O3V1;R1=L<6 MFTPZS)FBT,_%6@$$'!N5SU8-B,R:K]!'F9`O$G9`)5DN.0"(O29EB_0DF367 MC:1KSWX?]X:[O#?V!DM6+7RP/)YE2?#:/ MB_'4U0[>TK=/3'68$Q[+.VNUTOD3)FIJ,PK0W.P8`_.!PP_YO M8P;.P[!TZ+/Z;\O>8M!E33`&Z*:SLJ"[\MA' M\PN`=_?,C"?V&9YY+-YM:#R<9QL#XU[^/E.W4,WF#R&X4;;%UN])!FI5I#G* MMO^&1SCR6[`<3:Q?NGO4[<7O3"U>?3J.C`Q_W(-+,-GAD@*XJYHAN6`ZW<' MFWQKP`OVV#&XBO_7<-\L]"?%<5\,]M=7GR^__O+QRVNEMW;AO]_?*!^NO]R] M5OKX[SM]Q1SE"WM6OEHKU>SP#SK*+;/UI?+J_SZX;Y3$Z]Y]>G_Y]?6]Y3[R M-UU\N/S\\=/OKQ.O>D/?W7[\_][SI=X$V]!-_M^U&[[_'O_"/Y8`<+#2]:?K MKZ^5>T/5_GB5]D!B"7KFB^4RI3_\O^IJ_>;_]">]-Q=*#-.*M53>V6RANPHB M'5_Y,[[3?W_\'\&^?@8,'`T;!R-!"<'/`;!DL.[>_[]W%Q^_7+U'"@.XWBAI M@"HJ\+/YUU?_]AQ77[ZD@K47W.]4YU%1S86BX1_L/Y[^I!K(D(IJ,V6IF\"- MNFHHNNFXMD>LJCP_ZMJCL@:R,5WXSGA1'._^WTQS%?>1*9AWK9HOBFLA+X9D MY"`=:9R.;*"CKG(7>7K!UI:CP\OQO[07@#R^O.[RR$Q7N825.-80RO"+T$^+!0#!W;!;^\L9:&ZK!/;ZZ/J**;EPL_6P,8,=KU0 M\',=OM9MA%H!.0/*2P%V"':8AK;N<:GG1)GB2)*/U*[R#GC*6C';:27;*4FV M#W"TR.,O8/,X"C,7P--73".33!GV.PJ:`L3#>$W8";'DXJ6`HOE4H:B:9GE@ M5"R4);PR=6F!$>7/"9S\N?-G!^V"/PO,)8]F-HF=PI]H.Z6N,)G%5^@H-G.P M^PP8HL9+!R5D1!!R),P&_>D;1W%`HH$\"_"B?#05=0'B&X1P1U%)NF8@%-YK M.:P6M,ZG5:-UMC]:!=P._$)CH#;`#=A%:?C_P+]=_+%R;]D+9J,SX(/VK"_< MQ]?]7N]/;Q1ZYL)07RS/?;W4O[/%FU>*Q@S#6:N:;C[0[_#?:SQ;_N_@_7;P MUR+83/1/._P3E\%_Q=R17'-]\][TWOT8F!I@HK/+%6)KT_/J#;[U1L*OI,2W MC^83`]JRG4^&QAVO!=,_L0?5>`]FBON"GM6W6V;JEHT6;\PY^V29#^`CK7#Y MNYL)[J&B&2/PK_R<)QR(C!G@QQ@+"1.QZ&_#[(ZG?_P9N M3X5(2D"<$>LCB,>E0`S^,P-V<[^"'4=%?PMQ6:<^I/3G:`"AY%YD]@?;<):% MBS*Q>&Q*FM2!DL^JB^GC*8U>,)`P%H&$!A#4E-K%#"]ZLXO>:!N>HM#NBY=^ M[QN@0018CDPB,[_#T?AB.S&D`4DI`2%-7"]O+<]&7?B!I55#-.C<<[/V>C.1 M$;$-_#UP5",-Q.9;EP#PG:V:#K[;,IM."Y/L^^)^;T2:.`WLXBBI\^BS+Y3[ M@UXN?+[$H#TU_KRS;YP3Z0$!R`5Q.U$UE*&S,I#2_'8V5$AW2MF=FTJ']B][:GVBS+B MP9IX$%SG'4=5Q>$'[8B#-I$V7$OAS*X$W*Y\^O0.8^WXCK6MFYJ^5@U%Y:ZH MM51^*#/BTN\.8TA75KIA@#SGMPBTQ7O+QM@_-_X5E=]&V&BRPF9*C?[T!XGX MTIK9BFJ:WHHB3<^JHSB84.H9@#[`W`J-4(9W!V5NX])[@//WSS*VHPZ"SZ]I M\*($Z,6('A'L4=4T&T\[P!=N>N&QKO)WZYD],3M.&VM57XBCI<=`>B\8CZ\2 M[@&TS^J+,AB(*."S[C[2MW0_LK8MC;&%HRQM:\6/A3?$LY9+AK5H\!EL&.4X M;8F_"][3+1-?6W@9PYJ@,$Q&]D&XZK*1F016+%<5NJ-.J!? M$P3C")OX9S!"0QL/S/@%_C?ZF#S"7R#$3;AY7OLEDMD1?1:_O73'4;X M@0QX"@=(.A<4$P!1ZAD-4LB5+J=MMC2HC3X>%2#,=O7_!@D+"S`-E078AHC' M8XB16NY$][L\RP!`UCV#\?+%>N)73?U!`ZV7<6N])._>7_R3'$E@N]BP7'_& MMW.X]8)OPS=US\^X&&RJU#,U+J;C#4P@OQ]!9?;GFTN#40-,O%(71/`;PI0S MUH96C>M1P9:ZH]PSW+10NO`LO(YS%,:U_-OO%$G<52[7P$_?=1`JS'@IV9H; M;D*M.SO8"8@98GO+="Q#QSRQ!6Q,M!6EA`<+A*5(9Z/T+Z!6FST"S>E/C'+$ M*)O!SSNA/[:DGJ1<^M>E?>,&04V[N`X$9U^(X:@X0$0;C`YQ0_QRJ@1-X!DN MY_@'&T\B$-QE<_:@VT]7Y\=P5W-MI4MEC33.Z9N;-P(/J"<]1V3TY18A=@O& M8]\B](V'>:.^T%!+YEXOKWSUD=$W*''?D%%IA542_L55H65+W6CR8B2C%@HW MVA^.9^$]VT[;+=3G+S+Q.)AVO$?SE$F)K0=3MU3V<+X/EKUD.OI=P1S+/:`N MT&VP/^C/YI&^'15LO/29I3[6JQE;.IXF"J[2YQC&2Z^."U/I&$TYM9)QVB^" MT\&KOPV[@VF):-T1,!^Q"Z:_OK(TRB#"Z_8]`,8YE[V+?_[EY^2[HFMT/ M(/Y5`PL0/\`G>U063OD,M&%\W<1KMZ_,-[COVI-7?_OP>]K*D==&U[ZS5312 M;E]6]Y:QQWK35W_[\O[F[WS%V,NBJ_#T"BRCM4Q22UQ#97;`ZPV_#2BK9918 MLLBLB/%@`.)QQ+>5O_KF7K^R!]W!()#[15WM0X)SCIBOU[?*QR_OHAN)OSH% M392+;GP$;_S[/]G+[FO/4.3W>OW^?#+`L2];7QU=^QU&H:)DNC?WS?JO_G81 M9;UMK]X$_3A^8NML;N/&NS=T[8-AJ6FE%)-O@UG:XMG] M(/J]_JQ/QG_J.DDCY=(PK&>L[0:=?&5Y]^[2,RY%+]W3@K MMG+I^TUBLW"#ABKW^YNMN^QZN2PT;B$!0.$>##MNI1I(,KAJ7KBEPH&0W&() MW5<&]J>)+2Z"MSF_6-9BCR.89R?U1AV2S)5+V6<6@K.3<_??9Y9C_I6!^M+]1;S`H&FG8"E!!M/Q+-3QV$%82`&:5 M=PV+1%"R=[31F43$K3_8ULIO#(+C'H*#2H`P%"#T[RSXVY_)Q/LKB[N"?8\V MNP?4H!?O7I:[\5C([J.IV;0/U?B@ZC;AZ'H)QJ2GT<>%R+<4*'/T?:1B(&_/ M91#_C:Y%"N(*M#GO M#P:#\L)L*?B0!>4I^(YBD7]"KA);W%G<71!MU@\\A0(>+#BPNX27:CR%\-U% MW<5C$?OE2L84 M",LFPG_E4F"Y6"Q@W0\FH^FT1'),`[$R7H[?F!P3LP4F&>$MZ?KFY M-TX+3%":CD?CFF1G&[]LO7=T?&_5"K4>P;SP$I)][@9"QS&$[26(ENZ_&<+Z!E:S=W'JKE6KK_]T,[F/K0(PC MX'W2_ITL)OU1(SM9Y)29,F5IXKPZ36K5>OGIXR]?7G]B2WCO9N_6WSY>W?T='^_]*=R_.(L$ MG44>GV-J]]OKKU?OOUX`@)\N;VYA30T.4UT[;#/U7+G^U_NO'SY=__9:>=(= M;)&?FP3NUY(8L/'(SFQ_6W]___&7OR.]#];?(]\O_.\CL"O8(8K9_K;N?O\$ M^S(M&[@]CL\DWZ0``G#7[_[YR]?K7[]<`0EJVG*I:54)Z+KWP78]]:K0IF(:ONKF]2!=5VE*0( M_(OVI.4`;^]#W83^AY:\6_*61X\MZ3]5Z3&R8[BU4\G?-I2J)EJO66^-W>.1L3.S-M/?"E,.B/@\FH,YWV M?FJ/[\S`D\BIV56E],_Y-"51*=4Z+D%NPCD;#_L&X,O1.]4:AC^.9YU>;UJ; MVI'K?,\(O.9Z,F)`Y)F>IB1JI\9[G]H<61FLCEQ=-`1=M+"\>X,55D9-CIU/ MQYW1N-=21//`:_@%T(Y*:S*A?YFQJ'PR>0HVUMN]Y,_A2D_._W0+0`/`OS&2V:F#+DL5*-ZGS&`[_%FO&BJX_ MFIJU8D$CAD^6QM/!-[/-L]M,]'OS6)N)='#+10K#EMP`Y15[8H:UID82_`T% M(=PW\3Z[%\5HM@\F4LN!*JS=Z&>WJ.J/IW$H4O>7A"(H4F?VDZZQ]!\%MBGM MSKG#,0/1[]]9COO%BUHECP9AJ<"VY9*'[=<2``?2]CFC[5X6,,CN>-6/ M$V+ZJN7M[=LM_%)W+A]L1O+BCMD@0]5DOX7X).=-]AKDC+@=[P$4?>4+\3WP MG%VWDIC"&ELLN9-WANHXU\O?5*P:0>1X!M_Z\Y)`BQH+[W_]FNRM-AB' MYU-TXV5`&R?&T@YR7AVTT8$6H=Z$E=GE*L^628[RSM;#>X]MGPPS#)%4(;,- MF"307_U1-J!R:%_"O$JK.?4XGP^RBVWYDYDC*>DF\?[!LIC^8O!Y7>[D+9]!]LASG M+5O"]W?J]SVVF3W&/N[G%-Q%"?9`680BFSU0%ES5V0/7?#J<^8!'^@Z,VQ?'2<$4",&3'-\;#F/3-W<"A.XZ;3ND[ MS@Y_#'JCHVZYW_L&S".0W/_6'Z2:NI\,C7/5@NF?<*CL>QIEL,E,HQRK9#X^ M##HRIAXM8Q%T%45K,F4TW1ZDU*BV(-M&A-_[?V3VS?A"LQ9[_HS[<>^-$L5L M=(8PQ_+FU=E]ZB6:E-`J66U"I(`C;[`[G_HZ2AOJOM0-FOCJS_:A^YK@F@G' M]8*R62FW%_VT.<^J\L,PF#J:'!K[(Z[CT\*@]X8'(!6_A7KP3?_-3T>9$@J( MN%S;NJ'TIRF8B!"M4P0;-C-H>+%KT5L2P/&!Z4PS5)S+S.!3O%YEROT+/7W[ M_IU$PXGS*.B(;7)*V_-=RIF`!PO'J.$P[20IT*AIAI8I__:S^A)\=Q3BO#0, M?YAP&D$Z$?%*>WWFUI+B?T:SQQD@"COZ(%&N55"-FKY6PRGL27P`G"J.+E:` MT%7E7G5P[#B:G(JWYG.Z=1N_%\..\4W6LPFK/>KKK,UJ%+@0K:)HD:5G&"\7 M"]WPD&5HI:-@]<:S,9KB;N'2N"A<(,OK]Y[@:A^S`*CN)H""$_C9LOU#@&=, MG'=O7N!P-`?>+1IHW3N:K9/)SH4CM3"/8D?%" M@^']Q3O*(S-H\#H\S8EZ=$2Z?8^[Y<`Q-.I0FR!2.?:($#U0/D!52J_;GTVG M$SX(.P"P$!&I+OXDBL\U3<-H],O>&]MZ8=X^_ MU45H%LENC)/.\;_^,2-K/U"?^6`8/%+GL-L[ZNQZ)$WUX<$&+\M%HG,CL^E1 M1:AK^/=W<*E<9KPH/_2[(W][('V6+@Y(9]AQDOH`)N?7XP?PD]#D^\#N;4^U M7[@.=>C*`OZ'IE-'I]#_,)IT9H`K9/TMP^@[A%XN>KG[J`3^8T?Y].D=/[_( M;E13F?U)<2R0+[3;,-RK+!F7#?W>B,Z(C%58;0UFF,^0N7LG:0R+A.CDK^3' MCN=M,WUU#RJ&^5M*;CSJ"1GH^.+.'(!=PQCU(LVD+KZU%(76W3'A\8V2/]D> M2,IR`L2C/'-5S,]3?A@([*(DM]G28-0A$C21&O'+$2T+#*@OA&N>(O4:G%2Y M>/=&:=&'K)N$R:N_\0NU(.B>O6R1/!DW MZ$&/9*F[.G/>X1#-Q=L7-`GBSZ;`,?[6GZ;!,M=GO."?5)V]+,5)+?0$/P6Z;D;#M^G949`Q4C.!R%R^Z M59IS(F;K?ZHX.:36XAM/7K/ MSA,0;KG6H8C?SL'J<=%[_OS%MVXS<8%X;9:Q[^P@^V@R2]UT_E824$2LA^LE M!<8_L'VVFQ,UCR,Y==&V-;]EZYZR+^[[B7N*+>O1MO[R_UQ MH/^#JOLL*W+N>HF1]*!(=F#`B0W+:0L41;`F5](VU*YNE_+CBO[OW:5(623W M13W,H?0ICKTSG)G?['!F'\,/OSW-HM8#YH(P^K'=.WG3;F$:L)#0R__?E/'_[2Z;0^8XHYBG'8NG]N#5&,[C@*?HB,OM4[Z9W\TI(_G/[: M^8)XY_1-[^?6OWJG9Z>]L]-W_V[]]^;+_UKGH[M6I_7X^'@22@YQPN$D8+-6 MIZ.>$Q'ZXQX)W)*"4?&Q/8WC^5FWJ\8_W?/HA/%)]_3-F[?=;&![.?+L29#< MZ,>WV=A>]Y]?KD;!%,]0AU`1(QJ\4"DV.KK>^_?ON\E?Y5!!SD1"?\4"%">F M:>=M[^1)A&UI@U;K`V<1OL7C5B+`6?P\QQ_;@LSF MD1(\^=V4X_''-L7SJ3+SV][IDOZG`9O-.9YB*L@#OI10SO`5$Z+=4BR_W5[F M)%?DG"7F[ZJ_=XW472G7EI)=T@=,8\:?/659&[^#IP\8%2PBH7+?3RA2/C": M8AS[6\9(OP/I;CB>(Q*>/\VEZ;'HT_`ZGF(^6'`N;=`7PE]0/U8[D9G-,8^? MY1/.?U^0^4RR_XIC;S$-U#N0K!\$?(%7)O"4J$2U$Y]74^@./7E+D:/8L=^/ M9+S%RM#B>GP]5Z%:?96$[,2Q_W- M9?72#!<1OAX;!E35:LNG[#XV5%/`1+S;2%'5H\N$>Y&GM[%`O;U&L@$2TXN( M/6X;M-;X[$#:454;IXB@6 MV6\2,W7>]-*$]Z?TU]^SS&3).4+W.$J>][TX(#-&'>*E`=@IY6KHN9,BM.CVWI3]4FI>$=>K*G?]4X-0O; MJMH!3A5OU5$GBL-SQ"FA$[&FF\RG2$!L::,/<:.0]5'(.YVL96>CPG'6&K8] M-#/%(YI8J>J9-O+YZ]<,C*(7Q@&8#!X0%&=%00G`26#J\73B!8YV-`"(M,Y5 MVG?5"0\8FN04T@UG8^L;)3<*`!06ARH"DA,=,!`C%&&1[8Q9CXZ41@(`1.-& MI86%HM@-`>,S8Z'P1^1E.`!8#$YE@^9%?L#X7)$@N3*1RFS=D"V,;`XJ)=$! MKR<,F)#)2N([(YG16[/&PD@`@'A$KY+8;C`Z]>=;+[18\M+P5LH2C@-]H0R_(O($O+T[`_8SPF?R3_M6X06JB:!*M5$<#OO1&. M),_)LI5%I"0/9X02$2NU'W"JMBUU]&30)#!]=0*\YJZNA8A8A9;E"^B2QIAC M:P@VDP#`SFOMPJP!X!F8">F>:J61S<&E(+A[XM27WWQ&A"IEKJDJKSZ`=Z/67\?7XPM"$0UD@%=)E?6*M96L*?C9M7!O.]58 M!JI=T*^,LGPQY8Z4+L*F0.?20P_>7R%,.=L.]@7C4CRZ/$D7/-]Q1`4*TM0Y M^5\*2/B?Q?)][K&;MZ\'`O"5#?;6]F4-[T3JU7:I2RV,:MA_WO:&>1VB)FN& M/L*F`P',`YV9C??A4[$!+YFL1%7'[1+]U>(0?[`N=]J(F@:11@7_E<]7"S!5 MFH_5$'MVV5?A%<5.K7I)Q8*G'4A-0I>'`G!TL]DU)YX+X@..24,\9X+$PM>A M#.,;!9!!!\!K1HEN^;CD.?<-1(W"RZ8(O/X0VW9YK.&5LN^6,!!4<:6_+D(` M,\8')N^^-_#3Y=RAZ9?=-OESA#7;;D9-;0M^.WM$0]UC=P8`F,@;VM76T=QS M;U>?O90P=+!(GZ#.$6$A$N`N\.HQ5WBBO5_E3PI@3C@-GVMBX:757B*F$Z%P M$<2W6)K1`Y+UL0W&8%V-UVSLDDJ@%E-EW$@T-,]6)T53`=`J`_@`1"KV)T:E MD/[AM3B^27`Y5-G+_JQ]SF0;_W[SI32Z2<:W*K*75A%VT]]Q]("C+-?Q`\!` MTU08#.I`WS3=)#ET$38)0E^=]#C^6NM69.G;$S44%^?C,0[BU8ZO%.=6UG,# M1F-"%X1.7J[O6ARJ"I-ZYHI>0ID@,AI(5UDZ>'R!0W6&4UU?7J@MI]S@ROI7 MY`Y@UE5WAN(TW(DE`"\K^>B7W'[OT_!*BA'E/DFUE0.9V1Z-YYA-`'C[Q4>Q M])!-;L202$+U\B+63C6[87\T+N0V!>`RU4=!^KD97&U7I#_G!XNRG/N#B*DGU-FLBYR8]6-C=J@,N M=)+O)UPGHJD+)!Z]Y@P$!PNO2>'7/,JKOG(K-?L'XARIQFKA(L"&:U2.\0<' MDT/?USSUN^JI<$'&+&VGL$P*!U/$)[I9Y4EWF*BY]09\3/B`VYGM(8ANTO], M*Q$&7*V46B!UT!PNS M0V\]U.]!0&WNN)8I]8URC"+R![9]>J`:FX-UA&IF,"UY@'",XHK=)U`>]+0[A1WZPCN"GOL$!>D`=(,M,B:,-G)7NB"#/Z6W`&L:7,\JRITV, M"MO968%&B_D\ M>NY/.$[6)"\P3@4WKP=NQ.S@/&`;8QC0![%T6%8I>S6Z/T7H07MP?E!!=P/L M()82#499?C!G#R=JO!D#<)@]GJCQ-@/@C7D9UI+C;WI!>SSXEW6'_.'/Y$N4.!07TER: M+T'Y1H(J7`[7%:I8`?`1'H-U5INLN\XKO!D#\)P]YA7>9@#L.NM3X%*(A;H- M<#T>L-E,=85AP0_/(&*@!>``NYD/90MP0W_N^0>PL MCLP'="9H0&%1X023F>1PH3:J#/DCJNL.FIZ,/'_"/"#"N@!M)SM(OG*_=<1A]'[#81'"RT)H4A?W9UV;SF>GS^%"0M:E3KFFNJ3V]%#$QZ/\!4$L#!!0````(`*MS?$1%CX*4OUH` M`!_O!0`5`!P`;F5P:"TR,#$S,3(S,5]D968N>&UL550)``.!OS53@;\U4W5X M"P`!!"4.```$.0$``.U]6W/C.++F^T;L?ZCM?:XNWR\=T^>$?*OC,R[+8;NG M]\3&AH(F(9G3%.GFQ67WQO[W39"23(E(`"0!(:6:IW+9`)A??K@F$IE_^_>W M:?3IE:59F,2__K3[\\Y/GUCL)T$83W[]Z;?'J\\G/WWZ]W_[[__M;__C\^=/ M7UG,4B]GP:>G]T\77NX]II[_1S:O_VGWY]V?#S_!#WO'G[]YZ>>]G=V#3_][ M=^^7O=U?]D[^SZ?_>_?M_WVZ?'C\]/G3]^_??PZ@A;QLX6<_F7[Z_)E_)PKC M/YZ\C'T"P>+LUY^>\_SEER]?>/FWIS3Z.4DG7_9V=O:_S`O^5)7\Y2T+ETI_ MWY^7W?WRO[[=//C/;.I]#N,L]V+_HQ9O1E1O]_3T]$OY5RB:A;]D9?V;Q/?R M4E5*N3ZA)?C_/L^+?>:_^KR[]WE_]^>W+%C(!66"?/&9>@.'7ZH__@3J^O3I M;VD2L7LV_E3*^DO^_L)^_2D+IR\1QUC^[CEEXU]_BMG+,V=D?W>O^M3_/$_B M+(G"@#-ZYD5<+0_/C.793Y]XH[_=7R_!Y`VD26MF)%4K(<[+X5O/[,\]+VHKU)7&C,@]T.> M^'_RAV=HG/?&X,Y[G\)GLD$<_.ZEJ0<_MM)WRS8-H#CSLC`;CN]2EL%' M2I[A0U\3F,%*\M/X@N5>&&6/["TOM'EHWZSAGO0`'V6EWH;CX0NK>C#7X7DR M?4G9,XNS\)7=)%F7X=JF<9MCN1,UVJT9D/R>O;*X@,I^,HE#_L%.(JN;,36> MRQ''600*O<[RZC5E6V83PAJ1SNAFM7,\#L-\_GB"?->#LL/[,]# MUIECW?9,C.WB*6-_%O"U2ZZ;;A.1O`U;:RZL*L\>J":[CLO9Y3F)`CCD7/Y9 MA#DP/`[],.^S[.JU;P#=,)UXFV8^-$U*")0\`/SBQ2V#RR[?/.C(F#! M59I,+\*HR&'2ACFQG`WY3%[D71;2M8EC0'>P,W_QPN#RC:_XC,]G0S@=I>=% MRL])@RQCBR57$WZK%HT@2&#`Y._P(3[P7_C$<,NZS9.:;=F3^J-7R$7IAT?_ M*P:00M=/"[;H#^T`8)6-[%#XYNS1>^LXW4GJ6Y&NLUB6Y-GM+-"NU5/^N9<] M7T7)][X'^EH[Z[,2=3]FMF][[:BLP'&`0[?GMVYU[4CVK"#9YWF*&%-$[IE<9BDY1::!;=)WO7LHFQF+78(8P8(4RMLP+== M@7*)['A%TZUU`\@N$K_@7^';7E!>_GX=CY-T6IZN-,67-['V66/?RJRQ;P[) MBFVFZS9'VLQ"5B_UY^+.?JRWOK@&#N/\2Q!.O\S*?/&BZ"GZ?S&^B M#TO896M]18*?N2TYB3\';.P546Y00$';!L5-IEX8VY%VUG1O8OF,\@4>H73^SS0@4&A16VWE?D.,D'1L?2O,&%8-!CP^H*\`::6_H0 MS`8,EI9@_BDN45<7C-(Y!#X7)?[2-R+NP9*D0C0EDK&7/95PBNSSQ/->OO`9 M\0N+\FS^FW*._+RS.W-9^9^S7X\62R``8]?P8S;_2N0]L:C\]@@O/#HX^5"3 M(\E+OP0=J;T<9I,M=0W^V:BE+K(0(+D MAD%JMYGZJ:1XV= MCTUU+^_@#.C[0WRQW@]<+075-<_@*>.>J;ED*5@N.#HXMNN.$F#@D5_,^CPUTJFA@35J\U.B)@?3#! M6@,40ITSD\3LG4`3JYPX<9W1$0$#15?:))"0*U!GQHH+-F8@73![UJUF3%QA M=$3`?-&)+@D>A"MGQHQ6(TO4_S9MXZ'`@O#CS'2QTI6TS!=HG=&15?^#M>WH MY0`1"IT9.&J`]<;6Z(B`I77=[BM49'!&Q4!HA3042( M=&;XZ&3$DFCFF(#9R@"-"H0(B\Z<)N[2V;1>ROT/+RIDOJ:"TJ-C`@8KA=*Q M&Q4Q&(0B9U:/65`9'7Y6BXZ."5@Z.I$C1((PX\[&$01A) M)"$(J3$Z)F#;Z,23#!!"ETN[1C$M(OXPH;+!B,-+E8;01^]-;NUHT]+HF(`- MI!N]'8`B7LO.+"/W_&%;S()++XUA2Y75,"W"&J%,JRN/C@E83#J1JXD-X=.9 M]:2)M=6&>ND?R)M!W:J@))L[CW8O"?48QQ< M9/3)G&Y5P&MUBZ)\LMB.&%U212"MO'`D2RJ-!Y+K8I?L>\H'#W8NLVNLKTD2 M\./KMZ5-GVCY12L!5@*[4KWQAJS'"FS4'F$V'ELIV<.J`#X"UWY]N),CDS[1 M7-\10B=]R":>)/;=G20ZA@?9M>JTVOJ,L(^?$01RTSD0V(T0LKMOI:;1[0,`KH]W"H4)C;#.+O#QI^]@$?8*QN[-+P+-)3_DZ2(B% M"UEV_X"]Z#`ML0:EO\$\4X2V,PS6`'0Z$@XR;890&V3$@I(LBU[*F0V*_#E) MP[\^#BU*-E49;GK"W)6VUFH"6A--,7^X:D*A%.:EYVG58!#5J`VP2'C)MF-2&12U. M2DWP%HN?I!;`).$OTY$],1QJL5(:`BL7/:0&P"-P%]&3K3H4:H%3&L+J+7:R M:@"4P!U$3\X:>.016-9T]=`N];>+&P@NUMEJGN`!%VM2LG'V_E%D)OG@NY<& M6C<6O1L?[1X[.\G51EV6@&#[+*)RYT#J@%IOGG(Y>7$:X5ESLB35!S:EY;_3FB<2-E@2P+-U7(O4?Y_8OYE@KUR$'+@K0$#II8EQ=< M=^`@;%\Q=5[QK[PP+8T8`SAB34L!J\TOS_IU!B+\@3%F\9.@,PKG'RN[J/7H MCMC-FFH;L6J3^0T.=6DYXH8EAO+`=O9^^08[ES!C=VGHLWNN*UDO7=_'0><4 M[F6=[OI-:9'8[:$2]@?";.#GX6N8OROG3W.-CW9/*+ACN.UYFEHR=K.)K<'% M=.KQOI_=LRR'_IW/KGVT^T679D:[.SM;._GT4`BQ6]&/3ER^FD?4U7T":=TJ MC`D*7BAKFCDZJD=^,[LFDS5('&;\&1W+`'TER6B.3 MF?JC,GMSVR9&>SL=5OC.HF-&X#;5H8/8O%<3VG>[J54PI;;"N%4&V@>?Q;"8 M)+K&V7IY4(?-8ZF68;8]?0J;:Q,@,7OK7,#?XNR%^>$X9('2I(?6`816-TOM MK:]-_6-KF102,0.L<=*(FF.-L$?V[>--GP*/OSS+ MH$IV$_ERI6+E05J'3N_:"I:+3\W!?;%]JV*K<6M0$I<>@)JG0E$]@.H\^)+Q MTR$.E)J;^XJDRM.&L#Q`HQ%G28,`,7,26-1=:OEWY_L^'^%[JA5-7`/@;8^E4P:1 M6NY0@;!JNQE6!R`2,7;**-!FK0[*7+90HKP16],,$ZA:OE$9W%EA^D#2U]#7[74B8H#L(TWB*KQ4 MR9HI)TNT#D!T:TI5ZU_*%X:(6C91XZ316N&,LJ=:WKKD&47LC',Y[IGO19'< MQB@J"^(2"(BB&`L"@R..A5KJT)LDGN0LG5ZP)YT3F:@X`'/^(M#4,H7C(Y

]LXB#I<1O/.7;)L;KWMMW M9VGH&*][;Y]23I^]9GAFF3.EJGI;!$`L\:G2I)*"A&0I=LM(((1![ M,_X5#N7979J,I?G(:Z4`!0%C?CLB&N)3&3WBR>7;2SFS:FS)T#H`D68, MZ.FYG-\P5Y2YH?SFZO!-$GS\*_ROQ+R);4` M)@'S1L_L`C:G'QE,:"-N,C!%'2=E6DR7]D,N_3R0*;@!NL[X")`+&CDZ<(5BH>28OQ+R._61:7?AH$/11&F!1,'9TV_JL MPJ#F?UR]O..X*DFOXYRE3+JCP:J,]@XI6#Y:\23'0LW'>"Z=>L%:*0EP*)@_ M6E(C@$#-E?@KX.:#>QAS0PUW<$I@Y.?O/&AE^8[K978+B1["M1H`\)MW/F^! MC)JC<7U+.QQ?A;$7^Z6K6I;+%B]9-0"Z<;8N-1YJSL9EN+[;)$Z6UU_UA"FO M"&`WS_JB@%GHNLSN6FJ`IXK5H`M!_CZ1&C2ZH()+&(T)9)I>&0 MOBYV-\)[?>X8K'[3AU8"K`1L0GKC#;F15V`CYM0^\/VDB,MG]2Q\Y:N+DCVL M"N`C8+'IPYTEJ]6`CGT&^ABU:7!*?FBMS85M[!YHB'1)JP70$C.M4`J$/GA![F M1GUPYER.D;$QM^%_\_Z9I/..A.Z>Q:5!5(=GSKYF7QDFN4OQFBXM9F=A.%,E MDZK1/K<5IEZ%C%D*2I[)5DL_*KO=:%%[M'?BS+<1%^_LG8%J!"=45P9%V3QHM(I\TX+9MEUC&2ZQ^Q.YV$IS MNTYU&%!6CS[:]RBZ%'4AN`Z5V&W*FBBF8999+]=D[U9N>52^R"/<=YH+#>V"%3FWG)FMS"4>^N$PKLA M^1#2HJV.1W[_M2;3_4.>^'\\>1DK8[]#__5HF._GKW66Y5I:K3Z*W'GO_%<# M.!\&.M;]_HV/]G?<;4O\9Q84_-V^$D>&`5'&IS?UC=&>U63R\M#VAFA&1K99 M%6W#/<0]!ZS8(B_*`&SG"9`L<2GN,"O(B5TPE-(IE^=:*4!!(P?2BEXERJ\+ M3LSXWTG]M#:U77@@:YC_YKV%TV*J9&2I'"`BX![?Z.IB)@22$WNX\`UTI\5! MO1P@(7!6T.6@*3FQ8/M5Q(./1]C\2UR5\D5>4@M0.D]#O]9E7ZD+8H'\$7F5 MYA=I/4!*(VV]DHU6)-;!$8O\;XU&6IL.6WQ:>/JQSH#).DD76[0#YV`"\4,U M!B%R5&^/E=I%AC1JN_K?.4CF`0L9?9RW+J0`]M6P(W=%_@(L#'N'\UIMJ.)-8^!PH MEH;_D(!NY.!D30O4\C=L2?>BM>X[[V?*38$S\QR<5_,T]',6E!XX.B?X9GF` M2."NP]XD@1[U,5502U9Q.7V)DG?&2D&'I5Q*IM$Z`)%"_.4ULZU0ASS+!04G MNG]YSPG.^Y_7VKL9LZ>,^5>I4HOR[XQGO/`0I:9Z4N/&R9]]S^/H%,>HVN+F9" M(/E6>,_M[Q,P4>MRT)1=.R;;JXX&C_T%P0R'GK MTO0;2X5&^P=NLFT@BA#<9PCD=;NK1)0_F);]419"NE8$@-#(=R%0KX"$AN3& M]GER;VZP\/SC M6:CS=VY%2&)N-U`%WI#5`Z0TLB@HU\`6<(B]&E@15'D!*BP/R-PF8FBA?^2V M`H=%['V`,<)H+-[VF"/[$F`VFR@/^$OE`!&!I)Z282)F1X#!>@*)>YY*=#@> MLS2,)_+-@:`HG#,)/)G05K06ZT**F:>QI>ZA)G%Y_^_0-VH`J@IXWG>8/1Z87Z2`DF67;WY4`*@KT#Z?8(I\EJCE MTDMCV`UQ^4O)M59Q0Y\8[1_WG(U,^$GU1*/O+&7B0]#Y;9KDY'L.H[0CEB$+ MVJ*S@2%G.'2??M4F\9V,CW@65V=SE2%;EN,LL"WTW\J$A>>(=>:O98PP&ALU M>\R1]?#J:'QTF;%68YAH&1_Q[+7.?+T,OS-QF0*W,TL*/,0N.@V]_W*95KJ3M)WQT>4AX,TO$IW.NLFP8/B9S2I*PH6$4/K9UM+%FJK2:H;6C4?BXL-'BHG>YA8C-JOL!!KK71EP=&^W82ENB'K.BT7-03$#A,+$?_A1465 M^)UE+'UE6LPT*@%&`IO4CBPA:(@=)A;BWK);EX]9!')S#GBZ,)RSV0V;C!9#D:[*C@G;=T>[.D3D':\D755XETGK`ODVG M=OPY40L5+O?A%K!^F&.#U6QZK?Q)-%C1.#[@B?2H'A_LIE7K=GQHYE(3R[U9 MQX>38\+'!SV5K^^54^N$M_LG#B,CB;NG8/IOBFS[@=,W%H2^]_#B*0*5+A<# MV1Q>TVBK4RBUL9TYHM'_2(K).!H;(6L,*F..4DF&WC$7 M,V"D$'14,8JTF%M"9"XQ"+)UN"WXUX;CWT!9V6\Q-'\5IEG^&++T/GGWHOS] MGODL?)491MJT`5W8]76DP25EIBIQ%F;@K4O_9 MRUAV'?\7\])AC,YFV@T`((OR?]J(,&1@MC;H% M4G-Y,_I1!VWT''=E$P#*X>WM^NC[P&HN,X4F@>5B>AUGN1=%I8156%Q=\I#J M`,;A!:\%XJ0XS:5WT"2M6GJ[LX;5!S@.@Z!:H$T.U%S"!NW!!A_J,]B$U0&, MP["I5@:;!*<\YX(%TBIO_NPQF<_:Y4,VU,]!LSJ`V>SM?RN<"&G.\I[>)/'D MD:73N:P?JAA,DT(X(G6K`F"'UX']B&V'$2'5G+WC(UC_UR0).);;)&;SES8L M?84NF#VF7IQY/I?BR@O3;U[Z!\NYYQP;CF=]\BM_0/7A5=4XH9O]S.A@=[// M'%;T@7069X]`R[@\@RQC>0;H_,IA7S+LA>4!VL:>3S2`(9PY\]2NA56">2C- MP[]FK\Q+#!=LS$!XT$&6:T:Y4K4":MC88TQGN`CKSCS"JPZZ)/I":IBI)E+/ M<'5E`+VQ9YZV*!%JS9F'KKCFV$WXRN#0E7OQ)'R*6#6YU,6[?./I>1BW?62/ MWQ,`+;48]6L5H&_V390)^`CSYNQ*\SLQF&6>AS'#8.3Z#?`]!R]WW/?F6J9P]A3U0/Q-_;(U@(@PH\YVTSY]4O^ M7HU[NLE6HF9)$'%CCU522(C6S3F?J,B'']EW+T*-F.T;`6`;>SSJBA:AT9G= MHY0T\ML+H(GS*\9FPL?,KX[:Y=UPF0I' M=IFG6Y\K8&.)ZH(48V5QP4H#N/Q=NZ@X('/YZ,;,8),`0RAS M]C*'6R^'XU+(AR027?0@)3F>C=T.RC$A')VL-3S!BLN[^VP9*P+=2*(6J*J, M#@Z1K%SD:I0VA60Z*6.SGNI#*AVG-PH#)JN&O?=1GL=:1=0?!0RS< MLP&.B#T:-$<6V:!LYMY:'^P[3QS4>2Z402(6M\WL2]V#?;?YAK08T":M#HI8 M\#;CM!&;*@WSIYHOJ<2FZ/BZ^F#?H5U>(P26^3G&5J$]EJ68!&()>(;*P@MC$Q$'.!%`Q?@3_X+/;2 M,-&]_JZ7!V@V39CKN?IN`J(6/V$NX6]Q]L+\TNV/UJJC;E=V-CC^? M+C9JX0CJ*S'%QCX?EJ4S^!9RK*<]QL6/":+ M>P+,_J2JQ^5W>"W2A8\VN,R]_C>T@I6AP2II9>M6K1A'XC!L=9\1(X!A/5K` M&E\KV;T$L31P6N*3!Q98TV,*D#)+HC#PRMSUL[TN+)G/7CSAH63+5?,YB4"V M[/+/@E^RPN?],'?RT&(NX(W.$XM&X='!L;O#[5P:Y;.*I8*C`ZOO]N0/*A`% M*@P--;FWZA%%U?MA+_F2Q.6[*DU+DJ@>J,?FSJ"=14E`G()B'!*QIQ0K@BH- M$\+R@(Q(:B:U_L7$26`1>U=AC#"B5B1CS)%]9%$[;"MM2(VR@(S`QD\R7,0L M(3B(O:88!$%8R7+GA7"\._=>PMS#G2RTZ@%2`@X7K1G3P$3L444MY&9I(>%@ M4_;,9Z!7=AW#AIZIF=1M`S3@,'A8=U;;X2/VW.*>/V2/67#II7$83]27R>(* ML$EW&":B,WVSL64"1!1>R>"[73X/78XB<_+X/O^>RVW`H_BS/\7E2&> M!\$_BZP,%317S!V/_PQ_R/,T?"IR;A9Z3.X\G60&ZY(#J"!P<=.S#Z;(%A+=S4 MWO7(>NL]`T6$?GE%S,,"???2X&LJWPMV:F]T2L%VT7/V[H&C4WBO)NOAY$K^R-"O]7JJ?>-4Z]&."7.R5 M`)]X^DFN0-!>>8"^9W\681;F\P24E3+NF9],*F++826]&K7[:5#XYILYUJ,D MRG/3PHZ2DNSL!?Q/*:S#*;7<5#X3.8@:_`3H!0"=A`]^[@= M[/8S"8OGTGM67D`_)E4R:_C](@42-IWT:0[`$G#`:$%T+YSR9W-K\ID>IA,O MGB5(Y(F,O;Q(RPS%95*8),[ZA*3'DO2HOGDC<8ENV<+HX-36KSH*;E'=V:FV5J4516'*2MA5,\M7KB MZ1:Y\K2QT13+;<6SV:*F:7@L]U"Y!9=D9$VY+?AN9#B>1\VZCB_8*XN2%]GF M6EH)Y'>=.]C`6J(!4>J3O+8$/M.IE[X/QP\AG./&H0][^H'O\UQY?#N81"'/ M4V1A$Z7W8>5.JF4S_+F?N6S!>A^7;JI:-#$ZW+%Y(8/OK+KI6'3<:`OV1]ED M'>[8O'W5WV2U)DB]TRJA;=1.ZW#'JDMPIYU6J47%LE_*O5$[+9"8[DY+4^7K MVVF=L2CR$WDPH6A:;(Q-YJW?/G]XH7QHLR@(#&>;GG5(X` M(_80JY1._3;GHQ2@<'N,1O0J47Y=<&JOI+JHG\:,WX<'U93OS!7DF_<63HNI MDI&E\*O*21580QTF75T90#O/OVIRD==%3.TME%QN9<`*G>H`G$8&5UV.NC!< MATKM2=6:.*:U*UD/V(MWR2&CC_+N7LLH%H0Y"N;1JU!X=[A)P;MY66$TU0)I[@T0QT/CAKEN#JP8!"&-R2.2>%9EFC=:B M:98^Y>+H[B&0H?#PA[L4@FW(AY"<.!$@:L]S>/3LZSC+TX)W3>71<[4P@-HJ M>S*&D-K#EV4Y;[VISE%#7`4`TK`Y8[K786H5#K6')X;YHK6RF2-.F?3$6D+C M5MF,%Q,Z`32N_.PLQ#M9>/-7:M^_, M(#)[GZ]<\Y;*<4P$CMRRP2)F2(0"8<29MXHH_[J$&&&Z=D"V5>9@"4B$/F>. M*.*\["T(7'3C`ZNN!]IKF43W>F0M`4+H M)CE3)]]HE.78",0SE0X89(N/0$'H<68CZ1:&_G#/(2O&WK)*L"$TF0OA,O?S MFENT9ZYC56BF_V)>.HS1M\8Z=0&&0SN_V>?&^G@1VCI80[K2]O@]Z4P;U`48 M#ITYUDS;`B]"F[DLRU)1JIP`.9>H$W6U^@#'83C4-=+7P(Q0Z"[@Z*<.K,7`+3O,]8D%V!4F:=\(KQ M?NBS\%6:@%%1$^!NP\FB%5J$7',I?ZK/<>/X59*N;IBQPX2T$@B^-2<(#:`( M0^X\39[#EQ=`^1]>'$0\7O(L.=Q+DN:EN^%YDLFS:V@U`.`=YCTP?]AH`1IA MW)G#RF#*\_M5(2*'XZLP]F(?(*AXEE4#H`XO7XVSJX:*<.K,6:5,`GF;Q$D5 MYS.>5.;=RS>>!4&V-9)7!+"N`YJ:Y%4'+,*LN=";I1#5AY>R%=R$WE,8E1E2 M8#99R=[)[?1"NT[?)@'T-M@,S*@!"=]&,?^U9$C+\GX>VKW!7_-X5B)%"'5F M&1I$4?(=%A.^/;Q(BJ=\7$0S\-G'WE&V"&LU,#H]VJ8S;1O0"./.S$MZLO^> MACD;CL?2_5>[ED`=VW3Z[80>Z0SN'D=Y$3^PYT4:\Y5H@2G[FB2!](PEK0A@ MM^$$W08LPJPS(]9UG+.49?R:HK8+D3`JKL"=H;;)J"Q%B7#HS#&HE'!V%I`- MQJ5R',O6'9%6P"%$F7,-^NT%$,4Y-V="3SE/XICY\[-W"KT']O&!S+ZH6Y\C MWX8K[RZ@$1*=6:&6'T1?>3X;3+D2I+>EXBKR^/ MVL-QZ7YQY[TKCC%8%8YPFW:M"IP(D\YK%ZH)5%]A#?F?0TE5O+N&5WE](MM]F!.J7I(;[[H)K;[(!( M](,>*K>0VXQTM!BK6[RUS50MP!++M&8F\,CA@553LJE8,0>-O,$:L(CE7S-& M&(VITAYSJIG4F0&Y6YB8PP.'%P`:PT3,C@`#L01N]RS+T]#/65#:OM2I]43E M^7T3@>0FK>F1@2&6Y&U82G(=!^R-!8\)-URR-*L0:X3VT:D.FK+I4KCVW8@^ M9FK)Y%22*U<]O09&AXSLT&\G7 M<5:DW)],ZF^W7'1T>.3Z:5_OQ4:.C=B5SP5[2;(PSRI<,Y`2PH3E`9GK]Q[& M6),`)';Y4P)U@6H7RJT?QNV7Y["SZ"`T6(%NK(ZGEF(RR8ZM^96#`73S0A3\I*B=VN&W; M!,!<^_&V+0GB0=,.X0]SL#UR?K#M1I#&T?9HXXZV1P2/MD<:YZRCC3O:'E$^ MVNJIG.S1%DX'*?/#TI0N/R4MBHT.CPEX@_1;8)IXB!UCZ\_8>.2%X?B;YS\# MM'1IMR;?!NFT`.@)7"OV8[,55&.'7O3Z0DN8ZI9J%A?V+Q98V6GP4W\HS M^(DSK]BUGL&/;3Z0ZGT&/\%S/;="^,.U/10.=DS.#I\SW1\_S5J`WJ;QJJUS5JM(=,[U".( M=3S!-6H#:JMAH[5=_K49:DGP*E1B-]AK(9C&1+Q>IBT\=T3,-]^\N!A[?EZD M83Q92(.Z[2OKP!:;LK5T=4`)["UJ=,8>/:+9;3(&@)\UZ4"*@ZR4[1X:3$B! M$7O16+GHLU3-F:(&H*-LKY33IH6-VOO$JR(%_18IXVD9PC?^DSIE.EX)0#KT MYC%$H`H>M7>']UX\49T<%F4`@O.02B;/!RO`J#T++,53/\7_*`4PW$990A0K MT7Y=<&I/^CKIG]:NNPL1RG>RS@P@W[RW<%I,E90LE0-(#@-HHIU=3(5`$K9Q-"/TQI"A$YGU\@#WR^F1>3E+*C[D\'/$2N5'P?UE)4H M1`GQICX!"J1L^]#J(F9U@70FET'^Q>+>,H67'UH-@%*VG/2;%Q;XD!OKG;7Z M]T#?3`NV>"YD,IK#2M,WJL`-6'G0ECF+[,I'I.$81&5!F+6[Q6AH1V!SQ:7_ M85Q>3IV[O"B86*8-Q;!9OBVG!'U;3C4<+4XWSK?EE+)OBY[*+?BVR&=^6)?' M+,O*K_!<9[.WK:7XBH5`5A6PN,Y[W76%4,,RYHVBI"8H?.[Y7EL&<2X^RHYV M=W9<)TWLH?T&$-LO/6:?YG=[(&QYZ,!?NRMJC(YV7,<)Z:IZ%`VQYQ4S<<^2 M&`33B$L@+`_(7$<&:<.3!A;;SANS3\]SSNJ-D)72?$"[SA#:=7B(H1CSUI!K M_3'U7EDTEUE/]\(ZT%=@]A5$9^E(WA@I6$<"Z M3O'89=+2`47-[Z(+>3*(KG-`]EAL,#QR=XPU&>RJ9Z"/WMO"6-B2;%TEB=1$MUP*:+*YV.+&.509@LE=)#(=BYR!3%3GD9=EPW$9 M)ELW"]5J'5`+C9P/(K;$DX<"BQ4;7@\OUYJ02O_^9N'1T2Z-%`T*K8NIPO!8 ML?XYY8B&?=`"69;?Q-F]F#C:M7D4-SFYH=);>:!FRU!^M.(R2^%*HM2BPCY> MRFWEI9A%3=.8Y<_$$(K@-P.K1SBCBO8 M^RKDMVW1F^5Z5^BX7@CD6+QM;)!G'*)SP=#MGR39761FHQ61-(XBOM]OA>J@Z!VO.H=F\Y MCW8WS>2W(CNUAU'MGPON[EC-*];EO6:I68GZER2G]BJJ&P.TEH%.5"CG>V?. M--V>;`(F8L\%JPXO9D,D.[4W2-U>;0(6`DNU-@\"V:D]WQG"LNCQ3*<\*NVY MEZ;OXR3][J6!/&T[5FETM.?:'5#S,E87B_R9SOH)`V#G*0O"O"ZK,ENOI!;` M=.T9V)(R)1B$,X?)U+$^=OGV$J;5`-CL^=*0U0JMBCN^!`4= MCR#+5^%[-NW[K0(X2=AH7AH*<6S4.[VC/;='?52+364WY=ZH=WH@,8TC?0^5 MDXU!?3D>,S\/7]EB^-[#5H%G3XG],*HB+0SRF;&4.R`5(,C[4F').F.@==`> M@2-KI_7)&'IBX:QU<)6^:H,XN`$QHMINKV=GP9H%/1$(;V2ME\AA$PN&K0-H MYG&Q5.(BA(K\N4`H?$ILLOG1T3Z!R$G6NHL>?&+/-'6`+2P7V=Q?I&=':38( MNB$0,P3:+N@*0)QE:QU#05N M8AYQ.HC.G_E-PW5\P6#J@UX/A:J,[/_PHJ+:?D51\MV+_;Z;V!9?`FT2"(MM MK1>UU@0U+S\QR/,$5LZX"./)S-R:Q.WWLJ)&0`D.[YCS,RU8"&R99JPG>P.=`KP0L M`B8[D1F-$#-1-R=)A>U97`&P.7RB:WZE^,!$S&#<$%65?$5<`;`12#]EC*\: M)FJ&V'Y6>RW[\P&!5RG&J,0`4GNCW1"\%C!0GO1$41/@$G`5,L:G"!R)&(KG M29R5I\6@COYII]V`A] M(Y9[LURS#_=IV*)[J)RLS1D6?;ZBWJ7):PCK\]G[;QF/*K^PQ0WXW7NY/="P M1+=O#'1#X&#:;J'IBI*8N1I@5';Y&_D)=:D<("%P,.W*`,KG*D!BIN9!\,\B MR\L-\&,R]X1B2W(_)N:&L8W/@5X)'(/-=AQ[>B)G[U9G1)6>J-75`3>!8[4] M1K'CN*YFB-FE2PML77K]WJ"J"G@)O+)9=T_0TPHQ:W?I6#$LQ>$I=&(DWT6K@YJT5F_@@ZY#H;Q19B])%E8==;J[D["NK0>0"5@=%LW M\QHJH18<=O;$NDIPY[\_PH8C`Y0@WAS,;W'*O"C\Z^-F5=`9VC0#BB!@X%MW MWVBO(6I1;$$Q(&#&+ECU;UT590_7L/MIMP$J^`&--2W50RVH;E/\@>_S<(P9 MZ(Z%K^HG=UM2CX_YX32R#C2>J.C8P(F&DO,-G!2 MB__;%/DN92]>&*SX/`_BH$IKK-H>=FL0E$/`V&.I$^@K@%JPX2:6FR2>\"P5 M'U.51J+H-LV`(@@8BRSU!!5L:H&+)6JH>7?VV_\)&@)E_(!&HRXZD@=#IM!A MYGN;.^^=]W=^]]1(L]YI;RAK$)1#P`#5A="V6T:U%I`N8B[CDF":"_W9"O=0 MO+Q$[X-)RLJ+C"O&9@+C=PD=&@.@!*Q._>GNJP&$:F\`">2D.3LN[HZ(2`8=$R MX6+0",_.K(R`WFQ(;C3F-=OQ50`P%[HF'NV\)'GF(YLR;JJ\/, M5E&S85`6`8NCV;YB0B-(]W%FC$0P+;RK3&P5)8V!4@@8)8UL%94H$>J=F17K M4]]UEA4\.,1P?)Y,ISRW1.+_H;EJ".L"9`)G@*Y4J=<*"6B$9V=>B&*Q'U@< M)NG\[H3G1V]-=[,)4`!=`X%1UC'L"/G.K(7SO6T+SV.L"@`D8!`V3*X4*T*F M,[-@O2O.WC-!%BW>6T9R^+CEC-+(H)65P! MP-&UQG0D4X84H=&9\4T?N9FSF&;#HZ-3NC:;CMW"A$:0[N,XO]%P?/GFE_E2 M>.*,8Q`=#I]0CW9L&A1$P_;0[IYG!C'029U8_L?S5,[C5 MVTY)AVC3#"B"@"VG'?GM\2&!?IP9]KCH"@)!\(VSGGS(C2C`3.$BUC-;7!AK"K$L'NGEZISLOE#V]6BD)<`B< MCEKI'O6#:>)":#+GQ';/0++0+R.")OX?92SOC-M06/"8/+`\C]CE:6;OLBMJZ??*MHNJ(J`1=K,6.ZK!:3#.#-L MZ;S>:J#J\&I&NU50$P%+BM7.HJD#I*MT,)4AB\1'AH>O21)D(,QM$K/I2Y2\ M,_;`TM?09UGMA>^5%Z;?O/0/EO/8YFPXKF+R9%^YG4_XKMK&9T;'.P1L*GV7 M&BM*07K,\5K#D9=+)W?AJ#*(/'&,?9/A_A`P4(ZR)$N3#!R8"+ M-RF9/7O_*#)#,.`I=VYT0IKW;GRTNW/H+EZ9_\R"@COE*(%D&!)E^'13WX#. M;_,P+H^\;HIGY/!G5D=THKSWN(J#J>76FS)%_M-Z,0!O\_U4NZCO9AE%[N$: MX(EE1IT+J,RXN5P0L%BUWVAG1&TJ6$Y$77QB"5![4$$CV'Q_3BS$G$>VW(_? MD\?GI,B\..!B?%O:9:YNG(6%05X"AC%1OQ;LK@#R M$K!MM=>X"`6U<.WE:@9?42SF2^4`"9D$YFM9S07HB84][P[^`ULU16BM1#8^ M!WJED6Q=P#9R-K"F!6(AU+>D=]':+3GO9JI-5P?;!Q["^W)N6?L()9[)MP/2 M2J/C70HV2&L3@&!CH:$/Z['8SUFB3Z"P,`A*P9MJG<1)]$`M%>G*_2O*K[3\ M:'=GE\!^?5TQP%[XS?KY0U[FG%OL?Q=XS2@4QTZN$W/.7J' M!'VED(O5KI!.728M!FXU5M M/S"_2&>OR=*79/9`2&&ZT:@+$E7]6V1_T09E+NHVPLU%&">95Z0?HMQ$ MOIP22140VJ%W<`7F,K(XG#C39\" MKXK,E:3R54%4%L1U:*$7=UC!(H"+3BVB\7GD9=EP//.['J;WX>0Y5UA8T3H` M\<+@K`$K);*82&Z1L;`F`O.JZ/Q:MUMH?=Z!1"8P//_WMIO0C(7 M&E>'@_+)8@L*:N5!7`+>R[T9:"`R%UQ6RR"I-?U(JH#0!%PDNM"@!&4NUBO" MQ'\6T7O-R_HVC)D6':IZ(#Z!5_)=.-%#9BXXJ^PY\W,20;NEU`!CS-(PGFC1 MHU<;H!!XG=Z%I#;XJ(52O>?G.,61=5%F=+QOTS9&[XBZ@IQ:Z-12/+4KWT>I MT:G=;'?:1\X5Q4JT7Q><7(33+OJG=63L0H3J2.@N5NDW[RV<%E,E)4OE`!*! MHTNCLXNI$$A.+>+G-U">%@GU<@"%P.E%EX2FY.8B:B);L,&T#!8BJ4BY+R@`L+`=0")RXM1F18$#H M8E4`*(&K M\'8#47>BKB-$*'2,C/0G_$M>Y?&&6U`*8-@WF]!9FI2X0RIT9?1"!E9.T MM!X/.T(C3JN2CU8T+J%#F'29^L,2D[0666N4*I=69^:>!Q9!FY.O+&:I%PWB M8!!,0?D\Q4`>OK++-SZ),?Q5;*=VN$X(W';J#$5D[>V`%F'>87K:C('">$*] M"_;*HN2E-(]5HNO$QU+5YK@)[+6ZLZR/$>'6F57J,I@:$8F>6KH:LOX?Y\SV+JD?[S^'+8Z)XCMJQ)=#'D=N;?!VZ M-`G6@HI0[\SBY99Z6ENV]?0!U?[MR)QGS;?T[PE/;9SA,2J%Y;BFJ2Y)>FX+CFJVG&6#(G].TO`O8:HS:]\:'>\3Z#*V\QS9T1K2 M$9T9V#K#G`7O'19YEGLP;.-)!=Q&1\2^!2JU>HC#6FW*?V1I5-L@V^B;5`#@6YIHPJD'Y@+N*LG#,QCY=_1MPJM6@%H M!!Z7VYP(NN@#H=JM]Z+&9/:$3&;_8%G^L08NG$QV5?L4"Y\<'1]L0AHC`UL6 M:\I#>J>[Q-T]SZ_EJ2";H_V:)IF5+.?XUT"M_S)W==8;DA?2F3NH6:"_,_[B M@`6#5Y9Z$U;^\0*6D\6@7%M754H"=/S+6&9%IT@7W[S+A:;%\#K.TS#.0M]V M9T:_"2JV^HIO*[JM0GM(!]W82X=J`S2(`[X]YPGF'A/^JYH6!I-)RB8P5-?6 M@3O+!!01>&='O(/WU"XR`-Q>=O0^`"^#WYPFHQ_/SPHNX#7!\.DAXCKS@Z/MS^NRD=%2!\FPO:.?_4R)"X*`VWM7(X,L MYN3$W34+WXI7SE47!8_&5&UB*J>K6_:]_),\AI].`P#^!S">M5`%T@_W[X`JM]^J8T%C2. M2E[#^CMCY39$W@R`VUYK2'>%(&P[,SB+M\*@K&D2EYV]]4FB5G=T>KR]?:"E M%A#BS?G;7\=^6L+QHH7K1OG8M*@R=V'C6E4/Q-]>4U,+#2`$.K-"]KUMOGQ[ M"=/JZ;'--SOXUT:G)]MO>[*F-Z0[.C-Q=@;Z@9![G=GH@LM?&)V>;K^%RZBN MD*[F[BG`QPWH7>1IO/815^"1,'Z`GB##CC!+S(V^]9S`T?VH;L`S[&)F3YV9 M2NVY0RQ:JBJ5.8(?G[W8I;.+0B;.T?;[^[I6+S($G%F)1=>06>5J#]3\_ASZ MSZM7CS,C`@\=T/(.6+]AT);5S*TT.J,1'2$]RF`F+M]/BV4-G!=I*CF]XS6X MS-N[".J!1PC;O/@OLYGM*DG'+,P+'M/!_IE=\#4>:6Q[.Y5]Q2$=LH/Y%YM! M@B"L6I_=G"9Y=5UQS[(BRC^F0+7?08>F.,KMW=CTU`K"_&&4__=L&S9$+\FQ,B1\]X]C=98VQ0+\R#9D+)FSU\L>+(JL30$DS MLCR859%X7N!^[8`]R'_QDSB'@7X9E2W^^E/&)K/[G-G?HP0:__6G/.5O_QPG M,9WML\MI1C>!Z6H=4(O-&R=7L;6/\70U:(5BQK@V0IDY,ZRSK!9Q+%I+DH`PN43:L-O4ER!3D2 M>-XI=^K,(!^E`(55)V[M:7!%KQ+EUP5'`C!ME/IIS7!=>%!-9. M:(,L*Z8+7Z`RYL$_$IXR(@KS]WM+'C/Z7P>M;\<;`]EY?UUJ1"P!FQ=&3@3\ M/LS^N$H9#UW#4I;EZ^R[HF^#RK?#.7E=/1=7(M)OW<:&ZQ)E1C9@K4424GX4 ME+P=CK*JGFI1>T@7W;SH<#*\%SRO%(L#%]N"^K='QUOB8KON34%3B4B_W2=\ M:;A+Y]:PNJ+]2$]5OM!:\8C-EB**E">/[C>)?3\X.MEQMVHJK'A:V,[>F^CZ M7CGV^S",(YLGV@[WD&8Z2;>[21.ZI'-AF3'_YTGR"G-@6/5S^&&U>\.O1C=L MXD6796Y%Q+XN*`5@-R;%KPE:ESL4JA`KMY&Z1%[*<[>N%@&)K5HGE$9V5(M- M93?EMG*G:%'3-.SI/51.]F;0\*!7.6:8_QIHUV9P".)SJ77%$KL,-;KM4;HO M6/@::-6J;5#?1\56CS'>0>6J)'9=O!4=E,9RNUT]U<*%.N*HWY1B&.,>#*HJ M(#O9(!T&IH_E/J"G#&.W\=H$/GY/VA*XJ`(RD[7QKXO`%648N\K7)Q#*MQZ# MM4JCDQVR=N^UD;BJCLVXU.YJDTN^LW1FG9N&[?.PF_DL*)J`XY0#8Z=UG9*\ MV3:%^+>7%Q>==^6SH&@"'F<;WGF%.MV,.^^.B.?QVVNI?]01/]8D`:B?;,#F MC>G2*O7*;\:I.!UU!-\$K9G7:J^UA]+:)03ZR+J,6A\=5-2/C!ZW-QQK4\Y2 ME3,V"6.NJ3,OXL%;VSOYN1$3B"0;<'M[QI$.!\A@VH[[E_DZ7`N'Y&BCU90` MU$_6AWOC-EJ8>I'>[?;RQM3X;X*6C?^U+0TMQ0*BMLW\O_ZEH)/.D<%Q3-@_ M=X^.?RZ=J#XG#K>^&Q75YV37YK-UVU%]2IJ[>WHKNUS\:Z!5LB9$ M*ET151LUGU99(LS:Z5<:^+=[8Z/3?;*F.&-=J:-6B`5GZCLBW$QK5Y6:X.'<=N)0BT'UT M(#B[NNK@+449G1[\:T-B1:F:1_*DHT/`/W;.7ML^:OMNL54,(!QR^A*G/"B2L`1@)QIK"!(F9*AH2B M*]1S$H$4V>6?!2RX)52=:,WB6H#2I@EC'>N7"APQ-Z)%9X:0ING+.U&T" M\%NUR[:+42SC2$QM.YS47&S63#2Q)=,^XZJEU)U+RMP6>)OD#RS/(\;GL.OX MW,N>E67SC M39\";RZC/.2K?@L`BT_5E^3##J\!(A-P8.X]S%0`S=T3:W$RS)]9VH:26@40F(!GEV%&&OC( M!4*:6RYF")/I2Q*7-Y::]DY1O=&)50^F==H\<7CRJ#WK9W)%4N7105@>H!$S M?^($B)F3P$(8J4!SEGMIK9M*)[:)NO!`<$3*"2@2(]C=4Q M(+?3'2PJR/;B/XOHO7:*N`UCIG?@4E8$``13M&C5YM@$+`BM'>):&U=Y13-@6((6#P,N]-I848Z`RWO MR%IG;DM\K2H`)F!!,4QR`Q]"Z"%AS^+#K?(L/G1VH#;N67SH+.JICI);C)(: M'CJ>Q:1\)@[)!#15$:AKZ5\!9\4O>4.NT@_=QC_5YJCO#?JAK7BI&\,S,<.: M?<(M^&1K71RUN3.:FSH."3PI;3>8E-=%=6C&_*K7*?N?<$$>MMYW>=33FGL7993=:TAJ`(R$[CP M:\^8'BZY6_6:3&1_Y^:QF0'L$:H7((H#,]@%Q\2",Q;##WDI4YAQ&T>1?F2C MDLP,6O5')\?N@NDM\J,T1,0+J\G MZS,&/L)?V4P,D8QR*XA>;4#DT+_]?) M0:-1T!&!2T1;_4%;`;:MJ8KE?EN925&VL.M"%`\Q)\2Y M@+_%V0OSPW$HL68IZXQ.3JR>]EZ@>YX@J`D8!KA6(`R7D3`;(2HM5R).\3,A[TFNL5BL**HZ*JDRGVNN`+T0;<>%FK-ZS%5AT,M0JA!KFBL,N9)4T8%,K8GP7W2(:(6JE0@K/J6!*O#[W*M#C7]NRT9!]JT+:&B%J'4/'.T M%CWC%*H6M2[13:U0J3Y:BLISC`1\(%7#2(NY)43FHI[:\,*Y\GPVF":%PI%1 M7&5TNDO"3;&O9\XJ(G.A3VU0=AWG+&59?N_EK+Q&#V9.=-Y$WY]*U@@H@80K M8E]:U1BIQ4A=EO^;E_/@`E@`7'4E`$D@VDI_(IN8S,4S1>[U/GK*(2T/XA((D-*&`@TX\N"C)IYJI5Z<>3[_@$SI*\5`.`(6ZM:Z%J)` M5.S,<%%>Q"-<-,J,3O<DP6SBW8JJ.JQQ%OV/37!A?B)^W,^@`'MS0/__*X0#S" MR5/.GRSQP]Q=RJ9A,96,)V5=P&PW;(>]L:6+#>%S=ZV/KOA4'>;SP/'\A1AL M.%GLAXO75^V>76&!+/'/W$@>56G7'9V<&@R$BG\0>SNE56]TA&'E MY5(/]R*N2'83OI;;=R\N?3,&6<;R[.S]F_?/)-7)'-*B%=""\W=0G1>@SGB) MA3:2R/\A_:TW55^LMVP)M$$CU4AK!EMW!!P^L3A%3CL#C975?:^P\.[,D'=Y M&8*%3Y-E]!7/UW!"1.L`4@+7_IT&K9AI!5)BS]KF,A9>]+&%D?`H+`_('%X- M]S(':."B]L)-*.I%P:[C6_:6/WYGT2O[!F6>I1D)M1L!)3C,[QA<:L_W,`2#<<[2/HPO-S`ZW7$=8]@6UR*@\M=[:[N; M@O)Q5@8NS)(H#+@GX2)^438PV"R\, M2G=FS%A(H\S0LE001+9IBI"&!,04*.[W(KGIQ`&T&S7I=,?F@;%=,A0!#<^ M'E)AZ?C;HN'&H_T1FI-.Z6+Q"\=E&!?6'6PZWB&Y#JYLAJAZ\X^RX,'PB@"Q!^40X\D1YTAME0&;'<3R[:%T`P6ETX#F&*IWS M91P@3V#1LH#!X1Z_;^<70'$:0G@NUU68^5[$S;-7\!O5IGJE-.!P>#W5EQ(A M&"M.'MU(J;J,/BVU\H#%X?V1&6(:<*SX;.A2\YAZ01A/'MZG3TF$T+%49G3J M\L585PH$$.PX7K3;G-:>?3X\>RG+AD6>Y5[,995N6645`9Y#[^6N#.GBLN,] MT8ZV>S8)LSSUXIP[;4F)6BX*$!P&R.M'C0B)'9>&EF.(\4O:Z#H.V-O?V;M\ MV"R7!1`.XSCU'"DB*'9<#73Y."_2=&G_(=\-8\4!BD.?S:ZLR-'8B>W;;J#\ MSJ+H[W'R/7Y@7I;$+"B?38L!)7XW(3FC< M=B25G>8?3:-5UOER":`X M&LSC)$NX72H'\,FX%JI($E,K@$,M?S"?[PIP5JB8ZWHW?1\'(@T\W(.I3> MLRQ/0[]\P@';.74J%E'YT>Z.W=Q*FCZDUN8(<6>1Z8)81)2/'3JBFIEFGE8U M4^6WR6Z3,NPA"VX+#G(XKFY.5!.+^2\"'P2\E;OO7*VJA5A`%N5XQ(;C#.O7 M\OQX'5>WV5_A\*GL<&:_!EHE$.VR9V>SH1)BP5[Z#JI_K'=J$WT.]$H@:+&[ M>0W7";'0,<8F\-G_KY)TS$(G*ZM<`MC(N'Q<[;Y+MM,3L:@XQL#_SKC"63!X M9:DW8>62P.^<%QD0U]%3E4)P$AQZO1#JK+JJHA83R.Q>I7>O79\DG`\"F=ZH M[#)U]44MPI&9#9#+V593`JY_`O'N7&]5=?5$+2*3M5T1B8U":Z$X2P2R^Q'8 M.'15G=P?=)V^",])!-_.+O\L^'O%RNW@$=HJVD8?0D)\USY2?>,VX1$W%8DR MY+5`B<<=["9J";./CTG38TBJ<-ELSO1X:@PMG2V/!TTP=#P#[+ZE![0VIS7] MB.1J2II>3V(P&_6D'D2VZB7;Z4U]I4?,RVQ)\HUZ5<]%IG'AW$OKZTM6,2CR MYR0-828K5_+AN-QOP`9D#&10[`=;JB MKE.[+CAC%XWMV2FOULN%YY[YC.=PZ,!4LQ$.S.&MB"W64*#&[N#:,WC+\K[\ MK3;!03F\&+#%'@+3W'T40MX]>_F(&LGB,$G+51P$2H3/A]65N.0.+>&]"-(! M9NZ*18.2E73+P[@31^I6.#:'!E]CI&DC-7?R]8A*Z MA,6YM*ZSM'3G10:)6FX&VQG"K:93MKRYU\5G)]9"=TZ7,Z)#WP,@12P[WR,U M.+X-/K7+4&UL550)``.!OS53@;\U4W5X M"P`!!"4.```$.0$``.6]>W/E-I(O^/]&['?`=O>=L"-.E5UVS]RV>^;>T+-& M,W))*\GV=C@F)B@21V*;ASPF>50E;^QW7SSX!@$D^`!PJO^8Z;(.$LP$?IE( M`(G,?_W?GW8)>L%Y$6?IO_WAW=NO_X!P&F91G#[]VQ]^?+A\\Y<_H/_]O_[/ M_^-?_Z\W;]![G.(\*'&$'E_1>5`&#WD0_EK4].C=VW=O_QF1?WSS/]_\$.1O MOOGZW9_1+^^^^?Z;=]]_\Y?_0O_O[0__'[JX?T!OT,>/']]&I(>2]?`VS';H MS1OZG21.?WT,"HP(8VGQ;W]X+LO]]U]]1=M_>LR3MUG^]-4W7W_][5=UPS_P MEM]_*N)>ZX_?UFW???7__'!]'S[C7?`F3HLR2,.6BG8S1O?NN^^^^XK]2IH6 M\?<%H[_.PJ!D0Z7E"TE;T/]Z4S=[0__TYMTW;[Y]]_93$?V!C`%"_YIG";[# M6\08^+Y\W>-_^T,1[_8)99S][3G'VW$NDCS_BM)_E>(G.EGT"]_1+[S[%_J% M/U9_O@X>'B[7E\5T5>$2UM\WN(\SJ*+=!K#0VK[G-^705[. MX+U+;Y/[AZP,DDE\=REM-;X=R:8Y+D5OC015&,Z'_ M?4UXZ'&'/Y4XC7!4\T>I%7:5=<[L,3.1M-LL['684..B`#'&9/:4Q7@)/' M@JY=9?TU)B/CX;\A1/78U*/3$R3'17;(0VPT,GS,^\P$CR!FR%)(2.B*C],W M/][_X7]5C5&G-?JE;O]?_\H_-I#@)._/1I"'-3ODGQH1JA9?A1E9F_?EFYXT MVSS;P4>VXB&#B]^="WN0NG\.1ZD9:&`BZ2=-73( M^!R"H6[BQ>0K![>>:\#(VC,C%[\=XO(58#:&#:V;"8'3(1*HQN3XF2A-_(+1 M%=F&[C#ZXCHKBB^]`(=ZR(>60#7>%N$1Y"G9RQ=D+\%,$P0H4A+[D)%S/P0/ MA0DB[>B"LB-+"6OO%VPT4R$`"#0/]J#T`7\\",XK3? ML.[<*^`O")RACBR.&GOJ=)62'0GI^_4\+L(D*PX@XZRDL@Y_M0Q#6#>M4=O< M*Z`"IF0(0/!\.`76`_Y4GI)/_FJ&K`Z9#]#J2@'#%J5`C$2"KMEBO.#\,6M. MXQ:7QDN=$-`$4`H)E.QI!74+X[)9&3*V&F"R%N#"R``;]F-=;TSE'-F$U?3< MT^CVX*OAGC2Y0]3.F%G/8`PQ]Z8=^0EDE1&%(WG]9:+L7-DXDOA(M%2[N,P! MKL73_<-C@7\[$"XO7K#ZH%9/8O]$7\Z]<);?-$6\K5<+@VX:A.-[T!RX@Q'$ MLBMHG`-)9;U&D.2-_SY+#O_40&MD@1BRIP@W^5.0QK^SVS1B\XLLB2-^M99& MMV3B"9/L/V^VEW$:D-4@2.[)7ZJC(+WQ7:A_ZPJVU+@,0=SM=X-Z/3/7HMLW MRK:HZ1VUW7NU$BP*H*&ZK(">(U$MLTW'\I\Z+H6#N?&+Z)Z7QV"6!X^-UH>@ MI(-`QNEF3Z.7R=\]6)'74KI%+9-/^ZF:J0ZCMUD!#<6#D=MWCV%2B?O\-,(I MCYZJIY3\QVF0T-!V=/^,L6>KK\GT";ZH\=PY@.5#\-A&VJH`6#5T![6:4S$H MKVI`U@O:Q"?4]$97BH^1H35%0H'#MT_9RU<1CCD(R#^&M^$ZL3/>!N.,OU_/(&3DZXE^+2%@['YKL+0OED.UAZKN,47Y%_CEDA56-W M2U"78\4R1)LAULZGM4@8;NEZ)!EK>Q`Y*0H,.OT:-K0.#8'3(2Q.[N\O'NZY M3RMW:6WM8X'LND?M.`*&B%5-OVVTGAWRG.@.&+1">T?8%?D6,,':;5#54KL_ MLW/I#.6^YCI@[;_W!=H2N(PC7(D5BS$<0?&LBLQ@/]N/M^!<"?-._NPT*$+. M%CO>"^D_\&^'^"5(Y)=MLWG="V^Q%^-X@Q[Q4YS26']Z2OF*@WQ5(=K'\`N* M@,E?EA%W) ML/A5!*BEV"!&TRR(CEVZR1+E#85[Y,,0)JR.!O!R$,?^`8->1+!F[N+4.9?2 M2.X-(@TVB.7&\"067-B/(QXC[#NZE$?8"Z"W]/..\Y MUJJ;_Y'&]N_NQS@6+I!I(S38K#F^-H?P?9OC?1!'"'^B:0C6<RV=^EK]OA6NYMM M4Y?:;,9[4/%.8$]WB$$8'G:'A$6D!;LL+ZOH0_6%J=TO5_"[CH/'.(G+&-,GERQ[WW.61,24@+./P;NP#F$# MZ80`NJN3TZOKJX>KBWMT\N$KA M;^O?]0)/$E:3]2_?O/N?C;1?G%]<7IU=/7SI7JU,H3M4O&FX=:*:\,@)%9%+ M]=-'(70:^Q9(821'S7K2$GD04J$'DT(]9@=72%*=WN,TSO)[3%PP''W(2GP; MO-(K*K(GN=G2%RKTZFH$[";$=I.B0B420B,9':H($:5$%2D]!D`W6U13NU"$ M)60K*ME2*MN>DS8[BP@_EBBJ^F"74>_^O-;-4I2174S].,J)L!7Y6\?)<(W4 MKYG,&='6X88[Y/Y1KX`QE$3S&DEX?L;+8X[/?)*PJ>=#V-0-4=72 M"WTUYSZON:\#(_;TTLB'"R,UAH8J``&0,_R#[DX5-*ZU0'D/*2J"'_>H)C)< M9^G3&]+KKH8_/_'HZXAW*J&_1P5BRLF).>R(W.V9N.X0W/G]JII7?LG:.>9V M#^$1`"B.M3U,]*R`K9+*IQ3.8WS%)T*^9EI@TM/DS!I9Q-S37["C^W?? M>'`_"H"900)F=[DP)H0D>!6$8'05WVU"C9E5"9H=O`HPO2 MF2(27R@.X]*#:U+S*`+_X@9N\\HO8ZS]%"0'5?:RT=8.`J?'>!YY/5(YS:S9 M!K&&&W15%`<W77[]#^R!'+Y3DK^B?-U]__37]/U30RG!D MC3F4SUD>_TYC+F6/\^@[O+^B-*MI8C8@_''-H2Q*\@_Z!%U)[_`V$H!<,9Y9 M`UN[[ER6@I1-;.K$<1MP.^;AT#*+]G0,[*;!.)?IUG=?3U>N=W_9?/V7;S9? M_YG_\=V[S7=__F[SEV_^/%7GA(>T&T2ZV>.PC%]P\NJ!.LJ`/>8URE%M\4XG MBECFT""Y#>+H*CT+]C'9HJIN=&04]N]SI+P+-PI-2T2;TCJ156,/'@M-$H.^ M"'U#Q`AY8_?`UP!)N""!H,CJU6;]2H/?M'9K+_/2R[2B+HO5>0@^J2\\S7IR M<0UJ*.O(!5WSIH4_>E'4JF9O\NCI+>G+!VU;5/KJ&79/^IAUXH%&3L/TR%7F M=$#;T^`[7`9QBJ.Z3'2'[7.^558H+838NIZ")!J"LR9"-17ZHHO7BO!+#Q1Q MDGA=6:H3$/>*!H?>4+=,<>?R"-'HZ-"+(T/-.9KZE-"#JR201/Q&J>B=#_+7 M1TK]F"V!009`D!Q5M0;7J?[F\^KVZ!5^Y.K!A?/H$S+8+;2$U+O7DNK[ZB9[ M!3)!%N,_FP;BFULBG)Y"`2W``^*S'LA/WX39+8GKM"$D6K2!R%U7:1S\=DDAO[5Q8=/[BIS0FZDK3G@C,@6JN`CNP[R1")1,< MQY80C4+0FZ)RTT4\['9!_DJ/:C32NM#I)\0.IU#K6VF5Z'U45 MU4YR'Z^,MF+(%8EP7)OI#BN&=4=--\5J?K MU4N`$T^2\\"`I]`B5H0;/%CB7GVLC+F7, MS*2;=>,/*J&V4050+^W_0A*/Y#?U6`L-5H/I@+6HF_SM-3WO80\Z@P3BD2NI M[&N>4@8!=E5K!KNZO5\K@'Y.!*A!)\19`HJ:L]Z+8;,%8'*/KA-7&,BN2^G2 MHK;_E=D:SS\>S@_!^>:I!C30&ZS9`^-CGD(/K4\`=8/ M)96#@CXJ&<1J.2SRBS3OZ9Q'ZP=@3L3J,L`)<8HLR"*A)O,!6RKS)@&7-R[_ M9'%\L-001`$4P[G-;5FYV=)01;(0LH7X#K.PJK.L*(M[^OK@,2AP1!82_G)3 M;Y;G=FP_9<3\/B=@U?24YV;MG, M\6E_CNFN]><@SP-IO68O3:/:'$RVC1!;8/6A:L,JV6[>X3+.<,*DC[S>GS:C%TVOZ1(=QQVY>;XF&Y0V;ISC% MV]@T<&!ZE_;/O:=++QR*\ZXZ%_+]WE#=G9_;T@5'XL]?OT-?_/HE6\W($JO)'*P^2BG$Y:;3?,-#$E_1+]7_>J-T MAE+=YG$:QON$5Q7O$3.S0YRBF/UTV[E;<*^!$`2**R<4?O8TZ<>">*4711GO MB"^J2B@W;&A=6P1.AT@B#2A.FB;^JHBQ*#1M`S',B$7*Y4&=%?0R3@.B/$&" M[HE>,&/MP39J'%)#95#AR>:3K-\.<127KV;>H)K,P5,LI13B,ZRJ><]K\TU) M#(5ZG]$X_3,*T9RO'#\$:?#$E*)ZB560#5JQ)T;8@_>+$.")[["@J+/HB07% M,TW^2/Z'QC&]!`DU0@8N&8S>OF\&E$MPT@@!3_1)_]$A]7\B#"-?[M#HHY`Z'F/#YF&#.I4+?@/36]0TJE_`,E])USB>:P*B6 MUE_-FRKTB)#N=15.X*GCPG`J^:L&[\.<9%>2$6?&$RM^5;@&) MAZ*F7C^A`JZ-TT#J@1Y>[?9!G._4E;=`U/YH7T\F0\5K:8](^90"=R3:9CEB ME;RNXQ<<>?-^W0"<8+V3(=.>REV2[[-V@ M<@UQ2.EX)O[^+5&'UM]U;T6AW>N?$5*'&C@!IC:S$+.R?GQ7AXQ!3&C01TB?_5L(0'=ZQ08>6(.8B/86W>E2N=2-!U`X6,HA,HJ7G5%7QH8:N?F'OK]8M+*\G6F>` M3'&9,X2ES86N?O;2?55PLZ_>%ER1H4EI@2OVADBK?Y-Z<[`$3I%97"+:)W/= M?C:(]\1PW/3%'V%YJ[(+#8G1LSJ[2^9DF(OKYTR,V[PV+S$!3=_2P"[/U80. MKM`UDHA7SYS`_]726+2379:7\>]-#/(Y?BQ9N4>:Z\>7U1(&/?'6'8Z[&7?O M+,:%)Y`PNG_7T]F]@P?(,9Z\MDK_85TEE,^]%Q'IBPHZ7RKNVNQN'JH]O?MZ,]5QD,S(9'&4D;A+8@19$.N,/SXOA1/$\2J!$7B=@T#(GA;4 M->!N<<[<6[@R:"FMZX1>EB&6FG*%A(1GR?!71Y4! M0FZH.49XLWC_G>4X?DIYLGS"3T[V?D%(W0.:^97]9\*\!8.'.3/ZM']//D-^ MX1J9]X7JSE"W-W:JTNW/6TU=?T@23PY79H-?N&9?!OEV,_4,ZA)#-Y;F73C) MT0.4;BQ!S[`VM[^+Z\*"5D7(W2NH*3S'$@Z98].>^GW`'SNUM/(L)?\,<2*O?BX@.7W1EI;)*SJ)LCU-@"@=!O=J.Q76 M0_6=AVF+=_]Q\2M=X'^D&01H13K,H"I2=UD45-)XW:Y#%#UY`0DT>(/,`==)9&LHP93)%+U-5':3IES2Z,",(]$-6XJJ6(UDY;[8TI2I4Y!>?"=,.VSF@,%;G),A M9F]2;H/\)F<9NB/V?+^.'E*LQM`.'&2"`4HF)H.I"!&CW!#+D"."14Y=)6YH M0N!<^K$+B%AP$?=$Q!=*Y'X1-$.DF/O%'(ZNM(VQ4IPQUM1$7FA, M(P%46SB!;YH"$*.O);%"#-<:TD<51#O&(.56,VX.95$&:12G3X;JT:/T0D?Z MLD`5I4/EF[9`!>JK3*83R+7>C&`.HCQ2P%F-2MYEZ=0-$(C:12PR0*:1Z%SV M],7S?<\LX?S;\1C@;R3BV`Q\3K3*8*.CI'*I18`]05][O-K?3!+$WYT-`%L* M3?%E3R.PI-W02"G<:X9T#S"F%1L/-C+&$OBYA=&`2*L&;C1IQ1R[SD2RI)PW8W*Z5R]3@,I#JTW0Z4(! M3](RCN+D0'-RW=-KMY@^0+CX%":'"$>79&3H\[8#O^N[V0X?F)NIZG(?D0ZD'Y;6QI@1FSPV3+1S M=%X/9`NPS@=],MQ+&S:YB5_'JKE8#%@:JFJAXA5!)OAC^DX<&F^`A"I;PE.0 MU>X8[\!C"SM'VILMK^8>1W62R(*8TFAT"'S2>RB&Y?IL!F`/"C?-*IWF9=&T MR>72O%/&62(.*U)]\+H^VO3*:,Y5J[.8AV%^P-%U'#S&"5O()RR!^DY<[E_T M$BK=:4Z..O3>GDO,$?6F%;5>_]SKGCE.%6ZK$4A=Z.+%=HO#LDFJ\Q!\N@M* M5@XG#0G+[4-U,^VS%O#3?L MT:&!,)5=91OJOI@.5/M;ZH0Z6>V-S<+LD8B?TG@;AP&KJ[/;9RFK"WXS.BX^ MF8%)\)=;@!G8=Z'\XS5'3O*Q8$4G]6<[ZG[2[ M$*T[>J,*AL0JI3T%.ZT4K&K75S#ZV>K=4.?#WAP;N1C3SJ72^.BXS-3B`E_< M,(==?`5]`UYTVNTK?`4,7ULZ@NP1%PK:#[O.!V/!QO5\'VL&SI\3O>$+GA_3 M".=LJ\+K"[.:PJ>O%Y]P'L8%OLWC$-_1X3`[^5_OX]Z=`2XRHE,.!T<>RJ$# M_7BU=ZZ*A+/O;Z@YJ%E`C`?$F/!F27$[W(?=+LA?^?UEFY_^Y#$[E+W1[#V/ M9[%\U8?H('K@"5O3?M-#V:55WR.+V@I1G-`[W[A\G7!7.KUS_RPB9$0F6KRN M+FY0W?OQ6;%)0]1:JG$T`,5_%'2Y*8J+**B$' M6.^G=6-YKVPLY1"H1=,#:KNH=-<[E5U(YHYR2F5VND-=2$(VJWDK(7O;C8*J M$^<[R&D:VM\5SE%/J[566(&K0Y#VS6T;'_.J%%%KHZ2LK,0.Q;2VE)L"-'>$CP)GPX"N.Y#G!)7 M(8,&;_7;NPO<&O`M>'IU.[+AKEKZ%[DU-O;2J"WYP-L\2.(\_)@6>QS&VQA' MVL`M!8V#8Q\Y_^)I3@6;3F,OZM]-$6)C((7=,Q<-H,2C%!":[*O$99;C,"@` M]>TD!,Z40>!!FSOX'R[T(!QN$C0[\*.W-<RWL>Q< M]_D3G$OVLU-P^L,FS)%?@%-[WO@(.OLNMQ2:,W3B.M@]1@'-WU80DN(Z"=7Z M(6]O5U<4?`LET5A3U+1%U]=GODRZ;OA[`("-O8--%DUQ4;ZV;PFAFZUQ.G>; M+HD<0T#Q9MVWD]YMO50S(MV"Z:?#'K8&O&BW89+VUK$DXUN'(8\V+*FR#+"SP;P>Z4-!LOP_D>[J%7D9A?XF7\B[>H=;/*:^<"@"7'1Y-]AO0GD^/M7:-(?K`W1)`_BY9RZ#7` M<;N(W>99=`C+F_P>YR]QJ%O!QIN[2"$ZQO5(1DW:C,=\5$W]V9RJAGXDB:9F MW*U#AJ8'JL=4NVHI:%R!9Y1_((*\6;6T<][P>P_40PT800T@:'$#]_=9%A6$)R#6V^9.@=[A6K"SM!EJL,Y:,LB3 MG5A6!HDO<%>(4)]057A?*R\:-!.&R;A7+/NEH4.,J]1S'.`6#TCBD)59JMA1 MG8P,6]H_$A%X%,(TC6#A94L'7F>L' M=_GC>C3#,6$0IUBUV#IT[H%/G+HM(0797;-FZSY)(`6"A MI8-,'T->Q2P5!=L@LS:(-O+`;8.S_<38+D@CU\E#EN+8;KJ/42B+"3P4.+:G M>._SK"B(J[Z-5:M&KY5UA>OS.,0`^Q7QGSU8+2#,[H+\*4[=0W5D\H['$>E,0]K(NW`DZV%#36X:OB?XB/IBW"56,/SHFT$S`$#7#T[4'H#A>8 M"/U\DD;GQ-=),E:KNN+NXE.8'&@BW9/PMT.K<-P MWAB(/CKOC<70=?JK*RRC+YHN4=TGBE-4]8IHMU^Z=2]6')"H[<^]^BX`_J&" M+X9\>R;@'.]S',;U'>3)+LO+^/?1Z][.V"FIK*NP6H8A(KNM-T1']PGFU1D( M0+ND9)^=I7M^6LO^T_E69;J<3+B@T]Z]^@&`-U0O,.IL!BTEI,^G]S@E2WM" MF8IV<1K399W6EZY47W7P!.S`07@34#(QYHD1;E!%RA6K1UROAA[HU'PQGSIB M!CUB]TIF!D\Q^LL%=145_0AE_ZA'$E__3/B$*L1KJTKID3A(MX MD6)IC.C^B/-RE9+U&BL/%N0DUO&NX'X(FK9IA?H-JEN[='R,).`_ MH9BU=(]X'7:&L(QT42Q?::TPEDZ,'7ZI;L^`'=B_ M6(-*)EQC$<+*IT%9BL[C8I\5,3N`R>C[!MX-J_E'M*7NR(-=\#R)B7A%P&N# MX;JM6^WW7QZS,_E9\N@)W9L^,V,BW,9.L"3V#&7WG/)F>QFG01JRESY%J=K8 MJ;-HTB-X/+1E1Y7/./^0I5G_\$"_>=$1VC^ETDDB M'%A1`M2E:$ZN*J*5#Z^`BC-1L+B2I=H!K15X`+)EJXI@]3@.I"["R9R!KMA3 M_0^X!!U"#]I95^PAGV,/#'M'SNBD+//X\5"RNH!EAFZ#?/6M&%"9(<(DY">7 MY^7S>+2ICJ,0'FJ?`K^6U]F1!]24)UH5)7Y*SPXY@6GX^I`':1&$52`$^Z^$ MAT5$?S_PDTXBTLWV(?BD6Y]7^*";=7V-D1M?R,:5]HU6EF$.C85!2(DB-%L$*/BKQ\XG1=;*G/9Z@T,VG/W9$XZK3VT^%`$ MU5!TM;E`6=N7EZH]3QF$8D(+:,*,K)\LNV%:YM7]QEF.H[B\BXM?>\7F.QH, MHK*;VU,K@^A^=0B8!C(21&G0+XS*:?K.F0)E!@)9R]`)`UHO*:<)RN:H`-EV M$\\UEZ13'VEC&=Y]_H2YKWY6)DNWA-L%.+4'R)%I[\-/.N<+@$V:B7VTE1O` M27.NMQ.IS+.^KEOB%ZM&^C&76^LZ,IZU7@O5!?1$7<%EV,J-GDB3S;?3Z;I* M/)S5$R]JQ2_'KW5=41234<%U`5TYA2G+J5MM.=7/Z:D_"N,#MT8:LP##UE7F M%*`SHZA=0&G.8$ISYE9ISO2S>N:/TOC`K9'2+,"P=:4Y`RC-*&J7V+W`E.;< MK=*O`@1A![`2_-D,4>IP1CFZQ3G]0_"$WRFN'=5D#H*4E%*HT4;; M;U!+X3IV9W51[`;#Z/$E1L-`P35C,:GO!W\(_I[E]8HE74!DK>TN&E*>A1"/ MYDJ<-45-6Y<+PUK<6S/^:LCT##X$+S8S86YQ3M:<*NO_29Z3X6;US4Y?'\C' M95?4AO0.LF/"Y!+S1W*ZNKP+ZE!NT.-K5?O6]77OI.D3,TL:SYT/P*2L:P9$Z<6I`$67-]-+RR*JE?/; MX2D@-%,MMZ7//V1ID6W+CT&.J\I9'?:TQ=!!U/:?Y()D$KS:E@I59#U`NCP_ MG2=9(\U3CB&R6'TC"\>?\'+6%'P^+%FJHU`C:H\6+-7!H=+&^W%P.&'2X!;> M^0'B'>5$XZEWVM@O@M+A3ZC@07_SQK<61E*HP3$^C);G6KMH]UJYF6_I4E7- MN#=NW\B(CLZZV^7FA^!3O#OLM#,_:&=][H=\#F>_^GUM5PMXT@_DUCU(1Z=_ M"%/%W%L$:IS"@-IO9Q^H`SZ%J>>_^P)4&+<>`'5L^@6@RN?>9IIL^L;[O@Q* M[L71+]'4%6H_2DGE('VV2@8Q)S7+!=$T1W5[;_POP)R(^:J!$^(<6=IC3`V= M+^B2'O8I\.6-MP>:&R#&W![KP>HG%=J%V+`?3TN%%=*ET:!B6.'1J=FDZ9U6 M8VMT;CVI$ZO?ZD*H_:K[*M\:Z^J[^@-/@TDSJF/J%HH/<4DSO%^E4?P21P>B M,FIO4-+>.MQD?`NYLF@[^J:^;>F-[Z<<^R&&``/O$#4_Q^7S'>:I\(KG>/^0 M7:1E7+YJ/4#CGMPC32NK:.3:QC3M'&_ND8LX<3JU$#69RQE1E3_D_YF%ST%: M_*I^V"*VLQM).<*G<*J1OT5U(\<',5-8CKUXXK+L.%N+])3!N!?CJ<:PQ2(L M'X,\`L3+#=K9+[,RX%.H>4%_]RO<;71HA<(6\G&UN"&ODMSAB.:2),XL/XAJ M+XJ+T]>VS6WP2O_&.&_93R-:5>A#L-,'O:WS.?O;^W5&3<@F^=N!>AD%V\S;/H$)9W.`R21'ZOKVAK=UHE_`YGMVJ&JG:^S+)JM'N3 MK1_J&7-^1Q.JWVRW.(_3)_64CS:U.^/CW`I[6]H*UE?V[][, MI14!L8/N/H0"-`3M(R9@5_"(/W.#SD<1GC MXN)3F!S()N&2C!25X5!6F>F&9;-TF8&6_I#]&\"E1THX>ZT^0`/?NI]`[3=0 M_1%$D8LZGZ%$8BDZ]\O`NC@3[@Y7!)G%!6<>[Z"%:+%/V%^@EAL=8>%:2NO\ M6M(6AI.PU*V")9OOH%YP2OI^Y?6B2]U*)FGOX-W3.-_B>Z>JW::JQU[ZLRPH MQUY\WZ0=>`>H@9C;L<;N\*(R@4TCSXR8?+BE*/''L+S/B:L/@4?5T!TT:DX5 M-H0U6;G\.B0#E99G7G&=_8HZ_%_2EV7$343OLRSRH`CX.$JDJ!Z!R+SSLEU< MLJBZDS0ZR\A2GC[A-"0+N.[,3$-G_=Q,)\?(V5E-PLK]]HC\*$EJ4R:;9X(@ MR`W/!0WP-N=9"H[B,+C?!YI7*<-FEA^E"%P*;R58"T2:N"^W`N?V[?ZM'\7P M%F79WF.4Q"2,0Z&'0A4.%BC5\&,:E\6/:83SRS@ORH<8YW?9:Y"4KW@?))R"=D6'6@'Y/^3'M"6=H%*T@?*>2HX3TF'$=P/92WMZN("K[%A%"TJ7>JZ+<$ M(&5<501KZJA3@9X^PO`_0R'KO/=U8O\JW/B63.!S4.#B*OT;#O*;5.IV&W1@ M5V5-)-/7.ZC#R!MR%*>(=H!(#\Y.:):0,6ADW%9#T,7US0?I8Z;_477AI0FII)N%/-J'[V9$(R?(D*PHYY*F9-TI M]3ARS?),,AT4!G9D+C>HI305([Q8T$_R@9;J=D-.[-10*N?1`*_@IFM^F MXK@DG&0LK(KHS%SH5%!I+V#ZMZA?D0;)'+]"0N[:KY!)I?=E&2WJ$*-;[XR% MN7S=99?*Y[FIL"B@0[]"J7H:OP*@=PN:"9["KGC(ZDT/>SLE36`!)G=K)N12 MZ5%6)RDLLV:#CPI&[I&=."H!)QD*FQ(ZLQ0:[5-:"I#JV7N4=)VE3P\XW]7< MM)'U)[OL,.IXP$FM/UP"2"/`D)"\*0E-<398["3-/J0I;A.'8OS%Z++Q4,>I$404BV^#.+\AR#_ M%9<_!S;//L&?Y;'72YVOH/HS MJ/,=1#^$^)<0^Q2ZV5:YEPM4?^J^E01>A6T:P+9E/;X#@<*IDI"&<]'TKC$E_'+SBZ M(DY3^A0_)OBD*'!9=!FHJLS2J(;BX6-&%F1E[-+<7FT_1IHY!N*3&=HA8CVB MMDO$^V1;^A;!5;<;%AU3T%@[YBJN&?D$>^&T\*#TA,:UT*],Z)((36LW.P^# M.C8H6'QKM82=&#S)6LY(S$D57SW-)"Z-S)SUFEA.#=_C3DBM7K^A)3^[S`/O MFDF0;L_ETEYF>A&1_8ST,CC.T`)>GHJ=:-;W!/3`4Z81TN9VM4/.]7@]-';) MTU[LT[8.U68F]^5ZW(/T:1+[08_]MXXU38/ZGM:!(+^L!IZDZ2%([H,DR%\- M-+%/YEPC!U*`L,UI$"?R2T5!XN!._-"&N+9,FD=VG;RF2%/U%CY%K?Y60G%Y M/%3D,>71*;1<1B;M?6]RI5F/Z_+969(K`+JT*1'-U5@:NMC.L MS@T9Q8`FI;S&9-GY(4O+Y^3UCGRDVD_+S(R>SJY=`<@Q!%I#@A@-JH@0I:K/ M6!Q:C@D2U1*P7.EX50E`QF#6I"1L4G9@D:RI.U1E>OIMIB]S`G!I_Q>?2EJQ M)TM5F_.QEI;#:L=X%>+>&`Z:5JYWXP8\XX9GUWOPR4R[=MCE:.['KFJ@O.(" M2?Z)/P:)-`AU2B=^+9U#":>LHZCJQ&F8ZB+27A[*0X[I>H0_XLA@??)CR85/ MIGS]Y<*3R0Q8+ZYMQ"0--5J<%>II,0">\G:21I2O()&[YYKV]D/=)7QKS$BQ M\<`1-Y7AS@LO%808(79=#Q>+U1T/CP7^[4`UD)8/T=9H'&UNO]+B.-="S&_3 M#+%V[NM;0(9=*%FH'7-G<+D&5+:2D[B&S;6BRI4(G6N?BEWIYD&#(1"J'IH!Z>TC#"B7`+>:CL9/=BD1 M)T6_U,0^@,]D\@0DFL^Q"FJ M2#R"$VARA+<3\)EQ\D9)5A=>#SEX'R[?)VGE4[WDX:\,>M2(DZ,OKK.B^-)Q MB2:+\GJDAJ;@53QG,D&N/?6\PV5`O.>H+E*MU449@77%DW(NGJWPAFWAQS"1717$8S64PWLS^+JS/Y>A3\&*# M>(.5,+W'>9Q%9+>3ESI<:]@]#K M>\_A2O:8[*[&U7BTA?O1@;P'-G!FV'3\M/T$?XNLQS'3^G9(2>( M"E\[F2WHU_/0M4L65Q#)MT$-6!HD'3_P=3@4=KD.: MXR")?R?^^1/Q;HNO$C('N$!DY+;5-(3U-)3MI]U;02?V8C0;@1MC,2>3&CW! MY2[6^2$G6YE;YG&R_$#,_^(W`7?QTW-9W&RWF+:1A7E-[,QR5K2)$HN70_3H MGG>$>$^(=U6EI.ITAGAOJ.[.91W(I<3O2)=SZ;*J]0:EV&VAR$6G..93'/$I MYCNR:B,EDY\E=W,=%S9+M?MYQN;K]?(FBN\.E[)1VMZ\,%)ZF0VL%._LN,S4 MA`'0V*F5#W#FV*NILSUFL"HI56;+3W,%5'.(O3+2<9M1-W+K>H?)3CP.2QRQ M5B:V:$'UUG;HBW[K)3=1\/K6Z/@T M?.HX*+8C9!R&JH\"/@Y/*XZ#,J?VXJ.@,G0>W6_-4GN@Q3/2>>/0]*RC''!#K_:L["ICLZ$[_AB(">/TP3'J/T,5:?.AU#[ MI>8LO?,U+\[,UQZ_BT\X#^."61JB5#1)NH\F=#%Y;_,LQ#@J$#5GJ'RFCZ&A M(^"!;9UG7TRPJ..$5A!8[*CM(8D@8^@;C5;L_QUPQUFD:L/&:\31_[>)*IBO!C>-^B[\^+"`2"UP8U#U1NU MGDU_G21VK$?_[APFC$%WC]JO[Y170T!L1-(,09/GS<-+B,D(&+V%4(OO];TI MU`!`;B+,M'].]I[\*4BK#/&T/%1`D[?0ND\LUP0M;RE)+6!$;3E?#U0F(=RL M0\CKC#%27CNL)G:?C6#"Q/6SN4R8M34A=JU(1V#<@V=0NU8D*P#"[=J'#`83 M9](,=Y)IG(&]#P?Z[.9F>YMGQ`\LBZOT'+_@)-NK-K@:(KL(TTD@Q&FR]A1# M-07=>'9H'/I/$V4A/M*^EH7LDZ+590&Y0XL+X]JM`>E*3Z$-%&7.?NNPVP7Y MZ\WV/GY*V4E!6IZ$(4TU1OVEC/B),5;[*49=6-Y7&4DGYKMAU"S]2$N/V@Y0 MW8,G;LN$R>S[RU-GTM[MUCE^+*_2HLR9#3GY%*NNJ,8:6[]G&N5X"#7:"+6M MT"^TG0?O0$L+3/ MZS!O+_NS"B[]!-!ZK,R!+3NEPLT9U1UQ`],#YL?TM.+@32KUS6"TED$-DT>` M"2?KG%A7A/P"D+C[E!818A=1`DM(UI[$YI5D[/:*5A]%V6IB@=+.'Z-@,"/E M!HSVC)B!\>C;-&/+L::)>_B8339QC-8S$\?E,435584J0NROB5-+IK($Y6IB M+6+B?!1L&1.W#AC],7$=XV%FX@3+L9:)X\_32_K-26:N1^^1J>O+9;Z(5O0, M:7Z:/)B$$NL0URD=2F8H?+5^1R#C?$.X/E3],(@CI@9N%*5VQN+S!IS&6?XA M*['R<4*WE?VG!3T>A6L%]BMB/SL-:(=PF=*?JV@BQ^\-EF'7:JB\B%4AT%T& M5'L:=9MG>YR7K[<)O>Y)(YIVGETR_EC@[2&YCK>JZB<@:NL:")-IY`D&H]H@ M1LMXLL>G![?3(Y\6F MSAMHT]`6&*N2S3NU+29+?U1Y`\JKM$%+!S=H0U[%BS/>HG;B7&JS`;?YJMP" M=78I?NW>1(ZB5[R`5$#79C;U,'M*V6.,FRU<\=1D#C*K*Z40\ZLWS6F\C24- M!2=9GR-+Y)T^0!`FYER'PLNJY\J>S%X2":M]ZR6F3_)#3)P;53)V+:4+CU4C MB_K!<'U"08E03>783344Z"PHGM$^>.7O^'*E#)9=.@C,1MPY.,9FG"SS#FE0 MWF66#X]O9,?)&B*[9\@Z"48,;-6>9BA&PN&MJ;.ZM/RT;I;TXY4$JMH!@T0= MG1[9,SRAI`#OU>&2O>Q8#%)1)!WQJ]K8(&7:$'!I,%P[2`L M8!KZ3S.7L@L6:\"PA`E7:80_T8?R[`U]79#X@7Q<\_`&1FZ_X@I,*@'2C`Q5 M=!3(%655B'J#*+$W;W9,YDXHHV$\0U[K$BP8=^/C&]EK1:H%DW>RU][D6Y@XNQ,>S$JFUF+Y;,).%">' M,G[II$F\^!0FAPA']'R25DXZ<#?Q9EN75;W%.[*C`BD,ZT+]VR^[O="X M"'N`3K^=5*ZH[IF?V'?ZIJK3%!8FW?/$VAO$O^#R%'^M(6J&@FA,_*89K'ZZ M+KI'6#GU*[1@N=_#8',)7]28"*7.E[LF+Q*BT-.DW`J@S"&31U$70C\O,'JXJXC< ME%.723!^2S7P(SR!O[D@[H&OA\]HP6X`=BP&U(3/.#HDF*5<''^((=OLF7=A M/Z@&+IW1LRCWF[RI\R<$H$R:/`_>Z:DV@R;$_KS24V_^E&CT8L-G/F7@MV#. M-WC$;Y;5.?.3QL'N-,D2JZJT)&*:SSJA!W^/W,=73L=]Q=)5V8N'D1]=+]&W[1'N1 M\9""^++1U)NNII[T?!_>.VJ[ITFZNK&Y#H-LUQZ@IFAF49FS79`>MD%8\@)( MG30!`1^EO!VE.$59)VK592RNE6%JAZAK\9LATH^0ZP#=):W/X(9E:=/CP?;P M%!*Q"Z+V9X-XJHK7U:1Q\2I8UV#6P%M$V91Y@$50G"Z(VA\L*B-T05CT)CS7 M8-[`:%PA,/>'[MK>?$B=SU]-8]=;U/`_Q%"O>?>L:]TD__K,F+/DP$`YK'D5 M$%3UO`4XI&:][B\PD>(9"'-I<]LO^F54M[N(8]XS?FWSL\:Y`S>.$. M@(T]_X$'>>)<#WHMA74_01K3 M$I[T96C\B?Y+7K`(0F1=#Y02#)'4-&8.%VDI&17656!HF7*6IU<@USNC[1]NZU!H8X\)9X M!&X6'P.&X6%W8*FFNE>TY-\)KHI'G^RRO*QJ24N%4.C9SJ@=[=[&73_4R\WYM>[1 MF;R]T[F_5D03BO-_[4,`(6CX54"0C/U\,!!+LR6VF=B<(*'I3*N@[6O\%`CS M,1!$3>H$(AII9&CIDO&,N_6[0T;I\.!RGEQK<@^*?YC'_KX[+5LZ+77IJ812 MN@Y;,-"@,=6&J\\B6AX=0AKB$"0`M>ZV=:7'/7X5BDO;(=[0#Z0K&7]XQG4\ M3K:E_G`-="9&SL@:E`T)Y MH,-FTH3=&:DTUQ/E5*C%F(IJ=<+JH1;EZ#1+#P4&/-26M'=QW#3*MPP\54-/ M7JJ:.FY$S&1UHYB]-5VF)R925L&5):.UD21)YEB&@ M;NG/4F3.NP-?!G3>OCT2\T97IPGB@;Z:,E[R&<#U#/CE)BKU84P_`'(#,3ZJO=E5#>F,^;S$$8>1`K!YJ`'!.`$S,$$+XZ@P4&_D>6Y'W`H MS'=5Z\*7"1X;T/ZDRD?39BU4'I>L#7T<-G10[W3`J310G-KXLQQ',=D%!7G^ MNLWRCT$>.0Y[-Y?#/9+5*!$KF,HA8K-L6Y:7#SC?G>/'$O`P4]+>05&V<;[% M"F6DW1NR']LAVM*SYY;*T1*`E1FB5L*X3H2[*)2=R4/)( M(8%8YJAJS(H%]KPFQW4A)HI!Z]RA4"^&3=.FQY18C@D&*'MZ05QK[EEWN=&6 MKU%26=<,M0S".?_X9F+ETC%`[3`7)>2B>*8:`%@-=0.,*7O*T1S7_7N6Q%'P MJDMF*VEO72%D?"N.4*N6[H]206,_Q`Y@X-VAYAJ0;%9!XQP]UXI@\#$$7?L0 M#@Z>#!V4)#-A#TX7VRT.:76GAK.[H,0TE58:Q@E_Y')25D[V?1F4!\+(:Z^Q M`GB+]&X=HLN,B5!:K.X5=6!-VZ)^SQL4E*C>AC6]#XDVM"Q=Z#SB:)VA^O'M M_5NTK8:@:(:`.+<>Y-I=4&.&UF%Q=?'+CE".Z:OU:\)&TK3#JI5K7K=>6@[% M*$PW&:Q3]A25==MI3X,3C\94&(P-E_B?@MW^KRAA,I>TY7'8!YTF3#$,,#7P MRR)4=YJ]%NVHM1R:=;B/8(1TZ01VG"+_@).-9T_BQYY$8!#GPIY@`'>K]4OH/61IA^BXQ M?DQP%=#*TIC>S/>B2>F1"+A="M1J?S**3)IW]/TWEC@DDCJ\SV%"J,P9=4#U&;M MRX&)^(#+D\>BS(-0719>1>:@-J92"K$$I;">$E<=E^B7FLCQDX6I\E#="1C! M]^[5!P(ML<0F%%<.5612K*I1+^X5R"@,=%2?5"&NZZY64Y7,2&9J+K*1\%?D M3Y#?!.!J]=&_"%F!Q=%`1NV9IAJ+?>?].?5$ M&&L5U@3#;I6V_EMU9M;-Q7621JT0)/$V M)D-0E%GX*_$8>)*\[GA4.5'\-$%+*27$3BVKD2XW")K[,QF!>X,BN]09]_#E M-SWN?'C5K10J\6Z?Y0'QTA^S[%?TAFV8HRH\(_0A]DV-);U[[O*B2>!&5[U( M1N!>#V15?4;UP$:-(L@!+%@*QBEQ@X53(P_QKZQ'!`&00_P;79[Z>2$Z[8)N M5$U&;BR7UI;ON%`I?J)E9HSU9>KE(SWS.1)U@E\T>GQY*+!V'0>/<1*7,:8' MQB9*-J1TKV""+-#;"Q]7(*TP]!CU.#1G'&-:K5$!S&*N'1JM20^\;K9G0?%\ M212X`%SSJGKCP7-;MQ<(YS0ZW&F'0`X3NG,.D@G M22Q/K!(TS257NK:VVJO)Y5[9IH-TJ()S$6JQOD3T]T-1,C/XD-5!19CPST-5 MZ/7>0[:V-"O!R]:L!,QLNF;5I33X5R(*LKJO'091"N:GI2 M^[D<]=*,7S#U8#C4+I=J-4&B[L]4I3(FH2_G,U#`"2D>C=!F\X0F"W^]8>$! MM.1Y=0>N/)L9)W!P*B/A7'PRS$(@(4R!*4L>3N/5.P7)\R-(WS'5D M,1U5B$LWI&-#_,DP.434F>S&?13,)-"Z3GD=X'1=N>_N$AIL5&FK^YU:])XT(&(6*M@\3G\T80=H<::`!<>UI89=;C MM5;#UP?B^A;TIB9+:W9_3',<)/'O.%(HI5DWUG744$I93<::'G4Z0!U]WJ"V M&[?*-U-@]K:XDXLRK`4OVXX\.*V<`MZA5DY'KM7:"H2%`I]C_K_=JT%F/0"A M`@9]N*B]`)9O"-4O:N(O4521#^Z=59D;;)V"NI/0ZAMS=MS`CS";1`T^ MZN#$0:BEK5(D\/MS'H?"-WJE-_$H\R"OUVISO+M4]^LL?:)5HMOENN#[5K.- MGZH;#U1;*250H6D?O#QXIY=-=8"S^+WZ7#TVDK@5S6^_5`]6O7I"D>K%44SG M3>*\\YC1CCQ03(VD_7=N/WX85B9@U.,+33ZL,QQFWP2M6,AF^& M87X@UJSE>M+!AKI##U`-E-ST\*/JCHVH\ZF M22Q5W+HC=$7\1=X5(GTAWAEJ>D.DNUJ=G<:H+2-_+2I5TH*+&C2B;HFH^U5% M!<:S>3O7%F/?9FCX("!NMGJ[=$WJS?D=?L'IP>QZ1:#UP.$0Y0'Z%DV*FHK2 M+^=!+U;#?Z[BWZU+(`&;?O57(LW'S""&56'F=NQQQA!@,16:5(GEM;GM9@;X MLW+?_<:OXQ^3$]0XE.5&@G7]*:K6"J+ MD+(S7VR"6N*QN\W"KQ0@J\GEK<("0`I44C!"[2DF<<&K="$GX6^'.,=U1#<+ M"B=>>Q,6KE!(DTZL*Z*1A,+]945,$\Y4Y$W,^X8'SF_8]K83/>_!_>T\F0E3 MSW1+X'%4O#ELARHZ%;,.5?,J+M!X:9*..#<9EW$:I.%"QTO*SGPQ#6J)A<>F M=6OOCY?FR^6MP@)`"E12,$+=^-U717&@14=NMF?9;I>E+`T9T-N6T#KUL67R MJ)W,FHKZF9P.WD"KE4BM1XMHS)TJH"5]X&(_1Z6#FU%.WGF(07OPSYY.D#(6I;S'X8$&MGS(2A^<&E.X MPO10AU7[A_`WV\:[HI5J(6?O(HFS(_<1[J4G[01JK?_,6GMUI047A4JR;21A M"Y<'^J+!D^Q$70TF-\M3E;[TXA/.P[A0/MI0DSE=AD:D4!OE.GEN0^'+4F,L M":Y:4DVI$NKZH"(`B*F6$36^[*G*'=XWRLL7-(W?)B.PKAY2SH=P:AMV/!3: M=MV;(>#V;Z(8!1 M'SDOJ%''.4\;W2$2ZGMD9]L+W`5-4E![-F+B^T6A^7-]N)3^$RF$]\1 M2W^34D%.THC^#[U??PD2:M\,+<;\KJW;C`5&8Z@7O$NZUM6=(MHKS2'*C`F- MV6#_Z'1M]Q(;Z)ZL.C:X'AO2&+,$JV$]..P?N.W;O?U82F>&%F19A;%G0\8Y MY(4%AL_!%/;"K!OKML%02J$XN%S9J[H2(V\;/7`49HI-W8)X/-V)QQH^!=%# M;9X.9XM%X.@;9_:\.4CJ$NY7Z3;+=[Q4G3[Z!-R#_3)Q8-F$NG$=2IIT/TRR M@FQ/V:4CA>J6]$0`W'3E'J^&\RA46)LRB58?OF<[_!!\PL5M$*N2[0LM73QJ M'_`Z\H2=EGQA31!MXSS_MH9AMF"QM(@$$:BD+=TC7H*)D=?HEV6"Z]PVKR-XG="'W90RAO*))Y1-R4E>A)-W@'@/ MQ*E!O(\F[]/B%5D,TL#5#)FXS`GA1W/AMSFN.CT['QE7W10:J%SG-#K M(&K@$D7&+"]\A/G:,26['5`U?+`3;?Y8@>\)2=(->O7(1D#&8'J%CU$CL1^"'3[Y%"O#H'K-[(<]];D4 MUB/R7XC^CGZA+?[+/;C&AE4(_9&.J?WI/\]V02SL&$8$JALZ@T##J0($O(U' M,.@/KPP(8V,[XV3BX6/V\)P="K+JT"_\@&GA4]D1A*2QW;,&&]'O_"VDBE?=QTU8IWT^36$96N[8R5*>MM@`$260>LEF1\CQ`X)G*%6X%R) M7-K:"GPA9U\F4I">_^PKB,?!(P.R"CDSP/PA2R]V^R1[Q9@=&=WLV;6\&M`: M(KN@UDDP4OT=U035N6!%LC:X06>>4\3!M3C\,#?;.Z[H"T=6#^T&L)J!^#.< MP9$N:6P7X3*.A4LOG-D%-,1:@YF_N/%0&TV&OJ=\:,>:.M9!)=9[N@<`^@R= M(PM7R`Y33IYH0(ED"R]O:E??QKD=V<7Q5H@W4^[H[:#5D''>RC%$%=#H`52+ MB^7@*3UB4#5V"E'54<,`I,H3!RG(>IUD1 M'/+V8]=)J%8/)8E=K5!S+Q1CJ5IW`4/:>Z$#BTCB&/$`+/6`#@;2#'Q?![O' M*.!I`[-<#>SQMG81+>%7J&C&FJ&ZG1<0GL:Z8\RJ\-$#JQX<%M_E)$%1W&RK M!`,W^5W\]%QJKGP5-/9?W"CX%PX-:%L:H5^GNR!H9^V]N1S6SH;P@`0V%8[Q MI+U#5E+Y@2GIKDF!*F]NFP&S`D+6PCLK]HWSZA.:@^&QII:/A4>Y'8?#>8,& M'Y;329R[WO0HP-$_2=4A8RF`\F7;`*9]`H=@'7"N@VSE5GF'7#,QBDH.GV`\ M!B$YF.7X60K2+-[0`-&]]@X!W>=;AV<>6.L=G(V$*+@4/H%Y!#QR+$N1L]@U M`LB-4)*XO%+0+TB@Q52A:,X\=)O'+S3#3ZL,/BCRXO/D6JFA"M33 M;#/MF:'>[+GH#P5J5>+ MW9H".M86,SSV=&8*&"VFL*'/?D8 MY-&'`V7[9LL?=I\/-(>4/*]BKZFOD'^WW:BNV0:?X M*4Y3Z@V>9VW;M:I0L91Z]V60ESX(S@U-#P@H(/!I($#, M^BL.),=]"XW&1:I-U^YP+##92BI'X2B6,)U!7FP)@UGC(UC"!FOQ2Q`G-#G" M99:_IQL)"YZW^,GC6=#THV?%#Z^_RSS1]_*MK?>+V<3Q)-YX;PBVAY(F!WWR MI!S-VLJYEF.NULPC,&[=!'%7*<_SNX9%&__.\9@QR3BM8+OZ*0KCM$JT[3+K MDI51*ZH4E$=LC%3*M)@%TFO2W`N`Q^G>'JTDJ;P>F-VW@\N#^>,Q;B9.U6;B MM#(3Z%2Y=:>?<'CIN-8(]9Y2)_%VK<,'^!6+8QB\F0H#N[?Z#]5!4:@'5CWI<"2#6'?$/;R*%7;% MPBJQ;+HX9J@<^BY3(#G#*8%]CGA"['>9^V':BUU'PUA&C5*AD56EZH1N*'@C MAV[#;'FY@R#7,;0G4A8K2@ER'):>UC%G`3BMUMR`:>K:6_#GZ*KE0Q>`6_(H M<4M^PD79[N$N@SC_*4@.^)WN_&653[HYBEEG]-:\*>6?;<]E-HA^&K%O>W"D M;&=`F<@O]%=ZQE[OTEY8!^Z=F[7U=A)>U/*\S[-"]79[ ME:\=S\&R!%&F_-KC M.)V#FN9-4(W2=G0O]!DO*7-&38VMSW8Y`AO6=9I!&]`:%%?A\R^J>.G"=/3SE^(C;=FAV'8897P4 M<"N7-*(:=4:1QS$>UGO@RWBO>NR]ORNRM.$VQ/)R_Q"$>7W$_9"G'&9.] M>,C*(.G^?I85Y8>L_!LN[W"8/:4TST2W$IAB,;'T?>OKA*UQ'9J1MBHE_[`T M0'J#FJ]SVT]L?F_-(!]&K[A$[:)Z;HVYJP'^,VZ;D<_'M,I&>CT;2[D8 M-;2<%?;.OL.,R\@JYZ/>;#-$!SG'OQWB(BXQ*JH9V;?C=U`:[`W+QO*YKF5N MQ_8S7NZ41MG:N@>PR(ZKY%Q\PGD8%_@V)X(W/Q;5K\8%F;3=^5%71R\UN.#. M!M6=(=9;ITW1-')LOI8>@X_M&.2LZ!"NAV!?#\''SA#D:PZ!89S,0D-Q(0C< MN<9MA'?I#BPM*"-QOV#,,6*@:E-&%LRQ\6XR%;655H,DP='IZUP[;M*S'R;= M:"P,K'LGSUBG3"_KFI[4'X6IGS4V/(P<[0G#SVP#53[GV>'IN;9RGMH$<]T` MF8>IBF'/4MSF68AQ5%R2<;JJ\C&W=DQA"'2$UO5<*XE0Y:4B0!0CJ";I>F3N MP0J;GB$63>9F1AJ&NL-Z$1S+$R=K:#>9PABGPJ:YMLU-(X?9$(P8QBLS#$IL ML"3'UC(32!'<2SZ@@:_%>!)Z,,X3O9T?:.D*?F+`U]P/^"/[2?FT%MB!_3@, MJ&3C3Q:KW(BX) ML3T['B55QZO^E"6DFR0N7^_(^J8+^E_[Z\?SFLMH3%<(TV]?O*,.!YLV5+]E M`E$N/`B\MS[,;8.CS$@U#V)L!\$C!G3C3`9!A$//FR\;1FR51<'O14[@A?%JE5OM1?"@(\>SXM?R`BZV!H<\4/< M*4/:OEY>3VZXJ;_0E;14GWGX7'=C=5#"5D'Y+4+5M2\T69:33[%YK9&97_/$WYD[9NK'7;4.TL8^J.!ZL($M MN@MBYBB4313D/*./S-=1-OG7CDG9%&,&W4Z8K9SC*LL_>MQ*JX/?@DH+P]Z, M$"[Q`SL>Z4V0XT]?O_WS._0& M_>F;M__RM>.H*0!^>A%28/`LBNF'CYDIICLDKC'=Y1Z$:4+@(Z95*QZG'V$>>57+NXM*;-P\\>N4X+HVA/LS>(?;U2<_9] M'Z\;5QM9+G>V'0Q.;U@^-X,WKK3KFCV5QAZI\?MQOW=A_(3/'K?Q$T?1IO%C M7_],C9]^9*7&KS,LGYGQDRCMJL9/J;%':OSJ?&>=1_WZFA'6.#ANDZ@<6YO6 MLP7BV&)]KDM*C^04/\4I'8O3(*'9PLR?#KIB M\S-?7+2SY-\*`RD8\'FN*L:3!5M:?*O`X-F@>K"4F!BI(S\&JGZASPD<'0.- MQ91L:3E/K= M(M5;')<'(M=5RJ4TWB?/_)HG>^*Y8[:F*>E\<3UC8EB? MPLH@UE9FRUN3(Z%P5E/^1;+M@/5O.,Q61T/C.^S5S18(]\Z.G,U M-EX6_)[N"90'&SL;`]@7'@4EHHG"LBU+F'C\YDJJ>$L;*XW6'8^I^@D7=&.8 M1DVJQXS^J7-/L[H%@[-P=(;-8'37M'><#42^V&9++#/VY\U85.9Q&\.Y@]X? M,-P9L!?RY^,WDJ8JO[3MG*;OQV-2.X*H#MY6M*A@#H[.H,+'=DU[:A)DLD%- M%`.JPAA6,J^\YNU]&>3EVB9V^C1H1ZOW((#,2#-X2B=UH<&[2%<_5;`W=)^5 M9V]H5)=>LR995(^6K$(CW_N<%@6LSUW66K:6Y,*_I6O1,9ZR?!70]8MSTI[3 M'L.UM[.1UYO=Z@3XB7[E*`Y]E[<&QO9V+5-P1#:WN7UU;78-&3D^RVLZTJL: MWY%+]\_=_LX=?[`)]NFJWXEY6-P.S[`-]DSQ61(4Q_8?ODB?[_NKB]1@J;BJ`&T5`)(`BR[.$^9TE$ M)NWBMT-E5KQ)LC;FV]JN2AGI-1'P`R(?:0U138 MJKP/D3MMN0QX%]8Q9R#=$("=(G?U=F(XQ M"GQT',"X&RJ4(>AFY/O_@8CT_/`Q>WC.#D601A<)?L$I']*:"W7R?Y,>[%8" M,))MB"I&S&IQX_XSEM0O*DMK%O,VY/$VA*AQU1O28`":C&4WY3/.#8_`)<;[ MG`.`P0C\0_@JC[3)^<&#.P]93`$&F.+SJO`87!=(1^7'A>*PIU*2X]KWVJ MLP6;(M#MIV1^9MC>&L4G:<2W'YVXUO.@Q#RA@,P`0ZGM6F&P3-)334+9[,8Z M(=24&'%JAZ[(9/'69S_*P@.]I60Q)>M-#UTDE^](*F+GBEGU;N-L!].-B`P.4;7V1NMJT? M";,0KG,N(8C)@+S*6E5L.UN9BBA.(F;9(&.G95 M.QR:.JL]4C_U]U#+99S5!*$:NYBM+@+P]'V"$`]9&20TD'N7I74> M2;K.THM2]V\S)PC479H:,^CCX\D%9?/J=2/4V(&V?5)+M\#&[X(GINJFC-/M M]D9)W&SQQKF7VJBJ.>+MG>8DFR#&A2J'F-V]F^&X5]G/4,3'G5L'UTX70`-& M-V9:^%N\ZP^?<71(\,WV'&_C%$>G."7_*%D>V/.X").LH.G3="\?#/NQ'Q5@ M**=PRU[1\S3RK`=4=<$S0J-.)_Z\F9@TO<(5_/2YG;&\5-]BY9_BQT.=G/AB MMT^R5XR[?S]])4H4TMCVH*2\2J+)E^G6[C(U?Q2$,[P*O5U2!F%4=]K_Z?05 M5?VBJF/G@>M+XJ-GH!<%AQOL2X/-0]2#.9;)\W_Z/24)94S8S,/8T M:@H2YZC-QVRZTH!H+:L,3!Y!83YF1Z`NTV3[QG=E,8!@7U6,\6=OLRQN?]K= MSS4@8@9(;WUS#)5+YDAU-\*=?;!G431&LS?<`T^8.NNX'#IL/P2?XMUA=Y*F MAR#I_E@0#:NUJU(V/6KG]>X*TS/'!+QUV*"J9\2[[K4HZ#+4V.M-O2BYO>1: M9X#J4<#UXA1VNMC0B8KE%'N^"J3H;A\;5NL5:@%BCJ8Q44="5&^Z[-QXW\O5%I;+[KP)'Y!L'D MP@9L#6QZ08]E>X!R\EB4>1"J/9QQ`@?>BX1S$:6/9>\PK&[KQ5&8:OC%%50_ M]G:A].>/33L4/@1FP.:DO[S M$_A\K`$5==2,ELP3N$@C7I2`\2.4!3@U,-`L'(9RC8,":S))]-O8!<2`/R$A M(?O9EYOAL<'LS:I\)"TFDXW3N,37\0N.KLC6)GV*R8IU4A28)K?_(?A[ED/2 M%AOU8C^EK)&,0E991OV&D:.6'O$.Z+Z3=>%9JN,)\RHDEYTZJ5Z@MV7P0[## M^HS(ICWYA&*)K&9(WO1P3#OR8,6<.=$&D-;/LCU8\_,,NMRSHPRR!Y6OR0`: MZU!5\3]^9L_J$#2-/5C!P5,QA!AP'A;S[>E7XO0)IV&,BVM%;)8!K4LO7RJ/ MSM7O$0(BLNR27O[B18D?(^& M0O!VG1WR!K&W_8XS$@!%J*IM%>C\@)6,6WW)KL*-\'Q=#QK'B"=#>Y5^P)_* MAX\X><$_D#;/RCQY!IWXH1LR":$*0^AI'0?:`^)=(-Z'ATH$E;6K6>CGN'PF M`KY#?_,C580Q3$%:!\"H#ZIXC\DP162U?'B.\XC.R"1E'.O&(W4T](_$RW]9_^U5(Y>N);JH.M>2T^V M)<[GZ.>P`V\T4Y#,1"<#2MS113^54"MB3_U^R'),G(`@]5_[QE$)U3L5)"W6 M_:W&_F9[7V;AKRPS(!D4^B1!M754D]FO`:R60@JX;(L8`:HIV-,9Q[M!*\+8 MU!\(QH3BP&"`N0KPNPQ"?+++#IKW+S(2QZ%^/>Y'(T3;MAM$6R/>W/7S$S,A MXHX06RI$H!#"78BBB"5UG*(,2*YTX2HE:QDNRKN@Q/E[**#1`BQW9D(('6;M3MUZQ<,$&Y-&(T7$?. MBD9,'_ZN$=CI!7&G\6/:H-9PN2K,B&]IC01QUNDTQNG3)<;2F!9Y>[MQ+`J^ M)<\:25-:+Z5NC&AKAR\WIPE`MHE%+";/547S4L@@S[LAZ4;R">$J5>T+.J65J-BY&A+_D4[ M0*P'Q+OPYA&0\80*P>S39M/B`Z`^*R/\ZE_^@+NP_^0'+IWPUJ]TR:2GMHY94&M4]Y^LVLHV[`Y1!9545/MQFES7C-MEO,JBGY M\ZYH#`I#.,MQX"I_S0/^5)Z2K_VJ.2P=I7"QP>:/VP#UGI@]>KP8\Z`X\$/!;W9W'P&"=Q&>/B[)#GZMR48XWM[]C& M.!:V16VC#:J:K1MW6=*^M3LY".^\_FC(?T=)2^(>ZW*T"%L]#50LEL6C%5Q/ M@X)F3=O1G+CL+.B$EN][PBQBYO2U;5-%T9Q\#/*(^U@%V0]L<5S2LFA7*2_Q M]S.F"Q>.3HB-"Y[PQ2>/M'_490)U MN:!9+;H-*TX08Z7>4!#;T6&'!G1SAC:H9@E5/*&:*<2XC`'FO%I!I@> M+]!/D99D9<>JFJ8V[9PKFR&4:W1J,#RRT1HQ*R%H+KJU3/-2'/AGD1<;VRF& M&&J'.UP_([LYE[.C,\>R96--*<^;8>\>:/51F[,^D5I0>I&_W7B^^F4"C"?+U- M!?E3PTF'`5DB=W5S:\C2<"T%4P]!KA.W0X:^1@Q\W-<&R0/I5@,,WL0)&"KN MI`"@O_LQX]UQ')ME<1#7FMD3\KF(/;!+@B?)U`[:6)W;(7_#R6U^1[2!V]D= M''%VDD>4BD:.M$EX?\2I6:-R1>0J1X,&1;OT='>TS1%4.] M-B(NXR(,$IJ)X9+\92QB4MG:"2I$GJ6XX$U90@W$&ON!#,FHCV%#.>1VT,'A M"<='K[U#A/3YUF&D,B'>H61D].4XD0[]6DAYR`.Z+[Y_W3UFPJQ4\@S:6$7$ MD+^1-R'T=\0;N)WWT;'LSK5B(->:7[XOI4F0LY1E)&$'*$7G2$0RZ1!"JT@` M22*$T_-C!T[%T\QL^!EJT3T)=8L;^!QUP60Z0>LB[`X_Q?3`(RUI60,EIH9- M':!(X%:"F[8=*U3A`TS&!UH$AFJ45S8VF"8.2Z[2"'_Z3_RJMB_#MBY,BL"O MS(KPAHBU1*2I#WB0C/:(I5`-]5J(J*(.6R=8O7>5-[>*"P770IK#*D"TNU'Q M8Q>K&_HN0F#COJ[9^!DGR7^FV$L?`"(9;!$8RI%>V17A=NT.[[..B8Q[F7]2K44-`>(4 M/J!%/1,CW@I@&M;%#D/K&5D$G[)<[<0.6CI`RI!7"4!8,U2W\P$6HX,LHD$Q MPNN"X/;PF,3A99(%8Q$;DG8.`-#G4S+]O!%BK7R8_)'!%:=>.K)6L[N';/-$ M[^OOXN)7LX>J,'(7F=TA4HWD=6_)$*6S_*`5%#VXB'#9%IWE.(I+)J;[H#T3 M'(YD?9X;'<'I*3,*1I@HL['.+X11+*9-J!=1T# M2R8$1-2$+/-+38IJ6M02NX>EV?0-@3EE[GR#YL]Y7.*;[5:5L,BX)T_!VI5U M.FHWB/7S)B,='0N"A5F>!F7)%%M\A1(DF/!3'O*4ED1MN"[>9UFD@K".T/XK M#ITDPBL+2H`J"A:IW])L$*/RIL@G;)J$$'J#.;(8C'RM*!BM)W$=E'RMJ*`\ M'IA\[4/A9.A<:"*4)1-A<1&._GXH>`GGA^PD(@XYX2I(;H,XNDK/@GU,])5= M?C\.GX[F M/\>3*^""9O%A-$W.&=76;HVO'=VK_O$Q6S>A2O/%-K'5L6=.@0QBG7GJXFB2 M34W7M^6SG&B4[0BL5"N#IB;68E\X'FLDC,T*%JC]QIH5NM8V.=J1&I@9QV&9 M*VG-8O9%I3*6;8JP'1/9?Y281[(9?F&)0#X<:$;KFRU_&*&S,6M\T8W-667L MUO2"FJ^2?[+OLIK0[,L;=(J?XC2ET6RG04*/LE>R57NVD-Z705Z"[)6]4>Z. M$,TD=(Y#EJL=??MN@X@2?;/JB%RDT9&-Q[>>6/CU;-BHQ5_;@!W/"O"37?,_ M_KFCL_V245L_4YUH]9.Q M5HWQ[6>+=N&_ZC@X.IL&'ULK_FV3<+WAXW.S?3,'O,WU_SE81$/-7LVK,U'K M([2;@Z2>[^FC=WJ`T=SGV#"=`":.UWI"1MC2`8$V#>_G?%XP91Z$`6-4["04 M=:LW_H,<,3@;PL_I5`)L<5=;T@S-[?&L:C\Y7]+`'!S=>@8?6QN''C"KLI;A M)41UE-#[0QS1A=++D8?:WL_K%,69@9VD_,=C7:5;(B_V$!.8.CH;/&L&G!W2 M_"/9ZD5G"&J^_Q%.?=Q[S3,-C#T[?U,^X_PD#/,#CHR*(^L(K=M+K21"R!(E M0!4%&BNA[#98RUB@6A1&Z%Z]8=`:JJ`)KBRZ0^$SC@X)OMDR_B2!7V$9O\3E M*ZLT`DE8,JM7^P[)K#$0/(JJ-WH?PS51YF-L4-UI58<&K9_[!!I/N>R0''8[ MFGKN9DLDS'<%_4G!._X%U$%8>I?2!=8:EY+YF04;]N[O9UE1?LC*O^&R>C'Y.X[: MGC@1TZB'YR"MW%(%1!WR9%T+7(Z_D#FNX@75;Z[EFM?NGWGOF_Z.G#"#7C%- M3EFSTW_LS8FJ-;34523473&+^Q-1DI&O+Z*JF:CI%SUFI'_ M*$K2E$],WIF8;L><'F7MQ&2JB;%I99U;JJ$A]\1,V4R-:%18!$;F(!6B45&1 ML6HB&WTYD=EB`#,?3I&EX+(PO2>Z[D-E%!.(B=D.UZJ*,EU5KE(R?T3O3]*( M:>]52FRQZEI!1F!=/:2$.668NOY+RM-WZY>A*&,(+,P(R4'_>D][@X M>RJ"(L-4EXYW9LW^N;.Q*"+T4[I`?' M%1G*F39,"=?IVC^=E4"*X90M"Q)[&W.99B'%44!Z9 M"I_C1]45I*2]=7S+^!["MF['\;>I04K4#!4#`)D9 M?F9U;5E[LZPN4_207;%CB&RT3A*0SJZ?"9!#=O?<[$PX$7$;4$/F,A';2B*] M=>PZ0Q'7QCG9[9%9BW;C82:& M]';UPT"N(:@J4D1I$2%&+36][F7TJ.G`I<98$]*U#IFBM*=+TR!JSZ>ZPWL> MID;L%-P/,=;$V6(64R[%4RV/2S M=$@:NEHP&,U873HGA76I!]E",MK4[IHQSNWXJ0MOQBMW$(.Y=;D,F/`=<[X_ M,KZS[=:U95<@I&?$M?"P9Z\OLQS'3RD/=PQ?'\@>O0C8BG*=%<4IWI+?'X)/ M"O,-[L&Z-8?+-H1718EJ4M2A191X@QX9.2+T;LW]?"'#6LBR(V1"B&L92YF, M-I<#0Z`.5X=)*+6GAO18X"HMRIP9R&M%414MA74UD_,NE%0A+5';U)-J*L`Y M&"(*-`$6[X'VF&;X3)\HGL^"/'\ED&8A)>",O/`N[-\>P:43,\56I,QPHQZQ M9^ER%Y&26>ZP2XQP*V3D19Y<4[`*%VZ3D#JOB`=QUL@"H3+-TI;6"W6(O(Y4 M?:"N,VGEB176#/.PM(-RC.<59'A\$=E)\O/*.UP)\DK5@%JBG[Q+MA,<'5Z7754^?VM+D1E;T)7=O MBOZQ%AVO+#KL\+-BZKO2.M&T@NEM MCG?Q8:?P"P&T]HO=`>01`-NAH7/QVB,M7>O9\\DCVA4&H"B;1$=I_HZ>3 M1`SU;`D0IV#W(.B7FLB#33UL?H1W>P:3XQIK5!'(GN^0PYZ`P_OP!('C\H'! MV)*C7_QYQ[V0I/_TQV^_^VLEKJ^ZIL`G3.VTX)P5J3_VQ0?)C;6>Q'9\OHI[ MN+UF%*[W_H"I&`3D`^=A&7BTG]`>`>FHG(%D7`8%3OHP\>><"#8O,KAH)V7. M^=&A?,YRNM.K"H[R:.>;[1;GXT\G8626SX6T4@A;D(:B+?);Q;_75"X/>Z;* M\SN1IZF'FW-YLG7E@9W@&`MTAZMLO=LHFC3\.#SE/1Q4D"8Y.7R^"YB5%U5;AZR_0MQ=O M=TS'P^#Y3J=&1],WXIW3])*T>X'*O:.]&&@@[WAF(&;&.CK*"3]I69;-221F#)76Z6.V5`%4IMO!4MP9UG@*7*^L4N3IK M:]H8E&I%K>Y#XK3,*NEJMGX9ZM8[JO\^SHF#K]QT.>0QZC M:9&K+M3,Z/1V'9/S`9=S#8[8A3?F9D0Z8V-#^C@*4P.656%H4B+K49@9@+!= MKX6(=?PF1J:J4`.CUM,9YJ7[-.D>IW&6L[T4^6(V&I`+(;)K0G02*%Z6W="] M-:5`%0D[379H(F;(0BQ#P64I*EG2]60!F8`)PM1*G]>D$K%<:SI(:WJZ;:`R M"VGSX&G[33I)O2&]N--WD(QJ`R"D-KA)/38*G9YU[SUW%#U1;RU^PLTS12HGWH.QI_PS^6Y)J3D MO\E_D7_0%.M,P/\?4$L#!!0````(`*MS?$26[G161&8``.SD!@`5`!P`;F5P M:"TR,#$S,3(S,5]P&UL550)``.!OS53@;\U4W5X"P`!!"4.```$.0$` M`.V]67/D.+(N^#YF\Q]JZCY756J7VD[?:THM>71:*_C("-"C"`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`#3KI3(PP]CL MMJ6S@=DTC4;L[W3PP372P!15QU_I#VFKC4-SK%XL2^UV.N4PEL\G#[#P6?F1 MJW\>R@_>_"5ESZ#=L%5<)UF;:[S)X/;/IF:JCW6V>SHUW0N;'7N9ST[K">WT M-".S92/IO[USL>&WW'#0K>/0U0GC4;>.9+<7)+L.D.SU@F3/`9+]7I#L.T!R MT`N2@_Z^]+?3LV1J,MY796YMVOV]6+66M.9K]]ZR69BGI&!9F><]@X`(Z M!\DL#@V\=D0=;>U-Y5[(;W!P43+Q),(Z6YB7H7.`U==_[,)[YF?/EU'RO>O% MN3:.G1WFX^9=79N,+O=(;PLSXP/=L93O7$EM%"H_GAW2W,[;.?A1FWP;(,J%H^ M[GQ)0*]*^M)V1S'S87OYLK6:NWJ8WO2V_:E<.53?<[8Q65M[UX2;6R?*CU_+ MI_-VHUL\D;32DAYOE\@7O.W=2&>L7G9E,TV6]-^>'6+YW[LT?`4=A`[5,0": ME/T6E_7[6)G05KYKUKYDV_'9L.6EL44?!JL>"+5YO]2X MN(9IK@$`'6*P14^6$/A/=(A&*:-EX#>C)%C[F8C'Z22I2E#\;SS9#YP^93Q" M*5\.%/E/+"J'][3[>B?[M8<#W%O?/[\#R607S[M M+.*&_@?\U6HVM4F49U'![&7-8<)[:Q.N,WJ:KD_>3X/E\/#'!IWKD4^+%K^] ME!_?7X+G,%IIPC1-YJTDNYA-H@NLR&"*R0O_6[Z;)2GL>'__>>?GGP`F;'AP M#;JNY(3"*#&4PMP.K]=LYD>5%$[?P@RAS/TP1LBJ-P&81ZZ9$DJ^25!SVF)V]@BS(U!*^$RQ*[@C8$M+U@5T>=\U M>Z;K3(U'3.O^`&A]A&$5-/(F`/.`(&T;-.#4?6`04W5`F*I3`##A("XC?X9P MM=8&@%+\EBG)$H`0LW5(F*TE<+A-APDMRU(3@!&S M>#0`%B_#+/"C_V9^>@E_H_K@;;0&\,=#9E((1\SE\6"XK-13G\U:>Q#`R?#Y M;``2,WI"F-''U.YT])A+"XUL8[.?@T1.8$()#[^"?"=%77H(5MF5M> M2^-I=EOD/+O,I,P$(KGVR3J"3':&2*PN,H1MRN:7"MH]FX7<[!3G-_X<._^( MF@+NW>$R*L*"<$C?)'-6^CM$5_&$O?V#OBD;>BI4_TRB`AA(WR_#B*78)478%I`/TO`C`8/02-D" MM/B&5)O/*MD==ZM!KYRR+B"'0=J#U)@0;BG;A2I0I8*>P9=D5F99E%"ZUA)0 M#](>A$)!"*1L#*JPW!5/41A<1HDO\E40M@/$@S3^($`0ZKI8?4`FOVUZL_3D MY?*1XM3(I:6N,%,_>RJQ%-DO,]]_J;2&17FV_)M-]5G\M?>1@&.5V53B^*+1 MR]OKZ/%B%0MW7/L,/_F'&9A5-V_/Z6/B49NW:R>B09 M>;<[$:V$NPY6>#F+ZN;69Z2SO)`>`,*IE5-'Q.(%)`4TAL6RF:G? MQ2?+?R\C4&%_*F?C1SJ'/DDO[_C8U9)91)IDB]DM)P>:$/I/851FNC1;4BU' M](Z=&DMT61*ONBZ8+2W*NKR^%.&D*L*S=2O+1P$+)W:6Q<\;VEG07M[)CCL[ M2V-6>G86O)MWXM1/0E?>F)U%`6P,'S?=$BLNCH!G29:+ M)JUQC.PTL'?B[K2I._'/]8EKG4J[C>R=T#B\=B<6.>-:$,]H=HOU6D<.-H;F M+/@55F/ARSMZ.Y^./KE:VN*IF7V)MKF;ZF<5L&IH^6[0= MTCMQZHO1EC?$T-I%"&-8O7AM/"??T%6BW\LPAKF$?@24A(H4&2;=O7UG!^75 M]+!D&>*&GML`8F/A8E_&!J8?)4&&VYAB"0'K3&%3'W]>#/=APR*Y-]EI3)I. M4@P+N^*U)#D&WMAS&RFLO;H4".CDP>CPAJ+K][/AAN(V-EA!#/+0T41@*3U& M\S#HBLBE,YDNGQOM/;>!PQ*F9)2*0%A*I9&SU#&O/"FI["8,_^RYC0I6DR$F M;S5U2PDSW'.U?$KE:;[#5_Y1^0+WMJ5(--Z=Q1T]MS'";?G5`&4IO0:%_7?E M2\U]$65OG!_-/+=1PVUY;4"PE%*#`HLU'UKUJFTV]MR&#K=E%`%B*_D&!6)U M.=V0`@DKCO'&V\!@*[%&GN1^Y)1'U,E6ONW*NGENPXB-#[U*++92<+@_4-4V MIILD#DQVY(_VGMLX5&-^<1"VDG*X)W81[:3:ASVW4:@M[Z.>).34V#KD?LNM M^8'R4@"-UW(-8X/N$-XA"?N#D5G)")NM/!T4CE0UX/IF)[R3=TC"BF%$IU(C M1!AM)?GHLHLCY0X:T3P+IW`X6=Q.^8LZO]`+V-7O[)WLD3AM*3A:)]84GJU4 M'P2^T^O!`?J6K/4.WB$)"Y81Z1J(;&4$(<=S/3!=G^QZ+^^0A&W+!N,-6#UD M$W'"^$:0CQ;?XC[>(0F[5UNV):`01PIC&YC[)7Z^F.ZB1J*:;7$'[Y"$3:P5 MU1)$",_F%C+G/!NM:)'6#^]\ID"#<&MN#W-^%=]08"V;&-K'AU]B01L%<7BM_H6)WLZEW1,)\UHI:(1:$UR$:SB:3 ML()QYX>3J_C,?PES7U2F1]'#.R)A,&O%L0P20K6QL8P`U4%0S(LR3+\R"8KK MW9?O`8_^F]R.9C*2=T3"NM9.-5I`12)D!FASNV>Y'\9L*?N[!V1L,6U4@Q-=(@N#-`N)\AX87*T]XY(V.5:<8V@0;@=H%U.=='I MX!KC'8W%2J>%%-$)L^3%6O/4R;5A M-I!'PZ_%G"5CTQL&WE)J@,TO]7;S:@2,%\/CX]U.SV#*87X?9G^X6+?\=[GL MO\&<4GY6*C=.]3J5]O-.=ISEZE^3+I^EZ7)4=P=X)&[1&AQ@RTX7Y/!7VT/Q ME+$_"QCQ@@>4N4E>LS$'':L[TL7;7-*6BG>L#[>'HGG(ZF8D6N&%-(8 M$C\]%/.YG[[?3A_"61S"+9E'`%7>:O!YODNBD'^@E_]UL:":L]')18!V\G8^ M.4ND^)%E"\@K)_:N^9U"NP$<$H\T*H&C'R<%LM[6V/;9_Y:QV^E%EH=S/Y>^ MQ*\W!#F0>*MIQ[`(BZ544A0XO0[_+,()3\=D=/*4=0,9D3AQMN-;CT4PP#BB')JK3*=Z&\26!>0#0G[8#OZY:@LY=KJQC@2 MT7@'!YG5%J:F4=F'YP`?'H^:L"PEXJ*P=-$D&?I+67<(D!T)+^MV2]L,Y8@2 M=J'`K^8O?IC.Y5$5&KU!8B0L:9;U8A/@B+)_70*PTDFQEB[[*@99E77H,^5! M4*N_M[-#PCF[G5H80!Q3^K!%9!&<>)-9')H9!)5]05P#M@IJPK.5@HR"-CP\ MAR\O(";8%O_3CR57@-(ANPR5$;H*UD9Q1TXJ.B6[T"SNW+H@[.5?GH'[ZRLGRB M4D=:C`8B';!9LC5@6TG8*.C059PS(&U]J>B9I&0=05`#MDOJ8*.1H'T`=H;S2`1B&+FJV%O:@.;+*DQ5U`-`.T3NJALI54C<)>O@QZ MN6-I^6W39U[1$T0U8%ND%CA;2=(U&S9J0;Q=FC4-$%94"TX/8!CB*Y;NCQMU-1RM\Y0'RR-5:?L"[PY"P5' M)]?)+[.NDB1>R#4Y$*]`79AC6'F+'/S+SYW#%5>5?.`?W').?J3SA9/T`HZ< M94*I760:-0Y:?.E4@P!4$D^.2C:4USXMH,,_9*[>VURNN-4D#"]T:"]@QUTB MAI4.74RG+,A79F68Z;V?ETZ2<0!*55+88@V:#POB(/&JHV1,M2K;0A]13/J' M,)85#T`*BS-]W'%W-QK1VZ&18+RS4K5`W5L\_'8372TR.;#)9Q\.F`%[>&:, ME[SB8G]F>1@`.!<)>9:E-VOQ!7=)5OJ5:Z7$5W?W=MPEIUO-K]0L'2!E0Y@R MB:.5OGB1A2=`96E_CKIOS!D+?ITEK[]-6%@Q"G_8)!+^RKMF,S^ZB'.>]O(M M%.4&$;0"L"3>1$04K).%3M[2SK=%IBH$Y\G<#V.$IGH3@.G4>PJ5?).@YK0M M9>JPP(Z%[?%Z67A99XM<-09!D#CKJM>8"H.E[!I.R5R]U/!XP2JA(;"1ODJS M*>&=O)U]$F=.C#(QP2H\)+)E(+[II@6@T:+(.Y]H>!;J4:>#Q5+*"_?.Y^N5 M=^#X?YN64IJ40;Y+3P:I-5YG`%!V$DY?9HO7!)NEW!G4-*)$F)T6^7.2AO_^ MN&,J-6&S(TB)1#!K%PT08[*4$X,F\U=95ABS7G4"Z9!XA>O.>!V/I707--F^ M+?(L]^-)&,\,*:_U!#F1<#7JSGL#E*V4%N[9KY5E:_'1U^@-`B,15VJF!=K` M;*6S(*4)!A][22\0$"UCI2GS8D"VVTGL7CGI4U_WAJ(-'4U4]^W0;V=HZ<>4%^/$.+$YR</ M-@L,I]_]=*)\1[3U&R`H$KZ%=GA4/.V(IT'E*[7#`J"%#GUCQQB`(6A=$,5/(F0*!X_81%GG'*2=[ MOCP"?&7S)Y8*J$+;`C02%SI,Z(+G&QS&&%Y6E?L6MFUI/:MW'AP$3>-:N)6- MWI*X+#T$V]TY6H-;I0D^A;OUO$2E=DKM^R=!T#2NKY941K#O]2X]$K4>MG/] MVC0#?H,;>5I^?*K,D^5M^_/[Q1M+@S!C=VD8L'LN9S/'Z[Y^'/BBX731B[9O M6XXC*HVA%-F'=+)3'G$1YN\M`@K:#N[M'-/P\W*KMYIR(E&0`SL]E`F#8-5E M]RS+867EB]=5;:UJ,PS/WC3BC:^#2$94J6,C/0$BZO:;E_&HL!II.+AM:==J M*:#^:H)L-7IJ/@_SY=/*65)FF&*QV^QGDDD91=8:C0.D.DN>Q*?&YU#XT>U3 M%,Y*=B]ABG[TW\Q/O_HYS]?UOE19[4V@T[@@$!(V[A8L8H^GG:4QA@05M^G, MC\-_5S3&DQL.F^^"+RRMDLJ>L]P/H[+D?.$F,&$2SYX6I2\X3YK(@LZ[9K_QFOLG3G=R M8U[6:441T7EY["N(<__$Z;LB*ODF0I9T`K--GP5;<".C5`-E;5">Y=-_N MS[VVTW[OG[1(32JU@&JE3)=;/[6&\`X^D;"?'(:\XI*7G$4+:=-\BCZF451D,A=V.IM`(K3Z[M8M((-L#GI M,3BJE2_I"G_A51N`[?[&W7&O0T"Y=>ZRR"6Z\@2M`#H)!]\-+B2$U>=MR=') M*65?_;=P7LR5I*VU`_@DO'T;C(B)$\S=DJ^.6^K"6(^Z>CN`3\+Q5I>ZYMPM MN;,XI6Z94_2>O;*X8+6W]T?X:<774-T9!.74B]7F9U(7K27/%<)JH0R@T>D. MPB+A^:1+:QNEJ".UY4WB5"]N^&O>-/\.DKT.`U[_H(98N?]K]/8.=DB8A?1Y M%>N%-E1;N3EHA%X^`%0_#1/=L,MZ>Y#'X,U'&@!MI>9P2_@"UKV$!R(E- ME!\%M`_(A5:VM29I",MR1+;2L#OQ,O1B78I;3INKG[7S:)7%&,J90$QE"Y[",:0_%4\;^ M+`#FQ:N>!0WI`=)T[WUDZRHD@XC0/BQCF0"A^C*$]0&YT(C[E]&FS70=$^)! M,2P#V`9&]6U(U![D0<+TJ2!,B^4Z(H3A@=JR>`W;_)T'"R9Q&9B@:=,2]?,. M=IV:-7NQ;>%`$448EHUK`YYR2Q>VY\<;$O@1$RK"@1`Y+"O6=1+/X+8QYW<4C;.WJ#D7QVA,61*`"-_#LF9M MXE/NT.(.(!(:Q;HD?.D1O(8'H7A83F$/+`Z3E->WPNU>:%LN"!)Y+J0\(8548^SK)9%_KM79P M7AV*J\`F:8B[2!,=PNZ6,R!A;Q(+GY:E67?A)G/GAY.KF.?:N(W1(#&=OB`" MI^9N:P0;(D;B6"RD'-H&Z8_?D]:D0U\0@5,?@2V3OD*,D&XAZ4S?I)\5*1M[R!#:'7V$I& M@=Z[-'EA:?[.4]'FI_&$FY_*7`+?,C8MHNMP*J^_J^P-(AO*F5Y/';0Q(VK2 MN;"3\^@!_4`![V!O*,\D>N0+\2%$;[F.NB4;7/6AR]14;[0$48SK"B?$AU`] MP-KK]RQ(0$95VC;]!2[K!B(:QR5/'RRB#X-,S0X?MH"Q278)`ETH_R7C^A^P M\%51AEO:$T0UCGN@$5Y$-;9:FAVY`U83Y1;,RR3=O-I@%S]I)X`\HMN>!E2$ MW6'F,W\.7UY`0O_IQQ,8?`:'VL?4C[.7),T7.3^S7%ZU26<`$)Q3SPG[%T,# MV$A"E2T;`BTE/9L#P$4:NU7*UWBFTA)9-Q"2^\R+-G5##1;1B`$6<2_3\=\D M<5+E,8QGU=/'Q1O/RB\[3,H[@IB&XC2MIQ,Z73R;^* MK,KP_IAWH%;AR#K.XD2*Z(.`[0]GD91\AT^ MGOPH?IX43_FTB!9BRS[.Z;)CA]8`WLGAN&P7)K`1;1F6]Z`>X-_3,&>WTZGT MH&HV$LAP7.:-5O@1'1J8>Z(?<3-.7J0Q_]ZN!)%]29*)]`8L[0@2&H=UQ`0N MHA##RH1W%<,7D&7\G:]V1),H@K@#]_H=U^N(%"="_;`<&4M8B[N9;.FOM>," M&.&E=0,>PN^VHGR1^^FW%Q!#G'-+?%5V+&;!TOR2@J;"E6HB,W#K]N?B&H>' M2QO82#;A847]KF<]N/0#=CKGDI-Z-HB[<#_^<=T<%$@1!=BR=Z.M1_"7J@II M=CLM';SN_'?%=1+KPJ4SKFN``BFB!X-TOM'YY MRN$V],]L"O\NMRYKCL"%-JZ'3#/@B+:,L?C81SGR!Q;P.L3P=Q=O053`;_&- M\3R,BCQ\97>+4N7<9E]4J#U_U"&1+\F851D<2W78*%@G;TL45W")?6.3QX1;W%B:5=+2R(NFTQVD M/!1O2N576A_O&`J^J=`JO]YZ`W@'!R3V"'URVRE''>T8"K]=S%^BY)VQGFX<)2<[>!@*,_B/>Y15'4[!823 MA55:;+.NV:AOIQ=^&H-$LJ4!6^DB865\D/?PGM%+'1'O-!:%8JO2G-/'%5[\ M)08%?W?X"/(QAS`+HB0K0,[J5Q!)+V_OZ,#5JEY-:Y&&"GL?D;8'`"2R7RME M+%YD$DP_RM/'WA$)T=.C6BHY!7O'.6TQ_#.L=)1V1D9 M;PR"(%'M17NIJ:",XU+*L\[O-[0VSLF8=;`J%$06<-@Z4W"?<#G"MP_ M_:@H>;@'2M)7:1`&W@FD0\)FT9)A!$_7QXN3BNT8/@/YHJUSOF^8UND;FH$, M2!1/;,GI"H&E-XH\R?W(S6WN+F4O?CA9Q@+2YVB.%.1UA2[S;M`6#:)*YSJ$0%=CE#<#_*O>[@P'T\H2$UZHM> M"6K\%[V#`W(7O5+RBHM>.6VW%[T..ZCRX<-H$!"&^X?Q3NNO+>8QW`H7L*_B MK$AYD)+DX[_9U#LX=)\SJ`5MXK.G&-UH[HSG["7)0CADE!)9B$="MK`]R,1] MC@9KC$L@6O)\(^$:Q86S+C,U^W@GD(_[1VYK*J#".287N8^+AB;_F^O"_:.S M7=X%^"RYNSDU-U2U-^IE-VY8_A&*AS1P:()`RX5H&"24?;V#HWU72ZXI],8T M54_1ND,`3!(UMS7Y$*]*,[`_C'F#AM^!&3D:!@[<]6!4!@ZW3@>HY%4&#MS/ M8%@OV:BR?M8)#-#H#:(B$?#397T:PQV'Y0,3DTY,@$9O$!4)+PAM5@V58A.I MVY@_Q![ZU8^+*9P[BC2,9ZNIHP[^RC[>`0UW"&U6!*9.-3Y+]H]>"O-D#"3U MK$DETAQ0DG!YZ,*B%-J(#!>5\S=+U8PK>H!D2/A$M"1="YTM`X9S>_5ED<9A MSIV;X\EE^,;_E"F)QSN!=$BDLNG(O0J@I7@\]_3?^_%,=3A?M0'L3I/:V#R" M;X"R%6;G-@:?8U)'WG^T`NPDK%D;9$@8J\][%)%P7_VW<%[,E:RMM0/\)&Q5 M#4K$S`GF;BN`S"UW8:S'7;T=X"<1'J/+77/N"'T3LX MH6WJZJ81-8R(,@RP9OUI$!3S(N(A*^<,)A^$BW2Z+Q$K:8LG];JKJ'`D2F/K M)T#TM&UP6NIE5QJ((@[2;H="E4P=%@+M^'LA";#426 MG(2(7'!6-;YXN=_;Z5,P)((P$)#;+6`5'D) M[UF0S.+PWVQR%"=C&&W,<%JR6G*;44V%H=)6J9/99.R%JE[4PLODVN4/U3B*'8,H2/ M2K\J^XF@-4R>Q(.K3+38V0T!0\<48J&0TT/`8C\-$]T"3O7V(`X2US&4*<3P MA6.A8R'I8@>M4'V+LQ>X>TQ#-E%& MA#7P,[5SN+@#2(7$H4=!FYQK$21+YA-;1/=KO#ZFX>"ON1^C".@43^O+3GVR M2ZZ.92EYA9VZG+;;JFB(3>+:GS]-?)X_,X,NV744R..BL/8`T>G+GECD`@N! M'("E6[_3<\QU$L]@VYWSW40C5%G4')2:A!^]X0$5AS*&[ON M$-[)'HG[J2'-8ETQ`SV*D*S[--7+:"M2@\S#T4 M3QG[LP!97O#Z!1J'=:0'B(:$M='4H"Q#,XKH*P%"M4T9Z^/M?');*%2+-VVJ MUT#9"JNBQ+;Z&"]JSP5"(N6$BC(MHM7"@DSF:& MN[8H)"SI)@1J M`$*X,S:Q]<+=8^K'F1_PR8;+3Q M3G8)FCGT=LP-$`B'@S1CU9WNK[*LX%60;J=GR7R>Q`]Y$OPAX5;9%X2Z/[A= MUA0=H@W.O*WLZ$(94\'%ILG_JCV7RN#V:QU$",];+0N&?%A/@R`M>"1,=9[G MVLHFC\G*40;[TJKZ<5D-;M,V089P.BRC5CW5S.UTZ?//[_IW*9N'Q5RRA)5] M05!NP\N[+&===(@:6`@8VV(PT%D29TD43O@]?N4YGMU.;U]86OX&+YW%\TBG M[)G%6?C*>*B4BQ"AU>QNIU74WN;$%G^KCATR',G;W=MS]KZPG*HR'\M:0Y@R M"1-D*TDCKPP"@'3"B_IU5M_=(V$[%%&P3A8Z>3K10GWYJ>_N.?>&%DJ^25!S MVF/(I[)23IWWN69C$`0)7SKU&E-A&$,6%!Z(G=VS5Q87[(;IY%M#>H!(2)Q# M,;(0:F5@1E-GNH[R2Y),,GFV1U%SD`@)JX&4,#7'ZW`(5%2R9.D-@[+X[@*E MS-Z[WM+;W2=A0&A!JQ#)B#*+;(A$?T<&29!P?>FX5%=(>JK_[*)H5@;7LW(+ M>D@^)"=@=*,ER(&&;Z+1MU4(8C3%D,I,Y7=I,@VEV7T^6@%^&JZ'1B0V`-@* M'G*_'!>&MWBV*EVO/ORB?4`XM.Q`6NPJX(PB(&A9DO$TGIS#ER5*RB13"\`7 M;T%43$``I\&?19CR%XGRC2G+^.XE480.HX)L21B9%.2+-:8S;EN10Q2.:/5, MFALU!:1>:V@O$!$)M[56JJ'$92N\R/W'_X%%,.;L"XM!3A$'.YF'<O M;"$UV9%=:P`0&PE362MU,(%H*Q[)O68T1&5RF`!AD+"AM>(;06,K^(C0>;%Z M2KN6EW$2M`:!T+"AM3LC;@*Q5J#).;.5VTGE"URK#R/;CB+SPK`$P?OM>"MTWA2_K^H8F[RKZ(ZRH*H;J>/_IMJ\5O_0:"% MA!6OQ:;1DRQL162Y/UX(!*2A9Y)>("`2-C[3MUT%(&M15\XWI0L_C>$3FMVQ M].$91/G9S\*`/W^$49$SV2N^HB<(BH2USXQY+5"V8K$H'"Y^9SQ/&IN-*=VVD)_K;(L]R/^9.7OEJT&Q`$.T#C81>LMH*_-C\:6XSY682Y+2WB MB^H_3BHL^^_:6\ MUE>)`L^/$G1S<.+TN*Q@89TR=/[CC[LY.'%Z4$4EWR2H.6VW<3=ZN]ZU))Q& MVAX@.CU(&BT@#21NXVKD9'%72)9EY=1XQI'J2IR7BJG@3=85@#L]W6FP@M.H M!D:BP+"2V$D1\+JE?J3!Y$=;;^?3)Z<;8U?N&E!(%M-9S)<;'@!A*=N%GBG( M$O3P#C\Y?:3OQ!B*9T2Q+PNHGY,80&4XS]+V(!6G;_;&+&N@Z:TJKOTL-WJK MTS]5Q8M\>HQ)^P#6NK44Z(3?1)$MJ)>*&RN MY4//`O)UZ#^%49B'.KNLO",(RNE3>>OM5@>6K4@8"ORWH5XF'J>6MZX?60R1 MK3"5S?>K+1J?JV>Y1__-J>%Y-0NCHO.27M[AKK,D4:MI_6>9R>M=E2M*V!X` MD/`I4LI8O'`DF'X4@_6AVTJY&DRHC=:'>-G<,1FM#]V7SA5*7F&T/L0+Y@XK M6=2FCLJ,W,H^(!82OC+:"T\3T1@225U,IRS(5]Y`@)67K;AG01('<,"J*,HO MV81'`W(G@@(F\K[66.9*TWUT$#4)=QN%+H@5R!I^$I;X[6EM,Q.7!+#P=#4:Z%5^Q:B_,0.G**0N%[H,WAO4,:A2E[ M4S8]`8SHV4-'*/"79X`IS+-E*HZ.:M8<$.1*(MBQ-\7"()-X7=F>*MTDW*!4 M0#,XOBZ,9Z4QM*-&H>."E$D$TO6F6`KD)%Z"MJ=?9\]^/(,&YPMPT.@TRUB> M\=1E'SGA5LZ:IS!+P$3)&)Y>]-!8UF,Z6U++*"S!,X+<1'&LX]B"\8: M)QH$!$C+E-M=F7"8MM[`2#V)[(SD360C)_[PWD1H)(57RMCH301/$C^L%(JK MF)^SR,^RVVE97@UY+U'V`;&0M,/5.!.3K$!$YRVE0W1K#1GZQH(W!D&0,'\I MF!+3B\'YZQ6F<::@D3/>>`$K$(WA%:9QZ->KZ2'K!L*A;@WB[(DI5P,;T8-( M`^PJ=1_/X7#FI^G[-$F_^^E$MNX-1@$)DK#GJ%G6U`X5U!$]<#2PKXRB:[@U MC,R&(X$D21A@K"F-#MP1/5*(\"__;F'RK(>HG,:3SRQFTS#/EODB-F)8Y(G6 M^_@YX(2$V<:F"MJ1R8A>0)J;N^)I0]P!Y$+"V<_>-^X#U8C>(QHPR\(E)FR7 M'4`N)%)W66.[AFH\E5NZ/2AI/8S02+QO30TPB)UM^H12@#9`UV([Y`74%#U! M5"0LEM:T001OE`$OCS!(`7#&\<:SD69`"PP2][GZ'6FJI?56,`$2RT`IH_55 M@"+YZV6F81W_Y#X)B8@IX_>83WCZN$'1V_D]9H>$I5[!E/Y[S`YJIG?Q'M-S MD-F.^^P5ZL6(SIS.:TIOH64[3HW?J.2;!#6G;>G5PVZ*GT7XRFD\N6'?_XMG M[7S_RGC"4.Q\@G8`D$YMS&*A"\XE"@0D,S$MW/(5U-0;`1BG]E9].IJSMF2Y M=WJ,6+Y%H)2)&X(`G)H^=6B3S7Q$QNR'YR3-'UDZ/V=/^2/\FNJ,+VH/4G&? M:-7@?(]CL&2X=GMUVX2G/.`C/4`D)(R5$KXT":[CL66M[N6(HG4L66U%)*PF M4F'C)Y,ZB'&4`^?1$8K=<]4&<`_)(K(Q;ULF7?=\J0\N'ZV\G4\TRN]LL"&A M;&WBMJID.V7MJ_\6SHNYDK>U=EP`)+YD35+$Y(EF;ZN4M5OZPEB/OGH[+@`2 MGSIM^@2SMU6NVNZQ8_4)N%;EB&^VY,#RS-=Z0[!A>X^WZZUU2\$9ZLJ=5,UMNB54CY@\IK;E?/M$W>^O?/? M^7,HKQ/U.TC!AS\Z3-'ZX4=Q.ZV[!=^SB#MUE16C!7/7""OJ-+!W=.0LJ/DA M>&:3@E=-%WM,GW+29N6;=O;Y_:/-`L,IUVE5(+2UWP!!D;@VV:`;L13:%=5? MGC^;?AA'1R1N;I9Y1I1)+H6__(9B$`3Q..Z2*3&]&!PZ?D/;,EX?'=/P_MK& MHMY`3Q\=DXBB;C"B8_0NY^[63<0>.\VR8EX*@1O(6`"WZ'\F<)GFP5OOBI3Y6_AUH(I$;+0MI;.LTJ:"M.35 MEG,W8L?>BA8E=A]F?URFC"V+*VY3[46_#5R1L+8-2.EQ,5J+2:>A\T]J@3V9 M[!+<7V]'I>R]_"C00\,$U+^6]R@_:RES::BW[8_@>?@:3E@\<7&2J?^V=W1" MPU(VG"T=%Z,MK],!/=HZ22)-]M7V9)?JJVWYM]EID3\G:?AO-OD&2I&65-^6 M^EH2_OG]XHVE09BQNS0,6&E:Z?J4V^V'0:0DK$PV%*/=^ZX-^=%Y].TW;OSH M9!#6)AN4KBL3*@PZ+[I]A:(?G3@/U!1*ODE0<]IC>)>UK.+*X$[KOP94D(B9 MV?ZNT;M0Q_`4W4$X3=%HQ+E:_S6@@K#1SH*665=JN21)Y@]I3ODVQATH5%T` M*`V?N+XX7%<9/7%8>NGO8L_2)O_Q>V)*_JH+H"5L_MP6^1OBL.0KL!WRH;WQ MVJ]U\HX_$38);DT!-@5BZ5F>JCV[I5S;^Y%T_4%@A83+WR#/[4JYCB/-C$WY M)-]9NI#4/)09D?O\62"'A,-DGZJW#647275,Q6"M2NO;RXL+U=_X62")Q%/` MP%5?*%5;C_6C4_V;@A\`;Z>W19[E?CPI:P.7K\#;6@7X#(`Z&L\=PUX0*@%; MJPY`X^#?PY9Y-3V`7\&;MG_,8%_\S+:O-7T,*/N'_0KFKE MN)\A$$_8N;?WE46%`%OIP,A\E;8FV+4NG]DLC+F4/_L1+W]C[E7I9IJ@!#0> MYD:^"G58L)7:CV]E$RG!90/+ZGT.U_A%I)W5;BPP&Y4^_^Y4[]X35[O%'"B9`[-:TD6,=N MZR79I+N=D[2AJ'X4?^ACMV6:>F)/[?I\C-=Y&I/K\['[2D]"R2M]N$GK6<2U>)NF4A3G#45%C1&SC=RC7 M%]$_6<8?^^+)*E58PO]JFWNT[A2`O+].():E.7X'\U8?/=DC^'9.*[(9>,=N MB^P-8R$8"=.6,_E@+'2H15]H^^EK/=B;!=!(XJW=\9JP+=#1N7IW$=Y2/LZ7 MA=%$O).]OZX*OWG@`P2_NH"#;%MH%$)80PQ/?=P-()S#VS"Y8%!78-BUER+=4LFC3%$U@@W[VN-:"YY1Q`IB3"!=M\F'6QCJ'#_<2"37\2> MD(O831*_EG>Q94*1RB_=./%%YU\$2DCXINHHCN0;UI=@+$6=#,9%@WP0U0F- M:A0=U;4/H5@*7*D+]$L13GCBKZ'NLO_<[A8K^CG@AH0GA+O]%9?*V.)3;'R$ MUA^^79P/Y#.``SR-BB`$#@Q:DNH:OS)&)7=^Z`5J2-S)"2BQ4#*VHE4(N0[8 MD-7&XUAY%#N'9;FJ#+X-559.@G-(PI>&@';K"LM63,HX+WJ=]7Y[,^%\DGC6 MHW)#U)68M6B4T=T?7>[ZFC/@'-)]T=SB-5-74K9B3,:D[>B]AL2QQWA2G&D2 MK[$$CD%MA6)?'`:X,08S?'$CL=-\>>,WSOTGT:K=&Q3B(*A(Y+8V\INW>= MO@RBDF\2U)SV&-S['D#4Y?%AH;'EYU+A1HSV\8[WZ#Z+H:M/$]:(W/5*9$KG MX&9C$`2)%R,%4](O9`/.&#SQ[M+P%40"Q]R@E(O22U?<`01"Z-S4F1^/+F( MV"N+K_WYT\1?PD-)-QP!I$'"4-J%^E:0;7G[4#PJ*'<$K`N(AH3=S,9&(,=( M(Q\KL@%4")=:6^FP?,'C/0`N"0M9YP6N@FC+EV,+C-[FSRPU(;36`<"2\*VW MS&<#X:@28B[M%POI)/.7)"XM_9J&-U$_[YA&-KV.QC<*?G]@UXR@N< ML#W(@Y8=#B=-S+8$E:UG9PJW,]V;V'*?VR=A?9.0([UBU5'T5ZG-4G8$\"2,:MH4FL"RE4#._0VIKZP%Q_LDC&CMOL`ZV&RE/6NY M.2/K>:FLI_&DG'0]0RCW;*H*X&&+6J\WX"=A$M-A2;#$34`B)-.PA:WCSQ8" MJ,.Y>'L)TW<.2GJ7TAP#1$+"'M:2=W.HB,O)(<"86VELVQ*1K3W5\Q'`B5 MA`7-7'^ZHT94R=BF1O3`4%M$IDI3ZPJB(F&/LZP@#82(,E@PQY%U)C[XRYFX MYKMZ\(G4ZNWB3'Q`POIB@Q"#%5W#3L>9F)1#S0$)\XV*O!8.-0>H16=8V56W MZE!S0,(2I.2UJT/-`6H9VI8CM-83F\GKVM+H=4#"FF-&A?)AK0[.DDOS`-Z\ M#T@8;RQ3V81HR9>9_)/W`0F;C&4Z&P@M.2^3M<38L+@?T+6N*,]<.MC&X,?< MJ_7D8!#6DP.S9Y<&0DLNRV0R,W$[2O7F<%ZD@+)*TU.E7SOCD>II!E#YO9;_ M.0]A)3VP`)KFH3Q77J>!O>-#$C?[]MID`S^)9(V*I[[RU6(=H^I]3]`%\-*] MLDOYUD/6V:>94-[-7C\BAR3NZGU^1`YQ!XZ6^?V<9?2`K2M+HG#BEU4U%AYH ML*,]\TPHV55<[H%K9_%S-@V#,'=ACJ]-L#DO#:N[5G]O?T.!70!4&=37&\*4 M25A7#.2+?7&;L$9A'^_%1WG_D(0A1D2:@EX9Q.)F$%X,X/)SRH]27,_4A) MKK0?B(>$2<68:`U48\CU<1H$Q;PHG_A+BS&74,J>69R%K^PJAF,R4RN`[A@@ M-A+19>;*8(9P1*;V>^Y\%+/)A9_&T1@443.0`PF#I"&?#01V*^BXIU)PB+AA^>WTT7_3,.5I]`:QT;**:1&O M#8Q&D@T[N@`(*ZC7\OJ?:^U`#"3L7]J,B0D78**1;<,.M=B%X3))63B+SPI` M$P?OCZD?9R`I3ET\*?]?5!$Y^5>1Y7SY+(5ZEZ3E/^1Y&CX5.3_J/"9W)542 MU=GJ/(!&$L:[CJKI0&9CRDPBD7Z[+QN(B(39L*-:*1':2D[2B^LEXA52^B[6 M/!<7L:%3F*[X0;W]8-[^,0EK0DLUZ`K<5E*3;6I'=9RWI1Z*T4!,),P1/>B' M%G(:^5)Z=>XKU\D]`R&&0>FYP7-V\P(U9?EV"0WS90?I1*"[RM###N8_IE2TOI*5N*^^.NT';[,OX=^%J0 M,!#UN*VUE`F-K#7C=H_?/QZ#]VE!X3Q(E"7'WPGOU9A%F8@WC2 MUS!@E2#O69#,XG(4507(OG\:R!J#46L[8K*5KJ>72ZJ."!;N[R#?M'R\\*-5 MA.;M]"J>%%5]&.SF:O$G0*`DK%YZ[SC]H.\OX4]_-H]%ZI3'Y!K6"BS6>'8Z M2UD)"MO*N@P'@B+A:F>@)IV0(BHQ2$MY9Y>-8Q)7R>XN&\?HK7#7O$2V(+)H M(!X;)R3,35T\-DY0H]'NN(L^/\(/%`#WKVQMJ\/HT:==9ZLO>&:3(H)YE_/[ M+"EYGBT2;WS>K'FNC$6S]1L@*!*>6C;H1O8(NZ(:0V@9WZU6L8#/69Y+2M@8 MP)&P#HE$+KAZ23!8"F;K\BBC9NDR*5(CIM8[`%(2-A5SMD0X2&1JLV0_+C\* M\"N*[^%:.Y`"#=/'-CZ(`N26`L[9YI#/QTT27\Q?HN2=L?).?UO.3Y'-5=K).]JA8:GIC4C!QTA#(F[# MZ+"GDTKYK^()>^,/4Z65>_EJH7%:U>D.2XI&W.TV#K'Z`K$5YD=:?93' M5;T!0&(D#,CZ[+;3CCI:6[&";C-F-<]3RB\0V@?D0L(\;,*B6`\4$&W%RMD] M9L)7L_)<.9TQ/,,=UA20D;#P]OH5D(-W7)I;CU9TQ\8;`SJG%F*YU-4,U5$X M+JR-7?#]:D(?#K9G2?J2I+[./5^C+V!W>KQ7L2*ZK&O#LA4U9I?2\S!.,K]( M/^9_'05R)B5=`*E30W$+`I5H;(5F63@`92SX=9:\_C9A877V@3]L'GG@K[QK M-O.CBSCG67'%GT=!*T!+PKK:ZY<1Q>VX6'8;EBL(Z(=RLXEWM.O4EHJ*OLE0 M<]JV`H;L;IY53:>K^)5ET$6^:XK:`C:G]DZQK`6;)#YY6[$U;G/MBC+R*TQ. M:!^0RX]C9U)(P5:4"CWM4%J4)+U`-B3,2`KR#!BOX[(52F+Y<:I>O#1(U'&E237JBP>[9(P]70FK0G*5@A'C]29UHRL%U0\ MVB7AZM>9N`8F6Q$;?9K>M/9(21=`2N*-M@U[2E@(@8Z-./]51.\U%\:;,&9: M+*KZ`682?G]MJ-3#AO"YY;P[6-PKEH9*BUR]WB`&$E:?-A2;($2('E;F\7M^ M85/<2U=MO*,]&KYSV[B';J!&V-Z6N<@BVVI'J8]6W@F-A-0;9$@8J\\;B5L9 MEB7IJ_\6SHNYDK6U=H"?Q$6E08F8.<'<$>X&F2O\:QCK45AO!V(@<671I;`Y M=X1"&AE`3N=E3+G,UZ/6!`"1L*_U[^/1`(VPZ-BFLYBFW*=CK9%WXC8%L5BZ M.`/U62,<.#;.+"8JOS.L-0(T3E^G,/GB+-3GC;`PK/)Q_=1U/3DB<>7;RL5` M0Q*(I@PKO,].3=B38QH?3C5I8K8EJ!"6'8?,5;7?%V8+^=XL:`K(2%SX)&(7 M;-8H$(2B8=EH5+8Y83O`3^(&J$VD!`7"XK!L+S73XL*COC10JCZ[>"^0S8_C M%:*4`Y("8UBVGE4ZS86W'X\%)G"*5'!I1OP8.87];MC5+WP86P9BS+RQFJ1^=QI/3 MR3R,0Y[>,0]?V<4;7U),70O>:!PN0!+;B`[-R,>C!5Y$889E!KP'HD#(SP#Y MG+VR*'DIC2,57IU4&JK>7%@DSACME4,?):(2P[+W/89Y5.7Q#U_#20'+07Z^ M$+;G`B%A0-K*T4(F`D0G7`3Y6=2)W\/\N4PJS&-1G\.7QT01,]9R)!#B(0E? M(QG%FDJAA111%\<)N+ZF_TB"9S_.\/1*PG8<%(F\6^W($)B8$80(;0,T3%VW)"TDQ.RR+:&MIW!1\E2Z8RDZ+_#E)PW^K M"WK8_"WO:(_$)FA-I2QKK%QNB/X.T@.PM8@6*1QOBSS+??B(Q;-*:'VH,?9; M0`>-AR:B:BR7&Z+&6_:"I+4;O_IAQ+^#ETGZA3_V;F%3WOQ)((>$99.J4FN) M#]'M819T:RNI>A6MJ[BJA]>'0HM^!V@@88&EJL6XS!#5I5`S0US*5?]#],C2 M.791MS$V")".ZX!]I;,L)T31AEGJ(RH'9Q.QZ!>F<61@L([+[EOZ.1`D:C@%AHV(1ZW(3:2`11E"V'GUL\DFELPD_( M)OQ/EN4?W_V5L]&.ZG36PT]Z1_LDGC.V<5#K37R(;AN_D9#1[0[6AO(6EBTE M]25-LEZ,\/BO`25_&3<[2`Y1YD&68K$KI-\9#^=@DU.`YL]8^8_G\!E<;0=; M4W3E3(#*OTRC/4D5*9%G_'XUA@52LRU?Q7D:QED8]+T4T-\$>FC$]-%6>H7\ M$/7^(9^WJF/?:3SA5QI>D^HQX7]5D^#I;):R&6P26U/_UG,">FEXP-%>'AWE MBRR?X3ZK=;XUR42Y\^!&W6/9_,[8Q25"`'^;ICI#` MD14WR,>^59DJEKZ&`1,S>9.4V>E956$Q>TQR/ZK_^UF2Y3=)_M\LOV=!,HNY MZTJ][J9D,6WE]X&V'^%Q<(NR1):`\:/AJ)?`PG:7I(N_XNUD'Y;M3@2('//C MI4NA(JMCD"^=PN2Q%V\L#<*,W:4@TM4_9HM_-2[MH1@.A/HCO(*V%PVB;\9O MHG6Y?BG"B1\'C)3>K7RQ/BK"^5'$)I_?NZJ@_L@@\C&_MUJ5$J*8@WR#O4N3 M@+%)=@E,<#\JOC@^%J1$W^0=O:.#'^$]5$<(B+8XCOQ:SG&Y$XM<&L4-`=68 M'P9EH!$J!Q8-QJ\]E<$3JE5'OLJ5\H9]+_])GBI29P"0V`]A)C40AEA] MCHQ?O"9L&E8G<]?'&2GZ,W[]2#.8YNVT^G,>/D7LXRO;5L>4`X.X?P@+H@4A M(3II_$Q%7B?+MP6E4&Y8?CL]G?RKR/(RS--<1=O]#I#Q(]CR>I`9HL#&#T4] M./HW3A'?8ICDSZ!'_->_D^$LVEX"[R-0(FQ1UX_K$?0H]DZ!&] M&%$TD/%^Q"7SX\8C+-`C>C$L(WQ_3DVKD:I.94'QQV<_=NFTII@3)_9'B#AP M+6#QRCD>9,2-Z"$_J\*,@-;?G\/@>?/Q?F$6XFEN#/TH]`<&21.IH;Q]/PIC M*2'ZN*VR'5BV@R!(BW6QG15I*C&MX#TXT#%_L/7@(SP/JTA'UXOZ99).69@7 M/%]1_P85P:_QC+9CUL7^18?HL?X#PDFEQW$9]32QG*1E,@FKF2U\#Y*\>FB[ M9UD!^OWAEJ1T^6DQ%)?0F(]P'>6":(Z%P`*0])J#*\#X8T'"?VS^_1H'["TO M*^`ND398X)#3)/LU2.;5CY>W];5*3.X2Q"L#U/QT97-;F!*2PTZ>L M#'!2&5[0CD#;1D'P+DM3_%N/R$%4U87/C89GE8X(!?UMPL)**>$/F[H(?^5=PY8>7929YI&R&H)6'*U3/R5-.M8YQ(&(:7-QS-.E M[4)>W&*S"C*T6EGZ MP)"R%(XOSE6"=SCU+![6JWO_LFXS>MJ4=^.(G3HFZ+,B.C)J@4-R18W%+B<) ML+GP5X:B15M[(4[-L;FXG3H5M-4EVQ)``AD&99"A$,*Y\^G8J;6W%WW2`XT\ MP[G]!`GQ5'?TZLJ.?824'3EJIV%/G3Y#NO`0.P6)+,02#&7:Q?(#>\\"%K[B MIBVC0;A0G%I,^^(R>5B(*MIH]^7R M&J2-R!0AHA%#&45[%69X67/E!ZT$(A;16'-*#RV;05ATY+H3S+N%(6WPT M_@=W[';_3KSF#!!/[ED>5I%@?)U%208?3HU'8X-1O./#`U3 MSRR&/^2VK-7+*6LR^3/D:/A6K4(N% M*W+][S^_W[$T`$E]]7..'GG(MC$L"(Q&H+$YRX)3G!5AN'T\MZ\]Z*.ZG8%! M:.Y/?%:(MZM0=>F0?.Y_A']EBSF+`'UE2/UK@]X`W_V!T!*)`O4P$8(E3X%> M+`"/WY/VBJ#1USL^_TQV?Z6N(T9-0?I$8CQ6'7XTD+ MU&-P#4#6W%?_+9P7\],X+GA,W<<_9K".EFMHL:34*M1E=!`UB5`,`[V0*E9W M65AR)R"T16W*A`=N?H1LFNO7>G^0&HEXB[XT2(26A'="KSJR6!II>0!85FI9 M_GO;C4EC4)`OB9""OK1)6P24'2`4)\G%H7%SMT5TIN.(("T2&59;*XP5_/TY M36S10L_SWH551LW3N`0+"X3%0<@R$G9[='*&EGO]<;R]#=^03FY+^"]+(\!4 M_6"2)%9@"\F*'):TT/XH<6%[QTZ?4@P86:<2Q3+^R+`]MUXHJ.2;!#6G;5W&1;]+0[SK*P/?>C_+T*@9(984S&@$V0--V;K`DX M-X=+.LIH<_)W+.7(,+*1Y@"4M#5&@UX#J/DJH&XER M:#1BA1`6K\.`)W8_G:6L=,6^2Y-)$>1W11H\^QG/L_C?S$]O8W0?UAX`A.'> M\Z\;SX98;84$]6"JT$/R^#WI1CL,X.U_4S_._(`CX)56 MO_KI'XN\4[?3Q6KXPE-3X;FZ+/^,M^^VHIX-`U`?$D%4;:OET^WL/671J],L M8WD&<@G0DCW2]B"4`=\F-:`A?&_5VJA;&1;&F!&';7F?#PJM\9!#;@&ZHI3D0QMAQ6 MC+[]Q2'/O_1:YLGSXUGX%+%J2ZQ#6Y2&K;$*S2KO2\O+-;].850AS0'H M@.^2:F0(A30,AX*95W'B#W[DI^\&5-:[`?"A/_QJ(42HI6$@%"#@,6`I*Z>; MOG].XF(90>G/T`W6HH=Y\$!#*@*_#;?$B2C#(K-TEZC*+*K`6X5NWM#V(9\M1(0Q;L'J12N7SX^3P.=Y(R-'E&]I;#I]CM^DJ.DA6\/740TLR M2_[ZU&^?HG!6""DQ M(;*.C&2>^/*^E0 M[OWC]:Q,U0IG5/R[H>P#8B&1"KD5FV+%4&"E6 M::FUA1]]'*FDA@)!>Q#'0-)XE+QAMBL4&8G,Y3WR?5ZPJ_B&O>6/WUGT6CW% MR8Z-^H.`_`;BQ&>J&1*X-.J]]ZTO57QMZ7X:IA/NCMI*8YK#@!`'XD'82F

;/@/XRG.;/K;6F.0P(D;11L*/68(!I9)CJ5VM.ISG/EM9> M7]8'\$Z&DM"FA::(H/:7OVJK[V\Q]]!,%U$S9S#I,+\/LS_<%]+@L^`L?H,9 MIC`9X))E&H]NTG[>[N&.Q1L?(CS%$YNL%TR01)TU#2D*;WEJ;'1*8G3:4S]P M)=CHUNGY*S(\F3.4JD'3:T-X*%@A3/]4B,XW#ZK*2A1.,.L MM0(X!`Q=#?E*2*C/V]+35H_+0^[@LMX*,!$P'PG$+&&C/G-+;U$]LO%9CX[/ M2U1'!(PT9GRL3=W2FU&/A)SI$7*V0D7`!\R,D+6IVWJ5Z9&1P"'AD MF3&R-G5;+QY],((=5J[5#A*JG@!^B'83(W2VGB5HV4T^L@3L".C7Z0;2H1#( MIT>BIKFD`8]TO8QE'9[*T6NQ+:&K6=P:8%)P<&K#HA*5K9H7M96[Q5>BC4II M[M^&-B:D\RR$=?'V=P^=&0TWZM8AST:RYC!]BB7X-L2+&`A1/&-X(WH`#LJ\ M.*7?Z^WT(4\"U>,0V@?$0B+N#J<,H5@.:!3O0#5DZI>?1F,0A%,3B293R*D% M@>,V/JN?S?F]=>GC_3VG1I?6:U<&9PS17G8K'N_O.;7D:+&F370=TQ@BMNS4 M.][?(^&;H^!+B^0Z(CH151D+?ITEK[]-6%AQ"W_8I!3^RKMF,S^ZB/,P?T?V M9$$K`$LB>$YW'T8AT*DVK\M7A0#=7#>;`$RG]AQ4\DV"FM-V&[^$Q:;[\Z>) M?Q6_L@RZ9-=1H(A31]H#1*2Y%^X!<2!B(<,ZD'&.`;+URV=UFEY.^ M9X$?1?(M5M06L)$P\RB$+]AO<31CBJ7AQ=!REL[/V9..04#4'(1"P]YCN.?B M6&P]3#G=WJX<&`!8'";I39)+,C2A;4$. M)&P[,I:06[\8BJU:[#0>6!X"%OMIF.@^KM3;@SQ(VG2T'U::8&S56G=+[@+6 MMSA[84$X#=E$;9O%^H!<:%A^<-(0EN6(;!59)\'T99+"V3'3L,T*.X!$2,1, M*2B3\RR"9*NF.B7[^[7$WT_5!:1"(C2JXW/:!AY;9=1=&RX"QB;9)0CK*LL* M/P[8[90'Y2=Q^48L-V#(^WH[GTC:[S>(1*T96NALE58GHP:+&JU/,MD>Z-Q'9*I5NUW)U&@1I42;N8R#FG.LHFSPF*P,Z9L52]>.@*6[74AI- MD-DJ1^[V\\P+M6<51-DGN=:,PZ?X>*"U/@5`;)49M[LLMU@+A\8S@?$R-41H MJS:X&T?L133]/0N261SR09UDYFG,0B+Z/DNY,B-JN)U.:AHU:2;M[AP2?GUEYEE,1:0Y@R M"=.]6JP*.V\-#9WHB'[]]0X/:)CF!12LDX5.GDY\0U^>>H<'3FTRJ.2;!#6G M/8HHA:5R:IE4&XU!$#2,+,HUIL(PAH"$&Y;SC\-=FKR&<`#Y_/XMXP:(54G? M4[C9O(::>3#-!P-!TC#5(!2+%:(M3DMA#13%]/%SP`D)0Y-= MM>M/4I:"/2AH[SF#.0=AE52;O42LI#R>G,Z3-`__K2J2HM,=9$;"@;8_?1#K MG[YL"*0TLZ--BW>U#]SZFJ3J"I(BX:.[;2W2DPN!'&RV[DY)\,=M">0N\N.+ M-VY%E9N61!V\PT,2/K_;UA:9-&@4Z\&2%8%D0`P+R_%5/"D")GM$P]H#5!*V MQ6T1KR$,&N5V$-[YTWT,C=\OPRG(*6/I*[MC:9A,SI[]=(96;%#U`^@D#)5; MU0,]H8PI^*?^)>2OR[$/\HUG9TF6RR[=LFX@)!(N;=O^=*AE0B/;G<63ZF+? MK`2J/FJ@?4`\)"RV3LZFN$`Z!RF=5/H2LQE_Q76J+U_\,.;RNXW/P^PER<)J MF52E="4Z(^T'8B)AW-VVWF@(I7,T%"'=X1$$X2P^*V#6TS"\=HI:" M^!:GS(_"?TL]_4R&`2&2,"1O6[/,9=0Y,HN0HH%0`5S&SEGUW[H8R[6E85_6 M'@/$]T.:]0P%9"L>C,*AJ0F]65?&2+6:W4%H),Q\ABSKJ@H&N'-`&>E=:'DO MA15FI!ZU?MZAVRH9/>M%`VGGV#/2"G&7LA<_G)POD"QN#:?QI+Q1*`_5[08$ MP9(P#?:D0OHBZ!S01EJW>$*&1Y;./[;8K#H.FIUZ\&%`B"1,BSWID0IXYU@Y MTMJS$N%UZ#^%D:Y7AME`(,@?TL381DJCB.7##X)W_CM?8OQ1MXIMK`FBU5%: M-B!(E(2=LHT>F)ZPU7*P%5W80U$FP:XE5J!TMQ M%I+!0)PDK-E6XBR4.!&U&:11&C[6BQO,:?!G$:8,I`&K)'_G#G`Y?-\OX&]? M$%\R\T%`@"0,U&VI%RN2*7Y$@09IKVY@OP(VXUG(;P\J2Z2RKW=X3,)NW;.Z MB&$C6C)((W8]?=2#'[';::M]1G\4$"$)<[5ES3$5`!(0O-5BUML^X=@Y7&L. M#&(F8[>5P[42)Z(V@_2O[C=[ MZ.$QB3M76Z+57S@);$1+C*W/=9E]*<()_SE:VE+ENU\^*QKD'94-`4*D;!*R MJCL8>D2%C"W3[H]&R_N$00@'U@5$0^+APK)B2-$BBC!(9^GZ$E@$M%V\L30( M,^F#J*P;"(G$PT1_>X48,:(6YL9AY_O#/7M9+8!J-U1\1L0=0"R4;7P&&YC+B">WQC^PXU6KW[$%Z&A\G4=&D1-PDQH=K>V@QI1,..T%Q1N MVF+L5?3VIA^"1)U,A@$ADK#\F:F..4(D#:&Y"=GY/L1!*\@'R`.TM7W,'"'+ MV.CZ4BH$S"+-!T`9";?,5I3A:3Z-#9X591>QVV-FZ0Y8BL&/EFFAK^)IDLZU ML\#KC0#"(V&I,*/="!RB&<-*YULYPS_Z;RR[\T-9A/9&2Y`!";N#$65BUH7( M$':W[!F+N%#?,T`5!F7V_R3XHUY=YC%Y8'D>L:4WZ#OF.6TR!HB$A$&Z`]DM M,2-J,,BLO3KQ!&4\GU5U32E@"B:L9-L#_%!'W6&OB3)A!?9NDEB-G^)DG?&'ECZ&@8L MJR4_N?3#]*N?_L'R?_I1P6ZG58K([`M_-1`FG>GC9[RC3R0LI5T_D;V(!=&V MSDF`MUIR:0XC/K,X"U]9+?F]@T)+W#*4OVOKM[6Y<:%]$=2Q<.(ERU MG`C,3V/8__A,RCGHB`[IXNT>.BC"%\!HBPT>)G67)C'\L4J#ZD0#;]AW;#K< M>EE:O;/5-ZEL$\9!"!N3G@]>Y]&]W1,71=DX3^DBR>09;&IA?A]F?Y0E9ISP MQ'^=R^P;S"S-_3#6](*4]O-V=O>*K$`P_^J@KKT&(E?&]G8U0ABZO"&I6,'N!27>8,HGSH47Y"]X$C(0Q!NO" M2C8/*M6M`*$#N-+NFZ0:.0+-WM+6S+NOQ5 M"-!]=[,)P'0:W(%*ODE0<]J6+N4]>-Y\9E$4).B6V&@#>)R&8XCE*SK`-B9M MJ/&$?ILN`A84N[>H.4ACT,8A-;;.5:@),AN1"-VCN6D[UG@1Y' M,D_IF2]2>FJ#-2\[S8I5$IJ?/I6(IO%,Z15CTO=FE40Y*R9NIY ML8O7.QJ8(=F.XP6-D$L%7T:.%Y*XR6'Y/^+;G ME5S&%W(S!IFY!6&420.7ZH6/;Y_:/-HOSB*=RG)_HY]#K^!@B* MA/>&#IW(5FY7%&.P>-]SP(KS^JH-P":1;=$RCV)EV4`]!E-V"4EYA*NU`N@D MKF0;7$@(J\_;DIG9*65?_;=P7LR5I*VU`_@DKE0-1L3$">9NR0SLEKHPUJ.N MW@[@D[@JZ5+7G#L=VV_7$DL?*=KX+W'YR[^3DEX@&A)WH*U\.95RL)_CCHR* M*.U@TGX@'A(.`DH&C8BO8[-D]G;L7!G!F+,O+&:I'YW&D]/)'/;!K,SY^X.H2+@(M%8,;8QCL*<_ACG_^E[%D_`UG!2P$.1G"F%[$`<)QX&MG"8D$AB% M_;V![_4P4S@DM1P(9DK#G20C6U`@=G(ZS'"`.#U_3?R2\ MXGSVA]SI8;,=8")AB6M%A<`_0HS/5IH""K%UU6:G=HY8:P=B(&%_V\I&+T`^ MCMP%K47V(9%XR2,XQMWLD MK-$-1G1\ELJY_[@^2WM[)(S1NM0UYSX&GR7RM[&]D9FR)=]A6^(:=#'0LP3: MQZ4,EM7MN,EL6<+N=GKF9\^74?(]NRN9>V9Y&#@*+5G.JC8IG4N:I)MWLO%& M[P*.\IZUUA"F3.(3K!8KLNH$:.C<=_I-)7%"XSU81,$Z6>CDZ5Q6^LH9<>+V M,1>5?).@YK3'<"_I6G;\A,8CJ'J-J3",X::R.#7!,:(T^EYE6>''`3M+LER: M-U[2#81#XT$3H4U,LAJ1I=M-TXMFBX?)1=V:K$L8,N*#M1Q::F8R,EKLPD`<7IBQD0K(*`Q M:[?G+;GXT3-5LQ&`<9]POB%JN04R/U1UQH!&/=E#07BQ4FHS]OM M84A>::,J-X%'$J%M`9K3LZH!)?CT1V&5[:6.Z-Z^^USNRL^.`90Q!(3:J1:Z MMT_#74[-F9AL":HQA'ZV*Q:ZMT_"$4W"C9A,`0JW(9G(U_(^G#WGMU/X_3"> MR3^6@J;>W@$)'R%M>N1`+$5)=HN94=QR908X<4/`YKZVG]Y-"YE[#\&*6WW, MF\.(SRS.PE=6A?I>)UDGY)`[#8)B7D3< M+^0V?V8IHKHZSW6F0X$0W5O/39=J-[#V#5U;/']P/'(>74XK8PGJ0!)W#%3DSZ2&-]_P>2&]E:CW$ M*V(.2ELLF5H/AV!J/30UM1ZBIM9A'0Y;FEH/"=V9TE<<#2V(4MY#:=^7'X[W(Z'X%> MU=SJ4[V=7H:Q'P>A'WW$@&D83JR,[YTL4\%LD:_ZS&&R-WY>I+`5W+ZPM$J/ M^!==&%UM'*L)R.<\S((HR8!FOD-\AFG^T9>H!#_EN?4'MZ\!XD]=+V*S9$-S M&B+Q4,SG?OI^.WT(9W$X#0/XO)T&05+`V2">W8&<`C@3N-ATFK/0V$GP3MZ1 MN^1',M'J+'J]`;QC$G=5[DYM MU0P]+4I*M&RE*=B<,5B]5CD1^ M/!\/KX<7??S+\\IW'B%EB.!/1[WCDR,'8I=X""\^'7V=775^.G+^\N<__N'C MGSH=YS/$D((`>L[#QAF"`,PH<+^Q)+[3.^X=GSO\Q^F/G1M`.Z@' MGXY^#8&/Y@AZ1P[W$[,/(JJ!+1DX$^[I[)C0!0]RTNO^_>9Z*E$F5GV$OV5" M/S]0/PE_UA6O'P"#27#QU@NV$=*!S[O1RVU07V/W[]?<<-HHT@1&F`4`NSL0 M!="QB[V+BXNN?)L$#5EG`E$1`^!&RH#Q* M]*XD$@;(9>5QY"L1I9>-PI!;'H&_*`G."0@V:\A*J9%O2F"Q8$T5B?`W):EX M<$VA*^J]LGQ==`%U*?$A1^`&'?B\]@$&`:&;*_[W-D,(QN&JW(@7T*Y`W.6! M.CP4I,C=QJN.%$?@+8CC?`08$]ZT\"9)_BV>K-<(STG\)W\@RO<'`7C&HSOB MQ]?[L;)ED)X-B1N*%J:/O1$.4+`9)2?3T3V[*B6PY*6,?NWD+?_Q#WGS(H#?!?Y:_.7^,6Y-Q1:,1QX^#Z./N M$JD;TP6^&_K*1.-HW0P5*9--.!H0S(B//%%8+X$O&KSI$L*`102I7^O9.>64 M3'GVP9B>P>1V.KD>#_NST="Y[%_W;P*L>+&&`.*H* MGK)A]:2=F9/FO,L8_JXET8#$;=ZRR7RR%@-##H3Q!FM`5CQ#EA`S]`BO"2NI M?#7BZDE^KR-Y.N/_W8QN.<&3*V=R-[KOS\8\@-._'?*0-W?WHR^CV^GX;R/G M>C)MJVXMUB?SP1+@!61C/`V(^VU)?(_/`T:_AKRSXB-PY*)`0[Q1=#WWYT;< M"^H'7_JWGT=39WS+GT\&/W^97`]']]-__[>SB_]P1O_Y=3S[A_-N.+H:#\:S MMO+7K?P#P)97/GFJJ.>[8'I:?S"OTH/^](MS=3WYI:V[&M(\WII"KY*6\GZX M460]P3\6"1[R9G@T-*.Z[:P-J9_0!<#H-YDF[UIO01!2F.YO(Y*K@^GI_$G, M5Q!S?<)X1/Y'VJ`#^`0F,NF0N;,SVK*F8&T:KE:`;B;S*5I@Q/M!P">4KM1, M$%[<\5KH(AA39QA6S]]%GK_8JN`K9=?9&782RRV)"A+'^)'[2>@FXFGWIY:* MWDF>BFW$-J=5JLPVN\8X@!2M[N&:4%%*8TU&_5[/12_/18X8:) M#+?\*?DCO-,.-D+4Y).SM1BTW<(@H:S\I9ZELR)+D1G)SM;0]PXWU?*B&B=` MC`B=0I=GH7=+@NV8H/A9Z`./JVT6HS7SG,XC_A##PG&9]^H,_T'XH]NHCJR+AMAJL:'2'5W?D`L^F2 M3\+%JK9W!S92#>!]P"^`4CY52%HBP\!ZHGXL-$_"K"/M?N](RYU+8=I);,M> M)+'>4JFC,J.ZIEC+/M<35)C_IRW$$JNTTU*AH.)G49BCW(]^ZC.\,&%_?])[ M]^T[627:/%;JH*L5"I*V9T"DD`'Q3DO1!=#R<5J8M:=,R;8H8ZQE2*U4N]S1 M2!^\2^;;5HQ6L].X5Y?,:0$+DB4XZPU9*C5"4?&/PUY+Z.A"*U MU1]S3_54%&;GN_A.9*#-_[U4X2;JL)E*?%J8LR);_:M9K]^)V! M![\>NW$,/;=%!B8*.D1:0FU9.)"6FAGSU8JB9>^LH%K4TU5;?O=0G-*<5@?3\UBB;^S4 MIWY>?6IIVWO7W!`&`/EL!I^#,-DH63>2GM*"3F*TH\YY%R?BQ*FT'.\WVRXC MNE%,/=M*9<5D]MU2?E#*Q;E>+_1YU96['[ASD(V>73_TH'=%R6J(_#!`C_`. M4ME#BN,J891[,1-UBLD!4M,7K;V$G02=5/BV^)P$H",0.@E$AV.,!@U."N5W MVP+:%LQ*?2A3@`I/]43K%**6@0-(1!ERZD30\[:/2-3RVDPEVK6ZB@`YKO_GM*4;I$U`=M6MW'9*!ORF075\UP0K;0\MX.ZQGM@2\?L5:'TW!7/QY3L MCVU):ZH'9UI;Q3LM0>\+2E91$6[;0W-).#<.+3S7DU&0H[*B<$M$;2)Z*B9Z M%5049*12*IQ>2X8Y&9F.1?U:3TQ!\2DGINU)#K."DE5FZL71$UG45VJNH;3- MX4$I[C7AN*H9+6@K#4EN&]I#T7S:A.;3"IH+4DQ3FD];F@]#\UD3FL\J:-[S M.-&.YK.6YL/0_+X)S>\K:"X_E-2`YOA^;P)S><5-!>UF88TG[DLZ$6JTZ,MP#*>S(/KV2L(3=J3J2V?!^33E,@*!@L*DQF#+7.U3QF7UT.SP'H. M"P*2[@1R6PF;GDDNWZZI"Z*GK2@(Y4XKMU094W4/>8:%\!ZZ9!&!CO@I>:XG MI2#?Q!:C7&6)IU]I.RTE"DJR-R:978ET M7E`]VLN.JL=KN\\*1*NMZ0\3E+_4DO!#V:TO.S/)DNX[8:GM%U2\B-RY@U0, M:@F6VDU$2]-7: M,'I^"CI"9"US\B!CKZ6J[@0F>ZA0'TA/5HELH)NPM"<*FPR["N=Z52'T7)5O M02D9@K4\U>^,TAPIW^KY*4S^2SNFEIPJ9\)[#MDZT5+! MNW8L/9D%24#:%PUB.@6IR\DTG#B15BG80RDHX[4RE)Y'$Q6AY6S/#DZY6%@5 M4L^=L>;0$G@8`@V8JZ"L?)>&CK*6JBK!J*QV-=E/\6-!QVAW2C28DY4J2(JE M78.@>LK*KGQ124\MBWN,_S,MH/JUGJV"]*&8`;1-WV$VHB7_WU'T"`+((T22 M$@\BX\5[B^[18BD^83B'E(_4]]B]=HCT]"6H>$-,S2UOR:_OG1BDLT4I0Z9Q M1GNN(K1.`K=M1@XY4S6=FU84BX+T8S@;_7_$G/A'U-M[.'>>Y9.`!_MTQ-!J M[<.C^-F2POFG(T%DY_2D=]8[/>O]DSM]_+SRDR`BA0SMSP_4/R9TT3T].3F+ MB,_G4YQP8@)0MV#EZ4S:Z%U<7'1E*&Y$7@R`(.LFX(^<[@$=XXS4=2Q+HIUN M^>"AKEL\"O3M]8A7@+H>Y>K,8?V*ZAM8KQ&>$_DW_PMC$A7XV/&/W"U"`P># M%61KWL=H("/,`L!;I".'N4NX`M?$E:8T4<1?G21>1SSJ]$X[9[WC9^;MQ,U?*?0?=X01YY(7B$+#`&5!(M_KTO$+D.23>UD:3C)7_L MC45>]>1*HZ>UP*0C;O_J[,PT@@.?W67M?-E&DK_VS1$,D,N$N5X=#+M8T<_. MSD`C%`RYM3$D<<2/O=,/UK0^@"22_-4`0KX)NH@Z&PP7XG/P9BV73VDFEFB^ M+D2SV?MA;QB&C6<*0G"0Y./^E+>N;M"!SVL^'0/BRKTK_KP1W&F(A.#;QF#2 M_:>PQ@[4\TI;:HJ@'\WM!:"=+-Q_8`&593,:@HITT`?^C,\-QP%$B'@S&<\+:;QQ%"/?%^O625@6\L@H",7;SY2$ZR01Q,U' MLUXQQOUG$9$">N'JKCNP$0G>PF`R%W-?T=]F_5D17K\!W91Y-`<^*W4I&E(& M18^BH`_`%P/.3T>NW/=B[J@A?H7W=[RE%,(2\9&[B?X5ZLNE3]QOB=.\>/)R M_2%(GM=R>W\F]1`5?LG[+".5VF;?JF$J_'N#!;5VV1SX@+%A4I%OX.H!TAQO M'ED!A%^V92F'I6I=A.QYF5_3[(NX"QGN?B\N&>%*S[;H`>4;"Q,Z?JHE9X7ZWJ M2D,OW@=[P8<%W@^];X40ZK<;6Y1E@67/;ZP]=:8%7]IW:'MDW-0Q52 ME8,A+[Y\WM1_1B]/&7?'0RNQ'X+@O#L97!7@A[+>6%"9\H`J<%O3".0!5>"^ MM`[XI2'R@77(!X;(A]8A'U8A5[5(%O41)AA5T\=0>#^9WX!_$9KD2'!X]:FL*>@Z/?NH0#='M47'*82E\D%O5DHUJUKA0BJJBK;&H^RJ!I.R, M2S.X_[T+*1\K M,\C&^!\0T`G.%<9&*UCJ2I9;PO+@0YT5K!H^[)4+LR?RYG-!^K!?+BSYZ[>? M#Y$7ACDA&XFQJ)R^+VU&ZV4OF0MUEW6-73#,@JAE>=MYH/;!N!Q@X+_M/%"Z M8)@%DWA%F"052JXBY^(2*"^,7XG-W)<^GTP"?\H+ M"=W86Q@K@9L[++9^42@2Y!$O"0[%J6=1]L!B[Q*Y]]2F-E[5%D2."@B!Y!KR M%O"&X&#I\UDL#N+J:B_3UFBI:!JLA:?PG?`(^;WU?=K/E M@1G,N:$:J(C-:6/&0N@-0Z$[WDGDLF].G>?.'CNW>8S:T*%ZV1.-_@SSYU4& ML$V!J]:EO'^%+%*%9Z3O>?(8+_#O`.*CE@%8(SX%B,7^,>:4B9#`WV[_G,S' MF$^T3G(.Z6:](W4-?G&B:D6CJP9]ONR9IV^9L:^R2JH6F"X#C@:^84(`@ MI'*F`",'[%LU,47I3\7V.4?/_"FL7^^ISY?B; M.O_"2Q8'=[[.@`^$C3>;`1D?5)K1=OGUBM"\-8LER`KD(_$U26\>^,6(6\6!_$="&*O1UZ@MBHO]O)JKW[-HB%*;<#*?6UPS6M/ M/*$6&2>S-ZY+D4AK77=>`_0>;EO$=DVXZCV,+H0>NZ)D-04^%-N3W26/1C?< MHOAXJ!S\17)*?,'S;T*S3]4XFWN'P_BGVOL%<"ANGI"3OZTM:T:!>GC*WI#Q MSM)=VN>.$IE*O'%=;G];0:QKLEH/5^CG$`*9]=OQD? M"X#U_LTH>(1^4JG?C)<*V`I?H^Y]!IZMZQORR%2[0Z`'*?"%'@F?_@HI@QMK MNFL--I4WT?3,'@^R>/08YFJYAQ?#5E9O<6'AL6= M^(N?&O:+P6N:B^N2$AM]22/3=TJCY(]I(+9>).H-1Y5X%.=`X3$2F\4N%1* MV?;3%`NA+=MV.+P4GIDKUAP65^!25180;5.1%T1*B7]`Z)K$R_'6E#(SF`H? MAP@3!D*ZBVS395M:=$9+YM:X4@[+Y/I&:UPH167B0>2[G7YDL9EX(X5[.YW) M0#-JFVTK8UIT"H_^&OJ;U%#H%F%HFUO5$'4'GLJVE-KFH2E0G9^%#U@:7(6: MG""S9^+ZXCAU[YS;&Q+,GG\?)]+C^@BU;`?^'LJ(NXX@Z6T3.D M+F+YDWNOLA6\!),I>GE+PP"PI0_9]ND=)8^(24CV^5:%6'6`:1L2N?!>5($) MAM:T65ITQA[Q=MUBCU+HS#T21R!M]BF-3[EU@KK+5)<[\L6VO6BT9]V]Z'7` M&MWX;O.(F]4?EP@TJ^3FPM>_^*/?;`;W:4Y M>?#1(EI`L*WEJP!:USUK6JU*A+J+(^P916;AU+^XU:*-QV8H53+[]I:3R7Q* M0CZ#Q0NQC_?U&P\U,E5OD+IE"EI]2JN`5-7V$S>4PBN?:G-6@\T8SPE=15)M M#/_URY\92MT^K3=Z7<0>=T!P>"QSF13"P*HQ2S5$LWWAR6ZL[1ELBZME-72% MSU_7=I?Z'<^&0^M]C=4K15N^,M MZO/+,"GO[DGNL8GV1]Z2N&3?0Q;Z04I_L6G5JA%JW94[T9HO$X?F@HWX4*EU M9QVT,*M=VT6QJ)Q6X5.5V3!8$BI(C3O5@U]`]KN=OZE";B3;QDIH5.(/="ON M@=7:4HCUG>,),B:S*KK&X2"7W?Y>Y-;THWYNW,;7XK[MO"AZH3R&L(YVEG!# MA8^ZZ`+%S\ MV&7N$JZ`]/;_`%!+`0(>`Q0````(`*MS?$1VUD0?*?8``&>]#@`1`!@````` M``$```"D@0````!N97!H+3(P,3,Q,C,Q+GAM;%54!0`#@;\U4W5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`*MS?$1VDF5TR0P``/K"```5`!@```````$` M``"D@73V``!N97!H+3(P,3,Q,C,Q7V-A;"YX;6Q55`4``X&_-5-U>`L``00E M#@``!#D!``!02P$"'@,4````"`"K&UL550%``.!OS53=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`JW-\1/33,%NQ>@``]S0'`!4`&``````` M`0```*2!FEX!`&YE<&@M,C`Q,S$R,S%?;&%B+GAM;%54!0`#@;\U4W5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`*MS?$26[G161&8``.SD!@`5`!@````` M``$```"D@9K9`0!N97!H+3(P,3,Q,C,Q7W!R92YX;6Q55`4``X&_-5-U>`L` M`00E#@``!#D!``!02P$"'@,4````"`"K`L``00E >#@``!#D!``!02P4&``````8`!@`:`@``[58"```` ` end XML 44 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventory (Tables)
 12 Months Ended
Dec. 31, 2013
Inventory Disclosure [Abstract]  
Schedule Of Inventory, Current
The Company’s inventory components as of December 31, 2013 and 2012 were as follows:
 
 
 
December 31,
 
 
 
2013
 
 
2012
 
Total Gross Inventory, Finished Goods
 
$
527,000
 
 
$
581,000
 
Less: Inventory reserve
 
 
(365,000)
 
 
 
(269,000)
 
Total Inventory
 
$
162,000
 
 
$
312,000
 

XML 45 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 46 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Payments of Stock Issuance Costs $ 229
XML 47 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Inventory, allowances $ 365 $ 269
Note payable, net of debt discount $ 142  
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 90,000,000 90,000,000
Common stock, shares issued 18,082,043 11,949,824
Common stock, shares outstanding 18,082,043 11,949,824
XML 48 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity
 12 Months Ended
Dec. 31, 2013
Stockholders Equity Note [Abstract]  
Stockholders' Equity
Note 10 – Stockholders’ Equity
 
On March 4, 2013, the Company filed a Registration Statement on Form S-1 in connection with a $3 million rights offering (the “Rights Offering”).  On April 17, 2013, the Company’s Registration Statement on Form S-1 related to the Rights Offering was declared effective by the SEC.
 
The Rights Offering commenced on April 17, 2013 and expired on May 17, 2013.  All of the Company’s stockholders and warrant holders were eligible to participate in the Rights Offering on a pro rata basis based upon their proportionate ownership of the Company’s common stock on a fully-diluted basis.  Pursuant to the Rights Offering, the Company distributed to holders of its common stock and/or warrants one non-transferable subscription right for each share of common stock, and each share of common stock underlying a warrant, held as of April 4, 2013.  Each right entitled the holder to purchase 0.18776 of a share of the Company’s common stock at a subscription price of $0.60 per share.  The Company rounded up any fractional shares to the nearest whole share.
 
On May 22, 2013, the Company completed its Rights Offering which resulted in the issuance of 5,000,000 shares for gross proceeds of $3.0 million.  The aggregate net proceeds were approximately $1.4 million, after deducting the repayment of the $1.3 million February 2013 senior secured note, plus $46,800 of accrued interest thereon, issued to Lambda Investors, LLC, the payment of an 8% sourcing transaction fee of $104,000 with respect to the February 2013 senior secured note and an aggregate of $100,000 for reimbursement of Lambda Investors’ legal fees incurred in connection with the February 2013 senior secured note and the Rights Offering. Those payments totaling $204,000 are reflected as amortization of debt discount.
XML 49 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document And Entity Information (USD $)
 12 Months Ended
Dec. 31, 2013
Mar. 25, 2014
Jun. 28, 2013
Document Information [Line Items]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2013    
Document Fiscal Year Focus 2013    
Document Fiscal Period Focus FY    
Trading Symbol NEPH    
Entity Common Stock, Shares Outstanding   25,225,704  
Entity Registrant Name NEPHROS INC    
Entity Central Index Key 0001196298    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Smaller Reporting Company    
Entity Public Float     $ 10,181,000
XML 50 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
401(k) Plan
 12 Months Ended
Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]  
401 (k) Plan
Note 11 - 401(k) Plan
 
The Company has established a 401(k) deferred contribution retirement plan (the “401(k) Plan”) which covers all employees. The 401(k) Plan provides for voluntary employee contributions of up to 15% of annual earnings, as defined. As of January 1, 2004, the Company began matching 100% of the first 3% and 50% of the next 2% of employee earnings to the 401(k) Plan. The Company contributed and expensed $46,000 and $49,000 in 2013 and 2012, respectively.
XML 51 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Net revenue:    
Product revenues $ 1,029 $ 1,127
Licensing revenues 711 680
Total net revenues 1,740 1,807
Cost of goods sold 898 737
Gross margin 842 1,070
Operating expenses:    
Research and development 826 632
Depreciation and amortization 223 151
Selling, general and administrative 3,110 3,620
Total operating expenses 4,159 4,403
Loss from operations (3,317) (3,333)
Interest income 0 2
Interest expense (94) 0
Gain on sale of equipment 3 55
Amortization of debt discount (257) 0
Other income (expense) (33) 14
Net loss (3,698) (3,262)
Other comprehensive income, foreign currency translation adjustments (2) 27
Total comprehensive loss $ (3,700) $ (3,235)
Net loss per common share, basic and diluted $ (0.24) $ (0.29)
Weighted average common shares outstanding, basic and diluted 15,624,999 11,223,878
XML 52 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Property and Equipment, Net
 12 Months Ended
Dec. 31, 2013
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net
Note 5 - Property and Equipment, Net
 
Property and equipment as of December 31, 2013 and 2012 was as follows:
 
 
 
 
 
December 31,
 
 
 
Life
 
2013
 
 
2012
 
Manufacturing equipment
 
 
3-5 years
 
$
599,000
 
 
$
602,000
 
Research equipment
 
 
5 years
 
 
37,000
 
 
 
37,000
 
Computer equipment
 
 
3-4 years
 
 
59,000
 
 
 
59,000
 
Furniture and fixtures
 
 
7 years
 
 
39,000
 
 
 
39,000
 
Property and equipment, gross
 
 
 
 
 
734,000
 
 
 
737,000
 
Less: accumulated depreciation
 
 
 
 
 
727,000
 
 
 
721,000
 
Property and equipment, net
 
 
 
 
$
7,000
 
 
$
16,000
 
 
Depreciation expense for each of the years ended December 31, 2013 and 2012 was $9,000,  including amortization expense relating to research and development assets.
 
During 2013, the Company sold fully depreciated equipment totaling approximately $3,000 which is reflected as gain on sale of equipment on the consolidated statements of operations and comprehensive loss. During 2012, the Company agreed to sell its manufacturing equipment to Medica for approximately €42,500, or $55,000. All assets at the manufacturing plant were fully depreciated as of the date of the sale. Approximately €42,500, or $55,000, is recognized as gain on sale of equipment on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2012.
XML 53 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Prepaid Expenses and Other Current Assets
 12 Months Ended
Dec. 31, 2013
Other Assets [Abstract]  
Prepaid Expenses and Other Current Assets
Note 4 - Prepaid Expenses and Other Current Assets
 
Prepaid expenses and other current assets as of December 31, 2013 and 2012 were as follows:
 
 
 
December 31,
 
 
 
2013
 
2012
 
Prepaid insurance premiums
 
$
70,000
 
$
78,000
 
Security deposit
 
 
21,000
 
 
21,000
 
Other
 
 
34,000
 
 
10,000
 
Prepaid expenses and other current assets
 
$
125,000
 
$
109,000
 
XML 54 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2013
Accounting Policies [Abstract]  
Schedule Of Securities Excluded From Dilutive Per Share Computation
The following securities have been excluded from the dilutive per share computation as they are antidilutive:
 
 
 
2013
 
 
2012
 
Stock options
 
 
2,410,134
 
 
 
2,294,714
 
Warrants
 
 
13,887,598
 
 
 
14,679,971
 
Unvested restricted stock
 
 
75,450
 
 
 
-
 
XML 55 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 12 - Commitments and Contingencies
 
Manufacturing and Suppliers
 
The Company has not and does not intend in the near future, to manufacture any of its products and components. With regard to the OLpur MD190 and MD220, on June 27, 2011, the Company entered into a license agreement, effective July 1, 2011, with Bellco S.r.l., an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of our patented mid-dilution dialysis filters (MD 190, MD 220), referred to herein as the Products. Under the agreement, Nephros granted Bellco a license to manufacture, market and sell the Products under its own name, label and CE mark in Italy, France, Belgium, Spain and Canada on an exclusive basis, and to do the same on a non-exclusive basis in the United Kingdom and Greece and, upon our written approval, other European countries where the Company does not sell the Products as well as non-European countries (referred to as the “Territory”).
 
On February 19, 2014, the Company entered into the First Amendment to License Agreement (the “First Amendment”), by and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011 by and between the Company and Bellco.  Pursuant to the First Amendment, the Company and Bellco agreed to extend the term of the License Agreement through December 31, 2021. The First Amendment also expands the Territory covered by the License Agreement to include Sweden, Denmark, Norway, Finland, Korea, Mexico, Brazil, China and the Netherlands. The First Amendment further provides new minimum sales targets which, if not satisfied, will, at the discretion of the Company, result in conversion of the license to non-exclusive status. The Company has agreed to reduce the fixed royalty payment payable to the Company for the period beginning on January 1, 2015 through and including December 31, 2021. Beginning on January 1, 2015 through and including December 31, 2016, Bellco will pay us a royalty based on the number of units of Products sold per year in the Territory as follows: for the first 125,000 units sold,  €1.75 per unit; thereafter, €1.25 per unit.   In addition, the Company will receive a total of €450,000 in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. In addition, the First Amendment provides that, in the event that the Company pursues a transaction to sell, assign or transfer all right, title and interest to the licensed patents to a third party, the Company will provide Bellco with written notice thereof and a right of first offer with respect to the contemplated transaction for a period of thirty (30) days.
                   
License and Supply Agreement
 
On April 23, 2012, the Company entered into a License and Supply Agreement (the “License and Supply Agreement”) with Medica S.p.A. (“Medica”), an Italy-based medical product manufacturing company, for the marketing and sale of certain filtration products based upon Medica’s proprietary Medisulfone ultrafiltration technology in conjunction with the Company’s filtration products (collectively, the “Filtration Products”), and to engage in an exclusive supply arrangement for the Filtration Products. Under the License and Supply Agreement, Medica granted to the Company an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale and sell the Filtration Products worldwide, excluding Italy for the first three years, during the term of the License and Supply Agreement. In addition, the Company granted to Medica an exclusive license under the Company’s intellectual property to make the Filtration Products during the term of the License and Supply Agreement. In exchange for the rights granted, the Company has agreed to make minimum annual aggregate purchases from Medica of €300,000, €500,000 and €750,000 for the years 2012, 2013 and 2014, respectively. In the year ended December 31, 2013 the Company’s aggregate purchase commitments totaled approximately €532,000. For calendar years thereafter, annual minimum amounts will be mutually agreed upon between Medica and the Company.
 
In exchange for the license, the Company paid Medica  €1,500,000 in three installments: €500,000 on April 23, 2012, €600,000 on February 4, 2013, and €400,000 on May 23, 2013. As further consideration for the license and other rights granted to the Company, the Company granted Medica options to purchase 300,000 shares of the Company’s common stock. The fair market value of these stock options was approximately $273,000 at the time of their issuance, calculated as described in Note 2 under Stock-Based Compensation. The fair market value of the options has been capitalized as a long-term intangible asset along with the total installment payments described. Other long-term assets on the consolidated balance sheet is approximately $1,894,000, net of $356,000 accumulated amortization, and is related to the License and Supply Agreement. The asset is being amortized as an expense over the life of the agreement. Approximately $214,000 and $142,000 have been charged to amortization expense for the years ended December 31, 2013 and 2012, respectively, on the consolidated statement of operations and comprehensive loss. Approximately $208,000 of amortization expense will be recognized in the years ended December 31, 2014 and 2015, respectively. In addition, for the period beginning April 23, 2014 through December 31, 2022, the Company will pay Medica a royalty rate of 3% of net sales of the Filtration Products sold, subject to reduction as a result of a supply interruption pursuant to the terms of the License and Supply Agreement. The term of the License and Supply Agreement commenced on April 23, 2012 and continues in effect through December 31, 2022, unless earlier terminated by either party in accordance with the terms of the License and Supply Agreement.
 
As of September 2013, we have an understanding with Medica whereby we have agreed to pay interest to Medica at a 12% annual rate calculated on the principal amount of any outstanding invoices that are not paid pursuant to the original payment terms.
 
Employment Agreement
 
On April 20, 2012, the Company entered into an Employment Agreement, effective as of April 20, 2012, with John C. Houghton (“Employment Agreement”). The Employment Agreement has a term of four years, ending on April 20, 2016. The Employment Agreement provides that Mr. Houghton’s annual base salary will be $350,000. Mr. Houghton will be eligible to receive a target discretionary bonus of 30% of annual base salary, as determined by the Company.
 
Contractual Obligations
 
The Company had an operating lease that expired on November 30, 2013 for the rental of its U.S. office and research and development facilities with a monthly cost of approximately $8,000. On July 25, 2013, the Company signed a one year lease extension for the same office space which will expire on November 30, 2014 with a monthly cost of approximately $8,000 beginning December 1, 2013.
 
Rent expense for the years ended December 31, 2013 and 2012 totaled $108,000 and $109,000, respectively.
     
Contractual Obligations and Commercial Commitments
 
The following tables summarize our approximate minimum contractual obligations and commercial commitments as of December 31, 2013:
 
 
 
Payments Due in Period
 
 
 
Total
 
Within
1 Year
 
Years
1 - 3
 
Years
4 - 5
 
More than
5 Years
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Leases
 
$
108,000
 
$
100,000
 
$
8,000
 
$
-
 
$
-
 
Employment Contracts
 
 
788,000
 
 
350,000
 
 
438,000
 
 
-
 
 
-
 
Total
 
$
896,000
 
$
450,000
 
$
446,000
 
$
-
 
$
-
 
   
Product Recall
 
On October 30, 2013, the Company filed a Current Report on Form 8-K announcing the voluntary recalls of its point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications.  As a result, the Company has recalled all production lots of its POU filters, and also requested that customers remove and discard certain labeling/promotional materials for the products.  In addition, the Company also requested, for the DSU in-line ultrafilter, that customers remove and discard certain labeling/promotional materials for the product.  These voluntary recalls do not affect the Company’s dialysis products.  The consolidated financial statements for the year ended December 31, 2013 include product revenues and cost of goods sold adjustments of approximately $216,00 and $110,000, respectively, reflecting estimates of the financial impact of product recalled to the Company.  This recall and the related circumstances could subject the Company to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact the Company’s sales and revenues.  The Company has fully reserved the recalled product and will destroy the respective product by April 20, 2014.
XML 56 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes
 12 Months Ended
Dec. 31, 2013
Income Tax Disclosure [Abstract]  
Income Taxes
 
Note 8 - Income Taxes
 
A reconciliation of the income tax provision computed at the statutory tax rate to the Company’s effective tax rate is as follows:
 
 
2013
 
 
2012
 
U.S. federal statutory rate
 
 
35.00
%
 
35.00
%
State & local taxes
 
 
5.22
%
 
5.36
%
Tax on foreign operations
 
 
0.40
%
 
(0.78)
%
State research and development credits
 
 
1.09
%
 
1.06
%
Other
 
 
(3.00)
%
 
(2.29)
%
Valuation allowance
 
 
(38.71)
%
 
(38.35)
%
Effective tax rate
 
 
-
 
 
-
 
 
Significant components of the Company’s deferred tax assets as of December 31, 2013 and 2012 are as follows:
 
 
 
2013
 
 
2012
 
Deferred tax assets:
 
 
 
 
 
 
 
 
Net operating loss carry forwards
 
$
27,029,000
 
 
$
25,721,000
 
Research and development credits
 
 
1,096,000
 
 
 
1,054,000
 
Nonqualified stock option compensation expense
 
 
1,801,000
 
 
 
1,701,000
 
Other temporary book - tax differences
 
 
408,000
 
 
 
441,000
 
Total deferred tax assets
 
 
30,334,000
 
 
 
28,917,000
 
Valuation allowance for deferred tax assets
 
 
(30,334,000)
 
 
 
(28,917,000)
 
Net deferred tax assets
 
$
-
 
 
$
-
 
 
A valuation allowance has been recognized to offset the Company’s net deferred tax asset as it is more likely than not that such net asset will not be realized. The Company primarily considered its historical loss and potential Internal Revenue Code Section 382 limitations to arrive at its conclusion that a valuation allowance was required.
 
At December 31, 2013, the Company had Federal and New Jersey income tax net operating loss carryforwards of $87,292,000 and foreign income tax net operating loss carryforwards of $8,305,000. The Company also had Federal research tax credit carryforwards of $1,096,000 at December 31, 2013 and $1,054,000 at December 31, 2012. The Federal net operating loss and tax credit carryforwards will expire at various times between 2014 and 2026 unless utilized.
 
It is the Company’s policy to report interest and penalties, if any, related to unrecognized tax benefits in income tax expense.
XML 57 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Senior Secured Notes
 12 Months Ended
Dec. 31, 2013
Debt Disclosure [Abstract]  
Senior Secured Notes
Note 6 – Senior Secured Notes
 
On February 4, 2013, the Company issued a senior secured note to Lambda Investors LLC in the principal amount of $1.3 million. The note bore interest at the rate of 12% per annum and was scheduled to mature on August 4, 2013, at which time all principal and accrued interest was due. However, the Company paid amounts due under the note on May 22, 2013 with the cash proceeds from the rights offering that closed in May 2013.  In connection with the note, the Company paid Lambda Investors an 8%, or $104,000, sourcing/transaction fee. In addition, the Company paid Lambda Investors’ legal fees and other expenses incurred in connection with the note in the amount of $50,000 as well as Lambda Investors’ legal fees and other expenses incurred in connection with the May 2013 rights offering in the amount of $50,000.   Those payments totaling $204,000 are reflected as amortization of debt discount. 
 
On November 12, 2013, the Company issued a senior secured note to Lambda Investors LLC in the principal amount of $1.5 million. The note bore interest at the rate of 12% per annum and was scheduled to mature on May 12, 2014, at which time all principal and accrued interest was due. However, the Company paid amounts due under the note on March 18, 2014 with the cash proceeds from the rights offering that closed in March 2014. In connection with the note, the Company paid Lambda Investors an 8%, or $120,000, sourcing/transaction fee. In addition, the Company paid Lambda Investors’ legal fees and other expenses incurred in connection with the note in the amount of $75,000. Those payments totaling $195,000 were made on November 12, 2013 and are reflected as a debt discount which is being amortized over the term of the senior secured note. Approximately $53,000 is reflected as amortization of debt discount on the consolidated statements of operations and comprehensive loss for the year the ended December 31, 2013.
 
On March 21, 2014 the Company completed a rights offering which resulted in gross proceeds of $2.1 million.  A portion of the proceeds was used for the repayment of a $1.5 million note, plus all accrued interest thereon of $61,000.  See Note 13, Subsequent Events, for further discussion.
XML 58 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accrued Expenses
 12 Months Ended
Dec. 31, 2013
Payables and Accruals [Abstract]  
Accrued Expenses
Note 7 - Accrued Expenses
 
Accrued expenses as of December 31, 2013 and 2012 were as follows:
 
 
 
December 31,
 
 
 
2013
 
 
2012
 
Accrued Legal
 
$
149,000
 
 
$
90,000
 
Accrued Product Recall
 
 
60,000
 
 
 
 
 
Accrued Directors’ Compensation
 
 
-
 
 
 
77,000
 
Accrued Management Bonus
 
 
81,000
 
 
 
-
 
Accrued Interest
 
 
39,000
 
 
 
-
 
Accrued Travel
 
 
-
 
 
 
84,000
 
Accrued Other
 
 
36,000
 
 
 
70,000
 
Accrued Expenses
 
$
365,000
 
 
$
321,000
 
XML 59 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Plans, Share-Based Payments and Warrants
 12 Months Ended
Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Plans, Share-Based Payments and Warrants
Note 9 - Stock Plans, Share-Based Payments and Warrants
 
Stock Plans
 
In 2000, the Company adopted the Nephros 2000 Equity Incentive Plan. In January 2003, the Board of Directors adopted an amendment and restatement of the plan and renamed it the Amended and Restated Nephros 2000 Equity Incentive Plan (the “2000 Plan”), under which 106,538 shares of common stock had been authorized for issuance upon exercise of options granted.
 
As of December 31, 2013 and 2012, 831 and  2,053 options, respectively, had been issued to non-employees under the 2000 Plan and were outstanding. During the twelve months ended December 31, 2013, 1,222 non-employee options expired.  The remaining outstanding options, all of which are fully vested, will expire on March 15, 2014. As of December 31, 2013 and 2012, 2,003 and  7,230 options, respectively, had been issued to employees under the 2000 Plan and were outstanding. During the twelve months ended December 31, 2013, 5,227 employee options expired.  The remaining employee options, all of which are fully vested, will expire on March 15, 2014.
 
The Board retired the 2000 Plan in June 2004, and thereafter no additional awards may be granted under the 2000 Plan.
 
In 2004, the Board of Directors adopted and the Company’s stockholders approved the Nephros, Inc. 2004 Stock Incentive Plan. During the year ended December 31, 2013, the Company’s stockholders approved an amendment to such plan (as amended, the “2004 Plan”), that increased the number of shares of the Company’s common stock that are authorized for issuance by the Company pursuant to grants of awards under the 2004 Plan to 4,500,000.
 
As of December 31, 2013, 1,360,059 options had been issued to employees under the 2004 Plan and were outstanding. The options expire on various dates between April 27, 2015 and March 24, 2021, and vest upon a combination of the following: immediate vesting or straight line vesting of two or four years. At December 31, 2013, there were 2,407,318 shares available for future grants under the 2004 Plan. As of December 31, 2013, 715,692 options had been issued to non-employees under the 2004 Plan and were outstanding. Such options expire at various dates between November 11, 2014 and November 18, 2021, and vest upon a combination of the following: immediate vesting or straight line vesting of two or four years. In addition, 331,550 options were issued in 2012 to the Company’s CEO per terms of his employment agreement and are outstanding as of December 31, 2013.
 
As of December 31, 2012, 1,316,628 options had been issued to employees under the 2004 Plan and were outstanding. The options expire on various dates between April 27, 2015 and May 23, 2023, and vest upon a combination of the following: immediate vesting or straight line vesting of two to four years. At December 31, 2012, there were 19,904 shares available for future grants under the 2004 Plan. As of December 31, 2012, 637,253 options had been issued to non-employees under the 2004 Plan and were outstanding. Such options expire at various dates between November 11, 2014 and December 31, 2023, and vest upon a combination of the following: immediate vesting or straight line vesting of two to four years.
   
Share-Based Payment
 
Prior to the Company’s initial public offering, options were granted to employees, non-employees and non-employee directors at exercise prices which were lower than the fair market value of the Company’s stock on the date of grant. After the date of the Company’s initial public offering, stock options are granted to employees, non-employees and non-employee directors at exercise prices equal to the fair market value of the Company’s stock on the date of grant. Stock options granted have a life of 10 years. 
 
Expense is recognized, net of expected forfeitures, over the vesting period of the options. For options that vest upon the achievement of certain milestones, expense is recognized when it is probable that the condition will be met. Stock based compensation expense recognized for the years ended December 31, 2013 and 2012 was approximately $418,000 or less than $0.03 per share and approximately $443,000 or less than $0.04 per share, respectively.
 
Gerald J. Kochanski, Chief Financial Officer, Treasurer and Corporate Secretary of Nephros, Inc., resigned effective June 15, 2013. The Company agreed, in consideration of Mr. Kochanski providing certain consulting services to the Company, to extend the exercise period of his outstanding vested stock options from September 15, 2013 to March 14, 2014. This modification did not result in any additional compensation expense. In addition, as a result of Mr. Kochanski’s resignation, 90,945 stock options that were granted to him were forfeited on June 15, 2013. Of these 90,945 stock options, 25,000 were granted during the twelve month period ended December 31, 2013.
 
The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the below assumptions related to risk-free interest rates, expected dividend yield, expected lives and expected stock price volatility.
 
 
 
Option Pricing Assumptions
 
 
Grant Year
 
2013
 
 
2012
 
 
Stock Price Volatility
 
 
127.46-135.98
%
 
 
123.48 –128.54
%
 
Risk-Free Interest Rates
 
 
1.09-1.75
%
 
 
.093-1.32
%
 
Expected Life (in years)
 
 
5.00-6.25
 
 
 
5.75-62.5
 
 
Expected Dividend Yield
 
 
0
%
 
 
0
%
 
  
Expected volatility is based on historical volatility of the Company’s common stock at the time of grant. The risk-free interest rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected life of the options. For the expected life, the Company is using the simplified method as described in the SEC Staff Accounting Bulletin 107. This method assumes that stock option grants will be exercised based on the average of the vesting periods and the option’s life.
 
The total fair value of options vested during the fiscal year ended December 31, 2013 was approximately $519,000. The total fair value of options vested during the fiscal year ended December 31, 2012 was approximately $506,000.
 
The following table summarizes information about stock options outstanding and exercisable at December 31, 2013:
 
 
 
Options Outstanding
 
Options Exercisable
 
Range of Exercise
Price
 
Number
Outstanding as
of December
31, 2013
 
Weighted
Average
Remaining
Contractual
Life in
Years
 
Weighted
Average
Exercise
Price
 
Number
Exercisable as
of
December 31,
2013
 
Weighted
Average
Exercise Price
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$0.41 - $2.60
 
 
2,374,514
 
 
8.16
 
$
0.93
 
 
1,349,579
 
$
0.83
 
$15.00 - $29.80
 
 
27,909
 
 
4.58
 
$
17.82
 
 
27,909
 
$
17.82
 
$34.20-$96.00
 
 
7,711
 
 
1.38
 
$
51.49
 
 
7,711
 
$
51.49
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Outstanding
 
 
2,410,134
 
 
 
 
$
1.28
 
 
1,385,199
 
$
1.46
 
 
The number of new options granted in 2013 and 2012 is 237,315 and 1,547,550, respectively. The weighted-average fair value of options granted in 2013 and 2012 is $0.56 and $1.03, respectively.
 
The following table summarizes the option activity for the year ended December 31, 2013:
 
 
 
Shares
 
Weighted
Average
Exercise
Price
 
Outstanding at December 31, 2012
 
 
2,294,714
 
$
 
2.14
 
Options granted
 
 
237,315
 
 
 
0.64
 
Options exercised
 
 
-
 
 
 
-
 
Options forfeited or expired
 
 
(121,895)
 
 
 
3.27
 
Outstanding at December 31, 2013
 
 
2,410,134
 
$
 
1.28
 
Exercisable at December 31, 2013
 
 
1,385,199
 
$
 
1.46
 
Vested and expected to vest at December 31, 2013
 
 
2,350,688
 
$
 
1.29
 
 
The aggregate intrinsic value of stock options outstanding at December 31, 2013 is $0 and of stock options vested or expected to vest is approximately $0. A stock option has intrinsic value, at any given time, if and to the extent that the exercise price of such stock option is less than the market price of the underlying common stock at such time. The weighted-average remaining contractual life of options vested or expected to vest is 8.1 years.
 
The aggregate intrinsic value of stock options outstanding at December 31, 2012 is $793,000 and of stock options vested or expected to vest is approximately $768,000. A stock option has intrinsic value, at any given time, if and to the extent that the exercise price of such stock option is less than the market price of the underlying common stock at such time. The weighted-average remaining contractual life of options vested or expected to vest is 8.9 years. 
 
As of December 31, 2013, the total remaining unrecognized compensation cost related to non-vested stock options amounted to $727,000 and will be amortized over the weighted-average remaining requisite service period of 2.3 years.
 
Restricted Stock
 
The Company has issued restricted stock as compensation for the services of certain employees and non-employee directors.  The grant date fair value of restricted stock was based on the fair value of the common stock on the date of grant, and compensation expense is recognized based on the period in which the restrictions lapse. 
 
The following table summarizes restricted stock activity for the year end December 31, 2013:
 
 
 
Shares
 
Weighted
Average
Grant Date
Fair Value
 
Nonvested at December 31, 2012
 
-
 
$
-
 
Granted
 
398,227
 
 
0.73
 
Vested
 
(264,770)
 
 
0.71
 
Forfeited
 
(58,007)
 
 
0.88
 
Nonvested at December 31, 2013
 
75,450
 
$
0.66
 
Total stock-based compensation expense for the restricted stock was approximately $157,000 for the year ended December 31, 2013.  For the year ended December 31, 2013, approximately $109,000 and approximately $48,000 are included in Selling, General and Administrative expenses and Research and Development expenses, respectively, on the accompanying condensed consolidated statement of operations. The remaining expense related to the restricted stock awards issued to non-employee directors of approximately $77,000 was recorded to offset accrued director’s fees that were incurred prior to December 31, 2012. Any additional stock-based compensation related to non-employee directors will be recorded to stock-based compensation expense. As of December 31, 2013, there was approximately $4,000 of unrecognized compensation expense related to the restricted stock awards, which is expected to be recognized over the next six months.
 
Warrants
 
The following table summarizes certain terms of all of the Company’s outstanding warrants at December 31, 2013 and 2012: 
 
 
Total Outstanding Warrants at December 31, 2013
Title of Warrant
 
Date Issued
 
Expiry Date
 
Exercise Price
 
Total Common
Shares Issuable
 
 
 
 
 
 
 
 
 
 
2013
 
2012
 
Class D Warrants - Lambda
 
11/14/2007
 
3/10/2017
 
$
0.40
 
 
8,806,575
 
 
8,806,575
 
July 2009 Warrants
 
7/24/2009
 
7/24/2014
 
$
22.40
 
 
33,629
 
 
33,629
 
Shareholder Rights Offering Warrants
 
3/10/2011
 
3/10/2016
 
$
0.40
 
 
2,264,817
 
 
3,057,190
 
March 2011 Lambda Warrants
 
3/10/2011
 
3/10/2017
 
$
0.40
 
 
2,782,577
 
 
2,782,577
 
 
 
 
 
 
 
 
 
 
 
13,887,598
 
 
14,679,971
 
 
The weighted average exercise price of the outstanding warrants was $0.45 for December 31, 2013 and 2012. 
 
Following the closing of the rights offering in 2013, Lambda Investors’ existing warrants to purchase 8,806,575 shares that remain outstanding were amended to expire on March 10, 2017.
 
The following table summarizes the Class D outstanding warrants at December 31, 2013 and 2012:
 
 
 
Lambda Investors
 
Other Investors
 
Total Shares to be issued
 
As of December 31, 2011
 
 
8,806,575
 
 
447,197
 
 
9,253,772
 
Exercised in 2012
 
 
-
 
 
(352,034)
 
 
(352,034)
 
Expired in 2012
 
 
-
 
 
(95,163)
 
 
(95,163)
 
As of December 31, 2012
 
 
8,806,575
 
 
-
 
 
8,806,575
 
Exercised in 2013
 
 
-
 
 
-
 
 
-
 
Expired in 2013
 
 
-
 
 
-
 
 
-
 
As of December 31, 2013
 
 
8,806,575
 
 
-
 
 
8,806,575
 
   
Class D warrant holders elected to exercise 352,034 of the outstanding Class D Warrants in 2012. As a result, 190,326 were exercised pursuant to the cashless exercise provision of the warrant. In addition, 161,708 warrants were exercised resulting in proceeds of approximately $65,000.
 
Warrants exercised during 2013 and 2012
 
In connection with the 2013 Rights Offering, the Company temporarily reduced the exercise price for its warrants issued in March 2011 from $0.40 per share to $0.30 per share. The Company determined that this inducement was a modification of equity instruments and, therefore, an incremental fair value of the inducement was determined using the Black-Scholes option pricing model.
 
During the period that the 2013 Rights Offering was open, warrant holders exercised 14,879,708 warrants, issued in March 2011, for 687,793 shares of common stock, resulting in gross proceeds of approximately $206,000 to the Company. The incremental fair value of the inducement recorded in the year ended December 31, 2013 was approximately $14,000.

Additionally, during the twelve months ended December 31, 2013, 2,254,500 warrants were exercised outside the period that the 2013 Rights Offering was open, resulting in proceeds of approximately $42,000 and the issuance of 104,206 shares of the Company’s common stock.
 
An additional 374 common shares were not issued as a result of warrant exercises for the year ended December 31, 2013 due to rounding.
 
Shareholders exercised 23,720,667 warrants, resulting in proceeds of approximately $438,000 and the issuance of 1,096,313 shares of the Company’s common stock for the year ended December 31, 2012.
XML 60 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventory (Details) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Inventory [Line Items]    
Total Gross Inventory, Finished Goods $ 527,000 $ 581,000
Less: Inventory reserve (365,000) (269,000)
Total Inventory $ 162,000 $ 312,000
XML 61 R51.htm IDEA: XBRL DOCUMENT v2.4.0.8
401(k) Plan (Details Textual) (USD $)
 12 Months Ended 1 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Jan. 01, 2004
3% Employee Contribution [Member]
Jan. 01, 2004
2% Employee Contribution [Member]
Defined Benefit Plan Disclosure [Line Items]        
Maximum employee contribution, percentage 15.00%      
Contribution expense $ 46,000 $ 49,000    
Employer matching contribution, percentage     100.00% 50.00%
Percent of employee contributions matched by employer     3.00% 2.00%
XML 62 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Events
 12 Months Ended
Dec. 31, 2013
Subsequent Events [Abstract]  
Subsequent Events
Note 14 - Subsequent Events
 
On March 24, 2014, the Company announced the completion of a rights offering that resulted in gross proceeds of $2.1 million and the issuance of 7,140,822 shares of common stock. A portion of the proceeds was used for the repayment of the $1.5 million note issued to Lambda Investors LLC in November 2013 in connection with its loan to the Company, plus $61,000 of accrued interest thereon. The Company issued a total of 7,140,822 shares of common stock to the holders of subscription rights who validly exercised their subscription rights, which represents 77% of the total shares offered in the rights offering.
 
On February 19, 2014, the Company entered into the First Amendment to License Agreement (the “First Amendment”), by and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011 by and between the Company and Bellco.  Pursuant to the First Amendment, the Company and Bellco agreed to extend the term of the License Agreement through December 31, 2021. The First Amendment also expands the Territory covered by the License Agreement to include Sweden, Denmark, Norway, Finland, Korea, Mexico, Brazil, China and the Netherlands. The First Amendment further provides new minimum sales targets which, if not satisfied, will, at the discretion of the Company, result in conversion of the license to non-exclusive status. The Company has agreed to reduce the fixed royalty payment payable to the Company for the period beginning on January 1, 2015 through and including December 31, 2021. The Company will receive a total of €450,000 in upfront fees in connection with the First Amendment, half of which were paid on February 19, 2014, and the other half of which are payable on March 31, 2014. In addition, the First Amendment provides that, in the event that the Company pursues a transaction to sell, assign or transfer all right, title and interest to the licensed patents to a third party, the Company will provide Bellco with written notice thereof and a right of first offer with respect to the contemplated transaction for a period of thirty (30) days.
XML 63 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
Property and Equipment, Net (Tables)
 12 Months Ended
Dec. 31, 2013
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net
Property and equipment as of December 31, 2013 and 2012 was as follows:
 
 
 
 
 
December 31,
 
 
 
Life
 
2013
 
 
2012
 
Manufacturing equipment
 
 
3-5 years
 
$
599,000
 
 
$
602,000
 
Research equipment
 
 
5 years
 
 
37,000
 
 
 
37,000
 
Computer equipment
 
 
3-4 years
 
 
59,000
 
 
 
59,000
 
Furniture and fixtures
 
 
7 years
 
 
39,000
 
 
 
39,000
 
Property and equipment, gross
 
 
 
 
 
734,000
 
 
 
737,000
 
Less: accumulated depreciation
 
 
 
 
 
727,000
 
 
 
721,000
 
Property and equipment, net
 
 
 
 
$
7,000
 
 
$
16,000
 
XML 64 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Plans, Share-Based Payments and Warrants (Details Textual) (USD $)
 12 Months Ended 0 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
May 17, 2013
Jun. 15, 2013
Mr. Kochansk [Member]
Dec. 31, 2013
Mr. Kochansk [Member]
Dec. 31, 2013
Shareholders Equity [Member]
Mar. 31, 2011
Right Offering [Member]
Dec. 31, 2013
Right Offering [Member]
Dec. 31, 2012
Class D Warrant [Member]
Dec. 31, 2013
Class D Warrant Lambda [Member]
Dec. 31, 2013
Shareholder Rights Offering Warrant [Member]
Dec. 31, 2012
Shareholder Rights Offering Warrant [Member]
Dec. 31, 2013
Employee Stock Option [Member]
Dec. 31, 2013
CEO Stock Options [Member]
Dec. 31, 2013
Restricted Stock [Member]
Dec. 31, 2013
Restricted Stock [Member]
Selling, General and Administrative Expenses [Member]
Dec. 31, 2013
Restricted Stock [Member]
Research and Development Expense [Member]
Dec. 31, 2013
2000 Plan [Member]
Dec. 31, 2013
2000 Plan [Member]
Employee Stock Option [Member]
Dec. 31, 2012
2000 Plan [Member]
Employee Stock Option [Member]
Dec. 31, 2013
2000 Plan [Member]
Non Employee Stock Options [Member]
Dec. 31, 2012
2000 Plan [Member]
Non Employee Stock Options [Member]
Dec. 31, 2013
2004 Plan [Member]
Dec. 31, 2012
2004 Plan [Member]
Dec. 31, 2013
2004 Plan [Member]
Employee Stock Option [Member]
Dec. 31, 2012
2004 Plan [Member]
Employee Stock Option [Member]
Dec. 31, 2013
2004 Plan [Member]
Non Employee Stock Options [Member]
Dec. 31, 2012
2004 Plan [Member]
Non Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                                        
Number of shares authorized for issuance                                   106,538         4,500,000          
Options outstanding 2,410,134 2,294,714                                 2,003 7,230 831 2,053     1,360,059 1,316,628 715,692 637,253
Shares available for future grants                                             2,407,318 19,904        
Shares issued                           331,550                            
Stock options life   10 years                                                    
Share-based compensation expense $ 418,000 $ 443,000                                                    
Stock based compensation expense per share 0.03 0.04                                                    
Fair value of options vested 519,000 506,000                                                    
Shares, Options granted 237,315 1,547,550     90,945               25,000   398,227                          
Weighted-average fair value of options granted $ 0.56 $ 1.03                         $ 0.73                          
Intrinsic value of options outstanding 0 793,000                                                    
Intrinsic value of options vested or expected to vest 0 768,000                                                    
Weighted-average remaining contractual life of options vested or expected to vest 8 years 1 month 6 days 8 years 10 months 24 days                                                    
Unrecognized compensation cost related to non-vested options 727,000                                                      
Weighted average remaining requisite service period for unrecognized compensation cost 2 years 3 months 18 days                                                      
Exercise price of outstanding warrants 0.45 0.45 0.60     0.40 0.30                                          
Shares purchased through warrant                   8,806,575                                    
Proceeds from Issuance of Warrants                 65,000                                      
Warrants Exercised 2,254,500 23,720,667         14,879,708   161,708   104,206 1,096,313                                
Common stock, shares issued             687,793                                          
Outstanding warrants exercised                 352,034                                      
Proceeds from the exercise of warrants 248,000 503,000                 42,000 438,000                                
Warrants Exercised Under Cashless Exercise Provision                 190,326                                      
Proceeds from Issuance of Common Stock 2,771,000 0         206,000                                          
Incremental Fair Value Of Inducement               14,000                                        
Options Expired                                     5,227   1,222              
Options Expired Date                                     Mar. 15, 2014   Mar. 15, 2014              
Non-cash stock-based compensation, including stock options and restricted stock 575,000 443,000                           109,000 48,000                      
Share-based Compensation, Total                             157,000                          
Employee service share-based compensation, non vested awards, total compensation cost not yet recognized, share-based awards other than options 4,000                                                      
Class of Warrant or Right, Date from which Warrants or Rights Exercisable                   Mar. 10, 2017                                    
Accrued Compensation Current $ 0 $ 77,000                                                    
Options forfeited or expired (121,895)     90,945                                                
Additional shares not issued results of warrants exercised 374                                                      
XML 65 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes (Details 1) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Deferred tax assets:    
Net operating loss carry forwards $ 27,029,000 $ 25,721,000
Research and development credits 1,096,000 1,054,000
Nonqualified stock option compensation expense 1,801,000 1,701,000
Other temporary book - tax differences 408,000 441,000
Total deferred tax assets 30,334,000 28,917,000
Valuation allowance for deferred tax assets (30,334,000) (28,917,000)
Net deferred tax assets $ 0 $ 0
XML 66 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (USD $)
In Thousands, except Share data, unless otherwise specified
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2011 $ 1,421 $ 10 $ 95,630 $ 49 $ (94,268)
Balance, shares at Dec. 31, 2011   10,501,477      
Comprehensive income:          
Net loss (3,262)       (3,262)
Net unrealized gains/losses on foreign currency translation 27     27  
Comprehensive loss (3,235)        
Exercise of warrants 503 2 501    
Exercise of warrants, shares   1,448,347      
Noncash stock-based compensation 443   443    
Issuance of stock options related to licensing agreement 273   273    
Balance at Dec. 31, 2012 (595) 12 96,847 76 (97,530)
Balance, shares at Dec. 31, 2012   11,949,824      
Comprehensive income:          
Net loss (3,698)       (3,698)
Net unrealized gains/losses on foreign currency translation (2)     (2)  
Comprehensive loss (3,700)        
Shareholder rights offering, net 2,771 5 2,766    
Shareholder rights offering, net, shares   5,000,000      
Issuance of restricted stock 0        
Issuance of restricted stock, shares   340,220      
Exercise of warrants 248 1 247    
Exercise of warrants, shares   791,999      
Noncash stock-based compensation 652   652    
Warrant modification 14   14    
Balance at Dec. 31, 2013 $ (610) $ 18 $ 100,526 $ 74 $ (101,228)
Balance, shares at Dec. 31, 2013   18,082,043      
XML 67 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventory
 12 Months Ended
Dec. 31, 2013
Inventory Disclosure [Abstract]  
Inventory
Note 3 - Inventory
 
The Company’s inventory components as of December 31, 2013 and 2012 were as follows:
 
 
 
December 31,
 
 
 
2013
 
 
2012
 
Total Gross Inventory, Finished Goods
 
$
527,000
 
 
$
581,000
 
Less: Inventory reserve
 
 
(365,000)
 
 
 
(269,000)
 
Total Inventory
 
$
162,000
 
 
$
312,000
 
XML 68 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2013
Payables and Accruals [Abstract]  
Schedule Of Accrued Expenses
Accrued expenses as of December 31, 2013 and 2012 were as follows:
 
 
 
December 31,
 
 
 
2013
 
 
2012
 
Accrued Legal
 
$
149,000
 
 
$
90,000
 
Accrued Product Recall
 
 
60,000
 
 
 
 
 
Accrued Directors’ Compensation
 
 
-
 
 
 
77,000
 
Accrued Management Bonus
 
 
81,000
 
 
 
-
 
Accrued Interest
 
 
39,000
 
 
 
-
 
Accrued Travel
 
 
-
 
 
 
84,000
 
Accrued Other
 
 
36,000
 
 
 
70,000
 
Accrued Expenses
 
$
365,000
 
 
$
321,000
 
XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 165 327 1 false 54 0 false 8 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.nephros.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.nephros.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS false false R3.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.nephros.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.nephros.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS false false R5.htm 105 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://www.nephros.com/role/ConsolidatedStatementOfChangesInStockholdersEquityDeficit CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) false false R6.htm 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.nephros.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.nephros.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) false false R8.htm 108 - Disclosure - Organization and Nature of Operations Sheet http://www.nephros.com/role/OrganizationAndNatureOfOperations Organization and Nature of Operations false false R9.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.nephros.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R10.htm 110 - Disclosure - Inventory Sheet http://www.nephros.com/role/Inventory Inventory false false R11.htm 112 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.nephros.com/role/PrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets false false R12.htm 113 - Disclosure - Property and Equipment, Net Sheet http://www.nephros.com/role/PropertyAndEquipmentNet Property and Equipment, Net false false R13.htm 114 - Disclosure - Senior Secured Notes Notes http://www.nephros.com/role/SeniorSecuredNotes Senior Secured Notes false false R14.htm 115 - Disclosure - Accrued Expenses Sheet http://www.nephros.com/role/AccruedExpenses Accrued Expenses false false R15.htm 116 - Disclosure - Income Taxes Sheet http://www.nephros.com/role/IncomeTaxes Income Taxes false false R16.htm 117 - Disclosure - Stock Plans, Share-Based Payments and Warrants Sheet http://www.nephros.com/role/StockPlansSharebasedPaymentsAndWarrants Stock Plans, Share-Based Payments and Warrants false false R17.htm 118 - Disclosure - Stockholders' Equity Sheet http://www.nephros.com/role/StockholdersEquity Stockholders' Equity false false R18.htm 119 - Disclosure - 401(k) Plan Sheet http://www.nephros.com/role/KPlan 401(k) Plan false false R19.htm 120 - Disclosure - Commitments and Contingencies Sheet http://www.nephros.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R20.htm 121 - Disclosure - Concentration of Credit Risk Sheet http://www.nephros.com/role/ConcentrationOfCreditRisk Concentration of Credit Risk false false R21.htm 122 - Disclosure - Subsequent Events Sheet http://www.nephros.com/role/SubsequentEvents Subsequent Events false false R22.htm 123 - Disclosure - Summary Of Significant Accounting Policies (Policies) Sheet http://www.nephros.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary Of Significant Accounting Policies (Policies) false false R23.htm 124 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.nephros.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) false false R24.htm 125 - Disclosure - Inventory (Tables) Sheet http://www.nephros.com/role/InventoryTables Inventory (Tables) false false R25.htm 126 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.nephros.com/role/PrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) false false R26.htm 127 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.nephros.com/role/PropertyAndEquipmentNetTables Property and Equipment, Net (Tables) false false R27.htm 128 - Disclosure - Accrued Expenses (Tables) Sheet http://www.nephros.com/role/AccruedExpensesTables Accrued Expenses (Tables) false false R28.htm 129 - Disclosure - Income Taxes (Tables) Sheet http://www.nephros.com/role/IncomeTaxesTables Income Taxes (Tables) false false R29.htm 130 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Tables) Sheet http://www.nephros.com/role/StockPlansSharebasedPaymentsAndWarrantsTables Stock Plans, Share-Based Payments and Warrants (Tables) false false R30.htm 131 - Disclosure - Commitments And Contingencies (Tables) Sheet http://www.nephros.com/role/CommitmentsAndContingenciesTables Commitments And Contingencies (Tables) false false R31.htm 132 - Disclosure - Organization and Nature of Operations (Details Textual) Sheet http://www.nephros.com/role/OrganizationAndNatureOfOperationsDetailsTextual Organization and Nature of Operations (Details Textual) false false R32.htm 133 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.nephros.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) false false R33.htm 134 - Disclosure - Summary of Significant Accounting Policies (Schedule Of Securities Excluded From Dilutive Per Share Computation) (Details) Sheet http://www.nephros.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSecuritiesExcludedFromDilutivePerShareComputationDetails Summary of Significant Accounting Policies (Schedule Of Securities Excluded From Dilutive Per Share Computation) (Details) false false R34.htm 135 - Disclosure - Inventory (Details) Sheet http://www.nephros.com/role/InventoryDetails Inventory (Details) false false R35.htm 136 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.nephros.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) false false R36.htm 137 - Disclosure - Property and Equipment, Net (Schedule Of Property and Equipment, Net) (Details) Sheet http://www.nephros.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails Property and Equipment, Net (Schedule Of Property and Equipment, Net) (Details) false false R37.htm 138 - Disclosure - Property and Equipment, Net (Details Textual) Sheet http://www.nephros.com/role/PropertyAndEquipmentNetDetailsTextual Property and Equipment, Net (Details Textual) false false R38.htm 139 - Disclosure - Senior Secured Notes (Details Textual) Notes http://www.nephros.com/role/SeniorSecuredNotesDetailsTextual Senior Secured Notes (Details Textual) false false R39.htm 140 - Disclosure - Accrued Expenses (Details) Sheet http://www.nephros.com/role/AccruedExpensesDetails Accrued Expenses (Details) false false R40.htm 141 - Disclosure - Income Taxes (Details) Sheet http://www.nephros.com/role/IncomeTaxesDetails Income Taxes (Details) false false R41.htm 142 - Disclosure - Income Taxes (Details 1) Sheet http://www.nephros.com/role/IncomeTaxesDetails1 Income Taxes (Details 1) false false R42.htm 143 - Disclosure - Income Taxes (Details Textual) Sheet http://www.nephros.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) false false R43.htm 144 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details) Sheet http://www.nephros.com/role/StockPlansSharebasedPaymentsAndWarrantsDetails Stock Plans, Share-Based Payments and Warrants (Details) false false R44.htm 145 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details 1) Sheet http://www.nephros.com/role/StockPlansSharebasedPaymentsAndWarrantsDetails1 Stock Plans, Share-Based Payments and Warrants (Details 1) false false R45.htm 146 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details 2) Sheet http://www.nephros.com/role/StockPlansSharebasedPaymentsAndWarrantsDetails2 Stock Plans, Share-Based Payments and Warrants (Details 2) false false R46.htm 147 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details 3) Sheet http://www.nephros.com/role/StockPlansSharebasedPaymentsAndWarrantsDetails3 Stock Plans, Share-Based Payments and Warrants (Details 3) false false R47.htm 148 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details 4) Sheet http://www.nephros.com/role/StockPlansSharebasedPaymentsAndWarrantsDetails4 Stock Plans, Share-Based Payments and Warrants (Details 4) false false R48.htm 149 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details 5) Sheet http://www.nephros.com/role/StockPlansSharebasedPaymentsAndWarrantsDetails5 Stock Plans, Share-Based Payments and Warrants (Details 5) false false R49.htm 150 - Disclosure - Stock Plans, Share-Based Payments and Warrants (Details Textual) Sheet http://www.nephros.com/role/StockPlansSharebasedPaymentsAndWarrantsDetailsTextual Stock Plans, Share-Based Payments and Warrants (Details Textual) false false R50.htm 151 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.nephros.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) false false R51.htm 152 - Disclosure - 401(k) Plan (Details Textual) Sheet http://www.nephros.com/role/KPlanDetailsTextual 401(k) Plan (Details Textual) false false R52.htm 153 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.nephros.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) false false R53.htm 154 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.nephros.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R54.htm 155 - Disclosure - Concentration of Credit Risk (Details Textual) Sheet http://www.nephros.com/role/ConcentrationOfCreditRiskDetailsTextual Concentration of Credit Risk (Details Textual) false false R55.htm 156 - Disclosure - Subsequent Event (Details Textual) Sheet http://www.nephros.com/role/SubsequentEventDetailsTextual Subsequent Event (Details Textual) false false All Reports Book All Reports Element neph_ShareBasedGoodsAndNonemployeeServicesTransactionFairMarketValueOfOptionsGranted had a mix of decimals attribute values: -3 0. Element us-gaap_AmortizationOfFinancingCosts had a mix of decimals attribute values: -3 0. Element us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent had a mix of decimals attribute values: 0 1. Element us-gaap_LicensesRevenue had a mix of decimals attribute values: -3 0. Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -3 0. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate had a mix of decimals attribute values: 4 5. Element us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue had a mix of decimals attribute values: 0 2. Element us-gaap_StockOptionPlanExpense had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '133 - Disclosure - Summary of Significant Accounting Policies (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '139 - Disclosure - Senior Secured Notes (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '151 - Disclosure - Stockholders' Equity (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Process Flow-Through: 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) neph-20131231.xml neph-20131231.xsd neph-20131231_cal.xml neph-20131231_def.xml neph-20131231_lab.xml neph-20131231_pre.xml true true XML 70 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Senior Secured Notes (Details Textual) (USD $)
 1 Months Ended 12 Months Ended 1 Months Ended
May 31, 2013
Dec. 31, 2013
Dec. 31, 2012
Mar. 21, 2014
Subsequent Event [Member]
Mar. 24, 2014
Subsequent Event [Member]
Nov. 12, 2013
Lambda Investors LLC [Member]
Nov. 12, 2013
Lambda Investors LLC [Member]
Senior Notes [Member]
Feb. 04, 2013
Lambda Investors LLC [Member]
Senior Notes [Member]
Subsequent Event [Member]
Debt Instrument [Line Items]                
Debt instrument, face amount             $ 1,500,000 $ 1,300,000
Debt instrument, interest rate, stated percentage             12.00% 12.00%
Debt instrument, maturity date             May 12, 2014 Aug. 04, 2013
Percentage of sourcing fees             8.00% 8.00%
Transaction fees             120,000 104,000
Legal fees           75,000   50,000
Proceeds from issuance of common stock   2,771,000 0 2,100,000 2,100,000      
Proceeds from other debt       1,500,000 1,500,000      
Accrued Interest Issued To Investors       61,000 61,000      
Amortization of debt discount (premium) $ 204,000 $ 53,000       $ 195,000    
XML 71 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Concentration of Credit Risk
 12 Months Ended
Dec. 31, 2013
Concentration Of Credit Risk [Abstract]  
Concentration of Credit Risk
Note 13 - Concentration of Credit Risk
 
Cash and cash equivalents are financial instruments which potentially subject the Company to concentrations of credit risk. The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash and cash equivalents.
 
Major Customers
 
For the years ended December 31, 2013 and 2012, three customers accounted for 86% and 68%, respectively, of the Company’s sales.  In addition, as of December 31, 2013 and 2012, those three customers accounted for 97% and 88%, respectively, of the Company’s accounts receivable.